{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "2cf77706",
   "metadata": {},
   "source": [
    "# Pharmaceutical LLM RAG\n",
    "\n",
    "##### In this notebook we are testing the following models to analyze the performance of answering different pharmaceutical question:\n",
    " - Asi mini\n",
    " - Llama 3(locally)\n",
    " - ChatGPT 3.5\n",
    "\n",
    "For each model a langchain is built to give the models context of different drugs but we are also testing the models without RAG to analyse the performance.\n",
    "\n",
    "For testing **Giskard** is used to generate from pdfs questions and answers which are going to be compared against the output of the models mentioned above. Giskard used GPT 3.5 to analyse Asi mini and Llama 3, and GPT 4 to analyse GPT 3.5\n",
    "\n",
    "Afterwards query translations are used for one of the models(Asi mini) to see how it enhances the performance of the given tasks. The following querry translations methods are used:\n",
    "- Multi query\n",
    "- RAG-Fusion\n",
    "- Decomposition\n",
    "- Step Back\n",
    "- HyDE"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "5426bf38",
   "metadata": {},
   "source": [
    "##### Imports & Variables"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "663a228b",
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import requests\n",
    "import pandas as pd\n",
    "\n",
    "from operator import itemgetter\n",
    "from pathlib import Path\n",
    "\n",
    "from langchain_openai import OpenAIEmbeddings\n",
    "from langchain_openai.chat_models import ChatOpenAI\n",
    "from langchain_ollama import OllamaLLM \n",
    "from langchain_community.vectorstores import Chroma\n",
    "from langchain_community.document_loaders import PyPDFLoader\n",
    "from langchain.prompts import ChatPromptTemplate\n",
    "from langchain.load import dumps, loads\n",
    "from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
    "from langchain_core.prompts import FewShotChatMessagePromptTemplate\n",
    "from langchain_core.runnables import RunnableLambda\n",
    "from langchain_core.output_parsers import StrOutputParser\n",
    "\n",
    "import giskard\n",
    "from giskard.rag import KnowledgeBase\n",
    "from giskard.rag import generate_testset\n",
    "from giskard.rag import evaluate\n",
    "from giskard.rag import QATestset\n",
    "from giskard.rag.question_generators import ComplexQuestionsGenerator\n",
    "\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "\n",
    "ASI_ONE_KEY = os.getenv(\"ASI_ONE_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "0534e99e",
   "metadata": {},
   "outputs": [],
   "source": [
    "PDF_PATH = \"pdf_10\"\n",
    "VECTORSTORE_PATH = \"./chroma_db_100\"\n",
    "TESTSET_PATH = \"test-set-100.jsonl\"\n",
    "\n",
    "MODEL = \"asi1-mini\"\n",
    "MODEL_LLAMA3 = \"llama3\"\n",
    "MODEL_CHATGPT_3_5 = \"gpt-3.5-turbo\"\n",
    "\n",
    "SEARCH_KWARGS = 3\n",
    "NUM_QUESTIONS = 25"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a4ac7ea4",
   "metadata": {},
   "source": [
    "### Pre-processing ###"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "4ae384bb",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Parsed pdf_10/doc_57.pdf with 2 chunks.\n",
      "Parsed pdf_10/doc_85.pdf with 25 chunks.\n",
      "Parsed pdf_10/doc_8.pdf with 3 chunks.\n",
      "Parsed pdf_10/doc_98.pdf with 27 chunks.\n",
      "Parsed pdf_10/doc_15.pdf with 5 chunks.\n",
      "Parsed pdf_10/doc_97.pdf with 18 chunks.\n",
      "Parsed pdf_10/doc_7.pdf with 6 chunks.\n",
      "Parsed pdf_10/doc_3.pdf with 3 chunks.\n",
      "Parsed pdf_10/doc_86.pdf with 25 chunks.\n",
      "Parsed pdf_10/doc_28.pdf with 5 chunks.\n"
     ]
    }
   ],
   "source": [
    "full_documents = []\n",
    "\n",
    "pdf_folder = Path(PDF_PATH)\n",
    "pdf_files = list(pdf_folder.glob(\"*.pdf\"))\n",
    "\n",
    "for filepath in pdf_files:\n",
    "    try:\n",
    "        loader = PyPDFLoader(filepath)\n",
    "        docs = loader.load()\n",
    "        full_documents.extend(docs)\n",
    "        print(f\"Parsed {filepath} with {len(docs)} chunks.\")\n",
    "    except Exception as e:\n",
    "        print(f\"Error parsing {filepath}: {e}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "ba8a2d9e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "119"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(full_documents)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "5427bfe9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\n \\nK2resource co., ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\ntartar formation, plaque removal, oral cleansing\\nKeep out of reach of children\\nPut a tablet of Adea Gargle in your mouth and chew or melt according to your preference.\\nWhen foaming starts, please gaggle for more than 30 seconds so that every corner of the mouth can\\nreach Adea Gaggle.\\nWhen the gaggle is over, spit or swallow the bubbles.\\nAirtight container\\nStorage at room temperature\\nPlease close the lid tightly after opening.\\nAvoid direct sunlight and store in a cool place.\\nFor specific or unusual constitution, allergic constitution, please use after checking ingredients.\\nGLUCOSE, MENTHOL, MAGNESIUM STEARATE, ASPARTAME, SUCRALOSE\\nFor dental use only\\nADEA GARGLE  \\ncitric acid, sodium hydrogen carbonate, xylitol tablet, chewable'"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "full_documents[0].page_content"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "6c44a625",
   "metadata": {},
   "source": [
    "### Split"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "ef18eb91",
   "metadata": {},
   "outputs": [],
   "source": [
    "text_splitter = RecursiveCharacterTextSplitter.from_tiktoken_encoder(\n",
    "    chunk_size=300, \n",
    "    chunk_overlap=50)\n",
    "\n",
    "splits = text_splitter.split_documents(full_documents)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "dd04da9e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "314"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(splits)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4c5f6d57",
   "metadata": {},
   "source": [
    "### Index with Retrieval"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "c5940b69",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Using existing vector store\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_9434/2185640746.py:14: LangChainDeprecationWarning: The class `Chroma` was deprecated in LangChain 0.2.9 and will be removed in 1.0. An updated version of the class exists in the :class:`~langchain-chroma package and should be used instead. To use it run `pip install -U :class:`~langchain-chroma` and import as `from :class:`~langchain_chroma import Chroma``.\n",
      "  vectorstore = Chroma(\n"
     ]
    }
   ],
   "source": [
    "### Create vectorstore only if needed\n",
    "create = False\n",
    "\n",
    "if create:\n",
    "    print(\"Creating vectorstore\")\n",
    "    vectorstore = Chroma.from_documents(documents=splits, \n",
    "                                        embedding=OpenAIEmbeddings(model=\"text-embedding-3-small\"),\n",
    "                                        persist_directory=VECTORSTORE_PATH\n",
    "    )\n",
    "    vectorstore.persist()\n",
    "else:\n",
    "    print(\"Using existing vector store\")\n",
    "    embedding_function = OpenAIEmbeddings(model=\"text-embedding-3-small\")\n",
    "    vectorstore = Chroma(\n",
    "        persist_directory=VECTORSTORE_PATH,\n",
    "        embedding_function=embedding_function\n",
    "    )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "9f16dd2b",
   "metadata": {},
   "outputs": [],
   "source": [
    "retriever = vectorstore.as_retriever(search_kwargs={\"k\": SEARCH_KWARGS})"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2606ebaf",
   "metadata": {},
   "source": [
    "### Models"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "fc3349ac",
   "metadata": {},
   "outputs": [],
   "source": [
    "template = \"\"\"\n",
    "    Answer the given question: {question}\n",
    "\"\"\"\n",
    "\n",
    "prompt = ChatPromptTemplate.from_template(template)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "id": "f1b26bc1",
   "metadata": {},
   "outputs": [],
   "source": [
    "template_rag = \"\"\"\n",
    "Answer the question only based on the context below use only the given knowledge from the context do not invent or add details that you were treained. \n",
    "If you dont know the answer say that you dont know.\n",
    "\n",
    "Context: {context}\n",
    "\n",
    "Question: {question}\n",
    "\"\"\"\n",
    "prompt_rag = ChatPromptTemplate.from_template(template_rag)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2ecd84ae",
   "metadata": {},
   "source": [
    "#### Asi One Mini RAG"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "1e08b897",
   "metadata": {},
   "outputs": [],
   "source": [
    "def call_asi_one(prompt):\n",
    "    if hasattr(prompt, \"to_string\"):\n",
    "        prompt = prompt.to_string()\n",
    "\n",
    "    url = \"https://api.asi1.ai/v1/chat/completions\"\n",
    "    headers = {\n",
    "        'Content-Type': 'application/json',\n",
    "        'Authorization': f'Bearer {ASI_ONE_KEY}'\n",
    "    }\n",
    "    payload = {\n",
    "        \"model\": MODEL,\n",
    "        \"messages\": [{\"role\": \"user\", \"content\": prompt}],\n",
    "        \"temperature\": 0.2,\n",
    "        \"max_tokens\": 1000\n",
    "    }\n",
    "    response = requests.post(url, headers=headers, json=payload)\n",
    "    return response.json().get(\"choices\", [{}])[0].get(\"message\", {}).get(\"content\", \"No response\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "2ca465f4",
   "metadata": {},
   "outputs": [],
   "source": [
    "chain_asi_rag = ({\n",
    "    \"context\": itemgetter(\"question\") | vectorstore.as_retriever(),\n",
    "    \"question\": itemgetter(\"question\"),\n",
    "}\n",
    "| prompt_rag\n",
    "| call_asi_one\n",
    "| StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8ae322b9",
   "metadata": {},
   "source": [
    "#### Asi One Mini\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "id": "e1006315",
   "metadata": {},
   "outputs": [],
   "source": [
    "chain_asi = ({\n",
    "    \"question\": itemgetter(\"question\"),\n",
    "}\n",
    "| prompt\n",
    "| call_asi_one\n",
    "| StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7e9b4874",
   "metadata": {},
   "source": [
    "#### Llama 3 RAG\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 72,
   "id": "0c9d9221",
   "metadata": {},
   "outputs": [],
   "source": [
    "model_llama = OllamaLLM(model=MODEL_LLAMA3)\n",
    "\n",
    "chain_llama3_rag = (\n",
    "    {\n",
    "        \"context\": itemgetter(\"question\") | vectorstore.as_retriever(),\n",
    "        \"question\": itemgetter(\"question\"),\n",
    "    }\n",
    "    | prompt_rag\n",
    "    | model_llama\n",
    "    | StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a8eae6ab",
   "metadata": {},
   "source": [
    "#### LLama 3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "b5de2521",
   "metadata": {},
   "outputs": [],
   "source": [
    "chain_llama3 = ({\n",
    "    \"question\": itemgetter(\"question\"),\n",
    "}\n",
    "| prompt\n",
    "| model_llama\n",
    "| StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3cbbc90f",
   "metadata": {},
   "source": [
    "#### Gpt 3.5 RAG"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "id": "1cf9166a",
   "metadata": {},
   "outputs": [],
   "source": [
    "model_gpt_3_5 = ChatOpenAI(model=MODEL_CHATGPT_3_5)\n",
    "\n",
    "chain_gpt_3_5_rag = (\n",
    "    {\n",
    "        \"context\": itemgetter(\"question\") | vectorstore.as_retriever(),\n",
    "        \"question\": itemgetter(\"question\"),\n",
    "    }\n",
    "    | prompt_rag\n",
    "    | model_gpt_3_5\n",
    "    | StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e11f1e63",
   "metadata": {},
   "source": [
    "#### Gpt 3.5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "5351667b",
   "metadata": {},
   "outputs": [],
   "source": [
    "chain_gpt_3_5 = ({\n",
    "    \"question\": itemgetter(\"question\"),\n",
    "}\n",
    "| prompt\n",
    "| model_gpt_3_5\n",
    "| StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "16330b41",
   "metadata": {},
   "source": [
    "### Testing models (Giskard)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "1d141394",
   "metadata": {},
   "source": [
    "#### Preparint testsets"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "0aefc83c",
   "metadata": {},
   "outputs": [],
   "source": [
    "giskard.llm.set_llm_model(\"gpt-3.5-turbo\")\n",
    "giskard.llm.set_embedding_model(\"text-embedding-3-small\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "614b7bfc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "119"
      ]
     },
     "execution_count": 15,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(full_documents)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "id": "c3a7514a",
   "metadata": {},
   "outputs": [],
   "source": [
    "df = pd.DataFrame([d.page_content for d in full_documents], columns=[\"text\"])\n",
    "knowledge_base = KnowledgeBase(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "id": "14fcae38",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Using existing test set\n"
     ]
    }
   ],
   "source": [
    "generate_tests = False\n",
    "\n",
    "if generate_tests:\n",
    "    print(\"Create new test set\")\n",
    "    testset = generate_testset(\n",
    "        knowledge_base=knowledge_base,\n",
    "        num_questions=NUM_QUESTIONS,\n",
    "        question_generators = ComplexQuestionsGenerator(),\n",
    "        agent_description=\"A chatbot answering questions about medicine drugs based on a given context\",\n",
    "    )\n",
    "\n",
    "    testset.save(\"test-set-10.jsonl\")\n",
    "else:\n",
    "    print(\"Using existing test set\")\n",
    "    testset = QATestset.load(\"test-set-10.jsonl\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "19c62cef",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Create new test set\n",
      "2025-06-22 09:43:48,897 pid:11544 MainThread giskard.rag  INFO     Finding topics in the knowledge base.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/deni/Desktop/disi/.venv/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-06-22 09:43:54,202 pid:11544 MainThread giskard.rag  INFO     Found 3 topics in the knowledge base.\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "9e4cc0037cc1402faa5bddcbd53738ee",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Generating questions:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "generate_tests_gpt_4 = False\n",
    "\n",
    "if generate_tests_gpt_4:\n",
    "    print(\"Create new test set\")\n",
    "    giskard.llm.set_llm_model(\"gpt-4o\")\n",
    "    testset_gpt4o = generate_testset(\n",
    "        knowledge_base=knowledge_base,\n",
    "        num_questions=NUM_QUESTIONS,\n",
    "        question_generators = ComplexQuestionsGenerator(),\n",
    "        agent_description=\"A chatbot answering questions about medicine drugs based on a given context\",\n",
    "    )\n",
    "\n",
    "    testset_gpt4o.save(\"test-set-gpt-4o-10.jsonl\")\n",
    "else:\n",
    "    print(\"Using existing test set\")\n",
    "    testset_gpt4o = QATestset.load(\"test-set-gpt-4o-10.jsonl\")"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "71172262",
   "metadata": {},
   "source": [
    "#### Asi mini RAG"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 117,
   "id": "656b059f",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_asi_rag(question, history=None):\n",
    "    return chain_asi_rag.invoke({\"question\": question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 170,
   "id": "a7440dd1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "fd22f83bf5b94b5498dc2997882eb508",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7bef43ebf41c43b6831c10eefcd3fb55",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"d98779e9-461a-4c59-bdd5-b6a7fec3f4c0\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"d98779e9-461a-4c59-bdd5-b6a7fec3f4c0\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"d98779e9-461a-4c59-bdd5-b6a7fec3f4c0\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-red \">\n",
       "                        4.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=4.0 class=\" progress-red \">4.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        90.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=90.0 class=\" progress-green \">90.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">4%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Based on the scores, the most important action to improve your RAG system is to enhance the performance on complex questions, which currently has a low score of 0.04. This can be achieved by refining the Generator component to better handle complex question structures.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"a7898f8c-b8f9-45c7-acdf-c7ebd3c134ae\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p2429\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p2431\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p2438\",\"attributes\":{\"factors\":[\"Medical Products\",\"Others\",\"PROVENGE Treatment\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2439\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p2440\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p2436\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2458\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2426\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2427\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2428\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"AAAAAAAAAAAAAAAAAAAAAAAAAAAAACRA\"},\"shape\":[3],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Medical Products\",\"Others\",\"PROVENGE Treatment\"]],[\"colors\",[\"#a50026\",\"#a50026\",\"#006837\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2459\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2460\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2455\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2456\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2457\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2467\",\"attributes\":{\"data_source\":{\"id\":\"p2426\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2468\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2469\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2464\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2465\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2466\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2477\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2471\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2472\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2473\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2478\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2479\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p2474\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p2475\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p2476\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p2437\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p2451\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p2446\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p2447\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p2448\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2449\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2441\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2442\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2443\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2444\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2445\",\"attributes\":{\"axis\":{\"id\":\"p2441\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2450\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p2446\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p2470\",\"attributes\":{\"location\":4.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p2480\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2481\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p2477\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"a7898f8c-b8f9-45c7-acdf-c7ebd3c134ae\",\"roots\":{\"p2429\":\"c136db71-69a2-441f-ac1c-fb900580d329\"},\"root_ids\":[\"p2429\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"c136db71-69a2-441f-ac1c-fb900580d329\" data-root-id=\"p2429\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                None\n",
       "                None\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x7b1168da4c20>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_asi_rag, testset=testset)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 153,
   "id": "d19cfcae",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "report.to_html(f\"report-asi-mini_1.html\")\n",
    "dfc = pd.DataFrame(report.component_scores())\n",
    "dfc.to_csv(f\"component_scores_1.csv\", index=False)\n",
    "dfr = report.to_pandas()\n",
    "dfr.to_excel(f\"all_results_1.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "5c4a1d66",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>reference_answer</th>\n",
       "      <th>reference_context</th>\n",
       "      <th>conversation_history</th>\n",
       "      <th>metadata</th>\n",
       "      <th>agent_answer</th>\n",
       "      <th>correctness</th>\n",
       "      <th>correctness_reason</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>id</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>dd9a3fcd-acd0-494f-863e-82c591f95d44</th>\n",
       "      <td>How does nitisinone benefit patients with HT-1...</td>\n",
       "      <td>In patients with HT-1, nitisinone prevents the...</td>\n",
       "      <td>Document 8: Nitisinone is a competitive inhibi...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Nitisinone benefits patients with HT-1 by comp...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed explanation of h...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                               question  \\\n",
       "id                                                                                        \n",
       "dd9a3fcd-acd0-494f-863e-82c591f95d44  How does nitisinone benefit patients with HT-1...   \n",
       "\n",
       "                                                                       reference_answer  \\\n",
       "id                                                                                        \n",
       "dd9a3fcd-acd0-494f-863e-82c591f95d44  In patients with HT-1, nitisinone prevents the...   \n",
       "\n",
       "                                                                      reference_context  \\\n",
       "id                                                                                        \n",
       "dd9a3fcd-acd0-494f-863e-82c591f95d44  Document 8: Nitisinone is a competitive inhibi...   \n",
       "\n",
       "                                     conversation_history  \\\n",
       "id                                                          \n",
       "dd9a3fcd-acd0-494f-863e-82c591f95d44                   []   \n",
       "\n",
       "                                                                               metadata  \\\n",
       "id                                                                                        \n",
       "dd9a3fcd-acd0-494f-863e-82c591f95d44  {'question_type': 'complex', 'seed_document_id...   \n",
       "\n",
       "                                                                           agent_answer  \\\n",
       "id                                                                                        \n",
       "dd9a3fcd-acd0-494f-863e-82c591f95d44  Nitisinone benefits patients with HT-1 by comp...   \n",
       "\n",
       "                                      correctness  \\\n",
       "id                                                  \n",
       "dd9a3fcd-acd0-494f-863e-82c591f95d44        False   \n",
       "\n",
       "                                                                     correctness_reason  \n",
       "id                                                                                       \n",
       "dd9a3fcd-acd0-494f-863e-82c591f95d44  The agent provided a detailed explanation of h...  "
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "failures = report.get_failures()\n",
    "failures"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "id": "a6256023",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'No response'"
      ]
     },
     "execution_count": 84,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "failures.iloc[40].agent_answer"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "id": "bc8f8e42",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>correctness</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>question_type</th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>complex</th>\n",
       "      <td>0.318182</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "               correctness\n",
       "question_type             \n",
       "complex           0.318182"
      ]
     },
     "execution_count": 36,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "report.correctness_by_question_type()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9ac09d73",
   "metadata": {},
   "source": [
    "#### Asi Mini"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "f74d57c7",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_asi(question, history=None):\n",
    "    return chain_asi.invoke({\"question\": question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "id": "3dd2dc73",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ff2eb1c0884749348ea32d35c3bc2bf5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "335bbc64d7094125a7fd942d8e61520b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"b1b7e6d7-7335-412e-9da1-7aefc4d54b29\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"b1b7e6d7-7335-412e-9da1-7aefc4d54b29\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"b1b7e6d7-7335-412e-9da1-7aefc4d54b29\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-06-22 08:54:41,938 pid:8644 MainThread giskard.rag  INFO     Finding topics in the knowledge base.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/deni/Desktop/disi/.venv/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-06-22 08:54:49,702 pid:8644 MainThread giskard.rag  INFO     Found 6 topics in the knowledge base.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-red \">\n",
       "                        20.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=20.0 class=\" progress-red \">20.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-orange \">\n",
       "                        50.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=50.0 class=\" progress-orange \">50.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">20%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Focus on improving the performance of the RAG system on complex questions, as it has the lowest score. Consider fine-tuning the Generator for better handling of complex question paraphrasing.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"8824219e-c627-4d64-a981-ecdc07350a36\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1679\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1681\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1688\",\"attributes\":{\"factors\":[\"ACE Inhibitor Side Effects\",\"Candesartan Cilexetil\",\"NUCYNTA\\\\u2122 Medication\",\"Others\",\"Pharmaceuticals\",\"Povidone Iodine Solution\",\"Tizanidine Hydrochloride\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1689\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1690\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1686\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1708\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1676\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1677\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1678\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"JEmSJEmSPEAAAAAAAAAAAKqqqqqqqjBAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAElAAAAAAAAAOUA=\"},\"shape\":[7],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"ACE Inhibitor Side Effects\",\"Candesartan Cilexetil\",\"NUCYNTA\\\\u2122 Medication\",\"Others\",\"Pharmaceuticals\",\"Povidone Iodine Solution\",\"Tizanidine Hydrochloride\"]],[\"colors\",[\"#e3f399\",\"#a50026\",\"#fdbe6e\",\"#a50026\",\"#a50026\",\"#006837\",\"#fefebd\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1709\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1710\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1705\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1706\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1707\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1717\",\"attributes\":{\"data_source\":{\"id\":\"p1676\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1718\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1719\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1714\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1715\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1716\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1727\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1721\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1722\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1723\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1728\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1729\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1724\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1725\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1726\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1687\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1701\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1696\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1697\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1698\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1699\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1691\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1692\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1693\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1694\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1695\",\"attributes\":{\"axis\":{\"id\":\"p1691\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1700\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1696\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p1720\",\"attributes\":{\"location\":20.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1730\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1731\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p1727\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"8824219e-c627-4d64-a981-ecdc07350a36\",\"roots\":{\"p1679\":\"e19c009a-6c05-4167-962c-5244583ef0c0\"},\"root_ids\":[\"p1679\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"e19c009a-6c05-4167-962c-5244583ef0c0\" data-root-id=\"p1679\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"d8034ef8-2788-47b9-ad00-f34a376de50e\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p1610\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1540\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1490\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1499\",\"attributes\":{\"start\":2.6081478595733643,\"end\":17.234113693237305}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1500\",\"attributes\":{\"start\":13.671540260314941,\"end\":21.66947841644287}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1501\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1502\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1497\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1530\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1487\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1488\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1489\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Medication Information\",\"Others\",\"Others\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"ACE Inhibitors\",\"Others\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Medication Information\",\"Others\",\"Medication Information\",\"Medication Information\",\"Pharmaceutical Products\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Candesartan Cilexetil\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Pharmaceutical Products\",\"Others\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Others\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118]],[\"content\",[\"ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\\\n \\\\nK2resource co., ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\\\ntartar formation, plaque removal, oral cleansing\\\\nKeep...\",\"K2resource co., ltd.\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:72191-0100\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nSODIUM BICARBONATE\\\\n (UNII: 8MDF5V39QO) \\\\n(SODIUM CATION -\\\\nUNII:LYR4M0NH37)\\\\nSODIUM\\\\nBICARBONATE\\\\n36.2 g  in 100 mg\\\\nXYLITOL\\\\n (UNII: VCQ006KQ1E) \\\\n(XYLITOL - UNII:VCQ006KQ1E)\\\\nXYLITOL\\\\n5 g  in 100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMENTHOL\\\\n (UNII: L7T10EIP3A)\\\\n \\\\nProduct Characteristics\\\\nCo...\",\"NUCYNTA - tapentadol hydrochloride tablet, film coated \\\\n \\\\nStat Rx USA\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use NUCYNTA\\\\u2122 safely and effectively. See full\\\\nprescribing information for NUCYNTA\\\\u2122.\\\\n \\\\nNUCYNTA\\\\u2122 (tapentadol) immediate-release oral tablets    C-II\\\\nInitial U.S. Approval: 2008\\\\nRECENT MAJOR CHANGES\\\\nWarnings and Precautions (\\\\n5.4\\\\n)\\\\nJune 2009\\\\nINDICATIONS AND USAGE\\\\nNUCYNTA\\\\u2122 is an opioid analgesic indicated for the relief o...\",\"USE IN SPECIFIC POPULATIONS\\\\nLabor and delivery: \\\\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\\\nmothers have been taking NUCYNTA\\\\u2122, for respiratory depression. (\\\\n8.2\\\\n)\\\\nNursing mothers: should not breast-feed. (\\\\n8.3\\\\n)\\\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\\\n8.4\\\\n)\\\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\\\npatients with moder...\",\"8.7 Hepatic Impairment\\\\n9 DRUG ABUSE AND DEPENDENCE\\\\n9.1 Controlled Substance\\\\n9.2 Abuse\\\\n9.3 Dependence\\\\n10 OVERDOSAGE\\\\n10.1 Human Experience\\\\n10.2 Management of Overdose\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n13 NON-CLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\n14 CLINICAL STUDIES\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\n14.2 End-Stage Degenerative Joint Disea...\",\"Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\\\nbeen studied and are not recommended.\\\\nNUCYNTA\\\\u2122 may be given with or without food \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n].\\\\n2.1 Renal Impairment\\\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\\\n[see \\\\nClinical\\\\nPharmacology (12.3)\\\\n]\\\\n.\\\\nNUCYNTA\\\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\\\nis not recommended.\\\\n2.2 Hepatic Im...\",\"which may result in adverse cardiovascular events \\\\n[see \\\\nDrug Interactions (7.4)\\\\n]\\\\n.\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Respiratory Depression\\\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\\\nsignificantly decrease pulmonary ventilation.\\\\nNUCYNTA\\\\u2122 should be ...\",\"5.5 Driving and Operating Machinery\\\\nPatients should be cautioned that NUCYNTA\\\\u2122 may impair the mental and/or physical abilities required\\\\nfor the performance of potentially hazardous tasks such as driving a car or operating machinery. This is\\\\nto be expected especially at the beginning of treatment, at any change of dosage as well as in\\\\ncombination with alcohol or tranquilizers\\\\n [see \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\n5.6 Interactions with Alcohol and Drugs of Abuse\\\\nDue to its mu-opioid agonist activity,...\",\"Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\\\nconsidered drug-related.\\\\nBased on data from nine Phase 2/3 studies that administered multiple...\",\"*\\\\nInfections and infestations\\\\n  Nasopharyngitis\\\\n1\\\\n&lt;1\\\\n  Upper respiratory tract infection\\\\n1\\\\n&lt;1\\\\n  Urinary tract infection\\\\n1\\\\n&lt;1\\\\nMetabolism and nutrition disorders\\\\n  Decreased appetite\\\\n2\\\\n0\\\\nMusculoskeletal and connective tissue\\\\ndisorders\\\\n  Arthralgia\\\\n1\\\\n&lt;1\\\\nNervous system disorders\\\\n  Dizziness\\\\n24\\\\n8\\\\n  Somnolence\\\\n15\\\\n3\\\\n  Tremor\\\\n1\\\\n&lt;1\\\\n  Lethargy\\\\n1\\\\n&lt;1\\\\nPsychiatric disorders\\\\n  Insomnia\\\\n2\\\\n&lt;1\\\\n  Confusional state\\\\n1\\\\n0\\\\n  Abnormal dreams\\\\n1\\\\n&lt;1\\\\n  Anxiety\\\\n1\\\\n&lt;1\\\\nSkin and subcutaneous tissue disorders\\\\n  Pruritus\\\\n5\\\\n1\\\\n  Hyp...\",\"Psychiatric disorders:\\\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\\\nabnormal\\\\nRenal and urinary disorders:\\\\n urinary hesitation, pollakiuria\\\\nRespiratory, thoracic and mediastinal disorders: \\\\noxygen saturation decreased, cough, dyspnea,\\\\nrespiratory depression\\\\nSkin and subcutaneous tissue disorders: \\\\nurticaria\\\\nVascular disorders:\\\\n blood pressure decreased\\\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\\\nNUCYNTA\\\\u2122,...\",\"Pregnancy Category C.\\\\nTapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous\\\\nand subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was\\\\nadministered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day\\\\n[producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of\\\\n700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic eff...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and\\\\nproper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid\\\\nagonist properties.\\\\nInfants born to mothers physically dependent on opioids will also be physically dependent and may\\\\nexhibit respiratory difficulties and withdrawal symptoms \\\\n[see \\\\nWarnings and Precautions (5.1)\\\\n]\\\\n. Use of\\\\nNUCYNTA\\\\u2122 in this population has not been characterized. As NUCYNTA\\\\u2122 h...\",\"intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\\\nshould be taken to secure the airway.\\\\n11 DESCRIPTION\\\\nNUCYNTA\\\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\\\nThe chemical name is 3-[(1\\\\nR\\\\n,2\\\\nR\\\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\\\nmonohydrochloride. The structural formula is:\\\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\\\nH\\\\nNO\\\\u00b7HCl. The\\\\nn-octanol:water pa...\",\"extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\\\naround 1.25 hours after dosing.\\\\nDose-proportional increases in the C\\\\n and AUC values of tapentadol have been observed over the 50\\\\nto 150 mg dose range.\\\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\\\nglucuronide, which are primarily determined by the do...\",\"Pharmacokinetic Drug Interactions\\\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\\\nconsidered clinically relevant and no change in dose is required.\\\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\\\nac...\",\"14 CLINICAL STUDIES\\\\nThe efficacy and safety of NUCYNTA\\\\u2122 in the treatment of moderate to severe acute pain has been\\\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\\\u2122...\",\"50% or greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus\\\\nplacebo.\\\\n14.2 End-Stage Degenerative Joint Disease\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\\\u2122 given every 4 to 6 hours during\\\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\\\nend stage degenerative joint disease of the hip or knee, defined...\",\"The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\\\nor greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus placebo.\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nNUCYNTA\\\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\\\nbiconvex-shaped.\\\\n50 mg tablets are yellow and debossed with \\\\\"O-M\\\\\" on one side and \\\\\"50\\\\\" on the other side, and are\\\\navailable in bottles of 100 (NDC 50458-820-04) a...\",\"Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\\\u2122 \\\\n[see \\\\nUse in\\\\nSpecific Populations (8.3)\\\\n]\\\\n.\\\\n17.6 Monoamine Oxidase Inhibitors\\\\nPatients should be informed not to take NUCYNTA\\\\u2122 while using any drugs that inhibit monoamine\\\\noxidase. Patients should not start any new medications while taking NUCYNTA\\\\u2122 until they are assured\\\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\\\n17.7 Seizures\\\\nPatients should be informed that NU...\",\"you get a new prescription. There may be new information. This Medication Guide does not take\\\\nthe place of talking to your doctor about your medical condition or your treatment. Talk to your\\\\ndoctor if you have any questions.\\\\nWhat is the most important information I should know about NUCYNTA\\\\u2122?\\\\nNUCYNTA\\\\u2122 is a tablet that contains tapentadol, a strong medicine that is a pain medicine.\\\\nUse NUCYNTA\\\\u2122 exactly how your doctor tells you to. Do not use NUCYNTA\\\\u2122 if it has not been\\\\nprescribed for you.\\\\nYou sh...\",\"Do not change the dose of NUCYNTA\\\\u2122 unless your doctor tells you to. \\\\nYour doctor may\\\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\\\u2122 more often\\\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\\\u2122.\\\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\\\u2122 to help lessen\\\\nwithdrawal symptoms.\\\\nNUCYNTA\\\\u2122 can be taken with or without food.\\\\nWhat should I avoid while taking NUCYNTA\\\\u2122?\\\\nDo not drive, operate machinery, ...\",\"Store NUCYNTA\\\\u2122 at 59\\\\u00baF to 86\\\\u00baF (15\\\\u00baC to 30\\\\u00baC). Keep NUCYNTA\\\\u2122 tablets dry.\\\\nDispose of NUCYNTA\\\\u2122 tablets you no longer need.\\\\nKeep NUCYNTA\\\\u2122 in a safe place out of the reach of children.\\\\nGeneral information about NUCYNTA\\\\u2122\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\\\nuse NUCYNTA\\\\u2122 for a condition for which it was not prescribed. \\\\nDo not give NUCYNTA\\\\u2122 to other\\\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\\\u2122 could be harmful\\\\n...\",\"NUCYNTA 100MG PACKAGE LABEL\\\\n       \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\nNUCYNTA  \\\\ntapentadol hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN\\\\nPRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:16590-\\\\n863(NDC:50458-820)\\\\nRoute of Administration\\\\nORAL\\\\nDEA Schedule\\\\nCII\",\"Active Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n50 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII: 15FIX9V2JP)\\\\n...\",\"Stat Rx USA\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII:...\",\"GRX DYNE - povidone iodine solution \\\\n \\\\nGeritrex Corp.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nGRx Dyne Solution\\\\nDrug Facts\\\\nActive Ingredient:                      Purpose\\\\nPovidone Iodine USP, 10% w/v  Antiseptic\\\\n(equivalent to 1% titratable Iodine)\\\\nUses\\\\nFirst aid antiseptic to help the risk of infection in \\\\nminor cuts, scra...\",\"Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\\\nkeep out of reach of children. If swallowed get medical help \\\\nor contact a Poison Control Center right away.\\\\nEnter section text here\\\\nGRX DYNE  \\\\npovidone iodine solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:54162-269\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85...\",\"Geritrex Corp.\\\\nCITRIC ACID MONOHYDRATE\\\\n (UNII: 2968PHW8QP)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nSODIUM HYDROXIDE\\\\n (UNII: 55X04QC32I)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:54162-269-16\\\\n472 mL in 1 BOTTLE, PLASTIC\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOTC monograph not final\\\\npart333A\\\\n05/16/2012\\\\nLabeler - \\\\n...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE- lisinopril and hydrochlorothiazide\\\\ntablets tablet \\\\n \\\\nCipla USA Inc.\\\\n----------\\\\nLisinopril and Hydrochlorothiazide Tablets, USP\\\\nRx Only\\\\nWARNING: FETAL TOXICITY\\\\nSee full prescribing information for complete boxed warning.\\\\nWhen pregnancy is detected, discontinue lisinopril and\\\\nhydrochlorothiazide tablets as soon as possible.\\\\nDrugs that act directly on the renin-angiotensin system can cause\\\\ninjury and death to the developing fetus. See \\\\nWarnings: Fetal Toxicity\\\\n.\\\\n...\",\"Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\\\nhydroxide solution.\\\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\\\nlisinopril and hydrochlorothiazide tabl...\",\"Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\\\nadministration of the separate entities.\\\\nLisinopril\\\\nMechanism of Action\\\\n \\\\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...\",\"state is prolonged. Older patients, on average, have (approximately doubled) higher\\\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\\\npatients (see \\\\nDOSAGE AND ADMINISTRATION\\\\n). In a multiple dose pharmacokinetic study\\\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\\\nhe...\",\"accompanied by some loss of potassium and bicarbonate.\\\\nAfter oral use diuresis begins within two hours, peaks in about four hours and lasts\\\\nabout 6 to 12 hours.\\\\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When\\\\nplasma levels have been followed for at least 24 hours, the plasma half-life has been\\\\nobserved to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is\\\\neliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but...\",\"the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\\\nsimilar risk (See \\\\nWARNINGS\\\\n).\\\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\\\nthan in nonblack patients (see \\\\nWARNIN...\",\"Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of\\\\nrapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin\\\\ninhibitor may be at increased risk for angioedema (see \\\\nPRECAUTIONS\\\\n).\\\\nIntestinal Angioedema:\\\\n Intestinal angioedema has been reported in patients treated\\\\nwith ACE inhibitors. These patients presented with abdominal pain (with or without\\\\nnausea or vomiting); in some cases there was no prior history of facial angioedema and\\\\nC-1...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\\\nLisinopril and Hydrochlorothiazide\\\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\\\nMaternal or fetotoxic effects were not seen in mice with the com...\",\"Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\\\nInteractions, Lisinopril and Hydrochlorothiazide).\\\\nPRECAUTIONS\\\\nGeneral\\\\nLisinopril\\\\n \\\\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\\\n As with all vasodilators, lisinopril\\\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\\\nventricle.\\\\nImpaired Renal Function:\\\\n As a consequence of inhibiting the renin-angiotensin-\\\\naldosterone system, changes in renal function may be anticipated in suscept...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"therapy.\\\\nInformation for Patients\\\\nAngioedema:\\\\n Angioedema, including laryngeal edema may occur at any time during\\\\ntreatment with angiotensin-converting enzyme inhibitors, including lisinopril and\\\\nhydrochlorothiazide. Patients should be so advised and told to report immediately any\\\\nsigns or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips,\\\\ntongue, difficulty in swallowing or breathing) and to take no more drug until they have\\\\nconsulted with the prescribing physician.\\\\nSymp...\",\"DOSAGE AND ADMINISTRATION\\\\n)\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\\\nInhibitors (COX-2 Inhibitors):\\\\n \\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\\\nfunction, including possible acute renal failure. These effects are usually reversible.\\\\nMonitor ...\",\"mTOR (mammalian target of rapamycin) inhibitors\\\\n \\\\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\\\n(see \\\\nWARNINGS\\\\n)\\\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\\\nrisk for angioedema. (see \\\\nWARNINGS\\\\n)\\\\nHydrochlorothiazide\\\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\\\nAlcohol, barbiturates, or nar...\",\"in vitro\\\\n alkaline elution rat hepatocyte assay. In addition, it did not produce increases in\\\\nchromosomal aberrations in an \\\\nin vitro\\\\n test in Chinese hamster ovary cells or in an \\\\nin\\\\nvivo\\\\n study in mouse bone marrow.\\\\nLisinopril\\\\n \\\\nThere was no evidence of a tumorigenic effect when lisinopril was administered for 105\\\\nweeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the\\\\nmaximum daily human dose, based on body weight and body surface area,\\\\nrespectively). There was no ...\",\"Nursing Mothers\\\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\\\nrats contains radioactivity following administration of \\\\nC lisinopril. In another study,\\\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\\\nwhether to discontinue nursing and/or disco...\",\"adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\\\nfatigue and muscle cramps.\\\\nAdverse experiences occurring in greater than one percent of patients treated with\\\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\\\n                                                                         Percent of Patients in\\\\nControlled Studies\\\\n   Lisinopril and\\\\nHydrochlorothiazide\\\\n   (n=930)\\\\n   Incidence\\\\n(discontinuation)\\\\n   Placebo\\\\n   (n=207)\\\\n...\",\"In rare cases, intestinal angioedema has been reported in post marketing experience.\\\\nHypotension:\\\\n In clinical trials, adverse effects relating to hypotension occurred as\\\\nfollows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects\\\\n(3.2%). In addition syncope occurred in 0.8% of patients (See \\\\nWARNINGS\\\\n).\\\\nCough:\\\\n See \\\\nPRECAUTIONS - Cough\\\\n.\\\\nClinical Laboratory Test Findings Serum Electrolytes:\\\\n (See \\\\nPRECAUTIONS\\\\n).\\\\nCreatinine, Blood Urea Nitrogen:\\\\n Minor reversible incre...\",\"hallucinations; \\\\nRespiratory:\\\\n Malignant lung neoplasms, hemoptysis, pulmonary edema,\\\\npulmonary infiltrates, bronchospasm, asthma, pleural effusion, pneumonia, eosinophilic\\\\npneumonitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis,\\\\npharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; \\\\nSkin:\\\\n Urticaria, alopecia,\\\\nherpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema,\\\\npsoriasis, rare cases of other severe skin reactions, includin...\",\"Lisinopril\\\\n \\\\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\\\nnormal saline solution.\\\\nLisinopril can be removed by hemodialysis (see \\\\nWARNINGS, Anaphylactoid Reaction\\\\nDuring Membrane Exposure\\\\n).\\\\nHydrochlorothiazide\\\\n \\\\nOral administration of a single oral dose of 10 g/kg to mice and rats w...\",\"possible, be discontinued for two to three days before beginning therapy with lisinopril\\\\nto reduce the likelihood of hypotension (See \\\\nWARNINGS\\\\n). If the patient\\\\u2019s blood pressure\\\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\\\nfor at least an additional hour (See \\\\nWARNINGS\\\\n and \\\\nPRECAUTIONS\\\\n...\",\"Protect from excessive light and humidity.\\\\n*AN69 is a registered trademark of Hospal Ltd.\\\\nManufactured by:\\\\nInvaGen Pharmaceuticals, Inc.\\\\n(a subsidiary of Cipla Ltd.)\\\\nHauppauge, NY 11788\\\\nManufactured for:\\\\nCipla USA, Inc.\\\\n10 Independence Boulevard, Suite 300\\\\nWarren, NJ 07059\\\\nRevised: 10/2021\\\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\\\u2013 10 mg/12.5 mg\\\\nNDC 69097-968-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n10 mg/12.5 mg\\\\n100 Tablets\\\\nCipla\\\\nNDC 69097-969-07             ...\",\"Cipla\\\\nNDC 69097-971-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n20 mg/25 mg\\\\n100 Tablets\\\\nCipla\\\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"lisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-969\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS D...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-971\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n25 mg\\\\nInactive Ingredients\\\\nI...\",\"Cipla USA Inc.\\\\nLabeler - \\\\nCipla USA Inc. \\\\n(078719707)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen\\\\nPharmaceuticals, Inc\\\\n165104469\\\\nanalysis(69097-968, 69097-969, 69097-971) , manufacture(69097-968,\\\\n69097-969, 69097-971)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen Pharmaceuticals, Inc\\\\n080334903\\\\npack(69097-968, 69097-969, 69097-971)\\\\n \\\\nRevised: 11/2021\",\"ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and\\\\nphenylephrine hydrochloride tablet, coated \\\\n \\\\nMARC GLASSMAN, INC.\\\\n----------\\\\n1128B-MAR-2022-1005\\\\nDrug Facts\\\\nActive ingredients \\\\n(in each caplet)\\\\nPurpose\\\\nAcetaminophen 325 mg\\\\nPain reliever\\\\nChlorpheniramine maleate\\\\n2 mg\\\\nAntihistamine\\\\nPhenylephrine HCl 5 mg\\\\nNasal decongestant\\\\nUses\\\\ntemporarily relieves these symptoms of hay fever or other upper respiratory\\\\nallergies:\\\\nheadache\\\\nsinus congestion and pressure\\\\nnasal congestion\\\\nrunny nose...\",\"If a skin reaction occurs, stop use and seek medical help right away.\\\\nDo not use\\\\nwith any other drug containing acetaminophen (prescription or nonprescription). If\\\\nyou are not sure whether a drug contains acetaminophen, ask a doctor or\\\\npharmacist.\\\\nif you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain\\\\ndrugs for depression, psychiatric or emotional conditions, or Parkinson&#x27;s disease), or\\\\nfor 2 weeks after stopping the MAOI drug. If you do not know if your prescription\\\\ndr...\",\"800-222-1222). Quick medical attention is critical for adults as well as for children even if\\\\nyou do not notice any signs or symptoms.\\\\nDirections\\\\ndo not take more than directed (see \\\\noverdose warning\\\\n)\\\\nadults and\\\\nchildren 12\\\\nyears and over\\\\ntake 2 caplets every 4 hours\\\\nswallow whole; do not crush,\\\\nchew, or dissolve\\\\ndo not take more than 10 caplets\\\\nin 24 hours\\\\nchildren under \\\\n12 years\\\\nask a doctor\\\\nOther information\\\\nstore between 20\\\\u00b0-25\\\\u00b0C (68\\\\u00b0-77\\\\u00b0F) in a dry place\\\\nretain carton for complete product...\",\"ALLERGY MULTI SYMPTOM  \\\\nacetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:68998-228\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCHLORPHENIRAMINE MALEATE\\\\n (UNII: V1Q0O9OJ9Z) \\\\n(CHLORPHENIRAMINE -\\\\nUNII:3U6IO1965U)\\\\nCHLORPHENIRAMINE\\\\nMALEATE\\\\n2 mg\\\\nPHENYLEPHRINE HYDROCHLORIDE\\\\n (UNII: 04JA59TNSJ) \\\\n(PHENYLEPHRINE -\\\\nUNII:1WS297W6MV)\\\\nPHENYLE...\",\"MARC GLASSMAN, INC.\\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nFERRIC OXIDE YELLOW\\\\n (UNII: EX438O2MRT)\\\\n \\\\nMAGNESIUM STEARATE\\\\n (UNII: 70097M6I30)\\\\n \\\\nCROSPOVIDONE\\\\n (UNII: 2S7830E561)\\\\n \\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\\\n (UNII: 3WJQ0SDW1A)\\\\n \\\\nPOLYVINYL ALCOHOL, UNSPECIFIED\\\\n (UNII: 532B59J990)\\\\n \\\\nPOVIDONE, UNSPECIFIED\\\\n (UNII: FZ989GH94E)\\\\n \\\\nSTARCH, CORN\\\\n (UNII: O8232NY3SJ)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nSTEA...\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and\\\\nhydrochlorothiazide tablet \\\\n \\\\nANI Pharmaceuticals, Inc.\\\\n----------\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\nWARNING: \\\\nFETAL TOXICITY\\\\n\\\\u2022\\\\n\\\\u2022\\\\nDESCRIPTION\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP combine an angiotensin II receptor (type\\\\nAT\\\\n) antagonist and a diuretic, hydrochlorothiazide.\\\\nCandesartan cilexetil, a nonpeptide, is chemically described as (\\\\u00b1)-1-Hydroxyethyl 2-ethoxy-1-[\\\\np\\\\n-(\\\\no\\\\n-\\\\n1\\\\nH\\\\n...\",\"Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of\\\\n297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet\\\\nstrengths of candesartan cilexetil and hydrochlorothiazide.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil\\\\nand 12.5 mg or 25 mg of hydrochloroth...\",\"The mechanism of the antihypertensive effect of thiazides is unknown.\\\\nPharmacokinetics\\\\nGeneral\\\\nCandesartan Cilexetil\\\\nCandesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from\\\\nthe gastrointestinal tract to candesartan, a selective AT\\\\nsubtype angiotensin II receptor antagonist.\\\\nCandesartan is mainly excreted unchanged in urine and feces (via bile). \\\\nIt undergoes minor hepatic\\\\nmetabolism by O-deethylation to an inactive metabolite. \\\\nThe elimination half...\",\"Geriatric\\\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\\\u2265 65 years). \\\\nThe plasma\\\\nconcentration of candesartan was higher in the elderly (C\\\\n was approximately 50% higher, and AUC\\\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\\\nThe\\\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\\\nNo initia...\",\"plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\\\nadministered to hypertensive patients. \\\\nIn spite of the effect of candesartan cilexetil on aldosterone\\\\nsecretion, very little effect on serum potassium was observed.\\\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\\\nIn a\\\\n12-week study of 161 patients with n...\",\"in myocardial infarction and cardiovascular mortality also have been seen regularly.\\\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\\\nhypertension can provide substantial benefit. \\\\nRelative risk reduction from blood pressure reduction is\\\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\\\nare at h...\",\"candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\\\n). \\\\nIn each of\\\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\\\ntimes the MRHD\\\\n in mouse, rats, and rabbit, respectively). \\\\nThere was no evidence of harm to the rat or\\\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\\\nThiazides cross ...\",\"considered if the intraocular pressure remains uncontrolled. \\\\nRisk factors for developing acute angle-\\\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\\\nHypersensitivity Reaction\\\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\\\nPRECAUTIONS\\\\nMetabolic Disturbances\\\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...\",\"Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\\\npossible ac...\",\"Cytotoxic products \\\\u2013 Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.\\\\ncyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.\\\\nCyclosporine \\\\u2212 Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and\\\\ngout-type complications.\\\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\\\nNo carcinogenicity studies have been conducted with the combination of candesartan cilexetil and\\\\nhydrochlorothiazide. \\\\nThere was no evidence of c...\",\"Neonates with a history of in utero exposure to candesartan cilexetil and hydrochlorothiazide tablets:\\\\nIf oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.\\\\nExchange transfusions or dialysis may be required as a means of reversing hypotension and/or\\\\nsubstituting for disordered renal function.\\\\nSafety and effectiveness in pediatric patients have not been established.\\\\nADVERSE REACTIONS\\\\nCandesartan Cilexetil and Hydrochlorothiazide\\\\nCandesartan cile...\",\"melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\\\nfor white patients taking a cumulative dose of \\\\u226550,000 mg the risk increase was approximately 1\\\\nadditional SCC case for every 6,700 patients per year.\\\\nSkin:\\\\n \\\\nerythema multiforme including S...\",\"Dose Titration by Clinical Effect: \\\\nA patient whose blood pressure is not controlled on 25 mg of\\\\nhydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and\\\\nhydrochlorothiazide tablets 16 mg/12.5 mg. \\\\nA patient whose blood pressure is controlled on 25 mg of\\\\nhydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or\\\\nincremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16\\\\nmg/12.5 mg and ser...\",\"PRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/12.5 mg\\\\nNDC 62559-661-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/12.5 mg\\\\nRx only\\\\n90 Tablets\\\\nPRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/25 mg\\\\nNDC 62559-662-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/25 mg\\\\nRx only\\\\n90 Tablets\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:62559-660\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCANDESARTAN CILEXETIL\\\\n (UNII: R85M2X0D68) \\\\n(CANDESARTAN - UNII:S8Q36MD2XX)\\\\nCANDESARTAN\\\\nCILEXETIL\\\\n16 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n1...\",\"Flavor\\\\nImprint Code\\\\nACS\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-660-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type...\",\"Packaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-661-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (So...\",\"ANI Pharmaceuticals, Inc.\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-662-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nLabeler - \\\\nANI Pharmaceuticals, Inc. \\\\n(145588013)\\\\n \\\\nRevised: 5/2020\",\"CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\\\n \\\\nCertus Medical, Inc.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\\\nDrug Facts Box OTC Active Ingredient Section\\\\nPovidone Iodine USP 10%\\\\nequivalent to 1% titratable iodine\\\\nDrug Facts Box OTC Purpose Section\\\\nAntiseptic\\\\nDrug...\",\"Drug Facts Box OTC General Precautions Section\\\\nstore at room temperature 15\\\\n - 30\\\\n C (59\\\\n - 86\\\\n F)\\\\nDrug Facts Box OTC Inactive Ingredient Section\\\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\\\nCertus PVP-1 Prep Swabstick \\\\n210012 pouch\\\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\\\n0\\\\n0\\\\n0\\\\n0\",\"CERTUS PVP-1 PREP SWABSTICK  \\\\npovidone-iodine swab\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:75990-4019\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85H0HZU99M) \\\\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\\\nPOVIDONE-IODINE\\\\n0.1 mL  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\",\"Certus Medical, Inc.\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nSODIUM PHOSPHATE, DIBASIC\\\\n (UNII: GR686LBA74)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nDIMETHICONE\\\\n (UNII: 92RU3N3Y1O)\\\\n \\\\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\\\n (UNII: S38J6RZN16)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:75990-4019-4\\\\n2 mL in 1 POUCH\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOT...\",\"ABALONE CRYSTALDOUBLE EX CC- niacinamide, adenosine, titanium dioxide, ethylhexyl\\\\nmethoxycinnamate cream \\\\n \\\\nC&amp;BCOSMETIC Co.,Ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nDrug Facts\\\\nNiacinamide, Adenosine, Titanium Dioxide, Ethylhexyl Methoxycinnamate\\\\nWater, Glycerin, Butylene Glycol, Etc\\\\nSkin Protectant - Anti-Wrinkle, Whitening, UV Protecting\\\\nk...\",\"ABALONE CRYSTALDOUBLE EX CC  \\\\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:60611-0008\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\",\"C&amp;BCOSMETIC Co.,Ltd.\\\\nNIACINAMIDE\\\\n (UNII: 25X51I8RD4) \\\\n(NIACINAMIDE - UNII:25X51I8RD4)\\\\nNIACINAMIDE\\\\n2 g  in 100 mL\\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP) \\\\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\\\nTITANIUM DIOXIDE\\\\n4.694 g  in 100 mL\\\\nADENOSINE\\\\n (UNII: K72T3FS567) \\\\n(ADENOSINE - UNII:K72T3FS567)\\\\nADENOSINE\\\\n0.04 g  in 100 mL\\\\nOCTINOXATE\\\\n (UNII: 4Y5P7MUD51) \\\\n(OCTINOXATE - UNII:4Y5P7MUD51)\\\\nOCTINOXATE\\\\n7 g  in 100 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C...\",\"TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\\\n \\\\nAdvagen Pharma Limited\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use TIZANIDINE\\\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\\\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\\\n \\\\nInitial U.S. Approval: 1996\\\\nINDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...\",\"Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\\\nfour-fold ( \\\\n8.5\\\\n)\\\\nSee 17 for PATIENT COUNSELING INFORMATION.\\\\nRevised: 9/2020\\\\nFULL PRESCRIBING INFORMATION: CONTENTS\\\\n*\\\\n1 INDICATIONS AND USAGE\\\\n2 DOSAGE AND ADMINISTRATION\\\\n2.1 Dosing Information\\\\n2.2 Dosing in Patients with Renal Impairment\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\n2.4 Drug Discontinuation\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Hypo...\",\"12.1 Mechanism of Action\\\\n12.3 Pharmacokinetics\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n16.1 Tizanidine Hydrochloride Capsules\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\n1 INDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the\\\\nmanagement of spasticity. Because of the short duration of therapeutic effect,\\\\ntreatment with tizanid...\",\"been studied.\\\\n2.2 Dosing in Patients with Renal Impairment\\\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\\\ndoses are required, individual doses rather than dosing frequency should be increased\\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n)] \\\\n.\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\nT...\",\"Tizanidine is an \\\\u03b1 \\\\n-adrenergic agonist that can produce hypotension. Syncope has been\\\\nreported in the post marketing setting. The chance of significant hypotension may\\\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\\\na supine to fixed upright position may be at increased risk for hypotension and\\\\northostatic effects.\\\\nMonitor for hypotension when tizanidine is used in patients...\",\"Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n5.6 Hypersensitivity Reactions\\\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\\\nand symptoms occur. \\\\n[see Contraindications ( \\\\n4\\\\n)]\\\\n5.7 Increased Risk of Adverse Reactions in Patients...\",\"264 patients received tizanidine and 261 patients received placebo. Across the three\\\\nstudies patient ages ranged from 15\\\\u201369 years and 51.4 percent were women. The\\\\nmedian dose during the plateau phase ranged from 20\\\\u201328 mg/day.\\\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\\\nclinical studies involving 264 patients with spasticity were dry mouth,\\\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\\\nThree-quarters of the patients rated t...\",\"multiple sclerosis (Study 1) \\\\n[see Clinical Studies ( \\\\n14\\\\n)] \\\\n, the patients were specifically\\\\nasked if they had experienced any of the four most common adverse reactions: dry\\\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\\\nthese reactions is summarized in \\\\nTable 2\\\\n. Other events were, in general, reported at a\\\\nrate of 2% or less.\\\\nTable 2: Single Dose, Placebo-Controlled Study -...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"12.3\\\\n)]\\\\n7.7 \\\\u03b1 \\\\n-adrenergic agonists\\\\nBecause hypotensive effects may be cumulative, it is not recommended that tizanidine\\\\nbe used with other \\\\u03b1 \\\\n-adrenergic agonists. \\\\n[see Warnings and Precautions ( \\\\n5.1\\\\n)]\\\\n8 USE IN SPECIFIC POPULATIONS\\\\n8.1 Pregnancy\\\\nPregnancy Category C\\\\nTizanidine has not been studied in pregnant women. Tizanidine should be given to\\\\npregnant women only if the benefit outweighs the risk to the unborn fetus.\\\\nReproduction studies performed in rats at a dose of 3 mg/kg, equal to the...\",\"8.6 Impaired Renal Function\\\\nTizanidine is known to be substantially excreted by the kidney, and the risk of adverse\\\\nreactions to this drug may be greater in patients with impaired renal function. In patients\\\\nwith renal insufficiency (creatinine clearance &lt; 25 mL/min) clearance was reduced by\\\\nmore than 50%. In these patients, during titration, the individual doses should be\\\\nreduced. If higher doses are required, individual doses rather than dosing frequency\\\\nshould be increased. These patients sho...\",\"manifestations of tizanidine overdose were consistent with its known pharmacology. In\\\\nthe majority of cases a decrease in sensorium was observed including lethargy,\\\\nsomnolence, confusion and coma. Depressed cardiac function is also observed including\\\\nmost often bradycardia and hypotension. Respiratory depression is another common\\\\nfeature of tizanidine overdose.\\\\nShould overdose occur, basic steps to ensure the adequacy of an airway and the\\\\nmonitoring of cardiovascular and respiratory systems shou...\",\"12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\\\nreduce facilitation of spinal motor neurons.\\\\n12.3 Pharmacokinetics\\\\nAbsorption and Distribution\\\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\\\n...\",\"Metabolism and Excretion\\\\nTizanidine has linear pharmacokinetics over the doses studied in clinical development (1\\\\u2013\\\\n20 mg). Tizanidine has a half-life of approximately 2.5 hours (CV=33%). Approximately\\\\n95% of an administered dose is metabolized. The primary cytochrome P450 isoenzyme\\\\ninvolved in tizanidine metabolism is CYP1A2. Tizanidine metabolites are not known to be\\\\nactive; their half-lives range from 20 to 40 hours.\\\\nFollowing single and multiple oral dosing of \\\\nC-tizanidine, an average of 60%...\",\"this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\\\nused with caution in renally impaired patients \\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n) and\\\\nUse in Specific Populations ( \\\\n8.6\\\\n)] \\\\n.\\\\nGender Effects\\\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\\\npharmacokinetic...\",\"13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nCarcinogenesis\\\\nTizanidine was administered to mice for 78 weeks at oral doses up to 16 mg/kg/day,\\\\nwhich is 2 times the maximum recommended human dose (MRHD) on a mg/m \\\\nbasis.\\\\nTizanidine was administered to rats for 104 weeks at oral doses up to 9 mg/kg/day,\\\\nwhich is 2.5 times the MRHD on a mg/m \\\\nbasis. There was no increase in tumors in\\\\neither species.\\\\nMutagenesis\\\\nTizanidine was negative in \\\\nin vitro\\\\n(bacterial r...\",\"tone in placebo treated patients. Within a given patient, improvement in muscle tone was\\\\ncorrelated with plasma concentration. Plasma concentrations were variable from patient\\\\nto patient at a given dose. Although 16 mg produced a larger effect, adverse events\\\\nincluding hypotension were more common and more severe than in the 8 mg group.\\\\nThere were no differences in the number of spasms occurring in each group.\\\\nFigure 2: Single Dose Study - Mean Change in Muscle Tone from Baseline as\\\\nMeasured by ...\",\"from baseline as measured by the Ashworth scale.\\\\nFigure 3: Seven Week Study - Mean Change in Muscle Tone 0.5-2.5 Hours\\\\nAfter Dosing as Measured by the Ashworth Scale \\\\u00b1 95% Confidence Interval\\\\n(A Negative Ashworth Score Signifies an Improvement in Muscle Tone from\\\\nBaseline)\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n16.1 Tizanidine Hydrochloride Capsules\\\\nTizanidine Hydrochloride Capsules are available in three strengths as two-piece hard\\\\ngelatin capsules containing tizanidine hydrochloride 2.29 mg, 4.5...\",\"17 PATIENT COUNSELING INFORMATION\\\\nSerious Drug Interactions\\\\nAdvise patients they should not take tizanidine if they are taking fluvoxamine or\\\\nciprofloxacin because of the increased risk of serious adverse reactions including severe\\\\nlowering of blood pressure and sedation. Instruct patients to inform their physicians or\\\\npharmacists when they start or stop taking any medication because of the risks\\\\nassociated with interaction between tizanidine and other medicines.\\\\nTizanidine Dosing\\\\nTell patients ...\",\"PRINCIPAL DISPLAY PANEL - 4 mg 150 Capsules Bottle - NDC 72888-002-15\\\\nPRINCIPAL DISPLAY PANEL - 6 mg 150 Capsules Bottle - NDC 72888-003-15\",\"TIZANIDINE HYDROCHLORIDE  \\\\ntizanidine hydrochloride capsule\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:72888-001\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of\\\\nStrength\\\\nStrength\\\\nTIZANIDINE HYDROCHLORIDE\\\\n (UNII: B53E3NMY5C) \\\\n(TIZANIDINE -\\\\nUNII:6AI06C00GW)\\\\nTIZANIDINE\\\\n2 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE 101\\\\n (UNII: 7T9FYH5QMK)\\\\n \\\\nLACTOSE MONOHYDRATE\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\nHYPROMELLOSE...\",\"AMMONIA\\\\n (UNII: 5138Q19F1X)\\\\n \\\\nFERROSOFERRIC OXIDE\\\\n (UNII: XM0M87F357)\\\\n \\\\nPOTASSIUM HYDROXIDE\\\\n (UNII: WZH3C48M4T)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nblue (Cap: Blue opaque) , blue (Body: Light Blue opaque)\\\\nScore\\\\nno score\\\\nShape\\\\nCAPSULE\\\\nSize\\\\n11mm\\\\nFlavor\\\\nImprint Code\\\\nUpArrowhead;043\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:72888-001-\\\\n15\\\\n150 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n05/27/2020\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nAppl...\",\"GELATIN, UNSPECIFIED\\\\n (UNII: 2G86QN327L)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nFD&amp;C BLUE NO. 1\\\\n (UNII: H3R47K3TBD)\\\\n \\\\nFD&amp;C RED NO. 40\\\\n (UNII: WZB9127XOA)\\\\n \\\\nSHELLAC\\\\n (UNII: 46N107B71O)\\\\n \\\\nISOPROPYL ALCOHOL\\\\n (UNII: ND2M416302)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nALCOHOL\\\\n (UNII: 3K9958V90M)\\\\n \\\\nBUTYL ALCOHOL\\\\n (UNII: 8PJ61P6TS3)\\\\n \\\\nAMMONIA\\\\n (UNII: 5138Q19F1X)\\\\n \\\\nFERROSOFERRIC OXIDE\\\\n (UNII: XM0M87F357)\\\\n \\\\nPOTASSIUM HYDROXIDE\\\\n (UNII: WZH3C48M4T)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nblue (Cap: Blue opaque)...\",\"Inactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE 101\\\\n (UNII: 7T9FYH5QMK)\\\\n \\\\nLACTOSE MONOHYDRATE\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\nHYPROMELLOSE, UNSPECIFIED\\\\n (UNII: 3NXW29V3WO)\\\\n \\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nSTEARIC ACID\\\\n (UNII: 4ELV7Z65AP)\\\\n \\\\nGELATIN, UNSPECIFIED\\\\n (UNII: 2G86QN327L)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nFD&amp;C BLUE NO. 1\\\\n (UNII: H3R47K3TBD)\\\\n \\\\nFD&amp;C RED NO. 40\\\\n (UNII: WZB9127XOA)\\\\n \\\\nSHELLAC\\\\n (UNII: 46N107B71O)\\\\n \\\\nISOPRO...\",\"Advagen Pharma Limited\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nRubicon Research\\\\nPrivate Limited\\\\n677604197\\\\nanalysis(72888-001, 72888-002, 72888-003) , manufacture(72888-001,\\\\n72888-002, 72888-003) , pack(72888-001, 72888-002, 72888-003)\\\\n \\\\nRevised: 7/2024\",\"ATHLETES FOOT- butenafine hydrochloride cream \\\\n \\\\nRite Aid Corporation\\\\n----------\\\\nAthlete&#x27;s Foot Cream\\\\nDrug Facts\\\\nActive ingredient\\\\nButenafine hydrochloride 1%\\\\nPurpose\\\\nAntifungal\\\\nUses\\\\ncures most athlete&#x27;s foot between the toes. Effectiveness on the bottom or sides of\\\\nfoot is unknown.\\\\ncures most jock itch and ringworm\\\\nrelieves itching, burning, cracking, and scaling which accompany these conditions\\\\nWarnings\\\\nFor external use only\\\\nDo not use\\\\non nails or scalp\\\\nin or near the mouth or the eyes\\\\nfor vag...\",\"1 week twice a day or 4 weeks once a day\\\\nfor jock itch and ringworm:\\\\napply once a day to affected skin for 2 weeks or as\\\\ndirected by a doctor.\\\\nwash hands after each use\\\\nchildren under 12 years: ask a doctor\\\\nOther information\\\\ndo not use if seal on tube is broken or not visible\\\\nstore between 20\\\\u00ba to 25\\\\u00ba C (68\\\\u00ba to 77\\\\u00ba F)\\\\nInactive ingredients\\\\nbenzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23)\\\\ncetyl ether, propylene glycol dicaprylate, purified water, sodium benzoa...\",\"RITE \\\\nAID \\\\n \\\\nPHARMACY\\\\nclinically proven to cure \\\\nmost athlete&#x27;s foot between the toes\\\\nfoot care \\\\nbutenafine\\\\nhydrochloride cream 1%\\\\nantifungal\\\\nNET WT 0.42 OZ (12 g)\\\\n\\\\u00ae\",\"ATHLETES FOOT  \\\\nbutenafine hydrochloride cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:11822-2100\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nBUTENAFINE HYDROCHLORIDE\\\\n (UNII: R8XA2029ZI) \\\\n(BUTENAFINE -\\\\nUNII:91Y494NL0X)\\\\nBUTENAFINE\\\\nHYDROCHLORIDE\\\\n10 mg\\\\n in 1 g\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nBENZYL ALCOHOL\\\\n (UNII: LKG8494WBH)\\\\n \\\\nCETYL ALCOHOL\\\\n (UNII: 936JST6JCN)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n...\",\"Rite Aid Corporation\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nANDA\\\\nANDA205181\\\\n11/17/2017\\\\nLabeler - \\\\nRite Aid Corporation \\\\n(014578892)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nTaro Pharmaceuticals Inc.\\\\n206263295\\\\nmanufacture(11822-2100)\\\\n \\\\nRevised: 7/2024\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#ffbb78\",\"#ffbb78\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#999\",\"#999\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#aec7e8\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#ffbb78\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#ffbb78\",\"#999\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#999\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\"],\"shape\":[117],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1531\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1532\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1527\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1528\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1529\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1498\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1513\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1514\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1515\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1516\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1517\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1522\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1523\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1508\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1509\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1510\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1511\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1503\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1504\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1505\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1506\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1507\",\"attributes\":{\"axis\":{\"id\":\"p1503\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1512\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1508\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1533\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1534\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"ACE Inhibitors\"},\"renderers\":[{\"id\":\"p1530\"}],\"index\":31}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1535\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Candesartan Cilexetil\"},\"renderers\":[{\"id\":\"p1530\"}],\"index\":62}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1536\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Medication Information\"},\"renderers\":[{\"id\":\"p1530\"}],\"index\":2}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1537\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p1530\"}],\"index\":25}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1538\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Pharmaceutical Products\"},\"renderers\":[{\"id\":\"p1530\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1539\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Tizanidine Overdose\"},\"renderers\":[{\"id\":\"p1530\"}],\"index\":87}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1609\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1545\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1554\",\"attributes\":{\"start\":2.6081478595733643,\"end\":17.234113693237305}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1555\",\"attributes\":{\"start\":13.671540260314941,\"end\":21.66947841644287}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1556\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1557\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1552\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1584\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1541\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1542\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1543\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"2D/VQDIDEUG5uDZBUwLvQM/ef0D+0w5Bd7uRQHzWp0Bv3zZBLaQtQSIikUBnbaVA8/oVQd8AFUENH1NAoNsJQVC6xUCdjBpBYsAuQR1C+UAYsp5A3bhaQGgizkADdxBBDS0JQQ==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"4xd9Qd5zoEFiB5BB0aWFQYmLjkGnmY1Bs1qPQWHzkUFE9olBSpKOQViHlUGV/3hB/leeQQb/mEGAZ4xBMwiGQXdQjEHrP51BlNCRQQA+g0GbuHJBlemOQXHniUGZN5dBC0aiQQ==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Others\",\"NUCYNTA\\\\u2122 Medication\",\"Tizanidine Hydrochloride\",\"Povidone Iodine Solution\",\"ACE Inhibitor Side Effects\",\"Others\",\"ACE Inhibitor Side Effects\",\"ACE Inhibitor Side Effects\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"ACE Inhibitor Side Effects\",\"Candesartan Cilexetil\",\"NUCYNTA\\\\u2122 Medication\",\"NUCYNTA\\\\u2122 Medication\",\"ACE Inhibitor Side Effects\",\"Povidone Iodine Solution\",\"ACE Inhibitor Side Effects\",\"NUCYNTA\\\\u2122 Medication\",\"Tizanidine Hydrochloride\",\"Pharmaceuticals\",\"Candesartan Cilexetil\",\"ACE Inhibitor Side Effects\",\"Others\",\"NUCYNTA\\\\u2122 Medication\",\"NUCYNTA\\\\u2122 Medication\"]],[\"correctness\",[false,false,true,true,false,false,false,true,false,false,true,false,false,false,false,false,false,true,false,false,false,false,false,false,false]],[\"questions\",[\"What specific advantages does hydrochlorothiazide offer in the tablets containing candesartan cilexetil, and what are the strengths of hydrochlorothiazide in each of the different tablet formulations?\",\"What is the abuse potential of NUCYNTA\\\\u2122, how is it classified, and what precautions should be taken for patients with hepatic impairment?\",\"How does the consumption of alcohol impact the pharmacokinetics of tizanidine, specifically in terms of its area under the curve (AUC) and maximum concentration (Cmax)?\",\"What are the specific active ingredients present in the GRX DYNE povidone iodine solution and what is the concentration of the active ingredient in the solution?\",\"What are the most frequently reported clinical adverse experiences in trials involving lisinopril and hydrochlorothiazide tablets, and what precautions should be taken into account when considering the drug&#x27;s use in nursing mothers?\",\"What are the different strengths available for tapentadol hydrochloride medication and what are the corresponding colors of the tablets?\",\"What is the specific mechanism by which hydrochlorothiazide exerts its antihypertensive effect, and how does it impact the electrolyte reabsorption mechanism in the distal renal tubule?\",\"What are the available strengths of lisinopril and hydrochlorothiazide tablets, and how are they supplied?\",\"Can you explain the difference in bioavailability between Tizanidine Capsules and Tizanidine Tablets, particularly when administered with food, and how does it impact the peak plasma concentration and time to peak plasma concentration?\",\"What specific parameter should be monitored in patients taking tizanidine to mitigate the risk of hepatocellular liver injury, especially in those with hepatic impairment?\",\"In the case of hypotension resulting from an overdose of Lisinopril, what is the recommended treatment involving the administration of what type of solution?\",\"How does candesartan impact the pressor effects of angiotensin II infusion, and to what extent is this effect inhibited by the medication?\",\"What specific type of surgery was conducted to assess the effectiveness of NUCYNTA\\\\u2122 in the clinical trial mentioned in the document?\",\"Can you provide a list of psychiatric disorders that are mentioned as potential adverse reactions to NUCYNTA\\\\u2122, according to the provided document?\",\"What clinical signs should patients undergoing thiazide therapy be monitored for in terms of fluid and electrolyte imbalance, and what are some specific warning signs or symptoms that may indicate such an imbalance?\",\"What is the specific active component found in the foot care cream designed to treat athlete&#x27;s foot located between the toes?\",\"What is the strength of Lisinopril and Hydrochlorothiazide tablets with NDC 69097-969-07?\",\"What is the average duration of the terminal half-life of tapentadol following oral administration, and how does it compare in subjects with varying degrees of renal function?\",\"What are the specific contraindications for the simultaneous use of tizanidine with fluvoxamine and ciprofloxacin, and what potential effects on blood pressure, drowsiness, and psychomotor impairment should be considered?\",\"When did the marketing of the product with NDC:75990-4019-4 officially begin according to the provided document?\",\"What are the potential manifestations of overdosage with candesartan cilexetil, and what supportive treatment should be initiated if symptomatic hypotension occurs?\",\"What are the potential adverse effects on the fetus associated with the use of drugs that act on the renin-angiotensin system during pregnancy, specifically in terms of fetal renal function, morbidity, and mortality?\",\"What are the specific strengths of lisinopril and hydrochlorothiazide in the tablets with NDC:69097-969, and what are the color and shape of these tablets?\",\"How should the dosing regimen for NUCYNTA (tapentadol) be adjusted to maintain adequate pain relief with acceptable tolerability?\",\"What are some of the nervous system disorders observed as adverse reactions during the premarketing evaluation of NUCYNTA\\\\u2122, including symptoms such as disturbance in attention, sedation, dysarthria, and ataxia?\"]],[\"agent_answer\",[\"Great question about the combination tablets containing **candesartan cilexetil and hydrochlorothiazide (HCTZ)**! This combination is commonly used for **hypertension (high blood pressure)**, leveraging the complementary mechanisms of both drugs. Let me break it down clearly:\\\\n\\\\n### **1. Advantages of Hydrochlorothiazide in this Combination:**\\\\n- **Synergistic Blood Pressure Control**: Candesartan (an **ARB**) reduces blood pressure by blocking angiotensin II receptors, while **HCTZ (a thiazide diuretic)** enhances fluid and sodium excretion via the kidneys. Together, they provide **dual-action** lowering of blood pressure more effectively than either drug alone.  \\\\n- **Volume Reduction**: HCTZ counterbalances potential fluid retention (a rare side effect of ARBs) by promoting **diuresis**, ensuring better BP control.  \\\\n- **Lower Dosing Needs**: The combination allows for **lower doses** of each drug compared to monotherapy, reducing the risk of side effects.  \\\\n\\\\n### **2. Strengths of Hydrochlorothiazide in Different Tablet Formulations:**\\\\nThe combined tablets typically come in the following strengths (candesartan cilexetil / HCTZ):\\\\n\\\\n- **16 mg / 12.5 mg**  \\\\n  - **HCTZ Strength**: 12.5 mg (moderate diuretic effect, suitable for mild hypertension).  \\\\n- **32 mg / 12.5 mg**  \\\\n  - **HCTZ Strength**: 12.5 mg (same diuretic effect but paired with a higher ARB dose for enhanced BP lowering).  \\\\n- **32 mg / 25 mg**  \\\\n  - **HCTZ Strength**: 25 mg (stronger diuretic effect for patients needing more fluid removal).  \\\\n\\\\n### **Key Point on Hydrochlorothiazide Strengths:**\\\\n- **12.5 mg HCTZ** \\\\u2192 Balanced diuresis, ideal for patients who need mild to moderate fluid loss.  \\\\n- **25 mg HCTZ** \\\\u2192 Stronger effect, useful in those requiring **greater sodium/fluid excretion** or with resistant hypertension.  \\\\n\\\\nWould you like additional details on dosing adjustments or patient-specific considerations? Happy to help further!\",\"**NUCYNTA\\\\u2122 (tapentadol) Abuse Potential, Classification, and Hepatic Impairment Precautions:**  \\\\n\\\\n### **1. Abuse Potential**  \\\\nNUCYNTA\\\\u2122 (tapentadol) is an opioid analgesic with **significant abuse potential**, similar to other opioids like oxycodone or morphine. Its mechanism involves **\\\\u03bc-opioid receptor agonism** (though weaker than traditional opioids) and **noradrenaline reuptake inhibition**, which contributes to its pain-relieving effects but also poses addiction risks.  \\\\n\\\\n- **Misuse can lead to:**  \\\\n  - Psychological dependence  \\\\n  - Physical dependence (withdrawal symptoms upon discontinuation)  \\\\n  - Overdose (respiratory depression, sedation, death)  \\\\n- **Common routes of abuse:** Oral (crushed tablets), nasal insufflation, or intravenous injection.  \\\\n\\\\n### **2. Controlled Substance Classification (U.S.)**  \\\\n- NUCYNTA\\\\u2122 is classified as a **Schedule II controlled substance** under the U.S. Controlled Substances Act (CSA).  \\\\n- This reflects its **high abuse potential** but also recognized medical use.  \\\\n\\\\n### **3. Precautions for Hepatic Impairment**  \\\\nSince tapentadol is extensively metabolized by the liver (~95% via glucuronidation), hepatic impairment affects its pharmacokinetics:  \\\\n\\\\n- **Mild hepatic impairment (Child-Pugh A):**  \\\\n  - Initiate at **50 mg** (instead of 50\\\\u2013100 mg for adults).  \\\\n  - Maximum dosing interval: **\\\\u2264 50 mg every 6 hours** (max 200 mg/day).  \\\\n- **Moderate hepatic impairment (Child-Pugh B):**  \\\\n  - **Avoid or use extreme caution**\\\\u2014dose reduction likely needed (no strict guidelines, but start at **lower than 50 mg**).  \\\\n- **Severe hepatic impairment (Child-Pugh C):**  \\\\n  - **Contraindicated** due to high risk of **toxicity accumulation**.  \\\\n\\\\n#### **Additional Monitoring Recommendations:**  \\\\n- Look for signs of **opioid toxicity** (sedation, respiratory depression).  \\\\n- Avoid **concomitant CYP enzyme inhibitors/inducers** that may alter metabolism.  \\\\n\\\\n### **Conclusion**  \\\\nNUCYNTA\\\\u2122 should be prescribed cautiously, with strict adherence to dosing adjustments in liver dysfunction and monitoring for abuse behaviors. Alternative analgesics may be considered in severe hepatic impairment.  \\\\n\\\\nWould you like additional details on its pharmacokinetics or withdrawal management?\",\"Great question! The consumption of alcohol can significantly impact the pharmacokinetics of tizanidine, particularly its **AUC (area under the curve)** and **Cmax (maximum concentration)**. Here\\\\u2019s what we know:  \\\\n\\\\n### **1. Alcohol and Tizanidine Pharmacokinetics**  \\\\n- Alcohol is a **CYP1A2 inhibitor**, the same enzyme primarily responsible for metabolizing tizanidine.  \\\\n- When alcohol and tizanidine are co-administered, tizanidine&#x27;s metabolism is slowed, leading to:  \\\\n  - **\\\\u2191 AUC**: A higher total systemic exposure (AUC increases by ~20\\\\u201330%).  \\\\n  - **\\\\u2191 Cmax**: A higher peak plasma concentration (Cmax increases by ~15\\\\u201325%).  \\\\n\\\\n### **2. Mechanism**  \\\\n- Alcohol temporarily **inhibits CYP1A2**, decreasing tizanidine\\\\u2019s metabolism and prolonging its half-life.  \\\\n- This results in **increased plasma concentrations** of tizanidine, enhancing its sedative and hypotensive effects.  \\\\n\\\\n### **3. Clinical Implications**  \\\\n- Combining alcohol with tizanidine **intensifies side effects**, including:  \\\\n  - Severe drowsiness  \\\\n  - Dizziness  \\\\n  - Hypotension (low blood pressure)  \\\\n  - Risk of respiratory depression (in extreme cases)  \\\\n\\\\n### **Official Recommendations**  \\\\n- **FDA and medical guidelines strongly advise against alcohol consumption** while using tizanidine due to the risk of **toxicity** and amplified CNS depression.  \\\\n\\\\n### **Conclusion**  \\\\n- Alcohol significantly **\\\\u2191 AUC &amp; Cmax** of tizanidine by inhibiting CYP1A2.  \\\\n- This interaction increases both **therapeutic effects and risks**, making alcohol contraindicated with tizanidine.  \\\\n\\\\nNeed any more details? Happy to expand!  \\\\ud83d\\\\ude80\",\"Certainly! Here\\\\u2019s a detailed breakdown of the active ingredient in **GRX DYNE Povidone Iodine Solution** and its concentration:\\\\n\\\\n### **Active Ingredient**:  \\\\nThe primary active ingredient in GRX DYNE Povidone Iodine Solution is **Povidone-Iodine (PVP-I)**, a complex of **iodine** with **polyvinylpyrrolidone (povidone)**.  \\\\n\\\\n### **Concentration of Active Ingredient**:  \\\\nThe standard concentration of **available iodine** (the effective antimicrobial component) in povidone-iodine solutions is typically **10% w/v (weight/volume)**.  \\\\n\\\\n- This means **10 grams of povidone-iodine complex per 100 mL of solution**.  \\\\n- Of this, the **available (free) iodine** concentration is about **1% (10,000 ppm)**.  \\\\n\\\\n### **Additional Notes**:  \\\\n- **Mechanism**: Povidone-iodine acts as a broad-spectrum antiseptic, effective against bacteria, viruses, fungi, and protozoa by releasing free iodine.  \\\\n- **Common Uses**: Surgical scrubs, wound disinfection, and pre-operative skin preparation.  \\\\n\\\\nIf you&#x27;re looking for the *exact* concentration in GRX DYNE\\\\u2019s formulation (which may have slight variations), I recommend checking the **product label** or the manufacturer\\\\u2019s technical datasheet for precise details.  \\\\n\\\\nWould you like any further details on its applications or safety precautions?\",\"Great question! Let me break this down into two key parts for clarity.\\\\n\\\\n### **Most Frequently Reported Clinical Adverse Experiences with Lisinopril/Hydrochlorothiazide (HCTZ) Tablets**  \\\\nBased on clinical trials and post-marketing data, the most common adverse effects include:  \\\\n\\\\n1. **Respiratory**:  \\\\n   - Cough (ACE inhibitor-associated, more common with lisinopril)  \\\\n   - Upper respiratory infections  \\\\n\\\\n2. **Cardiovascular**:  \\\\n   - Dizziness (due to hypotension, especially in volume-depleted patients)  \\\\n   - Orthostatic hypotension  \\\\n\\\\n3. **Metabolic/Electrolyte Disturbances** (mainly due to HCTZ):  \\\\n   - Hypokalemia (low potassium)  \\\\n   - Hyponatremia (low sodium)  \\\\n   - Hyperuricemia (can exacerbate gout)  \\\\n   - Hyperglycemia (may worsen diabetes)  \\\\n\\\\n4. **Gastrointestinal**:  \\\\n   - Nausea/diarrhea (more common early in therapy)  \\\\n\\\\n5. **Dermatological**:  \\\\n   - Rash (sometimes photosensitivity due to HCTZ)  \\\\n\\\\n6. **Renal**:  \\\\n   - Increased serum creatinine (risk higher in renal impairment)  \\\\n\\\\n*Severe but less common*: Angioedema (ACE inhibitor-related), acute kidney injury, electrolyte imbalances (\\\\u2191Ca\\\\u00b2\\\\u207a, \\\\u2193Mg\\\\u00b2\\\\u207a), and severe hypotension.  \\\\n\\\\n---\\\\n\\\\n### **Precautions in Nursing Mothers**  \\\\n- **Lisinopril (ACE inhibitor)**:  \\\\n  - **Excreted in breast milk?** Yes, though in small amounts.  \\\\n  - **Potential risk**: Hypotension, hyperkalemia, or renal effects in the infant.  \\\\n  - **Precaution**: Avoid breastfeeding if possible; consider alternative antihypertensives (e.g., labetalol or nifedipine, which have better safety profiles). If used, monitor infant for lethargy, poor feeding, or hypotension.  \\\\n\\\\n- **Hydrochlorothiazide (HCTZ)**:  \\\\n  - **Excreted in breast milk?** Yes, though low concentrations.  \\\\n  - **Potential risk**: Suppressed lactation (thiazides reduce milk volume), possible electrolyte imbalances (hypokalemia), or thrombocytopenia in the infant.  \\\\n  - **Precaution**: Generally **contraindicated** during breastfeeding due to these risks. Switch to a safer diuretic (e.g., chlorthalidone may be considered in some cases) or a non-diuretic alternative.  \\\\n\\\\n---\\\\n\\\\n### **Key Recommendation**:  \\\\nThe *American Academy of Pediatrics* (AAP) discourages ACE inhibitors and thiazides in nursing mothers when safer alternatives exist. A **shared decision-making approach** with the healthcare provider is critical to weigh benefits vs. infant risks.  \\\\n\\\\nWould you like references to specific studies or guidelines? I can provide those as well!\",\"Here\\\\u2019s a detailed breakdown of the available strengths and corresponding colors of **tapentadol hydrochloride** tablets, which are commonly prescribed for moderate to severe pain:  \\\\n\\\\n### **Immediate-Release Tablets (e.g., Nucynta\\\\u00ae):**  \\\\n- **50 mg**: Light orange, round, film-coated, imprinted with \\\\u201cO-M\\\\u201d on one side and \\\\u201c50\\\\u201d on the other.  \\\\n- **75 mg**: Light yellow, round, film-coated, imprinted with \\\\u201cO-M\\\\u201d on one side and \\\\u201c75\\\\u201d on the other.  \\\\n- **100 mg**: Light blue, round, film-coated, imprinted with \\\\u201cO-M\\\\u201d on one side and \\\\u201c100\\\\u201d on the other.  \\\\n\\\\n### **Extended-Release Tablets (e.g., Nucynta ER\\\\u00ae):**  \\\\n- **50 mg**: Light orange, oval-shaped, film-coated, imprinted with \\\\u201cOMJ 50\\\\u201d on one side.  \\\\n- **100 mg**: Light blue, oval-shaped, film-coated, imprinted with \\\\u201cOMJ 100\\\\u201d on one side.  \\\\n- **150 mg**: Light green, oval-shaped, film-coated, imprinted with \\\\u201cOMJ 150\\\\u201d on one side.  \\\\n- **200 mg**: Light blue-green, oval-shaped, film-coated, imprinted with \\\\u201cOMJ 200\\\\u201d on one side.  \\\\n- **250 mg**: Light purple, oval-shaped, film-coated, imprinted with \\\\u201cOMJ 250\\\\u201d on one side.  \\\\n\\\\n### **Key Notes:**  \\\\n- **Colors and imprints** may vary slightly depending on the manufacturer (brand vs. generic).  \\\\n- These formulations are **controlled substances** (Schedule II in the U.S.) due to their opioid component.  \\\\n- Always **verify with the pharmacist** if you have doubts about the medication\\\\u2019s appearance to ensure correct dosing.  \\\\n\\\\nWould you like additional details on usage, precautions, or side effects? I\\\\u2019d be happy to assist!\",\"Great question! Let me break down the mechanism of hydrochlorothiazide (HCTZ) in detail:\\\\n\\\\n**Antihypertensive Effect Mechanism:**\\\\n1. **Primary Action:** HCTZ is a thiazide diuretic that works by inhibiting the **Na+-Cl- symporter (NCC)** in the **early distal convoluted tubule (DCT)** of the nephron.  \\\\n2. **Electrolyte Reabsorption Impact:**  \\\\n   - By blocking NCC, it reduces the reabsorption of **sodium (Na+)** and **chloride (Cl-)** ions, leading to increased excretion of these electrolytes in urine.  \\\\n   - This creates an osmotic gradient, pulling water into the tubule (diuresis), reducing blood volume \\\\u2192 lowering blood pressure.  \\\\n3. **Secondary Effects:**  \\\\n   - The reduced Na+ reabsorption in the DCT causes **compensatory increased Na+ reabsorption** in the collecting duct via **ENaC (epithelial sodium channels)**.  \\\\n   - However, this also leads to **potassium (K+) secretion** via ROMK channels, causing **hypokalemia** (a common side effect).  \\\\n\\\\n**Electrolyte-Specific Effects:**  \\\\n- **Calcium (Ca2+):** HCTZ paradoxically **enhances Ca2+ reabsorption** by increasing basolateral Na+/Ca2+ exchange due to decreased intracellular Na+ in the DCT. This can lead to *mild hypercalcemia*.  \\\\n- **Magnesium (Mg2+):** Thiazides reduce Mg2+ reabsorption (via TRPM6 channels), sometimes causing *hypomagnesemia*.  \\\\n- **Uric Acid:** Reduced tubular secretion of uric acid may cause *hyperuricemia* (gout risk).  \\\\n\\\\n**Long-Term Antihypertensive Effect:**  \\\\nBeyond diuresis, HCTZ reduces peripheral vascular resistance (PVR) by unclear mechanisms\\\\u2014possibly involving **vasodilatory prostaglandins** or **calcium channel modulation** in smooth muscle.  \\\\n\\\\n**Key Takeaways:**  \\\\n- **Target:** NCC in early DCT \\\\u2192 Na+/Cl- excretion.  \\\\n- **Major Side Effects:** Hypokalemia, hypercalcemia, hypomagnesemia.  \\\\n- **Net Result:** Reduced blood volume &amp; PVR \\\\u2192 sustained BP lowering.  \\\\n\\\\nLet me know if you\\\\u2019d like deeper details on any part!\",\"Lisinopril and hydrochlorothiazide tablets are available in several fixed-dose combination strengths, commonly prescribed for hypertension (high blood pressure). Here\\\\u2019s a breakdown of the available strengths and how they are typically supplied:  \\\\n\\\\n### **Available Strengths:**  \\\\nThese combinations are expressed as **lisinopril (mg) / hydrochlorothiazide (mg)**:  \\\\n1. **10/12.5 mg**  \\\\n2. **20/12.5 mg**  \\\\n3. **20/25 mg**  \\\\n\\\\n### **How They Are Supplied:**  \\\\n- **Tablets:** The most common form, usually oval or round, with distinct markings (e.g., imprints for identification).  \\\\n- **Packaging:** Typically supplied in bottles (e.g., 30, 90, or 100 tablets) or blister packs (unit doses for compliance aids).  \\\\n- **Colors &amp; Markings:** Vary by manufacturer but often follow standard identifiers (e.g., \\\\\"10/12.5\\\\\" might be a white tablet with \\\\\"AC295\\\\\" imprinted).  \\\\n\\\\n### **Notes:**  \\\\n- Always confirm the exact dose with the prescribing physician, as strengths differ for individual patient needs.  \\\\n- Some brands or generics may have slight variations in appearance, but the active ingredients remain consistent.  \\\\n\\\\nWould you like details on specific manufacturers or alternatives? I\\\\u2019d be happy to refine the answer further!\",\"Certainly! Let&#x27;s break down the differences in bioavailability between **Tizanidine capsules** and **Tizanidine tablets**, especially when administered with food, and how these differences impact **peak plasma concentration (C_max)** and **time to peak plasma concentration (T_max)**.\\\\n\\\\n### **1. Bioavailability Differences Between Capsules &amp; Tablets**\\\\n- **Tizanidine Capsules**: Typically have **higher bioavailability** (~20\\\\u201340%) compared to tablets due to differences in formulation (e.g., lipid-based or optimized dissolution properties).\\\\n- **Tizanidine Tablets**: Exhibit **lower bioavailability** (~20\\\\u201330%) as they rely on conventional disintegration and absorption mechanisms.\\\\n\\\\n### **2. Effect of Food on Bioavailability**\\\\n- **Tizanidine Capsules with Food**:  \\\\n  - **Increased absorption**: Fatty meals enhance bioavailability by **30\\\\u201350%**, increasing **C_max** (higher peak concentration).  \\\\n  - **Delayed T_max**: Food slows gastric emptying, delaying peak concentration (e.g., **T_max ~2\\\\u20133 hours** vs. fasting **~1\\\\u20131.5 hours**).  \\\\n  - **Reduced inter-individual variability**: More predictable absorption compared to fasting state.\\\\n  \\\\n- **Tizanidine Tablets with Food**:  \\\\n  - **Less pronounced impact**: Unlike capsules, food does not significantly enhance absorption in tablets (bioavailability increase ~10\\\\u201320%).  \\\\n  - **T_max delay similar to capsules** (but with lower **C_max** due to lower intrinsic absorption efficiency).\\\\n\\\\n### **3. Comparative Summary**\\\\n| Parameter               | Tizanidine Capsules | Tizanidine Tablets |\\\\n|-------------------------|---------------------|---------------------|\\\\n| **Fast-state C_max**    | Moderate (lower than fed) | Moderate (slightly lower than capsules) |\\\\n| **Fed-state C_max**     | **Significantly higher (~30\\\\u201350%)** | **Minimal increase (~10\\\\u201320%)** |\\\\n| **T_max (fasted)**      | **1\\\\u20131.5 hours**      | **1\\\\u20132 hours**       |\\\\n| **T_max (with food)**   | **2\\\\u20133 hours**        | **2\\\\u20133 hours**       |\\\\n| **Bioavailability (fasted)** | ~20\\\\u201340% | ~20\\\\u201330% |\\\\n| **Bioavailability (fed)** | **30\\\\u201350%** | **20\\\\u201335%** |\\\\n\\\\n### **4. Clinical Implications**\\\\n- **Capsules + Food = Stronger Effect**: Due to higher **C_max**, may require dose adjustments to avoid excessive sedation/hypotension.  \\\\n- **Tablets + Food = More Stable**: Predictable absorption, but less affected by food; may be preferable for controlled dosing.  \\\\n- **Morning vs. Night Dosing**: If taking with meals, **C_max delay (3h)** may influence sedation timing (e.g., bedtime vs. daytime dosing).  \\\\n\\\\n### **Conclusion**\\\\n**Capsules** show **greater food-enhanced bioavailability**, leading to higher **C_max** and a delayed **T_max**, while **tablets** are less affected. Clinicians should consider:\\\\n- **Pill formulation**  \\\\n- **Dosing with/without food**  \\\\n- **Timing of side effects (C_max-related sedation)**  \\\\n\\\\nWould you like a deeper dive into pharmacokinetic mechanisms or dosing recommendations?\",\"Great question! For patients taking **tizanidine (a muscle relaxant)**, especially those with **pre-existing hepatic impairment**, the key parameter that should be closely monitored is:  \\\\n\\\\n### **Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels**  \\\\n\\\\n#### **Why These Parameters?**  \\\\n- Tizanidine is **primarily metabolized in the liver** via CYP1A2.  \\\\n- Elevated **ALT/AST** levels can indicate **hepatocellular injury** (a known but rare side effect of tizanidine).  \\\\n- **Liver function tests (LFTs)**, including ALT, AST, **bilirubin, and alkaline phosphatase (ALP)**, should be done:  \\\\n  - **Before initiating therapy** (baseline).  \\\\n  - **Periodically thereafter** (e.g., within the first 6 months, then as clinically indicated).  \\\\n\\\\n#### **Additional Monitoring for High-Risk Patients**  \\\\nFor patients with **known hepatic impairment**:  \\\\n- **Reduced dosages** are usually necessary (due to slowed metabolism).  \\\\n- **More frequent LFT monitoring** is recommended (e.g., monthly or as per physician discretion).  \\\\n- Symptoms of liver injury (jaundice, dark urine, fatigue, abdominal pain) should prompt **immediate discontinuation** and liver function reassessment.  \\\\n\\\\n#### **FDA &amp; Clinical Guidelines**  \\\\n- The **FDA label for tizanidine** highlights the risk of **liver enzyme elevations** (ALT &gt;3x upper limit of normal in ~5% of patients in trials).  \\\\n- **Discontinue if ALT/AST &gt;3x ULN** (upper limit of normal) to prevent progression to severe liver injury.  \\\\n\\\\nWould you like any further details on dosing adjustments or alternative monitoring strategies?\",\"In the case of **hypotension resulting from an overdose of Lisinopril** (an ACE inhibitor), the recommended treatment involves **intravenous (IV) administration of normal saline (0.9% sodium chloride solution)**. This is the first-line therapy to restore intravascular volume and counteract the hypotension caused by vasodilation and reduced systemic vascular resistance due to excessive ACE inhibition.  \\\\n\\\\nAdditional supportive measures may include:  \\\\n- **Trendelenburg positioning** (raising the patient\\\\u2019s legs to improve venous return).  \\\\n- **Vasopressors** (e.g., norepinephrine) if hypotension persists despite fluid resuscitation.  \\\\n- **Atropine** for severe bradycardia (if present).  \\\\n- **Hemodialysis** in extreme cases (since Lisinopril is partially dialyzable).  \\\\n\\\\n**Key rationale for normal saline:**  \\\\nLisinopril-induced hypotension is primarily due to decreased angiotensin II production, leading to venous/arterial dilation and reduced blood pressure. Normal saline helps restore plasma volume, improving cardiac preload and perfusion.  \\\\n\\\\nWould you like further details on dosing or clinical monitoring in this scenario?\",\"Great question! Let me break this down for you clearly and completely:\\\\n\\\\n**How Candesartan Impacts Angiotensin II Pressor Effects:**\\\\nCandesartan is an ARB (angiotensin II receptor blocker) that selectively blocks the AT\\\\u2081 receptor subtype. When angiotensin II is infused, its pressor (blood pressure-raising) effects occur primarily through AT\\\\u2081 receptor activation in vascular smooth muscle. Candesartan competitively inhibits this binding.\\\\n\\\\n**Degree of Inhibition:**\\\\nClinical studies show:\\\\n1. At standard doses (8-32 mg daily), candesartan inhibits ~70-85% of angiotensin II&#x27;s pressor response.\\\\n2. The inhibition is dose-dependent - higher doses achieve greater receptor blockade.\\\\n3. Maximal inhibition typically occurs within 3-4 hours post-dose and lasts 24+ hours (due to candesartan&#x27;s tight receptor binding and long half-life).\\\\n4. Unlike ACE inhibitors, ARBs like candesartan don&#x27;t affect bradykinin metabolism, making the inhibition specific to the angiotensin pathway.\\\\n\\\\n**Key Mechanisms:**\\\\n- Prevents AT\\\\u2081-mediated vasoconstriction\\\\n- Blocks angiotensin II-induced aldosterone secretion\\\\n- Reduces\\\\u4ea4\\\\u611f\\\\u795e\\\\u7ecf\\\\u5174\\\\u594b\\\\u6027(sympathetic activation)\\\\n\\\\n**Important Notes:**\\\\n\\\\u2022 The remaining ~15-30% of pressor activity may occur via unblocked AT\\\\u2081 receptors or alternative pathways (like AT\\\\u2082 receptors in some conditions).\\\\n\\\\u2022 Patients may show individual variability in response based on genetics, sodium status, and baseline RAAS activity.\\\\n\\\\nWould you like me to elaborate on any particular aspect of this mechanism or the clinical studies demonstrating these effects?\",\"The document states that the clinical trial assessing the effectiveness of NUCYNTA\\\\u2122 (tapentadol) involved patients undergoing **bunionectomy surgery** (a common foot surgery to correct bunions). This specific type of surgery was chosen as a standardized, moderate-to-severe pain model to evaluate the drug&#x27;s efficacy in acute post-operative pain management.  \\\\n\\\\nLet me know if you&#x27;d like additional details about the trial design or outcomes!\",\"Certainly! Below is a list of psychiatric disorders identified as potential adverse reactions to NUCYNTA\\\\u2122 (tapentadol), according to the prescribing information:  \\\\n\\\\n### **Psychiatric Adverse Reactions Associated with NUCYNTA\\\\u2122:**  \\\\n- **Anxiety**  \\\\n- **Depression**  \\\\n- **Hallucinations**  \\\\n- **Confusion**  \\\\n- **Insomnia** (sleep disturbances)  \\\\n- **Abnormal dreams/nightmares**  \\\\n- **Nervousness**  \\\\n- **Euphoria** (elevated mood)  \\\\n- **Agitation**  \\\\n- **Decreased libido**  \\\\n\\\\nThese reactions may occur in some patients, particularly with prolonged use or higher doses. If you or someone you know experiences these symptoms while taking NUCYNTA\\\\u2122, it\\\\u2019s important to consult a healthcare provider.  \\\\n\\\\nLet me know if you&#x27;d like details on frequency (e.g., common vs. rare) or additional safety considerations.\",\"Great question! Patients undergoing thiazide diuretic therapy should be closely monitored for **fluid and electrolyte imbalances**, as these medications can significantly impact hydration and key electrolytes. Here\\\\u2019s what to look for:\\\\n\\\\n### **Fluid Imbalance**  \\\\nThiazides promote diuresis (increased urine output), which can lead to:  \\\\n- **Hypovolemia/dehydration**:  \\\\n  - **Signs/symptoms**: Dry mouth, excessive thirst, dizziness, fatigue, low blood pressure (especially orthostatic hypotension), dark or concentrated urine, and reduced skin turgor (elasticity).  \\\\n\\\\n### **Electrolyte Imbalances**  \\\\n1. **Hypokalemia (Low Potassium)**:  \\\\n   - **Warning signs**: Muscle weakness, cramps, fatigue, palpitations, arrhythmias, and constipation. Severe cases may lead to paralysis or life-threatening arrhythmias.  \\\\n   - **Risk factors**: Higher in patients with poor dietary potassium intake, on high-dose thiazides, or with concomitant steroid use.  \\\\n\\\\n2. **Hyponatremia (Low Sodium)**:  \\\\n   - **Symptoms**: Headache, confusion, nausea, lethargy, seizures, or even coma in severe cases. Older adults are at higher risk.  \\\\n\\\\n3. **Hypomagnesemia (Low Magnesium)**:  \\\\n   - **Signs**: Muscle twitching, tremors, cramps, arrhythmias, or worsening hypokalemia (since Mg is needed for potassium regulation).  \\\\n\\\\n4. **Hypercalcemia (High Calcium)**:  \\\\n   - **Rare but possible**: Thiazides reduce urinary calcium excretion, which may cause elevated calcium levels. Watch for constipation, kidney stones, bone pain, or confusion.  \\\\n\\\\n### **Metabolic Changes**  \\\\n- **Hyperglycemia**: Thiazides can impair glucose tolerance, so monitor for increased thirst, frequent urination, or fatigue (signs of rising blood sugar).  \\\\n- **Hyperuricemia**: Gout flare-ups (joint pain, swelling) due to elevated uric acid.  \\\\n\\\\n### **Monitoring Recommendations**  \\\\n- Regular **blood tests** (electrolytes, renal function) early in treatment and periodically thereafter, especially in high-risk patients (e.g., elderly, those with CKD).  \\\\n- **Weight tracking**: Sudden drops may indicate dehydration.  \\\\n- **Symptom awareness**: Educate patients to report weakness, dizziness, or irregular heartbeats promptly.  \\\\n\\\\nWould you like additional details on management strategies (e.g., potassium-sparing add-ons, dietary adjustments)? I\\\\u2019m happy to dive deeper!\",\"The specific active component commonly found in foot care creams designed to treat athlete&#x27;s foot (tinea pedis), especially for the interdigital (between the toes) fungal infections, is **clotrimazole** (1% concentration is typical). \\\\n\\\\n### Why Clotrimazole?  \\\\n- **Antifungal Action**: It disrupts fungal cell membranes by inhibiting ergosterol synthesis, which is essential for fungal growth.  \\\\n- **Broad-Spectrum**: Effective against dermatophytes like *Trichophyton rubrum*, the most common cause of athlete\\\\u2019s foot.  \\\\n- **Topical Efficacy**: Safe for skin application with minimal systemic absorption.  \\\\n\\\\n### Alternatives in Other Creams:  \\\\n- **Terbinafine (1%)**: Another potent antifungal, often used for resistant cases.  \\\\n- **Miconazole (2%)**: Works similarly to clotrimazole.  \\\\n- **Tolnaftate (1%)**: A non-imidazole antifungal, though less potent for severe infections.  \\\\n\\\\nWould you like details on application frequency or complementary treatments (e.g., keeping feet dry)?  \\\\n\\\\n*Note: Always check labels for the exact active ingredient, as formulations may vary by brand.*\",\"The combination tablet of **Lisinopril and Hydrochlorothiazide** with **NDC 69097-969-07** has the following strength:  \\\\n\\\\n- **Lisinopril: 10 mg** (an ACE inhibitor for high blood pressure and heart failure)  \\\\n- **Hydrochlorothiazide: 12.5 mg** (a diuretic/\\\\\"water pill\\\\\" to help remove excess fluid)  \\\\n\\\\nThis is a commonly prescribed **10/12.5 mg** strength combination for hypertension management.  \\\\n\\\\nWould you like any additional details on usage, side effects, or alternatives? I\\\\u2019m happy to help!\",\"The average terminal half-life of tapentadol following oral administration is approximately **4 hours** in healthy subjects with normal renal function.  \\\\n\\\\n### **Comparison in Subjects with Varying Renal Function:**  \\\\n1. **Normal Renal Function (Creatinine Clearance \\\\u226590 mL/min):**  \\\\n   - Half-life: ~4 hours  \\\\n2. **Mild Renal Impairment (CrCl 60\\\\u201389 mL/min):**  \\\\n   - Half-life: ~4.5 hours  \\\\n3. **Moderate Renal Impairment (CrCl 30\\\\u201359 mL/min):**  \\\\n   - Half-life: ~5\\\\u20136 hours  \\\\n4. **Severe Renal Impairment (CrCl &lt;30 mL/min or ESRD on dialysis):**  \\\\n   - Half-life: ~6\\\\u20137 hours (or longer if on dialysis)  \\\\n\\\\n**Key Observations:**  \\\\n- Tapentadol\\\\u2019s elimination is prolonged as renal function declines.  \\\\n- In severe renal impairment (including end-stage renal disease), the half-life increases significantly (up to ~7+ hours).  \\\\n- **Dosage adjustments** are recommended in moderate to severe renal impairment to avoid accumulation and toxicity.  \\\\n\\\\nWould you like any additional details on pharmacokinetics or dosing recommendations based on renal function?\",\"Here\\\\u2019s a detailed breakdown of the **contraindications** and **potential effects** when **tizanidine** is used with **fluvoxamine** and **ciprofloxacin**:\\\\n\\\\n### **1. Contraindications &amp; Pharmacokinetic Interactions:**  \\\\n- **Tizanidine + Fluvoxamine (CYP1A2 inhibitor):**  \\\\n  - **Contraindication:** *Concomitant use is contraindicated* due to significantly increased plasma concentrations of tizanidine (up to **33-fold**), leading to severe hypotension and CNS depression.  \\\\n  - **Mechanism:** Fluvoxamine strongly inhibits **CYP1A2**, the primary enzyme metabolizing tizanidine.  \\\\n\\\\n- **Tizanidine + Ciprofloxacin (CYP1A2 inhibitor):**  \\\\n  - **Contraindication:** *Avoid concurrent use*\\\\u2014reduces tizanidine clearance by **10-15x**, heightening toxicity risks.  \\\\n  - **Mechanism:** Ciprofloxacin is a **moderate-to-strong CYP1A2 inhibitor**, prolonging tizanidine\\\\u2019s half-life.  \\\\n\\\\n- **Triple Combination (Tizanidine + Fluvoxamine + Ciprofloxacin):**  \\\\n  - **Absolute contraindication**\\\\u2014additive CYP1A2 inhibition drastically amplifies tizanidine levels, posing life-threatening risks.  \\\\n\\\\n### **2. Adverse Effects to Monitor:**  \\\\n#### **A. Blood Pressure:**  \\\\n- **Severe hypotension** (\\\\u2193 BP), syncope risk due to excessive **\\\\u03b1\\\\u2082-adrenergic agonism** (tizanidine\\\\u2019s effect).  \\\\n- Risk highest in the first **24-48 hours** of coadministration.  \\\\n\\\\n#### **B. Drowsiness &amp; CNS Depression:**  \\\\n- **Potentiated sedation** (fluvoxamine and ciprofloxacin both enhance GABAergic/central \\\\u03b1\\\\u2082 effects).  \\\\n- Risk of **respiratory depression** in vulnerable patients (e.g., elderly, COPD).  \\\\n\\\\n#### **C. Psychomotor Impairment:**  \\\\n- **Dangerously impaired alertness** (avoid driving/operating machinery).  \\\\n- **Delayed reaction times**\\\\u2014fluvoxamine alone can cause drowsiness; tizanidine compounds this.  \\\\n\\\\n### **3. Clinical Recommendations:**  \\\\n- **Alternative Agents:** Use non-CYP1A2-metabolized muscle relaxants (e.g., **baclofen**), or switch to non-interacting antibiotics (e.g., **azithromycin**).  \\\\n- **If Must Use:**  \\\\n  - **Tizanidine dose reduction by ~75-90%** (if no alternative).  \\\\n  - **Continuous BP/HR monitoring** (first 72h).  \\\\n  - **Patient Warning:** Emphasize fall risks, sedation, and avoiding alcohol.  \\\\n\\\\nThis combination is **high-risk**\\\\u2014extreme caution is mandatory. Always consult a pharmacist or prescriber before adjustments.  \\\\n\\\\nWould you like specific management protocols for adverse events (e.g., hypotension treatment)?\",\"It looks like you&#x27;ve referenced an NDC (National Drug Code) number and are asking about the marketing start date for the corresponding product based on a provided document. However, I don&#x27;t have access to the document you mentioned, so I can&#x27;t retrieve the specific information about NDC:75990-4019-4. \\\\n\\\\nIf you can share the relevant details or excerpts from the document, I\\\\u2019d be happy to help extract and summarize the information for you. Alternatively, you could check the document&#x27;s FDA approval section, product label, or marketing history\\\\u2014those often contain official launch dates. Let me know how you&#x27;d like to proceed!\",\"Great question! Candesartan cilexetil is an angiotensin II receptor blocker (ARB) used to treat hypertension and heart failure. Let&#x27;s break down the potential manifestations of overdose and the management of symptomatic hypotension.  \\\\n\\\\n### **Potential Manifestations of Overdosage**:  \\\\n1. **Hypotension**: Profound drop in blood pressure, leading to dizziness, syncope, or shock.  \\\\n2. **Bradycardia or Tachycardia**: Abnormal heart rhythms due to excessive vasodilation.  \\\\n3. **Renal Dysfunction**: Reduced kidney perfusion, potentially causing acute kidney injury (oliguria, elevated creatinine).  \\\\n4. **Electrolyte Imbalances**: Hyperkalemia (due to reduced aldosterone secretion).  \\\\n5. **Neurological Symptoms**: Weakness, confusion, or seizures (rare).  \\\\n\\\\n### **Supportive Treatment for Symptomatic Hypotension**:  \\\\n1. **Immediate Actions**:  \\\\n   - Place the patient in **Trendelenburg position** (legs elevated) to improve venous return.  \\\\n   - Administer **IV fluids** (e.g., normal saline) to restore intravascular volume.  \\\\n2. **Pharmacological Support**:  \\\\n   - **Vasopressors** (e.g., norepinephrine or dopamine) if hypotension persists despite fluids.  \\\\n   - **Atropine** (if significant bradycardia is present).  \\\\n3. **Monitoring &amp; Further Measures**:  \\\\n   - Continuous **ECG, BP, and renal function monitoring**.  \\\\n   - Hemodialysis is **not effective** (candesartan is highly protein-bound), but in severe cases, extracorporeal removal may be considered if refractory hypotension develops.  \\\\n4. **Other Considerations**:  \\\\n   - Correct electrolyte imbalances (e.g., hyperkalemia with calcium gluconate, insulin/glucose, or Kayexalate).  \\\\n   - If ingestion was recent (\\\\u22641-2 hrs), **activated charcoal** may be considered if the patient is alert and cooperative.  \\\\n\\\\nWould you like additional details on any of these aspects?\",\"No response\",\"No response\",\"No response\",\"No response\"]],[\"reference_answer\",[\"The strengths of hydrochlorothiazide in the candesartan cilexetil and hydrochlorothiazide tablets are 25 mg, 12.5 mg, and 12.5 mg for the different formulations.\",\"NUCYNTA\\\\u2122 contains tapentadol, a mu-opioid agonist and is classified as a Schedule II controlled substance. It has an abuse potential similar to hydromorphone and can be abused, subject to criminal diversion.\",\"Alcohol increased the AUC of tizanidine by approximately 20%, while also increasing its Cmax by approximately 15%. This was associated with an increase in side effects of tizanidine. The CNS depressant effects of tizanidine and alcohol are additive.\",\"The active ingredient in the GRX DYNE povidone iodine solution is Povidone-Iodine.\",\"The most frequent clinical adverse experiences reported in trials with lisinopril and hydrochlorothiazide tablets were dizziness (7.5%), headache (5.2%), cough (3.9%), fatigue (3.7%), and orthostatic effects (3.2%).\",\"The medication tapentadol hydrochloride is available in strengths of 100 mg and 50 mg.\",\"Hydrochlorothiazide is a diuretic and antihypertensive that affects the distal renal tubular mechanism of electrolyte reabsorption. It increases the excretion of sodium and chloride in approximately equivalent amounts.\",\"Lisinopril and hydrochlorothiazide tablets are available in three combinations: 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.\",\"Tizanidine capsules and tizanidine tablets are bioequivalent to each other under fasting conditions, but not under fed conditions. When administered with food, the mean maximal plasma concentration for the capsule is approximately 66% the concentration for the tablet.\",\"Aminotransferase levels should be monitored in patients taking tizanidine due to the risk of hepatocellular liver injury. Monitoring is recommended for baseline and 1 month after the maximum dose is achieved, or if hepatic injury is suspected.\",\"The usual treatment for hypotension caused by an overdose of Lisinopril would be intravenous infusion of normal saline solution.\",\"Candesartan inhibits the pressor effects of angiotensin II infusion in a dose-dependent manner. After 1 week of once-daily dosing with 8 mg of candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak with approximately 50% inhibition persisting for 24 hours.\",\"The efficacy of NUCYNTA\\\\u2122 was evaluated in patients undergoing unilateral, first metatarsal bunionectomy surgery.\",\"Some of the psychiatric disorders listed as adverse reactions to NUCYNTA\\\\u2122 include euphoric mood, disorientation, restlessness, agitation, nervousness, and abnormal thinking.\",\"Some warning signs or symptoms of fluid and electrolyte imbalance that patients receiving thiazide therapy should be observed for include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.\",\"The active ingredient in the foot care cream for athlete&#x27;s foot is butenafine hydrochloride 1%.\",\"The Lisinopril and Hydrochlorothiazide tablets with NDC 69097-969-07 have a strength of 20 mg/12.5 mg.\",\"The terminal half-life of tapentadol after oral administration is on average 4 hours.\",\"The concomitant use of tizanidine with fluvoxamine and ciprofloxacin is contraindicated due to changes in the pharmacokinetics of tizanidine that result in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.\",\"The marketing start date for the product with NDC:75990-4019-4 is 05/01/2011.\",\"The most likely manifestations of overdosage with candesartan cilexetil would be hypotension, dizziness, and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.\",\"The potential adverse effects on the fetus associated with the use of drugs that act on the renin-angiotensin system during pregnancy include reduced fetal renal function, increased fetal and neonatal morbidity and death, oligohydramnios, fetal lung hypoplasia, skeletal deformations, skull hypoplasia, anuria, hypotension, renal failure, and death.\",\"The lisinopril in the tablets with NDC:69097-969 has a strength of 20 mg, while the hydrochlorothiazide has a strength of 12.5 mg.\",\"The recommended dosing regimen for NUCYNTA (tapentadol) for the relief of moderate to severe acute pain is 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. The second dose may be administered as soon as one hour after the first dose on the first day of dosing if adequate pain relief is not attained with the first dose.\",\"Some of the nervous system disorders observed as adverse reactions during the premarketing evaluation of NUCYNTA\\\\u2122 include dizziness, somnolence, tremor, lethargy, insomnia, confusional state, abnormal dreams, anxiety, hypoesthesia, paresthesia, disturbance in attention, sedation, dysarthria, depressed level of consciousness, memory impairment, ataxia, presyncope, syncope, coordination abnormal, and seizure.\"]],[\"id\",[78,12,103,28,45,26,33,50,101,93,49,65,17,10,40,116,51,15,97,85,73,37,53,4,9]],[\"content\",[\"Packaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-661-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (So...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\\\nused with caution in renally impaired patients \\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n) and\\\\nUse in Specific Populations ( \\\\n8.6\\\\n)] \\\\n.\\\\nGender Effects\\\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\\\npharmacokinetic...\",\"Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\\\nkeep out of reach of children. If swallowed get medical help \\\\nor contact a Poison Control Center right away.\\\\nEnter section text here\\\\nGRX DYNE  \\\\npovidone iodine solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:54162-269\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85...\",\"Nursing Mothers\\\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\\\nrats contains radioactivity following administration of \\\\nC lisinopril. In another study,\\\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\\\nwhether to discontinue nursing and/or disco...\",\"Stat Rx USA\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII:...\",\"state is prolonged. Older patients, on average, have (approximately doubled) higher\\\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\\\npatients (see \\\\nDOSAGE AND ADMINISTRATION\\\\n). In a multiple dose pharmacokinetic study\\\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\\\nhe...\",\"possible, be discontinued for two to three days before beginning therapy with lisinopril\\\\nto reduce the likelihood of hypotension (See \\\\nWARNINGS\\\\n). If the patient\\\\u2019s blood pressure\\\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\\\nfor at least an additional hour (See \\\\nWARNINGS\\\\n and \\\\nPRECAUTIONS\\\\n...\",\"12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\\\nreduce facilitation of spinal motor neurons.\\\\n12.3 Pharmacokinetics\\\\nAbsorption and Distribution\\\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\\\n...\",\"Tizanidine is an \\\\u03b1 \\\\n-adrenergic agonist that can produce hypotension. Syncope has been\\\\nreported in the post marketing setting. The chance of significant hypotension may\\\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\\\na supine to fixed upright position may be at increased risk for hypotension and\\\\northostatic effects.\\\\nMonitor for hypotension when tizanidine is used in patients...\",\"Lisinopril\\\\n \\\\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\\\nnormal saline solution.\\\\nLisinopril can be removed by hemodialysis (see \\\\nWARNINGS, Anaphylactoid Reaction\\\\nDuring Membrane Exposure\\\\n).\\\\nHydrochlorothiazide\\\\n \\\\nOral administration of a single oral dose of 10 g/kg to mice and rats w...\",\"Geriatric\\\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\\\u2265 65 years). \\\\nThe plasma\\\\nconcentration of candesartan was higher in the elderly (C\\\\n was approximately 50% higher, and AUC\\\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\\\nThe\\\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\\\nNo initia...\",\"14 CLINICAL STUDIES\\\\nThe efficacy and safety of NUCYNTA\\\\u2122 in the treatment of moderate to severe acute pain has been\\\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\\\u2122...\",\"Psychiatric disorders:\\\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\\\nabnormal\\\\nRenal and urinary disorders:\\\\n urinary hesitation, pollakiuria\\\\nRespiratory, thoracic and mediastinal disorders: \\\\noxygen saturation decreased, cough, dyspnea,\\\\nrespiratory depression\\\\nSkin and subcutaneous tissue disorders: \\\\nurticaria\\\\nVascular disorders:\\\\n blood pressure decreased\\\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\\\nNUCYNTA\\\\u2122,...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"RITE \\\\nAID \\\\n \\\\nPHARMACY\\\\nclinically proven to cure \\\\nmost athlete&#x27;s foot between the toes\\\\nfoot care \\\\nbutenafine\\\\nhydrochloride cream 1%\\\\nantifungal\\\\nNET WT 0.42 OZ (12 g)\\\\n\\\\u00ae\",\"Protect from excessive light and humidity.\\\\n*AN69 is a registered trademark of Hospal Ltd.\\\\nManufactured by:\\\\nInvaGen Pharmaceuticals, Inc.\\\\n(a subsidiary of Cipla Ltd.)\\\\nHauppauge, NY 11788\\\\nManufactured for:\\\\nCipla USA, Inc.\\\\n10 Independence Boulevard, Suite 300\\\\nWarren, NJ 07059\\\\nRevised: 10/2021\\\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\\\u2013 10 mg/12.5 mg\\\\nNDC 69097-968-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n10 mg/12.5 mg\\\\n100 Tablets\\\\nCipla\\\\nNDC 69097-969-07             ...\",\"extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\\\naround 1.25 hours after dosing.\\\\nDose-proportional increases in the C\\\\n and AUC values of tapentadol have been observed over the 50\\\\nto 150 mg dose range.\\\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\\\nglucuronide, which are primarily determined by the do...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"Certus Medical, Inc.\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nSODIUM PHOSPHATE, DIBASIC\\\\n (UNII: GR686LBA74)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nDIMETHICONE\\\\n (UNII: 92RU3N3Y1O)\\\\n \\\\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\\\n (UNII: S38J6RZN16)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:75990-4019-4\\\\n2 mL in 1 POUCH\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOT...\",\"melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\\\nfor white patients taking a cumulative dose of \\\\u226550,000 mg the risk increase was approximately 1\\\\nadditional SCC case for every 6,700 patients per year.\\\\nSkin:\\\\n \\\\nerythema multiforme including S...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"8.7 Hepatic Impairment\\\\n9 DRUG ABUSE AND DEPENDENCE\\\\n9.1 Controlled Substance\\\\n9.2 Abuse\\\\n9.3 Dependence\\\\n10 OVERDOSAGE\\\\n10.1 Human Experience\\\\n10.2 Management of Overdose\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n13 NON-CLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\n14 CLINICAL STUDIES\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\n14.2 End-Stage Degenerative Joint Disea...\",\"*\\\\nInfections and infestations\\\\n  Nasopharyngitis\\\\n1\\\\n&lt;1\\\\n  Upper respiratory tract infection\\\\n1\\\\n&lt;1\\\\n  Urinary tract infection\\\\n1\\\\n&lt;1\\\\nMetabolism and nutrition disorders\\\\n  Decreased appetite\\\\n2\\\\n0\\\\nMusculoskeletal and connective tissue\\\\ndisorders\\\\n  Arthralgia\\\\n1\\\\n&lt;1\\\\nNervous system disorders\\\\n  Dizziness\\\\n24\\\\n8\\\\n  Somnolence\\\\n15\\\\n3\\\\n  Tremor\\\\n1\\\\n&lt;1\\\\n  Lethargy\\\\n1\\\\n&lt;1\\\\nPsychiatric disorders\\\\n  Insomnia\\\\n2\\\\n&lt;1\\\\n  Confusional state\\\\n1\\\\n0\\\\n  Abnormal dreams\\\\n1\\\\n&lt;1\\\\n  Anxiety\\\\n1\\\\n&lt;1\\\\nSkin and subcutaneous tissue disorders\\\\n  Pruritus\\\\n5\\\\n1\\\\n  Hyp...\"]],[\"color\",[\"#ba0e0e\",\"#ba0e0e\",\"#0a980a\",\"#0a980a\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#0a980a\",\"#ba0e0e\",\"#ba0e0e\",\"#0a980a\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#0a980a\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1585\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1586\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1581\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1582\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1583\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1599\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1590\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1591\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1592\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1600\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1601\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1596\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1597\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1598\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1553\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1568\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1569\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1570\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1571\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1576\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1577\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1544\",\"attributes\":{\"renderers\":[{\"id\":\"p1584\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1563\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1564\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1565\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1566\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1558\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1559\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1560\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1561\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1562\",\"attributes\":{\"axis\":{\"id\":\"p1558\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1567\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1563\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1587\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1588\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"False\"},\"renderers\":[{\"id\":\"p1584\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1589\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p1584\"}],\"index\":2}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p1605\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1602\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1603\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1604\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"qqUxQWZoDUEzPX5At+fuQL+gmEA=\"},\"shape\":[5],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"LG+OQRTcmkFHb49BHSaFQam0ekE=\"},\"shape\":[5],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Tizanidine Overdose\",\"Medication Information\",\"ACE Inhibitors\",\"Pharmaceutical Products\",\"Candesartan Cilexetil\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"d8034ef8-2788-47b9-ad00-f34a376de50e\",\"roots\":{\"p1610\":\"b99f2c3d-c97c-4d6f-a669-1eac2750425c\"},\"root_ids\":[\"p1610\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"b99f2c3d-c97c-4d6f-a669-1eac2750425c\" data-root-id=\"p1610\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x70fd0f798e30>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_asi, testset=testset, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "id": "37070ed2",
   "metadata": {},
   "outputs": [],
   "source": [
    "report.to_html(f\"report-asi-mini_10.html\")\n",
    "dfc = pd.DataFrame(report.component_scores())\n",
    "dfc.to_csv(f\"component_scores_10.csv\", index=False)\n",
    "dfr = report.to_pandas()\n",
    "dfr.to_excel(f\"all_results_10.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 121,
   "id": "162b4eb5",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>question</th>\n",
       "      <th>reference_answer</th>\n",
       "      <th>reference_context</th>\n",
       "      <th>conversation_history</th>\n",
       "      <th>metadata</th>\n",
       "      <th>agent_answer</th>\n",
       "      <th>correctness</th>\n",
       "      <th>correctness_reason</th>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>id</th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "      <th></th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>8fc13a32-5c34-4809-be6e-411fb6fdc659</th>\n",
       "      <td>What are the specific inactive ingredients pre...</td>\n",
       "      <td>The inactive ingredients in the 100 mg Metopro...</td>\n",
       "      <td>Document 19: Product Information\\nProduct Type...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>The 100 mg **Metoprolol Tartrate** tablet typi...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided additional inactive ingredi...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>64868d56-c2ee-4a73-b878-bb4e177a3574</th>\n",
       "      <td>What are the strengths available for the drug ...</td>\n",
       "      <td>The strengths available for the drug LOPRESSOR...</td>\n",
       "      <td>Document 18: Product Type\\nHUMAN PRESCRIPTION ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Great question! Let me break down the availabl...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided additional information abou...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>aa6813b1-64a3-4bfe-b8ec-e06dae6eb46c</th>\n",
       "      <td>What adverse reactions related to the cardiova...</td>\n",
       "      <td>Shortness of breath, bradycardia, cold extremi...</td>\n",
       "      <td>Document 6: 5.\\n9\\n \\n  \\nPeripheral Vascular ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Here’s a detailed breakdown of cardiovascular ...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed breakdown of car...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>ca0d8cf3-c32c-4a73-8d25-10c7d05e5ef2</th>\n",
       "      <td>What is the specific indication of LOPRESSOR i...</td>\n",
       "      <td>LOPRESSOR is indicated for the treatment of hy...</td>\n",
       "      <td>Document 2: 8.6 \\n  \\nHepatic Impairment\\n8.7 ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>LOPRESSOR (metoprolol tartrate) is a beta-adre...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided detailed information about ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3e408a82-a894-419c-8aa5-f1b1dbf49565</th>\n",
       "      <td>In patients with hepatic impairment, what is t...</td>\n",
       "      <td>LOPRESSOR therapy should be considered to be i...</td>\n",
       "      <td>Document 1: CYP2D6 Inhibitors are likely to in...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>For patients with hepatic impairment initiatin...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided detailed dosage adjustment ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>65310709-e66e-4559-8d7a-fcd02bff44aa</th>\n",
       "      <td>In which year did LOPRESSOR (metoprolol tartra...</td>\n",
       "      <td>LOPRESSOR (metoprolol tartrate) tablets receiv...</td>\n",
       "      <td>Document 0: LOPRESSOR- metoprolol tartrate tab...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Metoprolol tartrate, marketed under the brand ...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent stated that LOPRESSOR received its i...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3a204c07-3317-4cdc-b8f9-b30c8241f0d3</th>\n",
       "      <td>Under what circumstance should patients with b...</td>\n",
       "      <td>Patients with bronchospastic disease should ge...</td>\n",
       "      <td>Document 5: dose of LOPRESSOR \\n[see \\nDosage ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>**Answer:**  \\n\\nPatients with **bronchospasti...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided detailed information about ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>a88b55b7-4dcc-4d5a-9971-368fe0b8e344</th>\n",
       "      <td>What are the different strengths of Lopressor ...</td>\n",
       "      <td>Lopressor tablets are available in two strengt...</td>\n",
       "      <td>Document 17: NDC 30698-458-01\\nLopressor\\n(met...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Lopressor (generic name: metoprolol tartrate) ...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided information on three streng...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4703bc81-6477-4795-bc48-e213b273ffed</th>\n",
       "      <td>What are some of the adverse reactions that ha...</td>\n",
       "      <td>Some adverse reactions reported during post ap...</td>\n",
       "      <td>Document 7: Lopressor\\nPlacebo\\nHypotension (s...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Here are the reported adverse reactions during...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed list of adverse ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>e450294e-2d26-45b4-a416-9fd5ac53aea6</th>\n",
       "      <td>What is the specific company name of the pharm...</td>\n",
       "      <td>Validus Pharmaceuticals LLC</td>\n",
       "      <td>Document 20: Validus Pharmaceuticals LLC\\n \\nR...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>I don't have access to the specific document y...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent asked for more specific details or t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>bafb7f9a-6bba-4688-979c-44ef5806e63c</th>\n",
       "      <td>What is the recommended initial daily dosage o...</td>\n",
       "      <td>The usual initial dosage of Lopressor tablets ...</td>\n",
       "      <td>Document 3: absolute risk increase per mmHg is...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>The recommended **initial daily dosage of Lopr...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed dosage recommend...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>60ae2e7a-f233-4b6f-bf07-fef9868e308b</th>\n",
       "      <td>What are the proposed mechanisms for the antih...</td>\n",
       "      <td>The mechanism of the antihypertensive effects ...</td>\n",
       "      <td>Document 12: Metoprolol is a beta\\n-selective ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Great question! Beta-blockers like metoprolol ...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed explanation of t...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>83834ed7-b4e8-4398-a245-4dcc0b70a90a</th>\n",
       "      <td>What is the range of estimated daily infant do...</td>\n",
       "      <td>The estimated daily infant dose of metoprolol ...</td>\n",
       "      <td>Document 9: Data\\nHuman Data\\nData from publis...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>According to the limited available data from p...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a range of 0.05–0.1 mg/kg/d...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>b7e02d60-e289-440d-a5bb-ea672a645e2c</th>\n",
       "      <td>What is the primary metabolic pathway for Lopr...</td>\n",
       "      <td>Lopressor is primarily metabolized by CYP2D6 i...</td>\n",
       "      <td>Document 13: the ratio of approximately 2.5:1....</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>**Answer:**  \\n\\nLopressor (metoprolol) is pri...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided additional information abou...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>09293f52-3d2d-4703-a5ae-5db98ca15677</th>\n",
       "      <td>What is the dosage range of Lopressor that has...</td>\n",
       "      <td>In controlled clinical studies, Lopressor has ...</td>\n",
       "      <td>Document 15: mg in a 60-kg patient.\\n14 \\n    ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>The dosage range of Lopressor (metoprolol tart...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed breakdown of the...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>b58ca274-6b2d-4175-99a2-40c562c78745</th>\n",
       "      <td>How does hepatic impairment affect the pharmac...</td>\n",
       "      <td>Hepatic impairment may impact the pharmacokine...</td>\n",
       "      <td>Document 14: Renal\\n \\nimpairment\\n: The syste...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Great question! Since metoprolol is primarily ...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed explanation on h...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>073e6f4f-6a32-46f5-bc70-958a61639dac</th>\n",
       "      <td>What are the potential clinical manifestations...</td>\n",
       "      <td>Overdosage of Lopressor may lead to severe bra...</td>\n",
       "      <td>Document 11: Signs and Symptoms - Overdosage o...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>**Potential Clinical Manifestations of Lopress...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed list of potentia...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>f85bdc35-cddf-495a-b48d-8fbeca4d891f</th>\n",
       "      <td>What steps should be followed to safely discon...</td>\n",
       "      <td>When discontinuing therapy with Lopressor, par...</td>\n",
       "      <td>Document 4: been studied. If treatment is to b...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Discontinuing Lopressor (metoprolol), a beta-b...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed step-by-step dis...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9d8ea49c-de2d-4e65-8910-361f43b6f1c9</th>\n",
       "      <td>What are the specific storage instructions for...</td>\n",
       "      <td>Lopressor tablets should be stored at 77°F (25...</td>\n",
       "      <td>Document 16: however, it is also reasonable to...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Here are the specific storage instructions for...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided detailed and accurate stora...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>649a3d8e-5cd8-44b0-8ffb-868ba4ce01e5</th>\n",
       "      <td>What reversible adverse effects on spermatogen...</td>\n",
       "      <td>In animal fertility studies, metoprolol has be...</td>\n",
       "      <td>Document 10: (range 17.0 to 158.7). The averag...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Great question! Let's break down the informati...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided detailed information about ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>878fbabf-46e5-461b-a597-49c041f935c5</th>\n",
       "      <td>What are the inactive ingredients present in t...</td>\n",
       "      <td>The inactive ingredients in the 100 mg Metopro...</td>\n",
       "      <td>Document 18: Product Type\\nHUMAN PRESCRIPTION ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>The 100 mg Metoprolol Tartrate tablet (generic...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a list of additional potent...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2f238ce2-3f72-4d6e-aa80-ca7b240bae2f</th>\n",
       "      <td>What are the proposed mechanisms for the antih...</td>\n",
       "      <td>The mechanism of the antihypertensive effects ...</td>\n",
       "      <td>Document 12: Metoprolol is a beta\\n-selective ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>Beta-blockers like metoprolol exert their anti...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided detailed mechanisms for the...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>45d0dfc6-5092-4017-b8d6-c8b760bcda7b</th>\n",
       "      <td>What is the specific medical condition in adul...</td>\n",
       "      <td>LOPRESSOR is indicated for the treatment of hy...</td>\n",
       "      <td>Document 2: 8.6 \\n  \\nHepatic Impairment\\n8.7 ...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>LOPRESSOR (metoprolol tartrate) is specificall...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided additional information abou...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5fed25c2-0e4f-44c1-b3c8-068933ba4baa</th>\n",
       "      <td>What is the range of the estimated daily infan...</td>\n",
       "      <td>The estimated daily infant dose of metoprolol ...</td>\n",
       "      <td>Document 9: Data\\nHuman Data\\nData from publis...</td>\n",
       "      <td>[]</td>\n",
       "      <td>{'question_type': 'complex', 'seed_document_id...</td>\n",
       "      <td>According to the limited available data from p...</td>\n",
       "      <td>False</td>\n",
       "      <td>The agent provided a detailed answer about the...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                                                               question  \\\n",
       "id                                                                                        \n",
       "8fc13a32-5c34-4809-be6e-411fb6fdc659  What are the specific inactive ingredients pre...   \n",
       "64868d56-c2ee-4a73-b878-bb4e177a3574  What are the strengths available for the drug ...   \n",
       "aa6813b1-64a3-4bfe-b8ec-e06dae6eb46c  What adverse reactions related to the cardiova...   \n",
       "ca0d8cf3-c32c-4a73-8d25-10c7d05e5ef2  What is the specific indication of LOPRESSOR i...   \n",
       "3e408a82-a894-419c-8aa5-f1b1dbf49565  In patients with hepatic impairment, what is t...   \n",
       "65310709-e66e-4559-8d7a-fcd02bff44aa  In which year did LOPRESSOR (metoprolol tartra...   \n",
       "3a204c07-3317-4cdc-b8f9-b30c8241f0d3  Under what circumstance should patients with b...   \n",
       "a88b55b7-4dcc-4d5a-9971-368fe0b8e344  What are the different strengths of Lopressor ...   \n",
       "4703bc81-6477-4795-bc48-e213b273ffed  What are some of the adverse reactions that ha...   \n",
       "e450294e-2d26-45b4-a416-9fd5ac53aea6  What is the specific company name of the pharm...   \n",
       "bafb7f9a-6bba-4688-979c-44ef5806e63c  What is the recommended initial daily dosage o...   \n",
       "60ae2e7a-f233-4b6f-bf07-fef9868e308b  What are the proposed mechanisms for the antih...   \n",
       "83834ed7-b4e8-4398-a245-4dcc0b70a90a  What is the range of estimated daily infant do...   \n",
       "b7e02d60-e289-440d-a5bb-ea672a645e2c  What is the primary metabolic pathway for Lopr...   \n",
       "09293f52-3d2d-4703-a5ae-5db98ca15677  What is the dosage range of Lopressor that has...   \n",
       "b58ca274-6b2d-4175-99a2-40c562c78745  How does hepatic impairment affect the pharmac...   \n",
       "073e6f4f-6a32-46f5-bc70-958a61639dac  What are the potential clinical manifestations...   \n",
       "f85bdc35-cddf-495a-b48d-8fbeca4d891f  What steps should be followed to safely discon...   \n",
       "9d8ea49c-de2d-4e65-8910-361f43b6f1c9  What are the specific storage instructions for...   \n",
       "649a3d8e-5cd8-44b0-8ffb-868ba4ce01e5  What reversible adverse effects on spermatogen...   \n",
       "878fbabf-46e5-461b-a597-49c041f935c5  What are the inactive ingredients present in t...   \n",
       "2f238ce2-3f72-4d6e-aa80-ca7b240bae2f  What are the proposed mechanisms for the antih...   \n",
       "45d0dfc6-5092-4017-b8d6-c8b760bcda7b  What is the specific medical condition in adul...   \n",
       "5fed25c2-0e4f-44c1-b3c8-068933ba4baa  What is the range of the estimated daily infan...   \n",
       "\n",
       "                                                                       reference_answer  \\\n",
       "id                                                                                        \n",
       "8fc13a32-5c34-4809-be6e-411fb6fdc659  The inactive ingredients in the 100 mg Metopro...   \n",
       "64868d56-c2ee-4a73-b878-bb4e177a3574  The strengths available for the drug LOPRESSOR...   \n",
       "aa6813b1-64a3-4bfe-b8ec-e06dae6eb46c  Shortness of breath, bradycardia, cold extremi...   \n",
       "ca0d8cf3-c32c-4a73-8d25-10c7d05e5ef2  LOPRESSOR is indicated for the treatment of hy...   \n",
       "3e408a82-a894-419c-8aa5-f1b1dbf49565  LOPRESSOR therapy should be considered to be i...   \n",
       "65310709-e66e-4559-8d7a-fcd02bff44aa  LOPRESSOR (metoprolol tartrate) tablets receiv...   \n",
       "3a204c07-3317-4cdc-b8f9-b30c8241f0d3  Patients with bronchospastic disease should ge...   \n",
       "a88b55b7-4dcc-4d5a-9971-368fe0b8e344  Lopressor tablets are available in two strengt...   \n",
       "4703bc81-6477-4795-bc48-e213b273ffed  Some adverse reactions reported during post ap...   \n",
       "e450294e-2d26-45b4-a416-9fd5ac53aea6                        Validus Pharmaceuticals LLC   \n",
       "bafb7f9a-6bba-4688-979c-44ef5806e63c  The usual initial dosage of Lopressor tablets ...   \n",
       "60ae2e7a-f233-4b6f-bf07-fef9868e308b  The mechanism of the antihypertensive effects ...   \n",
       "83834ed7-b4e8-4398-a245-4dcc0b70a90a  The estimated daily infant dose of metoprolol ...   \n",
       "b7e02d60-e289-440d-a5bb-ea672a645e2c  Lopressor is primarily metabolized by CYP2D6 i...   \n",
       "09293f52-3d2d-4703-a5ae-5db98ca15677  In controlled clinical studies, Lopressor has ...   \n",
       "b58ca274-6b2d-4175-99a2-40c562c78745  Hepatic impairment may impact the pharmacokine...   \n",
       "073e6f4f-6a32-46f5-bc70-958a61639dac  Overdosage of Lopressor may lead to severe bra...   \n",
       "f85bdc35-cddf-495a-b48d-8fbeca4d891f  When discontinuing therapy with Lopressor, par...   \n",
       "9d8ea49c-de2d-4e65-8910-361f43b6f1c9  Lopressor tablets should be stored at 77°F (25...   \n",
       "649a3d8e-5cd8-44b0-8ffb-868ba4ce01e5  In animal fertility studies, metoprolol has be...   \n",
       "878fbabf-46e5-461b-a597-49c041f935c5  The inactive ingredients in the 100 mg Metopro...   \n",
       "2f238ce2-3f72-4d6e-aa80-ca7b240bae2f  The mechanism of the antihypertensive effects ...   \n",
       "45d0dfc6-5092-4017-b8d6-c8b760bcda7b  LOPRESSOR is indicated for the treatment of hy...   \n",
       "5fed25c2-0e4f-44c1-b3c8-068933ba4baa  The estimated daily infant dose of metoprolol ...   \n",
       "\n",
       "                                                                      reference_context  \\\n",
       "id                                                                                        \n",
       "8fc13a32-5c34-4809-be6e-411fb6fdc659  Document 19: Product Information\\nProduct Type...   \n",
       "64868d56-c2ee-4a73-b878-bb4e177a3574  Document 18: Product Type\\nHUMAN PRESCRIPTION ...   \n",
       "aa6813b1-64a3-4bfe-b8ec-e06dae6eb46c  Document 6: 5.\\n9\\n \\n  \\nPeripheral Vascular ...   \n",
       "ca0d8cf3-c32c-4a73-8d25-10c7d05e5ef2  Document 2: 8.6 \\n  \\nHepatic Impairment\\n8.7 ...   \n",
       "3e408a82-a894-419c-8aa5-f1b1dbf49565  Document 1: CYP2D6 Inhibitors are likely to in...   \n",
       "65310709-e66e-4559-8d7a-fcd02bff44aa  Document 0: LOPRESSOR- metoprolol tartrate tab...   \n",
       "3a204c07-3317-4cdc-b8f9-b30c8241f0d3  Document 5: dose of LOPRESSOR \\n[see \\nDosage ...   \n",
       "a88b55b7-4dcc-4d5a-9971-368fe0b8e344  Document 17: NDC 30698-458-01\\nLopressor\\n(met...   \n",
       "4703bc81-6477-4795-bc48-e213b273ffed  Document 7: Lopressor\\nPlacebo\\nHypotension (s...   \n",
       "e450294e-2d26-45b4-a416-9fd5ac53aea6  Document 20: Validus Pharmaceuticals LLC\\n \\nR...   \n",
       "bafb7f9a-6bba-4688-979c-44ef5806e63c  Document 3: absolute risk increase per mmHg is...   \n",
       "60ae2e7a-f233-4b6f-bf07-fef9868e308b  Document 12: Metoprolol is a beta\\n-selective ...   \n",
       "83834ed7-b4e8-4398-a245-4dcc0b70a90a  Document 9: Data\\nHuman Data\\nData from publis...   \n",
       "b7e02d60-e289-440d-a5bb-ea672a645e2c  Document 13: the ratio of approximately 2.5:1....   \n",
       "09293f52-3d2d-4703-a5ae-5db98ca15677  Document 15: mg in a 60-kg patient.\\n14 \\n    ...   \n",
       "b58ca274-6b2d-4175-99a2-40c562c78745  Document 14: Renal\\n \\nimpairment\\n: The syste...   \n",
       "073e6f4f-6a32-46f5-bc70-958a61639dac  Document 11: Signs and Symptoms - Overdosage o...   \n",
       "f85bdc35-cddf-495a-b48d-8fbeca4d891f  Document 4: been studied. If treatment is to b...   \n",
       "9d8ea49c-de2d-4e65-8910-361f43b6f1c9  Document 16: however, it is also reasonable to...   \n",
       "649a3d8e-5cd8-44b0-8ffb-868ba4ce01e5  Document 10: (range 17.0 to 158.7). The averag...   \n",
       "878fbabf-46e5-461b-a597-49c041f935c5  Document 18: Product Type\\nHUMAN PRESCRIPTION ...   \n",
       "2f238ce2-3f72-4d6e-aa80-ca7b240bae2f  Document 12: Metoprolol is a beta\\n-selective ...   \n",
       "45d0dfc6-5092-4017-b8d6-c8b760bcda7b  Document 2: 8.6 \\n  \\nHepatic Impairment\\n8.7 ...   \n",
       "5fed25c2-0e4f-44c1-b3c8-068933ba4baa  Document 9: Data\\nHuman Data\\nData from publis...   \n",
       "\n",
       "                                     conversation_history  \\\n",
       "id                                                          \n",
       "8fc13a32-5c34-4809-be6e-411fb6fdc659                   []   \n",
       "64868d56-c2ee-4a73-b878-bb4e177a3574                   []   \n",
       "aa6813b1-64a3-4bfe-b8ec-e06dae6eb46c                   []   \n",
       "ca0d8cf3-c32c-4a73-8d25-10c7d05e5ef2                   []   \n",
       "3e408a82-a894-419c-8aa5-f1b1dbf49565                   []   \n",
       "65310709-e66e-4559-8d7a-fcd02bff44aa                   []   \n",
       "3a204c07-3317-4cdc-b8f9-b30c8241f0d3                   []   \n",
       "a88b55b7-4dcc-4d5a-9971-368fe0b8e344                   []   \n",
       "4703bc81-6477-4795-bc48-e213b273ffed                   []   \n",
       "e450294e-2d26-45b4-a416-9fd5ac53aea6                   []   \n",
       "bafb7f9a-6bba-4688-979c-44ef5806e63c                   []   \n",
       "60ae2e7a-f233-4b6f-bf07-fef9868e308b                   []   \n",
       "83834ed7-b4e8-4398-a245-4dcc0b70a90a                   []   \n",
       "b7e02d60-e289-440d-a5bb-ea672a645e2c                   []   \n",
       "09293f52-3d2d-4703-a5ae-5db98ca15677                   []   \n",
       "b58ca274-6b2d-4175-99a2-40c562c78745                   []   \n",
       "073e6f4f-6a32-46f5-bc70-958a61639dac                   []   \n",
       "f85bdc35-cddf-495a-b48d-8fbeca4d891f                   []   \n",
       "9d8ea49c-de2d-4e65-8910-361f43b6f1c9                   []   \n",
       "649a3d8e-5cd8-44b0-8ffb-868ba4ce01e5                   []   \n",
       "878fbabf-46e5-461b-a597-49c041f935c5                   []   \n",
       "2f238ce2-3f72-4d6e-aa80-ca7b240bae2f                   []   \n",
       "45d0dfc6-5092-4017-b8d6-c8b760bcda7b                   []   \n",
       "5fed25c2-0e4f-44c1-b3c8-068933ba4baa                   []   \n",
       "\n",
       "                                                                               metadata  \\\n",
       "id                                                                                        \n",
       "8fc13a32-5c34-4809-be6e-411fb6fdc659  {'question_type': 'complex', 'seed_document_id...   \n",
       "64868d56-c2ee-4a73-b878-bb4e177a3574  {'question_type': 'complex', 'seed_document_id...   \n",
       "aa6813b1-64a3-4bfe-b8ec-e06dae6eb46c  {'question_type': 'complex', 'seed_document_id...   \n",
       "ca0d8cf3-c32c-4a73-8d25-10c7d05e5ef2  {'question_type': 'complex', 'seed_document_id...   \n",
       "3e408a82-a894-419c-8aa5-f1b1dbf49565  {'question_type': 'complex', 'seed_document_id...   \n",
       "65310709-e66e-4559-8d7a-fcd02bff44aa  {'question_type': 'complex', 'seed_document_id...   \n",
       "3a204c07-3317-4cdc-b8f9-b30c8241f0d3  {'question_type': 'complex', 'seed_document_id...   \n",
       "a88b55b7-4dcc-4d5a-9971-368fe0b8e344  {'question_type': 'complex', 'seed_document_id...   \n",
       "4703bc81-6477-4795-bc48-e213b273ffed  {'question_type': 'complex', 'seed_document_id...   \n",
       "e450294e-2d26-45b4-a416-9fd5ac53aea6  {'question_type': 'complex', 'seed_document_id...   \n",
       "bafb7f9a-6bba-4688-979c-44ef5806e63c  {'question_type': 'complex', 'seed_document_id...   \n",
       "60ae2e7a-f233-4b6f-bf07-fef9868e308b  {'question_type': 'complex', 'seed_document_id...   \n",
       "83834ed7-b4e8-4398-a245-4dcc0b70a90a  {'question_type': 'complex', 'seed_document_id...   \n",
       "b7e02d60-e289-440d-a5bb-ea672a645e2c  {'question_type': 'complex', 'seed_document_id...   \n",
       "09293f52-3d2d-4703-a5ae-5db98ca15677  {'question_type': 'complex', 'seed_document_id...   \n",
       "b58ca274-6b2d-4175-99a2-40c562c78745  {'question_type': 'complex', 'seed_document_id...   \n",
       "073e6f4f-6a32-46f5-bc70-958a61639dac  {'question_type': 'complex', 'seed_document_id...   \n",
       "f85bdc35-cddf-495a-b48d-8fbeca4d891f  {'question_type': 'complex', 'seed_document_id...   \n",
       "9d8ea49c-de2d-4e65-8910-361f43b6f1c9  {'question_type': 'complex', 'seed_document_id...   \n",
       "649a3d8e-5cd8-44b0-8ffb-868ba4ce01e5  {'question_type': 'complex', 'seed_document_id...   \n",
       "878fbabf-46e5-461b-a597-49c041f935c5  {'question_type': 'complex', 'seed_document_id...   \n",
       "2f238ce2-3f72-4d6e-aa80-ca7b240bae2f  {'question_type': 'complex', 'seed_document_id...   \n",
       "45d0dfc6-5092-4017-b8d6-c8b760bcda7b  {'question_type': 'complex', 'seed_document_id...   \n",
       "5fed25c2-0e4f-44c1-b3c8-068933ba4baa  {'question_type': 'complex', 'seed_document_id...   \n",
       "\n",
       "                                                                           agent_answer  \\\n",
       "id                                                                                        \n",
       "8fc13a32-5c34-4809-be6e-411fb6fdc659  The 100 mg **Metoprolol Tartrate** tablet typi...   \n",
       "64868d56-c2ee-4a73-b878-bb4e177a3574  Great question! Let me break down the availabl...   \n",
       "aa6813b1-64a3-4bfe-b8ec-e06dae6eb46c  Here’s a detailed breakdown of cardiovascular ...   \n",
       "ca0d8cf3-c32c-4a73-8d25-10c7d05e5ef2  LOPRESSOR (metoprolol tartrate) is a beta-adre...   \n",
       "3e408a82-a894-419c-8aa5-f1b1dbf49565  For patients with hepatic impairment initiatin...   \n",
       "65310709-e66e-4559-8d7a-fcd02bff44aa  Metoprolol tartrate, marketed under the brand ...   \n",
       "3a204c07-3317-4cdc-b8f9-b30c8241f0d3  **Answer:**  \\n\\nPatients with **bronchospasti...   \n",
       "a88b55b7-4dcc-4d5a-9971-368fe0b8e344  Lopressor (generic name: metoprolol tartrate) ...   \n",
       "4703bc81-6477-4795-bc48-e213b273ffed  Here are the reported adverse reactions during...   \n",
       "e450294e-2d26-45b4-a416-9fd5ac53aea6  I don't have access to the specific document y...   \n",
       "bafb7f9a-6bba-4688-979c-44ef5806e63c  The recommended **initial daily dosage of Lopr...   \n",
       "60ae2e7a-f233-4b6f-bf07-fef9868e308b  Great question! Beta-blockers like metoprolol ...   \n",
       "83834ed7-b4e8-4398-a245-4dcc0b70a90a  According to the limited available data from p...   \n",
       "b7e02d60-e289-440d-a5bb-ea672a645e2c  **Answer:**  \\n\\nLopressor (metoprolol) is pri...   \n",
       "09293f52-3d2d-4703-a5ae-5db98ca15677  The dosage range of Lopressor (metoprolol tart...   \n",
       "b58ca274-6b2d-4175-99a2-40c562c78745  Great question! Since metoprolol is primarily ...   \n",
       "073e6f4f-6a32-46f5-bc70-958a61639dac  **Potential Clinical Manifestations of Lopress...   \n",
       "f85bdc35-cddf-495a-b48d-8fbeca4d891f  Discontinuing Lopressor (metoprolol), a beta-b...   \n",
       "9d8ea49c-de2d-4e65-8910-361f43b6f1c9  Here are the specific storage instructions for...   \n",
       "649a3d8e-5cd8-44b0-8ffb-868ba4ce01e5  Great question! Let's break down the informati...   \n",
       "878fbabf-46e5-461b-a597-49c041f935c5  The 100 mg Metoprolol Tartrate tablet (generic...   \n",
       "2f238ce2-3f72-4d6e-aa80-ca7b240bae2f  Beta-blockers like metoprolol exert their anti...   \n",
       "45d0dfc6-5092-4017-b8d6-c8b760bcda7b  LOPRESSOR (metoprolol tartrate) is specificall...   \n",
       "5fed25c2-0e4f-44c1-b3c8-068933ba4baa  According to the limited available data from p...   \n",
       "\n",
       "                                      correctness  \\\n",
       "id                                                  \n",
       "8fc13a32-5c34-4809-be6e-411fb6fdc659        False   \n",
       "64868d56-c2ee-4a73-b878-bb4e177a3574        False   \n",
       "aa6813b1-64a3-4bfe-b8ec-e06dae6eb46c        False   \n",
       "ca0d8cf3-c32c-4a73-8d25-10c7d05e5ef2        False   \n",
       "3e408a82-a894-419c-8aa5-f1b1dbf49565        False   \n",
       "65310709-e66e-4559-8d7a-fcd02bff44aa        False   \n",
       "3a204c07-3317-4cdc-b8f9-b30c8241f0d3        False   \n",
       "a88b55b7-4dcc-4d5a-9971-368fe0b8e344        False   \n",
       "4703bc81-6477-4795-bc48-e213b273ffed        False   \n",
       "e450294e-2d26-45b4-a416-9fd5ac53aea6        False   \n",
       "bafb7f9a-6bba-4688-979c-44ef5806e63c        False   \n",
       "60ae2e7a-f233-4b6f-bf07-fef9868e308b        False   \n",
       "83834ed7-b4e8-4398-a245-4dcc0b70a90a        False   \n",
       "b7e02d60-e289-440d-a5bb-ea672a645e2c        False   \n",
       "09293f52-3d2d-4703-a5ae-5db98ca15677        False   \n",
       "b58ca274-6b2d-4175-99a2-40c562c78745        False   \n",
       "073e6f4f-6a32-46f5-bc70-958a61639dac        False   \n",
       "f85bdc35-cddf-495a-b48d-8fbeca4d891f        False   \n",
       "9d8ea49c-de2d-4e65-8910-361f43b6f1c9        False   \n",
       "649a3d8e-5cd8-44b0-8ffb-868ba4ce01e5        False   \n",
       "878fbabf-46e5-461b-a597-49c041f935c5        False   \n",
       "2f238ce2-3f72-4d6e-aa80-ca7b240bae2f        False   \n",
       "45d0dfc6-5092-4017-b8d6-c8b760bcda7b        False   \n",
       "5fed25c2-0e4f-44c1-b3c8-068933ba4baa        False   \n",
       "\n",
       "                                                                     correctness_reason  \n",
       "id                                                                                       \n",
       "8fc13a32-5c34-4809-be6e-411fb6fdc659  The agent provided additional inactive ingredi...  \n",
       "64868d56-c2ee-4a73-b878-bb4e177a3574  The agent provided additional information abou...  \n",
       "aa6813b1-64a3-4bfe-b8ec-e06dae6eb46c  The agent provided a detailed breakdown of car...  \n",
       "ca0d8cf3-c32c-4a73-8d25-10c7d05e5ef2  The agent provided detailed information about ...  \n",
       "3e408a82-a894-419c-8aa5-f1b1dbf49565  The agent provided detailed dosage adjustment ...  \n",
       "65310709-e66e-4559-8d7a-fcd02bff44aa  The agent stated that LOPRESSOR received its i...  \n",
       "3a204c07-3317-4cdc-b8f9-b30c8241f0d3  The agent provided detailed information about ...  \n",
       "a88b55b7-4dcc-4d5a-9971-368fe0b8e344  The agent provided information on three streng...  \n",
       "4703bc81-6477-4795-bc48-e213b273ffed  The agent provided a detailed list of adverse ...  \n",
       "e450294e-2d26-45b4-a416-9fd5ac53aea6  The agent asked for more specific details or t...  \n",
       "bafb7f9a-6bba-4688-979c-44ef5806e63c  The agent provided a detailed dosage recommend...  \n",
       "60ae2e7a-f233-4b6f-bf07-fef9868e308b  The agent provided a detailed explanation of t...  \n",
       "83834ed7-b4e8-4398-a245-4dcc0b70a90a  The agent provided a range of 0.05–0.1 mg/kg/d...  \n",
       "b7e02d60-e289-440d-a5bb-ea672a645e2c  The agent provided additional information abou...  \n",
       "09293f52-3d2d-4703-a5ae-5db98ca15677  The agent provided a detailed breakdown of the...  \n",
       "b58ca274-6b2d-4175-99a2-40c562c78745  The agent provided a detailed explanation on h...  \n",
       "073e6f4f-6a32-46f5-bc70-958a61639dac  The agent provided a detailed list of potentia...  \n",
       "f85bdc35-cddf-495a-b48d-8fbeca4d891f  The agent provided a detailed step-by-step dis...  \n",
       "9d8ea49c-de2d-4e65-8910-361f43b6f1c9  The agent provided detailed and accurate stora...  \n",
       "649a3d8e-5cd8-44b0-8ffb-868ba4ce01e5  The agent provided detailed information about ...  \n",
       "878fbabf-46e5-461b-a597-49c041f935c5  The agent provided a list of additional potent...  \n",
       "2f238ce2-3f72-4d6e-aa80-ca7b240bae2f  The agent provided detailed mechanisms for the...  \n",
       "45d0dfc6-5092-4017-b8d6-c8b760bcda7b  The agent provided additional information abou...  \n",
       "5fed25c2-0e4f-44c1-b3c8-068933ba4baa  The agent provided a detailed answer about the...  "
      ]
     },
     "execution_count": 121,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "report.get_failures()"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ce80b9da",
   "metadata": {},
   "source": [
    "#### Llama 3 RAG"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 69,
   "id": "268914b7",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_llama3_rag(question, history=None):\n",
    "    return chain_llama3_rag.invoke({\"question\": question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "8b7b5104",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "382fcddf03784236b5be6f0f439184dd",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c30ed1bfb6654f09864113dedeabe359",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"e0970401-5d4e-41cd-b869-05ada4e55190\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"e0970401-5d4e-41cd-b869-05ada4e55190\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"e0970401-5d4e-41cd-b869-05ada4e55190\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">100%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">To improve your RAG system, focus on enhancing the Retriever component to better handle complex questions and ensure that the Generator performs consistently well across both topics.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"91b960cc-2856-4b99-8411-dbf409b11f97\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1686\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1688\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1695\",\"attributes\":{\"factors\":[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1696\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1697\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1693\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1715\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1683\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1684\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1685\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"AAAAAAAAWUAAAAAAAABZQA==\"},\"shape\":[2],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"colors\",[\"#a50026\",\"#a50026\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1716\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1717\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1712\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1713\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1714\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1724\",\"attributes\":{\"data_source\":{\"id\":\"p1683\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1725\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1726\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1721\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1722\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1723\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1734\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1728\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1729\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1730\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1735\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1736\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1731\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1732\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1733\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1694\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1708\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1703\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1704\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1705\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1706\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1698\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1699\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1700\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1701\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1702\",\"attributes\":{\"axis\":{\"id\":\"p1698\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1707\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1703\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p1727\",\"attributes\":{\"location\":100.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1737\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1738\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p1734\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"91b960cc-2856-4b99-8411-dbf409b11f97\",\"roots\":{\"p1686\":\"fa69cd20-18c5-4e94-a5fe-1b26bce4b1bb\"},\"root_ids\":[\"p1686\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"fa69cd20-18c5-4e94-a5fe-1b26bce4b1bb\" data-root-id=\"p1686\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"cf4e03d8-cfea-46ea-a23b-3d3f5c777ae8\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p1617\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1548\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1497\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1506\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1507\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1508\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1509\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1504\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1537\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1494\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1495\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1496\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"hl8Dwb/DCcFsGBDBaOMMwd0zB8GzKA3B1vP/wJAx+cBXVQjBA/YBwUai58AB2unAlI3LwMkE5MB2gt/A6FLswDAd6cA9uuHAopr5wLT24cAlLQXBWYnawPTbz8AS/AvBGpj2wD/pxsDtNPTAl5zZwO+gysAzMLvAucy4wAZOq8A1AKzAEzStwPmAycAjA8LAadO9wFn1vsCsybvAHc/TwLMC0cAxFuvAcjnewMjfEsEv/QrBltwKwSEzCsFFshDBdO4SwQNqBsEx6v/AYF3LwGC69sBSpgbBrBcDwc/W/8BZqu3AvP7kwPGD5MCx7ALBelQPwcC+EMGDjwfBTlsFwdRzA8G+IezA598GwZx4BMEuaOjAp2T8wPHS7cAQ7MvAnFfNwPk018B9EbvAdAW8wMrR0MAmeOzAAQ7xwFH2+MCytPzAE8f5wOVT/MB8KA7BBN8NwSnyC8ECcQnBrr8CwVfuD8FAWAPB8FDrwG7i2cCeX7bAxD+3wL6ztMAJWq7A3O/RwAV/ucCp7MPA6FLBwLY518CP+NHAgQPYwE/XycCi/NfA3a+/wLsV0cBqN6LAQ8k2wAg2H8CAmiLAgHNQwCuKM8AowRnAsVI/wAuniMCuh2PAaytLwEb4lMDDfCzAm0lEwFunesAoXlnA8gtKwIEBTsAiw2nAzMuWwJiHn8COHZDAEuWlwMM1qMD41pzArdddwOaom8AFeHzARtJZwPt9c8D9JnnAEUOBwK8KhsBxfQ7AEb0CwCJrEcC7utG/SB/4v9Z38r/kiz/AUPUOwE9SqMDJeJzAUXCewLI9BsDFHCHA6dpawHAKqMA=\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154]],[\"content\",[\"ATRIPLA ACCESS- efavirenz, emtricitabine, and tenofovir disoproxil\\\\nfumarate tablet, film coated \\\\n \\\\nGilead Sciences, Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ATRIPLA safely and\\\\neffectively. See full prescribing information for ATRIPLA.\\\\nATRIPLA\\\\u2122 (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets, for oral use\\\\nGILEAD ACCESS PROGRAM\\\\nInitial U.S. Approval: 2006\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION O...\",\"WARNINGS AND PRECAUTIONS\\\\nRash: Discontinue if severe rash develops. (\\\\n5.2\\\\n, \\\\n6.1\\\\n)\\\\nHepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying\\\\nhepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are\\\\ntaking medications associated with liver toxicity. Among reported cases of hepatic failure, a few\\\\noccurred in patients with no pre-existing hepatic disease. (\\\\n5.3\\\\n, \\\\n6.2\\\\n, \\\\n8.7\\\\n)\\\\nRisk of adverse reactions or loss of ...\",\"2.1 Testing Prior to Initiation and During Treatment with ATRIPLA\\\\n2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg\\\\n2.3 Not Recommended in Patients with Moderate or Severe Renal Impairment\\\\n2.4 Not Recommended in Patients with Moderate to Severe Hepatic Impairment\\\\n2.5 Dosage Adjustment with Rifampin\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and\\\\nHBV\\\\n5.2 Ra...\",\"16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B\\\\nSevere acute exacerbations of hepatitis B virus (HBV) have been\\\\nreported in patients who are coinfected with HIV-1 and HBV and have\\\\ndiscontinued products containing emtricitabine (FTC) and/or tenofovir\\\\ndisoproxil fumarate (TDF), which are components of ATRIPLA.\\\\nClosely monitor hepatic function with both clinical and laboratory follow-\\\\nup f...\",\"ATRIPLA is a three-drug fixed-dose combination product containing 600 mg of efavirenz\\\\n(EFV), 200 mg of emtricitabine (FTC), and 300 mg of tenofovir disoproxil fumarate (TDF).\\\\nThe recommended dosage of ATRIPLA in \\\\nadults and pediatric patients weighing at least\\\\n40 kg\\\\n is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may\\\\nimprove the tolerability of nervous system symptoms \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n2.3 Not Recommended in Patients with Moderate or Severe Ren...\",\"closely monitored, with both clinical and laboratory follow-up for at least several months\\\\nafter stopping treatment with ATRIPLA. If appropriate, initiation of anti-hepatitis B\\\\ntherapy may be warranted, especially in patients with advanced liver disease or cirrhosis,\\\\nsince posttreatment exacerbation of hepatitis may lead to hepatic decompensation and\\\\nliver failure.\\\\n5.2 Rash\\\\nIn controlled clinical trials, 26% (266/1,008) of adult subjects treated with 600 mg EFV\\\\nexperienced new-onset skin rash co...\",\"[see \\\\nDosage and Administration (2.1)\\\\n].\\\\n Consider discontinuing ATRIPLA in patients with\\\\npersistent elevations of serum transaminases to greater than five times the upper limit\\\\nof the normal range.\\\\nDiscontinue ATRIPLA if elevation of serum transaminases is accompanied by clinical\\\\nsigns or symptoms of hepatitis or hepatic decompensation \\\\n[see \\\\nAdverse Reactions\\\\n(6.1)\\\\n].\\\\n5.4 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug\\\\nInteractions\\\\nThe concomitant use of ATRIPLA and other d...\",\"discontinued or interrupted treatment because of one or more of these selected\\\\npsychiatric symptoms. There have also been occasional postmarketing reports of death\\\\nby suicide, delusions, and psychosis-like behavior, although a causal relationship to the\\\\nuse of EFV cannot be determined from these reports. Postmarketing cases of catatonia\\\\nhave also been reported and may be associated with increased EFV exposure. Patients\\\\nwith serious psychiatric adverse experiences should seek immediate medical ev...\",\"Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal\\\\ntubular injury with severe hypophosphatemia), has been reported with the use of TDF, a\\\\ncomponent of ATRIPLA \\\\n[see \\\\nAdverse Reactions (6.2)\\\\n].\\\\nPrior to initiation and during use of ATRIPLA, on a clinically appropriate schedule, assess\\\\nserum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all\\\\npatients. In patients with chronic kidney disease, also assess serum phosphorus.\\\\nATRIPLA is...\",\"considered for adult and pediatric patients who have a history of pathologic bone\\\\nfracture or other risk factors for osteoporosis or bone loss. Although the effect of\\\\nsupplementation with calcium and vitamin D was not studied, such supplementation may\\\\nbe beneficial for all patients. If bone abnormalities are suspected, then appropriate\\\\nconsultation should be obtained.\\\\nMineralization Defects\\\\nCases of osteomalacia associated with proximal renal tubulopathy, manifested as bone\\\\npain or pain in extre...\",\"enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and\\\\n\\\\\"cushingoid appearance,\\\\\" has been observed in patients receiving antiretroviral therapy,\\\\nincluding EFV. The mechanism and long-term consequences of these events are\\\\ncurrently unknown. A causal relationship has not been established.\\\\n6 ADVERSE REACTIONS\\\\nThe following adverse reactions are discussed in other sections of the labeling:\\\\nSevere Acute Exacerbations of Hepatitis B in Patients Coinfected with HIV-1 and...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nDizziness\\\\n8%\\\\n7%\\\\nUpper respiratory tract infections\\\\n8%\\\\n5%\\\\nSinusitis\\\\n8%\\\\n4%\\\\nRash Event\\\\n7%\\\\n9%\\\\nHeadache\\\\n6%\\\\n5%\\\\nInsomnia\\\\n5%\\\\n7%\\\\nAnxiety\\\\n5%\\\\n4%\\\\nNasopharyngitis\\\\n5%\\\\n3%\\\\nVomiting\\\\n2%\\\\n5%\\\\nIn Study 073, subjects with stable, virologic suppression on antiretroviral therapy and no\\\\nhistory of virologic failure were randomized to receive ATRIPLA or to stay on their\\\\nbaseline regimen. The adverse reactions observed in Study 073 were generally\\\\nconsistent with those seen in Study 934 and those seen with the individ...\",\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"subjects treated with EFV and fixed-dose zidovudine/lamivudine were hepatitis B surface\\\\nantigen or hepatitis C antibody positive. Among these coinfected subjects, one subject\\\\n(1/19) in the EFV, FTC, and TDF arm had elevations in transaminases to greater than five\\\\ntimes ULN through 144 weeks. In the fixed-dose zidovudine/lamivudine arm, two\\\\nsubjects (2/20) had elevations in transaminases to greater than five times ULN through\\\\n144 weeks. No HBV and/or HCV coinfected subject discontinued from the t...\",\"Dyspnea\\\\nSkin and Subcutaneous Tissue Disorders\\\\n \\\\nFlushing, erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome\\\\nEmtricitabine\\\\n:\\\\n No postmarketing adverse reactions have been identified for inclusion in\\\\nthis section.\\\\nTenofovir DF:\\\\nImmune System Disorders\\\\n \\\\nAllergic reaction, including angioedema\\\\nMetabolism and Nutrition Disorders\\\\n \\\\nLactic acidosis, hypokalemia, hypophosphatemia\\\\nRespiratory, Thoracic, and Mediastinal Disorders\\\\n \\\\nDyspnea\\\\nGastrointestinal Disorders\\\\n \\\\nPancreatitis,...\",\"There is limited information available on the potential for a pharmacodynamic interaction\\\\nbetween EFV and drugs that prolong the QTc interval. QTc prolongation has been\\\\nobserved with the use of EFV \\\\n[see \\\\nClinical Pharmacology (12.2)\\\\n].\\\\n Consider alternatives to\\\\nATRIPLA when coadministered with a drug with a known risk of Torsade de Pointes.\\\\n7.2 Drugs Affecting Renal Function\\\\nFTC and tenofovir are primarily eliminated by the kidneys\\\\n[see \\\\nClinical Pharmacology\\\\n(12.3)\\\\n].\\\\n Coadministration of ATRI...\",\"the increased indinavir metabolism due to\\\\nEFV.\\\\nProtease inhibitor:\\\\n  darunavir/ritonavir\\\\n\\\\u2191 tenofovir\\\\nMonitor patients receiving ATRIPLA\\\\nconcomitantly with ritonavir-boosted\\\\ndarunavir for TDF-associated adverse\\\\nreactions. Discontinue ATRIPLA in\\\\npatients who develop TDF-associated\\\\nadverse reactions.\\\\n  lopinavir/ritonavir\\\\n\\\\u2193 lopinavir\\\\n\\\\u2191 tenofovir\\\\nDo not use once daily administration of\\\\nlopinavir/ritonavir. Dose increase of\\\\nlopinavir/ritonavir is recommended for all\\\\npatients when coadministered with ...\",\"NRTI:\\\\n  didanosine\\\\n\\\\u2191 didanosine\\\\nreceiving TDF with didanosine 400 mg\\\\ndaily. \\\\nIn patients weighing greater than 60 kg,\\\\nreduce the didanosine dose to 250 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nIn patients weighing less than 60 kg,\\\\nreduce the didanosine dose to 200 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nWhen coadministered, ATRIPLA and\\\\nVidex EC may be taken under fasted\\\\nconditions or with a light meal (less than\\\\n400 kcal, 20% fat).\\\\nNNRTI:\\\\n  Other NNRTIs\\\\n\\\\u2191 or \\\\u2193 efavirenz\\\\nand/or NNRTI\\\\nCombini...\",\"Anticoagulant:\\\\n  warfarin\\\\n\\\\u2191 or \\\\u2193 warfarin\\\\nPlasma concentrations and effects\\\\npotentially increased or decreased by\\\\nEFV.\\\\nAnticonvulsants:\\\\n  carbamazepine\\\\n\\\\u2193 carbamazepine\\\\n\\\\u2193 efavirenz\\\\nThere are insufficient data to make a\\\\ndose recommendation for ATRIPLA.\\\\nAlternative anticonvulsant treatment\\\\nshould be used.\\\\n  phenytoin\\\\n  phenobarbital\\\\n\\\\u2193 anticonvulsant\\\\n\\\\u2193 efavirenz\\\\nPotential for reduction in anticonvulsant\\\\nand/or EFV plasma levels; periodic\\\\nmonitoring of anticonvulsant plasma\\\\nlevels should be conducted...\",\"artemether/lumefantrine\\\\n  atovaquone/proquanil\\\\n\\\\u2193 dihydroartemisinin\\\\n\\\\u2193 lumefantrine\\\\n\\\\u2193 atovaquone\\\\n\\\\u2193 proguanil\\\\nrisk of QT interval prolongation \\\\n[see\\\\nWarnings and Precautions (5.4)\\\\n]\\\\n.\\\\nConcomitant administration of\\\\natovaquone/proguanil with ATRIPLA is\\\\nnot recommended.\\\\nCalcium channel\\\\nblockers:\\\\n  diltiazem\\\\n\\\\u2193 diltiazem\\\\n\\\\u2193 desacetyl\\\\ndiltiazem\\\\n\\\\u2193 N-monodes-\\\\nmethyl diltiazem\\\\nDiltiazem dose adjustments should be\\\\nguided by clinical response (refer to the\\\\nfull prescribing information for diltiazem).\\\\nNo dose ...\",\"*\\\\ntacrolimus, sirolimus, and\\\\nothers metabolized by\\\\nCYP3A\\\\nsuppressant\\\\nmay be required. Close monitoring of\\\\nimmunosuppressant concentrations for\\\\nat least 2 weeks (until stable\\\\nconcentrations are reached) is\\\\nrecommended when starting or stopping\\\\ntreatment with ATRIPLA.\\\\nNarcotic analgesic:\\\\n  methadone\\\\n\\\\u2193 methadone\\\\nCoadministration of EFV in HIV-1 infected\\\\nindividuals with a history of injection drug\\\\nuse resulted in signs of opiate\\\\nwithdrawal. Methadone dose was\\\\nincreased by a mean of 22% to alleviate...\",\"for EFV, FTC, or TDF compared with the background rate for major birth defects of\\\\n2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects\\\\nProgram (MACDP) \\\\n(see \\\\nData\\\\n)\\\\n.\\\\nThe rate of miscarriage is not reported in the APR. The estimated background rate of\\\\nmiscarriage in clinically recognized pregnancies in the U.S. general population is 15-20%.\\\\nThe background risk of major birth defects and miscarriage for the indicated population\\\\nis unknown. The APR uses the MACDP as t...\",\"Animal Data\\\\nEfavirenz:\\\\n Effects of EFV on embryo-fetal development have been studied in three\\\\nnonclinical species (cynomolgus monkeys, rats, and rabbits). In monkeys, EFV 60\\\\nmg/kg/day was administered to pregnant females throughout pregnancy (gestation\\\\nDays 20 through 150). The maternal systemic drug exposures (AUC) were 1.3 times the\\\\nexposures at the RHD, with fetal umbilical venous drug concentrations approximately\\\\n0.7 times the maternal values. Three fetuses of 20 fetuses/infants had one or m...\",\"Based on limited published data, EFV, FTC, and tenofovir have been shown to be present\\\\nin human breast milk.\\\\nIt is not known if the components of ATRIPLA affect milk production or have effects on\\\\nthe breastfed child. Because of the potential for: (1) HIV transmission (in HIV-negative\\\\ninfants); (2) developing viral resistance (in HIV-positive infants); and (3) adverse\\\\nreactions in a breastfed infant similar to those seen in adults, instruct mothers not to\\\\nbreastfeed if they are receiving ATRIPLA....\",\"8.7 Hepatic Impairment\\\\nATRIPLA is not recommended for patients with moderate or severe hepatic impairment\\\\nbecause there are insufficient data to determine an appropriate dose. Patients with mild\\\\nhepatic impairment may be treated with ATRIPLA at the approved dose. Because of the\\\\nextensive cytochrome P450-mediated metabolism of EFV and limited clinical experience\\\\nin patients with hepatic impairment, caution should be exercised in administering\\\\nATRIPLA to these patients \\\\n[see \\\\nDosage and Administra...\",\"Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It\\\\nis practically insoluble in water (less than 10 \\\\u00b5g/mL).\\\\nEmtricitabine:\\\\n The chemical name of FTC is 5-fluoro-1-(2\\\\nR\\\\n,5\\\\nS\\\\n)-[2-(hydroxymethyl)-1,3-\\\\noxathiolan-5-yl]cytosine. FTC is the (-) enantiomer of a thio analog of cytidine, which\\\\ndiffers from other cytidine analogs in that it has a fluorine in the 5-position.\\\\nIt has a molecular formula of C\\\\nH\\\\nFN\\\\nO\\\\nS and a molecular weight of 247.24. It has the\\\\nfollo...\",\"12.1 Mechanism of Action\\\\nATRIPLA is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF \\\\n[see\\\\nMicrobiology (12.4)\\\\n].\\\\n12.2 Pharmacodynamics\\\\nCardiac Electrophysiology\\\\nEfavirenz:\\\\n \\\\nThe effect of EFV on the QTc interval was evaluated in an open-label, positive\\\\nand placebo-controlled, fixed single sequence 3-period, 3-treatment crossover QT study\\\\nin 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean C\\\\n of EFV in\\\\nsubjects with CYP2B6 *6/*6 genotype following the administration o...\",\"Tenofovir DF:\\\\n \\\\nFollowing oral administration of a single 300 mg dose of TDF to HIV-1\\\\ninfected subjects in the fasted state, maximum serum concentrations (C\\\\n) were\\\\nachieved in 1.0 \\\\u00b1 0.4 hrs (mean \\\\u00b1 SD) and C\\\\n and AUC values were 296 \\\\u00b1 90 ng/mL\\\\nand 2287 \\\\u00b1 685 ng\\\\u2219hr/mL, respectively. The oral bioavailability of tenofovir from TDF in\\\\nfasted subjects is approximately 25%. Less than 0.7% of tenofovir binds to human\\\\nplasma proteins in vitro, and the binding is independent of concentration over the ran...\",\"daily dose of 200 mg.\\\\nTenofovir DF:\\\\n Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1\\\\ninfected pediatric subjects (12 to less than 18 years). Mean \\\\u00b1 SD C\\\\n and AUC\\\\n are\\\\n0.38 \\\\u00b1 0.13 \\\\u03bcg/mL and 3.39 \\\\u00b1 1.22 \\\\u03bcg\\\\u2219hr/mL, respectively. Tenofovir exposure\\\\nachieved in these pediatric subjects receiving oral daily doses of TDF 300 mg was similar\\\\nto exposures achieved in adults receiving once-daily doses of TDF 300 mg.\\\\nGeriatric Patients\\\\nPharmacokinetics of EFV, FTC, and tenofovir have not...\",\"concentrations well above those achieved clinically. Coadministration of EFV with drugs\\\\nprimarily metabolized by CYP2C9, CYP2C19, CYP3A or CYP2B6 isozymes may result in\\\\naltered plasma concentrations of the coadministered drug. Drugs which induce CYP3A\\\\nand CYP2B6 activity would be expected to increase the clearance of EFV resulting in\\\\nlowered plasma concentrations.\\\\nDrug interaction trials were performed with EFV and other drugs likely to be\\\\ncoadministered or drugs commonly used as probes for phar...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\nCarbamazepine\\\\n200 mg qd \\\\u00d7 3\\\\ndays, 200 mg bid\\\\n\\\\u00d7 3 days, then\\\\n400 mg qd \\\\u00d7 15\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 35\\\\ndays\\\\n14\\\\n\\\\u2193 21\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 26)\\\\n\\\\u2193 36\\\\n(\\\\u2193 32 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 47\\\\n(\\\\u2193 41 to\\\\n\\\\u2193 53)\\\\nDiltiazem\\\\n240 mg \\\\u00d7 14\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 28\\\\ndays\\\\n12\\\\n\\\\u2191 16\\\\n(\\\\u2191 6 to \\\\u2191\\\\n26)\\\\n\\\\u2191 11\\\\n(\\\\u2191 5 to \\\\u2191\\\\n18)\\\\n\\\\u2191 13\\\\n(\\\\u2191 1 to \\\\u2191\\\\n26)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg\\\\nqd \\\\u00d7 9\\\\ndays\\\\nNA\\\\n\\\\u2191 38\\\\n\\\\u2191 44\\\\nNA\\\\n300 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 mg\\\\nqd \\\\u00d7 7\\\\ndays\\\\nNA\\\\n\\\\u2193 14\\\\n \\\\n(\\\\u2193 7 to \\\\u2193\\\\n21)\\\\n\\\\u2194\\\\nNA\\\\n400 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 m...\",\"meal\\\\n7\\\\u201320\\\\n300 mg\\\\nqd/ritonavir 100\\\\nmg qd d 1\\\\u201310\\\\n(pm), then 400\\\\nmg qd/ritonavir\\\\n100 mg qd d 11\\\\u2013\\\\n24 (pm)\\\\n(simultaneous\\\\nwith EFV)\\\\n600 mg qd\\\\nwith a light\\\\nsnack d\\\\n11\\\\u201324 (pm)\\\\n14\\\\n\\\\u2191 17\\\\n(\\\\u2191 8 to \\\\u2191\\\\n27)\\\\n\\\\u2194\\\\n\\\\u2193 42\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 51)\\\\nIndinavir\\\\n1000 mg q8h \\\\u00d7\\\\n10 days\\\\n600 mg qd\\\\n\\\\u00d7 10 days\\\\n20\\\\nAfter morning dose\\\\n\\\\u2194\\\\n\\\\u2193 33\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 39)\\\\n\\\\u2193 39\\\\n \\\\n(\\\\u2193 24 to\\\\n\\\\u2193 51)\\\\nAfter afternoon dose\\\\n\\\\u2194\\\\n\\\\u2193 37\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 46)\\\\n\\\\u2193 52\\\\n \\\\n(\\\\u2193 47 to\\\\n\\\\u2193 57)\\\\nAfter evening dose\\\\n\\\\u2193 29\\\\n \\\\n(\\\\u2193 11 to\\\\n\\\\u2193 43)\\\\n\\\\u2193 46\\\\n \\\\n(\\\\u2193 37 to\\\\n\\\\u2193 54)\\\\n\\\\u2193 57\\\\n \\\\n(\\\\u2193 50 to\\\\n\\\\u2193 63)\\\\nLopinavir/ritona...\",\"days\\\\n\\\\u00d7 16 days\\\\nto \\\\u2191 8)\\\\n25)\\\\n58)\\\\nSimeprevir\\\\n150 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n23\\\\n\\\\u2193 51\\\\n(\\\\u2193 46 to\\\\n\\\\u2193 56)\\\\n\\\\u2193 71\\\\n(\\\\u2193 67 to\\\\n\\\\u2193 74)\\\\n\\\\u2193 91\\\\n(\\\\u2193 88 to\\\\n\\\\u2193 92)\\\\nLedipasvir/sofosbuvir\\\\n90/400 mg qd \\\\u00d7\\\\n14 days\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\nLedipasvir\\\\n15\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 43)\\\\nSofosbuvir\\\\n\\\\u2194\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2194\\\\n\\\\u2194\\\\n\\\\u2194\\\\nSofosbuvir\\\\n400 mg qd single\\\\ndose\\\\n600 mg qd\\\\n\\\\u00d714 days\\\\n16\\\\n\\\\u2193 19\\\\n(\\\\u2193 40 to\\\\n\\\\u2191 10)\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2193 23\\\\n(\\\\u2193 16 to\\\\n\\\\u2193 30)\\\\n\\\\u2193 16\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 8)\\\\nNA\\\\nSofosbuvir/velpatasvir\\\\n400/100 mg qd \\\\u00d7\\\\n14 days\\\\n600...\",\"120 mg tablets (6\\\\n4-tablet doses\\\\nover 3 days)\\\\nArtemether\\\\n\\\\u2193 21\\\\u2193 38\\\\n\\\\u2193 51\\\\nNA\\\\ndihydroartemisinin\\\\n\\\\u2194\\\\n\\\\u2193 46\\\\nNA\\\\nlumefantrine\\\\n\\\\u219321\\\\nNA\\\\nAtorvastatin\\\\n10 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 14\\\\n(\\\\u2193 1 to \\\\u2193\\\\n26)\\\\n\\\\u2193 43\\\\n(\\\\u2193 34 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 69\\\\n(\\\\u2193 49 to\\\\n\\\\u2193 81)\\\\nTotal active (including\\\\nmetabolites)\\\\n\\\\u2193 15\\\\n(\\\\u2193 2 to \\\\u2193\\\\n26)\\\\n\\\\u2193 32\\\\n(\\\\u2193 21 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 48\\\\n(\\\\u2193 23 to\\\\n\\\\u2193 64)\\\\nPravastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n13\\\\n\\\\u2193 32\\\\n(\\\\u2193 59 to\\\\n\\\\u2191 12)\\\\n\\\\u2193 44\\\\n(\\\\u2193 26 to\\\\n\\\\u2193 57)\\\\n\\\\u2193 19\\\\n(\\\\u2193 0 to \\\\u2193\\\\n35)\\\\nSimvastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 7...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\n\\\\u00f0\\\\n\\\\u00f8\\\\n\\\\u00fd\\\\n\\\\u00a3\\\\nMethadone\\\\nmaintenance 35\\\\u2013\\\\n100 mg daily\\\\n\\\\u00d7 14\\\\u201321\\\\ndays\\\\n11\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 59)\\\\n(\\\\u2193 33 to\\\\n\\\\u2193 66)\\\\nNA\\\\nBupropion\\\\n150 mg single\\\\ndose (sustained-\\\\nrelease)\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 34\\\\n(\\\\u219321 to\\\\n\\\\u219347)\\\\n\\\\u2193 55\\\\n(\\\\u219348 to\\\\n\\\\u219362)\\\\nNA\\\\nHydroxybupropion\\\\n\\\\u2191 50\\\\n(\\\\u2191 20 to\\\\n\\\\u2191 80)\\\\n\\\\u2194\\\\nNA\\\\nSertraline\\\\n50 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 29\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 39\\\\n(\\\\u2193 27 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 46\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 58)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg qd\\\\n\\\\u00d7 9 days\\\\nNA\\\\n\\\\u2193 61\\\\n\\\\u2193 77\\\\nN...\",\"no clinically significant drug interactions have been observed between TDF and abacavir,\\\\nEFV, FTC, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral\\\\ncontraceptives, ribavirin, saquinavir/ritonavir, sofosbuvir, or tacrolimus in trials\\\\nconducted in healthy volunteers.\\\\nFollowing multiple dosing to HIV-negative subjects receiving either chronic methadone\\\\nmaintenance therapy, oral contraceptives, or single doses of ribavirin, steady-state\\\\ntenofovir pharmacokinetics we...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\nTable 7 Drug Interactions: Changes in Pharmacokinetic Parameters for\\\\nCoadministered Drug in the Presence of TDF\\\\nCoadministered\\\\nDrug\\\\nDose of\\\\nCoadministered\\\\nDrug (mg)\\\\nN\\\\nMean % Change of Coadministered\\\\nDrug Pharmacokinetic Parameters\\\\n \\\\n(90% CI)\\\\nC\\\\nAUC\\\\nC\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\nAtazanavir\\\\n400 once daily \\\\u00d7\\\\n14 days\\\\n34\\\\n\\\\u2193 21\\\\n(\\\\u2193 27 to \\\\u2193 14)\\\\n\\\\u2193 25\\\\n(\\\\u2193 30 to \\\\u2193 19)\\\\n\\\\u2193 40\\\\n(\\\\u2193 48 to \\\\u2193 32)\\\\nAtazanavir/ritonavir\\\\n300/100 once daily\\\\n\\\\u00d7 42 days\\\\n10\\\\n\\\\u2193 28\\\\n(\\\\u2193 50 to \\\\u2191 5)\\\\n\\\\u2193 25\\\\n \\\\n(\\\\u2193 42 to \\\\u2193 3)\\\\n\\\\u2193 23\\\\n \\\\n(\\\\u2193 46 to \\\\u2191 10)\\\\nDa...\",\"Efavirenz:\\\\n \\\\nEFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1.\\\\nEfavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1\\\\nreverse transcriptase. HIV-2 RT and human cellular DNA polymerases \\\\u03b1, \\\\u03b2, \\\\u03b3, and \\\\u03b4 are\\\\nnot inhibited by EFV.\\\\nEmtricitabine:\\\\n \\\\nEmtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated\\\\nby cellular enzymes to form FTC 5&#x27;-triphosphate. Emtricitabine 5&#x27;-triphosphate inhibits\\\\nthe activity of the HIV-1 RT by competing wi...\",\"tenofovir were in the range of 0.04\\\\u20138.5 \\\\u00b5M. In drug combination studies of tenofovir\\\\nwith NRTIs (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine),\\\\nNNRTIs (delavirdine, EFV, and nevirapine), and PIs (amprenavir, indinavir, nelfinavir,\\\\nritonavir, and saquinavir), additive to synergistic effects were observed. Tenofovir\\\\ndisplayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O\\\\n(EC\\\\n values ranged from 0.5\\\\u20132.2 \\\\u00b5M) and showed strain-specific ...\",\"susceptibility to FTC was associated with a substitution in the HIV-1 RT gene at codon\\\\n184 which resulted in an amino acid substitution of methionine by valine or isoleucine\\\\n(M184V/I).\\\\nTenofovir DF:\\\\n \\\\nHIV-1 isolates with reduced susceptibility to tenofovir have been selected\\\\nin cell culture. These viruses expressed a K65R substitution in RT and showed a 2- to 4-\\\\nfold reduction in susceptibility to tenofovir.\\\\nCross Resistance\\\\nEfavirenz, Emtricitabine, and Tenofovir DF:\\\\n Cross resistance has been ...\",\"Efavirenz:\\\\n \\\\nLong-term carcinogenicity studies in mice and rats were carried out with EFV.\\\\nMice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of\\\\nhepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas\\\\nwere increased above background in females. No increases in tumor incidence above\\\\nbackground were seen in males. In studies in which rats were administered EFV at\\\\ndoses of 0, 25, 50, or 100 mg/kg/day for 2 years, no increases in tumor incidence\\\\n...\",\"an alteration of the estrous cycle in female rats.\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\nEfavirenz:\\\\n \\\\nNonsustained convulsions were observed in 6 of 20 monkeys receiving EFV at\\\\ndoses yielding plasma AUC values 4- to 13-fold greater than those in humans given the\\\\nrecommended dose.\\\\nTenofovir DF:\\\\n \\\\nTenofovir and TDF administered in toxicology studies to rats, dogs, and\\\\nmonkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed\\\\nin humans caused bone toxicity. In monkeys...\",\"Outcomes\\\\nAt Week 48\\\\nAt Week 144\\\\nFTC+TDF+EFV\\\\n(N=244)\\\\nAZT/3TC+EFV\\\\n(N=243)\\\\nFTC+TDF+\\\\nEFV\\\\n(N=227)\\\\nAZT/3TC+EFV\\\\n(N=229)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\nResponder\\\\n84%\\\\n73%\\\\n71%\\\\n58%\\\\nVirologic failure\\\\n2%\\\\n4%\\\\n3%\\\\n6%\\\\n  Rebound\\\\n1%\\\\n3%\\\\n2%\\\\n5%\\\\n  Never suppressed\\\\n0%\\\\n0%\\\\n0%\\\\n0%\\\\n  Change in antiretroviral\\\\nregimen\\\\n1%\\\\n1%\\\\n1%\\\\n1%\\\\nDeath\\\\n&lt;1%\\\\n1%\\\\n1%\\\\n1%\\\\nDiscontinued due to\\\\nadverse event\\\\n4%\\\\n9%\\\\n5%\\\\n12%\\\\nDiscontinued for other\\\\nreasons\\\\n10%\\\\n14%\\\\n20%\\\\n22%\\\\nThrough Week 48, 84% and 73% of subjects in the FTC + TDF group and the\\\\nzidovudine/lamivudine group, respectiv...\",\"22-73 years); 88% were male, 68% were white, 29% were Black or African-American,\\\\nand 3% were of other races. At baseline, median CD4\\\\n cell count was 516 cells/mm\\\\n,\\\\nand 96% had HIV-1 RNA &lt;50 copies/mL. The median time since onset of antiretroviral\\\\ntherapy was 3 years, and 88% of subjects were receiving their first antiretroviral\\\\nregimen at trial enrollment.\\\\nAt Week 48, 89% and 87% of subjects who switched to ATRIPLA maintained HIV RNA\\\\n&lt;200 copies/mL and &lt;50 copies/mL, respectively, compared to 88...\",\"Interactions (7)\\\\n]\\\\n.\\\\nPsychiatric Symptoms\\\\nInform patients that serious psychiatric symptoms including severe depression,\\\\nsuicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms,\\\\nand catatonia have been reported in patients receiving EFV, a component of ATRIPLA\\\\n[see \\\\nWarnings and Precautions (5.5)\\\\n]\\\\n.\\\\nAdvise patients to seek immediate medical evaluation if they experience severe\\\\npsychiatric adverse experiences.\\\\nAdvise patients to inform their physician of any history o...\",\"Convulsions\\\\nInform patients that convulsions have been reported with the use of EFV, a component\\\\nof ATRIPLA. Patients who are receiving concomitant anticonvulsant medications primarily\\\\nmetabolized by the liver may require periodic monitoring of plasma levels \\\\n[see \\\\nWarnings\\\\nand Precautions (5.10)\\\\n and \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\nLactic Acidosis and Severe Hepatomegaly\\\\nInform patients that lactic acidosis and severe hepatomegaly with steatosis, including\\\\nfatal cases, have been reported. Treatmen...\",\"Patient Information\\\\n \\\\nATRIPLA\\\\u2122 (uh TRIP luh)\\\\n(efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets\\\\nWhat is the most important information I should know about ATRIPLA?\\\\nATRIPLA can cause serious side effects, including:\\\\nWorsening of hepatitis B virus (HBV) infection.\\\\n Your healthcare provider will\\\\ntest you for HBV before starting treatment with ATRIPLA. If you have HBV infection\\\\nand take ATRIPLA, your HBV may get worse (flare-up) if you stop taking ATRIPLA. \\\\nA\\\\n\\\\\"flare-up\\\\\" is when yo...\",\"be pregnant during treatment with ATRIPLA.\\\\nFemales who are able to become pregnant should use 2 effective\\\\nforms of birth control (contraception) during treatment with ATRIPLA\\\\nand for 12 weeks after stopping treatment.\\\\nA barrier form of birth control should always be used along with\\\\nanother type of birth control\\\\n. Barrier forms of birth control may include\\\\ncondoms, contraceptive sponges, diaphragm with spermicide, and cervical cap.\\\\nBirth control methods that contain the hormone progesterone such ...\",\"See \\\\\"\\\\nWhat is the most important information I should know about\\\\nATRIPLA?\\\\n\\\\\"\\\\nRash.\\\\n Rash is a serious side effect, but may also be common. Rashes will usually go\\\\naway without any change in your treatment. Tell your healthcare provider right away\\\\nif you develop a rash during treatment with ATRIPLA.\\\\nSevere liver problems. I\\\\nn rare cases, severe liver problems can happen that can\\\\nlead to death. \\\\nTell your healthcare provider right away if you get these\\\\nsymptoms:\\\\n skin or the white part of your eyes ...\",\"provider right away if you develop any of these symptoms:\\\\nweakness or being more tired than\\\\nusual\\\\nbeing short of breath or fast\\\\nbreathing\\\\ncold or blue hands and feet\\\\nfast or abnormal heartbeat\\\\nunusual muscle pain\\\\nstomach pain with nausea and vomiting\\\\nfeel dizzy or lightheaded\\\\nChanges in your immune system (Immune Reconstitution Syndrome) can\\\\nhappen when an HIV-1 infected person starts taking HIV-1 medicines.\\\\n Your\\\\nimmune system may get stronger and begin to fight infections that have been hidden...\",\"respective owners.\\\\n\\\\u00a9 2019 Gilead Sciences, LLC. All rights reserved.\\\\n21937-GS-020A\\\\nPRINCIPAL DISPLAY PANEL - 30 Tablet Bottle Label\\\\n61958-1601-3\\\\n30 tablets\\\\nATRIPLA\\\\u2122\\\\n(efavirenz 600 mg/emtricitabine 200 mg/\\\\ntenofovir disoproxil fumarate 300 mg)\\\\ntablets\\\\nGILEAD ACCESS PROGRAM\\\\nNote to pharmacist: Do not cover ALERT box with pharmacy label.\\\\nALERT: Find out about medicines that\\\\nshould NOT be taken with ATRIPLA\\\\nRx only\\\\nPOM\\\\nATRIPLA ACCESS  \\\\nefavirenz, emtricitabine, and tenofovir disoproxil fumarate tabl...\",\"Gilead Sciences, Inc.\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nEFAVIRENZ\\\\n (UNII: JE6H2O27P8) \\\\n(EFAVIRENZ - UNII:JE6H2O27P8)\\\\nEFAVIRENZ\\\\n600 mg\\\\nEMTRICITABINE\\\\n (UNII: G70B4ETF4S) \\\\n(EMTRICITABINE - UNII:G70B4ETF4S)\\\\nEMTRICITABINE\\\\n200 mg\\\\nTENOFOVIR DISOPROXIL FUMARATE\\\\n (UNII: OTT9J7900I) \\\\n(TENOFOVIR\\\\nANHYDROUS - UNII:W4HFE001U5)\\\\nTENOFOVIR DISOPROXIL\\\\nFUMARATE\\\\n300 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nHYDROXYPROPYL CELLULOSE (1600000 WAMW)\\\\n (UNII: RF...\",\"APRETUDE- cabotegravir \\\\n \\\\nViiV Healthcare Company\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use APRETUDE safely and\\\\neffectively. See full prescribing information for APRETUDE.\\\\nAPRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use\\\\nInitial U.S. Approval: 2021\\\\nWARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-\\\\nEXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION\\\\nSee full pres...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nADVERSE REACTIONS\\\\nThe most common adverse reactions (all grades) observed in at least 1% of participants receiving\\\\nAPRETUDE were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea,\\\\ndizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back\\\\npain, and upper respiratory tract infection. (\\\\n6.1\\\\n)\\\\nTo report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or\\\\nFDA at 1-800-FDA-1088 or \\\\nwww.fda.go...\",\"5.4 Hypersensitivity Reactions\\\\n5.5 Hepatotoxicity\\\\n5.6 Depressive Disorders\\\\n5.7 Risk of Reduced Drug Concentration of APRETUDE Due to Drug Interactions\\\\n6 ADVERSE REACTIONS\\\\n6.1 Clinical Trials Experience\\\\n6.2 Postmarketing Experience\\\\n7 DRUG INTERACTIONS\\\\n7.1 Use of Other Antiretroviral Drugs after Discontinuation of APRETUDE\\\\n7.2 Potential for Other Drugs to Affect APRETUDE\\\\n7.3 Established and Other Potentially Significant Drug Interactions\\\\n7.4 Drugs without Clinically Significant Interactions with C...\",\"WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR\\\\nHIV-1 PRE\\\\u2011EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1\\\\nINFECTION\\\\nIndividuals must be tested for HIV-1 infection prior to initiating\\\\nAPRETUDE or oral cabotegravir, and with each subsequent injection of\\\\nAPRETUDE, using a test approved or cleared by the FDA for the\\\\ndiagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1\\\\nvariants have been identified with use of APRETUDE by individuals with\\\\nundiagnosed HIV-1 infection. Do not ...\",\"Prior to starting APRETUDE, healthcare providers should carefully select individuals who\\\\nagree to the required injection dosing and testing schedule and counsel individuals about\\\\nthe importance of adherence to scheduled dosing visits to help reduce the risk of\\\\nacquiring HIV-1 infection and development of resistance \\\\n[see Dosage and Administration\\\\n(\\\\n2.1\\\\n), Warnings and Precautions (\\\\n5.1\\\\n, \\\\n5.3\\\\n), Microbiology (\\\\n12.4\\\\n)]\\\\n.\\\\n2.4 Optional Oral Lead-In Dosing to Assess Tolerability of APRETUDE\\\\nThe heal...\",\"Table 2. Recommended Dosing Schedule (Direct to Injection) for Pre-\\\\nExposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg\\\\n Individuals may be given APRETUDE up to 7 days before or after the date the individual\\\\nis scheduled to receive the injections.\\\\nIntramuscular (Gluteal) \\\\nInitiation Injection \\\\n(Month 1 and Month 2)\\\\nIntramuscular (Gluteal) \\\\nContinuation Injection \\\\n(Month 4 and Every 2 Months\\\\nOnwards)\\\\nAPRETUDE\\\\nAPRETUDE\\\\n600-mg (3 mL)\\\\n600-mg (3 mL)\\\\n2.6 Recommended Dosing Schedule ...\",\"Greater than 2 months\\\\nRestart with 600-mg (3-mL) gluteal intramuscular\\\\ninjection of APRETUDE, followed by a second 600-mg\\\\n(3-mL) initiation injection dose 1 month later. Then\\\\ncontinue to follow the every-2-month injection dosing\\\\nschedule thereafter.\\\\nIf third or subsequent\\\\ninjection is missed and time\\\\nsince prior injection is:\\\\nLess than or equal to 3 months\\\\nAdminister 600-mg (3-mL) intramuscular injection of\\\\nAPRETUDE as soon as possible, then continue with\\\\nthe every-2-month injection dosing sched...\",\"3 DOSAGE FORMS AND STRENGTHS\\\\nInjection: Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir\\\\nextended\\\\u2011release injectable suspension.\\\\n4 CONTRAINDICATIONS\\\\nAPRETUDE is contraindicated in individuals:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Comprehensive Management to Reduce the Risk of HIV-1 Infection\\\\nUse APRETUDE for HIV-1 PrEP to reduce the risk of HIV-1 infection as part of a\\\\ncomprehensive prevention strategy including adherence to the administration schedule\\\\nand safer sex practices,...\",\"\\\\u2022\\\\nWhen using APRETUDE for HIV-1 PrEP, HIV-1 testing should be repeated prior to each\\\\ninjection and upon diagnosis of any other STIs \\\\n[see Dosage and Administration (\\\\n2.2\\\\n,\\\\n2.5\\\\n)]\\\\n.\\\\n\\\\u2022\\\\nCounsel individuals without HIV-1 to strictly adhere to the recommended dosing and\\\\ntesting schedule for APRETUDE in order to reduce the risk of HIV-1 acquisition and the\\\\npotential development of resistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n, \\\\n2.5\\\\n),\\\\nMicrobiology (\\\\n12.4\\\\n)]\\\\n. Some individuals, such as adolescents,...\",\"include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) \\\\n[see Adverse\\\\nReactions (\\\\n6.2\\\\n)]\\\\n. Administration of cabotegravir oral lead-in dosing was used in clinical\\\\nstudies to help identify participants who may be at risk of a hypersensitivity reaction.\\\\nRemain vigilant and discontinue APRETUDE if a hypersensitivity reaction is suspected\\\\n[see Dosage and Administration (\\\\n2.4\\\\n), Contraindications (\\\\n4\\\\n), Adverse Reactions (\\\\n6\\\\n)]\\\\n.\\\\nDiscontinue APRETUDE immediately if signs or symptoms o...\",\"6.1 Clinical Trials Experience\\\\nBecause clinical trials are conducted under widely varying conditions, adverse reaction\\\\nrates observed in the clinical trials of a drug cannot be directly compared with rates in\\\\nthe clinical trials of another drug and may not reflect rates observed in practice.\\\\nClinical Trials Experience in Adults\\\\nThe safety assessment of APRETUDE is based on the analysis of data from 2\\\\ninternational, multicenter, double-blind trials, HPTN 083 and HPTN 084 \\\\n[see Clinical\\\\nStudies (\\\\n...\",\"Adverse reactions defined as \\\\u201ctreatment-related\\\\u201d as assessed by the investigator, with\\\\nexception of injection site reactions, where all injection site reactions were reported\\\\nregardless of causality.\\\\n Participants who received injection: HPTN 083, APRETUDE (n = 2,117) and TRUVADA\\\\n(n = 2,081); HPTN 084, APRETUDE (n = 1,519) and TRUVADA (n = 1,516).\\\\n Pyrexia includes pyrexia, feeling hot, chills, influenza-like illness.\\\\n Fatigue includes fatigue, malaise.\\\\n Sleep disorders includes insomnia, abnorm...\",\"grades) in at least 1% of participants who received APRETUDE and experienced at least\\\\none ISR from HPTN 084 are presented in \\\\nTable 5\\\\n.\\\\nTable 5. Injection Site Reactions (All Grades) Reported in at Least 1% of\\\\nParticipants Who Experienced at Least One Injection Site Reaction (All\\\\nCausality) with APRETUDE in Either HPTN 083 or HPTN 084\\\\n Placebo injectable suspension: intralipid 20% fat emulsion.\\\\nInjection Site\\\\nReactions\\\\nHPTN 083\\\\nHPTN 084\\\\nAPRETUDE\\\\n(n = 1,740)\\\\nTRUVADA\\\\n(n = 724)\\\\nAPRETUDE\\\\n(n = 578)\\\\nT...\",\"At the Week 41 and 97 timepoints in HPTN 084, participants who received APRETUDE\\\\ngained a median of 2 kg (IQR; 0.0, 5.0; n = 1,151) and 4 kg (IQR; 0.0, 8.0; n = 216) in\\\\nweight from baseline, respectively. Those who received TRUVADA gained a median of\\\\n1 kg (IQR; -1.0, 4.0; n = 1,131) and 3 kg (IQR; -1.0, 6.0; n = 218) in weight from\\\\nbaseline, respectively.\\\\nLaboratory Abnormalities: \\\\nGrade 3 or 4 post-baseline maximum toxicity laboratory\\\\nabnormalities for HPTN 083 or HPTN 084 are summarized in \\\\nTa...\",\"Nearly 60% of participants with baseline data available had Week 57 data available in\\\\nboth arms of both trials. Within each trial, baseline values were comparable among\\\\nparticipants receiving APRETUDE and TRUVADA.\\\\nHDL cholesterol\\\\nratio\\\\nClinical Trials Experience in Adolescents\\\\nIn adolescents receiving APRETUDE for HIV-1 PrEP, the safety data were comparable to\\\\nthe safety data reported in adults receiving APRETUDE for HIV-1 PrEP \\\\n[see Use in\\\\nSpecific Populations (\\\\n8.4\\\\n)].\\\\n6.2 Postmarketing Experi...\",\"inclusive.\\\\nTable 8. Drug Interactions with APRETUDE\\\\n\\\\u2191 = Increase, \\\\u2193 = Decrease, \\\\u2194 = No change.\\\\nConcomitant Drug\\\\nClass:\\\\nDrug Name\\\\nEffect on\\\\nConcentration\\\\nClinical Comment\\\\nAnticonvulsants:\\\\nCarbamazepine\\\\nOxcarbazepine\\\\nPhenobarbital\\\\nPhenytoin\\\\n\\\\u2193Cabotegravir\\\\nCoadministration is contraindicated with\\\\nAPRETUDE due to potential for significant\\\\ndecreases in plasma concentration of\\\\nAPRETUDE.\\\\nAntimycobacterials:\\\\nRifampin\\\\nRifapentine\\\\n\\\\u2193Cabotegravir\\\\nAntimycobacterial:\\\\nRifabutin\\\\n\\\\u2193Cabotegravir\\\\nWhen rifabutin is s...\",\"4263.\\\\nRisk Summary\\\\nThere are insufficient human data on the use of APRETUDE during pregnancy to\\\\nadequately assess a drug-associated risk of birth defects and miscarriage. Discuss the\\\\nbenefit-risk of using APRETUDE with individuals of childbearing potential or during\\\\npregnancy.\\\\nCabotegravir use in pregnant individuals has not been evaluated. APRETUDE should be\\\\nused during pregnancy only if the expected benefit justifies the potential risk to the\\\\nfetus.\\\\nThe APR has been established to monitor for ...\",\"exposure in humans at the RHD); there were no alterations to growth and development\\\\nof surviving offspring. In a cross-fostering study, similar incidences of stillbirths and\\\\nearly postnatal deaths were observed when rat pups born to cabotegravir-treated\\\\nmothers were nursed from birth by control mothers. There was no effect on neonatal\\\\nsurvival of control pups nursed from birth by cabotegravir-treated mothers. A lower\\\\ndose of 5 mg/kg/day (13 times the exposure at the RHD) was not associated with\\\\n...\",\"APRETUDE. Adolescents may benefit from more frequent visits and counseling to\\\\nsupport adherence to the dosing and testing schedule \\\\n[see Dosage and Administration\\\\n(\\\\n2.2\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)].\\\\nThe safety, efficacy, and pharmacokinetics of APRETUDE in pediatric participants\\\\nyounger than 12 years of age or weighing &lt;35 kg have not been established.\\\\n8.5 Geriatric Use\\\\nNo dose adjustment is required in elderly individuals. There are limited data available on\\\\nthe use of APRETUDE in indiv...\",\"Cabotegravir extended-release injectable suspension is a white to light pink free-flowing\\\\nsuspension for intramuscular injection in a sterile single-dose vial. Each vial contains\\\\n3 mL of the following: cabotegravir 200 mg/mL and the inactive ingredients mannitol\\\\n(35 mg/mL), polyethylene glycol (PEG) 3350 (20 mg/mL), polysorbate 20 (20 mg/mL),\\\\nand Water for Injection.\\\\nThe vial stoppers are not made with natural rubber latex.\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nCabotegravir is an HIV...\",\"CSF = Cerebrospinal fluid.\\\\n When taken orally with a high-fat meal versus fasted, the AUC\\\\n (geometric mean\\\\nratio [90% CI] of cabotegravir are 1.14 [1.02, 1.28]).\\\\n The clinical relevance of CSF-to-plasma concentration ratios is unknown.\\\\nConcentrations were measured at steady-state 1 week after intramuscular\\\\nadministration of cabotegravir extended-release injectable suspensions given monthly or\\\\nevery 2 months.\\\\n Elimination half-life driven by slow absorption rate from the intramuscular injection s...\",\"with HIV-1 (n = 110), the observed cabotegravir geometric mean (5th, 95th percentile)\\\\nC\\\\n (1-week post\\\\u2011initial injection) was 1.89 mcg/mL (0.438, 5.69) and C\\\\n was\\\\n1.43 mcg/mL (0.403, 3.90).\\\\n Pharmacokinetic parameter values represent steady state.\\\\nSpecific Populations\\\\nNo clinically significant differences in the pharmacokinetics of cabotegravir were\\\\nobserved based on age, sex, race/ethnicity, BMI, or UGT1A1 polymorphisms. There are\\\\nno data available for the use of cabotegravir in participants wit...\",\"IM = intramuscular.\\\\n Pharmacokinetic parameter values were based on individual post-hoc estimates from\\\\npopulation pharmacokinetic models in both adolescents with HIV-1 (n = 147) weighing\\\\n35.2 to 98.5 kg and adolescents without HIV-1 (n = 62) weighing 39.9 to 167 kg. \\\\n tau is dosing interval: 24 hours for oral administration, 1 month for the initial injection,\\\\nand 2 months for every 2 months for intramuscular injections of extended-release\\\\ninjectable suspension.\\\\n Oral lead-in pharmacokinetic para...\",\"n = Maximum number of participants with data, CI = Confidence Interval.\\\\nCoadministered\\\\nDrug(s)\\\\nand Dose(s)\\\\nDose of\\\\nCabotegravir\\\\nn\\\\nNo Effect = 1.00\\\\nC\\\\nAUC\\\\nC\\\\n or C\\\\nEtravirine\\\\n30 mg\\\\n12\\\\n1.04\\\\n1.01\\\\n1.00\\\\n    200 mg twice\\\\ndaily\\\\nonce daily\\\\n(0.99, 1.09)\\\\n(0.96, 1.06)\\\\n(0.94, 1.06)\\\\nRifabutin\\\\n30 mg\\\\n12\\\\n0.83\\\\n0.77\\\\n0.74\\\\n    300 mg once\\\\ndaily\\\\nonce daily\\\\n(0.76, 0.90)\\\\n(0.74, 0.83)\\\\n(0.70, 0.78)\\\\nRifampin\\\\n30-mg\\\\n15\\\\n0.94\\\\n0.41\\\\n0.50\\\\n    600 mg once\\\\ndaily\\\\nsingle dose\\\\n(0.87, 1.02)\\\\n(0.36, 0.46)\\\\n(0.44, 0.57)\\\\nRilpivirine\\\\n30 mg\\\\n1...\",\"12.4 Microbiology\\\\nMechanism of Action\\\\nCabotegravir inhibits HIV integrase by binding to the integrase active site and blocking\\\\nthe strand transfer step of retroviral deoxyribonucleic acid (DNA) integration that is\\\\nessential for the HIV replication cycle. The mean 50% inhibitory concentration (IC\\\\n)\\\\nvalue of cabotegravir in a strand transfer assay using purified recombinant HIV-1\\\\nintegrase was 3.0 nM.\\\\nAntiviral Activity in Cell Culture\\\\nCabotegravir exhibited antiviral activity against laboratory s...\",\"cabotegravir exposures below the target concentration. No variants expressing INSTI\\\\nresistance-associated substitutions were detected.\\\\nCross-Resistance\\\\nCross-resistance has been observed among INSTIs. Cabotegravir had reduced\\\\nsusceptibility (&gt;5-fold change) to recombinant HIV-1 strain NL432 viruses harboring the\\\\nfollowing integrase amino acid substitutions: G118R, Q148K, Q148R, T66K+L74M,\\\\nE92Q+N155H, E138A+Q148R, E138K+Q148K/R, G140C+Q148R, G140S+Q148H/K/R,\\\\nY143H+N155H, and Q148R+N155H (range: 5...\",\"in men and transgender women without HIV-1 who have sex with men and have\\\\nevidence of high-risk behavior for HIV-1 infection and HPTN 084 in cisgender women\\\\nwithout HIV-1 at risk of acquiring HIV-1.\\\\nParticipants randomized to receive APRETUDE initiated oral lead-in dosing with 1 oral\\\\ncabotegravir 30-mg tablet and a placebo daily for up to 5 weeks, followed by APRETUDE\\\\n600\\\\u2011mg (3-mL) intramuscular injection at months 1 and 2 and every 2 months\\\\nthereafter and a daily placebo tablet. Participants ra...\",\"Results from all subgroup analyses were consistent with the overall protective effect. A\\\\nlower rate of incident HIV\\\\u20111 infections was observed for participants randomized to\\\\nAPRETUDE compared with participants randomized to TRUVADA (\\\\nTable 15\\\\n).\\\\nTable 15. Incident of HIV-1 Infections by Subgroup in HPTN 083: Extended\\\\nRetrospective Virologic Testing with Readjudicated Endpoints\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence per\\\\n100 Person-\\\\nYears\\\\nAPRETUDE\\\\nPerson-Years\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nP...\",\"mITT from Supplemental Virology Report. \\\\n Cisgender men who have sex with men.\\\\n Transgender women who have sex with men.\\\\nTGW\\\\n0.54\\\\n371\\\\n1.80\\\\n389\\\\n0.34\\\\n(0.08,\\\\n1.56)\\\\nRace (US)\\\\nBlack\\\\n0.58\\\\n691\\\\n2.28\\\\n703\\\\n0.26\\\\n(0.09,\\\\n0.76)\\\\nNon-Black\\\\n0.00\\\\n836\\\\n0.50\\\\n801\\\\n0.11\\\\n(0.00,\\\\n2.80)\\\\nRegion\\\\nUS\\\\n0.26\\\\n1,528\\\\n1.33\\\\n1,504\\\\n0.21\\\\n(0.07,\\\\n0.60)\\\\nLatin\\\\nAmerica\\\\n0.49\\\\n1,020\\\\n1.09\\\\n1,011\\\\n0.47\\\\n(0.17,\\\\n1.35)\\\\nAsia\\\\n0.35\\\\n570\\\\n1.03\\\\n581\\\\n0.39\\\\n(0.08,\\\\n1.82)\\\\nAfrica\\\\n1.08\\\\n93\\\\n2.07\\\\n97\\\\n0.63\\\\n(0.06,\\\\n6.50)\\\\nTrial 201739 (HPTN 084 [NCT03164564])\\\\nIn HPTN 084, a su...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\",\"mITT from Supplemental Virology Report.\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nAPRETUDE\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nPerson-\\\\nYears\\\\nHazard\\\\nRatio\\\\n(95% CI)\\\\nAge\\\\n&lt;25 years\\\\n0.23\\\\n868\\\\n2.34\\\\n853\\\\n0.12\\\\n(0.03, 0.46)\\\\n\\\\u226525 years\\\\n0.09\\\\n1,093\\\\n1.46\\\\n1,093\\\\n0.09\\\\n(0.02, 0.49)\\\\nBody Mass Index\\\\n&lt;30\\\\n0.22\\\\n1,385\\\\n1.88\\\\n1,435\\\\n0.12\\\\n(0.04, 0.38)\\\\n\\\\u226530\\\\n0.00\\\\n575\\\\n1.76\\\\n511\\\\n0.04\\\\n(0.00, 0.93)\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nHow Supplied\\\\nAPRETUDE is supplied in a kit containing one 600-mg/3...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nPotential Risk of Resistance with APRETUDE\\\\nAdvise individuals there is a potential risk of developing resistance to APRETUDE if HIV-1\\\\nis acquired either before or while taking APRETUDE or following discontinuation of\\\\nAPRETUDE \\\\n[see Warnings and Precautions (\\\\n5.2\\\\n)]\\\\n.\\\\nTo minimize this, it is essential that individuals are clinically reassessed for risk of HIV-1\\\\nacquisition and tested frequently to confirm HIV-1 negative status. Advise individuals\\\\nwho are confirmed to have with HIV...\",\"Counsel individuals about the importance of continued medication adherence and\\\\nscheduled visits to help reduce the risk of acquiring HIV-1 infection and development of\\\\nresistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)]\\\\n.\\\\nHypersensitivity Reactions\\\\nAdvise individuals to immediately contact their healthcare provider if they develop a rash.\\\\nInstruct individuals to immediately stop taking APRETUDE and seek medical attention if\\\\nthey develop a rash associated with an...\",\"Warnings and Precautions (\\\\n5.3\\\\n), Use in Specific Populations (\\\\n8.1\\\\n)]\\\\n.\\\\nLactation\\\\nInform individuals that due to the potential for adverse reactions and residual\\\\nconcentrations in the systemic circulation for up to 12 months or longer after\\\\ndiscontinuing injections of APRETUDE, it is recommended that mothers breastfeed only\\\\nif the expected benefit justifies the potential risk to the infant. The benefits and risks of\\\\nAPRETUDE while breastfeeding should be evaluated, including the risk of HIV-1\\\\na...\",\"While you are receiving APRETUDE for HIV-1 PrEP:\\\\n\\\\u2022\\\\n\\\\u2022\\\\nIf you have HIV-1 and receive only APRETUDE, over time your HIV-1 may\\\\nbecome harder to treat.\\\\nWhat is APRETUDE?\\\\nAPRETUDE is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting\\\\nHIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg).\\\\nHIV-1 is the virus that causes acquired immune deficiency syndrome (AIDS).\\\\nIt is not known if APRETUDE is safe and effective in children younger than 12 years o...\",\"\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\nBefore receiving APRETUDE, tell your healthcare provider about all your\\\\nmedical conditions, including if you:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nTell your healthcare provider about all the medicines you take,\\\\n including\\\\nprescription and over-the-counter medicines, vitamins, and herbal supplements.\\\\nSome medicines may interact with APRETUDE. Keep a list of your medicines and show it\\\\nto your healthcare provider and pharmacist when you get a new medicine.\\\\nYou can ask your healthcare provider or pharmacist fo...\",\"What are the possible side effects of APRETUDE?\\\\nAPRETUDE may cause serious side effects including:\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\nThe most common side effects of APRETUDE include:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAllergic reactions.\\\\n Call your healthcare provider right away if you develop a rash\\\\nwith APRETUDE. \\\\nStop receiving APRETUDE and get medical help right away\\\\nif you develop a rash with any of the following signs or symptoms:\\\\n\\\\u25cb   fever\\\\n\\\\u25cb   generally ill feeling\\\\n\\\\u25cb   tiredness\\\\n\\\\u25cb   mu...\",\"These are not all the possible side effects of APRETUDE.\\\\nCall your doctor for medical advice about side effects. You may report side effects to\\\\nFDA at 1-800-FDA-1088.\\\\nGeneral information about the safe and effective use of APRETUDE.\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Patient\\\\nInformation leaflet. You can ask your pharmacist or healthcare provider for information\\\\nabout APRETUDE that is written for health professionals.\\\\nWhat are the ingredients in APRETUDE?...\",\"Overview:\\\\nA complete dose of APRETUDE requires 1 injection: 600-mg (3 mL) of cabotegravir.\\\\nAPRETUDE is a suspension that does not need further dilution or reconstitution.\\\\nCarefully follow these instructions when preparing the suspension for injection to avoid\\\\nleakage.\\\\nAPRETUDE is for gluteal intramuscular use only.\\\\nNote:\\\\n The ventrogluteal site is recommended.\\\\n Storage information\\\\nStore at 2\\\\u00b0C to 25\\\\u00b0C (36\\\\u00b0F to 77\\\\u00b0F). Exposure up to 30\\\\u00b0C (86\\\\u00b0F) permitted.\\\\nDo not \\\\nfreeze.\\\\nPrior to administration:\\\\n...\",\"\\\\u2022\\\\nYour pack contains:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nConsider the individual\\\\u2019s build and use medical judgment to select an appropriate\\\\ninjection needle length.\\\\nYou will also need:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\ntemperature prior to administration (not to exceed 30\\\\u00b0C [86\\\\u00b0F]).\\\\nOnce APRETUDE has been drawn into the syringe, the medicine can remain in the\\\\nsyringe for up to 2 hours before injection. The filled syringe should not be placed in\\\\nthe refrigerator. If the medicine remains in the syringe for more than 2 hours, the\\\\nfilled syringe and ne...\",\"Preparation:\\\\n1. Inspect the vial.\\\\nFigure A\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n\\\\u2022\\\\n2. Shake the vial vigorously.\\\\nFigure B\\\\n\\\\u2022\\\\n3. Inspect suspension.\\\\nFigure C\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n4. Remove the vial cap.\\\\nCheck that the\\\\nexpiration date has\\\\nnot passed. \\\\nSee\\\\nFigure A.\\\\nInspect the vial\\\\nimmediately. If you\\\\ncan see foreign\\\\nmatter, do not use\\\\nthe product.\\\\nNote:\\\\n The vial has a\\\\nbrown tint to the\\\\nglass.\\\\nDo not\\\\n use if the\\\\nexpiration date has\\\\npassed.\\\\nIf the pack has been\\\\nstored in the\\\\nrefrigerator, allow the\\\\nmedication to come to\\\\nroom temperature.\\\\nHold...\",\"Figure D\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n5. Peel open the vial adapter.\\\\nFigure E\\\\n\\\\u2022\\\\n \\\\n \\\\n6. Place vial on flat surface and attach the vial adapter.\\\\nFigure F\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n7. Lift off the packaging.\\\\nRemove the cap from\\\\nthe vial. \\\\nSee Figure\\\\nD.\\\\nWipe the rubber\\\\nstopper with an\\\\nalcohol wipe.\\\\nDo not\\\\n allow\\\\nanything to touch the\\\\nrubber stopper after\\\\nwiping it.\\\\nPeel off the paper\\\\nbacking from the vial\\\\nadapter packaging.\\\\nSee Figure E.\\\\nNote:\\\\n Do not remove\\\\nthe adapter from its\\\\npackaging for the\\\\nnext step. The\\\\nadapter \\\\nwill not\\\\n fall\\\\nout wh...\",\"Figure G\\\\n\\\\u2022\\\\n8. Prepare the syringe.\\\\nFigure H\\\\n\\\\u2022\\\\n\\\\u2022\\\\n9. Attach the syringe.\\\\nFigure I\\\\n\\\\u2022\\\\n\\\\u2022\\\\n10. Press the plunger.\\\\nLift off the vial\\\\nadapter packaging, as\\\\nshown.\\\\n See Figure\\\\nG.\\\\nRemove the syringe\\\\nfrom its packaging.\\\\nDraw 1 mL of air into\\\\nthe syringe. This will\\\\nmake it easier to draw\\\\nup the medicine later.\\\\nSee Figure H.\\\\nHold the vial adapter\\\\nand vial firmly, as\\\\nshown.\\\\nScrew the syringe\\\\nfirmly onto the vial\\\\nadapter. \\\\nSee Figure\\\\nI.\",\"Figure J\\\\n\\\\u2022\\\\n11. Slowly draw up the dose.\\\\nFigure K\\\\n\\\\u2022\\\\n \\\\n12. Unscrew the syringe.\\\\nFigure L\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n13. Attach the needle.\\\\nPress the plunger all\\\\nthe way down to push\\\\nthe air into the vial.\\\\nSee Figure J.\\\\nInvert the syringe and\\\\nvial and slowly\\\\nwithdraw as much of\\\\nthe medicine as\\\\npossible into the\\\\nsyringe. There may be\\\\nmore medicine than\\\\nthe dose amount.\\\\nSee Figure K.\\\\nNote:\\\\n Keep the\\\\nsyringe upright to\\\\navoid leakage.\\\\nHold the syringe\\\\nplunger firmly in place\\\\nas shown to prevent\\\\nleakage. It is normal\\\\nto fee...\",\"Figure M\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nInjection:\\\\n14. Prepare the injection site.\\\\nFigure N\\\\n \\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n15. Remove the cap.\\\\nPeel open the needle\\\\npackaging part way to\\\\nexpose the needle\\\\nbase.\\\\nKeeping the syringe\\\\nupright, firmly twist\\\\nthe syringe onto the\\\\nneedle.\\\\nRemove the needle\\\\npackaging from the\\\\nneedle. \\\\nSee Figure\\\\nM.\\\\nAPRETUDE must be\\\\nadministered to a\\\\ngluteal site. \\\\nSee\\\\nFigure N\\\\n.\\\\nSelect from the\\\\nfollowing areas for the\\\\ninjection:\\\\nVentrogluteal, as\\\\nshown\\\\n(recommended)\\\\nDorsogluteal, not\\\\nshown (upper outer\\\\nquadrant)\\\\nNote...\",\"Figure O\\\\n\\\\u2022\\\\n\\\\u2022\\\\n16. Remove extra liquid from the syringe.\\\\nFigure P\\\\n\\\\u2022\\\\n \\\\n17. Stretch the skin.\\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\nFold the needle guard\\\\naway from the needle.\\\\nSee Figure O.\\\\nPull off the injection\\\\nneedle cap.\\\\nHold the syringe with\\\\nthe needle pointing\\\\nup. Press the plunger\\\\nto the 3 mL dosing\\\\nmark to remove extra\\\\nliquid and any air\\\\nbubbles. \\\\nSee Figure\\\\nP.\\\\nNote:\\\\n Clean the\\\\ninjection site with an\\\\nalcohol wipe. Allow the\\\\nskin to air dry before\\\\ncontinuing.\\\\nUse the z-track\\\\ninjection technique to\\\\nminimize medicine\\\\nleakage ...\",\"Figure Q\\\\n18. Insert the needle.\\\\nFigure R\\\\n\\\\u2022\\\\n19. Inject the dose of medicine.\\\\nFigure S\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n20. Assess the injection site.\\\\nInsert the needle to\\\\nits full depth, or deep\\\\nenough to reach the\\\\nmuscle. \\\\nSee Figure\\\\nR.\\\\nStill holding the skin\\\\nstretched \\\\u2013 slowly\\\\npress the plunger all\\\\nthe way down. \\\\nSee\\\\nFigure S.\\\\nEnsure the syringe is\\\\nempty.\\\\nWithdraw the needle\\\\nand release the\\\\nstretched skin\\\\nimmediately.\",\"Figure T\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n21. Make the needle safe.\\\\nFigure U\\\\n\\\\u2022\\\\nFigure V\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAfter injection:\\\\n22. Dispose safely.\\\\nApply pressure to the\\\\ninjection site using a\\\\ngauze pad. \\\\nSee\\\\nFigure T.\\\\nA small bandage may\\\\nbe used if bleeding\\\\noccurs.\\\\nDo not\\\\n massage the\\\\narea.\\\\nFold the needle guard\\\\nover the needle. \\\\nSee\\\\nFigure U.\\\\nGently apply pressure\\\\nusing a hard surface\\\\nto lock the needle\\\\nguard in place.\\\\nThe needle guard will\\\\nmake a click when it\\\\nlocks. \\\\nSee Figure V.\",\"Figure W\\\\n\\\\u2022\\\\nQuestions and Answers\\\\n1.\\\\n \\\\n2.\\\\n3.\\\\n4.\\\\nManufactured for:\\\\nViiV Healthcare\\\\nDurham, NC 27701\\\\nTrademarks are owned by or licensed to the ViiV Healthcare group of companies.\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\nAPR:5IFU\\\\n \\\\nDispose of used\\\\nneedle, syringe, vial,\\\\nand vial adapter\\\\naccording to local\\\\nhealth and safety\\\\nlaws. \\\\nSee Figure W.\\\\nIf the pack has been stored in the refrigerator, is it safe to warm the\\\\nvial up to room temperature more quickly?\\\\n \\\\nThe vial should be broug...\",\"Principal Display Panel\\\\nNDC 49702-264-23\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nFor gluteal intramuscular use only.\\\\nHealthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 2/24\\\\n\\\\u00a92024 ViiV H...\",\"Principal Display Panel\\\\nNDC 49702-280-63\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nSample-Not for Sale\\\\nFor gluteal intramuscular use only.\",\"Healthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 5/24\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\n62000000094179\",\"APRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-264\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-264-\\\\n23\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n12/20/2021\",\"Quantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\nTotal Product Quantity\\\\nPart 1\\\\n1 VIAL\\\\n3 mL\\\\nPart 1 of 1\\\\nCABOTEGRAVIR  \\\\ncabotegravir injection, suspension, extended release\\\\nProduct Information\\\\nItem Code (Source)\\\\nNDC:49702-238\\\\nRoute of Administration\\\\nINTRAMUSCULAR\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCABOTEGRAVIR\\\\n (UNII: HMH0132Z1Q) \\\\n(CABOTEGRAVIR - UNII:HMH0132Z1Q)\\\\nCABOTEGRAVIR\\\\n200 mg  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)...\",\"NDA\\\\nNDA215499\\\\n12/20/2021\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nNDA\\\\nNDA215499\\\\n12/20/2021\\\\nAPRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-280\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-280-\\\\n63\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n03/31/2024\\\\nQuantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\n...\",\"ViiV Healthcare Company\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYSORBATE 20\\\\n (UNII: 7T1F30V5YH)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nWHITE (white to light pink)\\\\nScore\\\\n    \\\\nShape\\\\nSize\\\\nFlavor\\\\nImprint Code\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-238-\\\\n61\\\\n3 mL in 1 VIAL; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Mono...\",\"ISENTRESS- raltegravir tablet, film coated \\\\n \\\\nNuCare Pharmaceuticals,Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ISENTRESS safely and\\\\neffectively. See full prescribing information for ISENTRESS. \\\\nISENTRESS \\\\n (raltegravir) film-coated tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) chewable tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) for oral suspension \\\\nInitial U.S. Approval: 2007\\\\nINDICATIONS AND USAGE\\\\nISENTRESS is...\",\"The most common adverse reactions of moderate to severe intensity (\\\\u22652%) are insomnia, headache,\\\\ndizziness, nausea and fatigue ( \\\\n6.1\\\\n).\\\\nCreatine kinase elevations were observed in subjects who received ISENTRESS. Myopathy and\\\\nrhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or\\\\nrhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions\\\\nand patients with a history of rhabdomyolysis, myopathy or increased serum cre...\",\"8.5 Geriatric Use\\\\n8.6 Use in Patients with Hepatic Impairment\\\\n8.7 Use in Patients with Renal Impairment\\\\n10 OVERDOSAGE\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n12.4 Microbiology\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n14.1 \\\\nTreatment-Na\\\\u00efve Adult Subjects\\\\n14.2 Treatment-Experienced Adult Subjects\\\\n14.3 Pediatric Subjects\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT ...\",\"Each single-use packet for oral suspension contains 100 mg of raltegravir which is\\\\nsuspended in 5 mL of water giving a final concentration of 20 mg/mL.\\\\n2.2 Adults\\\\nFor the treatment of adult patients with HIV-1 infection, the dosage of ISENTRESS is one\\\\n400 mg film-coated tablet administered orally, twice daily.\\\\n2.3 Pediatrics\\\\nIf at least 25 kg:\\\\n One 400 mg film-coated tablet orally, twice daily.\\\\nIf unable to swallow a tablet, consider the chewable tablet, as specified in Table 1.\\\\nTable 1: Alterna...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n11 to less than 14 \\\\n4 mL (80 mg) twice\\\\ndaily\\\\n3 \\\\u00d7 25 mg twice daily\\\\n14 to less than 20 \\\\n5 mL (100 mg) twice\\\\ndaily\\\\n1 \\\\u00d7 100 mg twice\\\\ndaily\\\\n20 to less than 25\\\\n1.5 \\\\u00d7 100 mg \\\\n twice\\\\ndaily\\\\n2.4 Method of Administration\\\\nISENTRESS Film-Coated Tablets\\\\nFilm-Coated Tablets must be swallowed whole\\\\nISENTRESS Chewable Tablets\\\\nChewable Tablets may be chewed or swallowed whole\\\\nISENTRESS For Oral Suspension\\\\nEach single-use ISENTRESS packet for oral suspension contains 100 mg of raltegravir\\\\nwhich is to be sus...\",\"None\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Skin and Hypersensitivity Reactions\\\\nSevere, potentially life-threatening, and fatal skin reactions have been reported. These\\\\ninclude cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.\\\\nHypersensitivity reactions have also been reported and were characterized by rash,\\\\nconstitutional findings, and sometimes, organ dysfunction, including hepatic failure.\\\\nDiscontinue ISENTRESS and other suspect agents immediately if signs or symptoms of\\\\nsevere...\",\"STARTMRK (Protocol 021) with ISENTRESS 400 mg twice daily in combination with a fixed\\\\ndose of emtricitabine 200 mg (+) tenofovir 300 mg, (N=281) versus efavirenz (EFV) 600\\\\nmg at bedtime in combination with emtricitabine (+) tenofovir, (N=282). During double-\\\\nblind treatment, the total follow-up for subjects receiving ISENTRESS 400 mg twice daily\\\\n+ emtricitabine (+) tenofovir was 1104 patient-years and 1036 patient-years for\\\\nsubjects receiving efavirenz 600 mg at bedtime + emtricitabine (+) tenof...\",\"Analysis)\\\\nRandomized Study Protocol\\\\n021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm (Unit)\\\\nLimit\\\\nISENTRESS\\\\n400 mg \\\\nTwice Daily +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 281)\\\\nEfavirenz 600\\\\nmg \\\\nAt Bedtime +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 282)\\\\nHematology\\\\nAbsolute neutrophil count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n0.75 - 0.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n0.50 - 0.749\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&lt;0.50\\\\n1%\\\\n1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n1%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n1%\\\\n...\",\"ULN = Upper limit of normal range\\\\nLipids, Change from Baseline\\\\nChanges from baseline in fasting lipids are shown in Table 5.\\\\nTable 5: Lipid Values, Mean Change from Baseline, Protocol 021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm\\\\nISENTRESS 400 mg \\\\nTwice Daily + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 207\\\\nEfavirenz 600 mg \\\\nAt Bedtime + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 187\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean\\\\nMean\\\\nChange\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean...\",\"OBT. The median duration of therapy in these trials was 96 weeks for subjects receiving\\\\nISENTRESS and 38 weeks for subjects receiving placebo. The total exposure to\\\\nISENTRESS was 708 patient-years versus 244 patient-years on placebo. The rates of\\\\ndiscontinuation due to adverse events were 4% in subjects receiving ISENTRESS and 5%\\\\nin subjects receiving placebo.\\\\nClinical ADRs were considered by investigators to be causally related to ISENTRESS +\\\\nOBT or placebo + OBT. Clinical ADRs of moderate to s...\",\"Grade 4\\\\n&lt;0.50\\\\n1%\\\\n&lt;1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n3%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n25 - 49.999\\\\n1%\\\\n&lt;1%\\\\n  Grade 4\\\\n&lt;25\\\\n1%\\\\n&lt;1%\\\\nBlood chemistry\\\\nFasting (non-random) serum glucose test (mg/dL)\\\\n  Grade 2\\\\n126 - 250\\\\n10%\\\\n7%\\\\n  Grade 3\\\\n251 - 500\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&gt;500\\\\n0%\\\\n0%\\\\nTotal serum bilirubin\\\\n  Grade 2\\\\n1.6 - 2.5 \\\\u00d7 ULN\\\\n6%\\\\n3%\\\\n  Grade 3\\\\n2.6 - 5.0 \\\\u00d7 ULN\\\\n3%\\\\n3%\\\\n  Grade 4\\\\n&gt;5.0 \\\\u00d7 ULN\\\\n1%\\\\n0%\\\\nSerum aspartate aminotransferase...\",\"ULN = Upper limit of normal range\\\\nLess Common Adverse Reactions Observed in Treatment-Na\\\\u00efve and Treatment-\\\\nExperienced Studies\\\\nThe following ADRs occurred in &lt;2% of treatment-na\\\\u00efve or treatment-experienced\\\\nsubjects receiving ISENTRESS in a combination regimen. These events have been\\\\nincluded because of their seriousness, increased frequency on ISENTRESS compared\\\\nwith efavirenz or placebo, or investigator&#x27;s assessment of potential causal relationship.\\\\nGastrointestinal Disorders: \\\\nabdominal pain, ...\",\"upper limit of normal (ULN). In general the safety profile of ISENTRESS in subjects with\\\\nhepatitis B and/or hepatitis C virus co-infection was similar to that in subjects without\\\\nhepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT\\\\nabnormalities were higher in the subgroup with hepatitis B and/or hepatitis C virus co-\\\\ninfection for all treatment groups. At 96 weeks, in treatment-experienced subjects,\\\\nGrade 2 or higher laboratory abnormalities that represent a wors...\",\"patients with underlying liver disease and/or concomitant medications\\\\nMusculoskeletal and Connective Tissue Disorders:\\\\n rhabdomyolysis\\\\nNervous System Disorders: \\\\ncerebellar ataxia\\\\nPsychiatric Disorders: \\\\nanxiety, paranoia\\\\n7 DRUG INTERACTIONS\\\\n7.1 Effect of Raltegravir on the Pharmacokinetics of Other Agents\\\\nRaltegravir does not inhibit (IC \\\\n&gt;100 \\\\u00b5M) CYP1A2, CYP2B6, CYP2C8, CYP2C9,\\\\nCYP2C19, CYP2D6 or CYP3A \\\\nin vitro\\\\n. Moreover, \\\\nin vitro\\\\n, raltegravir did not induce\\\\nCYP1A2, CYP2B6 or CYP3A4. A mid...\",\"rifampin\\\\n\\\\u2193\\\\ndaily during coadministration\\\\nwith rifampin. There are no\\\\ndata to guide co-\\\\nadministration of ISENTRESS\\\\nwith rifampin in patients below\\\\n18 years of age \\\\n[see \\\\nDosage\\\\nand Administration (2.1)\\\\n].\\\\n7.3 Drugs without Clinically Significant Interactions with ISENTRESS\\\\nIn drug interaction studies, raltegravir did not have a clinically meaningful effect on the\\\\npharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine,\\\\ntenofovir, etravirine, darunavir/ritonavir, or boce...\",\"8.3 Nursing Mothers\\\\nBreastfeeding is not recommended while taking ISENTRESS. In addition, it is\\\\nrecommended that HIV-1-infected mothers not breastfeed their infants to avoid risking\\\\npostnatal transmission of HIV-1.\\\\nIt is not known whether raltegravir is secreted in human milk. However, raltegravir is\\\\nsecreted in the milk of lactating rats. Mean drug concentrations in milk were\\\\napproximately 3-fold greater than those in maternal plasma at a maternal dose of 600\\\\nmg/kg/day in rats. There were no ef...\",\"evidence of toxicity.\\\\nIn the event of an overdose, it is reasonable to employ the standard supportive\\\\nmeasures, e.g., remove unabsorbed material from the gastrointestinal tract, employ\\\\nclinical monitoring (including obtaining an electrocardiogram), and institute supportive\\\\ntherapy if required. The extent to which ISENTRESS may be dialyzable is unknown.\\\\n11 DESCRIPTION\\\\nISENTRESS contains raltegravir potassium, a human immunodeficiency virus integrase\\\\nstrand transfer inhibitor. The chemical name fo...\",\"fructose, hydroxypropyl cellulose, hypromellose 2910/6cP, magnesium stearate,\\\\nmannitol, medium chain triglycerides, monoammonium glycyrrhizinate, natural and\\\\nartificial flavors (orange, banana, and masking that contains aspartame), oleic acid, PEG\\\\n400, saccharin sodium, sodium citrate dihydrate, sodium stearyl fumarate, sorbitol,\\\\nsucralose and yellow iron oxide.\\\\nEach packet of ISENTRESS for oral suspension 100 mg, contains 108.6 mg of raltegravir\\\\n(as potassium salt), equivalent to 100 mg of ralt...\",\"formulation comparison study in healthy adult volunteers, the chewable tablet and oral\\\\nsuspension have higher oral bioavailability compared to the 400 mg film-coated tablet.\\\\nIn subjects who received 400 mg twice daily alone, raltegravir drug exposures were\\\\ncharacterized by a geometric mean AUC \\\\n of 14.3 \\\\u00b5M\\\\u2219hr and C \\\\n of 142 nM.\\\\nConsiderable variability was observed in the pharmacokinetics of raltegravir. For\\\\nobserved C \\\\nin Protocols 018 and 019, the coefficient of variation (CV) for inter-\\\\nsubje...\",\"approximately 70% of the total radioactivity; the remaining radioactivity in plasma was\\\\naccounted for by raltegravir-glucuronide. Studies using isoform-selective chemical\\\\ninhibitors and cDNA-expressed UDP-glucuronosyltransferases (UGT) show that UGT1A1\\\\nis the main enzyme responsible for the formation of raltegravir-glucuronide. Thus, the\\\\ndata indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-\\\\nmediated glucuronidation.\\\\nSpecial Populations\\\\nPediatric\\\\nTwo pediatric fo...\",\"*\\\\n\\\\u2020\\\\nkg\\\\nTable 2\\\\n3 to less\\\\nthan 20\\\\nkg\\\\nOral\\\\nsuspension\\\\nWeight\\\\nbased\\\\ndosing, see\\\\nTable 2\\\\n19\\\\n24.5 ( \\\\n43%\\\\n)\\\\n113 ( \\\\n69%\\\\n)\\\\nThe pharmacokinetics of raltegravir in infants under 4 weeks of age has not been\\\\nestablished.\\\\nAge\\\\nThe effect of age (18 years and older) on the pharmacokinetics of raltegravir was\\\\nevaluated in the composite analysis. No dosage adjustment is necessary.\\\\nRace\\\\nThe effect of race on the pharmacokinetics of raltegravir in adults was evaluated in the\\\\ncomposite analysis. No dosage adjustmen...\",\"with wild-type genotype, the geometric mean ratio (90% CI) of AUC was 1.41 (0.96,\\\\n2.09).\\\\nDrug Interactions\\\\n [see \\\\nDrug Interactions (7)\\\\n]\\\\nTable 10: Effect of Other Agents on the Pharmacokinetics of Raltegravir in\\\\nAdults\\\\nCoadministered\\\\nDrug\\\\nCoadministered\\\\nDrug\\\\nDose/Schedule\\\\nRaltegravir \\\\nDose/Schedule\\\\nRatio (90% Confidence\\\\nInterval) of Raltegravir\\\\nPharmacokinetic Parameters\\\\nwith/without Coadministered\\\\nDrug; \\\\nNo Effect = 1.00\\\\nn\\\\nC \\\\nAUC\\\\nC \\\\naluminum and\\\\nmagnesium\\\\nhydroxide antacid\\\\n20 mL single\\\\ndose gi...\",\"boceprevir\\\\n800 mg three\\\\ntimes daily\\\\n400 mg single\\\\ndose\\\\n22\\\\n(0.91-\\\\n1.36)\\\\n(0.88-\\\\n1.22)\\\\n(0.45-\\\\n1.23)\\\\ncalcium carbonate\\\\nantacid\\\\n3000 mg single\\\\ndose given with\\\\nraltegravir\\\\n400 mg twice\\\\ndaily\\\\n24\\\\n0.48 \\\\n(0.36,\\\\n0.63)\\\\n0.45 \\\\n(0.35,\\\\n0.57)\\\\n0.68 \\\\n(0.53,\\\\n0.87)\\\\nefavirenz\\\\n600 mg daily\\\\n400 mg single\\\\ndose\\\\n9\\\\n0.64\\\\n(0.41,\\\\n0.98)\\\\n0.64\\\\n(0.52,\\\\n0.80)\\\\n0.79\\\\n(0.49,\\\\n1.28)\\\\netravirine\\\\n200 mg twice\\\\ndaily\\\\n400 mg twice\\\\ndaily\\\\n19\\\\n0.89\\\\n(0.68,\\\\n1.15)\\\\n0.90\\\\n(0.68,\\\\n1.18)\\\\n0.66\\\\n(0.34,\\\\n1.26)\\\\nomeprazole\\\\n20 mg daily\\\\n400 mg single\\\\ndose\\\\n14 \\\\n(10\\\\nf...\",\"Raltegravir at concentrations of 31 \\\\u00b1 20 nM resulted in 95% inhibition (EC \\\\n) of viral\\\\nspread (relative to an untreated virus-infected culture) in human T-lymphoid cell cultures\\\\ninfected with the cell-line adapted HIV-1 variant H9IIIB. In addition, 5 clinical isolates of\\\\nHIV-1 subtype B had EC \\\\n values ranging from 9 to 19 nM in cultures of mitogen-\\\\nactivated human peripheral blood mononuclear cells. In a single-cycle infection assay,\\\\nraltegravir inhibited infection of 23 HIV-1 isolates represen...\",\"dolutegravir.\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nCarcinogenicity studies of raltegravir in mice did not show any carcinogenic potential. At\\\\nthe highest dose levels, 400 mg/kg/day in females and 250 mg/kg/day in males, systemic\\\\nexposure was 1.8-fold (females) or 1.2-fold (males) greater than the AUC (54 \\\\u00b5M\\\\u2219hr) at\\\\nthe 400-mg twice daily human dose. Treatment-related squamous cell carcinoma of\\\\nnose/nasopharynx was observed in female rats dosed with 6...\",\"Protocol 021\\\\n400 mg Twice\\\\nDaily\\\\n600 mg At\\\\nBedtime\\\\n(N = 281)\\\\n(N = 282)\\\\nGender\\\\n  Male\\\\n81%\\\\n82%\\\\n  Female\\\\n19%\\\\n18%\\\\nRace\\\\n  White\\\\n41%\\\\n44%\\\\n  Black\\\\n12%\\\\n8%\\\\n  Asian\\\\n13%\\\\n11%\\\\n  Hispanic\\\\n21%\\\\n24%\\\\n  Native American\\\\n&lt;1%\\\\n&lt;1%\\\\n  Multiracial\\\\n12%\\\\n13%\\\\nRegion\\\\n  Latin America\\\\n35%\\\\n34%\\\\n  Southeast Asia\\\\n12%\\\\n10%\\\\n  North America\\\\n29%\\\\n32%\\\\n  EU/Australia\\\\n23%\\\\n23%\\\\nAge (years)\\\\n  18-64\\\\n99%\\\\n99%\\\\n  \\\\u226565\\\\n1%\\\\n1%\\\\n  Mean (SD)\\\\n38 (9)\\\\n37 (10)\\\\n  Median (min, max)\\\\n37 (19 to 67)\\\\n36 (19 to 71)\\\\nCD4+ Cell Count (cells/microL)\\\\n  Mean (SD)\\\\n219 (124)\\\\n2...\",\"Notes: \\\\nISENTRESS and Efavirenz were administered with emtricitabine (+) tenofovir \\\\nN = Number of subjects in each group.\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n  Hepatitis B or C Positive \\\\n6%\\\\n6%\\\\nWeek 240 outcomes from Protocol 021 are shown in Table 12.\\\\nTable 12: Virologic Outcomes of Randomized Treatment\\\\nof Protocol 021 at 240 Weeks\\\\nISENTRESS\\\\n400 mg \\\\nTwice\\\\nDaily \\\\n(N = 281)\\\\nEfavirenz \\\\n600 mg \\\\nAt\\\\nBedtime \\\\n(N = 282)\\\\nDifference \\\\n(ISENTRESS \\\\u2013\\\\nEfavirenz) (CI)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with\\\\nHIV-1 RNA less\\\\nthan 50\\\\ncopies/mL\\\\n66%\\\\n60%\\\\n6.6% \\\\n(-1.4%...\",\"14.2 Treatment-Experienced Adult Subjects\\\\nBENCHMRK 1 and BENCHMRK 2 are Phase 3 studies to evaluate the safety and\\\\nantiretroviral activity of ISENTRESS 400 mg twice daily in combination with an optimized\\\\nbackground therapy (OBT), versus OBT alone, in HIV-1-infected subjects, 16 years or\\\\nolder, with documented resistance to at least 1 drug in each of 3 classes (NNRTIs,\\\\nNRTIs, PIs) of antiretroviral therapies. Randomization was stratified by degree of\\\\nresistance to PI (1PI vs. &gt;1PI) and the use of...\",\"*\\\\nvirus\\\\n83%\\\\n84%\\\\nHepatitis B virus only\\\\n8%\\\\n3%\\\\nHepatitis C virus only\\\\n8%\\\\n12%\\\\nCo-infection of\\\\nHepatitis B and C\\\\nvirus\\\\n1%\\\\n1%\\\\nStratum\\\\nEnfuvirtide in OBT\\\\n38%\\\\n38%\\\\nResistant to \\\\u22652 PI\\\\n97%\\\\n95%\\\\nTable 14 compares the characteristics of optimized background therapy at baseline in\\\\nthe group receiving ISENTRESS 400 mg twice daily and subjects in the control group.\\\\nTable 14: Characteristics of Optimized Background\\\\nTherapy at Baseline\\\\nRandomized Studies \\\\nProtocol 018 and 019\\\\nISENTRESS\\\\n400 mg Twice\\\\nDaily + OBT\\\\nPl...\",\"Week 96 outcomes for the 699 subjects randomized and treated with the\\\\nrecommended dose of ISENTRESS 400 mg twice daily or placebo in the pooled\\\\nBENCHMRK 1 and 2 studies are shown in Table 15.\\\\nTable 15: Virologic Outcomes of Randomized Treatment\\\\nof Protocols 018 and 019 at 96 Weeks (Pooled Analysis)\\\\nISENTRESS \\\\n400 mg Twice\\\\nDaily + OBT \\\\n(N = 462)\\\\nPlacebo + OBT \\\\n(N = 237)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with HIV-1\\\\nRNA less than 50\\\\ncopies/mL\\\\n55%\\\\n27%\\\\nVirologic Failure \\\\n35%\\\\n66%\\\\nNo virologic data at\\\\nWeek 96 Window\\\\nReas...\",\"&lt;50 copies/mL \\\\nAt Week 96\\\\nn\\\\nISENTRESS \\\\n400 mg \\\\nTwice Daily +\\\\nOBT \\\\n(N = 462) \\\\nn\\\\nPlacebo +\\\\nOBT \\\\n(N = 237)\\\\n*\\\\nPhenotypic Sensitivity Score (PSS) \\\\n0\\\\n67\\\\n43\\\\n43\\\\n5\\\\n1\\\\n144\\\\n58\\\\n71\\\\n23\\\\n2\\\\n142\\\\n61\\\\n66\\\\n32\\\\n3 or more\\\\n85\\\\n48\\\\n48\\\\n42\\\\nGenotypic Sensitivity Score (GSS) \\\\n0\\\\n116\\\\n39\\\\n65\\\\n5\\\\n1\\\\n177\\\\n62\\\\n95\\\\n26\\\\n2\\\\n111\\\\n61\\\\n49\\\\n53\\\\n3 or more\\\\n51\\\\n49\\\\n23\\\\n35\\\\nSwitch of Suppressed Subjects from Lopinavir (+) Ritonavir to Raltegravir\\\\nThe SWITCHMRK 1 &amp; 2 Phase 3 studies evaluated HIV-1 infected subjects receiving\\\\nsuppressive therapy (HIV-1 RNA &lt;50 cop...\",\"children. This study enrolled 126 treatment experienced children and adolescents 2 to\\\\n18 years of age. Subjects were stratified by age, enrolling adolescents first and then\\\\nsuccessively younger children. Subjects were enrolled into cohorts according to age and\\\\nreceived the following formulations: Cohort I (12 to less than 18 years old), 400 mg film-\\\\ncoated tablet; Cohort IIa (6 to less than 12 years old), 400 mg film-coated tablet; Cohort\\\\nIIb (6 to less than 12 years old), chewable tablet; Cohor...\",\"copies/mL. The mean CD4 count (percent) increase from baseline to Week 48 was 492\\\\ncells/mm \\\\n(7.8%).\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nISENTRESS tablets 400 mg are pink, oval-shaped, film-coated tablets with \\\\\"227\\\\\" on one\\\\nside. They are supplied as follows:\\\\nNDC\\\\n 68071-2113-6 \\\\nbottles of 6\\\\nStorage and Handling\\\\n400 mg Film-coated Tablets, Chewable Tablets and For Oral Suspension\\\\nStore at 20-25\\\\u00b0C (68-77\\\\u00b0F); excursions permitted to 15-30\\\\u00b0C (59-86\\\\u00b0F). See USP\\\\nControlled Room Temperature.\\\\nChewable Ta...\",\"General Dosing Instructions\\\\nInstruct patients that if they miss a dose of ISENTRESS, they should take it as soon as\\\\nthey remember. If they do not remember until it is time for the next dose, instruct them\\\\nto skip the missed dose and go back to the regular schedule. Instruct patients not to\\\\ndouble their next dose or take more than the prescribed dose.\\\\nFilm-Coated Tablets and Chewable Tablets\\\\nInform patients that the chewable tablet forms can be chewed or swallowed whole, but\\\\nthe film-coated table...\",\"Whitehouse Station, NJ 08889, USA\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nAll rights reserved.\\\\nuspi-mk0518-mf-1502r030\\\\nPatient Information\\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfilm-coated tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nchewable tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfor oral suspension\\\\nRead this Patient Information before you start taking I...\",\"Ask your doctor if you have any questions on how to prevent passing HIV to other\\\\npeople.\\\\nWhat should I tell my doctor before taking ISENTRESS?\\\\nBefore you take ISENTRESS, tell your doctor if you:\\\\nhave liver problems\\\\nhave a history of a muscle disorder called rhabdomyolysis or myopathy\\\\nhave increased levels of creatine kinase in your blood\\\\nhave phenylketonuria (PKU). ISENTRESS chewable tablets contain phenylalanine as\\\\npart of the artificial sweetener, aspartame. The artificial sweetener may be har...\",\"is time for your next dose, skip the missed dose and go back to your regular\\\\nschedule. Do not double your next dose or take more ISENTRESS than prescribed.\\\\nIf you take too much ISENTRESS, call your doctor or go to the nearest hospital\\\\nemergency room right away.\\\\nWhat are the possible side effects of ISENTRESS?\\\\nISENTRESS can cause serious side effects including:\\\\nSerious skin reactions and allergic reactions. \\\\nSome people who take\\\\nISENTRESS develop serious skin reactions and allergic reactions that...\",\"kidney stones\\\\nindigestion or stomach area pain\\\\nvomiting\\\\nsuicidal thoughts and actions\\\\nweakness\\\\nTell your doctor right away if you get unexplained muscle pain, tenderness, or weakness\\\\nwhile taking ISENTRESS. These may be signs of a rare serious muscle problem that can\\\\nlead to kidney problems.\\\\nTell your doctor if you have any side effect that bothers you or that does not go away.\\\\nThese are not all the possible side effects of ISENTRESS. For more information, ask your\\\\ndoctor or pharmacist.\\\\nCall you...\",\"Inactive ingredients:\\\\n calcium phosphate dibasic anhydrous, hypromellose 2208,\\\\nlactose monohydrate, magnesium stearate, microcrystalline cellulose, poloxamer 407\\\\n(contains 0.01% butylated hydroxytoluene as antioxidant), sodium stearyl fumarate.\\\\nThe film coating contains:\\\\n black iron oxide, polyethylene glycol 3350, polyvinyl\\\\nalcohol, red iron oxide, talc and titanium dioxide.\\\\nISENTRESS chewable tablets:\\\\nActive ingredient: \\\\nraltegravir\\\\nInactive ingredients:\\\\n ammonium hydroxide, crospovidone, ethy...\",\"more information about ISENTRESS.\\\\nYour doctor will decide the right dose based on your child&#x27;s weight.\\\\nAsk your doctor or pharmacist if you have any questions about how to mix or give\\\\nISENTRESS for oral suspension to your child.\\\\nEach ISENTRESS for oral suspension kit contains the following supplies (see\\\\nFigure A\\\\n):\\\\n2 reusable mixing cups with attached lids\\\\n2 reusable 5 mL dosing syringes\\\\n60 foil packets containing ISENTRESS for oral suspension\\\\nFor each dose of ISENTRESS for oral suspension you w...\",\"Step 2. \\\\nFill the dosing syringe. Start with the plunger pushed all the way inside the\\\\nbarrel of the syringe. Insert the tip of the syringe into the water and pull back on the\\\\nplunger to the 5 mL marking on the barrel of the syringe (see \\\\nFigure C\\\\n).\\\\nStep 3. \\\\nPour out remaining water from mixing cup (see \\\\nFigure D\\\\n).\",\"Step 4. \\\\nAdd the 5 mL of water from the dosing syringe back into the mixing cup by\\\\npressing down on the plunger (see \\\\nFigure E\\\\n).\\\\nStep 5. \\\\nOpen 1 foil packet. There is a notch that you can use to tear open the foil\\\\npacket, or you may use scissors to cut along the dotted line. Pour entire contents into\\\\nmixing cup (see \\\\nFigure F\\\\n).\",\"Step 6. \\\\nClose the attached lid to seal the mixing cup (see \\\\nFigure G\\\\n). It will snap shut.\\\\nStep 7. \\\\nSwirl the mixing cup to mix using a gentle circular motion for 30-60 seconds\\\\n(see \\\\nFigure H\\\\n). \\\\nDo not\\\\n turn the mixing cup upside down. The liquid will be cloudy.\\\\nStep 8. \\\\nOpen the mixing cup. Put the tip of the syringe into the liquid and \\\\npull back\\\\nthe plunger to the mL marking that matches your child&#x27;s prescribed dose\\\\n(see \\\\nFigure I\\\\n). Your child&#x27;s dose may be different from the one shown in ...\",\"How should I give a dose of ISENTRESS for oral suspension?\\\\nStep 9.\\\\n Place the tip of the dosing syringe in your child&#x27;s mouth and turn it toward\\\\neither cheek. Gently push down on the plunger to give the medicine (see \\\\nFigure J\\\\n). Give\\\\nthe dose of ISENTRESS oral suspension to your child within 30 minutes of mixing. If you\\\\nare not able to give your child&#x27;s dose within 30 minutes of mixing, pour the unused\\\\nmedicine into the trash. You will need to mix a new dose.\\\\nHow should I dispose of leftover IS...\",\"Step 11. \\\\nRemove plunger from the barrel of the dosing syringe. Hand wash the dosing\\\\nsyringe and mixing cup with warm water and dish soap. Rinse with water and air dry\\\\n(see \\\\nFigure L\\\\n).\\\\nHow should I store ISENTRESS for oral suspension?\\\\nStore ISENTRESS for oral suspension at room temperature between 68\\\\u00b0F to 77\\\\u00b0F\\\\n(20\\\\u00b0C to 25\\\\u00b0C).\\\\nStore in the original container. Do not open the foil packets until ready for use.\\\\nKeep ISENTRESS for oral suspension and all medicines out of the reach of\\\\nchildren.\\\\nFor m...\",\"Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nWhitehouse Station, NJ 08889, USA\\\\nIssued December 2013\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2013 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc. \\\\nAll rights reserved.\\\\nifu-mk0518-mf-1312r000\\\\nISENTRESS  \\\\nraltegravir tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION\\\\nDRUG\\\\nItem Code\\\\n(Source)\\\\nNDC:68071-2113(NDC:0006-\\\\n0227)\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredi...\",\"NuCare Pharmaceuticals,Inc.\\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLOXAMER 407\\\\n (UNII: TUF2IVW3M2)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYVINYL ALCOHOL\\\\n (UNII: 532B59J990)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)\\\\n \\\\nSODIUM STEARYL FUMARATE\\\\n (UNII: 7CV7WJK4UI)\\\\n \\\\nTALC\\\\n (UNII: 7SEV7J4R1U)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\npink (pink)\\\\nScore\\\\nno score\\\\nShape\\\\nOVAL (oval-shaped)\\\\nSize\\\\n16mm\\\\nFlavor\\\\nImprint Code\\\\n227\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem C...\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#98df8a\",\"#999\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ffbb78\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\"],\"shape\":[155],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1538\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1539\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1534\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1535\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1536\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1505\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1520\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1521\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1522\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1523\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1524\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1529\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1530\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1515\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1516\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1517\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1518\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1510\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1511\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1512\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1513\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1514\",\"attributes\":{\"axis\":{\"id\":\"p1510\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1519\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1515\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1540\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1541\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Drug Interactions\"},\"renderers\":[{\"id\":\"p1537\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1542\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Therapy Side Effects\"},\"renderers\":[{\"id\":\"p1537\"}],\"index\":10}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1543\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Drug Interactions\"},\"renderers\":[{\"id\":\"p1537\"}],\"index\":29}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1544\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"HIV-1 PrEP Safety\"},\"renderers\":[{\"id\":\"p1537\"}],\"index\":52}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1545\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Medication Injection Preparation\"},\"renderers\":[{\"id\":\"p1537\"}],\"index\":58}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1546\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p1537\"}],\"index\":7}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1547\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Raltegravir Side Effects\"},\"renderers\":[{\"id\":\"p1537\"}],\"index\":108}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1616\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1553\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1562\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1563\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1564\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1565\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1560\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1592\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1549\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1550\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1551\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"8hy7v8DvrcA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"lI3LwBPH+cA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"correctness\",[true,true]],[\"questions\",[\"What percentage of pediatric subjects experienced a Grade 3 or 4 rash when compared to adults in the study?\",\"What was the hazard ratio (with 95% confidence interval) for incident HIV-1 infections among participants who received APRETUDE compared to those who received TRUVADA, based on the extended retrospective virologic testing results?\"]],[\"agent_answer\",[\"According to the context, \\\\\"A higher frequency of Grade 3 or 4 rash was reported in 3% (6/182) of pediatric subjects compared to 0.9% of adults.\\\\\" Therefore, the answer is: 3%.\",\"The answer is 0.10 (0.04, 0.27).\"]],[\"reference_answer\",[\"In the study, 3% (6/182) of pediatric subjects experienced a Grade 3 or 4 rash, while only 0.9% of adults reported the same severity of rash.\",\"The hazard ratio for incident HIV-1 infections between participants receiving APRETUDE and TRUVADA was 0.10 (with a 95% CI of 0.04, 0.27), indicating a lower rate of infections in the APRETUDE group.\"]],[\"id\",[12,81]],[\"content\",[\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\"]],[\"color\",[\"#0a980a\",\"#0a980a\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1593\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1594\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1589\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1590\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1591\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1606\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1597\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1598\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1599\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1607\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1608\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1603\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1604\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1605\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1561\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1576\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1577\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1578\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1579\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1584\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1585\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1552\",\"attributes\":{\"renderers\":[{\"id\":\"p1592\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1571\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1572\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1573\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1574\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1566\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1567\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1568\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1569\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1570\",\"attributes\":{\"axis\":{\"id\":\"p1566\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1575\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1571\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1595\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1596\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p1592\"}],\"index\":0}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p1612\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1609\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1610\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1611\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"Xu3LwBlQ+8DXmYLA8rhBwBOkIsAvK9m/\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"VJP3wGZewMATu1LALg61wL8ZAsE6B9fA\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"cf4e03d8-cfea-46ea-a23b-3d3f5c777ae8\",\"roots\":{\"p1617\":\"cc15ce0d-990c-401b-8dbd-6ec3d91d8c5d\"},\"root_ids\":[\"p1617\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"cc15ce0d-990c-401b-8dbd-6ec3d91d8c5d\" data-root-id=\"p1617\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x1f56ca93f50>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_llama3_rag, testset=testset, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "089cf510",
   "metadata": {},
   "source": [
    "#### Llama 3"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "id": "1d1e01e7",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_llama3(question, history=None):\n",
    "    return chain_llama3.invoke({\"question\": question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "97fa0950",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "9a7efafd8e134d9faa44d39355c19f48",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "005b24ab0168468198e945e056ed4550",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"f87d80da-6cf8-4c78-937c-02fda03d90c7\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"f87d80da-6cf8-4c78-937c-02fda03d90c7\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"f87d80da-6cf8-4c78-937c-02fda03d90c7\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-red \">\n",
       "                        0.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=0.0 class=\" progress-red \">0.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-red \">\n",
       "                        0.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=0.0 class=\" progress-red \">0.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">0%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Based on the provided scores, the most important action to improve your RAG system is to focus on enhancing the performance for complex and simple question types across both topics.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"f607ed37-d2d5-4182-828e-b02de029c34b\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1932\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1934\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1941\",\"attributes\":{\"factors\":[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1942\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1943\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1939\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1961\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1929\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1930\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1931\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"AAAAAAAAAAAAAAAAAAAAAA==\"},\"shape\":[2],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"colors\",[\"#a50026\",\"#a50026\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1962\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1963\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1958\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1959\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1960\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1970\",\"attributes\":{\"data_source\":{\"id\":\"p1929\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1971\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1972\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1967\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1968\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1969\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1980\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1974\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1975\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1976\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1981\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1982\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1977\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1978\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1979\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1940\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1954\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1949\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1950\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1951\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1952\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1944\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1945\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1946\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1947\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1948\",\"attributes\":{\"axis\":{\"id\":\"p1944\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1953\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1949\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p1973\",\"attributes\":{\"location\":0.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1983\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1984\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p1980\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"f607ed37-d2d5-4182-828e-b02de029c34b\",\"roots\":{\"p1932\":\"cb25c103-7847-4029-a2ac-ea4170cb0e72\"},\"root_ids\":[\"p1932\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"cb25c103-7847-4029-a2ac-ea4170cb0e72\" data-root-id=\"p1932\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"3f4b6aa5-171c-4a72-a0ea-ebd4c57e0992\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p1863\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1794\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1743\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1752\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1753\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1754\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1755\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1750\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1783\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1740\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1741\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1742\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154]],[\"content\",[\"ATRIPLA ACCESS- efavirenz, emtricitabine, and tenofovir disoproxil\\\\nfumarate tablet, film coated \\\\n \\\\nGilead Sciences, Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ATRIPLA safely and\\\\neffectively. See full prescribing information for ATRIPLA.\\\\nATRIPLA\\\\u2122 (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets, for oral use\\\\nGILEAD ACCESS PROGRAM\\\\nInitial U.S. Approval: 2006\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION O...\",\"WARNINGS AND PRECAUTIONS\\\\nRash: Discontinue if severe rash develops. (\\\\n5.2\\\\n, \\\\n6.1\\\\n)\\\\nHepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying\\\\nhepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are\\\\ntaking medications associated with liver toxicity. Among reported cases of hepatic failure, a few\\\\noccurred in patients with no pre-existing hepatic disease. (\\\\n5.3\\\\n, \\\\n6.2\\\\n, \\\\n8.7\\\\n)\\\\nRisk of adverse reactions or loss of ...\",\"2.1 Testing Prior to Initiation and During Treatment with ATRIPLA\\\\n2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg\\\\n2.3 Not Recommended in Patients with Moderate or Severe Renal Impairment\\\\n2.4 Not Recommended in Patients with Moderate to Severe Hepatic Impairment\\\\n2.5 Dosage Adjustment with Rifampin\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and\\\\nHBV\\\\n5.2 Ra...\",\"16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B\\\\nSevere acute exacerbations of hepatitis B virus (HBV) have been\\\\nreported in patients who are coinfected with HIV-1 and HBV and have\\\\ndiscontinued products containing emtricitabine (FTC) and/or tenofovir\\\\ndisoproxil fumarate (TDF), which are components of ATRIPLA.\\\\nClosely monitor hepatic function with both clinical and laboratory follow-\\\\nup f...\",\"ATRIPLA is a three-drug fixed-dose combination product containing 600 mg of efavirenz\\\\n(EFV), 200 mg of emtricitabine (FTC), and 300 mg of tenofovir disoproxil fumarate (TDF).\\\\nThe recommended dosage of ATRIPLA in \\\\nadults and pediatric patients weighing at least\\\\n40 kg\\\\n is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may\\\\nimprove the tolerability of nervous system symptoms \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n2.3 Not Recommended in Patients with Moderate or Severe Ren...\",\"closely monitored, with both clinical and laboratory follow-up for at least several months\\\\nafter stopping treatment with ATRIPLA. If appropriate, initiation of anti-hepatitis B\\\\ntherapy may be warranted, especially in patients with advanced liver disease or cirrhosis,\\\\nsince posttreatment exacerbation of hepatitis may lead to hepatic decompensation and\\\\nliver failure.\\\\n5.2 Rash\\\\nIn controlled clinical trials, 26% (266/1,008) of adult subjects treated with 600 mg EFV\\\\nexperienced new-onset skin rash co...\",\"[see \\\\nDosage and Administration (2.1)\\\\n].\\\\n Consider discontinuing ATRIPLA in patients with\\\\npersistent elevations of serum transaminases to greater than five times the upper limit\\\\nof the normal range.\\\\nDiscontinue ATRIPLA if elevation of serum transaminases is accompanied by clinical\\\\nsigns or symptoms of hepatitis or hepatic decompensation \\\\n[see \\\\nAdverse Reactions\\\\n(6.1)\\\\n].\\\\n5.4 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug\\\\nInteractions\\\\nThe concomitant use of ATRIPLA and other d...\",\"discontinued or interrupted treatment because of one or more of these selected\\\\npsychiatric symptoms. There have also been occasional postmarketing reports of death\\\\nby suicide, delusions, and psychosis-like behavior, although a causal relationship to the\\\\nuse of EFV cannot be determined from these reports. Postmarketing cases of catatonia\\\\nhave also been reported and may be associated with increased EFV exposure. Patients\\\\nwith serious psychiatric adverse experiences should seek immediate medical ev...\",\"Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal\\\\ntubular injury with severe hypophosphatemia), has been reported with the use of TDF, a\\\\ncomponent of ATRIPLA \\\\n[see \\\\nAdverse Reactions (6.2)\\\\n].\\\\nPrior to initiation and during use of ATRIPLA, on a clinically appropriate schedule, assess\\\\nserum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all\\\\npatients. In patients with chronic kidney disease, also assess serum phosphorus.\\\\nATRIPLA is...\",\"considered for adult and pediatric patients who have a history of pathologic bone\\\\nfracture or other risk factors for osteoporosis or bone loss. Although the effect of\\\\nsupplementation with calcium and vitamin D was not studied, such supplementation may\\\\nbe beneficial for all patients. If bone abnormalities are suspected, then appropriate\\\\nconsultation should be obtained.\\\\nMineralization Defects\\\\nCases of osteomalacia associated with proximal renal tubulopathy, manifested as bone\\\\npain or pain in extre...\",\"enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and\\\\n\\\\\"cushingoid appearance,\\\\\" has been observed in patients receiving antiretroviral therapy,\\\\nincluding EFV. The mechanism and long-term consequences of these events are\\\\ncurrently unknown. A causal relationship has not been established.\\\\n6 ADVERSE REACTIONS\\\\nThe following adverse reactions are discussed in other sections of the labeling:\\\\nSevere Acute Exacerbations of Hepatitis B in Patients Coinfected with HIV-1 and...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nDizziness\\\\n8%\\\\n7%\\\\nUpper respiratory tract infections\\\\n8%\\\\n5%\\\\nSinusitis\\\\n8%\\\\n4%\\\\nRash Event\\\\n7%\\\\n9%\\\\nHeadache\\\\n6%\\\\n5%\\\\nInsomnia\\\\n5%\\\\n7%\\\\nAnxiety\\\\n5%\\\\n4%\\\\nNasopharyngitis\\\\n5%\\\\n3%\\\\nVomiting\\\\n2%\\\\n5%\\\\nIn Study 073, subjects with stable, virologic suppression on antiretroviral therapy and no\\\\nhistory of virologic failure were randomized to receive ATRIPLA or to stay on their\\\\nbaseline regimen. The adverse reactions observed in Study 073 were generally\\\\nconsistent with those seen in Study 934 and those seen with the individ...\",\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"subjects treated with EFV and fixed-dose zidovudine/lamivudine were hepatitis B surface\\\\nantigen or hepatitis C antibody positive. Among these coinfected subjects, one subject\\\\n(1/19) in the EFV, FTC, and TDF arm had elevations in transaminases to greater than five\\\\ntimes ULN through 144 weeks. In the fixed-dose zidovudine/lamivudine arm, two\\\\nsubjects (2/20) had elevations in transaminases to greater than five times ULN through\\\\n144 weeks. No HBV and/or HCV coinfected subject discontinued from the t...\",\"Dyspnea\\\\nSkin and Subcutaneous Tissue Disorders\\\\n \\\\nFlushing, erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome\\\\nEmtricitabine\\\\n:\\\\n No postmarketing adverse reactions have been identified for inclusion in\\\\nthis section.\\\\nTenofovir DF:\\\\nImmune System Disorders\\\\n \\\\nAllergic reaction, including angioedema\\\\nMetabolism and Nutrition Disorders\\\\n \\\\nLactic acidosis, hypokalemia, hypophosphatemia\\\\nRespiratory, Thoracic, and Mediastinal Disorders\\\\n \\\\nDyspnea\\\\nGastrointestinal Disorders\\\\n \\\\nPancreatitis,...\",\"There is limited information available on the potential for a pharmacodynamic interaction\\\\nbetween EFV and drugs that prolong the QTc interval. QTc prolongation has been\\\\nobserved with the use of EFV \\\\n[see \\\\nClinical Pharmacology (12.2)\\\\n].\\\\n Consider alternatives to\\\\nATRIPLA when coadministered with a drug with a known risk of Torsade de Pointes.\\\\n7.2 Drugs Affecting Renal Function\\\\nFTC and tenofovir are primarily eliminated by the kidneys\\\\n[see \\\\nClinical Pharmacology\\\\n(12.3)\\\\n].\\\\n Coadministration of ATRI...\",\"the increased indinavir metabolism due to\\\\nEFV.\\\\nProtease inhibitor:\\\\n  darunavir/ritonavir\\\\n\\\\u2191 tenofovir\\\\nMonitor patients receiving ATRIPLA\\\\nconcomitantly with ritonavir-boosted\\\\ndarunavir for TDF-associated adverse\\\\nreactions. Discontinue ATRIPLA in\\\\npatients who develop TDF-associated\\\\nadverse reactions.\\\\n  lopinavir/ritonavir\\\\n\\\\u2193 lopinavir\\\\n\\\\u2191 tenofovir\\\\nDo not use once daily administration of\\\\nlopinavir/ritonavir. Dose increase of\\\\nlopinavir/ritonavir is recommended for all\\\\npatients when coadministered with ...\",\"NRTI:\\\\n  didanosine\\\\n\\\\u2191 didanosine\\\\nreceiving TDF with didanosine 400 mg\\\\ndaily. \\\\nIn patients weighing greater than 60 kg,\\\\nreduce the didanosine dose to 250 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nIn patients weighing less than 60 kg,\\\\nreduce the didanosine dose to 200 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nWhen coadministered, ATRIPLA and\\\\nVidex EC may be taken under fasted\\\\nconditions or with a light meal (less than\\\\n400 kcal, 20% fat).\\\\nNNRTI:\\\\n  Other NNRTIs\\\\n\\\\u2191 or \\\\u2193 efavirenz\\\\nand/or NNRTI\\\\nCombini...\",\"Anticoagulant:\\\\n  warfarin\\\\n\\\\u2191 or \\\\u2193 warfarin\\\\nPlasma concentrations and effects\\\\npotentially increased or decreased by\\\\nEFV.\\\\nAnticonvulsants:\\\\n  carbamazepine\\\\n\\\\u2193 carbamazepine\\\\n\\\\u2193 efavirenz\\\\nThere are insufficient data to make a\\\\ndose recommendation for ATRIPLA.\\\\nAlternative anticonvulsant treatment\\\\nshould be used.\\\\n  phenytoin\\\\n  phenobarbital\\\\n\\\\u2193 anticonvulsant\\\\n\\\\u2193 efavirenz\\\\nPotential for reduction in anticonvulsant\\\\nand/or EFV plasma levels; periodic\\\\nmonitoring of anticonvulsant plasma\\\\nlevels should be conducted...\",\"artemether/lumefantrine\\\\n  atovaquone/proquanil\\\\n\\\\u2193 dihydroartemisinin\\\\n\\\\u2193 lumefantrine\\\\n\\\\u2193 atovaquone\\\\n\\\\u2193 proguanil\\\\nrisk of QT interval prolongation \\\\n[see\\\\nWarnings and Precautions (5.4)\\\\n]\\\\n.\\\\nConcomitant administration of\\\\natovaquone/proguanil with ATRIPLA is\\\\nnot recommended.\\\\nCalcium channel\\\\nblockers:\\\\n  diltiazem\\\\n\\\\u2193 diltiazem\\\\n\\\\u2193 desacetyl\\\\ndiltiazem\\\\n\\\\u2193 N-monodes-\\\\nmethyl diltiazem\\\\nDiltiazem dose adjustments should be\\\\nguided by clinical response (refer to the\\\\nfull prescribing information for diltiazem).\\\\nNo dose ...\",\"*\\\\ntacrolimus, sirolimus, and\\\\nothers metabolized by\\\\nCYP3A\\\\nsuppressant\\\\nmay be required. Close monitoring of\\\\nimmunosuppressant concentrations for\\\\nat least 2 weeks (until stable\\\\nconcentrations are reached) is\\\\nrecommended when starting or stopping\\\\ntreatment with ATRIPLA.\\\\nNarcotic analgesic:\\\\n  methadone\\\\n\\\\u2193 methadone\\\\nCoadministration of EFV in HIV-1 infected\\\\nindividuals with a history of injection drug\\\\nuse resulted in signs of opiate\\\\nwithdrawal. Methadone dose was\\\\nincreased by a mean of 22% to alleviate...\",\"for EFV, FTC, or TDF compared with the background rate for major birth defects of\\\\n2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects\\\\nProgram (MACDP) \\\\n(see \\\\nData\\\\n)\\\\n.\\\\nThe rate of miscarriage is not reported in the APR. The estimated background rate of\\\\nmiscarriage in clinically recognized pregnancies in the U.S. general population is 15-20%.\\\\nThe background risk of major birth defects and miscarriage for the indicated population\\\\nis unknown. The APR uses the MACDP as t...\",\"Animal Data\\\\nEfavirenz:\\\\n Effects of EFV on embryo-fetal development have been studied in three\\\\nnonclinical species (cynomolgus monkeys, rats, and rabbits). In monkeys, EFV 60\\\\nmg/kg/day was administered to pregnant females throughout pregnancy (gestation\\\\nDays 20 through 150). The maternal systemic drug exposures (AUC) were 1.3 times the\\\\nexposures at the RHD, with fetal umbilical venous drug concentrations approximately\\\\n0.7 times the maternal values. Three fetuses of 20 fetuses/infants had one or m...\",\"Based on limited published data, EFV, FTC, and tenofovir have been shown to be present\\\\nin human breast milk.\\\\nIt is not known if the components of ATRIPLA affect milk production or have effects on\\\\nthe breastfed child. Because of the potential for: (1) HIV transmission (in HIV-negative\\\\ninfants); (2) developing viral resistance (in HIV-positive infants); and (3) adverse\\\\nreactions in a breastfed infant similar to those seen in adults, instruct mothers not to\\\\nbreastfeed if they are receiving ATRIPLA....\",\"8.7 Hepatic Impairment\\\\nATRIPLA is not recommended for patients with moderate or severe hepatic impairment\\\\nbecause there are insufficient data to determine an appropriate dose. Patients with mild\\\\nhepatic impairment may be treated with ATRIPLA at the approved dose. Because of the\\\\nextensive cytochrome P450-mediated metabolism of EFV and limited clinical experience\\\\nin patients with hepatic impairment, caution should be exercised in administering\\\\nATRIPLA to these patients \\\\n[see \\\\nDosage and Administra...\",\"Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It\\\\nis practically insoluble in water (less than 10 \\\\u00b5g/mL).\\\\nEmtricitabine:\\\\n The chemical name of FTC is 5-fluoro-1-(2\\\\nR\\\\n,5\\\\nS\\\\n)-[2-(hydroxymethyl)-1,3-\\\\noxathiolan-5-yl]cytosine. FTC is the (-) enantiomer of a thio analog of cytidine, which\\\\ndiffers from other cytidine analogs in that it has a fluorine in the 5-position.\\\\nIt has a molecular formula of C\\\\nH\\\\nFN\\\\nO\\\\nS and a molecular weight of 247.24. It has the\\\\nfollo...\",\"12.1 Mechanism of Action\\\\nATRIPLA is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF \\\\n[see\\\\nMicrobiology (12.4)\\\\n].\\\\n12.2 Pharmacodynamics\\\\nCardiac Electrophysiology\\\\nEfavirenz:\\\\n \\\\nThe effect of EFV on the QTc interval was evaluated in an open-label, positive\\\\nand placebo-controlled, fixed single sequence 3-period, 3-treatment crossover QT study\\\\nin 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean C\\\\n of EFV in\\\\nsubjects with CYP2B6 *6/*6 genotype following the administration o...\",\"Tenofovir DF:\\\\n \\\\nFollowing oral administration of a single 300 mg dose of TDF to HIV-1\\\\ninfected subjects in the fasted state, maximum serum concentrations (C\\\\n) were\\\\nachieved in 1.0 \\\\u00b1 0.4 hrs (mean \\\\u00b1 SD) and C\\\\n and AUC values were 296 \\\\u00b1 90 ng/mL\\\\nand 2287 \\\\u00b1 685 ng\\\\u2219hr/mL, respectively. The oral bioavailability of tenofovir from TDF in\\\\nfasted subjects is approximately 25%. Less than 0.7% of tenofovir binds to human\\\\nplasma proteins in vitro, and the binding is independent of concentration over the ran...\",\"daily dose of 200 mg.\\\\nTenofovir DF:\\\\n Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1\\\\ninfected pediatric subjects (12 to less than 18 years). Mean \\\\u00b1 SD C\\\\n and AUC\\\\n are\\\\n0.38 \\\\u00b1 0.13 \\\\u03bcg/mL and 3.39 \\\\u00b1 1.22 \\\\u03bcg\\\\u2219hr/mL, respectively. Tenofovir exposure\\\\nachieved in these pediatric subjects receiving oral daily doses of TDF 300 mg was similar\\\\nto exposures achieved in adults receiving once-daily doses of TDF 300 mg.\\\\nGeriatric Patients\\\\nPharmacokinetics of EFV, FTC, and tenofovir have not...\",\"concentrations well above those achieved clinically. Coadministration of EFV with drugs\\\\nprimarily metabolized by CYP2C9, CYP2C19, CYP3A or CYP2B6 isozymes may result in\\\\naltered plasma concentrations of the coadministered drug. Drugs which induce CYP3A\\\\nand CYP2B6 activity would be expected to increase the clearance of EFV resulting in\\\\nlowered plasma concentrations.\\\\nDrug interaction trials were performed with EFV and other drugs likely to be\\\\ncoadministered or drugs commonly used as probes for phar...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\nCarbamazepine\\\\n200 mg qd \\\\u00d7 3\\\\ndays, 200 mg bid\\\\n\\\\u00d7 3 days, then\\\\n400 mg qd \\\\u00d7 15\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 35\\\\ndays\\\\n14\\\\n\\\\u2193 21\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 26)\\\\n\\\\u2193 36\\\\n(\\\\u2193 32 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 47\\\\n(\\\\u2193 41 to\\\\n\\\\u2193 53)\\\\nDiltiazem\\\\n240 mg \\\\u00d7 14\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 28\\\\ndays\\\\n12\\\\n\\\\u2191 16\\\\n(\\\\u2191 6 to \\\\u2191\\\\n26)\\\\n\\\\u2191 11\\\\n(\\\\u2191 5 to \\\\u2191\\\\n18)\\\\n\\\\u2191 13\\\\n(\\\\u2191 1 to \\\\u2191\\\\n26)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg\\\\nqd \\\\u00d7 9\\\\ndays\\\\nNA\\\\n\\\\u2191 38\\\\n\\\\u2191 44\\\\nNA\\\\n300 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 mg\\\\nqd \\\\u00d7 7\\\\ndays\\\\nNA\\\\n\\\\u2193 14\\\\n \\\\n(\\\\u2193 7 to \\\\u2193\\\\n21)\\\\n\\\\u2194\\\\nNA\\\\n400 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 m...\",\"meal\\\\n7\\\\u201320\\\\n300 mg\\\\nqd/ritonavir 100\\\\nmg qd d 1\\\\u201310\\\\n(pm), then 400\\\\nmg qd/ritonavir\\\\n100 mg qd d 11\\\\u2013\\\\n24 (pm)\\\\n(simultaneous\\\\nwith EFV)\\\\n600 mg qd\\\\nwith a light\\\\nsnack d\\\\n11\\\\u201324 (pm)\\\\n14\\\\n\\\\u2191 17\\\\n(\\\\u2191 8 to \\\\u2191\\\\n27)\\\\n\\\\u2194\\\\n\\\\u2193 42\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 51)\\\\nIndinavir\\\\n1000 mg q8h \\\\u00d7\\\\n10 days\\\\n600 mg qd\\\\n\\\\u00d7 10 days\\\\n20\\\\nAfter morning dose\\\\n\\\\u2194\\\\n\\\\u2193 33\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 39)\\\\n\\\\u2193 39\\\\n \\\\n(\\\\u2193 24 to\\\\n\\\\u2193 51)\\\\nAfter afternoon dose\\\\n\\\\u2194\\\\n\\\\u2193 37\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 46)\\\\n\\\\u2193 52\\\\n \\\\n(\\\\u2193 47 to\\\\n\\\\u2193 57)\\\\nAfter evening dose\\\\n\\\\u2193 29\\\\n \\\\n(\\\\u2193 11 to\\\\n\\\\u2193 43)\\\\n\\\\u2193 46\\\\n \\\\n(\\\\u2193 37 to\\\\n\\\\u2193 54)\\\\n\\\\u2193 57\\\\n \\\\n(\\\\u2193 50 to\\\\n\\\\u2193 63)\\\\nLopinavir/ritona...\",\"days\\\\n\\\\u00d7 16 days\\\\nto \\\\u2191 8)\\\\n25)\\\\n58)\\\\nSimeprevir\\\\n150 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n23\\\\n\\\\u2193 51\\\\n(\\\\u2193 46 to\\\\n\\\\u2193 56)\\\\n\\\\u2193 71\\\\n(\\\\u2193 67 to\\\\n\\\\u2193 74)\\\\n\\\\u2193 91\\\\n(\\\\u2193 88 to\\\\n\\\\u2193 92)\\\\nLedipasvir/sofosbuvir\\\\n90/400 mg qd \\\\u00d7\\\\n14 days\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\nLedipasvir\\\\n15\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 43)\\\\nSofosbuvir\\\\n\\\\u2194\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2194\\\\n\\\\u2194\\\\n\\\\u2194\\\\nSofosbuvir\\\\n400 mg qd single\\\\ndose\\\\n600 mg qd\\\\n\\\\u00d714 days\\\\n16\\\\n\\\\u2193 19\\\\n(\\\\u2193 40 to\\\\n\\\\u2191 10)\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2193 23\\\\n(\\\\u2193 16 to\\\\n\\\\u2193 30)\\\\n\\\\u2193 16\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 8)\\\\nNA\\\\nSofosbuvir/velpatasvir\\\\n400/100 mg qd \\\\u00d7\\\\n14 days\\\\n600...\",\"120 mg tablets (6\\\\n4-tablet doses\\\\nover 3 days)\\\\nArtemether\\\\n\\\\u2193 21\\\\u2193 38\\\\n\\\\u2193 51\\\\nNA\\\\ndihydroartemisinin\\\\n\\\\u2194\\\\n\\\\u2193 46\\\\nNA\\\\nlumefantrine\\\\n\\\\u219321\\\\nNA\\\\nAtorvastatin\\\\n10 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 14\\\\n(\\\\u2193 1 to \\\\u2193\\\\n26)\\\\n\\\\u2193 43\\\\n(\\\\u2193 34 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 69\\\\n(\\\\u2193 49 to\\\\n\\\\u2193 81)\\\\nTotal active (including\\\\nmetabolites)\\\\n\\\\u2193 15\\\\n(\\\\u2193 2 to \\\\u2193\\\\n26)\\\\n\\\\u2193 32\\\\n(\\\\u2193 21 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 48\\\\n(\\\\u2193 23 to\\\\n\\\\u2193 64)\\\\nPravastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n13\\\\n\\\\u2193 32\\\\n(\\\\u2193 59 to\\\\n\\\\u2191 12)\\\\n\\\\u2193 44\\\\n(\\\\u2193 26 to\\\\n\\\\u2193 57)\\\\n\\\\u2193 19\\\\n(\\\\u2193 0 to \\\\u2193\\\\n35)\\\\nSimvastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 7...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\n\\\\u00f0\\\\n\\\\u00f8\\\\n\\\\u00fd\\\\n\\\\u00a3\\\\nMethadone\\\\nmaintenance 35\\\\u2013\\\\n100 mg daily\\\\n\\\\u00d7 14\\\\u201321\\\\ndays\\\\n11\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 59)\\\\n(\\\\u2193 33 to\\\\n\\\\u2193 66)\\\\nNA\\\\nBupropion\\\\n150 mg single\\\\ndose (sustained-\\\\nrelease)\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 34\\\\n(\\\\u219321 to\\\\n\\\\u219347)\\\\n\\\\u2193 55\\\\n(\\\\u219348 to\\\\n\\\\u219362)\\\\nNA\\\\nHydroxybupropion\\\\n\\\\u2191 50\\\\n(\\\\u2191 20 to\\\\n\\\\u2191 80)\\\\n\\\\u2194\\\\nNA\\\\nSertraline\\\\n50 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 29\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 39\\\\n(\\\\u2193 27 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 46\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 58)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg qd\\\\n\\\\u00d7 9 days\\\\nNA\\\\n\\\\u2193 61\\\\n\\\\u2193 77\\\\nN...\",\"no clinically significant drug interactions have been observed between TDF and abacavir,\\\\nEFV, FTC, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral\\\\ncontraceptives, ribavirin, saquinavir/ritonavir, sofosbuvir, or tacrolimus in trials\\\\nconducted in healthy volunteers.\\\\nFollowing multiple dosing to HIV-negative subjects receiving either chronic methadone\\\\nmaintenance therapy, oral contraceptives, or single doses of ribavirin, steady-state\\\\ntenofovir pharmacokinetics we...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\nTable 7 Drug Interactions: Changes in Pharmacokinetic Parameters for\\\\nCoadministered Drug in the Presence of TDF\\\\nCoadministered\\\\nDrug\\\\nDose of\\\\nCoadministered\\\\nDrug (mg)\\\\nN\\\\nMean % Change of Coadministered\\\\nDrug Pharmacokinetic Parameters\\\\n \\\\n(90% CI)\\\\nC\\\\nAUC\\\\nC\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\nAtazanavir\\\\n400 once daily \\\\u00d7\\\\n14 days\\\\n34\\\\n\\\\u2193 21\\\\n(\\\\u2193 27 to \\\\u2193 14)\\\\n\\\\u2193 25\\\\n(\\\\u2193 30 to \\\\u2193 19)\\\\n\\\\u2193 40\\\\n(\\\\u2193 48 to \\\\u2193 32)\\\\nAtazanavir/ritonavir\\\\n300/100 once daily\\\\n\\\\u00d7 42 days\\\\n10\\\\n\\\\u2193 28\\\\n(\\\\u2193 50 to \\\\u2191 5)\\\\n\\\\u2193 25\\\\n \\\\n(\\\\u2193 42 to \\\\u2193 3)\\\\n\\\\u2193 23\\\\n \\\\n(\\\\u2193 46 to \\\\u2191 10)\\\\nDa...\",\"Efavirenz:\\\\n \\\\nEFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1.\\\\nEfavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1\\\\nreverse transcriptase. HIV-2 RT and human cellular DNA polymerases \\\\u03b1, \\\\u03b2, \\\\u03b3, and \\\\u03b4 are\\\\nnot inhibited by EFV.\\\\nEmtricitabine:\\\\n \\\\nEmtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated\\\\nby cellular enzymes to form FTC 5&#x27;-triphosphate. Emtricitabine 5&#x27;-triphosphate inhibits\\\\nthe activity of the HIV-1 RT by competing wi...\",\"tenofovir were in the range of 0.04\\\\u20138.5 \\\\u00b5M. In drug combination studies of tenofovir\\\\nwith NRTIs (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine),\\\\nNNRTIs (delavirdine, EFV, and nevirapine), and PIs (amprenavir, indinavir, nelfinavir,\\\\nritonavir, and saquinavir), additive to synergistic effects were observed. Tenofovir\\\\ndisplayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O\\\\n(EC\\\\n values ranged from 0.5\\\\u20132.2 \\\\u00b5M) and showed strain-specific ...\",\"susceptibility to FTC was associated with a substitution in the HIV-1 RT gene at codon\\\\n184 which resulted in an amino acid substitution of methionine by valine or isoleucine\\\\n(M184V/I).\\\\nTenofovir DF:\\\\n \\\\nHIV-1 isolates with reduced susceptibility to tenofovir have been selected\\\\nin cell culture. These viruses expressed a K65R substitution in RT and showed a 2- to 4-\\\\nfold reduction in susceptibility to tenofovir.\\\\nCross Resistance\\\\nEfavirenz, Emtricitabine, and Tenofovir DF:\\\\n Cross resistance has been ...\",\"Efavirenz:\\\\n \\\\nLong-term carcinogenicity studies in mice and rats were carried out with EFV.\\\\nMice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of\\\\nhepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas\\\\nwere increased above background in females. No increases in tumor incidence above\\\\nbackground were seen in males. In studies in which rats were administered EFV at\\\\ndoses of 0, 25, 50, or 100 mg/kg/day for 2 years, no increases in tumor incidence\\\\n...\",\"an alteration of the estrous cycle in female rats.\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\nEfavirenz:\\\\n \\\\nNonsustained convulsions were observed in 6 of 20 monkeys receiving EFV at\\\\ndoses yielding plasma AUC values 4- to 13-fold greater than those in humans given the\\\\nrecommended dose.\\\\nTenofovir DF:\\\\n \\\\nTenofovir and TDF administered in toxicology studies to rats, dogs, and\\\\nmonkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed\\\\nin humans caused bone toxicity. In monkeys...\",\"Outcomes\\\\nAt Week 48\\\\nAt Week 144\\\\nFTC+TDF+EFV\\\\n(N=244)\\\\nAZT/3TC+EFV\\\\n(N=243)\\\\nFTC+TDF+\\\\nEFV\\\\n(N=227)\\\\nAZT/3TC+EFV\\\\n(N=229)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\nResponder\\\\n84%\\\\n73%\\\\n71%\\\\n58%\\\\nVirologic failure\\\\n2%\\\\n4%\\\\n3%\\\\n6%\\\\n  Rebound\\\\n1%\\\\n3%\\\\n2%\\\\n5%\\\\n  Never suppressed\\\\n0%\\\\n0%\\\\n0%\\\\n0%\\\\n  Change in antiretroviral\\\\nregimen\\\\n1%\\\\n1%\\\\n1%\\\\n1%\\\\nDeath\\\\n&lt;1%\\\\n1%\\\\n1%\\\\n1%\\\\nDiscontinued due to\\\\nadverse event\\\\n4%\\\\n9%\\\\n5%\\\\n12%\\\\nDiscontinued for other\\\\nreasons\\\\n10%\\\\n14%\\\\n20%\\\\n22%\\\\nThrough Week 48, 84% and 73% of subjects in the FTC + TDF group and the\\\\nzidovudine/lamivudine group, respectiv...\",\"22-73 years); 88% were male, 68% were white, 29% were Black or African-American,\\\\nand 3% were of other races. At baseline, median CD4\\\\n cell count was 516 cells/mm\\\\n,\\\\nand 96% had HIV-1 RNA &lt;50 copies/mL. The median time since onset of antiretroviral\\\\ntherapy was 3 years, and 88% of subjects were receiving their first antiretroviral\\\\nregimen at trial enrollment.\\\\nAt Week 48, 89% and 87% of subjects who switched to ATRIPLA maintained HIV RNA\\\\n&lt;200 copies/mL and &lt;50 copies/mL, respectively, compared to 88...\",\"Interactions (7)\\\\n]\\\\n.\\\\nPsychiatric Symptoms\\\\nInform patients that serious psychiatric symptoms including severe depression,\\\\nsuicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms,\\\\nand catatonia have been reported in patients receiving EFV, a component of ATRIPLA\\\\n[see \\\\nWarnings and Precautions (5.5)\\\\n]\\\\n.\\\\nAdvise patients to seek immediate medical evaluation if they experience severe\\\\npsychiatric adverse experiences.\\\\nAdvise patients to inform their physician of any history o...\",\"Convulsions\\\\nInform patients that convulsions have been reported with the use of EFV, a component\\\\nof ATRIPLA. Patients who are receiving concomitant anticonvulsant medications primarily\\\\nmetabolized by the liver may require periodic monitoring of plasma levels \\\\n[see \\\\nWarnings\\\\nand Precautions (5.10)\\\\n and \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\nLactic Acidosis and Severe Hepatomegaly\\\\nInform patients that lactic acidosis and severe hepatomegaly with steatosis, including\\\\nfatal cases, have been reported. Treatmen...\",\"Patient Information\\\\n \\\\nATRIPLA\\\\u2122 (uh TRIP luh)\\\\n(efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets\\\\nWhat is the most important information I should know about ATRIPLA?\\\\nATRIPLA can cause serious side effects, including:\\\\nWorsening of hepatitis B virus (HBV) infection.\\\\n Your healthcare provider will\\\\ntest you for HBV before starting treatment with ATRIPLA. If you have HBV infection\\\\nand take ATRIPLA, your HBV may get worse (flare-up) if you stop taking ATRIPLA. \\\\nA\\\\n\\\\\"flare-up\\\\\" is when yo...\",\"be pregnant during treatment with ATRIPLA.\\\\nFemales who are able to become pregnant should use 2 effective\\\\nforms of birth control (contraception) during treatment with ATRIPLA\\\\nand for 12 weeks after stopping treatment.\\\\nA barrier form of birth control should always be used along with\\\\nanother type of birth control\\\\n. Barrier forms of birth control may include\\\\ncondoms, contraceptive sponges, diaphragm with spermicide, and cervical cap.\\\\nBirth control methods that contain the hormone progesterone such ...\",\"See \\\\\"\\\\nWhat is the most important information I should know about\\\\nATRIPLA?\\\\n\\\\\"\\\\nRash.\\\\n Rash is a serious side effect, but may also be common. Rashes will usually go\\\\naway without any change in your treatment. Tell your healthcare provider right away\\\\nif you develop a rash during treatment with ATRIPLA.\\\\nSevere liver problems. I\\\\nn rare cases, severe liver problems can happen that can\\\\nlead to death. \\\\nTell your healthcare provider right away if you get these\\\\nsymptoms:\\\\n skin or the white part of your eyes ...\",\"provider right away if you develop any of these symptoms:\\\\nweakness or being more tired than\\\\nusual\\\\nbeing short of breath or fast\\\\nbreathing\\\\ncold or blue hands and feet\\\\nfast or abnormal heartbeat\\\\nunusual muscle pain\\\\nstomach pain with nausea and vomiting\\\\nfeel dizzy or lightheaded\\\\nChanges in your immune system (Immune Reconstitution Syndrome) can\\\\nhappen when an HIV-1 infected person starts taking HIV-1 medicines.\\\\n Your\\\\nimmune system may get stronger and begin to fight infections that have been hidden...\",\"respective owners.\\\\n\\\\u00a9 2019 Gilead Sciences, LLC. All rights reserved.\\\\n21937-GS-020A\\\\nPRINCIPAL DISPLAY PANEL - 30 Tablet Bottle Label\\\\n61958-1601-3\\\\n30 tablets\\\\nATRIPLA\\\\u2122\\\\n(efavirenz 600 mg/emtricitabine 200 mg/\\\\ntenofovir disoproxil fumarate 300 mg)\\\\ntablets\\\\nGILEAD ACCESS PROGRAM\\\\nNote to pharmacist: Do not cover ALERT box with pharmacy label.\\\\nALERT: Find out about medicines that\\\\nshould NOT be taken with ATRIPLA\\\\nRx only\\\\nPOM\\\\nATRIPLA ACCESS  \\\\nefavirenz, emtricitabine, and tenofovir disoproxil fumarate tabl...\",\"Gilead Sciences, Inc.\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nEFAVIRENZ\\\\n (UNII: JE6H2O27P8) \\\\n(EFAVIRENZ - UNII:JE6H2O27P8)\\\\nEFAVIRENZ\\\\n600 mg\\\\nEMTRICITABINE\\\\n (UNII: G70B4ETF4S) \\\\n(EMTRICITABINE - UNII:G70B4ETF4S)\\\\nEMTRICITABINE\\\\n200 mg\\\\nTENOFOVIR DISOPROXIL FUMARATE\\\\n (UNII: OTT9J7900I) \\\\n(TENOFOVIR\\\\nANHYDROUS - UNII:W4HFE001U5)\\\\nTENOFOVIR DISOPROXIL\\\\nFUMARATE\\\\n300 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nHYDROXYPROPYL CELLULOSE (1600000 WAMW)\\\\n (UNII: RF...\",\"APRETUDE- cabotegravir \\\\n \\\\nViiV Healthcare Company\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use APRETUDE safely and\\\\neffectively. See full prescribing information for APRETUDE.\\\\nAPRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use\\\\nInitial U.S. Approval: 2021\\\\nWARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-\\\\nEXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION\\\\nSee full pres...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nADVERSE REACTIONS\\\\nThe most common adverse reactions (all grades) observed in at least 1% of participants receiving\\\\nAPRETUDE were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea,\\\\ndizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back\\\\npain, and upper respiratory tract infection. (\\\\n6.1\\\\n)\\\\nTo report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or\\\\nFDA at 1-800-FDA-1088 or \\\\nwww.fda.go...\",\"5.4 Hypersensitivity Reactions\\\\n5.5 Hepatotoxicity\\\\n5.6 Depressive Disorders\\\\n5.7 Risk of Reduced Drug Concentration of APRETUDE Due to Drug Interactions\\\\n6 ADVERSE REACTIONS\\\\n6.1 Clinical Trials Experience\\\\n6.2 Postmarketing Experience\\\\n7 DRUG INTERACTIONS\\\\n7.1 Use of Other Antiretroviral Drugs after Discontinuation of APRETUDE\\\\n7.2 Potential for Other Drugs to Affect APRETUDE\\\\n7.3 Established and Other Potentially Significant Drug Interactions\\\\n7.4 Drugs without Clinically Significant Interactions with C...\",\"WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR\\\\nHIV-1 PRE\\\\u2011EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1\\\\nINFECTION\\\\nIndividuals must be tested for HIV-1 infection prior to initiating\\\\nAPRETUDE or oral cabotegravir, and with each subsequent injection of\\\\nAPRETUDE, using a test approved or cleared by the FDA for the\\\\ndiagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1\\\\nvariants have been identified with use of APRETUDE by individuals with\\\\nundiagnosed HIV-1 infection. Do not ...\",\"Prior to starting APRETUDE, healthcare providers should carefully select individuals who\\\\nagree to the required injection dosing and testing schedule and counsel individuals about\\\\nthe importance of adherence to scheduled dosing visits to help reduce the risk of\\\\nacquiring HIV-1 infection and development of resistance \\\\n[see Dosage and Administration\\\\n(\\\\n2.1\\\\n), Warnings and Precautions (\\\\n5.1\\\\n, \\\\n5.3\\\\n), Microbiology (\\\\n12.4\\\\n)]\\\\n.\\\\n2.4 Optional Oral Lead-In Dosing to Assess Tolerability of APRETUDE\\\\nThe heal...\",\"Table 2. Recommended Dosing Schedule (Direct to Injection) for Pre-\\\\nExposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg\\\\n Individuals may be given APRETUDE up to 7 days before or after the date the individual\\\\nis scheduled to receive the injections.\\\\nIntramuscular (Gluteal) \\\\nInitiation Injection \\\\n(Month 1 and Month 2)\\\\nIntramuscular (Gluteal) \\\\nContinuation Injection \\\\n(Month 4 and Every 2 Months\\\\nOnwards)\\\\nAPRETUDE\\\\nAPRETUDE\\\\n600-mg (3 mL)\\\\n600-mg (3 mL)\\\\n2.6 Recommended Dosing Schedule ...\",\"Greater than 2 months\\\\nRestart with 600-mg (3-mL) gluteal intramuscular\\\\ninjection of APRETUDE, followed by a second 600-mg\\\\n(3-mL) initiation injection dose 1 month later. Then\\\\ncontinue to follow the every-2-month injection dosing\\\\nschedule thereafter.\\\\nIf third or subsequent\\\\ninjection is missed and time\\\\nsince prior injection is:\\\\nLess than or equal to 3 months\\\\nAdminister 600-mg (3-mL) intramuscular injection of\\\\nAPRETUDE as soon as possible, then continue with\\\\nthe every-2-month injection dosing sched...\",\"3 DOSAGE FORMS AND STRENGTHS\\\\nInjection: Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir\\\\nextended\\\\u2011release injectable suspension.\\\\n4 CONTRAINDICATIONS\\\\nAPRETUDE is contraindicated in individuals:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Comprehensive Management to Reduce the Risk of HIV-1 Infection\\\\nUse APRETUDE for HIV-1 PrEP to reduce the risk of HIV-1 infection as part of a\\\\ncomprehensive prevention strategy including adherence to the administration schedule\\\\nand safer sex practices,...\",\"\\\\u2022\\\\nWhen using APRETUDE for HIV-1 PrEP, HIV-1 testing should be repeated prior to each\\\\ninjection and upon diagnosis of any other STIs \\\\n[see Dosage and Administration (\\\\n2.2\\\\n,\\\\n2.5\\\\n)]\\\\n.\\\\n\\\\u2022\\\\nCounsel individuals without HIV-1 to strictly adhere to the recommended dosing and\\\\ntesting schedule for APRETUDE in order to reduce the risk of HIV-1 acquisition and the\\\\npotential development of resistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n, \\\\n2.5\\\\n),\\\\nMicrobiology (\\\\n12.4\\\\n)]\\\\n. Some individuals, such as adolescents,...\",\"include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) \\\\n[see Adverse\\\\nReactions (\\\\n6.2\\\\n)]\\\\n. Administration of cabotegravir oral lead-in dosing was used in clinical\\\\nstudies to help identify participants who may be at risk of a hypersensitivity reaction.\\\\nRemain vigilant and discontinue APRETUDE if a hypersensitivity reaction is suspected\\\\n[see Dosage and Administration (\\\\n2.4\\\\n), Contraindications (\\\\n4\\\\n), Adverse Reactions (\\\\n6\\\\n)]\\\\n.\\\\nDiscontinue APRETUDE immediately if signs or symptoms o...\",\"6.1 Clinical Trials Experience\\\\nBecause clinical trials are conducted under widely varying conditions, adverse reaction\\\\nrates observed in the clinical trials of a drug cannot be directly compared with rates in\\\\nthe clinical trials of another drug and may not reflect rates observed in practice.\\\\nClinical Trials Experience in Adults\\\\nThe safety assessment of APRETUDE is based on the analysis of data from 2\\\\ninternational, multicenter, double-blind trials, HPTN 083 and HPTN 084 \\\\n[see Clinical\\\\nStudies (\\\\n...\",\"Adverse reactions defined as \\\\u201ctreatment-related\\\\u201d as assessed by the investigator, with\\\\nexception of injection site reactions, where all injection site reactions were reported\\\\nregardless of causality.\\\\n Participants who received injection: HPTN 083, APRETUDE (n = 2,117) and TRUVADA\\\\n(n = 2,081); HPTN 084, APRETUDE (n = 1,519) and TRUVADA (n = 1,516).\\\\n Pyrexia includes pyrexia, feeling hot, chills, influenza-like illness.\\\\n Fatigue includes fatigue, malaise.\\\\n Sleep disorders includes insomnia, abnorm...\",\"grades) in at least 1% of participants who received APRETUDE and experienced at least\\\\none ISR from HPTN 084 are presented in \\\\nTable 5\\\\n.\\\\nTable 5. Injection Site Reactions (All Grades) Reported in at Least 1% of\\\\nParticipants Who Experienced at Least One Injection Site Reaction (All\\\\nCausality) with APRETUDE in Either HPTN 083 or HPTN 084\\\\n Placebo injectable suspension: intralipid 20% fat emulsion.\\\\nInjection Site\\\\nReactions\\\\nHPTN 083\\\\nHPTN 084\\\\nAPRETUDE\\\\n(n = 1,740)\\\\nTRUVADA\\\\n(n = 724)\\\\nAPRETUDE\\\\n(n = 578)\\\\nT...\",\"At the Week 41 and 97 timepoints in HPTN 084, participants who received APRETUDE\\\\ngained a median of 2 kg (IQR; 0.0, 5.0; n = 1,151) and 4 kg (IQR; 0.0, 8.0; n = 216) in\\\\nweight from baseline, respectively. Those who received TRUVADA gained a median of\\\\n1 kg (IQR; -1.0, 4.0; n = 1,131) and 3 kg (IQR; -1.0, 6.0; n = 218) in weight from\\\\nbaseline, respectively.\\\\nLaboratory Abnormalities: \\\\nGrade 3 or 4 post-baseline maximum toxicity laboratory\\\\nabnormalities for HPTN 083 or HPTN 084 are summarized in \\\\nTa...\",\"Nearly 60% of participants with baseline data available had Week 57 data available in\\\\nboth arms of both trials. Within each trial, baseline values were comparable among\\\\nparticipants receiving APRETUDE and TRUVADA.\\\\nHDL cholesterol\\\\nratio\\\\nClinical Trials Experience in Adolescents\\\\nIn adolescents receiving APRETUDE for HIV-1 PrEP, the safety data were comparable to\\\\nthe safety data reported in adults receiving APRETUDE for HIV-1 PrEP \\\\n[see Use in\\\\nSpecific Populations (\\\\n8.4\\\\n)].\\\\n6.2 Postmarketing Experi...\",\"inclusive.\\\\nTable 8. Drug Interactions with APRETUDE\\\\n\\\\u2191 = Increase, \\\\u2193 = Decrease, \\\\u2194 = No change.\\\\nConcomitant Drug\\\\nClass:\\\\nDrug Name\\\\nEffect on\\\\nConcentration\\\\nClinical Comment\\\\nAnticonvulsants:\\\\nCarbamazepine\\\\nOxcarbazepine\\\\nPhenobarbital\\\\nPhenytoin\\\\n\\\\u2193Cabotegravir\\\\nCoadministration is contraindicated with\\\\nAPRETUDE due to potential for significant\\\\ndecreases in plasma concentration of\\\\nAPRETUDE.\\\\nAntimycobacterials:\\\\nRifampin\\\\nRifapentine\\\\n\\\\u2193Cabotegravir\\\\nAntimycobacterial:\\\\nRifabutin\\\\n\\\\u2193Cabotegravir\\\\nWhen rifabutin is s...\",\"4263.\\\\nRisk Summary\\\\nThere are insufficient human data on the use of APRETUDE during pregnancy to\\\\nadequately assess a drug-associated risk of birth defects and miscarriage. Discuss the\\\\nbenefit-risk of using APRETUDE with individuals of childbearing potential or during\\\\npregnancy.\\\\nCabotegravir use in pregnant individuals has not been evaluated. APRETUDE should be\\\\nused during pregnancy only if the expected benefit justifies the potential risk to the\\\\nfetus.\\\\nThe APR has been established to monitor for ...\",\"exposure in humans at the RHD); there were no alterations to growth and development\\\\nof surviving offspring. In a cross-fostering study, similar incidences of stillbirths and\\\\nearly postnatal deaths were observed when rat pups born to cabotegravir-treated\\\\nmothers were nursed from birth by control mothers. There was no effect on neonatal\\\\nsurvival of control pups nursed from birth by cabotegravir-treated mothers. A lower\\\\ndose of 5 mg/kg/day (13 times the exposure at the RHD) was not associated with\\\\n...\",\"APRETUDE. Adolescents may benefit from more frequent visits and counseling to\\\\nsupport adherence to the dosing and testing schedule \\\\n[see Dosage and Administration\\\\n(\\\\n2.2\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)].\\\\nThe safety, efficacy, and pharmacokinetics of APRETUDE in pediatric participants\\\\nyounger than 12 years of age or weighing &lt;35 kg have not been established.\\\\n8.5 Geriatric Use\\\\nNo dose adjustment is required in elderly individuals. There are limited data available on\\\\nthe use of APRETUDE in indiv...\",\"Cabotegravir extended-release injectable suspension is a white to light pink free-flowing\\\\nsuspension for intramuscular injection in a sterile single-dose vial. Each vial contains\\\\n3 mL of the following: cabotegravir 200 mg/mL and the inactive ingredients mannitol\\\\n(35 mg/mL), polyethylene glycol (PEG) 3350 (20 mg/mL), polysorbate 20 (20 mg/mL),\\\\nand Water for Injection.\\\\nThe vial stoppers are not made with natural rubber latex.\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nCabotegravir is an HIV...\",\"CSF = Cerebrospinal fluid.\\\\n When taken orally with a high-fat meal versus fasted, the AUC\\\\n (geometric mean\\\\nratio [90% CI] of cabotegravir are 1.14 [1.02, 1.28]).\\\\n The clinical relevance of CSF-to-plasma concentration ratios is unknown.\\\\nConcentrations were measured at steady-state 1 week after intramuscular\\\\nadministration of cabotegravir extended-release injectable suspensions given monthly or\\\\nevery 2 months.\\\\n Elimination half-life driven by slow absorption rate from the intramuscular injection s...\",\"with HIV-1 (n = 110), the observed cabotegravir geometric mean (5th, 95th percentile)\\\\nC\\\\n (1-week post\\\\u2011initial injection) was 1.89 mcg/mL (0.438, 5.69) and C\\\\n was\\\\n1.43 mcg/mL (0.403, 3.90).\\\\n Pharmacokinetic parameter values represent steady state.\\\\nSpecific Populations\\\\nNo clinically significant differences in the pharmacokinetics of cabotegravir were\\\\nobserved based on age, sex, race/ethnicity, BMI, or UGT1A1 polymorphisms. There are\\\\nno data available for the use of cabotegravir in participants wit...\",\"IM = intramuscular.\\\\n Pharmacokinetic parameter values were based on individual post-hoc estimates from\\\\npopulation pharmacokinetic models in both adolescents with HIV-1 (n = 147) weighing\\\\n35.2 to 98.5 kg and adolescents without HIV-1 (n = 62) weighing 39.9 to 167 kg. \\\\n tau is dosing interval: 24 hours for oral administration, 1 month for the initial injection,\\\\nand 2 months for every 2 months for intramuscular injections of extended-release\\\\ninjectable suspension.\\\\n Oral lead-in pharmacokinetic para...\",\"n = Maximum number of participants with data, CI = Confidence Interval.\\\\nCoadministered\\\\nDrug(s)\\\\nand Dose(s)\\\\nDose of\\\\nCabotegravir\\\\nn\\\\nNo Effect = 1.00\\\\nC\\\\nAUC\\\\nC\\\\n or C\\\\nEtravirine\\\\n30 mg\\\\n12\\\\n1.04\\\\n1.01\\\\n1.00\\\\n    200 mg twice\\\\ndaily\\\\nonce daily\\\\n(0.99, 1.09)\\\\n(0.96, 1.06)\\\\n(0.94, 1.06)\\\\nRifabutin\\\\n30 mg\\\\n12\\\\n0.83\\\\n0.77\\\\n0.74\\\\n    300 mg once\\\\ndaily\\\\nonce daily\\\\n(0.76, 0.90)\\\\n(0.74, 0.83)\\\\n(0.70, 0.78)\\\\nRifampin\\\\n30-mg\\\\n15\\\\n0.94\\\\n0.41\\\\n0.50\\\\n    600 mg once\\\\ndaily\\\\nsingle dose\\\\n(0.87, 1.02)\\\\n(0.36, 0.46)\\\\n(0.44, 0.57)\\\\nRilpivirine\\\\n30 mg\\\\n1...\",\"12.4 Microbiology\\\\nMechanism of Action\\\\nCabotegravir inhibits HIV integrase by binding to the integrase active site and blocking\\\\nthe strand transfer step of retroviral deoxyribonucleic acid (DNA) integration that is\\\\nessential for the HIV replication cycle. The mean 50% inhibitory concentration (IC\\\\n)\\\\nvalue of cabotegravir in a strand transfer assay using purified recombinant HIV-1\\\\nintegrase was 3.0 nM.\\\\nAntiviral Activity in Cell Culture\\\\nCabotegravir exhibited antiviral activity against laboratory s...\",\"cabotegravir exposures below the target concentration. No variants expressing INSTI\\\\nresistance-associated substitutions were detected.\\\\nCross-Resistance\\\\nCross-resistance has been observed among INSTIs. Cabotegravir had reduced\\\\nsusceptibility (&gt;5-fold change) to recombinant HIV-1 strain NL432 viruses harboring the\\\\nfollowing integrase amino acid substitutions: G118R, Q148K, Q148R, T66K+L74M,\\\\nE92Q+N155H, E138A+Q148R, E138K+Q148K/R, G140C+Q148R, G140S+Q148H/K/R,\\\\nY143H+N155H, and Q148R+N155H (range: 5...\",\"in men and transgender women without HIV-1 who have sex with men and have\\\\nevidence of high-risk behavior for HIV-1 infection and HPTN 084 in cisgender women\\\\nwithout HIV-1 at risk of acquiring HIV-1.\\\\nParticipants randomized to receive APRETUDE initiated oral lead-in dosing with 1 oral\\\\ncabotegravir 30-mg tablet and a placebo daily for up to 5 weeks, followed by APRETUDE\\\\n600\\\\u2011mg (3-mL) intramuscular injection at months 1 and 2 and every 2 months\\\\nthereafter and a daily placebo tablet. Participants ra...\",\"Results from all subgroup analyses were consistent with the overall protective effect. A\\\\nlower rate of incident HIV\\\\u20111 infections was observed for participants randomized to\\\\nAPRETUDE compared with participants randomized to TRUVADA (\\\\nTable 15\\\\n).\\\\nTable 15. Incident of HIV-1 Infections by Subgroup in HPTN 083: Extended\\\\nRetrospective Virologic Testing with Readjudicated Endpoints\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence per\\\\n100 Person-\\\\nYears\\\\nAPRETUDE\\\\nPerson-Years\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nP...\",\"mITT from Supplemental Virology Report. \\\\n Cisgender men who have sex with men.\\\\n Transgender women who have sex with men.\\\\nTGW\\\\n0.54\\\\n371\\\\n1.80\\\\n389\\\\n0.34\\\\n(0.08,\\\\n1.56)\\\\nRace (US)\\\\nBlack\\\\n0.58\\\\n691\\\\n2.28\\\\n703\\\\n0.26\\\\n(0.09,\\\\n0.76)\\\\nNon-Black\\\\n0.00\\\\n836\\\\n0.50\\\\n801\\\\n0.11\\\\n(0.00,\\\\n2.80)\\\\nRegion\\\\nUS\\\\n0.26\\\\n1,528\\\\n1.33\\\\n1,504\\\\n0.21\\\\n(0.07,\\\\n0.60)\\\\nLatin\\\\nAmerica\\\\n0.49\\\\n1,020\\\\n1.09\\\\n1,011\\\\n0.47\\\\n(0.17,\\\\n1.35)\\\\nAsia\\\\n0.35\\\\n570\\\\n1.03\\\\n581\\\\n0.39\\\\n(0.08,\\\\n1.82)\\\\nAfrica\\\\n1.08\\\\n93\\\\n2.07\\\\n97\\\\n0.63\\\\n(0.06,\\\\n6.50)\\\\nTrial 201739 (HPTN 084 [NCT03164564])\\\\nIn HPTN 084, a su...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\",\"mITT from Supplemental Virology Report.\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nAPRETUDE\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nPerson-\\\\nYears\\\\nHazard\\\\nRatio\\\\n(95% CI)\\\\nAge\\\\n&lt;25 years\\\\n0.23\\\\n868\\\\n2.34\\\\n853\\\\n0.12\\\\n(0.03, 0.46)\\\\n\\\\u226525 years\\\\n0.09\\\\n1,093\\\\n1.46\\\\n1,093\\\\n0.09\\\\n(0.02, 0.49)\\\\nBody Mass Index\\\\n&lt;30\\\\n0.22\\\\n1,385\\\\n1.88\\\\n1,435\\\\n0.12\\\\n(0.04, 0.38)\\\\n\\\\u226530\\\\n0.00\\\\n575\\\\n1.76\\\\n511\\\\n0.04\\\\n(0.00, 0.93)\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nHow Supplied\\\\nAPRETUDE is supplied in a kit containing one 600-mg/3...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nPotential Risk of Resistance with APRETUDE\\\\nAdvise individuals there is a potential risk of developing resistance to APRETUDE if HIV-1\\\\nis acquired either before or while taking APRETUDE or following discontinuation of\\\\nAPRETUDE \\\\n[see Warnings and Precautions (\\\\n5.2\\\\n)]\\\\n.\\\\nTo minimize this, it is essential that individuals are clinically reassessed for risk of HIV-1\\\\nacquisition and tested frequently to confirm HIV-1 negative status. Advise individuals\\\\nwho are confirmed to have with HIV...\",\"Counsel individuals about the importance of continued medication adherence and\\\\nscheduled visits to help reduce the risk of acquiring HIV-1 infection and development of\\\\nresistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)]\\\\n.\\\\nHypersensitivity Reactions\\\\nAdvise individuals to immediately contact their healthcare provider if they develop a rash.\\\\nInstruct individuals to immediately stop taking APRETUDE and seek medical attention if\\\\nthey develop a rash associated with an...\",\"Warnings and Precautions (\\\\n5.3\\\\n), Use in Specific Populations (\\\\n8.1\\\\n)]\\\\n.\\\\nLactation\\\\nInform individuals that due to the potential for adverse reactions and residual\\\\nconcentrations in the systemic circulation for up to 12 months or longer after\\\\ndiscontinuing injections of APRETUDE, it is recommended that mothers breastfeed only\\\\nif the expected benefit justifies the potential risk to the infant. The benefits and risks of\\\\nAPRETUDE while breastfeeding should be evaluated, including the risk of HIV-1\\\\na...\",\"While you are receiving APRETUDE for HIV-1 PrEP:\\\\n\\\\u2022\\\\n\\\\u2022\\\\nIf you have HIV-1 and receive only APRETUDE, over time your HIV-1 may\\\\nbecome harder to treat.\\\\nWhat is APRETUDE?\\\\nAPRETUDE is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting\\\\nHIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg).\\\\nHIV-1 is the virus that causes acquired immune deficiency syndrome (AIDS).\\\\nIt is not known if APRETUDE is safe and effective in children younger than 12 years o...\",\"\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\nBefore receiving APRETUDE, tell your healthcare provider about all your\\\\nmedical conditions, including if you:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nTell your healthcare provider about all the medicines you take,\\\\n including\\\\nprescription and over-the-counter medicines, vitamins, and herbal supplements.\\\\nSome medicines may interact with APRETUDE. Keep a list of your medicines and show it\\\\nto your healthcare provider and pharmacist when you get a new medicine.\\\\nYou can ask your healthcare provider or pharmacist fo...\",\"What are the possible side effects of APRETUDE?\\\\nAPRETUDE may cause serious side effects including:\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\nThe most common side effects of APRETUDE include:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAllergic reactions.\\\\n Call your healthcare provider right away if you develop a rash\\\\nwith APRETUDE. \\\\nStop receiving APRETUDE and get medical help right away\\\\nif you develop a rash with any of the following signs or symptoms:\\\\n\\\\u25cb   fever\\\\n\\\\u25cb   generally ill feeling\\\\n\\\\u25cb   tiredness\\\\n\\\\u25cb   mu...\",\"These are not all the possible side effects of APRETUDE.\\\\nCall your doctor for medical advice about side effects. You may report side effects to\\\\nFDA at 1-800-FDA-1088.\\\\nGeneral information about the safe and effective use of APRETUDE.\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Patient\\\\nInformation leaflet. You can ask your pharmacist or healthcare provider for information\\\\nabout APRETUDE that is written for health professionals.\\\\nWhat are the ingredients in APRETUDE?...\",\"Overview:\\\\nA complete dose of APRETUDE requires 1 injection: 600-mg (3 mL) of cabotegravir.\\\\nAPRETUDE is a suspension that does not need further dilution or reconstitution.\\\\nCarefully follow these instructions when preparing the suspension for injection to avoid\\\\nleakage.\\\\nAPRETUDE is for gluteal intramuscular use only.\\\\nNote:\\\\n The ventrogluteal site is recommended.\\\\n Storage information\\\\nStore at 2\\\\u00b0C to 25\\\\u00b0C (36\\\\u00b0F to 77\\\\u00b0F). Exposure up to 30\\\\u00b0C (86\\\\u00b0F) permitted.\\\\nDo not \\\\nfreeze.\\\\nPrior to administration:\\\\n...\",\"\\\\u2022\\\\nYour pack contains:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nConsider the individual\\\\u2019s build and use medical judgment to select an appropriate\\\\ninjection needle length.\\\\nYou will also need:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\ntemperature prior to administration (not to exceed 30\\\\u00b0C [86\\\\u00b0F]).\\\\nOnce APRETUDE has been drawn into the syringe, the medicine can remain in the\\\\nsyringe for up to 2 hours before injection. The filled syringe should not be placed in\\\\nthe refrigerator. If the medicine remains in the syringe for more than 2 hours, the\\\\nfilled syringe and ne...\",\"Preparation:\\\\n1. Inspect the vial.\\\\nFigure A\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n\\\\u2022\\\\n2. Shake the vial vigorously.\\\\nFigure B\\\\n\\\\u2022\\\\n3. Inspect suspension.\\\\nFigure C\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n4. Remove the vial cap.\\\\nCheck that the\\\\nexpiration date has\\\\nnot passed. \\\\nSee\\\\nFigure A.\\\\nInspect the vial\\\\nimmediately. If you\\\\ncan see foreign\\\\nmatter, do not use\\\\nthe product.\\\\nNote:\\\\n The vial has a\\\\nbrown tint to the\\\\nglass.\\\\nDo not\\\\n use if the\\\\nexpiration date has\\\\npassed.\\\\nIf the pack has been\\\\nstored in the\\\\nrefrigerator, allow the\\\\nmedication to come to\\\\nroom temperature.\\\\nHold...\",\"Figure D\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n5. Peel open the vial adapter.\\\\nFigure E\\\\n\\\\u2022\\\\n \\\\n \\\\n6. Place vial on flat surface and attach the vial adapter.\\\\nFigure F\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n7. Lift off the packaging.\\\\nRemove the cap from\\\\nthe vial. \\\\nSee Figure\\\\nD.\\\\nWipe the rubber\\\\nstopper with an\\\\nalcohol wipe.\\\\nDo not\\\\n allow\\\\nanything to touch the\\\\nrubber stopper after\\\\nwiping it.\\\\nPeel off the paper\\\\nbacking from the vial\\\\nadapter packaging.\\\\nSee Figure E.\\\\nNote:\\\\n Do not remove\\\\nthe adapter from its\\\\npackaging for the\\\\nnext step. The\\\\nadapter \\\\nwill not\\\\n fall\\\\nout wh...\",\"Figure G\\\\n\\\\u2022\\\\n8. Prepare the syringe.\\\\nFigure H\\\\n\\\\u2022\\\\n\\\\u2022\\\\n9. Attach the syringe.\\\\nFigure I\\\\n\\\\u2022\\\\n\\\\u2022\\\\n10. Press the plunger.\\\\nLift off the vial\\\\nadapter packaging, as\\\\nshown.\\\\n See Figure\\\\nG.\\\\nRemove the syringe\\\\nfrom its packaging.\\\\nDraw 1 mL of air into\\\\nthe syringe. This will\\\\nmake it easier to draw\\\\nup the medicine later.\\\\nSee Figure H.\\\\nHold the vial adapter\\\\nand vial firmly, as\\\\nshown.\\\\nScrew the syringe\\\\nfirmly onto the vial\\\\nadapter. \\\\nSee Figure\\\\nI.\",\"Figure J\\\\n\\\\u2022\\\\n11. Slowly draw up the dose.\\\\nFigure K\\\\n\\\\u2022\\\\n \\\\n12. Unscrew the syringe.\\\\nFigure L\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n13. Attach the needle.\\\\nPress the plunger all\\\\nthe way down to push\\\\nthe air into the vial.\\\\nSee Figure J.\\\\nInvert the syringe and\\\\nvial and slowly\\\\nwithdraw as much of\\\\nthe medicine as\\\\npossible into the\\\\nsyringe. There may be\\\\nmore medicine than\\\\nthe dose amount.\\\\nSee Figure K.\\\\nNote:\\\\n Keep the\\\\nsyringe upright to\\\\navoid leakage.\\\\nHold the syringe\\\\nplunger firmly in place\\\\nas shown to prevent\\\\nleakage. It is normal\\\\nto fee...\",\"Figure M\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nInjection:\\\\n14. Prepare the injection site.\\\\nFigure N\\\\n \\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n15. Remove the cap.\\\\nPeel open the needle\\\\npackaging part way to\\\\nexpose the needle\\\\nbase.\\\\nKeeping the syringe\\\\nupright, firmly twist\\\\nthe syringe onto the\\\\nneedle.\\\\nRemove the needle\\\\npackaging from the\\\\nneedle. \\\\nSee Figure\\\\nM.\\\\nAPRETUDE must be\\\\nadministered to a\\\\ngluteal site. \\\\nSee\\\\nFigure N\\\\n.\\\\nSelect from the\\\\nfollowing areas for the\\\\ninjection:\\\\nVentrogluteal, as\\\\nshown\\\\n(recommended)\\\\nDorsogluteal, not\\\\nshown (upper outer\\\\nquadrant)\\\\nNote...\",\"Figure O\\\\n\\\\u2022\\\\n\\\\u2022\\\\n16. Remove extra liquid from the syringe.\\\\nFigure P\\\\n\\\\u2022\\\\n \\\\n17. Stretch the skin.\\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\nFold the needle guard\\\\naway from the needle.\\\\nSee Figure O.\\\\nPull off the injection\\\\nneedle cap.\\\\nHold the syringe with\\\\nthe needle pointing\\\\nup. Press the plunger\\\\nto the 3 mL dosing\\\\nmark to remove extra\\\\nliquid and any air\\\\nbubbles. \\\\nSee Figure\\\\nP.\\\\nNote:\\\\n Clean the\\\\ninjection site with an\\\\nalcohol wipe. Allow the\\\\nskin to air dry before\\\\ncontinuing.\\\\nUse the z-track\\\\ninjection technique to\\\\nminimize medicine\\\\nleakage ...\",\"Figure Q\\\\n18. Insert the needle.\\\\nFigure R\\\\n\\\\u2022\\\\n19. Inject the dose of medicine.\\\\nFigure S\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n20. Assess the injection site.\\\\nInsert the needle to\\\\nits full depth, or deep\\\\nenough to reach the\\\\nmuscle. \\\\nSee Figure\\\\nR.\\\\nStill holding the skin\\\\nstretched \\\\u2013 slowly\\\\npress the plunger all\\\\nthe way down. \\\\nSee\\\\nFigure S.\\\\nEnsure the syringe is\\\\nempty.\\\\nWithdraw the needle\\\\nand release the\\\\nstretched skin\\\\nimmediately.\",\"Figure T\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n21. Make the needle safe.\\\\nFigure U\\\\n\\\\u2022\\\\nFigure V\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAfter injection:\\\\n22. Dispose safely.\\\\nApply pressure to the\\\\ninjection site using a\\\\ngauze pad. \\\\nSee\\\\nFigure T.\\\\nA small bandage may\\\\nbe used if bleeding\\\\noccurs.\\\\nDo not\\\\n massage the\\\\narea.\\\\nFold the needle guard\\\\nover the needle. \\\\nSee\\\\nFigure U.\\\\nGently apply pressure\\\\nusing a hard surface\\\\nto lock the needle\\\\nguard in place.\\\\nThe needle guard will\\\\nmake a click when it\\\\nlocks. \\\\nSee Figure V.\",\"Figure W\\\\n\\\\u2022\\\\nQuestions and Answers\\\\n1.\\\\n \\\\n2.\\\\n3.\\\\n4.\\\\nManufactured for:\\\\nViiV Healthcare\\\\nDurham, NC 27701\\\\nTrademarks are owned by or licensed to the ViiV Healthcare group of companies.\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\nAPR:5IFU\\\\n \\\\nDispose of used\\\\nneedle, syringe, vial,\\\\nand vial adapter\\\\naccording to local\\\\nhealth and safety\\\\nlaws. \\\\nSee Figure W.\\\\nIf the pack has been stored in the refrigerator, is it safe to warm the\\\\nvial up to room temperature more quickly?\\\\n \\\\nThe vial should be broug...\",\"Principal Display Panel\\\\nNDC 49702-264-23\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nFor gluteal intramuscular use only.\\\\nHealthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 2/24\\\\n\\\\u00a92024 ViiV H...\",\"Principal Display Panel\\\\nNDC 49702-280-63\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nSample-Not for Sale\\\\nFor gluteal intramuscular use only.\",\"Healthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 5/24\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\n62000000094179\",\"APRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-264\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-264-\\\\n23\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n12/20/2021\",\"Quantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\nTotal Product Quantity\\\\nPart 1\\\\n1 VIAL\\\\n3 mL\\\\nPart 1 of 1\\\\nCABOTEGRAVIR  \\\\ncabotegravir injection, suspension, extended release\\\\nProduct Information\\\\nItem Code (Source)\\\\nNDC:49702-238\\\\nRoute of Administration\\\\nINTRAMUSCULAR\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCABOTEGRAVIR\\\\n (UNII: HMH0132Z1Q) \\\\n(CABOTEGRAVIR - UNII:HMH0132Z1Q)\\\\nCABOTEGRAVIR\\\\n200 mg  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)...\",\"NDA\\\\nNDA215499\\\\n12/20/2021\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nNDA\\\\nNDA215499\\\\n12/20/2021\\\\nAPRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-280\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-280-\\\\n63\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n03/31/2024\\\\nQuantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\n...\",\"ViiV Healthcare Company\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYSORBATE 20\\\\n (UNII: 7T1F30V5YH)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nWHITE (white to light pink)\\\\nScore\\\\n    \\\\nShape\\\\nSize\\\\nFlavor\\\\nImprint Code\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-238-\\\\n61\\\\n3 mL in 1 VIAL; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Mono...\",\"ISENTRESS- raltegravir tablet, film coated \\\\n \\\\nNuCare Pharmaceuticals,Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ISENTRESS safely and\\\\neffectively. See full prescribing information for ISENTRESS. \\\\nISENTRESS \\\\n (raltegravir) film-coated tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) chewable tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) for oral suspension \\\\nInitial U.S. Approval: 2007\\\\nINDICATIONS AND USAGE\\\\nISENTRESS is...\",\"The most common adverse reactions of moderate to severe intensity (\\\\u22652%) are insomnia, headache,\\\\ndizziness, nausea and fatigue ( \\\\n6.1\\\\n).\\\\nCreatine kinase elevations were observed in subjects who received ISENTRESS. Myopathy and\\\\nrhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or\\\\nrhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions\\\\nand patients with a history of rhabdomyolysis, myopathy or increased serum cre...\",\"8.5 Geriatric Use\\\\n8.6 Use in Patients with Hepatic Impairment\\\\n8.7 Use in Patients with Renal Impairment\\\\n10 OVERDOSAGE\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n12.4 Microbiology\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n14.1 \\\\nTreatment-Na\\\\u00efve Adult Subjects\\\\n14.2 Treatment-Experienced Adult Subjects\\\\n14.3 Pediatric Subjects\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT ...\",\"Each single-use packet for oral suspension contains 100 mg of raltegravir which is\\\\nsuspended in 5 mL of water giving a final concentration of 20 mg/mL.\\\\n2.2 Adults\\\\nFor the treatment of adult patients with HIV-1 infection, the dosage of ISENTRESS is one\\\\n400 mg film-coated tablet administered orally, twice daily.\\\\n2.3 Pediatrics\\\\nIf at least 25 kg:\\\\n One 400 mg film-coated tablet orally, twice daily.\\\\nIf unable to swallow a tablet, consider the chewable tablet, as specified in Table 1.\\\\nTable 1: Alterna...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n11 to less than 14 \\\\n4 mL (80 mg) twice\\\\ndaily\\\\n3 \\\\u00d7 25 mg twice daily\\\\n14 to less than 20 \\\\n5 mL (100 mg) twice\\\\ndaily\\\\n1 \\\\u00d7 100 mg twice\\\\ndaily\\\\n20 to less than 25\\\\n1.5 \\\\u00d7 100 mg \\\\n twice\\\\ndaily\\\\n2.4 Method of Administration\\\\nISENTRESS Film-Coated Tablets\\\\nFilm-Coated Tablets must be swallowed whole\\\\nISENTRESS Chewable Tablets\\\\nChewable Tablets may be chewed or swallowed whole\\\\nISENTRESS For Oral Suspension\\\\nEach single-use ISENTRESS packet for oral suspension contains 100 mg of raltegravir\\\\nwhich is to be sus...\",\"None\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Skin and Hypersensitivity Reactions\\\\nSevere, potentially life-threatening, and fatal skin reactions have been reported. These\\\\ninclude cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.\\\\nHypersensitivity reactions have also been reported and were characterized by rash,\\\\nconstitutional findings, and sometimes, organ dysfunction, including hepatic failure.\\\\nDiscontinue ISENTRESS and other suspect agents immediately if signs or symptoms of\\\\nsevere...\",\"STARTMRK (Protocol 021) with ISENTRESS 400 mg twice daily in combination with a fixed\\\\ndose of emtricitabine 200 mg (+) tenofovir 300 mg, (N=281) versus efavirenz (EFV) 600\\\\nmg at bedtime in combination with emtricitabine (+) tenofovir, (N=282). During double-\\\\nblind treatment, the total follow-up for subjects receiving ISENTRESS 400 mg twice daily\\\\n+ emtricitabine (+) tenofovir was 1104 patient-years and 1036 patient-years for\\\\nsubjects receiving efavirenz 600 mg at bedtime + emtricitabine (+) tenof...\",\"Analysis)\\\\nRandomized Study Protocol\\\\n021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm (Unit)\\\\nLimit\\\\nISENTRESS\\\\n400 mg \\\\nTwice Daily +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 281)\\\\nEfavirenz 600\\\\nmg \\\\nAt Bedtime +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 282)\\\\nHematology\\\\nAbsolute neutrophil count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n0.75 - 0.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n0.50 - 0.749\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&lt;0.50\\\\n1%\\\\n1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n1%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n1%\\\\n...\",\"ULN = Upper limit of normal range\\\\nLipids, Change from Baseline\\\\nChanges from baseline in fasting lipids are shown in Table 5.\\\\nTable 5: Lipid Values, Mean Change from Baseline, Protocol 021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm\\\\nISENTRESS 400 mg \\\\nTwice Daily + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 207\\\\nEfavirenz 600 mg \\\\nAt Bedtime + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 187\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean\\\\nMean\\\\nChange\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean...\",\"OBT. The median duration of therapy in these trials was 96 weeks for subjects receiving\\\\nISENTRESS and 38 weeks for subjects receiving placebo. The total exposure to\\\\nISENTRESS was 708 patient-years versus 244 patient-years on placebo. The rates of\\\\ndiscontinuation due to adverse events were 4% in subjects receiving ISENTRESS and 5%\\\\nin subjects receiving placebo.\\\\nClinical ADRs were considered by investigators to be causally related to ISENTRESS +\\\\nOBT or placebo + OBT. Clinical ADRs of moderate to s...\",\"Grade 4\\\\n&lt;0.50\\\\n1%\\\\n&lt;1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n3%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n25 - 49.999\\\\n1%\\\\n&lt;1%\\\\n  Grade 4\\\\n&lt;25\\\\n1%\\\\n&lt;1%\\\\nBlood chemistry\\\\nFasting (non-random) serum glucose test (mg/dL)\\\\n  Grade 2\\\\n126 - 250\\\\n10%\\\\n7%\\\\n  Grade 3\\\\n251 - 500\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&gt;500\\\\n0%\\\\n0%\\\\nTotal serum bilirubin\\\\n  Grade 2\\\\n1.6 - 2.5 \\\\u00d7 ULN\\\\n6%\\\\n3%\\\\n  Grade 3\\\\n2.6 - 5.0 \\\\u00d7 ULN\\\\n3%\\\\n3%\\\\n  Grade 4\\\\n&gt;5.0 \\\\u00d7 ULN\\\\n1%\\\\n0%\\\\nSerum aspartate aminotransferase...\",\"ULN = Upper limit of normal range\\\\nLess Common Adverse Reactions Observed in Treatment-Na\\\\u00efve and Treatment-\\\\nExperienced Studies\\\\nThe following ADRs occurred in &lt;2% of treatment-na\\\\u00efve or treatment-experienced\\\\nsubjects receiving ISENTRESS in a combination regimen. These events have been\\\\nincluded because of their seriousness, increased frequency on ISENTRESS compared\\\\nwith efavirenz or placebo, or investigator&#x27;s assessment of potential causal relationship.\\\\nGastrointestinal Disorders: \\\\nabdominal pain, ...\",\"upper limit of normal (ULN). In general the safety profile of ISENTRESS in subjects with\\\\nhepatitis B and/or hepatitis C virus co-infection was similar to that in subjects without\\\\nhepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT\\\\nabnormalities were higher in the subgroup with hepatitis B and/or hepatitis C virus co-\\\\ninfection for all treatment groups. At 96 weeks, in treatment-experienced subjects,\\\\nGrade 2 or higher laboratory abnormalities that represent a wors...\",\"patients with underlying liver disease and/or concomitant medications\\\\nMusculoskeletal and Connective Tissue Disorders:\\\\n rhabdomyolysis\\\\nNervous System Disorders: \\\\ncerebellar ataxia\\\\nPsychiatric Disorders: \\\\nanxiety, paranoia\\\\n7 DRUG INTERACTIONS\\\\n7.1 Effect of Raltegravir on the Pharmacokinetics of Other Agents\\\\nRaltegravir does not inhibit (IC \\\\n&gt;100 \\\\u00b5M) CYP1A2, CYP2B6, CYP2C8, CYP2C9,\\\\nCYP2C19, CYP2D6 or CYP3A \\\\nin vitro\\\\n. Moreover, \\\\nin vitro\\\\n, raltegravir did not induce\\\\nCYP1A2, CYP2B6 or CYP3A4. A mid...\",\"rifampin\\\\n\\\\u2193\\\\ndaily during coadministration\\\\nwith rifampin. There are no\\\\ndata to guide co-\\\\nadministration of ISENTRESS\\\\nwith rifampin in patients below\\\\n18 years of age \\\\n[see \\\\nDosage\\\\nand Administration (2.1)\\\\n].\\\\n7.3 Drugs without Clinically Significant Interactions with ISENTRESS\\\\nIn drug interaction studies, raltegravir did not have a clinically meaningful effect on the\\\\npharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine,\\\\ntenofovir, etravirine, darunavir/ritonavir, or boce...\",\"8.3 Nursing Mothers\\\\nBreastfeeding is not recommended while taking ISENTRESS. In addition, it is\\\\nrecommended that HIV-1-infected mothers not breastfeed their infants to avoid risking\\\\npostnatal transmission of HIV-1.\\\\nIt is not known whether raltegravir is secreted in human milk. However, raltegravir is\\\\nsecreted in the milk of lactating rats. Mean drug concentrations in milk were\\\\napproximately 3-fold greater than those in maternal plasma at a maternal dose of 600\\\\nmg/kg/day in rats. There were no ef...\",\"evidence of toxicity.\\\\nIn the event of an overdose, it is reasonable to employ the standard supportive\\\\nmeasures, e.g., remove unabsorbed material from the gastrointestinal tract, employ\\\\nclinical monitoring (including obtaining an electrocardiogram), and institute supportive\\\\ntherapy if required. The extent to which ISENTRESS may be dialyzable is unknown.\\\\n11 DESCRIPTION\\\\nISENTRESS contains raltegravir potassium, a human immunodeficiency virus integrase\\\\nstrand transfer inhibitor. The chemical name fo...\",\"fructose, hydroxypropyl cellulose, hypromellose 2910/6cP, magnesium stearate,\\\\nmannitol, medium chain triglycerides, monoammonium glycyrrhizinate, natural and\\\\nartificial flavors (orange, banana, and masking that contains aspartame), oleic acid, PEG\\\\n400, saccharin sodium, sodium citrate dihydrate, sodium stearyl fumarate, sorbitol,\\\\nsucralose and yellow iron oxide.\\\\nEach packet of ISENTRESS for oral suspension 100 mg, contains 108.6 mg of raltegravir\\\\n(as potassium salt), equivalent to 100 mg of ralt...\",\"formulation comparison study in healthy adult volunteers, the chewable tablet and oral\\\\nsuspension have higher oral bioavailability compared to the 400 mg film-coated tablet.\\\\nIn subjects who received 400 mg twice daily alone, raltegravir drug exposures were\\\\ncharacterized by a geometric mean AUC \\\\n of 14.3 \\\\u00b5M\\\\u2219hr and C \\\\n of 142 nM.\\\\nConsiderable variability was observed in the pharmacokinetics of raltegravir. For\\\\nobserved C \\\\nin Protocols 018 and 019, the coefficient of variation (CV) for inter-\\\\nsubje...\",\"approximately 70% of the total radioactivity; the remaining radioactivity in plasma was\\\\naccounted for by raltegravir-glucuronide. Studies using isoform-selective chemical\\\\ninhibitors and cDNA-expressed UDP-glucuronosyltransferases (UGT) show that UGT1A1\\\\nis the main enzyme responsible for the formation of raltegravir-glucuronide. Thus, the\\\\ndata indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-\\\\nmediated glucuronidation.\\\\nSpecial Populations\\\\nPediatric\\\\nTwo pediatric fo...\",\"*\\\\n\\\\u2020\\\\nkg\\\\nTable 2\\\\n3 to less\\\\nthan 20\\\\nkg\\\\nOral\\\\nsuspension\\\\nWeight\\\\nbased\\\\ndosing, see\\\\nTable 2\\\\n19\\\\n24.5 ( \\\\n43%\\\\n)\\\\n113 ( \\\\n69%\\\\n)\\\\nThe pharmacokinetics of raltegravir in infants under 4 weeks of age has not been\\\\nestablished.\\\\nAge\\\\nThe effect of age (18 years and older) on the pharmacokinetics of raltegravir was\\\\nevaluated in the composite analysis. No dosage adjustment is necessary.\\\\nRace\\\\nThe effect of race on the pharmacokinetics of raltegravir in adults was evaluated in the\\\\ncomposite analysis. No dosage adjustmen...\",\"with wild-type genotype, the geometric mean ratio (90% CI) of AUC was 1.41 (0.96,\\\\n2.09).\\\\nDrug Interactions\\\\n [see \\\\nDrug Interactions (7)\\\\n]\\\\nTable 10: Effect of Other Agents on the Pharmacokinetics of Raltegravir in\\\\nAdults\\\\nCoadministered\\\\nDrug\\\\nCoadministered\\\\nDrug\\\\nDose/Schedule\\\\nRaltegravir \\\\nDose/Schedule\\\\nRatio (90% Confidence\\\\nInterval) of Raltegravir\\\\nPharmacokinetic Parameters\\\\nwith/without Coadministered\\\\nDrug; \\\\nNo Effect = 1.00\\\\nn\\\\nC \\\\nAUC\\\\nC \\\\naluminum and\\\\nmagnesium\\\\nhydroxide antacid\\\\n20 mL single\\\\ndose gi...\",\"boceprevir\\\\n800 mg three\\\\ntimes daily\\\\n400 mg single\\\\ndose\\\\n22\\\\n(0.91-\\\\n1.36)\\\\n(0.88-\\\\n1.22)\\\\n(0.45-\\\\n1.23)\\\\ncalcium carbonate\\\\nantacid\\\\n3000 mg single\\\\ndose given with\\\\nraltegravir\\\\n400 mg twice\\\\ndaily\\\\n24\\\\n0.48 \\\\n(0.36,\\\\n0.63)\\\\n0.45 \\\\n(0.35,\\\\n0.57)\\\\n0.68 \\\\n(0.53,\\\\n0.87)\\\\nefavirenz\\\\n600 mg daily\\\\n400 mg single\\\\ndose\\\\n9\\\\n0.64\\\\n(0.41,\\\\n0.98)\\\\n0.64\\\\n(0.52,\\\\n0.80)\\\\n0.79\\\\n(0.49,\\\\n1.28)\\\\netravirine\\\\n200 mg twice\\\\ndaily\\\\n400 mg twice\\\\ndaily\\\\n19\\\\n0.89\\\\n(0.68,\\\\n1.15)\\\\n0.90\\\\n(0.68,\\\\n1.18)\\\\n0.66\\\\n(0.34,\\\\n1.26)\\\\nomeprazole\\\\n20 mg daily\\\\n400 mg single\\\\ndose\\\\n14 \\\\n(10\\\\nf...\",\"Raltegravir at concentrations of 31 \\\\u00b1 20 nM resulted in 95% inhibition (EC \\\\n) of viral\\\\nspread (relative to an untreated virus-infected culture) in human T-lymphoid cell cultures\\\\ninfected with the cell-line adapted HIV-1 variant H9IIIB. In addition, 5 clinical isolates of\\\\nHIV-1 subtype B had EC \\\\n values ranging from 9 to 19 nM in cultures of mitogen-\\\\nactivated human peripheral blood mononuclear cells. In a single-cycle infection assay,\\\\nraltegravir inhibited infection of 23 HIV-1 isolates represen...\",\"dolutegravir.\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nCarcinogenicity studies of raltegravir in mice did not show any carcinogenic potential. At\\\\nthe highest dose levels, 400 mg/kg/day in females and 250 mg/kg/day in males, systemic\\\\nexposure was 1.8-fold (females) or 1.2-fold (males) greater than the AUC (54 \\\\u00b5M\\\\u2219hr) at\\\\nthe 400-mg twice daily human dose. Treatment-related squamous cell carcinoma of\\\\nnose/nasopharynx was observed in female rats dosed with 6...\",\"Protocol 021\\\\n400 mg Twice\\\\nDaily\\\\n600 mg At\\\\nBedtime\\\\n(N = 281)\\\\n(N = 282)\\\\nGender\\\\n  Male\\\\n81%\\\\n82%\\\\n  Female\\\\n19%\\\\n18%\\\\nRace\\\\n  White\\\\n41%\\\\n44%\\\\n  Black\\\\n12%\\\\n8%\\\\n  Asian\\\\n13%\\\\n11%\\\\n  Hispanic\\\\n21%\\\\n24%\\\\n  Native American\\\\n&lt;1%\\\\n&lt;1%\\\\n  Multiracial\\\\n12%\\\\n13%\\\\nRegion\\\\n  Latin America\\\\n35%\\\\n34%\\\\n  Southeast Asia\\\\n12%\\\\n10%\\\\n  North America\\\\n29%\\\\n32%\\\\n  EU/Australia\\\\n23%\\\\n23%\\\\nAge (years)\\\\n  18-64\\\\n99%\\\\n99%\\\\n  \\\\u226565\\\\n1%\\\\n1%\\\\n  Mean (SD)\\\\n38 (9)\\\\n37 (10)\\\\n  Median (min, max)\\\\n37 (19 to 67)\\\\n36 (19 to 71)\\\\nCD4+ Cell Count (cells/microL)\\\\n  Mean (SD)\\\\n219 (124)\\\\n2...\",\"Notes: \\\\nISENTRESS and Efavirenz were administered with emtricitabine (+) tenofovir \\\\nN = Number of subjects in each group.\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n  Hepatitis B or C Positive \\\\n6%\\\\n6%\\\\nWeek 240 outcomes from Protocol 021 are shown in Table 12.\\\\nTable 12: Virologic Outcomes of Randomized Treatment\\\\nof Protocol 021 at 240 Weeks\\\\nISENTRESS\\\\n400 mg \\\\nTwice\\\\nDaily \\\\n(N = 281)\\\\nEfavirenz \\\\n600 mg \\\\nAt\\\\nBedtime \\\\n(N = 282)\\\\nDifference \\\\n(ISENTRESS \\\\u2013\\\\nEfavirenz) (CI)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with\\\\nHIV-1 RNA less\\\\nthan 50\\\\ncopies/mL\\\\n66%\\\\n60%\\\\n6.6% \\\\n(-1.4%...\",\"14.2 Treatment-Experienced Adult Subjects\\\\nBENCHMRK 1 and BENCHMRK 2 are Phase 3 studies to evaluate the safety and\\\\nantiretroviral activity of ISENTRESS 400 mg twice daily in combination with an optimized\\\\nbackground therapy (OBT), versus OBT alone, in HIV-1-infected subjects, 16 years or\\\\nolder, with documented resistance to at least 1 drug in each of 3 classes (NNRTIs,\\\\nNRTIs, PIs) of antiretroviral therapies. Randomization was stratified by degree of\\\\nresistance to PI (1PI vs. &gt;1PI) and the use of...\",\"*\\\\nvirus\\\\n83%\\\\n84%\\\\nHepatitis B virus only\\\\n8%\\\\n3%\\\\nHepatitis C virus only\\\\n8%\\\\n12%\\\\nCo-infection of\\\\nHepatitis B and C\\\\nvirus\\\\n1%\\\\n1%\\\\nStratum\\\\nEnfuvirtide in OBT\\\\n38%\\\\n38%\\\\nResistant to \\\\u22652 PI\\\\n97%\\\\n95%\\\\nTable 14 compares the characteristics of optimized background therapy at baseline in\\\\nthe group receiving ISENTRESS 400 mg twice daily and subjects in the control group.\\\\nTable 14: Characteristics of Optimized Background\\\\nTherapy at Baseline\\\\nRandomized Studies \\\\nProtocol 018 and 019\\\\nISENTRESS\\\\n400 mg Twice\\\\nDaily + OBT\\\\nPl...\",\"Week 96 outcomes for the 699 subjects randomized and treated with the\\\\nrecommended dose of ISENTRESS 400 mg twice daily or placebo in the pooled\\\\nBENCHMRK 1 and 2 studies are shown in Table 15.\\\\nTable 15: Virologic Outcomes of Randomized Treatment\\\\nof Protocols 018 and 019 at 96 Weeks (Pooled Analysis)\\\\nISENTRESS \\\\n400 mg Twice\\\\nDaily + OBT \\\\n(N = 462)\\\\nPlacebo + OBT \\\\n(N = 237)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with HIV-1\\\\nRNA less than 50\\\\ncopies/mL\\\\n55%\\\\n27%\\\\nVirologic Failure \\\\n35%\\\\n66%\\\\nNo virologic data at\\\\nWeek 96 Window\\\\nReas...\",\"&lt;50 copies/mL \\\\nAt Week 96\\\\nn\\\\nISENTRESS \\\\n400 mg \\\\nTwice Daily +\\\\nOBT \\\\n(N = 462) \\\\nn\\\\nPlacebo +\\\\nOBT \\\\n(N = 237)\\\\n*\\\\nPhenotypic Sensitivity Score (PSS) \\\\n0\\\\n67\\\\n43\\\\n43\\\\n5\\\\n1\\\\n144\\\\n58\\\\n71\\\\n23\\\\n2\\\\n142\\\\n61\\\\n66\\\\n32\\\\n3 or more\\\\n85\\\\n48\\\\n48\\\\n42\\\\nGenotypic Sensitivity Score (GSS) \\\\n0\\\\n116\\\\n39\\\\n65\\\\n5\\\\n1\\\\n177\\\\n62\\\\n95\\\\n26\\\\n2\\\\n111\\\\n61\\\\n49\\\\n53\\\\n3 or more\\\\n51\\\\n49\\\\n23\\\\n35\\\\nSwitch of Suppressed Subjects from Lopinavir (+) Ritonavir to Raltegravir\\\\nThe SWITCHMRK 1 &amp; 2 Phase 3 studies evaluated HIV-1 infected subjects receiving\\\\nsuppressive therapy (HIV-1 RNA &lt;50 cop...\",\"children. This study enrolled 126 treatment experienced children and adolescents 2 to\\\\n18 years of age. Subjects were stratified by age, enrolling adolescents first and then\\\\nsuccessively younger children. Subjects were enrolled into cohorts according to age and\\\\nreceived the following formulations: Cohort I (12 to less than 18 years old), 400 mg film-\\\\ncoated tablet; Cohort IIa (6 to less than 12 years old), 400 mg film-coated tablet; Cohort\\\\nIIb (6 to less than 12 years old), chewable tablet; Cohor...\",\"copies/mL. The mean CD4 count (percent) increase from baseline to Week 48 was 492\\\\ncells/mm \\\\n(7.8%).\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nISENTRESS tablets 400 mg are pink, oval-shaped, film-coated tablets with \\\\\"227\\\\\" on one\\\\nside. They are supplied as follows:\\\\nNDC\\\\n 68071-2113-6 \\\\nbottles of 6\\\\nStorage and Handling\\\\n400 mg Film-coated Tablets, Chewable Tablets and For Oral Suspension\\\\nStore at 20-25\\\\u00b0C (68-77\\\\u00b0F); excursions permitted to 15-30\\\\u00b0C (59-86\\\\u00b0F). See USP\\\\nControlled Room Temperature.\\\\nChewable Ta...\",\"General Dosing Instructions\\\\nInstruct patients that if they miss a dose of ISENTRESS, they should take it as soon as\\\\nthey remember. If they do not remember until it is time for the next dose, instruct them\\\\nto skip the missed dose and go back to the regular schedule. Instruct patients not to\\\\ndouble their next dose or take more than the prescribed dose.\\\\nFilm-Coated Tablets and Chewable Tablets\\\\nInform patients that the chewable tablet forms can be chewed or swallowed whole, but\\\\nthe film-coated table...\",\"Whitehouse Station, NJ 08889, USA\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nAll rights reserved.\\\\nuspi-mk0518-mf-1502r030\\\\nPatient Information\\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfilm-coated tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nchewable tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfor oral suspension\\\\nRead this Patient Information before you start taking I...\",\"Ask your doctor if you have any questions on how to prevent passing HIV to other\\\\npeople.\\\\nWhat should I tell my doctor before taking ISENTRESS?\\\\nBefore you take ISENTRESS, tell your doctor if you:\\\\nhave liver problems\\\\nhave a history of a muscle disorder called rhabdomyolysis or myopathy\\\\nhave increased levels of creatine kinase in your blood\\\\nhave phenylketonuria (PKU). ISENTRESS chewable tablets contain phenylalanine as\\\\npart of the artificial sweetener, aspartame. The artificial sweetener may be har...\",\"is time for your next dose, skip the missed dose and go back to your regular\\\\nschedule. Do not double your next dose or take more ISENTRESS than prescribed.\\\\nIf you take too much ISENTRESS, call your doctor or go to the nearest hospital\\\\nemergency room right away.\\\\nWhat are the possible side effects of ISENTRESS?\\\\nISENTRESS can cause serious side effects including:\\\\nSerious skin reactions and allergic reactions. \\\\nSome people who take\\\\nISENTRESS develop serious skin reactions and allergic reactions that...\",\"kidney stones\\\\nindigestion or stomach area pain\\\\nvomiting\\\\nsuicidal thoughts and actions\\\\nweakness\\\\nTell your doctor right away if you get unexplained muscle pain, tenderness, or weakness\\\\nwhile taking ISENTRESS. These may be signs of a rare serious muscle problem that can\\\\nlead to kidney problems.\\\\nTell your doctor if you have any side effect that bothers you or that does not go away.\\\\nThese are not all the possible side effects of ISENTRESS. For more information, ask your\\\\ndoctor or pharmacist.\\\\nCall you...\",\"Inactive ingredients:\\\\n calcium phosphate dibasic anhydrous, hypromellose 2208,\\\\nlactose monohydrate, magnesium stearate, microcrystalline cellulose, poloxamer 407\\\\n(contains 0.01% butylated hydroxytoluene as antioxidant), sodium stearyl fumarate.\\\\nThe film coating contains:\\\\n black iron oxide, polyethylene glycol 3350, polyvinyl\\\\nalcohol, red iron oxide, talc and titanium dioxide.\\\\nISENTRESS chewable tablets:\\\\nActive ingredient: \\\\nraltegravir\\\\nInactive ingredients:\\\\n ammonium hydroxide, crospovidone, ethy...\",\"more information about ISENTRESS.\\\\nYour doctor will decide the right dose based on your child&#x27;s weight.\\\\nAsk your doctor or pharmacist if you have any questions about how to mix or give\\\\nISENTRESS for oral suspension to your child.\\\\nEach ISENTRESS for oral suspension kit contains the following supplies (see\\\\nFigure A\\\\n):\\\\n2 reusable mixing cups with attached lids\\\\n2 reusable 5 mL dosing syringes\\\\n60 foil packets containing ISENTRESS for oral suspension\\\\nFor each dose of ISENTRESS for oral suspension you w...\",\"Step 2. \\\\nFill the dosing syringe. Start with the plunger pushed all the way inside the\\\\nbarrel of the syringe. Insert the tip of the syringe into the water and pull back on the\\\\nplunger to the 5 mL marking on the barrel of the syringe (see \\\\nFigure C\\\\n).\\\\nStep 3. \\\\nPour out remaining water from mixing cup (see \\\\nFigure D\\\\n).\",\"Step 4. \\\\nAdd the 5 mL of water from the dosing syringe back into the mixing cup by\\\\npressing down on the plunger (see \\\\nFigure E\\\\n).\\\\nStep 5. \\\\nOpen 1 foil packet. There is a notch that you can use to tear open the foil\\\\npacket, or you may use scissors to cut along the dotted line. Pour entire contents into\\\\nmixing cup (see \\\\nFigure F\\\\n).\",\"Step 6. \\\\nClose the attached lid to seal the mixing cup (see \\\\nFigure G\\\\n). It will snap shut.\\\\nStep 7. \\\\nSwirl the mixing cup to mix using a gentle circular motion for 30-60 seconds\\\\n(see \\\\nFigure H\\\\n). \\\\nDo not\\\\n turn the mixing cup upside down. The liquid will be cloudy.\\\\nStep 8. \\\\nOpen the mixing cup. Put the tip of the syringe into the liquid and \\\\npull back\\\\nthe plunger to the mL marking that matches your child&#x27;s prescribed dose\\\\n(see \\\\nFigure I\\\\n). Your child&#x27;s dose may be different from the one shown in ...\",\"How should I give a dose of ISENTRESS for oral suspension?\\\\nStep 9.\\\\n Place the tip of the dosing syringe in your child&#x27;s mouth and turn it toward\\\\neither cheek. Gently push down on the plunger to give the medicine (see \\\\nFigure J\\\\n). Give\\\\nthe dose of ISENTRESS oral suspension to your child within 30 minutes of mixing. If you\\\\nare not able to give your child&#x27;s dose within 30 minutes of mixing, pour the unused\\\\nmedicine into the trash. You will need to mix a new dose.\\\\nHow should I dispose of leftover IS...\",\"Step 11. \\\\nRemove plunger from the barrel of the dosing syringe. Hand wash the dosing\\\\nsyringe and mixing cup with warm water and dish soap. Rinse with water and air dry\\\\n(see \\\\nFigure L\\\\n).\\\\nHow should I store ISENTRESS for oral suspension?\\\\nStore ISENTRESS for oral suspension at room temperature between 68\\\\u00b0F to 77\\\\u00b0F\\\\n(20\\\\u00b0C to 25\\\\u00b0C).\\\\nStore in the original container. Do not open the foil packets until ready for use.\\\\nKeep ISENTRESS for oral suspension and all medicines out of the reach of\\\\nchildren.\\\\nFor m...\",\"Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nWhitehouse Station, NJ 08889, USA\\\\nIssued December 2013\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2013 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc. \\\\nAll rights reserved.\\\\nifu-mk0518-mf-1312r000\\\\nISENTRESS  \\\\nraltegravir tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION\\\\nDRUG\\\\nItem Code\\\\n(Source)\\\\nNDC:68071-2113(NDC:0006-\\\\n0227)\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredi...\",\"NuCare Pharmaceuticals,Inc.\\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLOXAMER 407\\\\n (UNII: TUF2IVW3M2)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYVINYL ALCOHOL\\\\n (UNII: 532B59J990)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)\\\\n \\\\nSODIUM STEARYL FUMARATE\\\\n (UNII: 7CV7WJK4UI)\\\\n \\\\nTALC\\\\n (UNII: 7SEV7J4R1U)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\npink (pink)\\\\nScore\\\\nno score\\\\nShape\\\\nOVAL (oval-shaped)\\\\nSize\\\\n16mm\\\\nFlavor\\\\nImprint Code\\\\n227\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem C...\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#98df8a\",\"#999\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ffbb78\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\"],\"shape\":[155],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1784\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1785\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1780\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1781\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1782\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1751\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1766\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1767\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1768\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1769\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1770\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1775\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1776\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1761\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1762\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1763\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1764\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1756\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1757\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1758\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1759\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1760\",\"attributes\":{\"axis\":{\"id\":\"p1756\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1765\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1761\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1786\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1787\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Drug Interactions\"},\"renderers\":[{\"id\":\"p1783\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1788\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Therapy Side Effects\"},\"renderers\":[{\"id\":\"p1783\"}],\"index\":10}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1789\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Drug Interactions\"},\"renderers\":[{\"id\":\"p1783\"}],\"index\":29}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1790\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"HIV-1 PrEP Safety\"},\"renderers\":[{\"id\":\"p1783\"}],\"index\":52}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1791\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Medication Injection Preparation\"},\"renderers\":[{\"id\":\"p1783\"}],\"index\":58}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1792\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p1783\"}],\"index\":7}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1793\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Raltegravir Side Effects\"},\"renderers\":[{\"id\":\"p1783\"}],\"index\":108}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1862\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1799\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1808\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1809\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1810\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1811\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1806\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1838\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1795\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1796\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1797\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"8hy7v8DvrcA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"lI3LwBPH+cA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"correctness\",[false,false]],[\"questions\",[\"What percentage of pediatric subjects experienced a Grade 3 or 4 rash when compared to adults in the study?\",\"What was the hazard ratio (with 95% confidence interval) for incident HIV-1 infections among participants who received APRETUDE compared to those who received TRUVADA, based on the extended retrospective virologic testing results?\"]],[\"agent_answer\",[\"A medical question!\\\\n\\\\nAccording to the study, the results showed that:\\\\n\\\\n* In pediatric patients (children), 22% experienced a Grade 3 or 4 rash.\\\\n* In adult patients, only 5% experienced a Grade 3 or 4 rash.\\\\n\\\\nSo, the percentage of pediatric subjects experiencing a Grade 3 or 4 rash is approximately 22%, which is significantly higher compared to adults, who had an incidence rate of around 5%.\",\"According to the data, the hazard ratio (HR) with a 95% confidence interval (CI) for incident HIV-1 infections among participants who received APRETUDE compared to those who received TRUVADA was:\\\\n\\\\nHR: 0.42 (95% CI: 0.24-0.74)\\\\n\\\\nThis means that the risk of incident HIV-1 infections was approximately 58% lower (0.42) in the APRETUDE group compared to the TRUVADA group, with a 95% confidence interval ranging from 24% to 74%.\"]],[\"reference_answer\",[\"In the study, 3% (6/182) of pediatric subjects experienced a Grade 3 or 4 rash, while only 0.9% of adults reported the same severity of rash.\",\"The hazard ratio for incident HIV-1 infections between participants receiving APRETUDE and TRUVADA was 0.10 (with a 95% CI of 0.04, 0.27), indicating a lower rate of infections in the APRETUDE group.\"]],[\"id\",[12,81]],[\"content\",[\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\"]],[\"color\",[\"#ba0e0e\",\"#ba0e0e\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1839\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1840\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1835\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1836\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1837\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1852\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1843\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1844\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1845\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"hl8Dwb/DCcFsGBDBaOMMwd0zB8GzKA3B1vP/wJAx+cBXVQjBA/YBwUai58AB2unAlI3LwMkE5MB2gt/A6FLswDAd6cA9uuHAopr5wLT24cAlLQXBWYnawPTbz8AS/AvBGpj2wD/pxsDtNPTAl5zZwO+gysAzMLvAucy4wAZOq8A1AKzAEzStwPmAycAjA8LAadO9wFn1vsCsybvAHc/TwLMC0cAxFuvAcjnewMjfEsEv/QrBltwKwSEzCsFFshDBdO4SwQNqBsEx6v/AYF3LwGC69sBSpgbBrBcDwc/W/8BZqu3AvP7kwPGD5MCx7ALBelQPwcC+EMGDjwfBTlsFwdRzA8G+IezA598GwZx4BMEuaOjAp2T8wPHS7cAQ7MvAnFfNwPk018B9EbvAdAW8wMrR0MAmeOzAAQ7xwFH2+MCytPzAE8f5wOVT/MB8KA7BBN8NwSnyC8ECcQnBrr8CwVfuD8FAWAPB8FDrwG7i2cCeX7bAxD+3wL6ztMAJWq7A3O/RwAV/ucCp7MPA6FLBwLY518CP+NHAgQPYwE/XycCi/NfA3a+/wLsV0cBqN6LAQ8k2wAg2H8CAmiLAgHNQwCuKM8AowRnAsVI/wAuniMCuh2PAaytLwEb4lMDDfCzAm0lEwFunesAoXlnA8gtKwIEBTsAiw2nAzMuWwJiHn8COHZDAEuWlwMM1qMD41pzArdddwOaom8AFeHzARtJZwPt9c8D9JnnAEUOBwK8KhsBxfQ7AEb0CwCJrEcC7utG/SB/4v9Z38r/kiz/AUPUOwE9SqMDJeJzAUXCewLI9BsDFHCHA6dpawHAKqMA=\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1853\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1854\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1849\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1850\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1851\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1807\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1822\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1823\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1824\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1825\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1830\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1831\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1798\",\"attributes\":{\"renderers\":[{\"id\":\"p1838\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1817\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1818\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1819\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1820\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1812\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1813\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1814\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1815\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1816\",\"attributes\":{\"axis\":{\"id\":\"p1812\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1821\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1817\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1841\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1842\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"False\"},\"renderers\":[{\"id\":\"p1838\"}],\"index\":0}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p1858\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1855\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1856\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1857\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"Xu3LwBlQ+8DXmYLA8rhBwBOkIsAvK9m/\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"VJP3wGZewMATu1LALg61wL8ZAsE6B9fA\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"3f4b6aa5-171c-4a72-a0ea-ebd4c57e0992\",\"roots\":{\"p1863\":\"e660a195-d8b3-4845-9fc7-196d076e9163\"},\"root_ids\":[\"p1863\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"e660a195-d8b3-4845-9fc7-196d076e9163\" data-root-id=\"p1863\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x1f56e4e0230>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_llama3, testset=testset, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d149fb8c",
   "metadata": {},
   "source": [
    "#### Gpt 3.5 RAG"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "id": "32e2dbfa",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_chain_gpt_3_5_rag(question, history=None):\n",
    "    return chain_gpt_3_5_rag.invoke({\"question\": question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "id": "a7afbe6a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "87332910612e4846aa2439f8534e7a4b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0cc7dc94ee024e1fac36b5f4bfcecba9",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABQAAAAUCAYAAACNiR0NAAAABHNCSVQICAgIfAhkiAAAAAlwSFlzAAALEgAACxIB0t1+/AAAABx0RVh0U29mdHdhcmUAQWRvYmUgRmlyZXdvcmtzIENTNui8sowAAAOkSURBVDiNjZRtaJVlGMd/1/08zzln5zjP1LWcU9N0NkN8m2CYjpgQYQXqSs0I84OLIC0hkEKoPtiH3gmKoiJDU7QpLgoLjLIQCpEsNJ1vqUOdO7ppbuec5+V+rj4ctwzd8IIbbi6u+8f1539dt3A78eXC7QizUF7gyV1fD1Yqg4JWz84yffhm0qkFqBogB9rM8tZdtwVsPUhWhGcFJngGeWrPzHm5oaMmkfEg1usvLFyc8jLRqDOMru7AyC8saQr7GG7f5fvDeH7Ej8CM66nIF+8yngt6HWaKh7k49Soy9nXurCi1o3qUbS3zWfrYeQDTB/Qj6kX6Ybhw4B+bOYoLKCC9H3Nu/leUTZ1JdRWkkn2ldcCamzrcf47KKXdAJllSlxAOkRgyHsGC/zRday5Qld9DyoM4/q/rUoy/CXh3jzOu3bHUVZeU+DEn8FInkPBFlu3+nW3Nw0mk6vCDiWg8CeJaxEwuHS3+z5RgY+YBR6V1Z1nxSOfoaPa4LASWxxdNp+VWTk7+4vzaou8v8PN+xo+KY2xsw6une2frhw05CTYOmQvsEhjhWjn0bmXPjpE1+kplmmkP3suftwTubK9Vq22qKmrBhpY4jvd5afdRA3wGjFAgcnTK2s4hY0/GPNIb0nErGMCRxWOOX64Z8RAC4oCXdklmEvcL8o0BfkNK4lUg9HTl+oPlQxdNo3Mg4Nv175e/1LDGzZen30MEjRUtmXSfiTVu1kK8W4txyV6BMKlbgk3lMwYCiusNy9fVfvvwMxv8Ynl6vxoByANLTWplvuj/nF9m2+PDtt1eiHPBr1oIfhCChQMBw6Aw0UulqTKZdfVvfG7VcfIqLG9bcldL/+pdWTLxLUy8Qq38heUIjh4XlzZxzQm19lLFlr8vdQ97rjZVOLf8nclzckbcD4wxXMidpX30sFd37Fv/GtwwhzhxGVAprjbg0gCAEeIgwCZyTV2Z1REEW8O4py0wsjeloKoMr6iCY6dP92H6Vw/oTyICIthibxjm/DfN9lVz8IqtqKYLUXfoKVMVQVVJOElGjrnnUt9T9wbgp8AyYKaGlqingHZU/uG2NTZSVqwHQTWkx9hxjkpWDaCg6Ckj5qebgBVbT3V3NNXMSiWSDdGV3hrtzla7J+duwPOToIg42ChPQOQjspnSlp1V+Gjdged7+8UN5CRAV7a5EdFNwCjEaBR27b3W890TE7g24NAP/mMDXRWrGoFPQI9ls/MWO2dWFAar/xcOIImbbpA3zgAAAABJRU5ErkJggg==);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"a6ebdfa0-42a1-4ec3-9738-1a9713df903d\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"a6ebdfa0-42a1-4ec3-9738-1a9713df903d\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"a6ebdfa0-42a1-4ec3-9738-1a9713df903d\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        76.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=76.0 class=\" progress-green \">76.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        72.73%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=72.72727272727273 class=\" progress-green \">72.73%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">76%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Focus on improving the Generator component, especially for complex questions, and enhance the knowledge base quality for Pharmaceutical Labeling to ensure more balanced performance across topics.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"9dff2862-1c78-44f8-a715-765213a8b85c\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1734\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1736\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1743\",\"attributes\":{\"factors\":[\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1744\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1745\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1741\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1763\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1731\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1732\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1733\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"L7rooosuUkAAAAAAAABZQA==\"},\"shape\":[2],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\"]],[\"colors\",[\"#a50026\",\"#006837\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1764\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1765\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1760\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1761\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1762\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1772\",\"attributes\":{\"data_source\":{\"id\":\"p1731\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1773\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1774\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1769\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1770\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1771\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1782\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1776\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1777\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1778\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1783\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1784\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1779\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1780\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1781\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1742\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1756\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1751\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1752\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1753\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1754\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1746\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1747\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1748\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1749\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1750\",\"attributes\":{\"axis\":{\"id\":\"p1746\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1755\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1751\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p1775\",\"attributes\":{\"location\":76.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1785\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1786\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p1782\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"9dff2862-1c78-44f8-a715-765213a8b85c\",\"roots\":{\"p1734\":\"fa26c188-4ab9-4833-a652-1e6cb0648694\"},\"root_ids\":[\"p1734\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"fa26c188-4ab9-4833-a652-1e6cb0648694\" data-root-id=\"p1734\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"635bd568-8072-4c65-9367-369073edf0d0\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p1665\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1595\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1549\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1558\",\"attributes\":{\"start\":-15.26738133430481,\"end\":-3.4757434844970705}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1559\",\"attributes\":{\"start\":-0.2422795295715332,\"end\":10.272449612617493}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1560\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1561\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1556\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1589\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1546\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1547\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1548\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[98],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[98],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99]],[\"content\",[\"ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\\\n \\\\nK2resource co., ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\\\ntartar formation, plaque removal, oral cleansing\\\\nKeep...\",\"K2resource co., ltd.\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:72191-0100\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nSODIUM BICARBONATE\\\\n (UNII: 8MDF5V39QO) \\\\n(SODIUM CATION -\\\\nUNII:LYR4M0NH37)\\\\nSODIUM\\\\nBICARBONATE\\\\n36.2 g  in 100 mg\\\\nXYLITOL\\\\n (UNII: VCQ006KQ1E) \\\\n(XYLITOL - UNII:VCQ006KQ1E)\\\\nXYLITOL\\\\n5 g  in 100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMENTHOL\\\\n (UNII: L7T10EIP3A)\\\\n \\\\nProduct Characteristics\\\\nCo...\",\"NUCYNTA - tapentadol hydrochloride tablet, film coated \\\\n \\\\nStat Rx USA\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use NUCYNTA\\\\u2122 safely and effectively. See full\\\\nprescribing information for NUCYNTA\\\\u2122.\\\\n \\\\nNUCYNTA\\\\u2122 (tapentadol) immediate-release oral tablets    C-II\\\\nInitial U.S. Approval: 2008\\\\nRECENT MAJOR CHANGES\\\\nWarnings and Precautions (\\\\n5.4\\\\n)\\\\nJune 2009\\\\nINDICATIONS AND USAGE\\\\nNUCYNTA\\\\u2122 is an opioid analgesic indicated for the relief o...\",\"USE IN SPECIFIC POPULATIONS\\\\nLabor and delivery: \\\\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\\\nmothers have been taking NUCYNTA\\\\u2122, for respiratory depression. (\\\\n8.2\\\\n)\\\\nNursing mothers: should not breast-feed. (\\\\n8.3\\\\n)\\\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\\\n8.4\\\\n)\\\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\\\npatients with moder...\",\"8.7 Hepatic Impairment\\\\n9 DRUG ABUSE AND DEPENDENCE\\\\n9.1 Controlled Substance\\\\n9.2 Abuse\\\\n9.3 Dependence\\\\n10 OVERDOSAGE\\\\n10.1 Human Experience\\\\n10.2 Management of Overdose\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n13 NON-CLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\n14 CLINICAL STUDIES\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\n14.2 End-Stage Degenerative Joint Disea...\",\"Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\\\nbeen studied and are not recommended.\\\\nNUCYNTA\\\\u2122 may be given with or without food \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n].\\\\n2.1 Renal Impairment\\\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\\\n[see \\\\nClinical\\\\nPharmacology (12.3)\\\\n]\\\\n.\\\\nNUCYNTA\\\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\\\nis not recommended.\\\\n2.2 Hepatic Im...\",\"which may result in adverse cardiovascular events \\\\n[see \\\\nDrug Interactions (7.4)\\\\n]\\\\n.\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Respiratory Depression\\\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\\\nsignificantly decrease pulmonary ventilation.\\\\nNUCYNTA\\\\u2122 should be ...\",\"5.5 Driving and Operating Machinery\\\\nPatients should be cautioned that NUCYNTA\\\\u2122 may impair the mental and/or physical abilities required\\\\nfor the performance of potentially hazardous tasks such as driving a car or operating machinery. This is\\\\nto be expected especially at the beginning of treatment, at any change of dosage as well as in\\\\ncombination with alcohol or tranquilizers\\\\n [see \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\n5.6 Interactions with Alcohol and Drugs of Abuse\\\\nDue to its mu-opioid agonist activity,...\",\"Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\\\nconsidered drug-related.\\\\nBased on data from nine Phase 2/3 studies that administered multiple...\",\"*\\\\nInfections and infestations\\\\n  Nasopharyngitis\\\\n1\\\\n&lt;1\\\\n  Upper respiratory tract infection\\\\n1\\\\n&lt;1\\\\n  Urinary tract infection\\\\n1\\\\n&lt;1\\\\nMetabolism and nutrition disorders\\\\n  Decreased appetite\\\\n2\\\\n0\\\\nMusculoskeletal and connective tissue\\\\ndisorders\\\\n  Arthralgia\\\\n1\\\\n&lt;1\\\\nNervous system disorders\\\\n  Dizziness\\\\n24\\\\n8\\\\n  Somnolence\\\\n15\\\\n3\\\\n  Tremor\\\\n1\\\\n&lt;1\\\\n  Lethargy\\\\n1\\\\n&lt;1\\\\nPsychiatric disorders\\\\n  Insomnia\\\\n2\\\\n&lt;1\\\\n  Confusional state\\\\n1\\\\n0\\\\n  Abnormal dreams\\\\n1\\\\n&lt;1\\\\n  Anxiety\\\\n1\\\\n&lt;1\\\\nSkin and subcutaneous tissue disorders\\\\n  Pruritus\\\\n5\\\\n1\\\\n  Hyp...\",\"Psychiatric disorders:\\\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\\\nabnormal\\\\nRenal and urinary disorders:\\\\n urinary hesitation, pollakiuria\\\\nRespiratory, thoracic and mediastinal disorders: \\\\noxygen saturation decreased, cough, dyspnea,\\\\nrespiratory depression\\\\nSkin and subcutaneous tissue disorders: \\\\nurticaria\\\\nVascular disorders:\\\\n blood pressure decreased\\\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\\\nNUCYNTA\\\\u2122,...\",\"Pregnancy Category C.\\\\nTapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous\\\\nand subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was\\\\nadministered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day\\\\n[producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of\\\\n700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic eff...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and\\\\nproper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid\\\\nagonist properties.\\\\nInfants born to mothers physically dependent on opioids will also be physically dependent and may\\\\nexhibit respiratory difficulties and withdrawal symptoms \\\\n[see \\\\nWarnings and Precautions (5.1)\\\\n]\\\\n. Use of\\\\nNUCYNTA\\\\u2122 in this population has not been characterized. As NUCYNTA\\\\u2122 h...\",\"intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\\\nshould be taken to secure the airway.\\\\n11 DESCRIPTION\\\\nNUCYNTA\\\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\\\nThe chemical name is 3-[(1\\\\nR\\\\n,2\\\\nR\\\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\\\nmonohydrochloride. The structural formula is:\\\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\\\nH\\\\nNO\\\\u00b7HCl. The\\\\nn-octanol:water pa...\",\"extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\\\naround 1.25 hours after dosing.\\\\nDose-proportional increases in the C\\\\n and AUC values of tapentadol have been observed over the 50\\\\nto 150 mg dose range.\\\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\\\nglucuronide, which are primarily determined by the do...\",\"Pharmacokinetic Drug Interactions\\\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\\\nconsidered clinically relevant and no change in dose is required.\\\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\\\nac...\",\"14 CLINICAL STUDIES\\\\nThe efficacy and safety of NUCYNTA\\\\u2122 in the treatment of moderate to severe acute pain has been\\\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\\\u2122...\",\"50% or greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus\\\\nplacebo.\\\\n14.2 End-Stage Degenerative Joint Disease\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\\\u2122 given every 4 to 6 hours during\\\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\\\nend stage degenerative joint disease of the hip or knee, defined...\",\"The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\\\nor greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus placebo.\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nNUCYNTA\\\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\\\nbiconvex-shaped.\\\\n50 mg tablets are yellow and debossed with \\\\\"O-M\\\\\" on one side and \\\\\"50\\\\\" on the other side, and are\\\\navailable in bottles of 100 (NDC 50458-820-04) a...\",\"Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\\\u2122 \\\\n[see \\\\nUse in\\\\nSpecific Populations (8.3)\\\\n]\\\\n.\\\\n17.6 Monoamine Oxidase Inhibitors\\\\nPatients should be informed not to take NUCYNTA\\\\u2122 while using any drugs that inhibit monoamine\\\\noxidase. Patients should not start any new medications while taking NUCYNTA\\\\u2122 until they are assured\\\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\\\n17.7 Seizures\\\\nPatients should be informed that NU...\",\"you get a new prescription. There may be new information. This Medication Guide does not take\\\\nthe place of talking to your doctor about your medical condition or your treatment. Talk to your\\\\ndoctor if you have any questions.\\\\nWhat is the most important information I should know about NUCYNTA\\\\u2122?\\\\nNUCYNTA\\\\u2122 is a tablet that contains tapentadol, a strong medicine that is a pain medicine.\\\\nUse NUCYNTA\\\\u2122 exactly how your doctor tells you to. Do not use NUCYNTA\\\\u2122 if it has not been\\\\nprescribed for you.\\\\nYou sh...\",\"Do not change the dose of NUCYNTA\\\\u2122 unless your doctor tells you to. \\\\nYour doctor may\\\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\\\u2122 more often\\\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\\\u2122.\\\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\\\u2122 to help lessen\\\\nwithdrawal symptoms.\\\\nNUCYNTA\\\\u2122 can be taken with or without food.\\\\nWhat should I avoid while taking NUCYNTA\\\\u2122?\\\\nDo not drive, operate machinery, ...\",\"Store NUCYNTA\\\\u2122 at 59\\\\u00baF to 86\\\\u00baF (15\\\\u00baC to 30\\\\u00baC). Keep NUCYNTA\\\\u2122 tablets dry.\\\\nDispose of NUCYNTA\\\\u2122 tablets you no longer need.\\\\nKeep NUCYNTA\\\\u2122 in a safe place out of the reach of children.\\\\nGeneral information about NUCYNTA\\\\u2122\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\\\nuse NUCYNTA\\\\u2122 for a condition for which it was not prescribed. \\\\nDo not give NUCYNTA\\\\u2122 to other\\\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\\\u2122 could be harmful\\\\n...\",\"NUCYNTA 100MG PACKAGE LABEL\\\\n       \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\nNUCYNTA  \\\\ntapentadol hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN\\\\nPRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:16590-\\\\n863(NDC:50458-820)\\\\nRoute of Administration\\\\nORAL\\\\nDEA Schedule\\\\nCII\",\"Active Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n50 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII: 15FIX9V2JP)\\\\n...\",\"Stat Rx USA\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII:...\",\"GRX DYNE - povidone iodine solution \\\\n \\\\nGeritrex Corp.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nGRx Dyne Solution\\\\nDrug Facts\\\\nActive Ingredient:                      Purpose\\\\nPovidone Iodine USP, 10% w/v  Antiseptic\\\\n(equivalent to 1% titratable Iodine)\\\\nUses\\\\nFirst aid antiseptic to help the risk of infection in \\\\nminor cuts, scra...\",\"Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\\\nkeep out of reach of children. If swallowed get medical help \\\\nor contact a Poison Control Center right away.\\\\nEnter section text here\\\\nGRX DYNE  \\\\npovidone iodine solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:54162-269\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85...\",\"Geritrex Corp.\\\\nCITRIC ACID MONOHYDRATE\\\\n (UNII: 2968PHW8QP)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nSODIUM HYDROXIDE\\\\n (UNII: 55X04QC32I)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:54162-269-16\\\\n472 mL in 1 BOTTLE, PLASTIC\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOTC monograph not final\\\\npart333A\\\\n05/16/2012\\\\nLabeler - \\\\n...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE- lisinopril and hydrochlorothiazide\\\\ntablets tablet \\\\n \\\\nCipla USA Inc.\\\\n----------\\\\nLisinopril and Hydrochlorothiazide Tablets, USP\\\\nRx Only\\\\nWARNING: FETAL TOXICITY\\\\nSee full prescribing information for complete boxed warning.\\\\nWhen pregnancy is detected, discontinue lisinopril and\\\\nhydrochlorothiazide tablets as soon as possible.\\\\nDrugs that act directly on the renin-angiotensin system can cause\\\\ninjury and death to the developing fetus. See \\\\nWarnings: Fetal Toxicity\\\\n.\\\\n...\",\"Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\\\nhydroxide solution.\\\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\\\nlisinopril and hydrochlorothiazide tabl...\",\"Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\\\nadministration of the separate entities.\\\\nLisinopril\\\\nMechanism of Action\\\\n \\\\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...\",\"state is prolonged. Older patients, on average, have (approximately doubled) higher\\\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\\\npatients (see \\\\nDOSAGE AND ADMINISTRATION\\\\n). In a multiple dose pharmacokinetic study\\\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\\\nhe...\",\"accompanied by some loss of potassium and bicarbonate.\\\\nAfter oral use diuresis begins within two hours, peaks in about four hours and lasts\\\\nabout 6 to 12 hours.\\\\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When\\\\nplasma levels have been followed for at least 24 hours, the plasma half-life has been\\\\nobserved to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is\\\\neliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but...\",\"the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\\\nsimilar risk (See \\\\nWARNINGS\\\\n).\\\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\\\nthan in nonblack patients (see \\\\nWARNIN...\",\"Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of\\\\nrapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin\\\\ninhibitor may be at increased risk for angioedema (see \\\\nPRECAUTIONS\\\\n).\\\\nIntestinal Angioedema:\\\\n Intestinal angioedema has been reported in patients treated\\\\nwith ACE inhibitors. These patients presented with abdominal pain (with or without\\\\nnausea or vomiting); in some cases there was no prior history of facial angioedema and\\\\nC-1...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\\\nLisinopril and Hydrochlorothiazide\\\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\\\nMaternal or fetotoxic effects were not seen in mice with the com...\",\"Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\\\nInteractions, Lisinopril and Hydrochlorothiazide).\\\\nPRECAUTIONS\\\\nGeneral\\\\nLisinopril\\\\n \\\\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\\\n As with all vasodilators, lisinopril\\\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\\\nventricle.\\\\nImpaired Renal Function:\\\\n As a consequence of inhibiting the renin-angiotensin-\\\\naldosterone system, changes in renal function may be anticipated in suscept...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"therapy.\\\\nInformation for Patients\\\\nAngioedema:\\\\n Angioedema, including laryngeal edema may occur at any time during\\\\ntreatment with angiotensin-converting enzyme inhibitors, including lisinopril and\\\\nhydrochlorothiazide. Patients should be so advised and told to report immediately any\\\\nsigns or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips,\\\\ntongue, difficulty in swallowing or breathing) and to take no more drug until they have\\\\nconsulted with the prescribing physician.\\\\nSymp...\",\"DOSAGE AND ADMINISTRATION\\\\n)\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\\\nInhibitors (COX-2 Inhibitors):\\\\n \\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\\\nfunction, including possible acute renal failure. These effects are usually reversible.\\\\nMonitor ...\",\"mTOR (mammalian target of rapamycin) inhibitors\\\\n \\\\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\\\n(see \\\\nWARNINGS\\\\n)\\\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\\\nrisk for angioedema. (see \\\\nWARNINGS\\\\n)\\\\nHydrochlorothiazide\\\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\\\nAlcohol, barbiturates, or nar...\",\"in vitro\\\\n alkaline elution rat hepatocyte assay. In addition, it did not produce increases in\\\\nchromosomal aberrations in an \\\\nin vitro\\\\n test in Chinese hamster ovary cells or in an \\\\nin\\\\nvivo\\\\n study in mouse bone marrow.\\\\nLisinopril\\\\n \\\\nThere was no evidence of a tumorigenic effect when lisinopril was administered for 105\\\\nweeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the\\\\nmaximum daily human dose, based on body weight and body surface area,\\\\nrespectively). There was no ...\",\"Nursing Mothers\\\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\\\nrats contains radioactivity following administration of \\\\nC lisinopril. In another study,\\\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\\\nwhether to discontinue nursing and/or disco...\",\"adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\\\nfatigue and muscle cramps.\\\\nAdverse experiences occurring in greater than one percent of patients treated with\\\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\\\n                                                                         Percent of Patients in\\\\nControlled Studies\\\\n   Lisinopril and\\\\nHydrochlorothiazide\\\\n   (n=930)\\\\n   Incidence\\\\n(discontinuation)\\\\n   Placebo\\\\n   (n=207)\\\\n...\",\"In rare cases, intestinal angioedema has been reported in post marketing experience.\\\\nHypotension:\\\\n In clinical trials, adverse effects relating to hypotension occurred as\\\\nfollows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects\\\\n(3.2%). In addition syncope occurred in 0.8% of patients (See \\\\nWARNINGS\\\\n).\\\\nCough:\\\\n See \\\\nPRECAUTIONS - Cough\\\\n.\\\\nClinical Laboratory Test Findings Serum Electrolytes:\\\\n (See \\\\nPRECAUTIONS\\\\n).\\\\nCreatinine, Blood Urea Nitrogen:\\\\n Minor reversible incre...\",\"hallucinations; \\\\nRespiratory:\\\\n Malignant lung neoplasms, hemoptysis, pulmonary edema,\\\\npulmonary infiltrates, bronchospasm, asthma, pleural effusion, pneumonia, eosinophilic\\\\npneumonitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis,\\\\npharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; \\\\nSkin:\\\\n Urticaria, alopecia,\\\\nherpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema,\\\\npsoriasis, rare cases of other severe skin reactions, includin...\",\"Lisinopril\\\\n \\\\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\\\nnormal saline solution.\\\\nLisinopril can be removed by hemodialysis (see \\\\nWARNINGS, Anaphylactoid Reaction\\\\nDuring Membrane Exposure\\\\n).\\\\nHydrochlorothiazide\\\\n \\\\nOral administration of a single oral dose of 10 g/kg to mice and rats w...\",\"possible, be discontinued for two to three days before beginning therapy with lisinopril\\\\nto reduce the likelihood of hypotension (See \\\\nWARNINGS\\\\n). If the patient\\\\u2019s blood pressure\\\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\\\nfor at least an additional hour (See \\\\nWARNINGS\\\\n and \\\\nPRECAUTIONS\\\\n...\",\"Protect from excessive light and humidity.\\\\n*AN69 is a registered trademark of Hospal Ltd.\\\\nManufactured by:\\\\nInvaGen Pharmaceuticals, Inc.\\\\n(a subsidiary of Cipla Ltd.)\\\\nHauppauge, NY 11788\\\\nManufactured for:\\\\nCipla USA, Inc.\\\\n10 Independence Boulevard, Suite 300\\\\nWarren, NJ 07059\\\\nRevised: 10/2021\\\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\\\u2013 10 mg/12.5 mg\\\\nNDC 69097-968-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n10 mg/12.5 mg\\\\n100 Tablets\\\\nCipla\\\\nNDC 69097-969-07             ...\",\"Cipla\\\\nNDC 69097-971-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n20 mg/25 mg\\\\n100 Tablets\\\\nCipla\\\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"lisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-969\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS D...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-971\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n25 mg\\\\nInactive Ingredients\\\\nI...\",\"Cipla USA Inc.\\\\nLabeler - \\\\nCipla USA Inc. \\\\n(078719707)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen\\\\nPharmaceuticals, Inc\\\\n165104469\\\\nanalysis(69097-968, 69097-969, 69097-971) , manufacture(69097-968,\\\\n69097-969, 69097-971)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen Pharmaceuticals, Inc\\\\n080334903\\\\npack(69097-968, 69097-969, 69097-971)\\\\n \\\\nRevised: 11/2021\",\"ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and\\\\nphenylephrine hydrochloride tablet, coated \\\\n \\\\nMARC GLASSMAN, INC.\\\\n----------\\\\n1128B-MAR-2022-1005\\\\nDrug Facts\\\\nActive ingredients \\\\n(in each caplet)\\\\nPurpose\\\\nAcetaminophen 325 mg\\\\nPain reliever\\\\nChlorpheniramine maleate\\\\n2 mg\\\\nAntihistamine\\\\nPhenylephrine HCl 5 mg\\\\nNasal decongestant\\\\nUses\\\\ntemporarily relieves these symptoms of hay fever or other upper respiratory\\\\nallergies:\\\\nheadache\\\\nsinus congestion and pressure\\\\nnasal congestion\\\\nrunny nose...\",\"If a skin reaction occurs, stop use and seek medical help right away.\\\\nDo not use\\\\nwith any other drug containing acetaminophen (prescription or nonprescription). If\\\\nyou are not sure whether a drug contains acetaminophen, ask a doctor or\\\\npharmacist.\\\\nif you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain\\\\ndrugs for depression, psychiatric or emotional conditions, or Parkinson&#x27;s disease), or\\\\nfor 2 weeks after stopping the MAOI drug. If you do not know if your prescription\\\\ndr...\",\"800-222-1222). Quick medical attention is critical for adults as well as for children even if\\\\nyou do not notice any signs or symptoms.\\\\nDirections\\\\ndo not take more than directed (see \\\\noverdose warning\\\\n)\\\\nadults and\\\\nchildren 12\\\\nyears and over\\\\ntake 2 caplets every 4 hours\\\\nswallow whole; do not crush,\\\\nchew, or dissolve\\\\ndo not take more than 10 caplets\\\\nin 24 hours\\\\nchildren under \\\\n12 years\\\\nask a doctor\\\\nOther information\\\\nstore between 20\\\\u00b0-25\\\\u00b0C (68\\\\u00b0-77\\\\u00b0F) in a dry place\\\\nretain carton for complete product...\",\"ALLERGY MULTI SYMPTOM  \\\\nacetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:68998-228\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCHLORPHENIRAMINE MALEATE\\\\n (UNII: V1Q0O9OJ9Z) \\\\n(CHLORPHENIRAMINE -\\\\nUNII:3U6IO1965U)\\\\nCHLORPHENIRAMINE\\\\nMALEATE\\\\n2 mg\\\\nPHENYLEPHRINE HYDROCHLORIDE\\\\n (UNII: 04JA59TNSJ) \\\\n(PHENYLEPHRINE -\\\\nUNII:1WS297W6MV)\\\\nPHENYLE...\",\"MARC GLASSMAN, INC.\\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nFERRIC OXIDE YELLOW\\\\n (UNII: EX438O2MRT)\\\\n \\\\nMAGNESIUM STEARATE\\\\n (UNII: 70097M6I30)\\\\n \\\\nCROSPOVIDONE\\\\n (UNII: 2S7830E561)\\\\n \\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\\\n (UNII: 3WJQ0SDW1A)\\\\n \\\\nPOLYVINYL ALCOHOL, UNSPECIFIED\\\\n (UNII: 532B59J990)\\\\n \\\\nPOVIDONE, UNSPECIFIED\\\\n (UNII: FZ989GH94E)\\\\n \\\\nSTARCH, CORN\\\\n (UNII: O8232NY3SJ)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nSTEA...\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and\\\\nhydrochlorothiazide tablet \\\\n \\\\nANI Pharmaceuticals, Inc.\\\\n----------\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\nWARNING: \\\\nFETAL TOXICITY\\\\n\\\\u2022\\\\n\\\\u2022\\\\nDESCRIPTION\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP combine an angiotensin II receptor (type\\\\nAT\\\\n) antagonist and a diuretic, hydrochlorothiazide.\\\\nCandesartan cilexetil, a nonpeptide, is chemically described as (\\\\u00b1)-1-Hydroxyethyl 2-ethoxy-1-[\\\\np\\\\n-(\\\\no\\\\n-\\\\n1\\\\nH\\\\n...\",\"Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of\\\\n297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet\\\\nstrengths of candesartan cilexetil and hydrochlorothiazide.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil\\\\nand 12.5 mg or 25 mg of hydrochloroth...\",\"The mechanism of the antihypertensive effect of thiazides is unknown.\\\\nPharmacokinetics\\\\nGeneral\\\\nCandesartan Cilexetil\\\\nCandesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from\\\\nthe gastrointestinal tract to candesartan, a selective AT\\\\nsubtype angiotensin II receptor antagonist.\\\\nCandesartan is mainly excreted unchanged in urine and feces (via bile). \\\\nIt undergoes minor hepatic\\\\nmetabolism by O-deethylation to an inactive metabolite. \\\\nThe elimination half...\",\"Geriatric\\\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\\\u2265 65 years). \\\\nThe plasma\\\\nconcentration of candesartan was higher in the elderly (C\\\\n was approximately 50% higher, and AUC\\\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\\\nThe\\\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\\\nNo initia...\",\"plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\\\nadministered to hypertensive patients. \\\\nIn spite of the effect of candesartan cilexetil on aldosterone\\\\nsecretion, very little effect on serum potassium was observed.\\\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\\\nIn a\\\\n12-week study of 161 patients with n...\",\"in myocardial infarction and cardiovascular mortality also have been seen regularly.\\\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\\\nhypertension can provide substantial benefit. \\\\nRelative risk reduction from blood pressure reduction is\\\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\\\nare at h...\",\"candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\\\n). \\\\nIn each of\\\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\\\ntimes the MRHD\\\\n in mouse, rats, and rabbit, respectively). \\\\nThere was no evidence of harm to the rat or\\\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\\\nThiazides cross ...\",\"considered if the intraocular pressure remains uncontrolled. \\\\nRisk factors for developing acute angle-\\\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\\\nHypersensitivity Reaction\\\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\\\nPRECAUTIONS\\\\nMetabolic Disturbances\\\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...\",\"Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\\\npossible ac...\",\"Cytotoxic products \\\\u2013 Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.\\\\ncyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.\\\\nCyclosporine \\\\u2212 Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and\\\\ngout-type complications.\\\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\\\nNo carcinogenicity studies have been conducted with the combination of candesartan cilexetil and\\\\nhydrochlorothiazide. \\\\nThere was no evidence of c...\",\"Neonates with a history of in utero exposure to candesartan cilexetil and hydrochlorothiazide tablets:\\\\nIf oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.\\\\nExchange transfusions or dialysis may be required as a means of reversing hypotension and/or\\\\nsubstituting for disordered renal function.\\\\nSafety and effectiveness in pediatric patients have not been established.\\\\nADVERSE REACTIONS\\\\nCandesartan Cilexetil and Hydrochlorothiazide\\\\nCandesartan cile...\",\"melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\\\nfor white patients taking a cumulative dose of \\\\u226550,000 mg the risk increase was approximately 1\\\\nadditional SCC case for every 6,700 patients per year.\\\\nSkin:\\\\n \\\\nerythema multiforme including S...\",\"Dose Titration by Clinical Effect: \\\\nA patient whose blood pressure is not controlled on 25 mg of\\\\nhydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and\\\\nhydrochlorothiazide tablets 16 mg/12.5 mg. \\\\nA patient whose blood pressure is controlled on 25 mg of\\\\nhydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or\\\\nincremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16\\\\nmg/12.5 mg and ser...\",\"PRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/12.5 mg\\\\nNDC 62559-661-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/12.5 mg\\\\nRx only\\\\n90 Tablets\\\\nPRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/25 mg\\\\nNDC 62559-662-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/25 mg\\\\nRx only\\\\n90 Tablets\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:62559-660\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCANDESARTAN CILEXETIL\\\\n (UNII: R85M2X0D68) \\\\n(CANDESARTAN - UNII:S8Q36MD2XX)\\\\nCANDESARTAN\\\\nCILEXETIL\\\\n16 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n1...\",\"Flavor\\\\nImprint Code\\\\nACS\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-660-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type...\",\"Packaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-661-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (So...\",\"ANI Pharmaceuticals, Inc.\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-662-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nLabeler - \\\\nANI Pharmaceuticals, Inc. \\\\n(145588013)\\\\n \\\\nRevised: 5/2020\",\"CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\\\n \\\\nCertus Medical, Inc.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\\\nDrug Facts Box OTC Active Ingredient Section\\\\nPovidone Iodine USP 10%\\\\nequivalent to 1% titratable iodine\\\\nDrug Facts Box OTC Purpose Section\\\\nAntiseptic\\\\nDrug...\",\"Drug Facts Box OTC General Precautions Section\\\\nstore at room temperature 15\\\\n - 30\\\\n C (59\\\\n - 86\\\\n F)\\\\nDrug Facts Box OTC Inactive Ingredient Section\\\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\\\nCertus PVP-1 Prep Swabstick \\\\n210012 pouch\\\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\\\n0\\\\n0\\\\n0\\\\n0\",\"CERTUS PVP-1 PREP SWABSTICK  \\\\npovidone-iodine swab\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:75990-4019\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85H0HZU99M) \\\\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\\\nPOVIDONE-IODINE\\\\n0.1 mL  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\",\"Certus Medical, Inc.\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nSODIUM PHOSPHATE, DIBASIC\\\\n (UNII: GR686LBA74)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nDIMETHICONE\\\\n (UNII: 92RU3N3Y1O)\\\\n \\\\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\\\n (UNII: S38J6RZN16)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:75990-4019-4\\\\n2 mL in 1 POUCH\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOT...\",\"ABALONE CRYSTALDOUBLE EX CC- niacinamide, adenosine, titanium dioxide, ethylhexyl\\\\nmethoxycinnamate cream \\\\n \\\\nC&amp;BCOSMETIC Co.,Ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nDrug Facts\\\\nNiacinamide, Adenosine, Titanium Dioxide, Ethylhexyl Methoxycinnamate\\\\nWater, Glycerin, Butylene Glycol, Etc\\\\nSkin Protectant - Anti-Wrinkle, Whitening, UV Protecting\\\\nk...\",\"ABALONE CRYSTALDOUBLE EX CC  \\\\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:60611-0008\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\",\"C&amp;BCOSMETIC Co.,Ltd.\\\\nNIACINAMIDE\\\\n (UNII: 25X51I8RD4) \\\\n(NIACINAMIDE - UNII:25X51I8RD4)\\\\nNIACINAMIDE\\\\n2 g  in 100 mL\\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP) \\\\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\\\nTITANIUM DIOXIDE\\\\n4.694 g  in 100 mL\\\\nADENOSINE\\\\n (UNII: K72T3FS567) \\\\n(ADENOSINE - UNII:K72T3FS567)\\\\nADENOSINE\\\\n0.04 g  in 100 mL\\\\nOCTINOXATE\\\\n (UNII: 4Y5P7MUD51) \\\\n(OCTINOXATE - UNII:4Y5P7MUD51)\\\\nOCTINOXATE\\\\n7 g  in 100 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C...\",\"TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\\\n \\\\nAdvagen Pharma Limited\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use TIZANIDINE\\\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\\\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\\\n \\\\nInitial U.S. Approval: 1996\\\\nINDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...\",\"Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\\\nfour-fold ( \\\\n8.5\\\\n)\\\\nSee 17 for PATIENT COUNSELING INFORMATION.\\\\nRevised: 9/2020\\\\nFULL PRESCRIBING INFORMATION: CONTENTS\\\\n*\\\\n1 INDICATIONS AND USAGE\\\\n2 DOSAGE AND ADMINISTRATION\\\\n2.1 Dosing Information\\\\n2.2 Dosing in Patients with Renal Impairment\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\n2.4 Drug Discontinuation\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Hypo...\",\"12.1 Mechanism of Action\\\\n12.3 Pharmacokinetics\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n16.1 Tizanidine Hydrochloride Capsules\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\n1 INDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the\\\\nmanagement of spasticity. Because of the short duration of therapeutic effect,\\\\ntreatment with tizanid...\",\"been studied.\\\\n2.2 Dosing in Patients with Renal Impairment\\\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\\\ndoses are required, individual doses rather than dosing frequency should be increased\\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n)] \\\\n.\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\nT...\",\"Tizanidine is an \\\\u03b1 \\\\n-adrenergic agonist that can produce hypotension. Syncope has been\\\\nreported in the post marketing setting. The chance of significant hypotension may\\\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\\\na supine to fixed upright position may be at increased risk for hypotension and\\\\northostatic effects.\\\\nMonitor for hypotension when tizanidine is used in patients...\",\"Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n5.6 Hypersensitivity Reactions\\\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\\\nand symptoms occur. \\\\n[see Contraindications ( \\\\n4\\\\n)]\\\\n5.7 Increased Risk of Adverse Reactions in Patients...\",\"264 patients received tizanidine and 261 patients received placebo. Across the three\\\\nstudies patient ages ranged from 15\\\\u201369 years and 51.4 percent were women. The\\\\nmedian dose during the plateau phase ranged from 20\\\\u201328 mg/day.\\\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\\\nclinical studies involving 264 patients with spasticity were dry mouth,\\\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\\\nThree-quarters of the patients rated t...\",\"multiple sclerosis (Study 1) \\\\n[see Clinical Studies ( \\\\n14\\\\n)] \\\\n, the patients were specifically\\\\nasked if they had experienced any of the four most common adverse reactions: dry\\\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\\\nthese reactions is summarized in \\\\nTable 2\\\\n. Other events were, in general, reported at a\\\\nrate of 2% or less.\\\\nTable 2: Single Dose, Placebo-Controlled Study -...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"12.3\\\\n)]\\\\n7.7 \\\\u03b1 \\\\n-adrenergic agonists\\\\nBecause hypotensive effects may be cumulative, it is not recommended that tizanidine\\\\nbe used with other \\\\u03b1 \\\\n-adrenergic agonists. \\\\n[see Warnings and Precautions ( \\\\n5.1\\\\n)]\\\\n8 USE IN SPECIFIC POPULATIONS\\\\n8.1 Pregnancy\\\\nPregnancy Category C\\\\nTizanidine has not been studied in pregnant women. Tizanidine should be given to\\\\npregnant women only if the benefit outweighs the risk to the unborn fetus.\\\\nReproduction studies performed in rats at a dose of 3 mg/kg, equal to the...\",\"8.6 Impaired Renal Function\\\\nTizanidine is known to be substantially excreted by the kidney, and the risk of adverse\\\\nreactions to this drug may be greater in patients with impaired renal function. In patients\\\\nwith renal insufficiency (creatinine clearance &lt; 25 mL/min) clearance was reduced by\\\\nmore than 50%. In these patients, during titration, the individual doses should be\\\\nreduced. If higher doses are required, individual doses rather than dosing frequency\\\\nshould be increased. These patients sho...\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\"],\"shape\":[98],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1590\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1591\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1586\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1587\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1588\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1557\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1572\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1573\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1574\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1575\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1576\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1581\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1582\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1567\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1568\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1569\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1570\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1562\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1563\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1564\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1565\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1566\",\"attributes\":{\"axis\":{\"id\":\"p1562\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1571\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1567\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1592\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1593\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Pharmaceutical Labeling\"},\"renderers\":[{\"id\":\"p1589\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1594\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Tizanidine Hydrochloride\"},\"renderers\":[{\"id\":\"p1589\"}],\"index\":87}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1664\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1600\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1609\",\"attributes\":{\"start\":-15.26738133430481,\"end\":-3.4757434844970705}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1610\",\"attributes\":{\"start\":-0.2422795295715332,\"end\":10.272449612617493}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1611\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1612\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1607\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1639\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1596\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1597\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1598\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"m236wF60UcEyux3Bvp0gwQASY8HYi0TBMxAawX+NaMFObyjB+bwnwVC4KsGkbz/BFAIIwcILGMFVV1jBhT0XwRKj/sBSQBnB4itewYPOG8F4JUnBwbEgwbiEZMHpZSfBDnkywQ==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"pg+1QF40MED9U6VAYUawQDBMOkDQ/hBAfY6JQI4wtUBo5YBAeOLqQIvrzkAmNB1AW7fIQMMq40CTsmRA3WHtQAIPuUC8vkxAJmuhQDap/UBg/DJA8gf0QEfZn0C7FJlAO3llQA==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\"]],[\"correctness\",[false,true,false,true,true,true,false,true,false,true,true,true,true,true,true,true,true,false,true,false,true,true,true,true,true]],[\"questions\",[\"Considering the information provided, under what specific conditions or patient characteristics should the use of candesartan cilexetil and hydrochlorothiazide tablets be avoided, especially in relation to hypersensitivity and co-administration with other drugs?\",\"Considering the clinical studies conducted on NUCYNTA\\\\u2122, what are the most frequently reported adverse events in patients, particularly those that were observed in at least 10% of any dosage group, and how do these compare to the placebo group in terms of percentage?\",\"Could you identify the inactive components found in the lisinopril and hydrochlorothiazide tablet with the specific NDC code 69097-971, ensuring that your response only includes those ingredients that are not active and are unique to this particular formulation?\",\"Considering the tablet with the NDC code 69097-971, what are the precise strengths of both lisinopril and hydrochlorothiazide, and how do these strengths compare to those in similar tablets with different NDC codes, if any?\",\"Considering the lack of studies on NUCYNTA\\\\u2122 for individuals with severe hepatic impairment, what is the advised course of action for prescribing this medication to such patients, especially when considering potential risks and the absence of established safety and effectiveness?\",\"Considering the detailed composition of NUCYNTA\\\\u2122, can you identify the primary pharmacological component responsible for its therapeutic effects, and ensure that your answer excludes any mention of the inactive ingredients?\",\"Considering the strength of 32 mg of Candesartan Cilexetil and 12.5 mg of Hydrochlorothiazide, what are the color and shape of the tablet, and how does this compare to the tablet with a different strength of 25 mg of Hydrochlorothiazide?\",\"In the context of a study on multiple sclerosis patients taking tizanidine, what are the four most frequently reported adverse reactions, considering only those reactions that were specifically inquired about by the researchers?\",\"Under the condition that the item code is NDC:62559-662-90, can you specify the precise date when the marketing activities commenced for this particular product?\",\"Under what specific circumstances might the concurrent administration of ACE inhibitors and mTOR inhibitors, such as temsirolimus, sirolimus, or everolimus, lead to an increased risk of developing angioedema, and what precautions should be considered to mitigate this risk?\",\"Considering the available options, what are the specific tablet combinations of lisinopril and hydrochlorothiazide, including their dosages, that can be used for oral administration?\",\"Considering the information provided in Document 24 about NUCYNTA 100MG, could you specify the method by which this medication is administered to patients?\",\"What crucial information should be communicated to female patients of childbearing age who are on candesartan cilexetil and hydrochlorothiazide tablets, particularly regarding potential risks during pregnancy and any necessary actions they should take if they plan to become pregnant or discover they are pregnant?\",\"Considering potential side effects, particularly those related to vision, what are the specific ocular complications associated with Hydrochlorothiazide, and under what conditions or time frame do these symptoms typically manifest?\",\"What specific considerations and initial dosing precautions are recommended when administering NUCYNTA\\\\u2122 to elderly patients, especially in light of the potential for renal or hepatic impairments?\",\"When monitoring patients on thiazide therapy, which specific electrolyte imbalances, such as hyponatremia, hypochloremic alkalosis, and hypokalemia, should be carefully observed, particularly in cases of excessive vomiting or when parenteral fluids are administered?\",\"Considering the use of candesartan cilexetil and hydrochlorothiazide tablets in patients diagnosed with heart failure, what are the potential risks, specifically focusing on renal function and electrolyte imbalances, and how should these be managed during the initial treatment period?\",\"Could you detail the primary components of ADEA GARGLE chewable tablets, ensuring to include only those ingredients that are explicitly mentioned in the context provided, and also consider any potential allergens?\",\"Considering the pharmacokinetics of Tizanidine, particularly its clearance rate, why is it advised to exercise caution when prescribing this medication to elderly patients, and what specific risks does this present?\",\"Considering the adverse effects of lisinopril combined with hydrochlorothiazide, which specific side effects are most frequently responsible for patients deciding to stop the medication, and what percentage of patients experience these effects leading to discontinuation?\",\"What specific precautions should patients take when using NUCYNTA\\\\u2122 in relation to monoamine oxidase inhibitors, and what steps should they follow before starting any new medications while on NUCYNTA\\\\u2122?\",\"In the context of a patient who is currently on ACE inhibitors and begins to exhibit symptoms such as jaundice or significantly elevated hepatic enzymes, what specific steps should be taken immediately, and what follow-up actions are recommended to ensure the patient&#x27;s safety?\",\"Under what circumstances might the simultaneous use of tizanidine and fluvoxamine lead to adverse effects, and what specific reactions should be anticipated?\",\"Could you specify the active ingredients and their respective strengths for the lisinopril and hydrochlorothiazide tablet identified by NDC code 69097-968, ensuring that you do not confuse it with other similar products listed in the provided context?\",\"Could you specify the method by which ABALONE CRYSTALDOUBLE EX CC should be applied or administered, considering it contains niacinamide and titanium dioxide among other ingredients?\"]],[\"agent_answer\",[\"The use of candesartan cilexetil and hydrochlorothiazide tablets should be avoided in patients who are hypersensitive to candesartan, to hydrochlorothiazide, or to other sulfonamide-derived drugs. Additionally, co-administration of aliskiren with candesartan cilexetil and hydrochlorothiazide tablets should be avoided in patients with diabetes.\",\"The most frequently reported adverse events in patients, particularly those observed in at least 10% of any NUCYNTA\\\\u2122 dosage group, were nausea, dizziness, vomiting, and somnolence. These adverse events were reported by 30%, 21%, 18%, and 14% of NUCYNTA\\\\u2122-treated patients, respectively. In comparison, the placebo group reported nausea in 13% of patients, vomiting in 4%, constipation in 3%, dry mouth in less than 1%, and dyspepsia in less than 1%.\",\"The inactive components found in the lisinopril and hydrochlorothiazide tablet with the specific NDC code 69097-971 are:\\\\n- ANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n- MANNITOL\\\\n- STARCH, CORN\\\\n- MAGNESIUM STEARATE\",\"For the tablet with NDC code 69097-971, the precise strengths are 20 mg for lisinopril and 25 mg for hydrochlorothiazide. \\\\n\\\\nThese strengths differ from the strengths in tablets with NDC code 69097-969, where the strengths are 20 mg for lisinopril and 12.5 mg for hydrochlorothiazide. The tablets with NDC code 69097-971 have higher strength hydrochlorothiazide compared to the tablets with NDC code 69097-969.\",\"The advised course of action for prescribing NUCYNTA\\\\u2122 to individuals with severe hepatic impairment is not to recommend its use in this population due to the lack of studies on its safety and effectiveness. This caution is in place to mitigate potential risks associated with administering the medication to patients with severe hepatic impairment.\",\"The primary pharmacological component responsible for the therapeutic effects of NUCYNTA\\\\u2122 is tapentadol.\",\"For Candesartan Cilexetil 32 mg and Hydrochlorothiazide 12.5 mg tablets, the tablet is yellow, oval, and biconvex. This is different from the tablet with a strength of 32 mg Candesartan Cilexetil and 25 mg Hydrochlorothiazide, which is pink, oval, and biconvex.\",\"The four most frequently reported adverse reactions in the study on multiple sclerosis patients taking tizanidine are dry mouth, somnolence (drowsiness), asthenia (weakness, fatigue, and/or tiredness), and dizziness.\",\"Based on the given context, the information provided does not include any details related to the item code NDC:62559-662-90 or the specific date when marketing activities commenced for that particular product. Therefore, I do not have the information to specify the precise date when the marketing activities commenced for the product with that item code.\",\"The concurrent administration of ACE inhibitors and mTOR inhibitors, such as temsirolimus, sirolimus, or everolimus, might lead to an increased risk of developing angioedema. Patients should be advised about the possibility of angioedema and monitored accordingly. Close monitoring for symptoms of angioedema, such as swelling in the face, extremities, lips, tongue, glottis, and larynx, is essential. If symptoms of angioedema occur, treatment with these medications should be discontinued, and appropriate medical intervention should be provided promptly to address potential airway obstruction.\",\"The specific tablet combinations of lisinopril and hydrochlorothiazide for oral administration are:\\\\n- 10 mg/12.5 mg tablets\\\\n- 20 mg/12.5 mg tablets\\\\n- 20 mg/25 mg tablets\",\"The medication NUCYNTA 100mg is administered orally via immediate-release oral tablets.\",\"Female patients of childbearing age who are on candesartan cilexetil and hydrochlorothiazide tablets should be informed about the consequences of exposure to the medication during pregnancy. They should discuss treatment options with their healthcare provider if they are planning to become pregnant. Additionally, patients should be advised to report pregnancies to their physicians as soon as possible.\",\"The specific ocular complications associated with Hydrochlorothiazide are acute transient myopia and acute angle-closure glaucoma. These symptoms typically manifest within hours to weeks of drug initiation. Symptoms may include acute onset of decreased visual acuity or ocular pain. Untreated acute angle-closure glaucoma can lead to permanent vision loss.\",\"Specific considerations and initial dosing precautions recommended when administering NUCYNTA\\\\u2122 to elderly patients include starting them with the lower range of recommended doses due to the likelihood of decreased renal and hepatic function. Additionally, it is advised to consider their renal and hepatic function before starting treatment.\",\"Hyponatremia, hypochloremic alkalosis, and hypokalemia should be carefully observed in patients on thiazide therapy, particularly in cases of excessive vomiting or when receiving parenteral fluids.\",\"Patients diagnosed with heart failure who are prescribed candesartan cilexetil and hydrochlorothiazide tablets may be at risk for excessive hypotension, which can lead to oliguria, azotemia, acute renal failure, and even death. During the initial treatment period, it is important to monitor their renal function closely. Changes in renal function, including acute renal failure, can be caused by drugs that inhibit the renin-angiotensin system and diuretics like hydrochlorothiazide. Additionally, electrolyte imbalances such as hyperkalemia from drugs that inhibit the renin-angiotensin system and hypokalemia and hyponatremia from hydrochlorothiazide should be monitored. Potassium abnormalities should be closely watched, and serum electrolytes should be regularly checked. If there is a clinically significant decrease in renal function, therapy with candesartan cilexetil and hydrochlorothiazide tablets may need to be withheld or discontinued.\",\"The primary components of ADEA GARGLE chewable tablets are citric acid, sodium hydrogen carbonate, xylitol, glucose, menthol, magnesium stearate, aspartame, and sucralose. Allergic individuals should use the product after checking the ingredients list for specific or unusual constitution.\",\"It is advised to exercise caution when prescribing Tizanidine to elderly patients because younger subjects clear the drug four times faster than elderly subjects. Additionally, in elderly patients with renal insufficiency (creatinine clearance &lt; 25 mL/min), tizanidine clearance is reduced by more than 50% compared to healthy elderly subjects. This reduced clearance can lead to a longer duration of clinical effect and an increased risk for adverse reactions associated with Tizanidine in elderly patients.\",\"The specific side effects of dizziness, cough, fatigue, and muscle cramps are most frequently responsible for patients deciding to stop lisinopril combined with hydrochlorothiazide medication. Approximately 4.4% of patients experience these effects leading to discontinuation.\",\"Patients using NUCYNTA\\\\u2122 should be informed not to take any drugs that inhibit monoamine oxidase. They should also be advised not to start any new medications while taking NUCYNTA\\\\u2122 until they are assured by their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\",\"The specific steps that should be taken immediately in the case of a patient on ACE inhibitors exhibiting jaundice or significantly elevated hepatic enzymes are to discontinue the ACE inhibitor and keep the patient under medical surveillance. Follow-up actions recommended to ensure the patient&#x27;s safety include appropriate medical follow-up.\",\"The simultaneous use of tizanidine and fluvoxamine can lead to adverse effects due to changes in the pharmacokinetics of tizanidine when administered with fluvoxamine. Specifically, significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment are the specific reactions that should be anticipated.\",\"The active ingredients and their respective strengths for the lisinopril and hydrochlorothiazide tablet identified by NDC code 69097-968 are:\\\\n\\\\n1. Lisinopril: 10 mg\\\\n2. Hydrochlorothiazide: 12.5 mg\",\"ABALONE CRYSTALDOUBLE EX CC should be applied topically on the skin.\"]],[\"reference_answer\",[\"Candesartan cilexetil and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs, in patients with anuria, and should not be co-administered with aliskiren in patients with diabetes.\",\"The most common adverse events reported by \\\\u226510% in any NUCYNTA\\\\u2122 dose group were nausea, dizziness, vomiting, and somnolence.\",\"The inactive ingredients are anhydrous dibasic calcium phosphate, mannitol, starch, corn, magnesium stearate, ferric oxide yellow, and ferric oxide red.\",\"Lisinopril 20 mg and Hydrochlorothiazide 25 mg\",\"NUCYNTA\\\\u2122 has not been studied in patients with severe hepatic impairment, therefore, use of NUCYNTA\\\\u2122 is not recommended in this population.\",\"The active ingredient in NUCYNTA\\\\u2122 is tapentadol.\",\"The tablet is yellow and oval (biconvex) in shape.\",\"The four most common adverse reactions reported are dry mouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness), and dizziness.\",\"The marketing start date for the product with item code NDC:62559-662-90 is 09/26/2018.\",\"Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\",\"Lisinopril and hydrochlorothiazide tablets are available in three combinations: 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.\",\"The route of administration for NUCYNTA 100MG is oral.\",\"Female patients of childbearing age should be told about the consequences of exposure to candesartan cilexetil and hydrochlorothiazide tablets during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.\",\"Hydrochlorothiazide can cause an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation.\",\"Care should be taken when selecting an initial dose for elderly patients.\",\"Patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance, namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\",\"In patients with heart failure, candesartan cilexetil and hydrochlorothiazide tablets may cause excessive hypotension, which may lead to oliguria, azotemia, and (rarely) with acute renal failure and death.\",\"The main ingredients in ADEA GARGLE chewable tablets are citric acid, sodium hydrogen carbonate, and xylitol.\",\"Tizanidine should be used with caution in elderly patients because clearance is decreased four-fold.\",\"The most common adverse effects leading to discontinuation are dizziness, cough, fatigue, and muscle cramps.\",\"Patients should be informed not to take NUCYNTA\\\\u2122 while using any drugs that inhibit monoamine oxidase. Patients should not start any new medications while taking NUCYNTA\\\\u2122 until they are assured by their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\",\"Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.\",\"Concomitant use of fluvoxamine and tizanidine is contraindicated due to changes in pharmacokinetics of tizanidine, resulting in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.\",\"The active ingredients are Lisinopril with a strength of 10 mg and Hydrochlorothiazide with a strength of 12.5 mg.\",\"TOPICAL\"]],[\"id\",[67,8,54,55,12,23,77,96,79,43,31,24,69,38,3,40,68,0,90,46,20,37,97,53,87]],[\"content\",[\"in myocardial infarction and cardiovascular mortality also have been seen regularly.\\\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\\\nhypertension can provide substantial benefit. \\\\nRelative risk reduction from blood pressure reduction is\\\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\\\nare at h...\",\"Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\\\nconsidered drug-related.\\\\nBased on data from nine Phase 2/3 studies that administered multiple...\",\"lisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-969\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS D...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-971\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n25 mg\\\\nInactive Ingredients\\\\nI...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"Store NUCYNTA\\\\u2122 at 59\\\\u00baF to 86\\\\u00baF (15\\\\u00baC to 30\\\\u00baC). Keep NUCYNTA\\\\u2122 tablets dry.\\\\nDispose of NUCYNTA\\\\u2122 tablets you no longer need.\\\\nKeep NUCYNTA\\\\u2122 in a safe place out of the reach of children.\\\\nGeneral information about NUCYNTA\\\\u2122\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\\\nuse NUCYNTA\\\\u2122 for a condition for which it was not prescribed. \\\\nDo not give NUCYNTA\\\\u2122 to other\\\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\\\u2122 could be harmful\\\\n...\",\"Flavor\\\\nImprint Code\\\\nACS\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-660-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type...\",\"multiple sclerosis (Study 1) \\\\n[see Clinical Studies ( \\\\n14\\\\n)] \\\\n, the patients were specifically\\\\nasked if they had experienced any of the four most common adverse reactions: dry\\\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\\\nthese reactions is summarized in \\\\nTable 2\\\\n. Other events were, in general, reported at a\\\\nrate of 2% or less.\\\\nTable 2: Single Dose, Placebo-Controlled Study -...\",\"ANI Pharmaceuticals, Inc.\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-662-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nLabeler - \\\\nANI Pharmaceuticals, Inc. \\\\n(145588013)\\\\n \\\\nRevised: 5/2020\",\"mTOR (mammalian target of rapamycin) inhibitors\\\\n \\\\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\\\n(see \\\\nWARNINGS\\\\n)\\\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\\\nrisk for angioedema. (see \\\\nWARNINGS\\\\n)\\\\nHydrochlorothiazide\\\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\\\nAlcohol, barbiturates, or nar...\",\"Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\\\nhydroxide solution.\\\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\\\nlisinopril and hydrochlorothiazide tabl...\",\"NUCYNTA 100MG PACKAGE LABEL\\\\n       \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\nNUCYNTA  \\\\ntapentadol hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN\\\\nPRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:16590-\\\\n863(NDC:50458-820)\\\\nRoute of Administration\\\\nORAL\\\\nDEA Schedule\\\\nCII\",\"considered if the intraocular pressure remains uncontrolled. \\\\nRisk factors for developing acute angle-\\\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\\\nHypersensitivity Reaction\\\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\\\nPRECAUTIONS\\\\nMetabolic Disturbances\\\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...\",\"rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\\\nLisinopril and Hydrochlorothiazide\\\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\\\nMaternal or fetotoxic effects were not seen in mice with the com...\",\"USE IN SPECIFIC POPULATIONS\\\\nLabor and delivery: \\\\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\\\nmothers have been taking NUCYNTA\\\\u2122, for respiratory depression. (\\\\n8.2\\\\n)\\\\nNursing mothers: should not breast-feed. (\\\\n8.3\\\\n)\\\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\\\n8.4\\\\n)\\\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\\\npatients with moder...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\\\n). \\\\nIn each of\\\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\\\ntimes the MRHD\\\\n in mouse, rats, and rabbit, respectively). \\\\nThere was no evidence of harm to the rat or\\\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\\\nThiazides cross ...\",\"ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\\\n \\\\nK2resource co., ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\\\ntartar formation, plaque removal, oral cleansing\\\\nKeep...\",\"Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\\\nfour-fold ( \\\\n8.5\\\\n)\\\\nSee 17 for PATIENT COUNSELING INFORMATION.\\\\nRevised: 9/2020\\\\nFULL PRESCRIBING INFORMATION: CONTENTS\\\\n*\\\\n1 INDICATIONS AND USAGE\\\\n2 DOSAGE AND ADMINISTRATION\\\\n2.1 Dosing Information\\\\n2.2 Dosing in Patients with Renal Impairment\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\n2.4 Drug Discontinuation\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Hypo...\",\"adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\\\nfatigue and muscle cramps.\\\\nAdverse experiences occurring in greater than one percent of patients treated with\\\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\\\n                                                                         Percent of Patients in\\\\nControlled Studies\\\\n   Lisinopril and\\\\nHydrochlorothiazide\\\\n   (n=930)\\\\n   Incidence\\\\n(discontinuation)\\\\n   Placebo\\\\n   (n=207)\\\\n...\",\"Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\\\u2122 \\\\n[see \\\\nUse in\\\\nSpecific Populations (8.3)\\\\n]\\\\n.\\\\n17.6 Monoamine Oxidase Inhibitors\\\\nPatients should be informed not to take NUCYNTA\\\\u2122 while using any drugs that inhibit monoamine\\\\noxidase. Patients should not start any new medications while taking NUCYNTA\\\\u2122 until they are assured\\\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\\\n17.7 Seizures\\\\nPatients should be informed that NU...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"ABALONE CRYSTALDOUBLE EX CC  \\\\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:60611-0008\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\"]],[\"color\",[\"#ba0e0e\",\"#0a980a\",\"#ba0e0e\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#ba0e0e\",\"#0a980a\",\"#ba0e0e\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#ba0e0e\",\"#0a980a\",\"#ba0e0e\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1640\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1641\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1636\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1637\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1638\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1654\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1645\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1646\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1647\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"UkAZwdrRJ8EsRUvBVVdYwYI4VMFU507B0xdUwVejW8FetFHB4PBWwQvoYsG1qF3BABJjwVGXYsFDKFLBF3BoweE0bMF621rBz0lgwf0aT8F4JUnB/LtLwWEzVcHYi0TBpG8/wW+rO8F8LD/B5V8xwS2QJMGEah3BDK0lwVC4KsFh1h7BW2oowdj6LsFMgSLBx30swcGxIMHCCxjB7oYnwYU9F8H7dBzBXocnwfm8J8GXsBvBZOccwYPOG8Gk9izBYUMQwQKXJcEvdCfBXvovwV+GKsHpZSfBMrsdwb6dIMFJ0irBN7g4wa2cSMHXATzBUQcxwWt6IsElow7Ba7QOwUx3BsEgEwTB6UYIwZtt+sASo/7AFAIIwb27C8HDFwHBfmMBwYJv+MB4xgbB/WMOwdBaE8EzEBrBFswUwU5vKMFHljLBy/8nwTGZLcG4zBrBfukrwQ55MsHbPCTBi1hWweIrXsFZ3GfBi7ZbwQivXMEmT2TBBEdswX+NaMG4hGTBb2lfwZqPbsE=\"},\"shape\":[98],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[98],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1655\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1656\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1651\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1652\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1653\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1608\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1623\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1624\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1625\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1626\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1631\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1632\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1599\",\"attributes\":{\"renderers\":[{\"id\":\"p1639\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1618\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1619\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1620\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1621\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1613\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1614\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1615\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1616\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1617\",\"attributes\":{\"axis\":{\"id\":\"p1613\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1622\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1618\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1642\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1643\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"False\"},\"renderers\":[{\"id\":\"p1639\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1644\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p1639\"}],\"index\":1}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p1660\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1657\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1658\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1659\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"mhwuwSnyYsE=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"muiTQIgRqEA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"635bd568-8072-4c65-9367-369073edf0d0\",\"roots\":{\"p1665\":\"b038e420-22ae-4cc1-81f5-573859a1b757\"},\"root_ids\":[\"p1665\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"b038e420-22ae-4cc1-81f5-573859a1b757\" data-root-id=\"p1665\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x7021787248c0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_chain_gpt_3_5_rag, testset=testset_gpt4o, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 47,
   "id": "75cbaf2e",
   "metadata": {},
   "outputs": [],
   "source": [
    "#report.to_html(\"report-gpt-3-5-rag-100.html\")\n",
    "\n",
    "report.to_html(f\"report-gpt-3-5-rag_10.html\")\n",
    "dfc = pd.DataFrame(report.component_scores())\n",
    "dfc.to_csv(f\"component_scores_10.csv\", index=False)\n",
    "dfr = report.to_pandas()\n",
    "dfr.to_excel(f\"all_results_10.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f3f34b1f",
   "metadata": {},
   "source": [
    "#### Gpt 3.5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "id": "d8c02a51",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_chain_gpt_3_5(question, history=None):\n",
    "    return chain_gpt_3_5.invoke({\"question\": question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "3f571cb3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "512414538b164742aa2534bc768e8310",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d68f32df41254e88bc8fa9adc5fa65e8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"d12ef63d-e11c-4977-9c42-da414fc98c84\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"d12ef63d-e11c-4977-9c42-da414fc98c84\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"d12ef63d-e11c-4977-9c42-da414fc98c84\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-orange \">\n",
       "                        48.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=48.0 class=\" progress-orange \">48.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        78.79%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=78.78787878787878 class=\" progress-green \">78.79%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">48%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Focus on enhancing the Generator&#39;s effectiveness for complex questions, as this low score suggests it struggles with paraphrased queries, and ensure parity in performance across topics by improving the knowledge base regarding Pharmaceutical Labeling.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"237c8a3f-309c-4927-a3b6-337f4b638a37\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p2218\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p2220\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p2227\",\"attributes\":{\"factors\":[\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2228\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p2229\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p2225\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2247\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2215\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2216\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2217\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"uuiiiy66RkCqqqqqqqpQQA==\"},\"shape\":[2],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\"]],[\"colors\",[\"#a50026\",\"#006837\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2248\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2249\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2244\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2245\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2246\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2256\",\"attributes\":{\"data_source\":{\"id\":\"p2215\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2257\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2258\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2253\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2254\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2255\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2266\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2260\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2261\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2262\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2267\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2268\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p2263\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p2264\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p2265\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p2226\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p2240\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p2235\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p2236\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p2237\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2238\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2230\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2231\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2232\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2233\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2234\",\"attributes\":{\"axis\":{\"id\":\"p2230\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2239\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p2235\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p2259\",\"attributes\":{\"location\":48.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p2269\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2270\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p2266\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"237c8a3f-309c-4927-a3b6-337f4b638a37\",\"roots\":{\"p2218\":\"cc726277-ce39-4d28-9cc5-b43171c35b82\"},\"root_ids\":[\"p2218\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"cc726277-ce39-4d28-9cc5-b43171c35b82\" data-root-id=\"p2218\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"bc141e53-d878-4bcb-a309-697aa228119c\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p2149\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p2079\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p2033\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p2042\",\"attributes\":{\"start\":-15.26738133430481,\"end\":-3.4757434844970705}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p2043\",\"attributes\":{\"start\":-0.2422795295715332,\"end\":10.272449612617493}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2044\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2045\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p2040\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2073\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2030\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2031\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2032\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[98],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[98],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99]],[\"content\",[\"ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\\\n \\\\nK2resource co., ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\\\ntartar formation, plaque removal, oral cleansing\\\\nKeep...\",\"K2resource co., ltd.\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:72191-0100\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nSODIUM BICARBONATE\\\\n (UNII: 8MDF5V39QO) \\\\n(SODIUM CATION -\\\\nUNII:LYR4M0NH37)\\\\nSODIUM\\\\nBICARBONATE\\\\n36.2 g  in 100 mg\\\\nXYLITOL\\\\n (UNII: VCQ006KQ1E) \\\\n(XYLITOL - UNII:VCQ006KQ1E)\\\\nXYLITOL\\\\n5 g  in 100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMENTHOL\\\\n (UNII: L7T10EIP3A)\\\\n \\\\nProduct Characteristics\\\\nCo...\",\"NUCYNTA - tapentadol hydrochloride tablet, film coated \\\\n \\\\nStat Rx USA\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use NUCYNTA\\\\u2122 safely and effectively. See full\\\\nprescribing information for NUCYNTA\\\\u2122.\\\\n \\\\nNUCYNTA\\\\u2122 (tapentadol) immediate-release oral tablets    C-II\\\\nInitial U.S. Approval: 2008\\\\nRECENT MAJOR CHANGES\\\\nWarnings and Precautions (\\\\n5.4\\\\n)\\\\nJune 2009\\\\nINDICATIONS AND USAGE\\\\nNUCYNTA\\\\u2122 is an opioid analgesic indicated for the relief o...\",\"USE IN SPECIFIC POPULATIONS\\\\nLabor and delivery: \\\\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\\\nmothers have been taking NUCYNTA\\\\u2122, for respiratory depression. (\\\\n8.2\\\\n)\\\\nNursing mothers: should not breast-feed. (\\\\n8.3\\\\n)\\\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\\\n8.4\\\\n)\\\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\\\npatients with moder...\",\"8.7 Hepatic Impairment\\\\n9 DRUG ABUSE AND DEPENDENCE\\\\n9.1 Controlled Substance\\\\n9.2 Abuse\\\\n9.3 Dependence\\\\n10 OVERDOSAGE\\\\n10.1 Human Experience\\\\n10.2 Management of Overdose\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n13 NON-CLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\n14 CLINICAL STUDIES\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\n14.2 End-Stage Degenerative Joint Disea...\",\"Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\\\nbeen studied and are not recommended.\\\\nNUCYNTA\\\\u2122 may be given with or without food \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n].\\\\n2.1 Renal Impairment\\\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\\\n[see \\\\nClinical\\\\nPharmacology (12.3)\\\\n]\\\\n.\\\\nNUCYNTA\\\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\\\nis not recommended.\\\\n2.2 Hepatic Im...\",\"which may result in adverse cardiovascular events \\\\n[see \\\\nDrug Interactions (7.4)\\\\n]\\\\n.\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Respiratory Depression\\\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\\\nsignificantly decrease pulmonary ventilation.\\\\nNUCYNTA\\\\u2122 should be ...\",\"5.5 Driving and Operating Machinery\\\\nPatients should be cautioned that NUCYNTA\\\\u2122 may impair the mental and/or physical abilities required\\\\nfor the performance of potentially hazardous tasks such as driving a car or operating machinery. This is\\\\nto be expected especially at the beginning of treatment, at any change of dosage as well as in\\\\ncombination with alcohol or tranquilizers\\\\n [see \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\n5.6 Interactions with Alcohol and Drugs of Abuse\\\\nDue to its mu-opioid agonist activity,...\",\"Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\\\nconsidered drug-related.\\\\nBased on data from nine Phase 2/3 studies that administered multiple...\",\"*\\\\nInfections and infestations\\\\n  Nasopharyngitis\\\\n1\\\\n&lt;1\\\\n  Upper respiratory tract infection\\\\n1\\\\n&lt;1\\\\n  Urinary tract infection\\\\n1\\\\n&lt;1\\\\nMetabolism and nutrition disorders\\\\n  Decreased appetite\\\\n2\\\\n0\\\\nMusculoskeletal and connective tissue\\\\ndisorders\\\\n  Arthralgia\\\\n1\\\\n&lt;1\\\\nNervous system disorders\\\\n  Dizziness\\\\n24\\\\n8\\\\n  Somnolence\\\\n15\\\\n3\\\\n  Tremor\\\\n1\\\\n&lt;1\\\\n  Lethargy\\\\n1\\\\n&lt;1\\\\nPsychiatric disorders\\\\n  Insomnia\\\\n2\\\\n&lt;1\\\\n  Confusional state\\\\n1\\\\n0\\\\n  Abnormal dreams\\\\n1\\\\n&lt;1\\\\n  Anxiety\\\\n1\\\\n&lt;1\\\\nSkin and subcutaneous tissue disorders\\\\n  Pruritus\\\\n5\\\\n1\\\\n  Hyp...\",\"Psychiatric disorders:\\\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\\\nabnormal\\\\nRenal and urinary disorders:\\\\n urinary hesitation, pollakiuria\\\\nRespiratory, thoracic and mediastinal disorders: \\\\noxygen saturation decreased, cough, dyspnea,\\\\nrespiratory depression\\\\nSkin and subcutaneous tissue disorders: \\\\nurticaria\\\\nVascular disorders:\\\\n blood pressure decreased\\\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\\\nNUCYNTA\\\\u2122,...\",\"Pregnancy Category C.\\\\nTapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous\\\\nand subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was\\\\nadministered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day\\\\n[producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of\\\\n700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic eff...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and\\\\nproper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid\\\\nagonist properties.\\\\nInfants born to mothers physically dependent on opioids will also be physically dependent and may\\\\nexhibit respiratory difficulties and withdrawal symptoms \\\\n[see \\\\nWarnings and Precautions (5.1)\\\\n]\\\\n. Use of\\\\nNUCYNTA\\\\u2122 in this population has not been characterized. As NUCYNTA\\\\u2122 h...\",\"intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\\\nshould be taken to secure the airway.\\\\n11 DESCRIPTION\\\\nNUCYNTA\\\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\\\nThe chemical name is 3-[(1\\\\nR\\\\n,2\\\\nR\\\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\\\nmonohydrochloride. The structural formula is:\\\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\\\nH\\\\nNO\\\\u00b7HCl. The\\\\nn-octanol:water pa...\",\"extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\\\naround 1.25 hours after dosing.\\\\nDose-proportional increases in the C\\\\n and AUC values of tapentadol have been observed over the 50\\\\nto 150 mg dose range.\\\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\\\nglucuronide, which are primarily determined by the do...\",\"Pharmacokinetic Drug Interactions\\\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\\\nconsidered clinically relevant and no change in dose is required.\\\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\\\nac...\",\"14 CLINICAL STUDIES\\\\nThe efficacy and safety of NUCYNTA\\\\u2122 in the treatment of moderate to severe acute pain has been\\\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\\\u2122...\",\"50% or greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus\\\\nplacebo.\\\\n14.2 End-Stage Degenerative Joint Disease\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\\\u2122 given every 4 to 6 hours during\\\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\\\nend stage degenerative joint disease of the hip or knee, defined...\",\"The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\\\nor greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus placebo.\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nNUCYNTA\\\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\\\nbiconvex-shaped.\\\\n50 mg tablets are yellow and debossed with \\\\\"O-M\\\\\" on one side and \\\\\"50\\\\\" on the other side, and are\\\\navailable in bottles of 100 (NDC 50458-820-04) a...\",\"Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\\\u2122 \\\\n[see \\\\nUse in\\\\nSpecific Populations (8.3)\\\\n]\\\\n.\\\\n17.6 Monoamine Oxidase Inhibitors\\\\nPatients should be informed not to take NUCYNTA\\\\u2122 while using any drugs that inhibit monoamine\\\\noxidase. Patients should not start any new medications while taking NUCYNTA\\\\u2122 until they are assured\\\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\\\n17.7 Seizures\\\\nPatients should be informed that NU...\",\"you get a new prescription. There may be new information. This Medication Guide does not take\\\\nthe place of talking to your doctor about your medical condition or your treatment. Talk to your\\\\ndoctor if you have any questions.\\\\nWhat is the most important information I should know about NUCYNTA\\\\u2122?\\\\nNUCYNTA\\\\u2122 is a tablet that contains tapentadol, a strong medicine that is a pain medicine.\\\\nUse NUCYNTA\\\\u2122 exactly how your doctor tells you to. Do not use NUCYNTA\\\\u2122 if it has not been\\\\nprescribed for you.\\\\nYou sh...\",\"Do not change the dose of NUCYNTA\\\\u2122 unless your doctor tells you to. \\\\nYour doctor may\\\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\\\u2122 more often\\\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\\\u2122.\\\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\\\u2122 to help lessen\\\\nwithdrawal symptoms.\\\\nNUCYNTA\\\\u2122 can be taken with or without food.\\\\nWhat should I avoid while taking NUCYNTA\\\\u2122?\\\\nDo not drive, operate machinery, ...\",\"Store NUCYNTA\\\\u2122 at 59\\\\u00baF to 86\\\\u00baF (15\\\\u00baC to 30\\\\u00baC). Keep NUCYNTA\\\\u2122 tablets dry.\\\\nDispose of NUCYNTA\\\\u2122 tablets you no longer need.\\\\nKeep NUCYNTA\\\\u2122 in a safe place out of the reach of children.\\\\nGeneral information about NUCYNTA\\\\u2122\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\\\nuse NUCYNTA\\\\u2122 for a condition for which it was not prescribed. \\\\nDo not give NUCYNTA\\\\u2122 to other\\\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\\\u2122 could be harmful\\\\n...\",\"NUCYNTA 100MG PACKAGE LABEL\\\\n       \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\nNUCYNTA  \\\\ntapentadol hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN\\\\nPRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:16590-\\\\n863(NDC:50458-820)\\\\nRoute of Administration\\\\nORAL\\\\nDEA Schedule\\\\nCII\",\"Active Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n50 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII: 15FIX9V2JP)\\\\n...\",\"Stat Rx USA\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII:...\",\"GRX DYNE - povidone iodine solution \\\\n \\\\nGeritrex Corp.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nGRx Dyne Solution\\\\nDrug Facts\\\\nActive Ingredient:                      Purpose\\\\nPovidone Iodine USP, 10% w/v  Antiseptic\\\\n(equivalent to 1% titratable Iodine)\\\\nUses\\\\nFirst aid antiseptic to help the risk of infection in \\\\nminor cuts, scra...\",\"Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\\\nkeep out of reach of children. If swallowed get medical help \\\\nor contact a Poison Control Center right away.\\\\nEnter section text here\\\\nGRX DYNE  \\\\npovidone iodine solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:54162-269\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85...\",\"Geritrex Corp.\\\\nCITRIC ACID MONOHYDRATE\\\\n (UNII: 2968PHW8QP)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nSODIUM HYDROXIDE\\\\n (UNII: 55X04QC32I)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:54162-269-16\\\\n472 mL in 1 BOTTLE, PLASTIC\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOTC monograph not final\\\\npart333A\\\\n05/16/2012\\\\nLabeler - \\\\n...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE- lisinopril and hydrochlorothiazide\\\\ntablets tablet \\\\n \\\\nCipla USA Inc.\\\\n----------\\\\nLisinopril and Hydrochlorothiazide Tablets, USP\\\\nRx Only\\\\nWARNING: FETAL TOXICITY\\\\nSee full prescribing information for complete boxed warning.\\\\nWhen pregnancy is detected, discontinue lisinopril and\\\\nhydrochlorothiazide tablets as soon as possible.\\\\nDrugs that act directly on the renin-angiotensin system can cause\\\\ninjury and death to the developing fetus. See \\\\nWarnings: Fetal Toxicity\\\\n.\\\\n...\",\"Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\\\nhydroxide solution.\\\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\\\nlisinopril and hydrochlorothiazide tabl...\",\"Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\\\nadministration of the separate entities.\\\\nLisinopril\\\\nMechanism of Action\\\\n \\\\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...\",\"state is prolonged. Older patients, on average, have (approximately doubled) higher\\\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\\\npatients (see \\\\nDOSAGE AND ADMINISTRATION\\\\n). In a multiple dose pharmacokinetic study\\\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\\\nhe...\",\"accompanied by some loss of potassium and bicarbonate.\\\\nAfter oral use diuresis begins within two hours, peaks in about four hours and lasts\\\\nabout 6 to 12 hours.\\\\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When\\\\nplasma levels have been followed for at least 24 hours, the plasma half-life has been\\\\nobserved to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is\\\\neliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but...\",\"the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\\\nsimilar risk (See \\\\nWARNINGS\\\\n).\\\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\\\nthan in nonblack patients (see \\\\nWARNIN...\",\"Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of\\\\nrapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin\\\\ninhibitor may be at increased risk for angioedema (see \\\\nPRECAUTIONS\\\\n).\\\\nIntestinal Angioedema:\\\\n Intestinal angioedema has been reported in patients treated\\\\nwith ACE inhibitors. These patients presented with abdominal pain (with or without\\\\nnausea or vomiting); in some cases there was no prior history of facial angioedema and\\\\nC-1...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\\\nLisinopril and Hydrochlorothiazide\\\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\\\nMaternal or fetotoxic effects were not seen in mice with the com...\",\"Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\\\nInteractions, Lisinopril and Hydrochlorothiazide).\\\\nPRECAUTIONS\\\\nGeneral\\\\nLisinopril\\\\n \\\\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\\\n As with all vasodilators, lisinopril\\\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\\\nventricle.\\\\nImpaired Renal Function:\\\\n As a consequence of inhibiting the renin-angiotensin-\\\\naldosterone system, changes in renal function may be anticipated in suscept...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"therapy.\\\\nInformation for Patients\\\\nAngioedema:\\\\n Angioedema, including laryngeal edema may occur at any time during\\\\ntreatment with angiotensin-converting enzyme inhibitors, including lisinopril and\\\\nhydrochlorothiazide. Patients should be so advised and told to report immediately any\\\\nsigns or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips,\\\\ntongue, difficulty in swallowing or breathing) and to take no more drug until they have\\\\nconsulted with the prescribing physician.\\\\nSymp...\",\"DOSAGE AND ADMINISTRATION\\\\n)\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\\\nInhibitors (COX-2 Inhibitors):\\\\n \\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\\\nfunction, including possible acute renal failure. These effects are usually reversible.\\\\nMonitor ...\",\"mTOR (mammalian target of rapamycin) inhibitors\\\\n \\\\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\\\n(see \\\\nWARNINGS\\\\n)\\\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\\\nrisk for angioedema. (see \\\\nWARNINGS\\\\n)\\\\nHydrochlorothiazide\\\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\\\nAlcohol, barbiturates, or nar...\",\"in vitro\\\\n alkaline elution rat hepatocyte assay. In addition, it did not produce increases in\\\\nchromosomal aberrations in an \\\\nin vitro\\\\n test in Chinese hamster ovary cells or in an \\\\nin\\\\nvivo\\\\n study in mouse bone marrow.\\\\nLisinopril\\\\n \\\\nThere was no evidence of a tumorigenic effect when lisinopril was administered for 105\\\\nweeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the\\\\nmaximum daily human dose, based on body weight and body surface area,\\\\nrespectively). There was no ...\",\"Nursing Mothers\\\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\\\nrats contains radioactivity following administration of \\\\nC lisinopril. In another study,\\\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\\\nwhether to discontinue nursing and/or disco...\",\"adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\\\nfatigue and muscle cramps.\\\\nAdverse experiences occurring in greater than one percent of patients treated with\\\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\\\n                                                                         Percent of Patients in\\\\nControlled Studies\\\\n   Lisinopril and\\\\nHydrochlorothiazide\\\\n   (n=930)\\\\n   Incidence\\\\n(discontinuation)\\\\n   Placebo\\\\n   (n=207)\\\\n...\",\"In rare cases, intestinal angioedema has been reported in post marketing experience.\\\\nHypotension:\\\\n In clinical trials, adverse effects relating to hypotension occurred as\\\\nfollows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects\\\\n(3.2%). In addition syncope occurred in 0.8% of patients (See \\\\nWARNINGS\\\\n).\\\\nCough:\\\\n See \\\\nPRECAUTIONS - Cough\\\\n.\\\\nClinical Laboratory Test Findings Serum Electrolytes:\\\\n (See \\\\nPRECAUTIONS\\\\n).\\\\nCreatinine, Blood Urea Nitrogen:\\\\n Minor reversible incre...\",\"hallucinations; \\\\nRespiratory:\\\\n Malignant lung neoplasms, hemoptysis, pulmonary edema,\\\\npulmonary infiltrates, bronchospasm, asthma, pleural effusion, pneumonia, eosinophilic\\\\npneumonitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis,\\\\npharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; \\\\nSkin:\\\\n Urticaria, alopecia,\\\\nherpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema,\\\\npsoriasis, rare cases of other severe skin reactions, includin...\",\"Lisinopril\\\\n \\\\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\\\nnormal saline solution.\\\\nLisinopril can be removed by hemodialysis (see \\\\nWARNINGS, Anaphylactoid Reaction\\\\nDuring Membrane Exposure\\\\n).\\\\nHydrochlorothiazide\\\\n \\\\nOral administration of a single oral dose of 10 g/kg to mice and rats w...\",\"possible, be discontinued for two to three days before beginning therapy with lisinopril\\\\nto reduce the likelihood of hypotension (See \\\\nWARNINGS\\\\n). If the patient\\\\u2019s blood pressure\\\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\\\nfor at least an additional hour (See \\\\nWARNINGS\\\\n and \\\\nPRECAUTIONS\\\\n...\",\"Protect from excessive light and humidity.\\\\n*AN69 is a registered trademark of Hospal Ltd.\\\\nManufactured by:\\\\nInvaGen Pharmaceuticals, Inc.\\\\n(a subsidiary of Cipla Ltd.)\\\\nHauppauge, NY 11788\\\\nManufactured for:\\\\nCipla USA, Inc.\\\\n10 Independence Boulevard, Suite 300\\\\nWarren, NJ 07059\\\\nRevised: 10/2021\\\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\\\u2013 10 mg/12.5 mg\\\\nNDC 69097-968-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n10 mg/12.5 mg\\\\n100 Tablets\\\\nCipla\\\\nNDC 69097-969-07             ...\",\"Cipla\\\\nNDC 69097-971-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n20 mg/25 mg\\\\n100 Tablets\\\\nCipla\\\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"lisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-969\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS D...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-971\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n25 mg\\\\nInactive Ingredients\\\\nI...\",\"Cipla USA Inc.\\\\nLabeler - \\\\nCipla USA Inc. \\\\n(078719707)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen\\\\nPharmaceuticals, Inc\\\\n165104469\\\\nanalysis(69097-968, 69097-969, 69097-971) , manufacture(69097-968,\\\\n69097-969, 69097-971)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen Pharmaceuticals, Inc\\\\n080334903\\\\npack(69097-968, 69097-969, 69097-971)\\\\n \\\\nRevised: 11/2021\",\"ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and\\\\nphenylephrine hydrochloride tablet, coated \\\\n \\\\nMARC GLASSMAN, INC.\\\\n----------\\\\n1128B-MAR-2022-1005\\\\nDrug Facts\\\\nActive ingredients \\\\n(in each caplet)\\\\nPurpose\\\\nAcetaminophen 325 mg\\\\nPain reliever\\\\nChlorpheniramine maleate\\\\n2 mg\\\\nAntihistamine\\\\nPhenylephrine HCl 5 mg\\\\nNasal decongestant\\\\nUses\\\\ntemporarily relieves these symptoms of hay fever or other upper respiratory\\\\nallergies:\\\\nheadache\\\\nsinus congestion and pressure\\\\nnasal congestion\\\\nrunny nose...\",\"If a skin reaction occurs, stop use and seek medical help right away.\\\\nDo not use\\\\nwith any other drug containing acetaminophen (prescription or nonprescription). If\\\\nyou are not sure whether a drug contains acetaminophen, ask a doctor or\\\\npharmacist.\\\\nif you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain\\\\ndrugs for depression, psychiatric or emotional conditions, or Parkinson&#x27;s disease), or\\\\nfor 2 weeks after stopping the MAOI drug. If you do not know if your prescription\\\\ndr...\",\"800-222-1222). Quick medical attention is critical for adults as well as for children even if\\\\nyou do not notice any signs or symptoms.\\\\nDirections\\\\ndo not take more than directed (see \\\\noverdose warning\\\\n)\\\\nadults and\\\\nchildren 12\\\\nyears and over\\\\ntake 2 caplets every 4 hours\\\\nswallow whole; do not crush,\\\\nchew, or dissolve\\\\ndo not take more than 10 caplets\\\\nin 24 hours\\\\nchildren under \\\\n12 years\\\\nask a doctor\\\\nOther information\\\\nstore between 20\\\\u00b0-25\\\\u00b0C (68\\\\u00b0-77\\\\u00b0F) in a dry place\\\\nretain carton for complete product...\",\"ALLERGY MULTI SYMPTOM  \\\\nacetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:68998-228\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCHLORPHENIRAMINE MALEATE\\\\n (UNII: V1Q0O9OJ9Z) \\\\n(CHLORPHENIRAMINE -\\\\nUNII:3U6IO1965U)\\\\nCHLORPHENIRAMINE\\\\nMALEATE\\\\n2 mg\\\\nPHENYLEPHRINE HYDROCHLORIDE\\\\n (UNII: 04JA59TNSJ) \\\\n(PHENYLEPHRINE -\\\\nUNII:1WS297W6MV)\\\\nPHENYLE...\",\"MARC GLASSMAN, INC.\\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nFERRIC OXIDE YELLOW\\\\n (UNII: EX438O2MRT)\\\\n \\\\nMAGNESIUM STEARATE\\\\n (UNII: 70097M6I30)\\\\n \\\\nCROSPOVIDONE\\\\n (UNII: 2S7830E561)\\\\n \\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\\\n (UNII: 3WJQ0SDW1A)\\\\n \\\\nPOLYVINYL ALCOHOL, UNSPECIFIED\\\\n (UNII: 532B59J990)\\\\n \\\\nPOVIDONE, UNSPECIFIED\\\\n (UNII: FZ989GH94E)\\\\n \\\\nSTARCH, CORN\\\\n (UNII: O8232NY3SJ)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nSTEA...\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and\\\\nhydrochlorothiazide tablet \\\\n \\\\nANI Pharmaceuticals, Inc.\\\\n----------\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\nWARNING: \\\\nFETAL TOXICITY\\\\n\\\\u2022\\\\n\\\\u2022\\\\nDESCRIPTION\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP combine an angiotensin II receptor (type\\\\nAT\\\\n) antagonist and a diuretic, hydrochlorothiazide.\\\\nCandesartan cilexetil, a nonpeptide, is chemically described as (\\\\u00b1)-1-Hydroxyethyl 2-ethoxy-1-[\\\\np\\\\n-(\\\\no\\\\n-\\\\n1\\\\nH\\\\n...\",\"Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of\\\\n297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet\\\\nstrengths of candesartan cilexetil and hydrochlorothiazide.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil\\\\nand 12.5 mg or 25 mg of hydrochloroth...\",\"The mechanism of the antihypertensive effect of thiazides is unknown.\\\\nPharmacokinetics\\\\nGeneral\\\\nCandesartan Cilexetil\\\\nCandesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from\\\\nthe gastrointestinal tract to candesartan, a selective AT\\\\nsubtype angiotensin II receptor antagonist.\\\\nCandesartan is mainly excreted unchanged in urine and feces (via bile). \\\\nIt undergoes minor hepatic\\\\nmetabolism by O-deethylation to an inactive metabolite. \\\\nThe elimination half...\",\"Geriatric\\\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\\\u2265 65 years). \\\\nThe plasma\\\\nconcentration of candesartan was higher in the elderly (C\\\\n was approximately 50% higher, and AUC\\\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\\\nThe\\\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\\\nNo initia...\",\"plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\\\nadministered to hypertensive patients. \\\\nIn spite of the effect of candesartan cilexetil on aldosterone\\\\nsecretion, very little effect on serum potassium was observed.\\\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\\\nIn a\\\\n12-week study of 161 patients with n...\",\"in myocardial infarction and cardiovascular mortality also have been seen regularly.\\\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\\\nhypertension can provide substantial benefit. \\\\nRelative risk reduction from blood pressure reduction is\\\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\\\nare at h...\",\"candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\\\n). \\\\nIn each of\\\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\\\ntimes the MRHD\\\\n in mouse, rats, and rabbit, respectively). \\\\nThere was no evidence of harm to the rat or\\\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\\\nThiazides cross ...\",\"considered if the intraocular pressure remains uncontrolled. \\\\nRisk factors for developing acute angle-\\\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\\\nHypersensitivity Reaction\\\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\\\nPRECAUTIONS\\\\nMetabolic Disturbances\\\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...\",\"Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\\\npossible ac...\",\"Cytotoxic products \\\\u2013 Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.\\\\ncyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.\\\\nCyclosporine \\\\u2212 Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and\\\\ngout-type complications.\\\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\\\nNo carcinogenicity studies have been conducted with the combination of candesartan cilexetil and\\\\nhydrochlorothiazide. \\\\nThere was no evidence of c...\",\"Neonates with a history of in utero exposure to candesartan cilexetil and hydrochlorothiazide tablets:\\\\nIf oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.\\\\nExchange transfusions or dialysis may be required as a means of reversing hypotension and/or\\\\nsubstituting for disordered renal function.\\\\nSafety and effectiveness in pediatric patients have not been established.\\\\nADVERSE REACTIONS\\\\nCandesartan Cilexetil and Hydrochlorothiazide\\\\nCandesartan cile...\",\"melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\\\nfor white patients taking a cumulative dose of \\\\u226550,000 mg the risk increase was approximately 1\\\\nadditional SCC case for every 6,700 patients per year.\\\\nSkin:\\\\n \\\\nerythema multiforme including S...\",\"Dose Titration by Clinical Effect: \\\\nA patient whose blood pressure is not controlled on 25 mg of\\\\nhydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and\\\\nhydrochlorothiazide tablets 16 mg/12.5 mg. \\\\nA patient whose blood pressure is controlled on 25 mg of\\\\nhydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or\\\\nincremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16\\\\nmg/12.5 mg and ser...\",\"PRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/12.5 mg\\\\nNDC 62559-661-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/12.5 mg\\\\nRx only\\\\n90 Tablets\\\\nPRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/25 mg\\\\nNDC 62559-662-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/25 mg\\\\nRx only\\\\n90 Tablets\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:62559-660\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCANDESARTAN CILEXETIL\\\\n (UNII: R85M2X0D68) \\\\n(CANDESARTAN - UNII:S8Q36MD2XX)\\\\nCANDESARTAN\\\\nCILEXETIL\\\\n16 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n1...\",\"Flavor\\\\nImprint Code\\\\nACS\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-660-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type...\",\"Packaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-661-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (So...\",\"ANI Pharmaceuticals, Inc.\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-662-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nLabeler - \\\\nANI Pharmaceuticals, Inc. \\\\n(145588013)\\\\n \\\\nRevised: 5/2020\",\"CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\\\n \\\\nCertus Medical, Inc.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\\\nDrug Facts Box OTC Active Ingredient Section\\\\nPovidone Iodine USP 10%\\\\nequivalent to 1% titratable iodine\\\\nDrug Facts Box OTC Purpose Section\\\\nAntiseptic\\\\nDrug...\",\"Drug Facts Box OTC General Precautions Section\\\\nstore at room temperature 15\\\\n - 30\\\\n C (59\\\\n - 86\\\\n F)\\\\nDrug Facts Box OTC Inactive Ingredient Section\\\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\\\nCertus PVP-1 Prep Swabstick \\\\n210012 pouch\\\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\\\n0\\\\n0\\\\n0\\\\n0\",\"CERTUS PVP-1 PREP SWABSTICK  \\\\npovidone-iodine swab\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:75990-4019\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85H0HZU99M) \\\\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\\\nPOVIDONE-IODINE\\\\n0.1 mL  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\",\"Certus Medical, Inc.\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nSODIUM PHOSPHATE, DIBASIC\\\\n (UNII: GR686LBA74)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nDIMETHICONE\\\\n (UNII: 92RU3N3Y1O)\\\\n \\\\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\\\n (UNII: S38J6RZN16)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:75990-4019-4\\\\n2 mL in 1 POUCH\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOT...\",\"ABALONE CRYSTALDOUBLE EX CC- niacinamide, adenosine, titanium dioxide, ethylhexyl\\\\nmethoxycinnamate cream \\\\n \\\\nC&amp;BCOSMETIC Co.,Ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nDrug Facts\\\\nNiacinamide, Adenosine, Titanium Dioxide, Ethylhexyl Methoxycinnamate\\\\nWater, Glycerin, Butylene Glycol, Etc\\\\nSkin Protectant - Anti-Wrinkle, Whitening, UV Protecting\\\\nk...\",\"ABALONE CRYSTALDOUBLE EX CC  \\\\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:60611-0008\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\",\"C&amp;BCOSMETIC Co.,Ltd.\\\\nNIACINAMIDE\\\\n (UNII: 25X51I8RD4) \\\\n(NIACINAMIDE - UNII:25X51I8RD4)\\\\nNIACINAMIDE\\\\n2 g  in 100 mL\\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP) \\\\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\\\nTITANIUM DIOXIDE\\\\n4.694 g  in 100 mL\\\\nADENOSINE\\\\n (UNII: K72T3FS567) \\\\n(ADENOSINE - UNII:K72T3FS567)\\\\nADENOSINE\\\\n0.04 g  in 100 mL\\\\nOCTINOXATE\\\\n (UNII: 4Y5P7MUD51) \\\\n(OCTINOXATE - UNII:4Y5P7MUD51)\\\\nOCTINOXATE\\\\n7 g  in 100 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C...\",\"TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\\\n \\\\nAdvagen Pharma Limited\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use TIZANIDINE\\\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\\\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\\\n \\\\nInitial U.S. Approval: 1996\\\\nINDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...\",\"Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\\\nfour-fold ( \\\\n8.5\\\\n)\\\\nSee 17 for PATIENT COUNSELING INFORMATION.\\\\nRevised: 9/2020\\\\nFULL PRESCRIBING INFORMATION: CONTENTS\\\\n*\\\\n1 INDICATIONS AND USAGE\\\\n2 DOSAGE AND ADMINISTRATION\\\\n2.1 Dosing Information\\\\n2.2 Dosing in Patients with Renal Impairment\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\n2.4 Drug Discontinuation\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Hypo...\",\"12.1 Mechanism of Action\\\\n12.3 Pharmacokinetics\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n16.1 Tizanidine Hydrochloride Capsules\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\n1 INDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the\\\\nmanagement of spasticity. Because of the short duration of therapeutic effect,\\\\ntreatment with tizanid...\",\"been studied.\\\\n2.2 Dosing in Patients with Renal Impairment\\\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\\\ndoses are required, individual doses rather than dosing frequency should be increased\\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n)] \\\\n.\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\nT...\",\"Tizanidine is an \\\\u03b1 \\\\n-adrenergic agonist that can produce hypotension. Syncope has been\\\\nreported in the post marketing setting. The chance of significant hypotension may\\\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\\\na supine to fixed upright position may be at increased risk for hypotension and\\\\northostatic effects.\\\\nMonitor for hypotension when tizanidine is used in patients...\",\"Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n5.6 Hypersensitivity Reactions\\\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\\\nand symptoms occur. \\\\n[see Contraindications ( \\\\n4\\\\n)]\\\\n5.7 Increased Risk of Adverse Reactions in Patients...\",\"264 patients received tizanidine and 261 patients received placebo. Across the three\\\\nstudies patient ages ranged from 15\\\\u201369 years and 51.4 percent were women. The\\\\nmedian dose during the plateau phase ranged from 20\\\\u201328 mg/day.\\\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\\\nclinical studies involving 264 patients with spasticity were dry mouth,\\\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\\\nThree-quarters of the patients rated t...\",\"multiple sclerosis (Study 1) \\\\n[see Clinical Studies ( \\\\n14\\\\n)] \\\\n, the patients were specifically\\\\nasked if they had experienced any of the four most common adverse reactions: dry\\\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\\\nthese reactions is summarized in \\\\nTable 2\\\\n. Other events were, in general, reported at a\\\\nrate of 2% or less.\\\\nTable 2: Single Dose, Placebo-Controlled Study -...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"12.3\\\\n)]\\\\n7.7 \\\\u03b1 \\\\n-adrenergic agonists\\\\nBecause hypotensive effects may be cumulative, it is not recommended that tizanidine\\\\nbe used with other \\\\u03b1 \\\\n-adrenergic agonists. \\\\n[see Warnings and Precautions ( \\\\n5.1\\\\n)]\\\\n8 USE IN SPECIFIC POPULATIONS\\\\n8.1 Pregnancy\\\\nPregnancy Category C\\\\nTizanidine has not been studied in pregnant women. Tizanidine should be given to\\\\npregnant women only if the benefit outweighs the risk to the unborn fetus.\\\\nReproduction studies performed in rats at a dose of 3 mg/kg, equal to the...\",\"8.6 Impaired Renal Function\\\\nTizanidine is known to be substantially excreted by the kidney, and the risk of adverse\\\\nreactions to this drug may be greater in patients with impaired renal function. In patients\\\\nwith renal insufficiency (creatinine clearance &lt; 25 mL/min) clearance was reduced by\\\\nmore than 50%. In these patients, during titration, the individual doses should be\\\\nreduced. If higher doses are required, individual doses rather than dosing frequency\\\\nshould be increased. These patients sho...\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\"],\"shape\":[98],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2074\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2075\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2070\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2071\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2072\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p2041\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p2056\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p2057\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p2058\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p2059\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p2060\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p2065\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p2066\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2051\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2052\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2053\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2054\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2046\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2047\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2048\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2049\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2050\",\"attributes\":{\"axis\":{\"id\":\"p2046\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2055\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p2051\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p2076\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2077\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Pharmaceutical Labeling\"},\"renderers\":[{\"id\":\"p2073\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2078\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Tizanidine Hydrochloride\"},\"renderers\":[{\"id\":\"p2073\"}],\"index\":87}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p2148\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p2084\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p2093\",\"attributes\":{\"start\":-15.26738133430481,\"end\":-3.4757434844970705}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p2094\",\"attributes\":{\"start\":-0.2422795295715332,\"end\":10.272449612617493}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2095\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2096\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p2091\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2123\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2080\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2081\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2082\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"m236wF60UcEyux3Bvp0gwQASY8HYi0TBMxAawX+NaMFObyjB+bwnwVC4KsGkbz/BFAIIwcILGMFVV1jBhT0XwRKj/sBSQBnB4itewYPOG8F4JUnBwbEgwbiEZMHpZSfBDnkywQ==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"pg+1QF40MED9U6VAYUawQDBMOkDQ/hBAfY6JQI4wtUBo5YBAeOLqQIvrzkAmNB1AW7fIQMMq40CTsmRA3WHtQAIPuUC8vkxAJmuhQDap/UBg/DJA8gf0QEfZn0C7FJlAO3llQA==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\",\"Pharmaceutical Labeling\",\"Pharmaceutical Labeling\"]],[\"correctness\",[false,false,false,false,false,true,false,false,false,true,true,true,true,false,true,true,false,false,true,false,true,true,true,true,false]],[\"questions\",[\"Considering the information provided, under what specific conditions or patient characteristics should the use of candesartan cilexetil and hydrochlorothiazide tablets be avoided, especially in relation to hypersensitivity and co-administration with other drugs?\",\"Considering the clinical studies conducted on NUCYNTA\\\\u2122, what are the most frequently reported adverse events in patients, particularly those that were observed in at least 10% of any dosage group, and how do these compare to the placebo group in terms of percentage?\",\"Could you identify the inactive components found in the lisinopril and hydrochlorothiazide tablet with the specific NDC code 69097-971, ensuring that your response only includes those ingredients that are not active and are unique to this particular formulation?\",\"Considering the tablet with the NDC code 69097-971, what are the precise strengths of both lisinopril and hydrochlorothiazide, and how do these strengths compare to those in similar tablets with different NDC codes, if any?\",\"Considering the lack of studies on NUCYNTA\\\\u2122 for individuals with severe hepatic impairment, what is the advised course of action for prescribing this medication to such patients, especially when considering potential risks and the absence of established safety and effectiveness?\",\"Considering the detailed composition of NUCYNTA\\\\u2122, can you identify the primary pharmacological component responsible for its therapeutic effects, and ensure that your answer excludes any mention of the inactive ingredients?\",\"Considering the strength of 32 mg of Candesartan Cilexetil and 12.5 mg of Hydrochlorothiazide, what are the color and shape of the tablet, and how does this compare to the tablet with a different strength of 25 mg of Hydrochlorothiazide?\",\"In the context of a study on multiple sclerosis patients taking tizanidine, what are the four most frequently reported adverse reactions, considering only those reactions that were specifically inquired about by the researchers?\",\"Under the condition that the item code is NDC:62559-662-90, can you specify the precise date when the marketing activities commenced for this particular product?\",\"Under what specific circumstances might the concurrent administration of ACE inhibitors and mTOR inhibitors, such as temsirolimus, sirolimus, or everolimus, lead to an increased risk of developing angioedema, and what precautions should be considered to mitigate this risk?\",\"Considering the available options, what are the specific tablet combinations of lisinopril and hydrochlorothiazide, including their dosages, that can be used for oral administration?\",\"Considering the information provided in Document 24 about NUCYNTA 100MG, could you specify the method by which this medication is administered to patients?\",\"What crucial information should be communicated to female patients of childbearing age who are on candesartan cilexetil and hydrochlorothiazide tablets, particularly regarding potential risks during pregnancy and any necessary actions they should take if they plan to become pregnant or discover they are pregnant?\",\"Considering potential side effects, particularly those related to vision, what are the specific ocular complications associated with Hydrochlorothiazide, and under what conditions or time frame do these symptoms typically manifest?\",\"What specific considerations and initial dosing precautions are recommended when administering NUCYNTA\\\\u2122 to elderly patients, especially in light of the potential for renal or hepatic impairments?\",\"When monitoring patients on thiazide therapy, which specific electrolyte imbalances, such as hyponatremia, hypochloremic alkalosis, and hypokalemia, should be carefully observed, particularly in cases of excessive vomiting or when parenteral fluids are administered?\",\"Considering the use of candesartan cilexetil and hydrochlorothiazide tablets in patients diagnosed with heart failure, what are the potential risks, specifically focusing on renal function and electrolyte imbalances, and how should these be managed during the initial treatment period?\",\"Could you detail the primary components of ADEA GARGLE chewable tablets, ensuring to include only those ingredients that are explicitly mentioned in the context provided, and also consider any potential allergens?\",\"Considering the pharmacokinetics of Tizanidine, particularly its clearance rate, why is it advised to exercise caution when prescribing this medication to elderly patients, and what specific risks does this present?\",\"Considering the adverse effects of lisinopril combined with hydrochlorothiazide, which specific side effects are most frequently responsible for patients deciding to stop the medication, and what percentage of patients experience these effects leading to discontinuation?\",\"What specific precautions should patients take when using NUCYNTA\\\\u2122 in relation to monoamine oxidase inhibitors, and what steps should they follow before starting any new medications while on NUCYNTA\\\\u2122?\",\"In the context of a patient who is currently on ACE inhibitors and begins to exhibit symptoms such as jaundice or significantly elevated hepatic enzymes, what specific steps should be taken immediately, and what follow-up actions are recommended to ensure the patient&#x27;s safety?\",\"Under what circumstances might the simultaneous use of tizanidine and fluvoxamine lead to adverse effects, and what specific reactions should be anticipated?\",\"Could you specify the active ingredients and their respective strengths for the lisinopril and hydrochlorothiazide tablet identified by NDC code 69097-968, ensuring that you do not confuse it with other similar products listed in the provided context?\",\"Could you specify the method by which ABALONE CRYSTALDOUBLE EX CC should be applied or administered, considering it contains niacinamide and titanium dioxide among other ingredients?\"]],[\"agent_answer\",[\"The use of candesartan cilexetil and hydrochlorothiazide tablets should be avoided in patients who have a known hypersensitivity to either of the active ingredients or to any other sulfonamide-derived medications. Additionally, caution should be exercised when co-administering these tablets with other drugs that may increase the risk of hyperkalemia, such as potassium-sparing diuretics, potassium supplements, or nonsteroidal anti-inflammatory drugs (NSAIDs). Patients with a history of gout or impaired kidney function should also be monitored closely when using this medication combination.\",\"The most frequently reported adverse events in patients taking NUCYNTA\\\\u2122, particularly those that were observed in at least 10% of any dosage group, include nausea, constipation, dizziness, and somnolence. In comparison to the placebo group, these adverse events were reported at a higher percentage in the patients taking NUCYNTA\\\\u2122. This indicates that these side effects are more common in patients taking the medication compared to those taking a placebo. It is important for healthcare providers to monitor patients closely for these adverse events and manage them appropriately to ensure the safety and well-being of the patients.\",\"Yes, the inactive components found in the lisinopril and hydrochlorothiazide tablet with the specific NDC code 69097-971 include microcrystalline cellulose, crospovidone, lactose anhydrous, magnesium stearate, and mannitol. These ingredients are not active and are unique to this particular formulation.\",\"The tablet with the NDC code 69097-971 contains lisinopril 10 mg and hydrochlorothiazide 12.5 mg. This means that the precise strengths of lisinopril and hydrochlorothiazide in this tablet are 10 mg and 12.5 mg, respectively.\\\\n\\\\nWhen comparing these strengths to similar tablets with different NDC codes, it is important to consider the therapeutic equivalence and bioequivalence of the medications. Different tablets may have varying strengths of lisinopril and hydrochlorothiazide, but they are usually within a similar range to maintain their therapeutic effect.\\\\n\\\\nIt is always recommended to consult with a healthcare professional or pharmacist for specific information on different tablets and their strengths to ensure proper dosing and effectiveness of the medication.\",\"The advised course of action for prescribing NUCYNTA\\\\u2122 to individuals with severe hepatic impairment would be to proceed with caution and carefully weigh the potential risks against the expected benefits. It is important to monitor these patients closely for any signs of adverse effects or drug interactions, as their impaired liver function may affect how the medication is metabolized and eliminated from the body. Additionally, it would be prudent to start at a lower dose and titrate up slowly, if necessary, while closely monitoring the patient&#x27;s response to treatment. Ultimately, the decision to prescribe NUCYNTA\\\\u2122 to individuals with severe hepatic impairment should be made on a case-by-case basis, taking into account the specific patient&#x27;s medical history, overall health status, and pain management needs, as well as consulting with a healthcare provider with experience in managing pain in this population.\",\"The primary pharmacological component responsible for the therapeutic effects of NUCYNTA is tapentadol, which is a centrally-acting synthetic opioid analgesic.\",\"The tablet containing 32 mg of Candesartan Cilexetil and 12.5 mg of Hydrochlorothiazide is typically pink and round in shape. This tablet is not the same as the tablet containing 25 mg of Hydrochlorothiazide, which is typically yellow and oval in shape.\",\"The four most frequently reported adverse reactions among multiple sclerosis patients taking tizanidine, based on inquiries by the researchers, are likely to be:\\\\n\\\\n1. Drowsiness\\\\n2. Fatigue\\\\n3. Dry mouth\\\\n4. Weakness\",\"I&#x27;m sorry, but as an AI, I do not have real-time access to specific product marketing information. I recommend contacting the manufacturer or brand of the product with the NDC:62559-662-90 item code to inquire about the precise date when marketing activities commenced for this particular product.\",\"The concurrent administration of ACE inhibitors and mTOR inhibitors can lead to an increased risk of developing angioedema due to their combined effects on the renin-angiotensin-aldosterone system. ACE inhibitors can increase levels of bradykinin, a potent vasodilator that can cause angioedema when levels are elevated. mTOR inhibitors, such as temsirolimus, sirolimus, or everolimus, can also increase bradykinin levels, further exacerbating the risk of angioedema when combined with ACE inhibitors.\\\\n\\\\nTo mitigate this risk, precautions that should be considered include monitoring patients closely for symptoms of angioedema, such as swelling of the face, lips, or throat, difficulty breathing, or difficulty swallowing. If angioedema is suspected, prompt discontinuation of the mTOR inhibitor and/or ACE inhibitor and immediate medical attention should be sought. Alternative medications that do not affect the renin-angiotensin-aldosterone system may need to be considered for the treatment of the underlying conditions for which these medications were prescribed. Additionally, patients should be educated about the signs and symptoms of angioedema and advised to seek medical attention if they experience any concerning symptoms.\",\"Some specific tablet combinations of lisinopril and hydrochlorothiazide for oral administration include:\\\\n\\\\n- Lisinopril 10 mg / Hydrochlorothiazide 12.5 mg\\\\n- Lisinopril 20 mg / Hydrochlorothiazide 12.5 mg\\\\n- Lisinopril 20 mg / Hydrochlorothiazide 25 mg\\\\n\\\\nThese combinations are commonly used for the treatment of hypertension and can vary based on the specific needs of the individual patient. It is important to consult with a healthcare provider to determine the appropriate dosage and combination for each patient.\",\"NUCYNTA 100MG is administered to patients orally, as mentioned in Document 24.\",\"Female patients of childbearing age who are on candesartan cilexetil and hydrochlorothiazide tablets should be informed that these medications are not recommended during pregnancy as they may cause harm to the developing fetus, particularly during the second and third trimesters. It is important for these patients to use effective contraception while taking these medications and to discuss alternative treatment options with their healthcare provider if they are planning to become pregnant or discover they are pregnant.\\\\n\\\\nIf a patient becomes pregnant while taking candesartan cilexetil and hydrochlorothiazide tablets, they should contact their healthcare provider immediately to discuss the potential risks to the fetus and to determine if alternative treatment options are necessary. It is important for patients to weigh the potential risks and benefits of continuing these medications during pregnancy and to follow their healthcare provider&#x27;s guidance closely.\",\"Hydrochlorothiazide, a commonly prescribed diuretic, has been associated with several ocular complications, including acute angle-closure glaucoma, myopia, and non-arteritic anterior ischemic optic neuropathy (NAION).\\\\n\\\\nAcute angle-closure glaucoma is a serious side effect of Hydrochlorothiazide that can occur shortly after starting the medication. Symptoms include sudden onset of severe eye pain, blurred vision, halos around lights, and nausea or vomiting.\\\\n\\\\nMyopia, or nearsightedness, has also been reported in patients taking Hydrochlorothiazide. This condition may manifest gradually, with symptoms such as difficulty seeing objects at a distance and eye strain.\\\\n\\\\nNon-arteritic anterior ischemic optic neuropathy (NAION) is a rare but serious complication that has been associated with Hydrochlorothiazide use. This condition causes sudden vision loss, often in one eye, and is typically painless. The exact time frame for the manifestation of NAION is not well-defined, but it is typically reported within weeks to months of starting Hydrochlorothiazide.\\\\n\\\\nIt is important to seek immediate medical attention if any of these ocular complications occur while taking Hydrochlorothiazide, as prompt intervention may help prevent permanent vision loss. Consulting with a healthcare provider before starting or discontinuing any medication is recommended to minimize potential side effects.\",\"When administering NUCYNTA\\\\u2122 to elderly patients, specific considerations and initial dosing precautions should be taken into account, especially in light of the potential for renal or hepatic impairments. \\\\n\\\\n1. Renal Impairments: Elderly patients are more likely to have decreased renal function, therefore, the dose of NUCYNTA\\\\u2122 should be adjusted according to the patient&#x27;s estimated creatinine clearance. Close monitoring of renal function is essential to ensure that the medication is being metabolized and eliminated properly.\\\\n\\\\n2. Hepatic Impairments: Elderly patients may also have reduced hepatic function, which can affect the metabolism and clearance of NUCYNTA\\\\u2122. Dosing adjustments may be necessary in patients with hepatic impairment to prevent adverse effects or toxicity. Liver function tests should be monitored regularly to assess the patient&#x27;s ability to metabolize the medication.\\\\n\\\\n3. Initial Dosing Precautions: When initiating NUCYNTA\\\\u2122 therapy in elderly patients, it is recommended to start with a lower initial dose and titrate carefully based on the patient&#x27;s response and tolerance. This gradual titration allows for better control of potential side effects and allows for the patient to adjust to the medication.\\\\n\\\\nOverall, it is important to consider the individual patient&#x27;s renal and hepatic function when prescribing NUCYNTA\\\\u2122 to elderly patients. Close monitoring and dose adjustments may be necessary to ensure the safe and effective use of the medication in this population.\",\"When monitoring patients on thiazide therapy, it is important to carefully observe for electrolyte imbalances such as hyponatremia, hypochloremic alkalosis, and hypokalemia. This is especially important in cases of excessive vomiting or when parenteral fluids are administered because these conditions can exacerbate the risk of electrolyte imbalances. Electrolyte imbalances can have serious consequences for the patient&#x27;s health and must be promptly identified and corrected to prevent complications.\",\"When using candesartan cilexetil and hydrochlorothiazide tablets in patients diagnosed with heart failure, there are potential risks related to renal function and electrolyte imbalances that need to be monitored and managed during the initial treatment period.\\\\n\\\\n1. Renal Function: Both candesartan cilexetil and hydrochlorothiazide can individually affect renal function. Candesartan can cause a decrease in renal function, particularly in patients with severe heart failure or those who are elderly. Hydrochlorothiazide can lead to electrolyte disturbances and dehydration, which can further impact renal function. Therefore, it is important to monitor renal function through regular blood tests, including serum creatinine levels, especially in patients with pre-existing renal impairment.\\\\n\\\\n2. Electrolyte Imbalances: Hydrochlorothiazide is a diuretic that can lead to electrolyte imbalances, such as hypokalemia (low potassium levels), hyponatremia (low sodium levels), and hypomagnesemia (low magnesium levels). These imbalances can potentially worsen heart failure symptoms and lead to adverse events. Monitoring electrolyte levels through regular blood tests is crucial during the initial treatment period. Additionally, patients should be advised on maintaining a diet rich in potassium and magnesium or may require supplementation under medical supervision.\\\\n\\\\nManagement during the initial treatment period should include close monitoring of renal function and electrolyte levels, particularly in high-risk patients. Dose adjustments may be necessary based on individual patient factors, and regular follow-up appointments should be scheduled to assess the patient&#x27;s response to treatment and any potential adverse effects. Education on the signs and symptoms of electrolyte imbalances should be provided to patients, and they should be advised to seek medical attention if they experience any concerning symptoms.\\\\n\\\\nOverall, in patients diagnosed with heart failure who are prescribed candesartan cilexetil and hydrochlorothiazide tablets, careful monitoring and proactive management of renal function and electrolyte imbalances are essential to ensure the safety and effectiveness of treatment.\",\"The primary components of ADEA GARGLE chewable tablets, as explicitly mentioned in the provided context, include the following ingredients:\\\\n\\\\n- Glycerin\\\\n- Fumaric acid\\\\n- Xylitol\\\\n- Peppermint menthol flavoring\\\\n- Magnesium stearate\\\\n\\\\nPotential allergens that may be present in these ingredients include:\\\\n\\\\n- Xylitol (may cause gastrointestinal upset or allergic reactions in some individuals)\\\\n- Peppermint menthol flavoring (may cause sensitivities or allergic reactions in some individuals)\",\"Tizanidine has a relatively low clearance rate, meaning it is cleared from the body at a slower rate compared to other medications. In elderly patients, who often have decreased renal and hepatic function, this slow clearance can lead to an accumulation of the medication in the body. This can result in an increased risk of side effects and toxicity from the drug.\\\\n\\\\nSome specific risks that elderly patients may face when taking Tizanidine include an increased likelihood of experiencing sedation, dizziness, and hypotension. These side effects can be more severe in elderly individuals due to age-related changes in metabolism and clearance of the medication. Additionally, elderly patients may be more sensitive to the effects of Tizanidine, increasing the risk of adverse reactions.\\\\n\\\\nTherefore, it is advised to exercise caution when prescribing Tizanidine to elderly patients and to carefully monitor their response to the medication. Dosing adjustments may be necessary to minimize the risk of side effects and toxicity in this population. Consulting with a healthcare provider and conducting regular follow-up assessments can help mitigate these risks and ensure the safe use of Tizanidine in elderly patients.\",\"Common side effects of lisinopril combined with hydrochlorothiazide that may lead to patients discontinuation of the medication include dizziness, lightheadedness, electrolyte imbalances, hypotension, and kidney dysfunction. These side effects can be particularly troublesome for some individuals.\\\\n\\\\nIn a study examining the discontinuation rates of lisinopril combined with hydrochlorothiazide, it was found that approximately 10-15% of patients experience adverse effects leading to discontinuation. Out of these patients, the most frequently cited reasons for stopping the medication were dizziness and hypotension.\\\\n\\\\nOverall, dizziness and hypotension were the primary side effects responsible for patients deciding to stop lisinopril combined with hydrochlorothiazide, with approximately 5-8% of patients experiencing these effects leading to discontinuation.\",\"Patients should take specific precautions when using NUCYNTA\\\\u2122 in relation to monoamine oxidase inhibitors (MAOIs) by avoiding concomitant use of NUCYNTA\\\\u2122 with MAOIs or within 14 days of discontinuing MAOIs. This is because the combination of NUCYNTA\\\\u2122 with MAOIs can result in serotonin syndrome, a potentially life-threatening condition characterized by agitation, hallucinations, coma, and death. Patients should also be cautious when using NUCYNTA\\\\u2122 with other serotonergic agents, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), as this can also increase the risk of serotonin syndrome.\\\\n\\\\nBefore starting any new medications while on NUCYNTA\\\\u2122, patients should consult with their healthcare provider to ensure that the new medication does not interact with NUCYNTA\\\\u2122. It is important to provide a complete list of all medications, including prescription, over-the-counter, and herbal supplements, to the healthcare provider to avoid potential drug interactions. Patients should also be aware of the signs and symptoms of serotonin syndrome and seek medical attention immediately if they experience any concerning symptoms while taking NUCYNTA\\\\u2122 and a new medication.\",\"If a patient on ACE inhibitors begins to exhibit symptoms such as jaundice or significantly elevated hepatic enzymes, it is important to take immediate action. The first step should be to discontinue the ACE inhibitors and consult with a healthcare provider. This may involve contacting the patient&#x27;s primary care physician, a specialist in hepatology or nephrology, or seeking care at an emergency department if the symptoms are severe.\\\\n\\\\nFollow-up actions may include conducting further testing to determine the cause of the symptoms, such as liver function tests, imaging studies, or a liver biopsy. It is important to monitor the patient closely for any worsening of symptoms and to ensure proper management of any underlying liver or kidney disease that may be contributing to the elevated enzymes. Depending on the severity of the symptoms and the underlying cause, additional treatments or interventions may be necessary to ensure the patient&#x27;s safety and well-being.\",\"The simultaneous use of tizanidine and fluvoxamine can lead to adverse effects due to the potential for drug interactions. Tizanidine is a muscle relaxant commonly used to treat muscle spasms, while fluvoxamine is an antidepressant primarily used to treat obsessive-compulsive disorder and other psychiatric conditions. When taken together, fluvoxamine can increase the levels of tizanidine in the body, leading to an increased risk of side effects such as drowsiness, dizziness, and impaired cognitive function. In severe cases, this drug interaction can result in respiratory depression, hypotension, and even potentially life-threatening complications.\\\\n\\\\nSpecific reactions that can be anticipated when tizanidine and fluvoxamine are used together include increased sedation, dizziness, weakness, and difficulty concentrating. Patients may also experience confusion, blurred vision, and impaired motor coordination. It is important for healthcare providers to monitor patients closely when these medications are used concurrently and adjust the dosages as needed to minimize the risk of adverse effects. In some cases, alternative medications or treatment options may need to be considered to avoid potential drug interactions and ensure patient safety.\",\"The lisinopril and hydrochlorothiazide tablet with NDC code 69097-968 contains 10 mg of lisinopril and 12.5 mg of hydrochlorothiazide as the active ingredients.\",\"ABALONE CRYSTALDOUBLE EX CC should be applied to the skin as a cream or lotion. When applying, make sure to cleanse the skin first and then apply a thin, even layer of the product to the face or desired area. Gently massage the product into the skin until fully absorbed. As ABALONE CRYSTALDOUBLE EX CC contains niacinamide and titanium dioxide, it is important to apply sunscreen on top if using during the daytime, as titanium dioxide is a physical sunscreen ingredient that helps protect the skin from the sun&#x27;s harmful rays.\"]],[\"reference_answer\",[\"Candesartan cilexetil and hydrochlorothiazide tablets are contraindicated in patients who are hypersensitive to candesartan, to hydrochlorothiazide or to other sulfonamide-derived drugs, in patients with anuria, and should not be co-administered with aliskiren in patients with diabetes.\",\"The most common adverse events reported by \\\\u226510% in any NUCYNTA\\\\u2122 dose group were nausea, dizziness, vomiting, and somnolence.\",\"The inactive ingredients are anhydrous dibasic calcium phosphate, mannitol, starch, corn, magnesium stearate, ferric oxide yellow, and ferric oxide red.\",\"Lisinopril 20 mg and Hydrochlorothiazide 25 mg\",\"NUCYNTA\\\\u2122 has not been studied in patients with severe hepatic impairment, therefore, use of NUCYNTA\\\\u2122 is not recommended in this population.\",\"The active ingredient in NUCYNTA\\\\u2122 is tapentadol.\",\"The tablet is yellow and oval (biconvex) in shape.\",\"The four most common adverse reactions reported are dry mouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness), and dizziness.\",\"The marketing start date for the product with item code NDC:62559-662-90 is 09/26/2018.\",\"Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\",\"Lisinopril and hydrochlorothiazide tablets are available in three combinations: 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.\",\"The route of administration for NUCYNTA 100MG is oral.\",\"Female patients of childbearing age should be told about the consequences of exposure to candesartan cilexetil and hydrochlorothiazide tablets during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.\",\"Hydrochlorothiazide can cause an idiosyncratic reaction resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation.\",\"Care should be taken when selecting an initial dose for elderly patients.\",\"Patients receiving thiazide therapy should be observed for clinical signs of fluid or electrolyte imbalance, namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\",\"In patients with heart failure, candesartan cilexetil and hydrochlorothiazide tablets may cause excessive hypotension, which may lead to oliguria, azotemia, and (rarely) with acute renal failure and death.\",\"The main ingredients in ADEA GARGLE chewable tablets are citric acid, sodium hydrogen carbonate, and xylitol.\",\"Tizanidine should be used with caution in elderly patients because clearance is decreased four-fold.\",\"The most common adverse effects leading to discontinuation are dizziness, cough, fatigue, and muscle cramps.\",\"Patients should be informed not to take NUCYNTA\\\\u2122 while using any drugs that inhibit monoamine oxidase. Patients should not start any new medications while taking NUCYNTA\\\\u2122 until they are assured by their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\",\"Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.\",\"Concomitant use of fluvoxamine and tizanidine is contraindicated due to changes in pharmacokinetics of tizanidine, resulting in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.\",\"The active ingredients are Lisinopril with a strength of 10 mg and Hydrochlorothiazide with a strength of 12.5 mg.\",\"TOPICAL\"]],[\"id\",[67,8,54,55,12,23,77,96,79,43,31,24,69,38,3,40,68,0,90,46,20,37,97,53,87]],[\"content\",[\"in myocardial infarction and cardiovascular mortality also have been seen regularly.\\\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\\\nhypertension can provide substantial benefit. \\\\nRelative risk reduction from blood pressure reduction is\\\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\\\nare at h...\",\"Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\\\nconsidered drug-related.\\\\nBased on data from nine Phase 2/3 studies that administered multiple...\",\"lisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-969\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS D...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-971\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n25 mg\\\\nInactive Ingredients\\\\nI...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"Store NUCYNTA\\\\u2122 at 59\\\\u00baF to 86\\\\u00baF (15\\\\u00baC to 30\\\\u00baC). Keep NUCYNTA\\\\u2122 tablets dry.\\\\nDispose of NUCYNTA\\\\u2122 tablets you no longer need.\\\\nKeep NUCYNTA\\\\u2122 in a safe place out of the reach of children.\\\\nGeneral information about NUCYNTA\\\\u2122\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\\\nuse NUCYNTA\\\\u2122 for a condition for which it was not prescribed. \\\\nDo not give NUCYNTA\\\\u2122 to other\\\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\\\u2122 could be harmful\\\\n...\",\"Flavor\\\\nImprint Code\\\\nACS\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-660-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type...\",\"multiple sclerosis (Study 1) \\\\n[see Clinical Studies ( \\\\n14\\\\n)] \\\\n, the patients were specifically\\\\nasked if they had experienced any of the four most common adverse reactions: dry\\\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\\\nthese reactions is summarized in \\\\nTable 2\\\\n. Other events were, in general, reported at a\\\\nrate of 2% or less.\\\\nTable 2: Single Dose, Placebo-Controlled Study -...\",\"ANI Pharmaceuticals, Inc.\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-662-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nLabeler - \\\\nANI Pharmaceuticals, Inc. \\\\n(145588013)\\\\n \\\\nRevised: 5/2020\",\"mTOR (mammalian target of rapamycin) inhibitors\\\\n \\\\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\\\n(see \\\\nWARNINGS\\\\n)\\\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\\\nrisk for angioedema. (see \\\\nWARNINGS\\\\n)\\\\nHydrochlorothiazide\\\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\\\nAlcohol, barbiturates, or nar...\",\"Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\\\nhydroxide solution.\\\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\\\nlisinopril and hydrochlorothiazide tabl...\",\"NUCYNTA 100MG PACKAGE LABEL\\\\n       \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\nNUCYNTA  \\\\ntapentadol hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN\\\\nPRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:16590-\\\\n863(NDC:50458-820)\\\\nRoute of Administration\\\\nORAL\\\\nDEA Schedule\\\\nCII\",\"considered if the intraocular pressure remains uncontrolled. \\\\nRisk factors for developing acute angle-\\\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\\\nHypersensitivity Reaction\\\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\\\nPRECAUTIONS\\\\nMetabolic Disturbances\\\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...\",\"rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\\\nLisinopril and Hydrochlorothiazide\\\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\\\nMaternal or fetotoxic effects were not seen in mice with the com...\",\"USE IN SPECIFIC POPULATIONS\\\\nLabor and delivery: \\\\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\\\nmothers have been taking NUCYNTA\\\\u2122, for respiratory depression. (\\\\n8.2\\\\n)\\\\nNursing mothers: should not breast-feed. (\\\\n8.3\\\\n)\\\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\\\n8.4\\\\n)\\\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\\\npatients with moder...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\\\n). \\\\nIn each of\\\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\\\ntimes the MRHD\\\\n in mouse, rats, and rabbit, respectively). \\\\nThere was no evidence of harm to the rat or\\\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\\\nThiazides cross ...\",\"ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\\\n \\\\nK2resource co., ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\\\ntartar formation, plaque removal, oral cleansing\\\\nKeep...\",\"Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\\\nfour-fold ( \\\\n8.5\\\\n)\\\\nSee 17 for PATIENT COUNSELING INFORMATION.\\\\nRevised: 9/2020\\\\nFULL PRESCRIBING INFORMATION: CONTENTS\\\\n*\\\\n1 INDICATIONS AND USAGE\\\\n2 DOSAGE AND ADMINISTRATION\\\\n2.1 Dosing Information\\\\n2.2 Dosing in Patients with Renal Impairment\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\n2.4 Drug Discontinuation\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Hypo...\",\"adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\\\nfatigue and muscle cramps.\\\\nAdverse experiences occurring in greater than one percent of patients treated with\\\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\\\n                                                                         Percent of Patients in\\\\nControlled Studies\\\\n   Lisinopril and\\\\nHydrochlorothiazide\\\\n   (n=930)\\\\n   Incidence\\\\n(discontinuation)\\\\n   Placebo\\\\n   (n=207)\\\\n...\",\"Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\\\u2122 \\\\n[see \\\\nUse in\\\\nSpecific Populations (8.3)\\\\n]\\\\n.\\\\n17.6 Monoamine Oxidase Inhibitors\\\\nPatients should be informed not to take NUCYNTA\\\\u2122 while using any drugs that inhibit monoamine\\\\noxidase. Patients should not start any new medications while taking NUCYNTA\\\\u2122 until they are assured\\\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\\\n17.7 Seizures\\\\nPatients should be informed that NU...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"ABALONE CRYSTALDOUBLE EX CC  \\\\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:60611-0008\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\"]],[\"color\",[\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#0a980a\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#ba0e0e\",\"#0a980a\",\"#0a980a\",\"#ba0e0e\",\"#ba0e0e\",\"#0a980a\",\"#ba0e0e\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#0a980a\",\"#ba0e0e\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2124\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2125\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2120\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2121\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2122\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2138\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2129\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2130\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2131\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[98],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[98],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2139\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2140\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2135\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2136\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2137\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p2092\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p2107\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p2108\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p2109\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p2110\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p2115\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p2116\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p2083\",\"attributes\":{\"renderers\":[{\"id\":\"p2123\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2102\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2103\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2104\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2105\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2097\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2098\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2099\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2100\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2101\",\"attributes\":{\"axis\":{\"id\":\"p2097\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2106\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p2102\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p2126\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2127\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"False\"},\"renderers\":[{\"id\":\"p2123\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2128\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p2123\"}],\"index\":5}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p2144\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2141\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2142\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2143\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"mhwuwSnyYsE=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"muiTQIgRqEA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Labeling\",\"Tizanidine Hydrochloride\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"bc141e53-d878-4bcb-a309-697aa228119c\",\"roots\":{\"p2149\":\"e22ff370-cf3c-4bbe-a0b4-15fe6b3328b6\"},\"root_ids\":[\"p2149\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"e22ff370-cf3c-4bbe-a0b4-15fe6b3328b6\" data-root-id=\"p2149\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x702178843a40>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_chain_gpt_3_5, testset=testset_gpt4o, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "id": "2d4f1ec6",
   "metadata": {},
   "outputs": [],
   "source": [
    "#report.to_html(\"report-gpt-3-5-100.html\")\n",
    "report.to_html(f\"report-gpt-3-5_10.html\")\n",
    "dfc = pd.DataFrame(report.component_scores())\n",
    "dfc.to_csv(f\"component_scores_10.csv\", index=False)\n",
    "dfr = report.to_pandas()\n",
    "dfr.to_excel(f\"all_results_10.xlsx\", index=False)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "f00090b1",
   "metadata": {},
   "source": [
    "## Asi Mini with query translations"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e70f11c8",
   "metadata": {},
   "source": [
    "#### Multi query"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "a954b370",
   "metadata": {},
   "outputs": [],
   "source": [
    "template = \"\"\"You are an AI language model assistant. Your task is to generate five \n",
    "different versions of the given user question to retrieve relevant documents from a vector \n",
    "database. By generating multiple perspectives on the user question, your goal is to help\n",
    "the user overcome some of the limitations of the distance-based similarity search. \n",
    "Provide these alternative questions separated by newlines. Original question: {question}\n",
    "\"\"\"\n",
    "\n",
    "prompt_perspectives = ChatPromptTemplate.from_template(template)\n",
    "\n",
    "generate_queries = (\n",
    "    prompt_perspectives \n",
    "    | call_asi_one \n",
    "    | StrOutputParser() \n",
    "    | (lambda x: x.split(\"\\n\"))\n",
    ")\n",
    "\n",
    "def get_unique_union(documents: list[list]):\n",
    "    flattened_docs = [dumps(doc) for sublist in documents for doc in sublist]\n",
    "    unique_docs = list(set(flattened_docs))\n",
    "    return [loads(doc) for doc in unique_docs]\n",
    "\n",
    "retrieval_chain = generate_queries | retriever.map() | get_unique_union\n",
    "\n",
    "chain_multiquery = (\n",
    "    {\"context\": retrieval_chain, \n",
    "     \"question\": itemgetter(\"question\")} \n",
    "    | prompt_rag\n",
    "    | call_asi_one\n",
    "    | StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "3063aa14",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_chain_multiquery(question, history=None):\n",
    "    return chain_multiquery.invoke({\"question\": question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "cacb69b3",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "33adf83ebf444fbdb7c4b742fbe8660a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/tmp/ipykernel_11544/3778061180.py:20: LangChainBetaWarning: The function `loads` is in beta. It is actively being worked on, so the API may change.\n",
      "  return [loads(doc) for doc in unique_docs]\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ed032468e2334b0b98b95ed81708ecdb",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"c26fbc7c-ebc5-4660-8fae-05fa75cff1cd\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"c26fbc7c-ebc5-4660-8fae-05fa75cff1cd\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"c26fbc7c-ebc5-4660-8fae-05fa75cff1cd\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-06-22 08:58:22,538 pid:11544 MainThread giskard.rag  INFO     Finding topics in the knowledge base.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/deni/Desktop/disi/.venv/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-06-22 08:58:38,581 pid:11544 MainThread giskard.rag  INFO     Found 6 topics in the knowledge base.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-red \">\n",
       "                        0.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=0.0 class=\" progress-red \">0.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">0%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Based on the provided scores, it is evident that the RAG system is currently performing poorly on all question types and topics. The most important action to take is to thoroughly review and optimize the Retriever component to ensure better document retrieval accuracy across different topics and question types.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"47e8a5ea-5002-4e18-969b-14d708358e29\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1192\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1194\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1201\",\"attributes\":{\"factors\":[\"ACE Inhibitor Side Effects\",\"Candesartan Cilexetil\",\"NUCYNTA\\\\u2122 Medication\",\"Others\",\"Pharmaceuticals\",\"Povidone Iodine Solution\",\"Tizanidine Hydrochloride\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1202\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1203\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1199\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1221\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1189\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1190\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1191\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA=\"},\"shape\":[7],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"ACE Inhibitor Side Effects\",\"Candesartan Cilexetil\",\"NUCYNTA\\\\u2122 Medication\",\"Others\",\"Pharmaceuticals\",\"Povidone Iodine Solution\",\"Tizanidine Hydrochloride\"]],[\"colors\",[\"#a50026\",\"#a50026\",\"#a50026\",\"#a50026\",\"#a50026\",\"#a50026\",\"#a50026\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1222\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1223\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1218\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1219\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1220\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1230\",\"attributes\":{\"data_source\":{\"id\":\"p1189\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1231\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1232\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1227\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1228\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1229\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1240\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1234\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1235\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1236\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1241\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1242\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1237\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1238\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1239\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1200\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1214\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1209\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1210\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1211\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1212\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1204\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1205\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1206\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1207\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1208\",\"attributes\":{\"axis\":{\"id\":\"p1204\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1213\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1209\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p1233\",\"attributes\":{\"location\":0.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1243\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1244\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p1240\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"47e8a5ea-5002-4e18-969b-14d708358e29\",\"roots\":{\"p1192\":\"e041a005-372b-42be-acc3-5cee05abbb2f\"},\"root_ids\":[\"p1192\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"e041a005-372b-42be-acc3-5cee05abbb2f\" data-root-id=\"p1192\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"004a8147-5b27-40bd-b264-d8e8610e5341\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p1123\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1054\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1004\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1013\",\"attributes\":{\"start\":9.502403783798218,\"end\":23.160186195373534}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1014\",\"attributes\":{\"start\":6.291248083114624,\"end\":14.863864183425903}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1015\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1016\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1011\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1044\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1001\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1002\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1003\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Topical Medications\",\"Topical Medications\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"Others\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"NUCYNTA\\\\u2122 Pain Medication\",\"Others\",\"Others\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"ACE Inhibitors Side Effects\",\"Others\",\"ACE Inhibitors Side Effects\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"Topical Medications\",\"Others\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Others\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Blood Pressure Medication\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Tizanidine Overdose\",\"Topical Medications\",\"Others\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\",\"Topical Medications\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118]],[\"content\",[\"ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\\\n \\\\nK2resource co., ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\\\ntartar formation, plaque removal, oral cleansing\\\\nKeep...\",\"K2resource co., ltd.\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:72191-0100\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nSODIUM BICARBONATE\\\\n (UNII: 8MDF5V39QO) \\\\n(SODIUM CATION -\\\\nUNII:LYR4M0NH37)\\\\nSODIUM\\\\nBICARBONATE\\\\n36.2 g  in 100 mg\\\\nXYLITOL\\\\n (UNII: VCQ006KQ1E) \\\\n(XYLITOL - UNII:VCQ006KQ1E)\\\\nXYLITOL\\\\n5 g  in 100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMENTHOL\\\\n (UNII: L7T10EIP3A)\\\\n \\\\nProduct Characteristics\\\\nCo...\",\"NUCYNTA - tapentadol hydrochloride tablet, film coated \\\\n \\\\nStat Rx USA\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use NUCYNTA\\\\u2122 safely and effectively. See full\\\\nprescribing information for NUCYNTA\\\\u2122.\\\\n \\\\nNUCYNTA\\\\u2122 (tapentadol) immediate-release oral tablets    C-II\\\\nInitial U.S. Approval: 2008\\\\nRECENT MAJOR CHANGES\\\\nWarnings and Precautions (\\\\n5.4\\\\n)\\\\nJune 2009\\\\nINDICATIONS AND USAGE\\\\nNUCYNTA\\\\u2122 is an opioid analgesic indicated for the relief o...\",\"USE IN SPECIFIC POPULATIONS\\\\nLabor and delivery: \\\\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\\\nmothers have been taking NUCYNTA\\\\u2122, for respiratory depression. (\\\\n8.2\\\\n)\\\\nNursing mothers: should not breast-feed. (\\\\n8.3\\\\n)\\\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\\\n8.4\\\\n)\\\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\\\npatients with moder...\",\"8.7 Hepatic Impairment\\\\n9 DRUG ABUSE AND DEPENDENCE\\\\n9.1 Controlled Substance\\\\n9.2 Abuse\\\\n9.3 Dependence\\\\n10 OVERDOSAGE\\\\n10.1 Human Experience\\\\n10.2 Management of Overdose\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n13 NON-CLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\n14 CLINICAL STUDIES\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\n14.2 End-Stage Degenerative Joint Disea...\",\"Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\\\nbeen studied and are not recommended.\\\\nNUCYNTA\\\\u2122 may be given with or without food \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n].\\\\n2.1 Renal Impairment\\\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\\\n[see \\\\nClinical\\\\nPharmacology (12.3)\\\\n]\\\\n.\\\\nNUCYNTA\\\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\\\nis not recommended.\\\\n2.2 Hepatic Im...\",\"which may result in adverse cardiovascular events \\\\n[see \\\\nDrug Interactions (7.4)\\\\n]\\\\n.\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Respiratory Depression\\\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\\\nsignificantly decrease pulmonary ventilation.\\\\nNUCYNTA\\\\u2122 should be ...\",\"5.5 Driving and Operating Machinery\\\\nPatients should be cautioned that NUCYNTA\\\\u2122 may impair the mental and/or physical abilities required\\\\nfor the performance of potentially hazardous tasks such as driving a car or operating machinery. This is\\\\nto be expected especially at the beginning of treatment, at any change of dosage as well as in\\\\ncombination with alcohol or tranquilizers\\\\n [see \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\n5.6 Interactions with Alcohol and Drugs of Abuse\\\\nDue to its mu-opioid agonist activity,...\",\"Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\\\nconsidered drug-related.\\\\nBased on data from nine Phase 2/3 studies that administered multiple...\",\"*\\\\nInfections and infestations\\\\n  Nasopharyngitis\\\\n1\\\\n&lt;1\\\\n  Upper respiratory tract infection\\\\n1\\\\n&lt;1\\\\n  Urinary tract infection\\\\n1\\\\n&lt;1\\\\nMetabolism and nutrition disorders\\\\n  Decreased appetite\\\\n2\\\\n0\\\\nMusculoskeletal and connective tissue\\\\ndisorders\\\\n  Arthralgia\\\\n1\\\\n&lt;1\\\\nNervous system disorders\\\\n  Dizziness\\\\n24\\\\n8\\\\n  Somnolence\\\\n15\\\\n3\\\\n  Tremor\\\\n1\\\\n&lt;1\\\\n  Lethargy\\\\n1\\\\n&lt;1\\\\nPsychiatric disorders\\\\n  Insomnia\\\\n2\\\\n&lt;1\\\\n  Confusional state\\\\n1\\\\n0\\\\n  Abnormal dreams\\\\n1\\\\n&lt;1\\\\n  Anxiety\\\\n1\\\\n&lt;1\\\\nSkin and subcutaneous tissue disorders\\\\n  Pruritus\\\\n5\\\\n1\\\\n  Hyp...\",\"Psychiatric disorders:\\\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\\\nabnormal\\\\nRenal and urinary disorders:\\\\n urinary hesitation, pollakiuria\\\\nRespiratory, thoracic and mediastinal disorders: \\\\noxygen saturation decreased, cough, dyspnea,\\\\nrespiratory depression\\\\nSkin and subcutaneous tissue disorders: \\\\nurticaria\\\\nVascular disorders:\\\\n blood pressure decreased\\\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\\\nNUCYNTA\\\\u2122,...\",\"Pregnancy Category C.\\\\nTapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous\\\\nand subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was\\\\nadministered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day\\\\n[producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of\\\\n700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic eff...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and\\\\nproper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid\\\\nagonist properties.\\\\nInfants born to mothers physically dependent on opioids will also be physically dependent and may\\\\nexhibit respiratory difficulties and withdrawal symptoms \\\\n[see \\\\nWarnings and Precautions (5.1)\\\\n]\\\\n. Use of\\\\nNUCYNTA\\\\u2122 in this population has not been characterized. As NUCYNTA\\\\u2122 h...\",\"intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\\\nshould be taken to secure the airway.\\\\n11 DESCRIPTION\\\\nNUCYNTA\\\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\\\nThe chemical name is 3-[(1\\\\nR\\\\n,2\\\\nR\\\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\\\nmonohydrochloride. The structural formula is:\\\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\\\nH\\\\nNO\\\\u00b7HCl. The\\\\nn-octanol:water pa...\",\"extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\\\naround 1.25 hours after dosing.\\\\nDose-proportional increases in the C\\\\n and AUC values of tapentadol have been observed over the 50\\\\nto 150 mg dose range.\\\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\\\nglucuronide, which are primarily determined by the do...\",\"Pharmacokinetic Drug Interactions\\\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\\\nconsidered clinically relevant and no change in dose is required.\\\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\\\nac...\",\"14 CLINICAL STUDIES\\\\nThe efficacy and safety of NUCYNTA\\\\u2122 in the treatment of moderate to severe acute pain has been\\\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\\\u2122...\",\"50% or greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus\\\\nplacebo.\\\\n14.2 End-Stage Degenerative Joint Disease\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\\\u2122 given every 4 to 6 hours during\\\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\\\nend stage degenerative joint disease of the hip or knee, defined...\",\"The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\\\nor greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus placebo.\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nNUCYNTA\\\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\\\nbiconvex-shaped.\\\\n50 mg tablets are yellow and debossed with \\\\\"O-M\\\\\" on one side and \\\\\"50\\\\\" on the other side, and are\\\\navailable in bottles of 100 (NDC 50458-820-04) a...\",\"Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\\\u2122 \\\\n[see \\\\nUse in\\\\nSpecific Populations (8.3)\\\\n]\\\\n.\\\\n17.6 Monoamine Oxidase Inhibitors\\\\nPatients should be informed not to take NUCYNTA\\\\u2122 while using any drugs that inhibit monoamine\\\\noxidase. Patients should not start any new medications while taking NUCYNTA\\\\u2122 until they are assured\\\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\\\n17.7 Seizures\\\\nPatients should be informed that NU...\",\"you get a new prescription. There may be new information. This Medication Guide does not take\\\\nthe place of talking to your doctor about your medical condition or your treatment. Talk to your\\\\ndoctor if you have any questions.\\\\nWhat is the most important information I should know about NUCYNTA\\\\u2122?\\\\nNUCYNTA\\\\u2122 is a tablet that contains tapentadol, a strong medicine that is a pain medicine.\\\\nUse NUCYNTA\\\\u2122 exactly how your doctor tells you to. Do not use NUCYNTA\\\\u2122 if it has not been\\\\nprescribed for you.\\\\nYou sh...\",\"Do not change the dose of NUCYNTA\\\\u2122 unless your doctor tells you to. \\\\nYour doctor may\\\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\\\u2122 more often\\\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\\\u2122.\\\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\\\u2122 to help lessen\\\\nwithdrawal symptoms.\\\\nNUCYNTA\\\\u2122 can be taken with or without food.\\\\nWhat should I avoid while taking NUCYNTA\\\\u2122?\\\\nDo not drive, operate machinery, ...\",\"Store NUCYNTA\\\\u2122 at 59\\\\u00baF to 86\\\\u00baF (15\\\\u00baC to 30\\\\u00baC). Keep NUCYNTA\\\\u2122 tablets dry.\\\\nDispose of NUCYNTA\\\\u2122 tablets you no longer need.\\\\nKeep NUCYNTA\\\\u2122 in a safe place out of the reach of children.\\\\nGeneral information about NUCYNTA\\\\u2122\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\\\nuse NUCYNTA\\\\u2122 for a condition for which it was not prescribed. \\\\nDo not give NUCYNTA\\\\u2122 to other\\\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\\\u2122 could be harmful\\\\n...\",\"NUCYNTA 100MG PACKAGE LABEL\\\\n       \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\nNUCYNTA  \\\\ntapentadol hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN\\\\nPRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:16590-\\\\n863(NDC:50458-820)\\\\nRoute of Administration\\\\nORAL\\\\nDEA Schedule\\\\nCII\",\"Active Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n50 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII: 15FIX9V2JP)\\\\n...\",\"Stat Rx USA\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII:...\",\"GRX DYNE - povidone iodine solution \\\\n \\\\nGeritrex Corp.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nGRx Dyne Solution\\\\nDrug Facts\\\\nActive Ingredient:                      Purpose\\\\nPovidone Iodine USP, 10% w/v  Antiseptic\\\\n(equivalent to 1% titratable Iodine)\\\\nUses\\\\nFirst aid antiseptic to help the risk of infection in \\\\nminor cuts, scra...\",\"Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\\\nkeep out of reach of children. If swallowed get medical help \\\\nor contact a Poison Control Center right away.\\\\nEnter section text here\\\\nGRX DYNE  \\\\npovidone iodine solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:54162-269\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85...\",\"Geritrex Corp.\\\\nCITRIC ACID MONOHYDRATE\\\\n (UNII: 2968PHW8QP)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nSODIUM HYDROXIDE\\\\n (UNII: 55X04QC32I)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:54162-269-16\\\\n472 mL in 1 BOTTLE, PLASTIC\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOTC monograph not final\\\\npart333A\\\\n05/16/2012\\\\nLabeler - \\\\n...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE- lisinopril and hydrochlorothiazide\\\\ntablets tablet \\\\n \\\\nCipla USA Inc.\\\\n----------\\\\nLisinopril and Hydrochlorothiazide Tablets, USP\\\\nRx Only\\\\nWARNING: FETAL TOXICITY\\\\nSee full prescribing information for complete boxed warning.\\\\nWhen pregnancy is detected, discontinue lisinopril and\\\\nhydrochlorothiazide tablets as soon as possible.\\\\nDrugs that act directly on the renin-angiotensin system can cause\\\\ninjury and death to the developing fetus. See \\\\nWarnings: Fetal Toxicity\\\\n.\\\\n...\",\"Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\\\nhydroxide solution.\\\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\\\nlisinopril and hydrochlorothiazide tabl...\",\"Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\\\nadministration of the separate entities.\\\\nLisinopril\\\\nMechanism of Action\\\\n \\\\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...\",\"state is prolonged. Older patients, on average, have (approximately doubled) higher\\\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\\\npatients (see \\\\nDOSAGE AND ADMINISTRATION\\\\n). In a multiple dose pharmacokinetic study\\\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\\\nhe...\",\"accompanied by some loss of potassium and bicarbonate.\\\\nAfter oral use diuresis begins within two hours, peaks in about four hours and lasts\\\\nabout 6 to 12 hours.\\\\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When\\\\nplasma levels have been followed for at least 24 hours, the plasma half-life has been\\\\nobserved to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is\\\\neliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but...\",\"the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\\\nsimilar risk (See \\\\nWARNINGS\\\\n).\\\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\\\nthan in nonblack patients (see \\\\nWARNIN...\",\"Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of\\\\nrapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin\\\\ninhibitor may be at increased risk for angioedema (see \\\\nPRECAUTIONS\\\\n).\\\\nIntestinal Angioedema:\\\\n Intestinal angioedema has been reported in patients treated\\\\nwith ACE inhibitors. These patients presented with abdominal pain (with or without\\\\nnausea or vomiting); in some cases there was no prior history of facial angioedema and\\\\nC-1...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\\\nLisinopril and Hydrochlorothiazide\\\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\\\nMaternal or fetotoxic effects were not seen in mice with the com...\",\"Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\\\nInteractions, Lisinopril and Hydrochlorothiazide).\\\\nPRECAUTIONS\\\\nGeneral\\\\nLisinopril\\\\n \\\\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\\\n As with all vasodilators, lisinopril\\\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\\\nventricle.\\\\nImpaired Renal Function:\\\\n As a consequence of inhibiting the renin-angiotensin-\\\\naldosterone system, changes in renal function may be anticipated in suscept...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"therapy.\\\\nInformation for Patients\\\\nAngioedema:\\\\n Angioedema, including laryngeal edema may occur at any time during\\\\ntreatment with angiotensin-converting enzyme inhibitors, including lisinopril and\\\\nhydrochlorothiazide. Patients should be so advised and told to report immediately any\\\\nsigns or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips,\\\\ntongue, difficulty in swallowing or breathing) and to take no more drug until they have\\\\nconsulted with the prescribing physician.\\\\nSymp...\",\"DOSAGE AND ADMINISTRATION\\\\n)\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\\\nInhibitors (COX-2 Inhibitors):\\\\n \\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\\\nfunction, including possible acute renal failure. These effects are usually reversible.\\\\nMonitor ...\",\"mTOR (mammalian target of rapamycin) inhibitors\\\\n \\\\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\\\n(see \\\\nWARNINGS\\\\n)\\\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\\\nrisk for angioedema. (see \\\\nWARNINGS\\\\n)\\\\nHydrochlorothiazide\\\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\\\nAlcohol, barbiturates, or nar...\",\"in vitro\\\\n alkaline elution rat hepatocyte assay. In addition, it did not produce increases in\\\\nchromosomal aberrations in an \\\\nin vitro\\\\n test in Chinese hamster ovary cells or in an \\\\nin\\\\nvivo\\\\n study in mouse bone marrow.\\\\nLisinopril\\\\n \\\\nThere was no evidence of a tumorigenic effect when lisinopril was administered for 105\\\\nweeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the\\\\nmaximum daily human dose, based on body weight and body surface area,\\\\nrespectively). There was no ...\",\"Nursing Mothers\\\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\\\nrats contains radioactivity following administration of \\\\nC lisinopril. In another study,\\\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\\\nwhether to discontinue nursing and/or disco...\",\"adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\\\nfatigue and muscle cramps.\\\\nAdverse experiences occurring in greater than one percent of patients treated with\\\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\\\n                                                                         Percent of Patients in\\\\nControlled Studies\\\\n   Lisinopril and\\\\nHydrochlorothiazide\\\\n   (n=930)\\\\n   Incidence\\\\n(discontinuation)\\\\n   Placebo\\\\n   (n=207)\\\\n...\",\"In rare cases, intestinal angioedema has been reported in post marketing experience.\\\\nHypotension:\\\\n In clinical trials, adverse effects relating to hypotension occurred as\\\\nfollows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects\\\\n(3.2%). In addition syncope occurred in 0.8% of patients (See \\\\nWARNINGS\\\\n).\\\\nCough:\\\\n See \\\\nPRECAUTIONS - Cough\\\\n.\\\\nClinical Laboratory Test Findings Serum Electrolytes:\\\\n (See \\\\nPRECAUTIONS\\\\n).\\\\nCreatinine, Blood Urea Nitrogen:\\\\n Minor reversible incre...\",\"hallucinations; \\\\nRespiratory:\\\\n Malignant lung neoplasms, hemoptysis, pulmonary edema,\\\\npulmonary infiltrates, bronchospasm, asthma, pleural effusion, pneumonia, eosinophilic\\\\npneumonitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis,\\\\npharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; \\\\nSkin:\\\\n Urticaria, alopecia,\\\\nherpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema,\\\\npsoriasis, rare cases of other severe skin reactions, includin...\",\"Lisinopril\\\\n \\\\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\\\nnormal saline solution.\\\\nLisinopril can be removed by hemodialysis (see \\\\nWARNINGS, Anaphylactoid Reaction\\\\nDuring Membrane Exposure\\\\n).\\\\nHydrochlorothiazide\\\\n \\\\nOral administration of a single oral dose of 10 g/kg to mice and rats w...\",\"possible, be discontinued for two to three days before beginning therapy with lisinopril\\\\nto reduce the likelihood of hypotension (See \\\\nWARNINGS\\\\n). If the patient\\\\u2019s blood pressure\\\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\\\nfor at least an additional hour (See \\\\nWARNINGS\\\\n and \\\\nPRECAUTIONS\\\\n...\",\"Protect from excessive light and humidity.\\\\n*AN69 is a registered trademark of Hospal Ltd.\\\\nManufactured by:\\\\nInvaGen Pharmaceuticals, Inc.\\\\n(a subsidiary of Cipla Ltd.)\\\\nHauppauge, NY 11788\\\\nManufactured for:\\\\nCipla USA, Inc.\\\\n10 Independence Boulevard, Suite 300\\\\nWarren, NJ 07059\\\\nRevised: 10/2021\\\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\\\u2013 10 mg/12.5 mg\\\\nNDC 69097-968-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n10 mg/12.5 mg\\\\n100 Tablets\\\\nCipla\\\\nNDC 69097-969-07             ...\",\"Cipla\\\\nNDC 69097-971-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n20 mg/25 mg\\\\n100 Tablets\\\\nCipla\\\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"lisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-969\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS D...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-971\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n25 mg\\\\nInactive Ingredients\\\\nI...\",\"Cipla USA Inc.\\\\nLabeler - \\\\nCipla USA Inc. \\\\n(078719707)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen\\\\nPharmaceuticals, Inc\\\\n165104469\\\\nanalysis(69097-968, 69097-969, 69097-971) , manufacture(69097-968,\\\\n69097-969, 69097-971)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen Pharmaceuticals, Inc\\\\n080334903\\\\npack(69097-968, 69097-969, 69097-971)\\\\n \\\\nRevised: 11/2021\",\"ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and\\\\nphenylephrine hydrochloride tablet, coated \\\\n \\\\nMARC GLASSMAN, INC.\\\\n----------\\\\n1128B-MAR-2022-1005\\\\nDrug Facts\\\\nActive ingredients \\\\n(in each caplet)\\\\nPurpose\\\\nAcetaminophen 325 mg\\\\nPain reliever\\\\nChlorpheniramine maleate\\\\n2 mg\\\\nAntihistamine\\\\nPhenylephrine HCl 5 mg\\\\nNasal decongestant\\\\nUses\\\\ntemporarily relieves these symptoms of hay fever or other upper respiratory\\\\nallergies:\\\\nheadache\\\\nsinus congestion and pressure\\\\nnasal congestion\\\\nrunny nose...\",\"If a skin reaction occurs, stop use and seek medical help right away.\\\\nDo not use\\\\nwith any other drug containing acetaminophen (prescription or nonprescription). If\\\\nyou are not sure whether a drug contains acetaminophen, ask a doctor or\\\\npharmacist.\\\\nif you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain\\\\ndrugs for depression, psychiatric or emotional conditions, or Parkinson&#x27;s disease), or\\\\nfor 2 weeks after stopping the MAOI drug. If you do not know if your prescription\\\\ndr...\",\"800-222-1222). Quick medical attention is critical for adults as well as for children even if\\\\nyou do not notice any signs or symptoms.\\\\nDirections\\\\ndo not take more than directed (see \\\\noverdose warning\\\\n)\\\\nadults and\\\\nchildren 12\\\\nyears and over\\\\ntake 2 caplets every 4 hours\\\\nswallow whole; do not crush,\\\\nchew, or dissolve\\\\ndo not take more than 10 caplets\\\\nin 24 hours\\\\nchildren under \\\\n12 years\\\\nask a doctor\\\\nOther information\\\\nstore between 20\\\\u00b0-25\\\\u00b0C (68\\\\u00b0-77\\\\u00b0F) in a dry place\\\\nretain carton for complete product...\",\"ALLERGY MULTI SYMPTOM  \\\\nacetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:68998-228\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCHLORPHENIRAMINE MALEATE\\\\n (UNII: V1Q0O9OJ9Z) \\\\n(CHLORPHENIRAMINE -\\\\nUNII:3U6IO1965U)\\\\nCHLORPHENIRAMINE\\\\nMALEATE\\\\n2 mg\\\\nPHENYLEPHRINE HYDROCHLORIDE\\\\n (UNII: 04JA59TNSJ) \\\\n(PHENYLEPHRINE -\\\\nUNII:1WS297W6MV)\\\\nPHENYLE...\",\"MARC GLASSMAN, INC.\\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nFERRIC OXIDE YELLOW\\\\n (UNII: EX438O2MRT)\\\\n \\\\nMAGNESIUM STEARATE\\\\n (UNII: 70097M6I30)\\\\n \\\\nCROSPOVIDONE\\\\n (UNII: 2S7830E561)\\\\n \\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\\\n (UNII: 3WJQ0SDW1A)\\\\n \\\\nPOLYVINYL ALCOHOL, UNSPECIFIED\\\\n (UNII: 532B59J990)\\\\n \\\\nPOVIDONE, UNSPECIFIED\\\\n (UNII: FZ989GH94E)\\\\n \\\\nSTARCH, CORN\\\\n (UNII: O8232NY3SJ)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nSTEA...\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and\\\\nhydrochlorothiazide tablet \\\\n \\\\nANI Pharmaceuticals, Inc.\\\\n----------\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\nWARNING: \\\\nFETAL TOXICITY\\\\n\\\\u2022\\\\n\\\\u2022\\\\nDESCRIPTION\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP combine an angiotensin II receptor (type\\\\nAT\\\\n) antagonist and a diuretic, hydrochlorothiazide.\\\\nCandesartan cilexetil, a nonpeptide, is chemically described as (\\\\u00b1)-1-Hydroxyethyl 2-ethoxy-1-[\\\\np\\\\n-(\\\\no\\\\n-\\\\n1\\\\nH\\\\n...\",\"Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of\\\\n297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet\\\\nstrengths of candesartan cilexetil and hydrochlorothiazide.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil\\\\nand 12.5 mg or 25 mg of hydrochloroth...\",\"The mechanism of the antihypertensive effect of thiazides is unknown.\\\\nPharmacokinetics\\\\nGeneral\\\\nCandesartan Cilexetil\\\\nCandesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from\\\\nthe gastrointestinal tract to candesartan, a selective AT\\\\nsubtype angiotensin II receptor antagonist.\\\\nCandesartan is mainly excreted unchanged in urine and feces (via bile). \\\\nIt undergoes minor hepatic\\\\nmetabolism by O-deethylation to an inactive metabolite. \\\\nThe elimination half...\",\"Geriatric\\\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\\\u2265 65 years). \\\\nThe plasma\\\\nconcentration of candesartan was higher in the elderly (C\\\\n was approximately 50% higher, and AUC\\\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\\\nThe\\\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\\\nNo initia...\",\"plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\\\nadministered to hypertensive patients. \\\\nIn spite of the effect of candesartan cilexetil on aldosterone\\\\nsecretion, very little effect on serum potassium was observed.\\\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\\\nIn a\\\\n12-week study of 161 patients with n...\",\"in myocardial infarction and cardiovascular mortality also have been seen regularly.\\\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\\\nhypertension can provide substantial benefit. \\\\nRelative risk reduction from blood pressure reduction is\\\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\\\nare at h...\",\"candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\\\n). \\\\nIn each of\\\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\\\ntimes the MRHD\\\\n in mouse, rats, and rabbit, respectively). \\\\nThere was no evidence of harm to the rat or\\\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\\\nThiazides cross ...\",\"considered if the intraocular pressure remains uncontrolled. \\\\nRisk factors for developing acute angle-\\\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\\\nHypersensitivity Reaction\\\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\\\nPRECAUTIONS\\\\nMetabolic Disturbances\\\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...\",\"Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\\\npossible ac...\",\"Cytotoxic products \\\\u2013 Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.\\\\ncyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.\\\\nCyclosporine \\\\u2212 Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and\\\\ngout-type complications.\\\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\\\nNo carcinogenicity studies have been conducted with the combination of candesartan cilexetil and\\\\nhydrochlorothiazide. \\\\nThere was no evidence of c...\",\"Neonates with a history of in utero exposure to candesartan cilexetil and hydrochlorothiazide tablets:\\\\nIf oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.\\\\nExchange transfusions or dialysis may be required as a means of reversing hypotension and/or\\\\nsubstituting for disordered renal function.\\\\nSafety and effectiveness in pediatric patients have not been established.\\\\nADVERSE REACTIONS\\\\nCandesartan Cilexetil and Hydrochlorothiazide\\\\nCandesartan cile...\",\"melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\\\nfor white patients taking a cumulative dose of \\\\u226550,000 mg the risk increase was approximately 1\\\\nadditional SCC case for every 6,700 patients per year.\\\\nSkin:\\\\n \\\\nerythema multiforme including S...\",\"Dose Titration by Clinical Effect: \\\\nA patient whose blood pressure is not controlled on 25 mg of\\\\nhydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and\\\\nhydrochlorothiazide tablets 16 mg/12.5 mg. \\\\nA patient whose blood pressure is controlled on 25 mg of\\\\nhydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or\\\\nincremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16\\\\nmg/12.5 mg and ser...\",\"PRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/12.5 mg\\\\nNDC 62559-661-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/12.5 mg\\\\nRx only\\\\n90 Tablets\\\\nPRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/25 mg\\\\nNDC 62559-662-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/25 mg\\\\nRx only\\\\n90 Tablets\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:62559-660\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCANDESARTAN CILEXETIL\\\\n (UNII: R85M2X0D68) \\\\n(CANDESARTAN - UNII:S8Q36MD2XX)\\\\nCANDESARTAN\\\\nCILEXETIL\\\\n16 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n1...\",\"Flavor\\\\nImprint Code\\\\nACS\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-660-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type...\",\"Packaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-661-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (So...\",\"ANI Pharmaceuticals, Inc.\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-662-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nLabeler - \\\\nANI Pharmaceuticals, Inc. \\\\n(145588013)\\\\n \\\\nRevised: 5/2020\",\"CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\\\n \\\\nCertus Medical, Inc.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\\\nDrug Facts Box OTC Active Ingredient Section\\\\nPovidone Iodine USP 10%\\\\nequivalent to 1% titratable iodine\\\\nDrug Facts Box OTC Purpose Section\\\\nAntiseptic\\\\nDrug...\",\"Drug Facts Box OTC General Precautions Section\\\\nstore at room temperature 15\\\\n - 30\\\\n C (59\\\\n - 86\\\\n F)\\\\nDrug Facts Box OTC Inactive Ingredient Section\\\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\\\nCertus PVP-1 Prep Swabstick \\\\n210012 pouch\\\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\\\n0\\\\n0\\\\n0\\\\n0\",\"CERTUS PVP-1 PREP SWABSTICK  \\\\npovidone-iodine swab\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:75990-4019\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85H0HZU99M) \\\\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\\\nPOVIDONE-IODINE\\\\n0.1 mL  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\",\"Certus Medical, Inc.\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nSODIUM PHOSPHATE, DIBASIC\\\\n (UNII: GR686LBA74)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nDIMETHICONE\\\\n (UNII: 92RU3N3Y1O)\\\\n \\\\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\\\n (UNII: S38J6RZN16)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:75990-4019-4\\\\n2 mL in 1 POUCH\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOT...\",\"ABALONE CRYSTALDOUBLE EX CC- niacinamide, adenosine, titanium dioxide, ethylhexyl\\\\nmethoxycinnamate cream \\\\n \\\\nC&amp;BCOSMETIC Co.,Ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nDrug Facts\\\\nNiacinamide, Adenosine, Titanium Dioxide, Ethylhexyl Methoxycinnamate\\\\nWater, Glycerin, Butylene Glycol, Etc\\\\nSkin Protectant - Anti-Wrinkle, Whitening, UV Protecting\\\\nk...\",\"ABALONE CRYSTALDOUBLE EX CC  \\\\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:60611-0008\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\",\"C&amp;BCOSMETIC Co.,Ltd.\\\\nNIACINAMIDE\\\\n (UNII: 25X51I8RD4) \\\\n(NIACINAMIDE - UNII:25X51I8RD4)\\\\nNIACINAMIDE\\\\n2 g  in 100 mL\\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP) \\\\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\\\nTITANIUM DIOXIDE\\\\n4.694 g  in 100 mL\\\\nADENOSINE\\\\n (UNII: K72T3FS567) \\\\n(ADENOSINE - UNII:K72T3FS567)\\\\nADENOSINE\\\\n0.04 g  in 100 mL\\\\nOCTINOXATE\\\\n (UNII: 4Y5P7MUD51) \\\\n(OCTINOXATE - UNII:4Y5P7MUD51)\\\\nOCTINOXATE\\\\n7 g  in 100 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C...\",\"TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\\\n \\\\nAdvagen Pharma Limited\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use TIZANIDINE\\\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\\\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\\\n \\\\nInitial U.S. Approval: 1996\\\\nINDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...\",\"Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\\\nfour-fold ( \\\\n8.5\\\\n)\\\\nSee 17 for PATIENT COUNSELING INFORMATION.\\\\nRevised: 9/2020\\\\nFULL PRESCRIBING INFORMATION: CONTENTS\\\\n*\\\\n1 INDICATIONS AND USAGE\\\\n2 DOSAGE AND ADMINISTRATION\\\\n2.1 Dosing Information\\\\n2.2 Dosing in Patients with Renal Impairment\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\n2.4 Drug Discontinuation\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Hypo...\",\"12.1 Mechanism of Action\\\\n12.3 Pharmacokinetics\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n16.1 Tizanidine Hydrochloride Capsules\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\n1 INDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the\\\\nmanagement of spasticity. Because of the short duration of therapeutic effect,\\\\ntreatment with tizanid...\",\"been studied.\\\\n2.2 Dosing in Patients with Renal Impairment\\\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\\\ndoses are required, individual doses rather than dosing frequency should be increased\\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n)] \\\\n.\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\nT...\",\"Tizanidine is an \\\\u03b1 \\\\n-adrenergic agonist that can produce hypotension. Syncope has been\\\\nreported in the post marketing setting. The chance of significant hypotension may\\\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\\\na supine to fixed upright position may be at increased risk for hypotension and\\\\northostatic effects.\\\\nMonitor for hypotension when tizanidine is used in patients...\",\"Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n5.6 Hypersensitivity Reactions\\\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\\\nand symptoms occur. \\\\n[see Contraindications ( \\\\n4\\\\n)]\\\\n5.7 Increased Risk of Adverse Reactions in Patients...\",\"264 patients received tizanidine and 261 patients received placebo. Across the three\\\\nstudies patient ages ranged from 15\\\\u201369 years and 51.4 percent were women. The\\\\nmedian dose during the plateau phase ranged from 20\\\\u201328 mg/day.\\\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\\\nclinical studies involving 264 patients with spasticity were dry mouth,\\\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\\\nThree-quarters of the patients rated t...\",\"multiple sclerosis (Study 1) \\\\n[see Clinical Studies ( \\\\n14\\\\n)] \\\\n, the patients were specifically\\\\nasked if they had experienced any of the four most common adverse reactions: dry\\\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\\\nthese reactions is summarized in \\\\nTable 2\\\\n. Other events were, in general, reported at a\\\\nrate of 2% or less.\\\\nTable 2: Single Dose, Placebo-Controlled Study -...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"12.3\\\\n)]\\\\n7.7 \\\\u03b1 \\\\n-adrenergic agonists\\\\nBecause hypotensive effects may be cumulative, it is not recommended that tizanidine\\\\nbe used with other \\\\u03b1 \\\\n-adrenergic agonists. \\\\n[see Warnings and Precautions ( \\\\n5.1\\\\n)]\\\\n8 USE IN SPECIFIC POPULATIONS\\\\n8.1 Pregnancy\\\\nPregnancy Category C\\\\nTizanidine has not been studied in pregnant women. Tizanidine should be given to\\\\npregnant women only if the benefit outweighs the risk to the unborn fetus.\\\\nReproduction studies performed in rats at a dose of 3 mg/kg, equal to the...\",\"8.6 Impaired Renal Function\\\\nTizanidine is known to be substantially excreted by the kidney, and the risk of adverse\\\\nreactions to this drug may be greater in patients with impaired renal function. In patients\\\\nwith renal insufficiency (creatinine clearance &lt; 25 mL/min) clearance was reduced by\\\\nmore than 50%. In these patients, during titration, the individual doses should be\\\\nreduced. If higher doses are required, individual doses rather than dosing frequency\\\\nshould be increased. These patients sho...\",\"manifestations of tizanidine overdose were consistent with its known pharmacology. In\\\\nthe majority of cases a decrease in sensorium was observed including lethargy,\\\\nsomnolence, confusion and coma. Depressed cardiac function is also observed including\\\\nmost often bradycardia and hypotension. Respiratory depression is another common\\\\nfeature of tizanidine overdose.\\\\nShould overdose occur, basic steps to ensure the adequacy of an airway and the\\\\nmonitoring of cardiovascular and respiratory systems shou...\",\"12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\\\nreduce facilitation of spinal motor neurons.\\\\n12.3 Pharmacokinetics\\\\nAbsorption and Distribution\\\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\\\n...\",\"Metabolism and Excretion\\\\nTizanidine has linear pharmacokinetics over the doses studied in clinical development (1\\\\u2013\\\\n20 mg). Tizanidine has a half-life of approximately 2.5 hours (CV=33%). Approximately\\\\n95% of an administered dose is metabolized. The primary cytochrome P450 isoenzyme\\\\ninvolved in tizanidine metabolism is CYP1A2. Tizanidine metabolites are not known to be\\\\nactive; their half-lives range from 20 to 40 hours.\\\\nFollowing single and multiple oral dosing of \\\\nC-tizanidine, an average of 60%...\",\"this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\\\nused with caution in renally impaired patients \\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n) and\\\\nUse in Specific Populations ( \\\\n8.6\\\\n)] \\\\n.\\\\nGender Effects\\\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\\\npharmacokinetic...\",\"13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nCarcinogenesis\\\\nTizanidine was administered to mice for 78 weeks at oral doses up to 16 mg/kg/day,\\\\nwhich is 2 times the maximum recommended human dose (MRHD) on a mg/m \\\\nbasis.\\\\nTizanidine was administered to rats for 104 weeks at oral doses up to 9 mg/kg/day,\\\\nwhich is 2.5 times the MRHD on a mg/m \\\\nbasis. There was no increase in tumors in\\\\neither species.\\\\nMutagenesis\\\\nTizanidine was negative in \\\\nin vitro\\\\n(bacterial r...\",\"tone in placebo treated patients. Within a given patient, improvement in muscle tone was\\\\ncorrelated with plasma concentration. Plasma concentrations were variable from patient\\\\nto patient at a given dose. Although 16 mg produced a larger effect, adverse events\\\\nincluding hypotension were more common and more severe than in the 8 mg group.\\\\nThere were no differences in the number of spasms occurring in each group.\\\\nFigure 2: Single Dose Study - Mean Change in Muscle Tone from Baseline as\\\\nMeasured by ...\",\"from baseline as measured by the Ashworth scale.\\\\nFigure 3: Seven Week Study - Mean Change in Muscle Tone 0.5-2.5 Hours\\\\nAfter Dosing as Measured by the Ashworth Scale \\\\u00b1 95% Confidence Interval\\\\n(A Negative Ashworth Score Signifies an Improvement in Muscle Tone from\\\\nBaseline)\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n16.1 Tizanidine Hydrochloride Capsules\\\\nTizanidine Hydrochloride Capsules are available in three strengths as two-piece hard\\\\ngelatin capsules containing tizanidine hydrochloride 2.29 mg, 4.5...\",\"17 PATIENT COUNSELING INFORMATION\\\\nSerious Drug Interactions\\\\nAdvise patients they should not take tizanidine if they are taking fluvoxamine or\\\\nciprofloxacin because of the increased risk of serious adverse reactions including severe\\\\nlowering of blood pressure and sedation. Instruct patients to inform their physicians or\\\\npharmacists when they start or stop taking any medication because of the risks\\\\nassociated with interaction between tizanidine and other medicines.\\\\nTizanidine Dosing\\\\nTell patients ...\",\"PRINCIPAL DISPLAY PANEL - 4 mg 150 Capsules Bottle - NDC 72888-002-15\\\\nPRINCIPAL DISPLAY PANEL - 6 mg 150 Capsules Bottle - NDC 72888-003-15\",\"TIZANIDINE HYDROCHLORIDE  \\\\ntizanidine hydrochloride capsule\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:72888-001\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of\\\\nStrength\\\\nStrength\\\\nTIZANIDINE HYDROCHLORIDE\\\\n (UNII: B53E3NMY5C) \\\\n(TIZANIDINE -\\\\nUNII:6AI06C00GW)\\\\nTIZANIDINE\\\\n2 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE 101\\\\n (UNII: 7T9FYH5QMK)\\\\n \\\\nLACTOSE MONOHYDRATE\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\nHYPROMELLOSE...\",\"AMMONIA\\\\n (UNII: 5138Q19F1X)\\\\n \\\\nFERROSOFERRIC OXIDE\\\\n (UNII: XM0M87F357)\\\\n \\\\nPOTASSIUM HYDROXIDE\\\\n (UNII: WZH3C48M4T)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nblue (Cap: Blue opaque) , blue (Body: Light Blue opaque)\\\\nScore\\\\nno score\\\\nShape\\\\nCAPSULE\\\\nSize\\\\n11mm\\\\nFlavor\\\\nImprint Code\\\\nUpArrowhead;043\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:72888-001-\\\\n15\\\\n150 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n05/27/2020\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nAppl...\",\"GELATIN, UNSPECIFIED\\\\n (UNII: 2G86QN327L)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nFD&amp;C BLUE NO. 1\\\\n (UNII: H3R47K3TBD)\\\\n \\\\nFD&amp;C RED NO. 40\\\\n (UNII: WZB9127XOA)\\\\n \\\\nSHELLAC\\\\n (UNII: 46N107B71O)\\\\n \\\\nISOPROPYL ALCOHOL\\\\n (UNII: ND2M416302)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nALCOHOL\\\\n (UNII: 3K9958V90M)\\\\n \\\\nBUTYL ALCOHOL\\\\n (UNII: 8PJ61P6TS3)\\\\n \\\\nAMMONIA\\\\n (UNII: 5138Q19F1X)\\\\n \\\\nFERROSOFERRIC OXIDE\\\\n (UNII: XM0M87F357)\\\\n \\\\nPOTASSIUM HYDROXIDE\\\\n (UNII: WZH3C48M4T)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nblue (Cap: Blue opaque)...\",\"Inactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE 101\\\\n (UNII: 7T9FYH5QMK)\\\\n \\\\nLACTOSE MONOHYDRATE\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\nHYPROMELLOSE, UNSPECIFIED\\\\n (UNII: 3NXW29V3WO)\\\\n \\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nSTEARIC ACID\\\\n (UNII: 4ELV7Z65AP)\\\\n \\\\nGELATIN, UNSPECIFIED\\\\n (UNII: 2G86QN327L)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nFD&amp;C BLUE NO. 1\\\\n (UNII: H3R47K3TBD)\\\\n \\\\nFD&amp;C RED NO. 40\\\\n (UNII: WZB9127XOA)\\\\n \\\\nSHELLAC\\\\n (UNII: 46N107B71O)\\\\n \\\\nISOPRO...\",\"Advagen Pharma Limited\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nRubicon Research\\\\nPrivate Limited\\\\n677604197\\\\nanalysis(72888-001, 72888-002, 72888-003) , manufacture(72888-001,\\\\n72888-002, 72888-003) , pack(72888-001, 72888-002, 72888-003)\\\\n \\\\nRevised: 7/2024\",\"ATHLETES FOOT- butenafine hydrochloride cream \\\\n \\\\nRite Aid Corporation\\\\n----------\\\\nAthlete&#x27;s Foot Cream\\\\nDrug Facts\\\\nActive ingredient\\\\nButenafine hydrochloride 1%\\\\nPurpose\\\\nAntifungal\\\\nUses\\\\ncures most athlete&#x27;s foot between the toes. Effectiveness on the bottom or sides of\\\\nfoot is unknown.\\\\ncures most jock itch and ringworm\\\\nrelieves itching, burning, cracking, and scaling which accompany these conditions\\\\nWarnings\\\\nFor external use only\\\\nDo not use\\\\non nails or scalp\\\\nin or near the mouth or the eyes\\\\nfor vag...\",\"1 week twice a day or 4 weeks once a day\\\\nfor jock itch and ringworm:\\\\napply once a day to affected skin for 2 weeks or as\\\\ndirected by a doctor.\\\\nwash hands after each use\\\\nchildren under 12 years: ask a doctor\\\\nOther information\\\\ndo not use if seal on tube is broken or not visible\\\\nstore between 20\\\\u00ba to 25\\\\u00ba C (68\\\\u00ba to 77\\\\u00ba F)\\\\nInactive ingredients\\\\nbenzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23)\\\\ncetyl ether, propylene glycol dicaprylate, purified water, sodium benzoa...\",\"RITE \\\\nAID \\\\n \\\\nPHARMACY\\\\nclinically proven to cure \\\\nmost athlete&#x27;s foot between the toes\\\\nfoot care \\\\nbutenafine\\\\nhydrochloride cream 1%\\\\nantifungal\\\\nNET WT 0.42 OZ (12 g)\\\\n\\\\u00ae\",\"ATHLETES FOOT  \\\\nbutenafine hydrochloride cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:11822-2100\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nBUTENAFINE HYDROCHLORIDE\\\\n (UNII: R8XA2029ZI) \\\\n(BUTENAFINE -\\\\nUNII:91Y494NL0X)\\\\nBUTENAFINE\\\\nHYDROCHLORIDE\\\\n10 mg\\\\n in 1 g\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nBENZYL ALCOHOL\\\\n (UNII: LKG8494WBH)\\\\n \\\\nCETYL ALCOHOL\\\\n (UNII: 936JST6JCN)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n...\",\"Rite Aid Corporation\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nANDA\\\\nANDA205181\\\\n11/17/2017\\\\nLabeler - \\\\nRite Aid Corporation \\\\n(014578892)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nTaro Pharmaceuticals Inc.\\\\n206263295\\\\nmanufacture(11822-2100)\\\\n \\\\nRevised: 7/2024\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#ffbb78\",\"#ffbb78\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#999\",\"#999\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#2ca02c\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#ffbb78\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#ffbb78\",\"#999\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\"],\"shape\":[117],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1045\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1046\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1041\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1042\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1043\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1012\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1027\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1028\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1029\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1030\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1031\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1036\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1037\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1022\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1023\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1024\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1025\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1017\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1018\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1019\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1020\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1021\",\"attributes\":{\"axis\":{\"id\":\"p1017\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1026\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1022\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1047\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1048\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"ACE Inhibitors Side Effects\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":30}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1049\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Blood Pressure Medication\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":63}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1050\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"NUCYNTA\\\\u2122 Pain Medication\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":2}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1051\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":16}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1052\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Tizanidine Overdose\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":87}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1053\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Topical Medications\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":0}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1122\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1059\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1068\",\"attributes\":{\"start\":9.502403783798218,\"end\":23.160186195373534}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1069\",\"attributes\":{\"start\":6.291248083114624,\"end\":14.863864183425903}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1070\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1071\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1066\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1098\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1055\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1056\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1057\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"rndPQcbodEG9jJFBPY5uQRIXMkGqFHdBSqY4QWmzPkFrF49BGwqLQZqiMEGaCDBBeTKCQWIVfEHW+SRBD4ZvQTX6TEEIA4BBuoeIQTjMZ0H3VTJBG7wnQWX7U0E+r29BsB+AQQ==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"BloHQXhtSUEk1ypBsxcOQUHmPEEnDyZB37EzQQC+KUGeEiNB4FgzQeA7MkG4bQpBgypMQUTXSkHX8StBUnUZQQsvG0HsLj9BrBs0QZb/CEFU0BNBiB89QSNkF0FfmD9Bf3BOQQ==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Others\",\"NUCYNTA\\\\u2122 Medication\",\"Tizanidine Hydrochloride\",\"Povidone Iodine Solution\",\"ACE Inhibitor Side Effects\",\"Others\",\"ACE Inhibitor Side Effects\",\"ACE Inhibitor Side Effects\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"ACE Inhibitor Side Effects\",\"Candesartan Cilexetil\",\"NUCYNTA\\\\u2122 Medication\",\"NUCYNTA\\\\u2122 Medication\",\"ACE Inhibitor Side Effects\",\"Povidone Iodine Solution\",\"ACE Inhibitor Side Effects\",\"NUCYNTA\\\\u2122 Medication\",\"Tizanidine Hydrochloride\",\"Pharmaceuticals\",\"Candesartan Cilexetil\",\"ACE Inhibitor Side Effects\",\"Others\",\"NUCYNTA\\\\u2122 Medication\",\"NUCYNTA\\\\u2122 Medication\"]],[\"correctness\",[false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false]],[\"questions\",[\"What specific advantages does hydrochlorothiazide offer in the tablets containing candesartan cilexetil, and what are the strengths of hydrochlorothiazide in each of the different tablet formulations?\",\"What is the abuse potential of NUCYNTA\\\\u2122, how is it classified, and what precautions should be taken for patients with hepatic impairment?\",\"How does the consumption of alcohol impact the pharmacokinetics of tizanidine, specifically in terms of its area under the curve (AUC) and maximum concentration (Cmax)?\",\"What are the specific active ingredients present in the GRX DYNE povidone iodine solution and what is the concentration of the active ingredient in the solution?\",\"What are the most frequently reported clinical adverse experiences in trials involving lisinopril and hydrochlorothiazide tablets, and what precautions should be taken into account when considering the drug&#x27;s use in nursing mothers?\",\"What are the different strengths available for tapentadol hydrochloride medication and what are the corresponding colors of the tablets?\",\"What is the specific mechanism by which hydrochlorothiazide exerts its antihypertensive effect, and how does it impact the electrolyte reabsorption mechanism in the distal renal tubule?\",\"What are the available strengths of lisinopril and hydrochlorothiazide tablets, and how are they supplied?\",\"Can you explain the difference in bioavailability between Tizanidine Capsules and Tizanidine Tablets, particularly when administered with food, and how does it impact the peak plasma concentration and time to peak plasma concentration?\",\"What specific parameter should be monitored in patients taking tizanidine to mitigate the risk of hepatocellular liver injury, especially in those with hepatic impairment?\",\"In the case of hypotension resulting from an overdose of Lisinopril, what is the recommended treatment involving the administration of what type of solution?\",\"How does candesartan impact the pressor effects of angiotensin II infusion, and to what extent is this effect inhibited by the medication?\",\"What specific type of surgery was conducted to assess the effectiveness of NUCYNTA\\\\u2122 in the clinical trial mentioned in the document?\",\"Can you provide a list of psychiatric disorders that are mentioned as potential adverse reactions to NUCYNTA\\\\u2122, according to the provided document?\",\"What clinical signs should patients undergoing thiazide therapy be monitored for in terms of fluid and electrolyte imbalance, and what are some specific warning signs or symptoms that may indicate such an imbalance?\",\"What is the specific active component found in the foot care cream designed to treat athlete&#x27;s foot located between the toes?\",\"What is the strength of Lisinopril and Hydrochlorothiazide tablets with NDC 69097-969-07?\",\"What is the average duration of the terminal half-life of tapentadol following oral administration, and how does it compare in subjects with varying degrees of renal function?\",\"What are the specific contraindications for the simultaneous use of tizanidine with fluvoxamine and ciprofloxacin, and what potential effects on blood pressure, drowsiness, and psychomotor impairment should be considered?\",\"When did the marketing of the product with NDC:75990-4019-4 officially begin according to the provided document?\",\"What are the potential manifestations of overdosage with candesartan cilexetil, and what supportive treatment should be initiated if symptomatic hypotension occurs?\",\"What are the potential adverse effects on the fetus associated with the use of drugs that act on the renin-angiotensin system during pregnancy, specifically in terms of fetal renal function, morbidity, and mortality?\",\"What are the specific strengths of lisinopril and hydrochlorothiazide in the tablets with NDC:69097-969, and what are the color and shape of these tablets?\",\"How should the dosing regimen for NUCYNTA (tapentadol) be adjusted to maintain adequate pain relief with acceptable tolerability?\",\"What are some of the nervous system disorders observed as adverse reactions during the premarketing evaluation of NUCYNTA\\\\u2122, including symptoms such as disturbance in attention, sedation, dysarthria, and ataxia?\"]],[\"agent_answer\",[\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\"]],[\"reference_answer\",[\"The strengths of hydrochlorothiazide in the candesartan cilexetil and hydrochlorothiazide tablets are 25 mg, 12.5 mg, and 12.5 mg for the different formulations.\",\"NUCYNTA\\\\u2122 contains tapentadol, a mu-opioid agonist and is classified as a Schedule II controlled substance. It has an abuse potential similar to hydromorphone and can be abused, subject to criminal diversion.\",\"Alcohol increased the AUC of tizanidine by approximately 20%, while also increasing its Cmax by approximately 15%. This was associated with an increase in side effects of tizanidine. The CNS depressant effects of tizanidine and alcohol are additive.\",\"The active ingredient in the GRX DYNE povidone iodine solution is Povidone-Iodine.\",\"The most frequent clinical adverse experiences reported in trials with lisinopril and hydrochlorothiazide tablets were dizziness (7.5%), headache (5.2%), cough (3.9%), fatigue (3.7%), and orthostatic effects (3.2%).\",\"The medication tapentadol hydrochloride is available in strengths of 100 mg and 50 mg.\",\"Hydrochlorothiazide is a diuretic and antihypertensive that affects the distal renal tubular mechanism of electrolyte reabsorption. It increases the excretion of sodium and chloride in approximately equivalent amounts.\",\"Lisinopril and hydrochlorothiazide tablets are available in three combinations: 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.\",\"Tizanidine capsules and tizanidine tablets are bioequivalent to each other under fasting conditions, but not under fed conditions. When administered with food, the mean maximal plasma concentration for the capsule is approximately 66% the concentration for the tablet.\",\"Aminotransferase levels should be monitored in patients taking tizanidine due to the risk of hepatocellular liver injury. Monitoring is recommended for baseline and 1 month after the maximum dose is achieved, or if hepatic injury is suspected.\",\"The usual treatment for hypotension caused by an overdose of Lisinopril would be intravenous infusion of normal saline solution.\",\"Candesartan inhibits the pressor effects of angiotensin II infusion in a dose-dependent manner. After 1 week of once-daily dosing with 8 mg of candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak with approximately 50% inhibition persisting for 24 hours.\",\"The efficacy of NUCYNTA\\\\u2122 was evaluated in patients undergoing unilateral, first metatarsal bunionectomy surgery.\",\"Some of the psychiatric disorders listed as adverse reactions to NUCYNTA\\\\u2122 include euphoric mood, disorientation, restlessness, agitation, nervousness, and abnormal thinking.\",\"Some warning signs or symptoms of fluid and electrolyte imbalance that patients receiving thiazide therapy should be observed for include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.\",\"The active ingredient in the foot care cream for athlete&#x27;s foot is butenafine hydrochloride 1%.\",\"The Lisinopril and Hydrochlorothiazide tablets with NDC 69097-969-07 have a strength of 20 mg/12.5 mg.\",\"The terminal half-life of tapentadol after oral administration is on average 4 hours.\",\"The concomitant use of tizanidine with fluvoxamine and ciprofloxacin is contraindicated due to changes in the pharmacokinetics of tizanidine that result in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.\",\"The marketing start date for the product with NDC:75990-4019-4 is 05/01/2011.\",\"The most likely manifestations of overdosage with candesartan cilexetil would be hypotension, dizziness, and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.\",\"The potential adverse effects on the fetus associated with the use of drugs that act on the renin-angiotensin system during pregnancy include reduced fetal renal function, increased fetal and neonatal morbidity and death, oligohydramnios, fetal lung hypoplasia, skeletal deformations, skull hypoplasia, anuria, hypotension, renal failure, and death.\",\"The lisinopril in the tablets with NDC:69097-969 has a strength of 20 mg, while the hydrochlorothiazide has a strength of 12.5 mg.\",\"The recommended dosing regimen for NUCYNTA (tapentadol) for the relief of moderate to severe acute pain is 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. The second dose may be administered as soon as one hour after the first dose on the first day of dosing if adequate pain relief is not attained with the first dose.\",\"Some of the nervous system disorders observed as adverse reactions during the premarketing evaluation of NUCYNTA\\\\u2122 include dizziness, somnolence, tremor, lethargy, insomnia, confusional state, abnormal dreams, anxiety, hypoesthesia, paresthesia, disturbance in attention, sedation, dysarthria, depressed level of consciousness, memory impairment, ataxia, presyncope, syncope, coordination abnormal, and seizure.\"]],[\"id\",[78,12,103,28,45,26,33,50,101,93,49,65,17,10,40,116,51,15,97,85,73,37,53,4,9]],[\"content\",[\"Packaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-661-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (So...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\\\nused with caution in renally impaired patients \\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n) and\\\\nUse in Specific Populations ( \\\\n8.6\\\\n)] \\\\n.\\\\nGender Effects\\\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\\\npharmacokinetic...\",\"Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\\\nkeep out of reach of children. If swallowed get medical help \\\\nor contact a Poison Control Center right away.\\\\nEnter section text here\\\\nGRX DYNE  \\\\npovidone iodine solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:54162-269\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85...\",\"Nursing Mothers\\\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\\\nrats contains radioactivity following administration of \\\\nC lisinopril. In another study,\\\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\\\nwhether to discontinue nursing and/or disco...\",\"Stat Rx USA\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII:...\",\"state is prolonged. Older patients, on average, have (approximately doubled) higher\\\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\\\npatients (see \\\\nDOSAGE AND ADMINISTRATION\\\\n). In a multiple dose pharmacokinetic study\\\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\\\nhe...\",\"possible, be discontinued for two to three days before beginning therapy with lisinopril\\\\nto reduce the likelihood of hypotension (See \\\\nWARNINGS\\\\n). If the patient\\\\u2019s blood pressure\\\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\\\nfor at least an additional hour (See \\\\nWARNINGS\\\\n and \\\\nPRECAUTIONS\\\\n...\",\"12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\\\nreduce facilitation of spinal motor neurons.\\\\n12.3 Pharmacokinetics\\\\nAbsorption and Distribution\\\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\\\n...\",\"Tizanidine is an \\\\u03b1 \\\\n-adrenergic agonist that can produce hypotension. Syncope has been\\\\nreported in the post marketing setting. The chance of significant hypotension may\\\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\\\na supine to fixed upright position may be at increased risk for hypotension and\\\\northostatic effects.\\\\nMonitor for hypotension when tizanidine is used in patients...\",\"Lisinopril\\\\n \\\\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\\\nnormal saline solution.\\\\nLisinopril can be removed by hemodialysis (see \\\\nWARNINGS, Anaphylactoid Reaction\\\\nDuring Membrane Exposure\\\\n).\\\\nHydrochlorothiazide\\\\n \\\\nOral administration of a single oral dose of 10 g/kg to mice and rats w...\",\"Geriatric\\\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\\\u2265 65 years). \\\\nThe plasma\\\\nconcentration of candesartan was higher in the elderly (C\\\\n was approximately 50% higher, and AUC\\\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\\\nThe\\\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\\\nNo initia...\",\"14 CLINICAL STUDIES\\\\nThe efficacy and safety of NUCYNTA\\\\u2122 in the treatment of moderate to severe acute pain has been\\\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\\\u2122...\",\"Psychiatric disorders:\\\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\\\nabnormal\\\\nRenal and urinary disorders:\\\\n urinary hesitation, pollakiuria\\\\nRespiratory, thoracic and mediastinal disorders: \\\\noxygen saturation decreased, cough, dyspnea,\\\\nrespiratory depression\\\\nSkin and subcutaneous tissue disorders: \\\\nurticaria\\\\nVascular disorders:\\\\n blood pressure decreased\\\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\\\nNUCYNTA\\\\u2122,...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"RITE \\\\nAID \\\\n \\\\nPHARMACY\\\\nclinically proven to cure \\\\nmost athlete&#x27;s foot between the toes\\\\nfoot care \\\\nbutenafine\\\\nhydrochloride cream 1%\\\\nantifungal\\\\nNET WT 0.42 OZ (12 g)\\\\n\\\\u00ae\",\"Protect from excessive light and humidity.\\\\n*AN69 is a registered trademark of Hospal Ltd.\\\\nManufactured by:\\\\nInvaGen Pharmaceuticals, Inc.\\\\n(a subsidiary of Cipla Ltd.)\\\\nHauppauge, NY 11788\\\\nManufactured for:\\\\nCipla USA, Inc.\\\\n10 Independence Boulevard, Suite 300\\\\nWarren, NJ 07059\\\\nRevised: 10/2021\\\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\\\u2013 10 mg/12.5 mg\\\\nNDC 69097-968-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n10 mg/12.5 mg\\\\n100 Tablets\\\\nCipla\\\\nNDC 69097-969-07             ...\",\"extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\\\naround 1.25 hours after dosing.\\\\nDose-proportional increases in the C\\\\n and AUC values of tapentadol have been observed over the 50\\\\nto 150 mg dose range.\\\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\\\nglucuronide, which are primarily determined by the do...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"Certus Medical, Inc.\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nSODIUM PHOSPHATE, DIBASIC\\\\n (UNII: GR686LBA74)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nDIMETHICONE\\\\n (UNII: 92RU3N3Y1O)\\\\n \\\\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\\\n (UNII: S38J6RZN16)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:75990-4019-4\\\\n2 mL in 1 POUCH\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOT...\",\"melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\\\nfor white patients taking a cumulative dose of \\\\u226550,000 mg the risk increase was approximately 1\\\\nadditional SCC case for every 6,700 patients per year.\\\\nSkin:\\\\n \\\\nerythema multiforme including S...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"8.7 Hepatic Impairment\\\\n9 DRUG ABUSE AND DEPENDENCE\\\\n9.1 Controlled Substance\\\\n9.2 Abuse\\\\n9.3 Dependence\\\\n10 OVERDOSAGE\\\\n10.1 Human Experience\\\\n10.2 Management of Overdose\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n13 NON-CLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\n14 CLINICAL STUDIES\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\n14.2 End-Stage Degenerative Joint Disea...\",\"*\\\\nInfections and infestations\\\\n  Nasopharyngitis\\\\n1\\\\n&lt;1\\\\n  Upper respiratory tract infection\\\\n1\\\\n&lt;1\\\\n  Urinary tract infection\\\\n1\\\\n&lt;1\\\\nMetabolism and nutrition disorders\\\\n  Decreased appetite\\\\n2\\\\n0\\\\nMusculoskeletal and connective tissue\\\\ndisorders\\\\n  Arthralgia\\\\n1\\\\n&lt;1\\\\nNervous system disorders\\\\n  Dizziness\\\\n24\\\\n8\\\\n  Somnolence\\\\n15\\\\n3\\\\n  Tremor\\\\n1\\\\n&lt;1\\\\n  Lethargy\\\\n1\\\\n&lt;1\\\\nPsychiatric disorders\\\\n  Insomnia\\\\n2\\\\n&lt;1\\\\n  Confusional state\\\\n1\\\\n0\\\\n  Abnormal dreams\\\\n1\\\\n&lt;1\\\\n  Anxiety\\\\n1\\\\n&lt;1\\\\nSkin and subcutaneous tissue disorders\\\\n  Pruritus\\\\n5\\\\n1\\\\n  Hyp...\"]],[\"color\",[\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1099\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1100\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1095\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1096\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1097\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1112\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1103\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1104\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1105\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"h2tqQTNsc0FV2GxBf4NmQT6vb0HDgnRBy1d6QSxtbkFQrnhBsB+AQWIVfEFUjXhBxuh0QdLrc0HXSHdBCAOAQcnGgUF5MoJBUh98Qcb1bUHOpmJB099oQUzXakGeCGlBl/BsQTEfcUGqFHdBw0d3QT2ObkHAB2pBs+BEQbhIPkE8FzFBSqY4Qc8wOEFDMx9BEakeQRu8J0H9yTJBwyAjQdb5JEG/WCZBKNshQdMrLEFNtDpBEhcyQZiJM0GYkitBy1wtQZqiMEFpsz5BNfpMQaH4SkFl+1NBQT9EQdUPS0FVeFlBGLNZQchvX0GpKmJByFdeQY0ZcEEvbT1BauY1QZ33K0GaCDBBrhI4QTptJkHE9SxBUewjQVirJkH8rShB/igqQfdVMkFauEFBdaJIQQvrSEH8+lBBrndPQeBjW0GDQ3VBeZ5qQckCc0E4zGdBbjpiQRpJZkG/mmNBpBaEQcSlhkHXLolBYDCIQRsKi0HD6opBhgmMQRI+jUG6h4hBPP2NQdQQjEH6yIRBaxePQQMIkUG9jJFBJfSPQX8MjkHx/oZBNuaIQZc3W0FRdoBBRUp6QePidEGKh2pBGc1fQdmzaEHKMm5BD4ZvQepea0FT82BB\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1113\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1114\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1109\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1110\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1111\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1067\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1082\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1083\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1084\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1085\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1090\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1091\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1058\",\"attributes\":{\"renderers\":[{\"id\":\"p1098\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1077\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1078\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1079\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1080\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1072\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1073\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1074\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1075\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1076\",\"attributes\":{\"axis\":{\"id\":\"p1072\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1081\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1077\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1101\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1102\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"False\"},\"renderers\":[{\"id\":\"p1098\"}],\"index\":0}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p1118\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1115\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1116\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1117\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"TRGLQaBPc0F30DRBb/pqQdc4NEE=\"},\"shape\":[5],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"A9clQYRcSUEHgQ1BN4oMQWj3L0E=\"},\"shape\":[5],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Tizanidine Overdose\",\"NUCYNTA\\\\u2122 Pain Medication\",\"Blood Pressure Medication\",\"Topical Medications\",\"ACE Inhibitors Side Effects\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"004a8147-5b27-40bd-b264-d8e8610e5341\",\"roots\":{\"p1123\":\"e30d643a-8a82-43bb-852b-2155a0efee59\"},\"root_ids\":[\"p1123\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"e30d643a-8a82-43bb-852b-2155a0efee59\" data-root-id=\"p1123\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x7021c07b8860>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_chain_multiquery, testset=testset, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "27659fb9",
   "metadata": {},
   "source": [
    "#### RAG-Fusion"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 95,
   "id": "1806f37a",
   "metadata": {},
   "outputs": [],
   "source": [
    "template = \"\"\"You are a helpful assistant that generates multiple search queries based on a single input query. \\n\n",
    "Generate multiple search queries related to: {question} \\n\n",
    "Output (4 queries):\"\"\"\n",
    "prompt_rag_fusion = ChatPromptTemplate.from_template(template)\n",
    "\n",
    "generate_queries = (\n",
    "    prompt_rag_fusion \n",
    "    | call_asi_one\n",
    "    | StrOutputParser() \n",
    "    | (lambda x: x.split(\"\\n\"))\n",
    ")\n",
    "\n",
    "def reciprocal_rank_fusion(results: list[list], k=60):\n",
    "    fused_scores = {}\n",
    "\n",
    "    for docs in results:\n",
    "        for rank, doc in enumerate(docs):\n",
    "            doc_str = dumps(doc)\n",
    "            if doc_str not in fused_scores:\n",
    "                fused_scores[doc_str] = 0\n",
    "            previous_score = fused_scores[doc_str]\n",
    "            fused_scores[doc_str] += 1 / (rank + k)\n",
    "\n",
    "    reranked_results = [\n",
    "        (loads(doc), score)\n",
    "        for doc, score in sorted(fused_scores.items(), key=lambda x: x[1], reverse=True)\n",
    "    ]\n",
    "\n",
    "    return reranked_results\n",
    "\n",
    "retrieval_chain_rag_fusion = generate_queries | retriever.map() | reciprocal_rank_fusion\n",
    "\n",
    "chain_rag_fusion = (\n",
    "    {\"context\": retrieval_chain_rag_fusion, \n",
    "     \"question\": itemgetter(\"question\")} \n",
    "    | prompt_rag\n",
    "    | call_asi_one\n",
    "    | StrOutputParser()\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "id": "3202f91c",
   "metadata": {},
   "outputs": [],
   "source": [
    "def answer_fn_chain_rag_fusion(question, history=None):\n",
    "    return chain_rag_fusion.invoke({\"question\": question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "e2f4b649",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "714ba79715fa4fd99bb92783a5188869",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0f4301204f284060860fac137839f6da",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"c7ad2fd6-4407-4839-a18f-572b2e8b5e4e\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"c7ad2fd6-4407-4839-a18f-572b2e8b5e4e\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"c7ad2fd6-4407-4839-a18f-572b2e8b5e4e\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">100%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Since all scores are perfect, no immediate improvements are necessary. However, continuing to monitor and test across varied datasets can ensure consistent performance.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"7c8e78da-6d5c-4967-b445-813b8f8f7a03\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p2917\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p2919\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p2926\",\"attributes\":{\"factors\":[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2927\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p2928\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p2924\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2946\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2914\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2915\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2916\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"AAAAAAAAWUAAAAAAAABZQA==\"},\"shape\":[2],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"colors\",[\"#a50026\",\"#a50026\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2947\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2948\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2943\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2944\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2945\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2955\",\"attributes\":{\"data_source\":{\"id\":\"p2914\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2956\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2957\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2952\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2953\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p2954\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2965\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2959\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2960\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2961\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2966\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2967\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p2962\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p2963\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p2964\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p2925\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p2939\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p2934\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p2935\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p2936\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2937\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2929\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2930\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2931\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2932\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2933\",\"attributes\":{\"axis\":{\"id\":\"p2929\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2938\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p2934\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p2958\",\"attributes\":{\"location\":100.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p2968\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2969\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p2965\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"7c8e78da-6d5c-4967-b445-813b8f8f7a03\",\"roots\":{\"p2917\":\"b74e8694-abec-44a0-88cf-49739c21fa5b\"},\"root_ids\":[\"p2917\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"b74e8694-abec-44a0-88cf-49739c21fa5b\" data-root-id=\"p2917\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"3dbac6fc-a8c9-4af1-a110-e4581a5f1bb4\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p2848\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p2779\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p2728\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p2737\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p2738\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2739\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2740\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p2735\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2768\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2725\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2726\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2727\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154]],[\"content\",[\"ATRIPLA ACCESS- efavirenz, emtricitabine, and tenofovir disoproxil\\\\nfumarate tablet, film coated \\\\n \\\\nGilead Sciences, Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ATRIPLA safely and\\\\neffectively. See full prescribing information for ATRIPLA.\\\\nATRIPLA\\\\u2122 (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets, for oral use\\\\nGILEAD ACCESS PROGRAM\\\\nInitial U.S. Approval: 2006\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION O...\",\"WARNINGS AND PRECAUTIONS\\\\nRash: Discontinue if severe rash develops. (\\\\n5.2\\\\n, \\\\n6.1\\\\n)\\\\nHepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying\\\\nhepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are\\\\ntaking medications associated with liver toxicity. Among reported cases of hepatic failure, a few\\\\noccurred in patients with no pre-existing hepatic disease. (\\\\n5.3\\\\n, \\\\n6.2\\\\n, \\\\n8.7\\\\n)\\\\nRisk of adverse reactions or loss of ...\",\"2.1 Testing Prior to Initiation and During Treatment with ATRIPLA\\\\n2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg\\\\n2.3 Not Recommended in Patients with Moderate or Severe Renal Impairment\\\\n2.4 Not Recommended in Patients with Moderate to Severe Hepatic Impairment\\\\n2.5 Dosage Adjustment with Rifampin\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and\\\\nHBV\\\\n5.2 Ra...\",\"16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B\\\\nSevere acute exacerbations of hepatitis B virus (HBV) have been\\\\nreported in patients who are coinfected with HIV-1 and HBV and have\\\\ndiscontinued products containing emtricitabine (FTC) and/or tenofovir\\\\ndisoproxil fumarate (TDF), which are components of ATRIPLA.\\\\nClosely monitor hepatic function with both clinical and laboratory follow-\\\\nup f...\",\"ATRIPLA is a three-drug fixed-dose combination product containing 600 mg of efavirenz\\\\n(EFV), 200 mg of emtricitabine (FTC), and 300 mg of tenofovir disoproxil fumarate (TDF).\\\\nThe recommended dosage of ATRIPLA in \\\\nadults and pediatric patients weighing at least\\\\n40 kg\\\\n is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may\\\\nimprove the tolerability of nervous system symptoms \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n2.3 Not Recommended in Patients with Moderate or Severe Ren...\",\"closely monitored, with both clinical and laboratory follow-up for at least several months\\\\nafter stopping treatment with ATRIPLA. If appropriate, initiation of anti-hepatitis B\\\\ntherapy may be warranted, especially in patients with advanced liver disease or cirrhosis,\\\\nsince posttreatment exacerbation of hepatitis may lead to hepatic decompensation and\\\\nliver failure.\\\\n5.2 Rash\\\\nIn controlled clinical trials, 26% (266/1,008) of adult subjects treated with 600 mg EFV\\\\nexperienced new-onset skin rash co...\",\"[see \\\\nDosage and Administration (2.1)\\\\n].\\\\n Consider discontinuing ATRIPLA in patients with\\\\npersistent elevations of serum transaminases to greater than five times the upper limit\\\\nof the normal range.\\\\nDiscontinue ATRIPLA if elevation of serum transaminases is accompanied by clinical\\\\nsigns or symptoms of hepatitis or hepatic decompensation \\\\n[see \\\\nAdverse Reactions\\\\n(6.1)\\\\n].\\\\n5.4 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug\\\\nInteractions\\\\nThe concomitant use of ATRIPLA and other d...\",\"discontinued or interrupted treatment because of one or more of these selected\\\\npsychiatric symptoms. There have also been occasional postmarketing reports of death\\\\nby suicide, delusions, and psychosis-like behavior, although a causal relationship to the\\\\nuse of EFV cannot be determined from these reports. Postmarketing cases of catatonia\\\\nhave also been reported and may be associated with increased EFV exposure. Patients\\\\nwith serious psychiatric adverse experiences should seek immediate medical ev...\",\"Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal\\\\ntubular injury with severe hypophosphatemia), has been reported with the use of TDF, a\\\\ncomponent of ATRIPLA \\\\n[see \\\\nAdverse Reactions (6.2)\\\\n].\\\\nPrior to initiation and during use of ATRIPLA, on a clinically appropriate schedule, assess\\\\nserum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all\\\\npatients. In patients with chronic kidney disease, also assess serum phosphorus.\\\\nATRIPLA is...\",\"considered for adult and pediatric patients who have a history of pathologic bone\\\\nfracture or other risk factors for osteoporosis or bone loss. Although the effect of\\\\nsupplementation with calcium and vitamin D was not studied, such supplementation may\\\\nbe beneficial for all patients. If bone abnormalities are suspected, then appropriate\\\\nconsultation should be obtained.\\\\nMineralization Defects\\\\nCases of osteomalacia associated with proximal renal tubulopathy, manifested as bone\\\\npain or pain in extre...\",\"enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and\\\\n\\\\\"cushingoid appearance,\\\\\" has been observed in patients receiving antiretroviral therapy,\\\\nincluding EFV. The mechanism and long-term consequences of these events are\\\\ncurrently unknown. A causal relationship has not been established.\\\\n6 ADVERSE REACTIONS\\\\nThe following adverse reactions are discussed in other sections of the labeling:\\\\nSevere Acute Exacerbations of Hepatitis B in Patients Coinfected with HIV-1 and...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nDizziness\\\\n8%\\\\n7%\\\\nUpper respiratory tract infections\\\\n8%\\\\n5%\\\\nSinusitis\\\\n8%\\\\n4%\\\\nRash Event\\\\n7%\\\\n9%\\\\nHeadache\\\\n6%\\\\n5%\\\\nInsomnia\\\\n5%\\\\n7%\\\\nAnxiety\\\\n5%\\\\n4%\\\\nNasopharyngitis\\\\n5%\\\\n3%\\\\nVomiting\\\\n2%\\\\n5%\\\\nIn Study 073, subjects with stable, virologic suppression on antiretroviral therapy and no\\\\nhistory of virologic failure were randomized to receive ATRIPLA or to stay on their\\\\nbaseline regimen. The adverse reactions observed in Study 073 were generally\\\\nconsistent with those seen in Study 934 and those seen with the individ...\",\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"subjects treated with EFV and fixed-dose zidovudine/lamivudine were hepatitis B surface\\\\nantigen or hepatitis C antibody positive. Among these coinfected subjects, one subject\\\\n(1/19) in the EFV, FTC, and TDF arm had elevations in transaminases to greater than five\\\\ntimes ULN through 144 weeks. In the fixed-dose zidovudine/lamivudine arm, two\\\\nsubjects (2/20) had elevations in transaminases to greater than five times ULN through\\\\n144 weeks. No HBV and/or HCV coinfected subject discontinued from the t...\",\"Dyspnea\\\\nSkin and Subcutaneous Tissue Disorders\\\\n \\\\nFlushing, erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome\\\\nEmtricitabine\\\\n:\\\\n No postmarketing adverse reactions have been identified for inclusion in\\\\nthis section.\\\\nTenofovir DF:\\\\nImmune System Disorders\\\\n \\\\nAllergic reaction, including angioedema\\\\nMetabolism and Nutrition Disorders\\\\n \\\\nLactic acidosis, hypokalemia, hypophosphatemia\\\\nRespiratory, Thoracic, and Mediastinal Disorders\\\\n \\\\nDyspnea\\\\nGastrointestinal Disorders\\\\n \\\\nPancreatitis,...\",\"There is limited information available on the potential for a pharmacodynamic interaction\\\\nbetween EFV and drugs that prolong the QTc interval. QTc prolongation has been\\\\nobserved with the use of EFV \\\\n[see \\\\nClinical Pharmacology (12.2)\\\\n].\\\\n Consider alternatives to\\\\nATRIPLA when coadministered with a drug with a known risk of Torsade de Pointes.\\\\n7.2 Drugs Affecting Renal Function\\\\nFTC and tenofovir are primarily eliminated by the kidneys\\\\n[see \\\\nClinical Pharmacology\\\\n(12.3)\\\\n].\\\\n Coadministration of ATRI...\",\"the increased indinavir metabolism due to\\\\nEFV.\\\\nProtease inhibitor:\\\\n  darunavir/ritonavir\\\\n\\\\u2191 tenofovir\\\\nMonitor patients receiving ATRIPLA\\\\nconcomitantly with ritonavir-boosted\\\\ndarunavir for TDF-associated adverse\\\\nreactions. Discontinue ATRIPLA in\\\\npatients who develop TDF-associated\\\\nadverse reactions.\\\\n  lopinavir/ritonavir\\\\n\\\\u2193 lopinavir\\\\n\\\\u2191 tenofovir\\\\nDo not use once daily administration of\\\\nlopinavir/ritonavir. Dose increase of\\\\nlopinavir/ritonavir is recommended for all\\\\npatients when coadministered with ...\",\"NRTI:\\\\n  didanosine\\\\n\\\\u2191 didanosine\\\\nreceiving TDF with didanosine 400 mg\\\\ndaily. \\\\nIn patients weighing greater than 60 kg,\\\\nreduce the didanosine dose to 250 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nIn patients weighing less than 60 kg,\\\\nreduce the didanosine dose to 200 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nWhen coadministered, ATRIPLA and\\\\nVidex EC may be taken under fasted\\\\nconditions or with a light meal (less than\\\\n400 kcal, 20% fat).\\\\nNNRTI:\\\\n  Other NNRTIs\\\\n\\\\u2191 or \\\\u2193 efavirenz\\\\nand/or NNRTI\\\\nCombini...\",\"Anticoagulant:\\\\n  warfarin\\\\n\\\\u2191 or \\\\u2193 warfarin\\\\nPlasma concentrations and effects\\\\npotentially increased or decreased by\\\\nEFV.\\\\nAnticonvulsants:\\\\n  carbamazepine\\\\n\\\\u2193 carbamazepine\\\\n\\\\u2193 efavirenz\\\\nThere are insufficient data to make a\\\\ndose recommendation for ATRIPLA.\\\\nAlternative anticonvulsant treatment\\\\nshould be used.\\\\n  phenytoin\\\\n  phenobarbital\\\\n\\\\u2193 anticonvulsant\\\\n\\\\u2193 efavirenz\\\\nPotential for reduction in anticonvulsant\\\\nand/or EFV plasma levels; periodic\\\\nmonitoring of anticonvulsant plasma\\\\nlevels should be conducted...\",\"artemether/lumefantrine\\\\n  atovaquone/proquanil\\\\n\\\\u2193 dihydroartemisinin\\\\n\\\\u2193 lumefantrine\\\\n\\\\u2193 atovaquone\\\\n\\\\u2193 proguanil\\\\nrisk of QT interval prolongation \\\\n[see\\\\nWarnings and Precautions (5.4)\\\\n]\\\\n.\\\\nConcomitant administration of\\\\natovaquone/proguanil with ATRIPLA is\\\\nnot recommended.\\\\nCalcium channel\\\\nblockers:\\\\n  diltiazem\\\\n\\\\u2193 diltiazem\\\\n\\\\u2193 desacetyl\\\\ndiltiazem\\\\n\\\\u2193 N-monodes-\\\\nmethyl diltiazem\\\\nDiltiazem dose adjustments should be\\\\nguided by clinical response (refer to the\\\\nfull prescribing information for diltiazem).\\\\nNo dose ...\",\"*\\\\ntacrolimus, sirolimus, and\\\\nothers metabolized by\\\\nCYP3A\\\\nsuppressant\\\\nmay be required. Close monitoring of\\\\nimmunosuppressant concentrations for\\\\nat least 2 weeks (until stable\\\\nconcentrations are reached) is\\\\nrecommended when starting or stopping\\\\ntreatment with ATRIPLA.\\\\nNarcotic analgesic:\\\\n  methadone\\\\n\\\\u2193 methadone\\\\nCoadministration of EFV in HIV-1 infected\\\\nindividuals with a history of injection drug\\\\nuse resulted in signs of opiate\\\\nwithdrawal. Methadone dose was\\\\nincreased by a mean of 22% to alleviate...\",\"for EFV, FTC, or TDF compared with the background rate for major birth defects of\\\\n2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects\\\\nProgram (MACDP) \\\\n(see \\\\nData\\\\n)\\\\n.\\\\nThe rate of miscarriage is not reported in the APR. The estimated background rate of\\\\nmiscarriage in clinically recognized pregnancies in the U.S. general population is 15-20%.\\\\nThe background risk of major birth defects and miscarriage for the indicated population\\\\nis unknown. The APR uses the MACDP as t...\",\"Animal Data\\\\nEfavirenz:\\\\n Effects of EFV on embryo-fetal development have been studied in three\\\\nnonclinical species (cynomolgus monkeys, rats, and rabbits). In monkeys, EFV 60\\\\nmg/kg/day was administered to pregnant females throughout pregnancy (gestation\\\\nDays 20 through 150). The maternal systemic drug exposures (AUC) were 1.3 times the\\\\nexposures at the RHD, with fetal umbilical venous drug concentrations approximately\\\\n0.7 times the maternal values. Three fetuses of 20 fetuses/infants had one or m...\",\"Based on limited published data, EFV, FTC, and tenofovir have been shown to be present\\\\nin human breast milk.\\\\nIt is not known if the components of ATRIPLA affect milk production or have effects on\\\\nthe breastfed child. Because of the potential for: (1) HIV transmission (in HIV-negative\\\\ninfants); (2) developing viral resistance (in HIV-positive infants); and (3) adverse\\\\nreactions in a breastfed infant similar to those seen in adults, instruct mothers not to\\\\nbreastfeed if they are receiving ATRIPLA....\",\"8.7 Hepatic Impairment\\\\nATRIPLA is not recommended for patients with moderate or severe hepatic impairment\\\\nbecause there are insufficient data to determine an appropriate dose. Patients with mild\\\\nhepatic impairment may be treated with ATRIPLA at the approved dose. Because of the\\\\nextensive cytochrome P450-mediated metabolism of EFV and limited clinical experience\\\\nin patients with hepatic impairment, caution should be exercised in administering\\\\nATRIPLA to these patients \\\\n[see \\\\nDosage and Administra...\",\"Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It\\\\nis practically insoluble in water (less than 10 \\\\u00b5g/mL).\\\\nEmtricitabine:\\\\n The chemical name of FTC is 5-fluoro-1-(2\\\\nR\\\\n,5\\\\nS\\\\n)-[2-(hydroxymethyl)-1,3-\\\\noxathiolan-5-yl]cytosine. FTC is the (-) enantiomer of a thio analog of cytidine, which\\\\ndiffers from other cytidine analogs in that it has a fluorine in the 5-position.\\\\nIt has a molecular formula of C\\\\nH\\\\nFN\\\\nO\\\\nS and a molecular weight of 247.24. It has the\\\\nfollo...\",\"12.1 Mechanism of Action\\\\nATRIPLA is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF \\\\n[see\\\\nMicrobiology (12.4)\\\\n].\\\\n12.2 Pharmacodynamics\\\\nCardiac Electrophysiology\\\\nEfavirenz:\\\\n \\\\nThe effect of EFV on the QTc interval was evaluated in an open-label, positive\\\\nand placebo-controlled, fixed single sequence 3-period, 3-treatment crossover QT study\\\\nin 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean C\\\\n of EFV in\\\\nsubjects with CYP2B6 *6/*6 genotype following the administration o...\",\"Tenofovir DF:\\\\n \\\\nFollowing oral administration of a single 300 mg dose of TDF to HIV-1\\\\ninfected subjects in the fasted state, maximum serum concentrations (C\\\\n) were\\\\nachieved in 1.0 \\\\u00b1 0.4 hrs (mean \\\\u00b1 SD) and C\\\\n and AUC values were 296 \\\\u00b1 90 ng/mL\\\\nand 2287 \\\\u00b1 685 ng\\\\u2219hr/mL, respectively. The oral bioavailability of tenofovir from TDF in\\\\nfasted subjects is approximately 25%. Less than 0.7% of tenofovir binds to human\\\\nplasma proteins in vitro, and the binding is independent of concentration over the ran...\",\"daily dose of 200 mg.\\\\nTenofovir DF:\\\\n Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1\\\\ninfected pediatric subjects (12 to less than 18 years). Mean \\\\u00b1 SD C\\\\n and AUC\\\\n are\\\\n0.38 \\\\u00b1 0.13 \\\\u03bcg/mL and 3.39 \\\\u00b1 1.22 \\\\u03bcg\\\\u2219hr/mL, respectively. Tenofovir exposure\\\\nachieved in these pediatric subjects receiving oral daily doses of TDF 300 mg was similar\\\\nto exposures achieved in adults receiving once-daily doses of TDF 300 mg.\\\\nGeriatric Patients\\\\nPharmacokinetics of EFV, FTC, and tenofovir have not...\",\"concentrations well above those achieved clinically. Coadministration of EFV with drugs\\\\nprimarily metabolized by CYP2C9, CYP2C19, CYP3A or CYP2B6 isozymes may result in\\\\naltered plasma concentrations of the coadministered drug. Drugs which induce CYP3A\\\\nand CYP2B6 activity would be expected to increase the clearance of EFV resulting in\\\\nlowered plasma concentrations.\\\\nDrug interaction trials were performed with EFV and other drugs likely to be\\\\ncoadministered or drugs commonly used as probes for phar...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\nCarbamazepine\\\\n200 mg qd \\\\u00d7 3\\\\ndays, 200 mg bid\\\\n\\\\u00d7 3 days, then\\\\n400 mg qd \\\\u00d7 15\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 35\\\\ndays\\\\n14\\\\n\\\\u2193 21\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 26)\\\\n\\\\u2193 36\\\\n(\\\\u2193 32 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 47\\\\n(\\\\u2193 41 to\\\\n\\\\u2193 53)\\\\nDiltiazem\\\\n240 mg \\\\u00d7 14\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 28\\\\ndays\\\\n12\\\\n\\\\u2191 16\\\\n(\\\\u2191 6 to \\\\u2191\\\\n26)\\\\n\\\\u2191 11\\\\n(\\\\u2191 5 to \\\\u2191\\\\n18)\\\\n\\\\u2191 13\\\\n(\\\\u2191 1 to \\\\u2191\\\\n26)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg\\\\nqd \\\\u00d7 9\\\\ndays\\\\nNA\\\\n\\\\u2191 38\\\\n\\\\u2191 44\\\\nNA\\\\n300 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 mg\\\\nqd \\\\u00d7 7\\\\ndays\\\\nNA\\\\n\\\\u2193 14\\\\n \\\\n(\\\\u2193 7 to \\\\u2193\\\\n21)\\\\n\\\\u2194\\\\nNA\\\\n400 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 m...\",\"meal\\\\n7\\\\u201320\\\\n300 mg\\\\nqd/ritonavir 100\\\\nmg qd d 1\\\\u201310\\\\n(pm), then 400\\\\nmg qd/ritonavir\\\\n100 mg qd d 11\\\\u2013\\\\n24 (pm)\\\\n(simultaneous\\\\nwith EFV)\\\\n600 mg qd\\\\nwith a light\\\\nsnack d\\\\n11\\\\u201324 (pm)\\\\n14\\\\n\\\\u2191 17\\\\n(\\\\u2191 8 to \\\\u2191\\\\n27)\\\\n\\\\u2194\\\\n\\\\u2193 42\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 51)\\\\nIndinavir\\\\n1000 mg q8h \\\\u00d7\\\\n10 days\\\\n600 mg qd\\\\n\\\\u00d7 10 days\\\\n20\\\\nAfter morning dose\\\\n\\\\u2194\\\\n\\\\u2193 33\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 39)\\\\n\\\\u2193 39\\\\n \\\\n(\\\\u2193 24 to\\\\n\\\\u2193 51)\\\\nAfter afternoon dose\\\\n\\\\u2194\\\\n\\\\u2193 37\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 46)\\\\n\\\\u2193 52\\\\n \\\\n(\\\\u2193 47 to\\\\n\\\\u2193 57)\\\\nAfter evening dose\\\\n\\\\u2193 29\\\\n \\\\n(\\\\u2193 11 to\\\\n\\\\u2193 43)\\\\n\\\\u2193 46\\\\n \\\\n(\\\\u2193 37 to\\\\n\\\\u2193 54)\\\\n\\\\u2193 57\\\\n \\\\n(\\\\u2193 50 to\\\\n\\\\u2193 63)\\\\nLopinavir/ritona...\",\"days\\\\n\\\\u00d7 16 days\\\\nto \\\\u2191 8)\\\\n25)\\\\n58)\\\\nSimeprevir\\\\n150 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n23\\\\n\\\\u2193 51\\\\n(\\\\u2193 46 to\\\\n\\\\u2193 56)\\\\n\\\\u2193 71\\\\n(\\\\u2193 67 to\\\\n\\\\u2193 74)\\\\n\\\\u2193 91\\\\n(\\\\u2193 88 to\\\\n\\\\u2193 92)\\\\nLedipasvir/sofosbuvir\\\\n90/400 mg qd \\\\u00d7\\\\n14 days\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\nLedipasvir\\\\n15\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 43)\\\\nSofosbuvir\\\\n\\\\u2194\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2194\\\\n\\\\u2194\\\\n\\\\u2194\\\\nSofosbuvir\\\\n400 mg qd single\\\\ndose\\\\n600 mg qd\\\\n\\\\u00d714 days\\\\n16\\\\n\\\\u2193 19\\\\n(\\\\u2193 40 to\\\\n\\\\u2191 10)\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2193 23\\\\n(\\\\u2193 16 to\\\\n\\\\u2193 30)\\\\n\\\\u2193 16\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 8)\\\\nNA\\\\nSofosbuvir/velpatasvir\\\\n400/100 mg qd \\\\u00d7\\\\n14 days\\\\n600...\",\"120 mg tablets (6\\\\n4-tablet doses\\\\nover 3 days)\\\\nArtemether\\\\n\\\\u2193 21\\\\u2193 38\\\\n\\\\u2193 51\\\\nNA\\\\ndihydroartemisinin\\\\n\\\\u2194\\\\n\\\\u2193 46\\\\nNA\\\\nlumefantrine\\\\n\\\\u219321\\\\nNA\\\\nAtorvastatin\\\\n10 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 14\\\\n(\\\\u2193 1 to \\\\u2193\\\\n26)\\\\n\\\\u2193 43\\\\n(\\\\u2193 34 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 69\\\\n(\\\\u2193 49 to\\\\n\\\\u2193 81)\\\\nTotal active (including\\\\nmetabolites)\\\\n\\\\u2193 15\\\\n(\\\\u2193 2 to \\\\u2193\\\\n26)\\\\n\\\\u2193 32\\\\n(\\\\u2193 21 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 48\\\\n(\\\\u2193 23 to\\\\n\\\\u2193 64)\\\\nPravastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n13\\\\n\\\\u2193 32\\\\n(\\\\u2193 59 to\\\\n\\\\u2191 12)\\\\n\\\\u2193 44\\\\n(\\\\u2193 26 to\\\\n\\\\u2193 57)\\\\n\\\\u2193 19\\\\n(\\\\u2193 0 to \\\\u2193\\\\n35)\\\\nSimvastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 7...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\n\\\\u00f0\\\\n\\\\u00f8\\\\n\\\\u00fd\\\\n\\\\u00a3\\\\nMethadone\\\\nmaintenance 35\\\\u2013\\\\n100 mg daily\\\\n\\\\u00d7 14\\\\u201321\\\\ndays\\\\n11\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 59)\\\\n(\\\\u2193 33 to\\\\n\\\\u2193 66)\\\\nNA\\\\nBupropion\\\\n150 mg single\\\\ndose (sustained-\\\\nrelease)\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 34\\\\n(\\\\u219321 to\\\\n\\\\u219347)\\\\n\\\\u2193 55\\\\n(\\\\u219348 to\\\\n\\\\u219362)\\\\nNA\\\\nHydroxybupropion\\\\n\\\\u2191 50\\\\n(\\\\u2191 20 to\\\\n\\\\u2191 80)\\\\n\\\\u2194\\\\nNA\\\\nSertraline\\\\n50 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 29\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 39\\\\n(\\\\u2193 27 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 46\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 58)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg qd\\\\n\\\\u00d7 9 days\\\\nNA\\\\n\\\\u2193 61\\\\n\\\\u2193 77\\\\nN...\",\"no clinically significant drug interactions have been observed between TDF and abacavir,\\\\nEFV, FTC, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral\\\\ncontraceptives, ribavirin, saquinavir/ritonavir, sofosbuvir, or tacrolimus in trials\\\\nconducted in healthy volunteers.\\\\nFollowing multiple dosing to HIV-negative subjects receiving either chronic methadone\\\\nmaintenance therapy, oral contraceptives, or single doses of ribavirin, steady-state\\\\ntenofovir pharmacokinetics we...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\nTable 7 Drug Interactions: Changes in Pharmacokinetic Parameters for\\\\nCoadministered Drug in the Presence of TDF\\\\nCoadministered\\\\nDrug\\\\nDose of\\\\nCoadministered\\\\nDrug (mg)\\\\nN\\\\nMean % Change of Coadministered\\\\nDrug Pharmacokinetic Parameters\\\\n \\\\n(90% CI)\\\\nC\\\\nAUC\\\\nC\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\nAtazanavir\\\\n400 once daily \\\\u00d7\\\\n14 days\\\\n34\\\\n\\\\u2193 21\\\\n(\\\\u2193 27 to \\\\u2193 14)\\\\n\\\\u2193 25\\\\n(\\\\u2193 30 to \\\\u2193 19)\\\\n\\\\u2193 40\\\\n(\\\\u2193 48 to \\\\u2193 32)\\\\nAtazanavir/ritonavir\\\\n300/100 once daily\\\\n\\\\u00d7 42 days\\\\n10\\\\n\\\\u2193 28\\\\n(\\\\u2193 50 to \\\\u2191 5)\\\\n\\\\u2193 25\\\\n \\\\n(\\\\u2193 42 to \\\\u2193 3)\\\\n\\\\u2193 23\\\\n \\\\n(\\\\u2193 46 to \\\\u2191 10)\\\\nDa...\",\"Efavirenz:\\\\n \\\\nEFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1.\\\\nEfavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1\\\\nreverse transcriptase. HIV-2 RT and human cellular DNA polymerases \\\\u03b1, \\\\u03b2, \\\\u03b3, and \\\\u03b4 are\\\\nnot inhibited by EFV.\\\\nEmtricitabine:\\\\n \\\\nEmtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated\\\\nby cellular enzymes to form FTC 5&#x27;-triphosphate. Emtricitabine 5&#x27;-triphosphate inhibits\\\\nthe activity of the HIV-1 RT by competing wi...\",\"tenofovir were in the range of 0.04\\\\u20138.5 \\\\u00b5M. In drug combination studies of tenofovir\\\\nwith NRTIs (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine),\\\\nNNRTIs (delavirdine, EFV, and nevirapine), and PIs (amprenavir, indinavir, nelfinavir,\\\\nritonavir, and saquinavir), additive to synergistic effects were observed. Tenofovir\\\\ndisplayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O\\\\n(EC\\\\n values ranged from 0.5\\\\u20132.2 \\\\u00b5M) and showed strain-specific ...\",\"susceptibility to FTC was associated with a substitution in the HIV-1 RT gene at codon\\\\n184 which resulted in an amino acid substitution of methionine by valine or isoleucine\\\\n(M184V/I).\\\\nTenofovir DF:\\\\n \\\\nHIV-1 isolates with reduced susceptibility to tenofovir have been selected\\\\nin cell culture. These viruses expressed a K65R substitution in RT and showed a 2- to 4-\\\\nfold reduction in susceptibility to tenofovir.\\\\nCross Resistance\\\\nEfavirenz, Emtricitabine, and Tenofovir DF:\\\\n Cross resistance has been ...\",\"Efavirenz:\\\\n \\\\nLong-term carcinogenicity studies in mice and rats were carried out with EFV.\\\\nMice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of\\\\nhepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas\\\\nwere increased above background in females. No increases in tumor incidence above\\\\nbackground were seen in males. In studies in which rats were administered EFV at\\\\ndoses of 0, 25, 50, or 100 mg/kg/day for 2 years, no increases in tumor incidence\\\\n...\",\"an alteration of the estrous cycle in female rats.\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\nEfavirenz:\\\\n \\\\nNonsustained convulsions were observed in 6 of 20 monkeys receiving EFV at\\\\ndoses yielding plasma AUC values 4- to 13-fold greater than those in humans given the\\\\nrecommended dose.\\\\nTenofovir DF:\\\\n \\\\nTenofovir and TDF administered in toxicology studies to rats, dogs, and\\\\nmonkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed\\\\nin humans caused bone toxicity. In monkeys...\",\"Outcomes\\\\nAt Week 48\\\\nAt Week 144\\\\nFTC+TDF+EFV\\\\n(N=244)\\\\nAZT/3TC+EFV\\\\n(N=243)\\\\nFTC+TDF+\\\\nEFV\\\\n(N=227)\\\\nAZT/3TC+EFV\\\\n(N=229)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\nResponder\\\\n84%\\\\n73%\\\\n71%\\\\n58%\\\\nVirologic failure\\\\n2%\\\\n4%\\\\n3%\\\\n6%\\\\n  Rebound\\\\n1%\\\\n3%\\\\n2%\\\\n5%\\\\n  Never suppressed\\\\n0%\\\\n0%\\\\n0%\\\\n0%\\\\n  Change in antiretroviral\\\\nregimen\\\\n1%\\\\n1%\\\\n1%\\\\n1%\\\\nDeath\\\\n&lt;1%\\\\n1%\\\\n1%\\\\n1%\\\\nDiscontinued due to\\\\nadverse event\\\\n4%\\\\n9%\\\\n5%\\\\n12%\\\\nDiscontinued for other\\\\nreasons\\\\n10%\\\\n14%\\\\n20%\\\\n22%\\\\nThrough Week 48, 84% and 73% of subjects in the FTC + TDF group and the\\\\nzidovudine/lamivudine group, respectiv...\",\"22-73 years); 88% were male, 68% were white, 29% were Black or African-American,\\\\nand 3% were of other races. At baseline, median CD4\\\\n cell count was 516 cells/mm\\\\n,\\\\nand 96% had HIV-1 RNA &lt;50 copies/mL. The median time since onset of antiretroviral\\\\ntherapy was 3 years, and 88% of subjects were receiving their first antiretroviral\\\\nregimen at trial enrollment.\\\\nAt Week 48, 89% and 87% of subjects who switched to ATRIPLA maintained HIV RNA\\\\n&lt;200 copies/mL and &lt;50 copies/mL, respectively, compared to 88...\",\"Interactions (7)\\\\n]\\\\n.\\\\nPsychiatric Symptoms\\\\nInform patients that serious psychiatric symptoms including severe depression,\\\\nsuicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms,\\\\nand catatonia have been reported in patients receiving EFV, a component of ATRIPLA\\\\n[see \\\\nWarnings and Precautions (5.5)\\\\n]\\\\n.\\\\nAdvise patients to seek immediate medical evaluation if they experience severe\\\\npsychiatric adverse experiences.\\\\nAdvise patients to inform their physician of any history o...\",\"Convulsions\\\\nInform patients that convulsions have been reported with the use of EFV, a component\\\\nof ATRIPLA. Patients who are receiving concomitant anticonvulsant medications primarily\\\\nmetabolized by the liver may require periodic monitoring of plasma levels \\\\n[see \\\\nWarnings\\\\nand Precautions (5.10)\\\\n and \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\nLactic Acidosis and Severe Hepatomegaly\\\\nInform patients that lactic acidosis and severe hepatomegaly with steatosis, including\\\\nfatal cases, have been reported. Treatmen...\",\"Patient Information\\\\n \\\\nATRIPLA\\\\u2122 (uh TRIP luh)\\\\n(efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets\\\\nWhat is the most important information I should know about ATRIPLA?\\\\nATRIPLA can cause serious side effects, including:\\\\nWorsening of hepatitis B virus (HBV) infection.\\\\n Your healthcare provider will\\\\ntest you for HBV before starting treatment with ATRIPLA. If you have HBV infection\\\\nand take ATRIPLA, your HBV may get worse (flare-up) if you stop taking ATRIPLA. \\\\nA\\\\n\\\\\"flare-up\\\\\" is when yo...\",\"be pregnant during treatment with ATRIPLA.\\\\nFemales who are able to become pregnant should use 2 effective\\\\nforms of birth control (contraception) during treatment with ATRIPLA\\\\nand for 12 weeks after stopping treatment.\\\\nA barrier form of birth control should always be used along with\\\\nanother type of birth control\\\\n. Barrier forms of birth control may include\\\\ncondoms, contraceptive sponges, diaphragm with spermicide, and cervical cap.\\\\nBirth control methods that contain the hormone progesterone such ...\",\"See \\\\\"\\\\nWhat is the most important information I should know about\\\\nATRIPLA?\\\\n\\\\\"\\\\nRash.\\\\n Rash is a serious side effect, but may also be common. Rashes will usually go\\\\naway without any change in your treatment. Tell your healthcare provider right away\\\\nif you develop a rash during treatment with ATRIPLA.\\\\nSevere liver problems. I\\\\nn rare cases, severe liver problems can happen that can\\\\nlead to death. \\\\nTell your healthcare provider right away if you get these\\\\nsymptoms:\\\\n skin or the white part of your eyes ...\",\"provider right away if you develop any of these symptoms:\\\\nweakness or being more tired than\\\\nusual\\\\nbeing short of breath or fast\\\\nbreathing\\\\ncold or blue hands and feet\\\\nfast or abnormal heartbeat\\\\nunusual muscle pain\\\\nstomach pain with nausea and vomiting\\\\nfeel dizzy or lightheaded\\\\nChanges in your immune system (Immune Reconstitution Syndrome) can\\\\nhappen when an HIV-1 infected person starts taking HIV-1 medicines.\\\\n Your\\\\nimmune system may get stronger and begin to fight infections that have been hidden...\",\"respective owners.\\\\n\\\\u00a9 2019 Gilead Sciences, LLC. All rights reserved.\\\\n21937-GS-020A\\\\nPRINCIPAL DISPLAY PANEL - 30 Tablet Bottle Label\\\\n61958-1601-3\\\\n30 tablets\\\\nATRIPLA\\\\u2122\\\\n(efavirenz 600 mg/emtricitabine 200 mg/\\\\ntenofovir disoproxil fumarate 300 mg)\\\\ntablets\\\\nGILEAD ACCESS PROGRAM\\\\nNote to pharmacist: Do not cover ALERT box with pharmacy label.\\\\nALERT: Find out about medicines that\\\\nshould NOT be taken with ATRIPLA\\\\nRx only\\\\nPOM\\\\nATRIPLA ACCESS  \\\\nefavirenz, emtricitabine, and tenofovir disoproxil fumarate tabl...\",\"Gilead Sciences, Inc.\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nEFAVIRENZ\\\\n (UNII: JE6H2O27P8) \\\\n(EFAVIRENZ - UNII:JE6H2O27P8)\\\\nEFAVIRENZ\\\\n600 mg\\\\nEMTRICITABINE\\\\n (UNII: G70B4ETF4S) \\\\n(EMTRICITABINE - UNII:G70B4ETF4S)\\\\nEMTRICITABINE\\\\n200 mg\\\\nTENOFOVIR DISOPROXIL FUMARATE\\\\n (UNII: OTT9J7900I) \\\\n(TENOFOVIR\\\\nANHYDROUS - UNII:W4HFE001U5)\\\\nTENOFOVIR DISOPROXIL\\\\nFUMARATE\\\\n300 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nHYDROXYPROPYL CELLULOSE (1600000 WAMW)\\\\n (UNII: RF...\",\"APRETUDE- cabotegravir \\\\n \\\\nViiV Healthcare Company\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use APRETUDE safely and\\\\neffectively. See full prescribing information for APRETUDE.\\\\nAPRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use\\\\nInitial U.S. Approval: 2021\\\\nWARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-\\\\nEXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION\\\\nSee full pres...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nADVERSE REACTIONS\\\\nThe most common adverse reactions (all grades) observed in at least 1% of participants receiving\\\\nAPRETUDE were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea,\\\\ndizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back\\\\npain, and upper respiratory tract infection. (\\\\n6.1\\\\n)\\\\nTo report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or\\\\nFDA at 1-800-FDA-1088 or \\\\nwww.fda.go...\",\"5.4 Hypersensitivity Reactions\\\\n5.5 Hepatotoxicity\\\\n5.6 Depressive Disorders\\\\n5.7 Risk of Reduced Drug Concentration of APRETUDE Due to Drug Interactions\\\\n6 ADVERSE REACTIONS\\\\n6.1 Clinical Trials Experience\\\\n6.2 Postmarketing Experience\\\\n7 DRUG INTERACTIONS\\\\n7.1 Use of Other Antiretroviral Drugs after Discontinuation of APRETUDE\\\\n7.2 Potential for Other Drugs to Affect APRETUDE\\\\n7.3 Established and Other Potentially Significant Drug Interactions\\\\n7.4 Drugs without Clinically Significant Interactions with C...\",\"WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR\\\\nHIV-1 PRE\\\\u2011EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1\\\\nINFECTION\\\\nIndividuals must be tested for HIV-1 infection prior to initiating\\\\nAPRETUDE or oral cabotegravir, and with each subsequent injection of\\\\nAPRETUDE, using a test approved or cleared by the FDA for the\\\\ndiagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1\\\\nvariants have been identified with use of APRETUDE by individuals with\\\\nundiagnosed HIV-1 infection. Do not ...\",\"Prior to starting APRETUDE, healthcare providers should carefully select individuals who\\\\nagree to the required injection dosing and testing schedule and counsel individuals about\\\\nthe importance of adherence to scheduled dosing visits to help reduce the risk of\\\\nacquiring HIV-1 infection and development of resistance \\\\n[see Dosage and Administration\\\\n(\\\\n2.1\\\\n), Warnings and Precautions (\\\\n5.1\\\\n, \\\\n5.3\\\\n), Microbiology (\\\\n12.4\\\\n)]\\\\n.\\\\n2.4 Optional Oral Lead-In Dosing to Assess Tolerability of APRETUDE\\\\nThe heal...\",\"Table 2. Recommended Dosing Schedule (Direct to Injection) for Pre-\\\\nExposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg\\\\n Individuals may be given APRETUDE up to 7 days before or after the date the individual\\\\nis scheduled to receive the injections.\\\\nIntramuscular (Gluteal) \\\\nInitiation Injection \\\\n(Month 1 and Month 2)\\\\nIntramuscular (Gluteal) \\\\nContinuation Injection \\\\n(Month 4 and Every 2 Months\\\\nOnwards)\\\\nAPRETUDE\\\\nAPRETUDE\\\\n600-mg (3 mL)\\\\n600-mg (3 mL)\\\\n2.6 Recommended Dosing Schedule ...\",\"Greater than 2 months\\\\nRestart with 600-mg (3-mL) gluteal intramuscular\\\\ninjection of APRETUDE, followed by a second 600-mg\\\\n(3-mL) initiation injection dose 1 month later. Then\\\\ncontinue to follow the every-2-month injection dosing\\\\nschedule thereafter.\\\\nIf third or subsequent\\\\ninjection is missed and time\\\\nsince prior injection is:\\\\nLess than or equal to 3 months\\\\nAdminister 600-mg (3-mL) intramuscular injection of\\\\nAPRETUDE as soon as possible, then continue with\\\\nthe every-2-month injection dosing sched...\",\"3 DOSAGE FORMS AND STRENGTHS\\\\nInjection: Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir\\\\nextended\\\\u2011release injectable suspension.\\\\n4 CONTRAINDICATIONS\\\\nAPRETUDE is contraindicated in individuals:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Comprehensive Management to Reduce the Risk of HIV-1 Infection\\\\nUse APRETUDE for HIV-1 PrEP to reduce the risk of HIV-1 infection as part of a\\\\ncomprehensive prevention strategy including adherence to the administration schedule\\\\nand safer sex practices,...\",\"\\\\u2022\\\\nWhen using APRETUDE for HIV-1 PrEP, HIV-1 testing should be repeated prior to each\\\\ninjection and upon diagnosis of any other STIs \\\\n[see Dosage and Administration (\\\\n2.2\\\\n,\\\\n2.5\\\\n)]\\\\n.\\\\n\\\\u2022\\\\nCounsel individuals without HIV-1 to strictly adhere to the recommended dosing and\\\\ntesting schedule for APRETUDE in order to reduce the risk of HIV-1 acquisition and the\\\\npotential development of resistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n, \\\\n2.5\\\\n),\\\\nMicrobiology (\\\\n12.4\\\\n)]\\\\n. Some individuals, such as adolescents,...\",\"include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) \\\\n[see Adverse\\\\nReactions (\\\\n6.2\\\\n)]\\\\n. Administration of cabotegravir oral lead-in dosing was used in clinical\\\\nstudies to help identify participants who may be at risk of a hypersensitivity reaction.\\\\nRemain vigilant and discontinue APRETUDE if a hypersensitivity reaction is suspected\\\\n[see Dosage and Administration (\\\\n2.4\\\\n), Contraindications (\\\\n4\\\\n), Adverse Reactions (\\\\n6\\\\n)]\\\\n.\\\\nDiscontinue APRETUDE immediately if signs or symptoms o...\",\"6.1 Clinical Trials Experience\\\\nBecause clinical trials are conducted under widely varying conditions, adverse reaction\\\\nrates observed in the clinical trials of a drug cannot be directly compared with rates in\\\\nthe clinical trials of another drug and may not reflect rates observed in practice.\\\\nClinical Trials Experience in Adults\\\\nThe safety assessment of APRETUDE is based on the analysis of data from 2\\\\ninternational, multicenter, double-blind trials, HPTN 083 and HPTN 084 \\\\n[see Clinical\\\\nStudies (\\\\n...\",\"Adverse reactions defined as \\\\u201ctreatment-related\\\\u201d as assessed by the investigator, with\\\\nexception of injection site reactions, where all injection site reactions were reported\\\\nregardless of causality.\\\\n Participants who received injection: HPTN 083, APRETUDE (n = 2,117) and TRUVADA\\\\n(n = 2,081); HPTN 084, APRETUDE (n = 1,519) and TRUVADA (n = 1,516).\\\\n Pyrexia includes pyrexia, feeling hot, chills, influenza-like illness.\\\\n Fatigue includes fatigue, malaise.\\\\n Sleep disorders includes insomnia, abnorm...\",\"grades) in at least 1% of participants who received APRETUDE and experienced at least\\\\none ISR from HPTN 084 are presented in \\\\nTable 5\\\\n.\\\\nTable 5. Injection Site Reactions (All Grades) Reported in at Least 1% of\\\\nParticipants Who Experienced at Least One Injection Site Reaction (All\\\\nCausality) with APRETUDE in Either HPTN 083 or HPTN 084\\\\n Placebo injectable suspension: intralipid 20% fat emulsion.\\\\nInjection Site\\\\nReactions\\\\nHPTN 083\\\\nHPTN 084\\\\nAPRETUDE\\\\n(n = 1,740)\\\\nTRUVADA\\\\n(n = 724)\\\\nAPRETUDE\\\\n(n = 578)\\\\nT...\",\"At the Week 41 and 97 timepoints in HPTN 084, participants who received APRETUDE\\\\ngained a median of 2 kg (IQR; 0.0, 5.0; n = 1,151) and 4 kg (IQR; 0.0, 8.0; n = 216) in\\\\nweight from baseline, respectively. Those who received TRUVADA gained a median of\\\\n1 kg (IQR; -1.0, 4.0; n = 1,131) and 3 kg (IQR; -1.0, 6.0; n = 218) in weight from\\\\nbaseline, respectively.\\\\nLaboratory Abnormalities: \\\\nGrade 3 or 4 post-baseline maximum toxicity laboratory\\\\nabnormalities for HPTN 083 or HPTN 084 are summarized in \\\\nTa...\",\"Nearly 60% of participants with baseline data available had Week 57 data available in\\\\nboth arms of both trials. Within each trial, baseline values were comparable among\\\\nparticipants receiving APRETUDE and TRUVADA.\\\\nHDL cholesterol\\\\nratio\\\\nClinical Trials Experience in Adolescents\\\\nIn adolescents receiving APRETUDE for HIV-1 PrEP, the safety data were comparable to\\\\nthe safety data reported in adults receiving APRETUDE for HIV-1 PrEP \\\\n[see Use in\\\\nSpecific Populations (\\\\n8.4\\\\n)].\\\\n6.2 Postmarketing Experi...\",\"inclusive.\\\\nTable 8. Drug Interactions with APRETUDE\\\\n\\\\u2191 = Increase, \\\\u2193 = Decrease, \\\\u2194 = No change.\\\\nConcomitant Drug\\\\nClass:\\\\nDrug Name\\\\nEffect on\\\\nConcentration\\\\nClinical Comment\\\\nAnticonvulsants:\\\\nCarbamazepine\\\\nOxcarbazepine\\\\nPhenobarbital\\\\nPhenytoin\\\\n\\\\u2193Cabotegravir\\\\nCoadministration is contraindicated with\\\\nAPRETUDE due to potential for significant\\\\ndecreases in plasma concentration of\\\\nAPRETUDE.\\\\nAntimycobacterials:\\\\nRifampin\\\\nRifapentine\\\\n\\\\u2193Cabotegravir\\\\nAntimycobacterial:\\\\nRifabutin\\\\n\\\\u2193Cabotegravir\\\\nWhen rifabutin is s...\",\"4263.\\\\nRisk Summary\\\\nThere are insufficient human data on the use of APRETUDE during pregnancy to\\\\nadequately assess a drug-associated risk of birth defects and miscarriage. Discuss the\\\\nbenefit-risk of using APRETUDE with individuals of childbearing potential or during\\\\npregnancy.\\\\nCabotegravir use in pregnant individuals has not been evaluated. APRETUDE should be\\\\nused during pregnancy only if the expected benefit justifies the potential risk to the\\\\nfetus.\\\\nThe APR has been established to monitor for ...\",\"exposure in humans at the RHD); there were no alterations to growth and development\\\\nof surviving offspring. In a cross-fostering study, similar incidences of stillbirths and\\\\nearly postnatal deaths were observed when rat pups born to cabotegravir-treated\\\\nmothers were nursed from birth by control mothers. There was no effect on neonatal\\\\nsurvival of control pups nursed from birth by cabotegravir-treated mothers. A lower\\\\ndose of 5 mg/kg/day (13 times the exposure at the RHD) was not associated with\\\\n...\",\"APRETUDE. Adolescents may benefit from more frequent visits and counseling to\\\\nsupport adherence to the dosing and testing schedule \\\\n[see Dosage and Administration\\\\n(\\\\n2.2\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)].\\\\nThe safety, efficacy, and pharmacokinetics of APRETUDE in pediatric participants\\\\nyounger than 12 years of age or weighing &lt;35 kg have not been established.\\\\n8.5 Geriatric Use\\\\nNo dose adjustment is required in elderly individuals. There are limited data available on\\\\nthe use of APRETUDE in indiv...\",\"Cabotegravir extended-release injectable suspension is a white to light pink free-flowing\\\\nsuspension for intramuscular injection in a sterile single-dose vial. Each vial contains\\\\n3 mL of the following: cabotegravir 200 mg/mL and the inactive ingredients mannitol\\\\n(35 mg/mL), polyethylene glycol (PEG) 3350 (20 mg/mL), polysorbate 20 (20 mg/mL),\\\\nand Water for Injection.\\\\nThe vial stoppers are not made with natural rubber latex.\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nCabotegravir is an HIV...\",\"CSF = Cerebrospinal fluid.\\\\n When taken orally with a high-fat meal versus fasted, the AUC\\\\n (geometric mean\\\\nratio [90% CI] of cabotegravir are 1.14 [1.02, 1.28]).\\\\n The clinical relevance of CSF-to-plasma concentration ratios is unknown.\\\\nConcentrations were measured at steady-state 1 week after intramuscular\\\\nadministration of cabotegravir extended-release injectable suspensions given monthly or\\\\nevery 2 months.\\\\n Elimination half-life driven by slow absorption rate from the intramuscular injection s...\",\"with HIV-1 (n = 110), the observed cabotegravir geometric mean (5th, 95th percentile)\\\\nC\\\\n (1-week post\\\\u2011initial injection) was 1.89 mcg/mL (0.438, 5.69) and C\\\\n was\\\\n1.43 mcg/mL (0.403, 3.90).\\\\n Pharmacokinetic parameter values represent steady state.\\\\nSpecific Populations\\\\nNo clinically significant differences in the pharmacokinetics of cabotegravir were\\\\nobserved based on age, sex, race/ethnicity, BMI, or UGT1A1 polymorphisms. There are\\\\nno data available for the use of cabotegravir in participants wit...\",\"IM = intramuscular.\\\\n Pharmacokinetic parameter values were based on individual post-hoc estimates from\\\\npopulation pharmacokinetic models in both adolescents with HIV-1 (n = 147) weighing\\\\n35.2 to 98.5 kg and adolescents without HIV-1 (n = 62) weighing 39.9 to 167 kg. \\\\n tau is dosing interval: 24 hours for oral administration, 1 month for the initial injection,\\\\nand 2 months for every 2 months for intramuscular injections of extended-release\\\\ninjectable suspension.\\\\n Oral lead-in pharmacokinetic para...\",\"n = Maximum number of participants with data, CI = Confidence Interval.\\\\nCoadministered\\\\nDrug(s)\\\\nand Dose(s)\\\\nDose of\\\\nCabotegravir\\\\nn\\\\nNo Effect = 1.00\\\\nC\\\\nAUC\\\\nC\\\\n or C\\\\nEtravirine\\\\n30 mg\\\\n12\\\\n1.04\\\\n1.01\\\\n1.00\\\\n    200 mg twice\\\\ndaily\\\\nonce daily\\\\n(0.99, 1.09)\\\\n(0.96, 1.06)\\\\n(0.94, 1.06)\\\\nRifabutin\\\\n30 mg\\\\n12\\\\n0.83\\\\n0.77\\\\n0.74\\\\n    300 mg once\\\\ndaily\\\\nonce daily\\\\n(0.76, 0.90)\\\\n(0.74, 0.83)\\\\n(0.70, 0.78)\\\\nRifampin\\\\n30-mg\\\\n15\\\\n0.94\\\\n0.41\\\\n0.50\\\\n    600 mg once\\\\ndaily\\\\nsingle dose\\\\n(0.87, 1.02)\\\\n(0.36, 0.46)\\\\n(0.44, 0.57)\\\\nRilpivirine\\\\n30 mg\\\\n1...\",\"12.4 Microbiology\\\\nMechanism of Action\\\\nCabotegravir inhibits HIV integrase by binding to the integrase active site and blocking\\\\nthe strand transfer step of retroviral deoxyribonucleic acid (DNA) integration that is\\\\nessential for the HIV replication cycle. The mean 50% inhibitory concentration (IC\\\\n)\\\\nvalue of cabotegravir in a strand transfer assay using purified recombinant HIV-1\\\\nintegrase was 3.0 nM.\\\\nAntiviral Activity in Cell Culture\\\\nCabotegravir exhibited antiviral activity against laboratory s...\",\"cabotegravir exposures below the target concentration. No variants expressing INSTI\\\\nresistance-associated substitutions were detected.\\\\nCross-Resistance\\\\nCross-resistance has been observed among INSTIs. Cabotegravir had reduced\\\\nsusceptibility (&gt;5-fold change) to recombinant HIV-1 strain NL432 viruses harboring the\\\\nfollowing integrase amino acid substitutions: G118R, Q148K, Q148R, T66K+L74M,\\\\nE92Q+N155H, E138A+Q148R, E138K+Q148K/R, G140C+Q148R, G140S+Q148H/K/R,\\\\nY143H+N155H, and Q148R+N155H (range: 5...\",\"in men and transgender women without HIV-1 who have sex with men and have\\\\nevidence of high-risk behavior for HIV-1 infection and HPTN 084 in cisgender women\\\\nwithout HIV-1 at risk of acquiring HIV-1.\\\\nParticipants randomized to receive APRETUDE initiated oral lead-in dosing with 1 oral\\\\ncabotegravir 30-mg tablet and a placebo daily for up to 5 weeks, followed by APRETUDE\\\\n600\\\\u2011mg (3-mL) intramuscular injection at months 1 and 2 and every 2 months\\\\nthereafter and a daily placebo tablet. Participants ra...\",\"Results from all subgroup analyses were consistent with the overall protective effect. A\\\\nlower rate of incident HIV\\\\u20111 infections was observed for participants randomized to\\\\nAPRETUDE compared with participants randomized to TRUVADA (\\\\nTable 15\\\\n).\\\\nTable 15. Incident of HIV-1 Infections by Subgroup in HPTN 083: Extended\\\\nRetrospective Virologic Testing with Readjudicated Endpoints\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence per\\\\n100 Person-\\\\nYears\\\\nAPRETUDE\\\\nPerson-Years\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nP...\",\"mITT from Supplemental Virology Report. \\\\n Cisgender men who have sex with men.\\\\n Transgender women who have sex with men.\\\\nTGW\\\\n0.54\\\\n371\\\\n1.80\\\\n389\\\\n0.34\\\\n(0.08,\\\\n1.56)\\\\nRace (US)\\\\nBlack\\\\n0.58\\\\n691\\\\n2.28\\\\n703\\\\n0.26\\\\n(0.09,\\\\n0.76)\\\\nNon-Black\\\\n0.00\\\\n836\\\\n0.50\\\\n801\\\\n0.11\\\\n(0.00,\\\\n2.80)\\\\nRegion\\\\nUS\\\\n0.26\\\\n1,528\\\\n1.33\\\\n1,504\\\\n0.21\\\\n(0.07,\\\\n0.60)\\\\nLatin\\\\nAmerica\\\\n0.49\\\\n1,020\\\\n1.09\\\\n1,011\\\\n0.47\\\\n(0.17,\\\\n1.35)\\\\nAsia\\\\n0.35\\\\n570\\\\n1.03\\\\n581\\\\n0.39\\\\n(0.08,\\\\n1.82)\\\\nAfrica\\\\n1.08\\\\n93\\\\n2.07\\\\n97\\\\n0.63\\\\n(0.06,\\\\n6.50)\\\\nTrial 201739 (HPTN 084 [NCT03164564])\\\\nIn HPTN 084, a su...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\",\"mITT from Supplemental Virology Report.\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nAPRETUDE\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nPerson-\\\\nYears\\\\nHazard\\\\nRatio\\\\n(95% CI)\\\\nAge\\\\n&lt;25 years\\\\n0.23\\\\n868\\\\n2.34\\\\n853\\\\n0.12\\\\n(0.03, 0.46)\\\\n\\\\u226525 years\\\\n0.09\\\\n1,093\\\\n1.46\\\\n1,093\\\\n0.09\\\\n(0.02, 0.49)\\\\nBody Mass Index\\\\n&lt;30\\\\n0.22\\\\n1,385\\\\n1.88\\\\n1,435\\\\n0.12\\\\n(0.04, 0.38)\\\\n\\\\u226530\\\\n0.00\\\\n575\\\\n1.76\\\\n511\\\\n0.04\\\\n(0.00, 0.93)\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nHow Supplied\\\\nAPRETUDE is supplied in a kit containing one 600-mg/3...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nPotential Risk of Resistance with APRETUDE\\\\nAdvise individuals there is a potential risk of developing resistance to APRETUDE if HIV-1\\\\nis acquired either before or while taking APRETUDE or following discontinuation of\\\\nAPRETUDE \\\\n[see Warnings and Precautions (\\\\n5.2\\\\n)]\\\\n.\\\\nTo minimize this, it is essential that individuals are clinically reassessed for risk of HIV-1\\\\nacquisition and tested frequently to confirm HIV-1 negative status. Advise individuals\\\\nwho are confirmed to have with HIV...\",\"Counsel individuals about the importance of continued medication adherence and\\\\nscheduled visits to help reduce the risk of acquiring HIV-1 infection and development of\\\\nresistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)]\\\\n.\\\\nHypersensitivity Reactions\\\\nAdvise individuals to immediately contact their healthcare provider if they develop a rash.\\\\nInstruct individuals to immediately stop taking APRETUDE and seek medical attention if\\\\nthey develop a rash associated with an...\",\"Warnings and Precautions (\\\\n5.3\\\\n), Use in Specific Populations (\\\\n8.1\\\\n)]\\\\n.\\\\nLactation\\\\nInform individuals that due to the potential for adverse reactions and residual\\\\nconcentrations in the systemic circulation for up to 12 months or longer after\\\\ndiscontinuing injections of APRETUDE, it is recommended that mothers breastfeed only\\\\nif the expected benefit justifies the potential risk to the infant. The benefits and risks of\\\\nAPRETUDE while breastfeeding should be evaluated, including the risk of HIV-1\\\\na...\",\"While you are receiving APRETUDE for HIV-1 PrEP:\\\\n\\\\u2022\\\\n\\\\u2022\\\\nIf you have HIV-1 and receive only APRETUDE, over time your HIV-1 may\\\\nbecome harder to treat.\\\\nWhat is APRETUDE?\\\\nAPRETUDE is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting\\\\nHIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg).\\\\nHIV-1 is the virus that causes acquired immune deficiency syndrome (AIDS).\\\\nIt is not known if APRETUDE is safe and effective in children younger than 12 years o...\",\"\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\nBefore receiving APRETUDE, tell your healthcare provider about all your\\\\nmedical conditions, including if you:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nTell your healthcare provider about all the medicines you take,\\\\n including\\\\nprescription and over-the-counter medicines, vitamins, and herbal supplements.\\\\nSome medicines may interact with APRETUDE. Keep a list of your medicines and show it\\\\nto your healthcare provider and pharmacist when you get a new medicine.\\\\nYou can ask your healthcare provider or pharmacist fo...\",\"What are the possible side effects of APRETUDE?\\\\nAPRETUDE may cause serious side effects including:\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\nThe most common side effects of APRETUDE include:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAllergic reactions.\\\\n Call your healthcare provider right away if you develop a rash\\\\nwith APRETUDE. \\\\nStop receiving APRETUDE and get medical help right away\\\\nif you develop a rash with any of the following signs or symptoms:\\\\n\\\\u25cb   fever\\\\n\\\\u25cb   generally ill feeling\\\\n\\\\u25cb   tiredness\\\\n\\\\u25cb   mu...\",\"These are not all the possible side effects of APRETUDE.\\\\nCall your doctor for medical advice about side effects. You may report side effects to\\\\nFDA at 1-800-FDA-1088.\\\\nGeneral information about the safe and effective use of APRETUDE.\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Patient\\\\nInformation leaflet. You can ask your pharmacist or healthcare provider for information\\\\nabout APRETUDE that is written for health professionals.\\\\nWhat are the ingredients in APRETUDE?...\",\"Overview:\\\\nA complete dose of APRETUDE requires 1 injection: 600-mg (3 mL) of cabotegravir.\\\\nAPRETUDE is a suspension that does not need further dilution or reconstitution.\\\\nCarefully follow these instructions when preparing the suspension for injection to avoid\\\\nleakage.\\\\nAPRETUDE is for gluteal intramuscular use only.\\\\nNote:\\\\n The ventrogluteal site is recommended.\\\\n Storage information\\\\nStore at 2\\\\u00b0C to 25\\\\u00b0C (36\\\\u00b0F to 77\\\\u00b0F). Exposure up to 30\\\\u00b0C (86\\\\u00b0F) permitted.\\\\nDo not \\\\nfreeze.\\\\nPrior to administration:\\\\n...\",\"\\\\u2022\\\\nYour pack contains:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nConsider the individual\\\\u2019s build and use medical judgment to select an appropriate\\\\ninjection needle length.\\\\nYou will also need:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\ntemperature prior to administration (not to exceed 30\\\\u00b0C [86\\\\u00b0F]).\\\\nOnce APRETUDE has been drawn into the syringe, the medicine can remain in the\\\\nsyringe for up to 2 hours before injection. The filled syringe should not be placed in\\\\nthe refrigerator. If the medicine remains in the syringe for more than 2 hours, the\\\\nfilled syringe and ne...\",\"Preparation:\\\\n1. Inspect the vial.\\\\nFigure A\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n\\\\u2022\\\\n2. Shake the vial vigorously.\\\\nFigure B\\\\n\\\\u2022\\\\n3. Inspect suspension.\\\\nFigure C\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n4. Remove the vial cap.\\\\nCheck that the\\\\nexpiration date has\\\\nnot passed. \\\\nSee\\\\nFigure A.\\\\nInspect the vial\\\\nimmediately. If you\\\\ncan see foreign\\\\nmatter, do not use\\\\nthe product.\\\\nNote:\\\\n The vial has a\\\\nbrown tint to the\\\\nglass.\\\\nDo not\\\\n use if the\\\\nexpiration date has\\\\npassed.\\\\nIf the pack has been\\\\nstored in the\\\\nrefrigerator, allow the\\\\nmedication to come to\\\\nroom temperature.\\\\nHold...\",\"Figure D\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n5. Peel open the vial adapter.\\\\nFigure E\\\\n\\\\u2022\\\\n \\\\n \\\\n6. Place vial on flat surface and attach the vial adapter.\\\\nFigure F\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n7. Lift off the packaging.\\\\nRemove the cap from\\\\nthe vial. \\\\nSee Figure\\\\nD.\\\\nWipe the rubber\\\\nstopper with an\\\\nalcohol wipe.\\\\nDo not\\\\n allow\\\\nanything to touch the\\\\nrubber stopper after\\\\nwiping it.\\\\nPeel off the paper\\\\nbacking from the vial\\\\nadapter packaging.\\\\nSee Figure E.\\\\nNote:\\\\n Do not remove\\\\nthe adapter from its\\\\npackaging for the\\\\nnext step. The\\\\nadapter \\\\nwill not\\\\n fall\\\\nout wh...\",\"Figure G\\\\n\\\\u2022\\\\n8. Prepare the syringe.\\\\nFigure H\\\\n\\\\u2022\\\\n\\\\u2022\\\\n9. Attach the syringe.\\\\nFigure I\\\\n\\\\u2022\\\\n\\\\u2022\\\\n10. Press the plunger.\\\\nLift off the vial\\\\nadapter packaging, as\\\\nshown.\\\\n See Figure\\\\nG.\\\\nRemove the syringe\\\\nfrom its packaging.\\\\nDraw 1 mL of air into\\\\nthe syringe. This will\\\\nmake it easier to draw\\\\nup the medicine later.\\\\nSee Figure H.\\\\nHold the vial adapter\\\\nand vial firmly, as\\\\nshown.\\\\nScrew the syringe\\\\nfirmly onto the vial\\\\nadapter. \\\\nSee Figure\\\\nI.\",\"Figure J\\\\n\\\\u2022\\\\n11. Slowly draw up the dose.\\\\nFigure K\\\\n\\\\u2022\\\\n \\\\n12. Unscrew the syringe.\\\\nFigure L\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n13. Attach the needle.\\\\nPress the plunger all\\\\nthe way down to push\\\\nthe air into the vial.\\\\nSee Figure J.\\\\nInvert the syringe and\\\\nvial and slowly\\\\nwithdraw as much of\\\\nthe medicine as\\\\npossible into the\\\\nsyringe. There may be\\\\nmore medicine than\\\\nthe dose amount.\\\\nSee Figure K.\\\\nNote:\\\\n Keep the\\\\nsyringe upright to\\\\navoid leakage.\\\\nHold the syringe\\\\nplunger firmly in place\\\\nas shown to prevent\\\\nleakage. It is normal\\\\nto fee...\",\"Figure M\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nInjection:\\\\n14. Prepare the injection site.\\\\nFigure N\\\\n \\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n15. Remove the cap.\\\\nPeel open the needle\\\\npackaging part way to\\\\nexpose the needle\\\\nbase.\\\\nKeeping the syringe\\\\nupright, firmly twist\\\\nthe syringe onto the\\\\nneedle.\\\\nRemove the needle\\\\npackaging from the\\\\nneedle. \\\\nSee Figure\\\\nM.\\\\nAPRETUDE must be\\\\nadministered to a\\\\ngluteal site. \\\\nSee\\\\nFigure N\\\\n.\\\\nSelect from the\\\\nfollowing areas for the\\\\ninjection:\\\\nVentrogluteal, as\\\\nshown\\\\n(recommended)\\\\nDorsogluteal, not\\\\nshown (upper outer\\\\nquadrant)\\\\nNote...\",\"Figure O\\\\n\\\\u2022\\\\n\\\\u2022\\\\n16. Remove extra liquid from the syringe.\\\\nFigure P\\\\n\\\\u2022\\\\n \\\\n17. Stretch the skin.\\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\nFold the needle guard\\\\naway from the needle.\\\\nSee Figure O.\\\\nPull off the injection\\\\nneedle cap.\\\\nHold the syringe with\\\\nthe needle pointing\\\\nup. Press the plunger\\\\nto the 3 mL dosing\\\\nmark to remove extra\\\\nliquid and any air\\\\nbubbles. \\\\nSee Figure\\\\nP.\\\\nNote:\\\\n Clean the\\\\ninjection site with an\\\\nalcohol wipe. Allow the\\\\nskin to air dry before\\\\ncontinuing.\\\\nUse the z-track\\\\ninjection technique to\\\\nminimize medicine\\\\nleakage ...\",\"Figure Q\\\\n18. Insert the needle.\\\\nFigure R\\\\n\\\\u2022\\\\n19. Inject the dose of medicine.\\\\nFigure S\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n20. Assess the injection site.\\\\nInsert the needle to\\\\nits full depth, or deep\\\\nenough to reach the\\\\nmuscle. \\\\nSee Figure\\\\nR.\\\\nStill holding the skin\\\\nstretched \\\\u2013 slowly\\\\npress the plunger all\\\\nthe way down. \\\\nSee\\\\nFigure S.\\\\nEnsure the syringe is\\\\nempty.\\\\nWithdraw the needle\\\\nand release the\\\\nstretched skin\\\\nimmediately.\",\"Figure T\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n21. Make the needle safe.\\\\nFigure U\\\\n\\\\u2022\\\\nFigure V\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAfter injection:\\\\n22. Dispose safely.\\\\nApply pressure to the\\\\ninjection site using a\\\\ngauze pad. \\\\nSee\\\\nFigure T.\\\\nA small bandage may\\\\nbe used if bleeding\\\\noccurs.\\\\nDo not\\\\n massage the\\\\narea.\\\\nFold the needle guard\\\\nover the needle. \\\\nSee\\\\nFigure U.\\\\nGently apply pressure\\\\nusing a hard surface\\\\nto lock the needle\\\\nguard in place.\\\\nThe needle guard will\\\\nmake a click when it\\\\nlocks. \\\\nSee Figure V.\",\"Figure W\\\\n\\\\u2022\\\\nQuestions and Answers\\\\n1.\\\\n \\\\n2.\\\\n3.\\\\n4.\\\\nManufactured for:\\\\nViiV Healthcare\\\\nDurham, NC 27701\\\\nTrademarks are owned by or licensed to the ViiV Healthcare group of companies.\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\nAPR:5IFU\\\\n \\\\nDispose of used\\\\nneedle, syringe, vial,\\\\nand vial adapter\\\\naccording to local\\\\nhealth and safety\\\\nlaws. \\\\nSee Figure W.\\\\nIf the pack has been stored in the refrigerator, is it safe to warm the\\\\nvial up to room temperature more quickly?\\\\n \\\\nThe vial should be broug...\",\"Principal Display Panel\\\\nNDC 49702-264-23\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nFor gluteal intramuscular use only.\\\\nHealthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 2/24\\\\n\\\\u00a92024 ViiV H...\",\"Principal Display Panel\\\\nNDC 49702-280-63\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nSample-Not for Sale\\\\nFor gluteal intramuscular use only.\",\"Healthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 5/24\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\n62000000094179\",\"APRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-264\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-264-\\\\n23\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n12/20/2021\",\"Quantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\nTotal Product Quantity\\\\nPart 1\\\\n1 VIAL\\\\n3 mL\\\\nPart 1 of 1\\\\nCABOTEGRAVIR  \\\\ncabotegravir injection, suspension, extended release\\\\nProduct Information\\\\nItem Code (Source)\\\\nNDC:49702-238\\\\nRoute of Administration\\\\nINTRAMUSCULAR\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCABOTEGRAVIR\\\\n (UNII: HMH0132Z1Q) \\\\n(CABOTEGRAVIR - UNII:HMH0132Z1Q)\\\\nCABOTEGRAVIR\\\\n200 mg  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)...\",\"NDA\\\\nNDA215499\\\\n12/20/2021\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nNDA\\\\nNDA215499\\\\n12/20/2021\\\\nAPRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-280\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-280-\\\\n63\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n03/31/2024\\\\nQuantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\n...\",\"ViiV Healthcare Company\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYSORBATE 20\\\\n (UNII: 7T1F30V5YH)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nWHITE (white to light pink)\\\\nScore\\\\n    \\\\nShape\\\\nSize\\\\nFlavor\\\\nImprint Code\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-238-\\\\n61\\\\n3 mL in 1 VIAL; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Mono...\",\"ISENTRESS- raltegravir tablet, film coated \\\\n \\\\nNuCare Pharmaceuticals,Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ISENTRESS safely and\\\\neffectively. See full prescribing information for ISENTRESS. \\\\nISENTRESS \\\\n (raltegravir) film-coated tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) chewable tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) for oral suspension \\\\nInitial U.S. Approval: 2007\\\\nINDICATIONS AND USAGE\\\\nISENTRESS is...\",\"The most common adverse reactions of moderate to severe intensity (\\\\u22652%) are insomnia, headache,\\\\ndizziness, nausea and fatigue ( \\\\n6.1\\\\n).\\\\nCreatine kinase elevations were observed in subjects who received ISENTRESS. Myopathy and\\\\nrhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or\\\\nrhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions\\\\nand patients with a history of rhabdomyolysis, myopathy or increased serum cre...\",\"8.5 Geriatric Use\\\\n8.6 Use in Patients with Hepatic Impairment\\\\n8.7 Use in Patients with Renal Impairment\\\\n10 OVERDOSAGE\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n12.4 Microbiology\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n14.1 \\\\nTreatment-Na\\\\u00efve Adult Subjects\\\\n14.2 Treatment-Experienced Adult Subjects\\\\n14.3 Pediatric Subjects\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT ...\",\"Each single-use packet for oral suspension contains 100 mg of raltegravir which is\\\\nsuspended in 5 mL of water giving a final concentration of 20 mg/mL.\\\\n2.2 Adults\\\\nFor the treatment of adult patients with HIV-1 infection, the dosage of ISENTRESS is one\\\\n400 mg film-coated tablet administered orally, twice daily.\\\\n2.3 Pediatrics\\\\nIf at least 25 kg:\\\\n One 400 mg film-coated tablet orally, twice daily.\\\\nIf unable to swallow a tablet, consider the chewable tablet, as specified in Table 1.\\\\nTable 1: Alterna...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n11 to less than 14 \\\\n4 mL (80 mg) twice\\\\ndaily\\\\n3 \\\\u00d7 25 mg twice daily\\\\n14 to less than 20 \\\\n5 mL (100 mg) twice\\\\ndaily\\\\n1 \\\\u00d7 100 mg twice\\\\ndaily\\\\n20 to less than 25\\\\n1.5 \\\\u00d7 100 mg \\\\n twice\\\\ndaily\\\\n2.4 Method of Administration\\\\nISENTRESS Film-Coated Tablets\\\\nFilm-Coated Tablets must be swallowed whole\\\\nISENTRESS Chewable Tablets\\\\nChewable Tablets may be chewed or swallowed whole\\\\nISENTRESS For Oral Suspension\\\\nEach single-use ISENTRESS packet for oral suspension contains 100 mg of raltegravir\\\\nwhich is to be sus...\",\"None\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Skin and Hypersensitivity Reactions\\\\nSevere, potentially life-threatening, and fatal skin reactions have been reported. These\\\\ninclude cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.\\\\nHypersensitivity reactions have also been reported and were characterized by rash,\\\\nconstitutional findings, and sometimes, organ dysfunction, including hepatic failure.\\\\nDiscontinue ISENTRESS and other suspect agents immediately if signs or symptoms of\\\\nsevere...\",\"STARTMRK (Protocol 021) with ISENTRESS 400 mg twice daily in combination with a fixed\\\\ndose of emtricitabine 200 mg (+) tenofovir 300 mg, (N=281) versus efavirenz (EFV) 600\\\\nmg at bedtime in combination with emtricitabine (+) tenofovir, (N=282). During double-\\\\nblind treatment, the total follow-up for subjects receiving ISENTRESS 400 mg twice daily\\\\n+ emtricitabine (+) tenofovir was 1104 patient-years and 1036 patient-years for\\\\nsubjects receiving efavirenz 600 mg at bedtime + emtricitabine (+) tenof...\",\"Analysis)\\\\nRandomized Study Protocol\\\\n021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm (Unit)\\\\nLimit\\\\nISENTRESS\\\\n400 mg \\\\nTwice Daily +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 281)\\\\nEfavirenz 600\\\\nmg \\\\nAt Bedtime +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 282)\\\\nHematology\\\\nAbsolute neutrophil count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n0.75 - 0.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n0.50 - 0.749\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&lt;0.50\\\\n1%\\\\n1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n1%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n1%\\\\n...\",\"ULN = Upper limit of normal range\\\\nLipids, Change from Baseline\\\\nChanges from baseline in fasting lipids are shown in Table 5.\\\\nTable 5: Lipid Values, Mean Change from Baseline, Protocol 021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm\\\\nISENTRESS 400 mg \\\\nTwice Daily + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 207\\\\nEfavirenz 600 mg \\\\nAt Bedtime + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 187\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean\\\\nMean\\\\nChange\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean...\",\"OBT. The median duration of therapy in these trials was 96 weeks for subjects receiving\\\\nISENTRESS and 38 weeks for subjects receiving placebo. The total exposure to\\\\nISENTRESS was 708 patient-years versus 244 patient-years on placebo. The rates of\\\\ndiscontinuation due to adverse events were 4% in subjects receiving ISENTRESS and 5%\\\\nin subjects receiving placebo.\\\\nClinical ADRs were considered by investigators to be causally related to ISENTRESS +\\\\nOBT or placebo + OBT. Clinical ADRs of moderate to s...\",\"Grade 4\\\\n&lt;0.50\\\\n1%\\\\n&lt;1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n3%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n25 - 49.999\\\\n1%\\\\n&lt;1%\\\\n  Grade 4\\\\n&lt;25\\\\n1%\\\\n&lt;1%\\\\nBlood chemistry\\\\nFasting (non-random) serum glucose test (mg/dL)\\\\n  Grade 2\\\\n126 - 250\\\\n10%\\\\n7%\\\\n  Grade 3\\\\n251 - 500\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&gt;500\\\\n0%\\\\n0%\\\\nTotal serum bilirubin\\\\n  Grade 2\\\\n1.6 - 2.5 \\\\u00d7 ULN\\\\n6%\\\\n3%\\\\n  Grade 3\\\\n2.6 - 5.0 \\\\u00d7 ULN\\\\n3%\\\\n3%\\\\n  Grade 4\\\\n&gt;5.0 \\\\u00d7 ULN\\\\n1%\\\\n0%\\\\nSerum aspartate aminotransferase...\",\"ULN = Upper limit of normal range\\\\nLess Common Adverse Reactions Observed in Treatment-Na\\\\u00efve and Treatment-\\\\nExperienced Studies\\\\nThe following ADRs occurred in &lt;2% of treatment-na\\\\u00efve or treatment-experienced\\\\nsubjects receiving ISENTRESS in a combination regimen. These events have been\\\\nincluded because of their seriousness, increased frequency on ISENTRESS compared\\\\nwith efavirenz or placebo, or investigator&#x27;s assessment of potential causal relationship.\\\\nGastrointestinal Disorders: \\\\nabdominal pain, ...\",\"upper limit of normal (ULN). In general the safety profile of ISENTRESS in subjects with\\\\nhepatitis B and/or hepatitis C virus co-infection was similar to that in subjects without\\\\nhepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT\\\\nabnormalities were higher in the subgroup with hepatitis B and/or hepatitis C virus co-\\\\ninfection for all treatment groups. At 96 weeks, in treatment-experienced subjects,\\\\nGrade 2 or higher laboratory abnormalities that represent a wors...\",\"patients with underlying liver disease and/or concomitant medications\\\\nMusculoskeletal and Connective Tissue Disorders:\\\\n rhabdomyolysis\\\\nNervous System Disorders: \\\\ncerebellar ataxia\\\\nPsychiatric Disorders: \\\\nanxiety, paranoia\\\\n7 DRUG INTERACTIONS\\\\n7.1 Effect of Raltegravir on the Pharmacokinetics of Other Agents\\\\nRaltegravir does not inhibit (IC \\\\n&gt;100 \\\\u00b5M) CYP1A2, CYP2B6, CYP2C8, CYP2C9,\\\\nCYP2C19, CYP2D6 or CYP3A \\\\nin vitro\\\\n. Moreover, \\\\nin vitro\\\\n, raltegravir did not induce\\\\nCYP1A2, CYP2B6 or CYP3A4. A mid...\",\"rifampin\\\\n\\\\u2193\\\\ndaily during coadministration\\\\nwith rifampin. There are no\\\\ndata to guide co-\\\\nadministration of ISENTRESS\\\\nwith rifampin in patients below\\\\n18 years of age \\\\n[see \\\\nDosage\\\\nand Administration (2.1)\\\\n].\\\\n7.3 Drugs without Clinically Significant Interactions with ISENTRESS\\\\nIn drug interaction studies, raltegravir did not have a clinically meaningful effect on the\\\\npharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine,\\\\ntenofovir, etravirine, darunavir/ritonavir, or boce...\",\"8.3 Nursing Mothers\\\\nBreastfeeding is not recommended while taking ISENTRESS. In addition, it is\\\\nrecommended that HIV-1-infected mothers not breastfeed their infants to avoid risking\\\\npostnatal transmission of HIV-1.\\\\nIt is not known whether raltegravir is secreted in human milk. However, raltegravir is\\\\nsecreted in the milk of lactating rats. Mean drug concentrations in milk were\\\\napproximately 3-fold greater than those in maternal plasma at a maternal dose of 600\\\\nmg/kg/day in rats. There were no ef...\",\"evidence of toxicity.\\\\nIn the event of an overdose, it is reasonable to employ the standard supportive\\\\nmeasures, e.g., remove unabsorbed material from the gastrointestinal tract, employ\\\\nclinical monitoring (including obtaining an electrocardiogram), and institute supportive\\\\ntherapy if required. The extent to which ISENTRESS may be dialyzable is unknown.\\\\n11 DESCRIPTION\\\\nISENTRESS contains raltegravir potassium, a human immunodeficiency virus integrase\\\\nstrand transfer inhibitor. The chemical name fo...\",\"fructose, hydroxypropyl cellulose, hypromellose 2910/6cP, magnesium stearate,\\\\nmannitol, medium chain triglycerides, monoammonium glycyrrhizinate, natural and\\\\nartificial flavors (orange, banana, and masking that contains aspartame), oleic acid, PEG\\\\n400, saccharin sodium, sodium citrate dihydrate, sodium stearyl fumarate, sorbitol,\\\\nsucralose and yellow iron oxide.\\\\nEach packet of ISENTRESS for oral suspension 100 mg, contains 108.6 mg of raltegravir\\\\n(as potassium salt), equivalent to 100 mg of ralt...\",\"formulation comparison study in healthy adult volunteers, the chewable tablet and oral\\\\nsuspension have higher oral bioavailability compared to the 400 mg film-coated tablet.\\\\nIn subjects who received 400 mg twice daily alone, raltegravir drug exposures were\\\\ncharacterized by a geometric mean AUC \\\\n of 14.3 \\\\u00b5M\\\\u2219hr and C \\\\n of 142 nM.\\\\nConsiderable variability was observed in the pharmacokinetics of raltegravir. For\\\\nobserved C \\\\nin Protocols 018 and 019, the coefficient of variation (CV) for inter-\\\\nsubje...\",\"approximately 70% of the total radioactivity; the remaining radioactivity in plasma was\\\\naccounted for by raltegravir-glucuronide. Studies using isoform-selective chemical\\\\ninhibitors and cDNA-expressed UDP-glucuronosyltransferases (UGT) show that UGT1A1\\\\nis the main enzyme responsible for the formation of raltegravir-glucuronide. Thus, the\\\\ndata indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-\\\\nmediated glucuronidation.\\\\nSpecial Populations\\\\nPediatric\\\\nTwo pediatric fo...\",\"*\\\\n\\\\u2020\\\\nkg\\\\nTable 2\\\\n3 to less\\\\nthan 20\\\\nkg\\\\nOral\\\\nsuspension\\\\nWeight\\\\nbased\\\\ndosing, see\\\\nTable 2\\\\n19\\\\n24.5 ( \\\\n43%\\\\n)\\\\n113 ( \\\\n69%\\\\n)\\\\nThe pharmacokinetics of raltegravir in infants under 4 weeks of age has not been\\\\nestablished.\\\\nAge\\\\nThe effect of age (18 years and older) on the pharmacokinetics of raltegravir was\\\\nevaluated in the composite analysis. No dosage adjustment is necessary.\\\\nRace\\\\nThe effect of race on the pharmacokinetics of raltegravir in adults was evaluated in the\\\\ncomposite analysis. No dosage adjustmen...\",\"with wild-type genotype, the geometric mean ratio (90% CI) of AUC was 1.41 (0.96,\\\\n2.09).\\\\nDrug Interactions\\\\n [see \\\\nDrug Interactions (7)\\\\n]\\\\nTable 10: Effect of Other Agents on the Pharmacokinetics of Raltegravir in\\\\nAdults\\\\nCoadministered\\\\nDrug\\\\nCoadministered\\\\nDrug\\\\nDose/Schedule\\\\nRaltegravir \\\\nDose/Schedule\\\\nRatio (90% Confidence\\\\nInterval) of Raltegravir\\\\nPharmacokinetic Parameters\\\\nwith/without Coadministered\\\\nDrug; \\\\nNo Effect = 1.00\\\\nn\\\\nC \\\\nAUC\\\\nC \\\\naluminum and\\\\nmagnesium\\\\nhydroxide antacid\\\\n20 mL single\\\\ndose gi...\",\"boceprevir\\\\n800 mg three\\\\ntimes daily\\\\n400 mg single\\\\ndose\\\\n22\\\\n(0.91-\\\\n1.36)\\\\n(0.88-\\\\n1.22)\\\\n(0.45-\\\\n1.23)\\\\ncalcium carbonate\\\\nantacid\\\\n3000 mg single\\\\ndose given with\\\\nraltegravir\\\\n400 mg twice\\\\ndaily\\\\n24\\\\n0.48 \\\\n(0.36,\\\\n0.63)\\\\n0.45 \\\\n(0.35,\\\\n0.57)\\\\n0.68 \\\\n(0.53,\\\\n0.87)\\\\nefavirenz\\\\n600 mg daily\\\\n400 mg single\\\\ndose\\\\n9\\\\n0.64\\\\n(0.41,\\\\n0.98)\\\\n0.64\\\\n(0.52,\\\\n0.80)\\\\n0.79\\\\n(0.49,\\\\n1.28)\\\\netravirine\\\\n200 mg twice\\\\ndaily\\\\n400 mg twice\\\\ndaily\\\\n19\\\\n0.89\\\\n(0.68,\\\\n1.15)\\\\n0.90\\\\n(0.68,\\\\n1.18)\\\\n0.66\\\\n(0.34,\\\\n1.26)\\\\nomeprazole\\\\n20 mg daily\\\\n400 mg single\\\\ndose\\\\n14 \\\\n(10\\\\nf...\",\"Raltegravir at concentrations of 31 \\\\u00b1 20 nM resulted in 95% inhibition (EC \\\\n) of viral\\\\nspread (relative to an untreated virus-infected culture) in human T-lymphoid cell cultures\\\\ninfected with the cell-line adapted HIV-1 variant H9IIIB. In addition, 5 clinical isolates of\\\\nHIV-1 subtype B had EC \\\\n values ranging from 9 to 19 nM in cultures of mitogen-\\\\nactivated human peripheral blood mononuclear cells. In a single-cycle infection assay,\\\\nraltegravir inhibited infection of 23 HIV-1 isolates represen...\",\"dolutegravir.\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nCarcinogenicity studies of raltegravir in mice did not show any carcinogenic potential. At\\\\nthe highest dose levels, 400 mg/kg/day in females and 250 mg/kg/day in males, systemic\\\\nexposure was 1.8-fold (females) or 1.2-fold (males) greater than the AUC (54 \\\\u00b5M\\\\u2219hr) at\\\\nthe 400-mg twice daily human dose. Treatment-related squamous cell carcinoma of\\\\nnose/nasopharynx was observed in female rats dosed with 6...\",\"Protocol 021\\\\n400 mg Twice\\\\nDaily\\\\n600 mg At\\\\nBedtime\\\\n(N = 281)\\\\n(N = 282)\\\\nGender\\\\n  Male\\\\n81%\\\\n82%\\\\n  Female\\\\n19%\\\\n18%\\\\nRace\\\\n  White\\\\n41%\\\\n44%\\\\n  Black\\\\n12%\\\\n8%\\\\n  Asian\\\\n13%\\\\n11%\\\\n  Hispanic\\\\n21%\\\\n24%\\\\n  Native American\\\\n&lt;1%\\\\n&lt;1%\\\\n  Multiracial\\\\n12%\\\\n13%\\\\nRegion\\\\n  Latin America\\\\n35%\\\\n34%\\\\n  Southeast Asia\\\\n12%\\\\n10%\\\\n  North America\\\\n29%\\\\n32%\\\\n  EU/Australia\\\\n23%\\\\n23%\\\\nAge (years)\\\\n  18-64\\\\n99%\\\\n99%\\\\n  \\\\u226565\\\\n1%\\\\n1%\\\\n  Mean (SD)\\\\n38 (9)\\\\n37 (10)\\\\n  Median (min, max)\\\\n37 (19 to 67)\\\\n36 (19 to 71)\\\\nCD4+ Cell Count (cells/microL)\\\\n  Mean (SD)\\\\n219 (124)\\\\n2...\",\"Notes: \\\\nISENTRESS and Efavirenz were administered with emtricitabine (+) tenofovir \\\\nN = Number of subjects in each group.\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n  Hepatitis B or C Positive \\\\n6%\\\\n6%\\\\nWeek 240 outcomes from Protocol 021 are shown in Table 12.\\\\nTable 12: Virologic Outcomes of Randomized Treatment\\\\nof Protocol 021 at 240 Weeks\\\\nISENTRESS\\\\n400 mg \\\\nTwice\\\\nDaily \\\\n(N = 281)\\\\nEfavirenz \\\\n600 mg \\\\nAt\\\\nBedtime \\\\n(N = 282)\\\\nDifference \\\\n(ISENTRESS \\\\u2013\\\\nEfavirenz) (CI)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with\\\\nHIV-1 RNA less\\\\nthan 50\\\\ncopies/mL\\\\n66%\\\\n60%\\\\n6.6% \\\\n(-1.4%...\",\"14.2 Treatment-Experienced Adult Subjects\\\\nBENCHMRK 1 and BENCHMRK 2 are Phase 3 studies to evaluate the safety and\\\\nantiretroviral activity of ISENTRESS 400 mg twice daily in combination with an optimized\\\\nbackground therapy (OBT), versus OBT alone, in HIV-1-infected subjects, 16 years or\\\\nolder, with documented resistance to at least 1 drug in each of 3 classes (NNRTIs,\\\\nNRTIs, PIs) of antiretroviral therapies. Randomization was stratified by degree of\\\\nresistance to PI (1PI vs. &gt;1PI) and the use of...\",\"*\\\\nvirus\\\\n83%\\\\n84%\\\\nHepatitis B virus only\\\\n8%\\\\n3%\\\\nHepatitis C virus only\\\\n8%\\\\n12%\\\\nCo-infection of\\\\nHepatitis B and C\\\\nvirus\\\\n1%\\\\n1%\\\\nStratum\\\\nEnfuvirtide in OBT\\\\n38%\\\\n38%\\\\nResistant to \\\\u22652 PI\\\\n97%\\\\n95%\\\\nTable 14 compares the characteristics of optimized background therapy at baseline in\\\\nthe group receiving ISENTRESS 400 mg twice daily and subjects in the control group.\\\\nTable 14: Characteristics of Optimized Background\\\\nTherapy at Baseline\\\\nRandomized Studies \\\\nProtocol 018 and 019\\\\nISENTRESS\\\\n400 mg Twice\\\\nDaily + OBT\\\\nPl...\",\"Week 96 outcomes for the 699 subjects randomized and treated with the\\\\nrecommended dose of ISENTRESS 400 mg twice daily or placebo in the pooled\\\\nBENCHMRK 1 and 2 studies are shown in Table 15.\\\\nTable 15: Virologic Outcomes of Randomized Treatment\\\\nof Protocols 018 and 019 at 96 Weeks (Pooled Analysis)\\\\nISENTRESS \\\\n400 mg Twice\\\\nDaily + OBT \\\\n(N = 462)\\\\nPlacebo + OBT \\\\n(N = 237)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with HIV-1\\\\nRNA less than 50\\\\ncopies/mL\\\\n55%\\\\n27%\\\\nVirologic Failure \\\\n35%\\\\n66%\\\\nNo virologic data at\\\\nWeek 96 Window\\\\nReas...\",\"&lt;50 copies/mL \\\\nAt Week 96\\\\nn\\\\nISENTRESS \\\\n400 mg \\\\nTwice Daily +\\\\nOBT \\\\n(N = 462) \\\\nn\\\\nPlacebo +\\\\nOBT \\\\n(N = 237)\\\\n*\\\\nPhenotypic Sensitivity Score (PSS) \\\\n0\\\\n67\\\\n43\\\\n43\\\\n5\\\\n1\\\\n144\\\\n58\\\\n71\\\\n23\\\\n2\\\\n142\\\\n61\\\\n66\\\\n32\\\\n3 or more\\\\n85\\\\n48\\\\n48\\\\n42\\\\nGenotypic Sensitivity Score (GSS) \\\\n0\\\\n116\\\\n39\\\\n65\\\\n5\\\\n1\\\\n177\\\\n62\\\\n95\\\\n26\\\\n2\\\\n111\\\\n61\\\\n49\\\\n53\\\\n3 or more\\\\n51\\\\n49\\\\n23\\\\n35\\\\nSwitch of Suppressed Subjects from Lopinavir (+) Ritonavir to Raltegravir\\\\nThe SWITCHMRK 1 &amp; 2 Phase 3 studies evaluated HIV-1 infected subjects receiving\\\\nsuppressive therapy (HIV-1 RNA &lt;50 cop...\",\"children. This study enrolled 126 treatment experienced children and adolescents 2 to\\\\n18 years of age. Subjects were stratified by age, enrolling adolescents first and then\\\\nsuccessively younger children. Subjects were enrolled into cohorts according to age and\\\\nreceived the following formulations: Cohort I (12 to less than 18 years old), 400 mg film-\\\\ncoated tablet; Cohort IIa (6 to less than 12 years old), 400 mg film-coated tablet; Cohort\\\\nIIb (6 to less than 12 years old), chewable tablet; Cohor...\",\"copies/mL. The mean CD4 count (percent) increase from baseline to Week 48 was 492\\\\ncells/mm \\\\n(7.8%).\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nISENTRESS tablets 400 mg are pink, oval-shaped, film-coated tablets with \\\\\"227\\\\\" on one\\\\nside. They are supplied as follows:\\\\nNDC\\\\n 68071-2113-6 \\\\nbottles of 6\\\\nStorage and Handling\\\\n400 mg Film-coated Tablets, Chewable Tablets and For Oral Suspension\\\\nStore at 20-25\\\\u00b0C (68-77\\\\u00b0F); excursions permitted to 15-30\\\\u00b0C (59-86\\\\u00b0F). See USP\\\\nControlled Room Temperature.\\\\nChewable Ta...\",\"General Dosing Instructions\\\\nInstruct patients that if they miss a dose of ISENTRESS, they should take it as soon as\\\\nthey remember. If they do not remember until it is time for the next dose, instruct them\\\\nto skip the missed dose and go back to the regular schedule. Instruct patients not to\\\\ndouble their next dose or take more than the prescribed dose.\\\\nFilm-Coated Tablets and Chewable Tablets\\\\nInform patients that the chewable tablet forms can be chewed or swallowed whole, but\\\\nthe film-coated table...\",\"Whitehouse Station, NJ 08889, USA\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nAll rights reserved.\\\\nuspi-mk0518-mf-1502r030\\\\nPatient Information\\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfilm-coated tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nchewable tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfor oral suspension\\\\nRead this Patient Information before you start taking I...\",\"Ask your doctor if you have any questions on how to prevent passing HIV to other\\\\npeople.\\\\nWhat should I tell my doctor before taking ISENTRESS?\\\\nBefore you take ISENTRESS, tell your doctor if you:\\\\nhave liver problems\\\\nhave a history of a muscle disorder called rhabdomyolysis or myopathy\\\\nhave increased levels of creatine kinase in your blood\\\\nhave phenylketonuria (PKU). ISENTRESS chewable tablets contain phenylalanine as\\\\npart of the artificial sweetener, aspartame. The artificial sweetener may be har...\",\"is time for your next dose, skip the missed dose and go back to your regular\\\\nschedule. Do not double your next dose or take more ISENTRESS than prescribed.\\\\nIf you take too much ISENTRESS, call your doctor or go to the nearest hospital\\\\nemergency room right away.\\\\nWhat are the possible side effects of ISENTRESS?\\\\nISENTRESS can cause serious side effects including:\\\\nSerious skin reactions and allergic reactions. \\\\nSome people who take\\\\nISENTRESS develop serious skin reactions and allergic reactions that...\",\"kidney stones\\\\nindigestion or stomach area pain\\\\nvomiting\\\\nsuicidal thoughts and actions\\\\nweakness\\\\nTell your doctor right away if you get unexplained muscle pain, tenderness, or weakness\\\\nwhile taking ISENTRESS. These may be signs of a rare serious muscle problem that can\\\\nlead to kidney problems.\\\\nTell your doctor if you have any side effect that bothers you or that does not go away.\\\\nThese are not all the possible side effects of ISENTRESS. For more information, ask your\\\\ndoctor or pharmacist.\\\\nCall you...\",\"Inactive ingredients:\\\\n calcium phosphate dibasic anhydrous, hypromellose 2208,\\\\nlactose monohydrate, magnesium stearate, microcrystalline cellulose, poloxamer 407\\\\n(contains 0.01% butylated hydroxytoluene as antioxidant), sodium stearyl fumarate.\\\\nThe film coating contains:\\\\n black iron oxide, polyethylene glycol 3350, polyvinyl\\\\nalcohol, red iron oxide, talc and titanium dioxide.\\\\nISENTRESS chewable tablets:\\\\nActive ingredient: \\\\nraltegravir\\\\nInactive ingredients:\\\\n ammonium hydroxide, crospovidone, ethy...\",\"more information about ISENTRESS.\\\\nYour doctor will decide the right dose based on your child&#x27;s weight.\\\\nAsk your doctor or pharmacist if you have any questions about how to mix or give\\\\nISENTRESS for oral suspension to your child.\\\\nEach ISENTRESS for oral suspension kit contains the following supplies (see\\\\nFigure A\\\\n):\\\\n2 reusable mixing cups with attached lids\\\\n2 reusable 5 mL dosing syringes\\\\n60 foil packets containing ISENTRESS for oral suspension\\\\nFor each dose of ISENTRESS for oral suspension you w...\",\"Step 2. \\\\nFill the dosing syringe. Start with the plunger pushed all the way inside the\\\\nbarrel of the syringe. Insert the tip of the syringe into the water and pull back on the\\\\nplunger to the 5 mL marking on the barrel of the syringe (see \\\\nFigure C\\\\n).\\\\nStep 3. \\\\nPour out remaining water from mixing cup (see \\\\nFigure D\\\\n).\",\"Step 4. \\\\nAdd the 5 mL of water from the dosing syringe back into the mixing cup by\\\\npressing down on the plunger (see \\\\nFigure E\\\\n).\\\\nStep 5. \\\\nOpen 1 foil packet. There is a notch that you can use to tear open the foil\\\\npacket, or you may use scissors to cut along the dotted line. Pour entire contents into\\\\nmixing cup (see \\\\nFigure F\\\\n).\",\"Step 6. \\\\nClose the attached lid to seal the mixing cup (see \\\\nFigure G\\\\n). It will snap shut.\\\\nStep 7. \\\\nSwirl the mixing cup to mix using a gentle circular motion for 30-60 seconds\\\\n(see \\\\nFigure H\\\\n). \\\\nDo not\\\\n turn the mixing cup upside down. The liquid will be cloudy.\\\\nStep 8. \\\\nOpen the mixing cup. Put the tip of the syringe into the liquid and \\\\npull back\\\\nthe plunger to the mL marking that matches your child&#x27;s prescribed dose\\\\n(see \\\\nFigure I\\\\n). Your child&#x27;s dose may be different from the one shown in ...\",\"How should I give a dose of ISENTRESS for oral suspension?\\\\nStep 9.\\\\n Place the tip of the dosing syringe in your child&#x27;s mouth and turn it toward\\\\neither cheek. Gently push down on the plunger to give the medicine (see \\\\nFigure J\\\\n). Give\\\\nthe dose of ISENTRESS oral suspension to your child within 30 minutes of mixing. If you\\\\nare not able to give your child&#x27;s dose within 30 minutes of mixing, pour the unused\\\\nmedicine into the trash. You will need to mix a new dose.\\\\nHow should I dispose of leftover IS...\",\"Step 11. \\\\nRemove plunger from the barrel of the dosing syringe. Hand wash the dosing\\\\nsyringe and mixing cup with warm water and dish soap. Rinse with water and air dry\\\\n(see \\\\nFigure L\\\\n).\\\\nHow should I store ISENTRESS for oral suspension?\\\\nStore ISENTRESS for oral suspension at room temperature between 68\\\\u00b0F to 77\\\\u00b0F\\\\n(20\\\\u00b0C to 25\\\\u00b0C).\\\\nStore in the original container. Do not open the foil packets until ready for use.\\\\nKeep ISENTRESS for oral suspension and all medicines out of the reach of\\\\nchildren.\\\\nFor m...\",\"Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nWhitehouse Station, NJ 08889, USA\\\\nIssued December 2013\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2013 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc. \\\\nAll rights reserved.\\\\nifu-mk0518-mf-1312r000\\\\nISENTRESS  \\\\nraltegravir tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION\\\\nDRUG\\\\nItem Code\\\\n(Source)\\\\nNDC:68071-2113(NDC:0006-\\\\n0227)\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredi...\",\"NuCare Pharmaceuticals,Inc.\\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLOXAMER 407\\\\n (UNII: TUF2IVW3M2)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYVINYL ALCOHOL\\\\n (UNII: 532B59J990)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)\\\\n \\\\nSODIUM STEARYL FUMARATE\\\\n (UNII: 7CV7WJK4UI)\\\\n \\\\nTALC\\\\n (UNII: 7SEV7J4R1U)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\npink (pink)\\\\nScore\\\\nno score\\\\nShape\\\\nOVAL (oval-shaped)\\\\nSize\\\\n16mm\\\\nFlavor\\\\nImprint Code\\\\n227\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem C...\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#98df8a\",\"#999\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ffbb78\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\"],\"shape\":[155],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2769\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2770\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2765\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2766\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2767\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p2736\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p2751\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p2752\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p2753\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p2754\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p2755\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p2760\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p2761\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2746\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2747\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2748\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2749\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2741\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2742\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2743\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2744\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2745\",\"attributes\":{\"axis\":{\"id\":\"p2741\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2750\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p2746\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p2771\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2772\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Drug Interactions\"},\"renderers\":[{\"id\":\"p2768\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2773\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Therapy Side Effects\"},\"renderers\":[{\"id\":\"p2768\"}],\"index\":10}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2774\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Drug Interactions\"},\"renderers\":[{\"id\":\"p2768\"}],\"index\":29}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2775\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"HIV-1 PrEP Safety\"},\"renderers\":[{\"id\":\"p2768\"}],\"index\":52}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2776\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Medication Injection Preparation\"},\"renderers\":[{\"id\":\"p2768\"}],\"index\":58}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2777\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p2768\"}],\"index\":7}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2778\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Raltegravir Side Effects\"},\"renderers\":[{\"id\":\"p2768\"}],\"index\":108}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p2847\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p2784\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p2793\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p2794\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2795\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p2796\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p2791\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2823\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2780\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2781\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2782\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"8hy7v8DvrcA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"lI3LwBPH+cA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"correctness\",[true,true]],[\"questions\",[\"What percentage of pediatric subjects experienced a Grade 3 or 4 rash when compared to adults in the study?\",\"What was the hazard ratio (with 95% confidence interval) for incident HIV-1 infections among participants who received APRETUDE compared to those who received TRUVADA, based on the extended retrospective virologic testing results?\"]],[\"agent_answer\",[\"3% (6/182) of pediatric subjects experienced a Grade 3 or 4 rash, compared to 0.9% of adults.\",\"The hazard ratio (with 95% confidence interval) for incident HIV-1 infections among participants who received APRETUDE compared to those who received TRUVADA, based on the extended retrospective virologic testing results, was **0.10 (0.04, 0.27)**.  \\\\n\\\\nThis indicates a **90% reduction** in the risk of HIV-1 incident infection for participants receiving APRETUDE compared to TRUVADA.  \\\\n\\\\n*(Data sourced from HPTN 084 with extended retrospective virologic testing adjustments.)*\"]],[\"reference_answer\",[\"In the study, 3% (6/182) of pediatric subjects experienced a Grade 3 or 4 rash, while only 0.9% of adults reported the same severity of rash.\",\"The hazard ratio for incident HIV-1 infections between participants receiving APRETUDE and TRUVADA was 0.10 (with a 95% CI of 0.04, 0.27), indicating a lower rate of infections in the APRETUDE group.\"]],[\"id\",[12,81]],[\"content\",[\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\"]],[\"color\",[\"#0a980a\",\"#0a980a\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2824\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2825\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2820\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2821\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2822\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p2837\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2828\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2829\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2830\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p2838\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p2839\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2834\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2835\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p2836\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p2792\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p2807\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p2808\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p2809\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p2810\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p2815\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p2816\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p2783\",\"attributes\":{\"renderers\":[{\"id\":\"p2823\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2802\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2803\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2804\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2805\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p2797\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p2798\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p2799\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p2800\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2801\",\"attributes\":{\"axis\":{\"id\":\"p2797\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p2806\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p2802\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p2826\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p2827\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p2823\"}],\"index\":0}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p2843\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p2840\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p2841\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p2842\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"Xu3LwBlQ+8DXmYLA8rhBwBOkIsAvK9m/\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"VJP3wGZewMATu1LALg61wL8ZAsE6B9fA\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"3dbac6fc-a8c9-4af1-a110-e4581a5f1bb4\",\"roots\":{\"p2848\":\"adf73824-d191-422e-ba4d-78534f71fafa\"},\"root_ids\":[\"p2848\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"adf73824-d191-422e-ba4d-78534f71fafa\" data-root-id=\"p2848\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x1f58790c2f0>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_chain_rag_fusion, testset=testset, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "2e11a74d",
   "metadata": {},
   "source": [
    "#### Decomposition"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "c424093a",
   "metadata": {},
   "outputs": [],
   "source": [
    "template = \"\"\"You are a helpful assistant that generates multiple sub-questions related to an input question. \\n\n",
    "The goal is to break down the input into a set of sub-problems / sub-questions that can be answers in isolation. \\n\n",
    "Generate multiple search queries related to: {question} \\n\n",
    "Output (3 queries):\"\"\"\n",
    "prompt_decomposition = ChatPromptTemplate.from_template(template)\n",
    "\n",
    "template = \"\"\"Here is the question you need to answer:\n",
    "\n",
    "\\n --- \\n {question} \\n --- \\n\n",
    "\n",
    "Here is any available background question + answer pairs:\n",
    "\n",
    "\\n --- \\n {q_a_pairs} \\n --- \\n\n",
    "\n",
    "Here is additional context relevant to the question: \n",
    "\n",
    "\\n --- \\n {context} \\n --- \\n\n",
    "\n",
    "Use the above context and any background question + answer pairs to answer the question: \\n {question}\n",
    "\"\"\"\n",
    "\n",
    "decomposition_prompt = ChatPromptTemplate.from_template(template)\n",
    "\n",
    "def format_qa_pair(question, answer):\n",
    "    formatted_string = \"\"\n",
    "    formatted_string += f\"Question: {question}\\nAnswer: {answer}\\n\\n\"\n",
    "    return formatted_string.strip()\n",
    "\n",
    "generate_queries_decomposition = (\n",
    "    prompt_decomposition \n",
    "    | call_asi_one \n",
    "    | StrOutputParser() \n",
    "    | (lambda x: x.split(\"\\n\"))\n",
    ")\n",
    "\n",
    "def answer_fn_chain_decomposition(question, history=None):\n",
    "    questions = generate_queries_decomposition.invoke({\"question\": question})\n",
    "    \n",
    "    q_a_pairs = \"\"\n",
    "    \n",
    "    for q in questions:\n",
    "        rag_chain = (\n",
    "            {\n",
    "                \"context\": itemgetter(\"question\") | retriever,\n",
    "                \"question\": itemgetter(\"question\"),\n",
    "                \"q_a_pairs\": itemgetter(\"q_a_pairs\")\n",
    "            }\n",
    "            | decomposition_prompt\n",
    "            | call_asi_one\n",
    "            | StrOutputParser()\n",
    "        )\n",
    "        \n",
    "        answer = rag_chain.invoke({\"question\": q, \"q_a_pairs\": q_a_pairs})\n",
    "        q_a_pair = format_qa_pair(q, answer)\n",
    "        q_a_pairs = q_a_pairs + \"\\n---\\n\" + q_a_pair\n",
    "    \n",
    "    chain_decomposition = (\n",
    "        {\n",
    "            \"context\": itemgetter(\"question\") | retriever,\n",
    "            \"question\": itemgetter(\"question\"),\n",
    "            \"q_a_pairs\": itemgetter(\"q_a_pairs\")\n",
    "        }\n",
    "        | decomposition_prompt\n",
    "        | call_asi_one\n",
    "        | StrOutputParser()\n",
    "    )\n",
    "    \n",
    "    return chain_decomposition.invoke({\"question\": question, \"q_a_pairs\": q_a_pairs})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "4247d9ff",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a8de6cf92da24f97be4c408e0a930472",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "2ab608987d274669984cb1855e2ad344",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/25 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"b4ce8e2a-9480-47a0-b512-d63e58c44105\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"b4ce8e2a-9480-47a0-b512-d63e58c44105\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"b4ce8e2a-9480-47a0-b512-d63e58c44105\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-06-23 09:37:54,138 pid:9434 MainThread giskard.rag  INFO     Finding topics in the knowledge base.\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/deni/Desktop/disi/.venv/lib/python3.12/site-packages/sklearn/utils/deprecation.py:151: FutureWarning: 'force_all_finite' was renamed to 'ensure_all_finite' in 1.6 and will be removed in 1.8.\n",
      "  warnings.warn(\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2025-06-23 09:38:14,378 pid:9434 MainThread giskard.rag  INFO     Found 6 topics in the knowledge base.\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-red \">\n",
       "                        8.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=8.0 class=\" progress-red \">8.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-orange \">\n",
       "                        50.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=50.0 class=\" progress-orange \">50.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">8%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Focus on improving the performance on complex questions by fine-tuning the Generator component to better handle paraphrasing.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"4fbe4ecf-d9de-44aa-8498-ac697f60cdc3\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1193\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p1195\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p1202\",\"attributes\":{\"factors\":[\"ACE Inhibitor Side Effects\",\"Candesartan Cilexetil\",\"NUCYNTA\\\\u2122 Medication\",\"Others\",\"Pharmaceuticals\",\"Povidone Iodine Solution\",\"Tizanidine Hydrochloride\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1203\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p1204\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1200\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1222\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1190\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1191\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1192\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAElAAAAAAAAAOUA=\"},\"shape\":[7],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"ACE Inhibitor Side Effects\",\"Candesartan Cilexetil\",\"NUCYNTA\\\\u2122 Medication\",\"Others\",\"Pharmaceuticals\",\"Povidone Iodine Solution\",\"Tizanidine Hydrochloride\"]],[\"colors\",[\"#a50026\",\"#a50026\",\"#a50026\",\"#a50026\",\"#a50026\",\"#006837\",\"#fefebd\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1223\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1224\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1219\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1220\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1221\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1231\",\"attributes\":{\"data_source\":{\"id\":\"p1190\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1232\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1233\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1228\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1229\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p1230\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1241\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1235\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1236\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1237\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1242\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1243\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1238\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1239\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p1240\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1201\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1215\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p1210\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p1211\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p1212\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1213\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1205\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1206\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1207\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1208\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1209\",\"attributes\":{\"axis\":{\"id\":\"p1205\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1214\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1210\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p1234\",\"attributes\":{\"location\":8.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1244\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1245\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p1241\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"4fbe4ecf-d9de-44aa-8498-ac697f60cdc3\",\"roots\":{\"p1193\":\"dd276ffc-b56a-4678-829c-574352d9ce8f\"},\"root_ids\":[\"p1193\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"dd276ffc-b56a-4678-829c-574352d9ce8f\" data-root-id=\"p1193\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"93a4ab16-8796-4dd8-b36b-cb9de240f92f\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p1124\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1054\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1004\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1013\",\"attributes\":{\"start\":7.730230808258057,\"end\":17.376468658447266}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1014\",\"attributes\":{\"start\":-1.6865412592887878,\"end\":11.504014730453491}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1015\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1016\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1011\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1044\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1001\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1002\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1003\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"Others\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"NUCYNTA Safety\",\"Others\",\"Others\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"NUCYNTA Safety\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\",\"Others\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"ACE Inhibitors and mTOR Inhibitors\",\"Pharmaceutical Products\",\"Others\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"ACE Inhibitors and mTOR Inhibitors\",\"Others\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\",\"Pharmaceutical Products\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118]],[\"content\",[\"ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\\\n \\\\nK2resource co., ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\\\ntartar formation, plaque removal, oral cleansing\\\\nKeep...\",\"K2resource co., ltd.\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:72191-0100\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nSODIUM BICARBONATE\\\\n (UNII: 8MDF5V39QO) \\\\n(SODIUM CATION -\\\\nUNII:LYR4M0NH37)\\\\nSODIUM\\\\nBICARBONATE\\\\n36.2 g  in 100 mg\\\\nXYLITOL\\\\n (UNII: VCQ006KQ1E) \\\\n(XYLITOL - UNII:VCQ006KQ1E)\\\\nXYLITOL\\\\n5 g  in 100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMENTHOL\\\\n (UNII: L7T10EIP3A)\\\\n \\\\nProduct Characteristics\\\\nCo...\",\"NUCYNTA - tapentadol hydrochloride tablet, film coated \\\\n \\\\nStat Rx USA\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use NUCYNTA\\\\u2122 safely and effectively. See full\\\\nprescribing information for NUCYNTA\\\\u2122.\\\\n \\\\nNUCYNTA\\\\u2122 (tapentadol) immediate-release oral tablets    C-II\\\\nInitial U.S. Approval: 2008\\\\nRECENT MAJOR CHANGES\\\\nWarnings and Precautions (\\\\n5.4\\\\n)\\\\nJune 2009\\\\nINDICATIONS AND USAGE\\\\nNUCYNTA\\\\u2122 is an opioid analgesic indicated for the relief o...\",\"USE IN SPECIFIC POPULATIONS\\\\nLabor and delivery: \\\\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\\\nmothers have been taking NUCYNTA\\\\u2122, for respiratory depression. (\\\\n8.2\\\\n)\\\\nNursing mothers: should not breast-feed. (\\\\n8.3\\\\n)\\\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\\\n8.4\\\\n)\\\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\\\npatients with moder...\",\"8.7 Hepatic Impairment\\\\n9 DRUG ABUSE AND DEPENDENCE\\\\n9.1 Controlled Substance\\\\n9.2 Abuse\\\\n9.3 Dependence\\\\n10 OVERDOSAGE\\\\n10.1 Human Experience\\\\n10.2 Management of Overdose\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n13 NON-CLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\n14 CLINICAL STUDIES\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\n14.2 End-Stage Degenerative Joint Disea...\",\"Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\\\nbeen studied and are not recommended.\\\\nNUCYNTA\\\\u2122 may be given with or without food \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n].\\\\n2.1 Renal Impairment\\\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\\\n[see \\\\nClinical\\\\nPharmacology (12.3)\\\\n]\\\\n.\\\\nNUCYNTA\\\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\\\nis not recommended.\\\\n2.2 Hepatic Im...\",\"which may result in adverse cardiovascular events \\\\n[see \\\\nDrug Interactions (7.4)\\\\n]\\\\n.\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Respiratory Depression\\\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\\\nsignificantly decrease pulmonary ventilation.\\\\nNUCYNTA\\\\u2122 should be ...\",\"5.5 Driving and Operating Machinery\\\\nPatients should be cautioned that NUCYNTA\\\\u2122 may impair the mental and/or physical abilities required\\\\nfor the performance of potentially hazardous tasks such as driving a car or operating machinery. This is\\\\nto be expected especially at the beginning of treatment, at any change of dosage as well as in\\\\ncombination with alcohol or tranquilizers\\\\n [see \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\n5.6 Interactions with Alcohol and Drugs of Abuse\\\\nDue to its mu-opioid agonist activity,...\",\"Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\\\nconsidered drug-related.\\\\nBased on data from nine Phase 2/3 studies that administered multiple...\",\"*\\\\nInfections and infestations\\\\n  Nasopharyngitis\\\\n1\\\\n&lt;1\\\\n  Upper respiratory tract infection\\\\n1\\\\n&lt;1\\\\n  Urinary tract infection\\\\n1\\\\n&lt;1\\\\nMetabolism and nutrition disorders\\\\n  Decreased appetite\\\\n2\\\\n0\\\\nMusculoskeletal and connective tissue\\\\ndisorders\\\\n  Arthralgia\\\\n1\\\\n&lt;1\\\\nNervous system disorders\\\\n  Dizziness\\\\n24\\\\n8\\\\n  Somnolence\\\\n15\\\\n3\\\\n  Tremor\\\\n1\\\\n&lt;1\\\\n  Lethargy\\\\n1\\\\n&lt;1\\\\nPsychiatric disorders\\\\n  Insomnia\\\\n2\\\\n&lt;1\\\\n  Confusional state\\\\n1\\\\n0\\\\n  Abnormal dreams\\\\n1\\\\n&lt;1\\\\n  Anxiety\\\\n1\\\\n&lt;1\\\\nSkin and subcutaneous tissue disorders\\\\n  Pruritus\\\\n5\\\\n1\\\\n  Hyp...\",\"Psychiatric disorders:\\\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\\\nabnormal\\\\nRenal and urinary disorders:\\\\n urinary hesitation, pollakiuria\\\\nRespiratory, thoracic and mediastinal disorders: \\\\noxygen saturation decreased, cough, dyspnea,\\\\nrespiratory depression\\\\nSkin and subcutaneous tissue disorders: \\\\nurticaria\\\\nVascular disorders:\\\\n blood pressure decreased\\\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\\\nNUCYNTA\\\\u2122,...\",\"Pregnancy Category C.\\\\nTapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous\\\\nand subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was\\\\nadministered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day\\\\n[producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of\\\\n700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic eff...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and\\\\nproper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid\\\\nagonist properties.\\\\nInfants born to mothers physically dependent on opioids will also be physically dependent and may\\\\nexhibit respiratory difficulties and withdrawal symptoms \\\\n[see \\\\nWarnings and Precautions (5.1)\\\\n]\\\\n. Use of\\\\nNUCYNTA\\\\u2122 in this population has not been characterized. As NUCYNTA\\\\u2122 h...\",\"intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\\\nshould be taken to secure the airway.\\\\n11 DESCRIPTION\\\\nNUCYNTA\\\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\\\nThe chemical name is 3-[(1\\\\nR\\\\n,2\\\\nR\\\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\\\nmonohydrochloride. The structural formula is:\\\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\\\nH\\\\nNO\\\\u00b7HCl. The\\\\nn-octanol:water pa...\",\"extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\\\naround 1.25 hours after dosing.\\\\nDose-proportional increases in the C\\\\n and AUC values of tapentadol have been observed over the 50\\\\nto 150 mg dose range.\\\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\\\nglucuronide, which are primarily determined by the do...\",\"Pharmacokinetic Drug Interactions\\\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\\\nconsidered clinically relevant and no change in dose is required.\\\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\\\nac...\",\"14 CLINICAL STUDIES\\\\nThe efficacy and safety of NUCYNTA\\\\u2122 in the treatment of moderate to severe acute pain has been\\\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\\\u2122...\",\"50% or greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus\\\\nplacebo.\\\\n14.2 End-Stage Degenerative Joint Disease\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\\\u2122 given every 4 to 6 hours during\\\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\\\nend stage degenerative joint disease of the hip or knee, defined...\",\"The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\\\nor greater were significantly higher in patients treated with NUCYNTA\\\\u2122 at each dose versus placebo.\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nNUCYNTA\\\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\\\nbiconvex-shaped.\\\\n50 mg tablets are yellow and debossed with \\\\\"O-M\\\\\" on one side and \\\\\"50\\\\\" on the other side, and are\\\\navailable in bottles of 100 (NDC 50458-820-04) a...\",\"Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\\\u2122 \\\\n[see \\\\nUse in\\\\nSpecific Populations (8.3)\\\\n]\\\\n.\\\\n17.6 Monoamine Oxidase Inhibitors\\\\nPatients should be informed not to take NUCYNTA\\\\u2122 while using any drugs that inhibit monoamine\\\\noxidase. Patients should not start any new medications while taking NUCYNTA\\\\u2122 until they are assured\\\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\\\n17.7 Seizures\\\\nPatients should be informed that NU...\",\"you get a new prescription. There may be new information. This Medication Guide does not take\\\\nthe place of talking to your doctor about your medical condition or your treatment. Talk to your\\\\ndoctor if you have any questions.\\\\nWhat is the most important information I should know about NUCYNTA\\\\u2122?\\\\nNUCYNTA\\\\u2122 is a tablet that contains tapentadol, a strong medicine that is a pain medicine.\\\\nUse NUCYNTA\\\\u2122 exactly how your doctor tells you to. Do not use NUCYNTA\\\\u2122 if it has not been\\\\nprescribed for you.\\\\nYou sh...\",\"Do not change the dose of NUCYNTA\\\\u2122 unless your doctor tells you to. \\\\nYour doctor may\\\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\\\u2122 more often\\\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\\\u2122.\\\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\\\u2122 to help lessen\\\\nwithdrawal symptoms.\\\\nNUCYNTA\\\\u2122 can be taken with or without food.\\\\nWhat should I avoid while taking NUCYNTA\\\\u2122?\\\\nDo not drive, operate machinery, ...\",\"Store NUCYNTA\\\\u2122 at 59\\\\u00baF to 86\\\\u00baF (15\\\\u00baC to 30\\\\u00baC). Keep NUCYNTA\\\\u2122 tablets dry.\\\\nDispose of NUCYNTA\\\\u2122 tablets you no longer need.\\\\nKeep NUCYNTA\\\\u2122 in a safe place out of the reach of children.\\\\nGeneral information about NUCYNTA\\\\u2122\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\\\nuse NUCYNTA\\\\u2122 for a condition for which it was not prescribed. \\\\nDo not give NUCYNTA\\\\u2122 to other\\\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\\\u2122 could be harmful\\\\n...\",\"NUCYNTA 100MG PACKAGE LABEL\\\\n       \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\n   \\\\nNUCYNTA  \\\\ntapentadol hydrochloride tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN\\\\nPRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:16590-\\\\n863(NDC:50458-820)\\\\nRoute of Administration\\\\nORAL\\\\nDEA Schedule\\\\nCII\",\"Active Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n50 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII: 15FIX9V2JP)\\\\n...\",\"Stat Rx USA\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII:...\",\"GRX DYNE - povidone iodine solution \\\\n \\\\nGeritrex Corp.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nGRx Dyne Solution\\\\nDrug Facts\\\\nActive Ingredient:                      Purpose\\\\nPovidone Iodine USP, 10% w/v  Antiseptic\\\\n(equivalent to 1% titratable Iodine)\\\\nUses\\\\nFirst aid antiseptic to help the risk of infection in \\\\nminor cuts, scra...\",\"Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\\\nkeep out of reach of children. If swallowed get medical help \\\\nor contact a Poison Control Center right away.\\\\nEnter section text here\\\\nGRX DYNE  \\\\npovidone iodine solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:54162-269\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85...\",\"Geritrex Corp.\\\\nCITRIC ACID MONOHYDRATE\\\\n (UNII: 2968PHW8QP)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nSODIUM HYDROXIDE\\\\n (UNII: 55X04QC32I)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:54162-269-16\\\\n472 mL in 1 BOTTLE, PLASTIC\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOTC monograph not final\\\\npart333A\\\\n05/16/2012\\\\nLabeler - \\\\n...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE- lisinopril and hydrochlorothiazide\\\\ntablets tablet \\\\n \\\\nCipla USA Inc.\\\\n----------\\\\nLisinopril and Hydrochlorothiazide Tablets, USP\\\\nRx Only\\\\nWARNING: FETAL TOXICITY\\\\nSee full prescribing information for complete boxed warning.\\\\nWhen pregnancy is detected, discontinue lisinopril and\\\\nhydrochlorothiazide tablets as soon as possible.\\\\nDrugs that act directly on the renin-angiotensin system can cause\\\\ninjury and death to the developing fetus. See \\\\nWarnings: Fetal Toxicity\\\\n.\\\\n...\",\"Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\\\nhydroxide solution.\\\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\\\nlisinopril and hydrochlorothiazide tabl...\",\"Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\\\nadministration of the separate entities.\\\\nLisinopril\\\\nMechanism of Action\\\\n \\\\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...\",\"state is prolonged. Older patients, on average, have (approximately doubled) higher\\\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\\\npatients (see \\\\nDOSAGE AND ADMINISTRATION\\\\n). In a multiple dose pharmacokinetic study\\\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\\\nhe...\",\"accompanied by some loss of potassium and bicarbonate.\\\\nAfter oral use diuresis begins within two hours, peaks in about four hours and lasts\\\\nabout 6 to 12 hours.\\\\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When\\\\nplasma levels have been followed for at least 24 hours, the plasma half-life has been\\\\nobserved to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is\\\\neliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but...\",\"the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\\\nsimilar risk (See \\\\nWARNINGS\\\\n).\\\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\\\nthan in nonblack patients (see \\\\nWARNIN...\",\"Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of\\\\nrapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin\\\\ninhibitor may be at increased risk for angioedema (see \\\\nPRECAUTIONS\\\\n).\\\\nIntestinal Angioedema:\\\\n Intestinal angioedema has been reported in patients treated\\\\nwith ACE inhibitors. These patients presented with abdominal pain (with or without\\\\nnausea or vomiting); in some cases there was no prior history of facial angioedema and\\\\nC-1...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\\\nLisinopril and Hydrochlorothiazide\\\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\\\nMaternal or fetotoxic effects were not seen in mice with the com...\",\"Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\\\nInteractions, Lisinopril and Hydrochlorothiazide).\\\\nPRECAUTIONS\\\\nGeneral\\\\nLisinopril\\\\n \\\\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\\\n As with all vasodilators, lisinopril\\\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\\\nventricle.\\\\nImpaired Renal Function:\\\\n As a consequence of inhibiting the renin-angiotensin-\\\\naldosterone system, changes in renal function may be anticipated in suscept...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"therapy.\\\\nInformation for Patients\\\\nAngioedema:\\\\n Angioedema, including laryngeal edema may occur at any time during\\\\ntreatment with angiotensin-converting enzyme inhibitors, including lisinopril and\\\\nhydrochlorothiazide. Patients should be so advised and told to report immediately any\\\\nsigns or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips,\\\\ntongue, difficulty in swallowing or breathing) and to take no more drug until they have\\\\nconsulted with the prescribing physician.\\\\nSymp...\",\"DOSAGE AND ADMINISTRATION\\\\n)\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\\\nInhibitors (COX-2 Inhibitors):\\\\n \\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\\\nfunction, including possible acute renal failure. These effects are usually reversible.\\\\nMonitor ...\",\"mTOR (mammalian target of rapamycin) inhibitors\\\\n \\\\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\\\n(see \\\\nWARNINGS\\\\n)\\\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\\\nrisk for angioedema. (see \\\\nWARNINGS\\\\n)\\\\nHydrochlorothiazide\\\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\\\nAlcohol, barbiturates, or nar...\",\"in vitro\\\\n alkaline elution rat hepatocyte assay. In addition, it did not produce increases in\\\\nchromosomal aberrations in an \\\\nin vitro\\\\n test in Chinese hamster ovary cells or in an \\\\nin\\\\nvivo\\\\n study in mouse bone marrow.\\\\nLisinopril\\\\n \\\\nThere was no evidence of a tumorigenic effect when lisinopril was administered for 105\\\\nweeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the\\\\nmaximum daily human dose, based on body weight and body surface area,\\\\nrespectively). There was no ...\",\"Nursing Mothers\\\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\\\nrats contains radioactivity following administration of \\\\nC lisinopril. In another study,\\\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\\\nwhether to discontinue nursing and/or disco...\",\"adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\\\nfatigue and muscle cramps.\\\\nAdverse experiences occurring in greater than one percent of patients treated with\\\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\\\n                                                                         Percent of Patients in\\\\nControlled Studies\\\\n   Lisinopril and\\\\nHydrochlorothiazide\\\\n   (n=930)\\\\n   Incidence\\\\n(discontinuation)\\\\n   Placebo\\\\n   (n=207)\\\\n...\",\"In rare cases, intestinal angioedema has been reported in post marketing experience.\\\\nHypotension:\\\\n In clinical trials, adverse effects relating to hypotension occurred as\\\\nfollows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects\\\\n(3.2%). In addition syncope occurred in 0.8% of patients (See \\\\nWARNINGS\\\\n).\\\\nCough:\\\\n See \\\\nPRECAUTIONS - Cough\\\\n.\\\\nClinical Laboratory Test Findings Serum Electrolytes:\\\\n (See \\\\nPRECAUTIONS\\\\n).\\\\nCreatinine, Blood Urea Nitrogen:\\\\n Minor reversible incre...\",\"hallucinations; \\\\nRespiratory:\\\\n Malignant lung neoplasms, hemoptysis, pulmonary edema,\\\\npulmonary infiltrates, bronchospasm, asthma, pleural effusion, pneumonia, eosinophilic\\\\npneumonitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis,\\\\npharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; \\\\nSkin:\\\\n Urticaria, alopecia,\\\\nherpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema,\\\\npsoriasis, rare cases of other severe skin reactions, includin...\",\"Lisinopril\\\\n \\\\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\\\nnormal saline solution.\\\\nLisinopril can be removed by hemodialysis (see \\\\nWARNINGS, Anaphylactoid Reaction\\\\nDuring Membrane Exposure\\\\n).\\\\nHydrochlorothiazide\\\\n \\\\nOral administration of a single oral dose of 10 g/kg to mice and rats w...\",\"possible, be discontinued for two to three days before beginning therapy with lisinopril\\\\nto reduce the likelihood of hypotension (See \\\\nWARNINGS\\\\n). If the patient\\\\u2019s blood pressure\\\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\\\nfor at least an additional hour (See \\\\nWARNINGS\\\\n and \\\\nPRECAUTIONS\\\\n...\",\"Protect from excessive light and humidity.\\\\n*AN69 is a registered trademark of Hospal Ltd.\\\\nManufactured by:\\\\nInvaGen Pharmaceuticals, Inc.\\\\n(a subsidiary of Cipla Ltd.)\\\\nHauppauge, NY 11788\\\\nManufactured for:\\\\nCipla USA, Inc.\\\\n10 Independence Boulevard, Suite 300\\\\nWarren, NJ 07059\\\\nRevised: 10/2021\\\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\\\u2013 10 mg/12.5 mg\\\\nNDC 69097-968-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n10 mg/12.5 mg\\\\n100 Tablets\\\\nCipla\\\\nNDC 69097-969-07             ...\",\"Cipla\\\\nNDC 69097-971-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n20 mg/25 mg\\\\n100 Tablets\\\\nCipla\\\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"lisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-969\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS D...\",\"LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\\\nlisinopril and hydrochlorothiazide tablets tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-971\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n20 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n25 mg\\\\nInactive Ingredients\\\\nI...\",\"Cipla USA Inc.\\\\nLabeler - \\\\nCipla USA Inc. \\\\n(078719707)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen\\\\nPharmaceuticals, Inc\\\\n165104469\\\\nanalysis(69097-968, 69097-969, 69097-971) , manufacture(69097-968,\\\\n69097-969, 69097-971)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nInvaGen Pharmaceuticals, Inc\\\\n080334903\\\\npack(69097-968, 69097-969, 69097-971)\\\\n \\\\nRevised: 11/2021\",\"ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and\\\\nphenylephrine hydrochloride tablet, coated \\\\n \\\\nMARC GLASSMAN, INC.\\\\n----------\\\\n1128B-MAR-2022-1005\\\\nDrug Facts\\\\nActive ingredients \\\\n(in each caplet)\\\\nPurpose\\\\nAcetaminophen 325 mg\\\\nPain reliever\\\\nChlorpheniramine maleate\\\\n2 mg\\\\nAntihistamine\\\\nPhenylephrine HCl 5 mg\\\\nNasal decongestant\\\\nUses\\\\ntemporarily relieves these symptoms of hay fever or other upper respiratory\\\\nallergies:\\\\nheadache\\\\nsinus congestion and pressure\\\\nnasal congestion\\\\nrunny nose...\",\"If a skin reaction occurs, stop use and seek medical help right away.\\\\nDo not use\\\\nwith any other drug containing acetaminophen (prescription or nonprescription). If\\\\nyou are not sure whether a drug contains acetaminophen, ask a doctor or\\\\npharmacist.\\\\nif you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain\\\\ndrugs for depression, psychiatric or emotional conditions, or Parkinson&#x27;s disease), or\\\\nfor 2 weeks after stopping the MAOI drug. If you do not know if your prescription\\\\ndr...\",\"800-222-1222). Quick medical attention is critical for adults as well as for children even if\\\\nyou do not notice any signs or symptoms.\\\\nDirections\\\\ndo not take more than directed (see \\\\noverdose warning\\\\n)\\\\nadults and\\\\nchildren 12\\\\nyears and over\\\\ntake 2 caplets every 4 hours\\\\nswallow whole; do not crush,\\\\nchew, or dissolve\\\\ndo not take more than 10 caplets\\\\nin 24 hours\\\\nchildren under \\\\n12 years\\\\nask a doctor\\\\nOther information\\\\nstore between 20\\\\u00b0-25\\\\u00b0C (68\\\\u00b0-77\\\\u00b0F) in a dry place\\\\nretain carton for complete product...\",\"ALLERGY MULTI SYMPTOM  \\\\nacetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:68998-228\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCHLORPHENIRAMINE MALEATE\\\\n (UNII: V1Q0O9OJ9Z) \\\\n(CHLORPHENIRAMINE -\\\\nUNII:3U6IO1965U)\\\\nCHLORPHENIRAMINE\\\\nMALEATE\\\\n2 mg\\\\nPHENYLEPHRINE HYDROCHLORIDE\\\\n (UNII: 04JA59TNSJ) \\\\n(PHENYLEPHRINE -\\\\nUNII:1WS297W6MV)\\\\nPHENYLE...\",\"MARC GLASSMAN, INC.\\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nFERRIC OXIDE YELLOW\\\\n (UNII: EX438O2MRT)\\\\n \\\\nMAGNESIUM STEARATE\\\\n (UNII: 70097M6I30)\\\\n \\\\nCROSPOVIDONE\\\\n (UNII: 2S7830E561)\\\\n \\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\\\n (UNII: 3WJQ0SDW1A)\\\\n \\\\nPOLYVINYL ALCOHOL, UNSPECIFIED\\\\n (UNII: 532B59J990)\\\\n \\\\nPOVIDONE, UNSPECIFIED\\\\n (UNII: FZ989GH94E)\\\\n \\\\nSTARCH, CORN\\\\n (UNII: O8232NY3SJ)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nSTEA...\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and\\\\nhydrochlorothiazide tablet \\\\n \\\\nANI Pharmaceuticals, Inc.\\\\n----------\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\nWARNING: \\\\nFETAL TOXICITY\\\\n\\\\u2022\\\\n\\\\u2022\\\\nDESCRIPTION\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP combine an angiotensin II receptor (type\\\\nAT\\\\n) antagonist and a diuretic, hydrochlorothiazide.\\\\nCandesartan cilexetil, a nonpeptide, is chemically described as (\\\\u00b1)-1-Hydroxyethyl 2-ethoxy-1-[\\\\np\\\\n-(\\\\no\\\\n-\\\\n1\\\\nH\\\\n...\",\"Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of\\\\n297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet\\\\nstrengths of candesartan cilexetil and hydrochlorothiazide.\\\\nCandesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil\\\\nand 12.5 mg or 25 mg of hydrochloroth...\",\"The mechanism of the antihypertensive effect of thiazides is unknown.\\\\nPharmacokinetics\\\\nGeneral\\\\nCandesartan Cilexetil\\\\nCandesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from\\\\nthe gastrointestinal tract to candesartan, a selective AT\\\\nsubtype angiotensin II receptor antagonist.\\\\nCandesartan is mainly excreted unchanged in urine and feces (via bile). \\\\nIt undergoes minor hepatic\\\\nmetabolism by O-deethylation to an inactive metabolite. \\\\nThe elimination half...\",\"Geriatric\\\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\\\u2265 65 years). \\\\nThe plasma\\\\nconcentration of candesartan was higher in the elderly (C\\\\n was approximately 50% higher, and AUC\\\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\\\nThe\\\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\\\nNo initia...\",\"plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\\\nadministered to hypertensive patients. \\\\nIn spite of the effect of candesartan cilexetil on aldosterone\\\\nsecretion, very little effect on serum potassium was observed.\\\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\\\nIn a\\\\n12-week study of 161 patients with n...\",\"in myocardial infarction and cardiovascular mortality also have been seen regularly.\\\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\\\nhypertension can provide substantial benefit. \\\\nRelative risk reduction from blood pressure reduction is\\\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\\\nare at h...\",\"candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\\\n). \\\\nIn each of\\\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\\\ntimes the MRHD\\\\n in mouse, rats, and rabbit, respectively). \\\\nThere was no evidence of harm to the rat or\\\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\\\nThiazides cross ...\",\"considered if the intraocular pressure remains uncontrolled. \\\\nRisk factors for developing acute angle-\\\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\\\nHypersensitivity Reaction\\\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\\\nPRECAUTIONS\\\\nMetabolic Disturbances\\\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...\",\"Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\\\npossible ac...\",\"Cytotoxic products \\\\u2013 Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.\\\\ncyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.\\\\nCyclosporine \\\\u2212 Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and\\\\ngout-type complications.\\\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\\\nNo carcinogenicity studies have been conducted with the combination of candesartan cilexetil and\\\\nhydrochlorothiazide. \\\\nThere was no evidence of c...\",\"Neonates with a history of in utero exposure to candesartan cilexetil and hydrochlorothiazide tablets:\\\\nIf oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.\\\\nExchange transfusions or dialysis may be required as a means of reversing hypotension and/or\\\\nsubstituting for disordered renal function.\\\\nSafety and effectiveness in pediatric patients have not been established.\\\\nADVERSE REACTIONS\\\\nCandesartan Cilexetil and Hydrochlorothiazide\\\\nCandesartan cile...\",\"melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\\\nfor white patients taking a cumulative dose of \\\\u226550,000 mg the risk increase was approximately 1\\\\nadditional SCC case for every 6,700 patients per year.\\\\nSkin:\\\\n \\\\nerythema multiforme including S...\",\"Dose Titration by Clinical Effect: \\\\nA patient whose blood pressure is not controlled on 25 mg of\\\\nhydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and\\\\nhydrochlorothiazide tablets 16 mg/12.5 mg. \\\\nA patient whose blood pressure is controlled on 25 mg of\\\\nhydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or\\\\nincremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16\\\\nmg/12.5 mg and ser...\",\"PRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/12.5 mg\\\\nNDC 62559-661-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/12.5 mg\\\\nRx only\\\\n90 Tablets\\\\nPRINCIPAL DISPLAY PANEL \\\\u2013 32 mg/25 mg\\\\nNDC 62559-662-90\\\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\\\n32 mg/25 mg\\\\nRx only\\\\n90 Tablets\",\"CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:62559-660\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCANDESARTAN CILEXETIL\\\\n (UNII: R85M2X0D68) \\\\n(CANDESARTAN - UNII:S8Q36MD2XX)\\\\nCANDESARTAN\\\\nCILEXETIL\\\\n16 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n1...\",\"Flavor\\\\nImprint Code\\\\nACS\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-660-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type...\",\"Packaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-661-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (So...\",\"ANI Pharmaceuticals, Inc.\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-662-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nLabeler - \\\\nANI Pharmaceuticals, Inc. \\\\n(145588013)\\\\n \\\\nRevised: 5/2020\",\"CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\\\n \\\\nCertus Medical, Inc.\\\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\\\n----------\\\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\\\nDrug Facts Box OTC Active Ingredient Section\\\\nPovidone Iodine USP 10%\\\\nequivalent to 1% titratable iodine\\\\nDrug Facts Box OTC Purpose Section\\\\nAntiseptic\\\\nDrug...\",\"Drug Facts Box OTC General Precautions Section\\\\nstore at room temperature 15\\\\n - 30\\\\n C (59\\\\n - 86\\\\n F)\\\\nDrug Facts Box OTC Inactive Ingredient Section\\\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\\\nCertus PVP-1 Prep Swabstick \\\\n210012 pouch\\\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\\\n0\\\\n0\\\\n0\\\\n0\",\"CERTUS PVP-1 PREP SWABSTICK  \\\\npovidone-iodine swab\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:75990-4019\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85H0HZU99M) \\\\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\\\nPOVIDONE-IODINE\\\\n0.1 mL  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\",\"Certus Medical, Inc.\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nSODIUM PHOSPHATE, DIBASIC\\\\n (UNII: GR686LBA74)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nDIMETHICONE\\\\n (UNII: 92RU3N3Y1O)\\\\n \\\\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\\\n (UNII: S38J6RZN16)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:75990-4019-4\\\\n2 mL in 1 POUCH\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOT...\",\"ABALONE CRYSTALDOUBLE EX CC- niacinamide, adenosine, titanium dioxide, ethylhexyl\\\\nmethoxycinnamate cream \\\\n \\\\nC&amp;BCOSMETIC Co.,Ltd.\\\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\\\napproved by FDA. \\\\nFor further information about unapproved drugs, click here.\\\\n----------\\\\nDrug Facts\\\\nNiacinamide, Adenosine, Titanium Dioxide, Ethylhexyl Methoxycinnamate\\\\nWater, Glycerin, Butylene Glycol, Etc\\\\nSkin Protectant - Anti-Wrinkle, Whitening, UV Protecting\\\\nk...\",\"ABALONE CRYSTALDOUBLE EX CC  \\\\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:60611-0008\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\",\"C&amp;BCOSMETIC Co.,Ltd.\\\\nNIACINAMIDE\\\\n (UNII: 25X51I8RD4) \\\\n(NIACINAMIDE - UNII:25X51I8RD4)\\\\nNIACINAMIDE\\\\n2 g  in 100 mL\\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP) \\\\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\\\nTITANIUM DIOXIDE\\\\n4.694 g  in 100 mL\\\\nADENOSINE\\\\n (UNII: K72T3FS567) \\\\n(ADENOSINE - UNII:K72T3FS567)\\\\nADENOSINE\\\\n0.04 g  in 100 mL\\\\nOCTINOXATE\\\\n (UNII: 4Y5P7MUD51) \\\\n(OCTINOXATE - UNII:4Y5P7MUD51)\\\\nOCTINOXATE\\\\n7 g  in 100 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C...\",\"TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\\\n \\\\nAdvagen Pharma Limited\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use TIZANIDINE\\\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\\\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\\\n \\\\nInitial U.S. Approval: 1996\\\\nINDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...\",\"Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\\\nfour-fold ( \\\\n8.5\\\\n)\\\\nSee 17 for PATIENT COUNSELING INFORMATION.\\\\nRevised: 9/2020\\\\nFULL PRESCRIBING INFORMATION: CONTENTS\\\\n*\\\\n1 INDICATIONS AND USAGE\\\\n2 DOSAGE AND ADMINISTRATION\\\\n2.1 Dosing Information\\\\n2.2 Dosing in Patients with Renal Impairment\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\n2.4 Drug Discontinuation\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Hypo...\",\"12.1 Mechanism of Action\\\\n12.3 Pharmacokinetics\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n16.1 Tizanidine Hydrochloride Capsules\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\n1 INDICATIONS AND USAGE\\\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the\\\\nmanagement of spasticity. Because of the short duration of therapeutic effect,\\\\ntreatment with tizanid...\",\"been studied.\\\\n2.2 Dosing in Patients with Renal Impairment\\\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\\\ndoses are required, individual doses rather than dosing frequency should be increased\\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n)] \\\\n.\\\\n2.3 Dosing in Patients with Hepatic Impairment\\\\nT...\",\"Tizanidine is an \\\\u03b1 \\\\n-adrenergic agonist that can produce hypotension. Syncope has been\\\\nreported in the post marketing setting. The chance of significant hypotension may\\\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\\\na supine to fixed upright position may be at increased risk for hypotension and\\\\northostatic effects.\\\\nMonitor for hypotension when tizanidine is used in patients...\",\"Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n5.6 Hypersensitivity Reactions\\\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\\\nand symptoms occur. \\\\n[see Contraindications ( \\\\n4\\\\n)]\\\\n5.7 Increased Risk of Adverse Reactions in Patients...\",\"264 patients received tizanidine and 261 patients received placebo. Across the three\\\\nstudies patient ages ranged from 15\\\\u201369 years and 51.4 percent were women. The\\\\nmedian dose during the plateau phase ranged from 20\\\\u201328 mg/day.\\\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\\\nclinical studies involving 264 patients with spasticity were dry mouth,\\\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\\\nThree-quarters of the patients rated t...\",\"multiple sclerosis (Study 1) \\\\n[see Clinical Studies ( \\\\n14\\\\n)] \\\\n, the patients were specifically\\\\nasked if they had experienced any of the four most common adverse reactions: dry\\\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\\\nthese reactions is summarized in \\\\nTable 2\\\\n. Other events were, in general, reported at a\\\\nrate of 2% or less.\\\\nTable 2: Single Dose, Placebo-Controlled Study -...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"12.3\\\\n)]\\\\n7.7 \\\\u03b1 \\\\n-adrenergic agonists\\\\nBecause hypotensive effects may be cumulative, it is not recommended that tizanidine\\\\nbe used with other \\\\u03b1 \\\\n-adrenergic agonists. \\\\n[see Warnings and Precautions ( \\\\n5.1\\\\n)]\\\\n8 USE IN SPECIFIC POPULATIONS\\\\n8.1 Pregnancy\\\\nPregnancy Category C\\\\nTizanidine has not been studied in pregnant women. Tizanidine should be given to\\\\npregnant women only if the benefit outweighs the risk to the unborn fetus.\\\\nReproduction studies performed in rats at a dose of 3 mg/kg, equal to the...\",\"8.6 Impaired Renal Function\\\\nTizanidine is known to be substantially excreted by the kidney, and the risk of adverse\\\\nreactions to this drug may be greater in patients with impaired renal function. In patients\\\\nwith renal insufficiency (creatinine clearance &lt; 25 mL/min) clearance was reduced by\\\\nmore than 50%. In these patients, during titration, the individual doses should be\\\\nreduced. If higher doses are required, individual doses rather than dosing frequency\\\\nshould be increased. These patients sho...\",\"manifestations of tizanidine overdose were consistent with its known pharmacology. In\\\\nthe majority of cases a decrease in sensorium was observed including lethargy,\\\\nsomnolence, confusion and coma. Depressed cardiac function is also observed including\\\\nmost often bradycardia and hypotension. Respiratory depression is another common\\\\nfeature of tizanidine overdose.\\\\nShould overdose occur, basic steps to ensure the adequacy of an airway and the\\\\nmonitoring of cardiovascular and respiratory systems shou...\",\"12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\\\nreduce facilitation of spinal motor neurons.\\\\n12.3 Pharmacokinetics\\\\nAbsorption and Distribution\\\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\\\n...\",\"Metabolism and Excretion\\\\nTizanidine has linear pharmacokinetics over the doses studied in clinical development (1\\\\u2013\\\\n20 mg). Tizanidine has a half-life of approximately 2.5 hours (CV=33%). Approximately\\\\n95% of an administered dose is metabolized. The primary cytochrome P450 isoenzyme\\\\ninvolved in tizanidine metabolism is CYP1A2. Tizanidine metabolites are not known to be\\\\nactive; their half-lives range from 20 to 40 hours.\\\\nFollowing single and multiple oral dosing of \\\\nC-tizanidine, an average of 60%...\",\"this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\\\nused with caution in renally impaired patients \\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n) and\\\\nUse in Specific Populations ( \\\\n8.6\\\\n)] \\\\n.\\\\nGender Effects\\\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\\\npharmacokinetic...\",\"13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nCarcinogenesis\\\\nTizanidine was administered to mice for 78 weeks at oral doses up to 16 mg/kg/day,\\\\nwhich is 2 times the maximum recommended human dose (MRHD) on a mg/m \\\\nbasis.\\\\nTizanidine was administered to rats for 104 weeks at oral doses up to 9 mg/kg/day,\\\\nwhich is 2.5 times the MRHD on a mg/m \\\\nbasis. There was no increase in tumors in\\\\neither species.\\\\nMutagenesis\\\\nTizanidine was negative in \\\\nin vitro\\\\n(bacterial r...\",\"tone in placebo treated patients. Within a given patient, improvement in muscle tone was\\\\ncorrelated with plasma concentration. Plasma concentrations were variable from patient\\\\nto patient at a given dose. Although 16 mg produced a larger effect, adverse events\\\\nincluding hypotension were more common and more severe than in the 8 mg group.\\\\nThere were no differences in the number of spasms occurring in each group.\\\\nFigure 2: Single Dose Study - Mean Change in Muscle Tone from Baseline as\\\\nMeasured by ...\",\"from baseline as measured by the Ashworth scale.\\\\nFigure 3: Seven Week Study - Mean Change in Muscle Tone 0.5-2.5 Hours\\\\nAfter Dosing as Measured by the Ashworth Scale \\\\u00b1 95% Confidence Interval\\\\n(A Negative Ashworth Score Signifies an Improvement in Muscle Tone from\\\\nBaseline)\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n16.1 Tizanidine Hydrochloride Capsules\\\\nTizanidine Hydrochloride Capsules are available in three strengths as two-piece hard\\\\ngelatin capsules containing tizanidine hydrochloride 2.29 mg, 4.5...\",\"17 PATIENT COUNSELING INFORMATION\\\\nSerious Drug Interactions\\\\nAdvise patients they should not take tizanidine if they are taking fluvoxamine or\\\\nciprofloxacin because of the increased risk of serious adverse reactions including severe\\\\nlowering of blood pressure and sedation. Instruct patients to inform their physicians or\\\\npharmacists when they start or stop taking any medication because of the risks\\\\nassociated with interaction between tizanidine and other medicines.\\\\nTizanidine Dosing\\\\nTell patients ...\",\"PRINCIPAL DISPLAY PANEL - 4 mg 150 Capsules Bottle - NDC 72888-002-15\\\\nPRINCIPAL DISPLAY PANEL - 6 mg 150 Capsules Bottle - NDC 72888-003-15\",\"TIZANIDINE HYDROCHLORIDE  \\\\ntizanidine hydrochloride capsule\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:72888-001\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of\\\\nStrength\\\\nStrength\\\\nTIZANIDINE HYDROCHLORIDE\\\\n (UNII: B53E3NMY5C) \\\\n(TIZANIDINE -\\\\nUNII:6AI06C00GW)\\\\nTIZANIDINE\\\\n2 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE 101\\\\n (UNII: 7T9FYH5QMK)\\\\n \\\\nLACTOSE MONOHYDRATE\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\nHYPROMELLOSE...\",\"AMMONIA\\\\n (UNII: 5138Q19F1X)\\\\n \\\\nFERROSOFERRIC OXIDE\\\\n (UNII: XM0M87F357)\\\\n \\\\nPOTASSIUM HYDROXIDE\\\\n (UNII: WZH3C48M4T)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nblue (Cap: Blue opaque) , blue (Body: Light Blue opaque)\\\\nScore\\\\nno score\\\\nShape\\\\nCAPSULE\\\\nSize\\\\n11mm\\\\nFlavor\\\\nImprint Code\\\\nUpArrowhead;043\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:72888-001-\\\\n15\\\\n150 \\\\nin 1 BOTTLE; Type 0: Not a Combination\\\\nProduct\\\\n05/27/2020\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nAppl...\",\"GELATIN, UNSPECIFIED\\\\n (UNII: 2G86QN327L)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nFD&amp;C BLUE NO. 1\\\\n (UNII: H3R47K3TBD)\\\\n \\\\nFD&amp;C RED NO. 40\\\\n (UNII: WZB9127XOA)\\\\n \\\\nSHELLAC\\\\n (UNII: 46N107B71O)\\\\n \\\\nISOPROPYL ALCOHOL\\\\n (UNII: ND2M416302)\\\\n \\\\nPROPYLENE GLYCOL\\\\n (UNII: 6DC9Q167V3)\\\\n \\\\nALCOHOL\\\\n (UNII: 3K9958V90M)\\\\n \\\\nBUTYL ALCOHOL\\\\n (UNII: 8PJ61P6TS3)\\\\n \\\\nAMMONIA\\\\n (UNII: 5138Q19F1X)\\\\n \\\\nFERROSOFERRIC OXIDE\\\\n (UNII: XM0M87F357)\\\\n \\\\nPOTASSIUM HYDROXIDE\\\\n (UNII: WZH3C48M4T)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nblue (Cap: Blue opaque)...\",\"Inactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMICROCRYSTALLINE CELLULOSE 101\\\\n (UNII: 7T9FYH5QMK)\\\\n \\\\nLACTOSE MONOHYDRATE\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\nHYPROMELLOSE, UNSPECIFIED\\\\n (UNII: 3NXW29V3WO)\\\\n \\\\nSILICON DIOXIDE\\\\n (UNII: ETJ7Z6XBU4)\\\\n \\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nSTEARIC ACID\\\\n (UNII: 4ELV7Z65AP)\\\\n \\\\nGELATIN, UNSPECIFIED\\\\n (UNII: 2G86QN327L)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nFD&amp;C BLUE NO. 1\\\\n (UNII: H3R47K3TBD)\\\\n \\\\nFD&amp;C RED NO. 40\\\\n (UNII: WZB9127XOA)\\\\n \\\\nSHELLAC\\\\n (UNII: 46N107B71O)\\\\n \\\\nISOPRO...\",\"Advagen Pharma Limited\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nRubicon Research\\\\nPrivate Limited\\\\n677604197\\\\nanalysis(72888-001, 72888-002, 72888-003) , manufacture(72888-001,\\\\n72888-002, 72888-003) , pack(72888-001, 72888-002, 72888-003)\\\\n \\\\nRevised: 7/2024\",\"ATHLETES FOOT- butenafine hydrochloride cream \\\\n \\\\nRite Aid Corporation\\\\n----------\\\\nAthlete&#x27;s Foot Cream\\\\nDrug Facts\\\\nActive ingredient\\\\nButenafine hydrochloride 1%\\\\nPurpose\\\\nAntifungal\\\\nUses\\\\ncures most athlete&#x27;s foot between the toes. Effectiveness on the bottom or sides of\\\\nfoot is unknown.\\\\ncures most jock itch and ringworm\\\\nrelieves itching, burning, cracking, and scaling which accompany these conditions\\\\nWarnings\\\\nFor external use only\\\\nDo not use\\\\non nails or scalp\\\\nin or near the mouth or the eyes\\\\nfor vag...\",\"1 week twice a day or 4 weeks once a day\\\\nfor jock itch and ringworm:\\\\napply once a day to affected skin for 2 weeks or as\\\\ndirected by a doctor.\\\\nwash hands after each use\\\\nchildren under 12 years: ask a doctor\\\\nOther information\\\\ndo not use if seal on tube is broken or not visible\\\\nstore between 20\\\\u00ba to 25\\\\u00ba C (68\\\\u00ba to 77\\\\u00ba F)\\\\nInactive ingredients\\\\nbenzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23)\\\\ncetyl ether, propylene glycol dicaprylate, purified water, sodium benzoa...\",\"RITE \\\\nAID \\\\n \\\\nPHARMACY\\\\nclinically proven to cure \\\\nmost athlete&#x27;s foot between the toes\\\\nfoot care \\\\nbutenafine\\\\nhydrochloride cream 1%\\\\nantifungal\\\\nNET WT 0.42 OZ (12 g)\\\\n\\\\u00ae\",\"ATHLETES FOOT  \\\\nbutenafine hydrochloride cream\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:11822-2100\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nBUTENAFINE HYDROCHLORIDE\\\\n (UNII: R8XA2029ZI) \\\\n(BUTENAFINE -\\\\nUNII:91Y494NL0X)\\\\nBUTENAFINE\\\\nHYDROCHLORIDE\\\\n10 mg\\\\n in 1 g\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nBENZYL ALCOHOL\\\\n (UNII: LKG8494WBH)\\\\n \\\\nCETYL ALCOHOL\\\\n (UNII: 936JST6JCN)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n...\",\"Rite Aid Corporation\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nANDA\\\\nANDA205181\\\\n11/17/2017\\\\nLabeler - \\\\nRite Aid Corporation \\\\n(014578892)\\\\nEstablishment\\\\nName\\\\nAddress\\\\nID/FEI\\\\nBusiness Operations\\\\nTaro Pharmaceuticals Inc.\\\\n206263295\\\\nmanufacture(11822-2100)\\\\n \\\\nRevised: 7/2024\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#ff7f0e\",\"#ff7f0e\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#999\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ff7f0e\",\"#ff7f0e\",\"#aec7e8\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ff7f0e\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#ffbb78\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\"],\"shape\":[117],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1045\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1046\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1041\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1042\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1043\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1012\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1027\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1028\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1029\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1030\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1031\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1036\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1037\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1022\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1023\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1024\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1025\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1017\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1018\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1019\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1020\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1021\",\"attributes\":{\"axis\":{\"id\":\"p1017\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1026\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1022\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1047\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1048\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"ACE Inhibitors and mTOR Inhibitors\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":30}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1049\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Candesartan Cilexetil and\\\\nHydrochlorothiazide\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":62}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1050\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"NUCYNTA Safety\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":2}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1051\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":16}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1052\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Pharmaceutical Products\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1053\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Tizanidine Hydrochloride\"},\"renderers\":[{\"id\":\"p1044\"}],\"index\":87}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p1123\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p1059\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1068\",\"attributes\":{\"start\":7.730230808258057,\"end\":17.376468658447266}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p1069\",\"attributes\":{\"start\":-1.6865412592887878,\"end\":11.504014730453491}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1070\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p1071\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p1066\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1098\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1055\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1056\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1057\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"TBw0QRbJBkHXBVNBnngnQY9BRUHFJSVB+KI8Qby2OUFSM0hBZ/dRQSKTS0HLiFZBrN8aQdNFC0G2VDhBG2ksQZdYKEHslBdB5IhIQRmMFUFi5l1B1oNBQdq6LEF7YBdBcsIUQQ==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"tPOoQPw6iD/8f3s/De+RQPFAC0Hoti9AraMAQTGM30CGGfY/0LOmPxzQA0E2qsZAh8ioPwBeQD9m6QVBeDVgQPVr0EAPbUI/m/81P/zdm0Cn+M5A1yYSQfTJuUBgkfY/ZUWMPw==\"},\"shape\":[25],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Others\",\"NUCYNTA\\\\u2122 Medication\",\"Tizanidine Hydrochloride\",\"Povidone Iodine Solution\",\"ACE Inhibitor Side Effects\",\"Others\",\"ACE Inhibitor Side Effects\",\"ACE Inhibitor Side Effects\",\"Tizanidine Hydrochloride\",\"Tizanidine Hydrochloride\",\"ACE Inhibitor Side Effects\",\"Candesartan Cilexetil\",\"NUCYNTA\\\\u2122 Medication\",\"NUCYNTA\\\\u2122 Medication\",\"ACE Inhibitor Side Effects\",\"Povidone Iodine Solution\",\"ACE Inhibitor Side Effects\",\"NUCYNTA\\\\u2122 Medication\",\"Tizanidine Hydrochloride\",\"Pharmaceuticals\",\"Candesartan Cilexetil\",\"ACE Inhibitor Side Effects\",\"Others\",\"NUCYNTA\\\\u2122 Medication\",\"NUCYNTA\\\\u2122 Medication\"]],[\"correctness\",[false,false,true,true,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false,false]],[\"questions\",[\"What specific advantages does hydrochlorothiazide offer in the tablets containing candesartan cilexetil, and what are the strengths of hydrochlorothiazide in each of the different tablet formulations?\",\"What is the abuse potential of NUCYNTA\\\\u2122, how is it classified, and what precautions should be taken for patients with hepatic impairment?\",\"How does the consumption of alcohol impact the pharmacokinetics of tizanidine, specifically in terms of its area under the curve (AUC) and maximum concentration (Cmax)?\",\"What are the specific active ingredients present in the GRX DYNE povidone iodine solution and what is the concentration of the active ingredient in the solution?\",\"What are the most frequently reported clinical adverse experiences in trials involving lisinopril and hydrochlorothiazide tablets, and what precautions should be taken into account when considering the drug&#x27;s use in nursing mothers?\",\"What are the different strengths available for tapentadol hydrochloride medication and what are the corresponding colors of the tablets?\",\"What is the specific mechanism by which hydrochlorothiazide exerts its antihypertensive effect, and how does it impact the electrolyte reabsorption mechanism in the distal renal tubule?\",\"What are the available strengths of lisinopril and hydrochlorothiazide tablets, and how are they supplied?\",\"Can you explain the difference in bioavailability between Tizanidine Capsules and Tizanidine Tablets, particularly when administered with food, and how does it impact the peak plasma concentration and time to peak plasma concentration?\",\"What specific parameter should be monitored in patients taking tizanidine to mitigate the risk of hepatocellular liver injury, especially in those with hepatic impairment?\",\"In the case of hypotension resulting from an overdose of Lisinopril, what is the recommended treatment involving the administration of what type of solution?\",\"How does candesartan impact the pressor effects of angiotensin II infusion, and to what extent is this effect inhibited by the medication?\",\"What specific type of surgery was conducted to assess the effectiveness of NUCYNTA\\\\u2122 in the clinical trial mentioned in the document?\",\"Can you provide a list of psychiatric disorders that are mentioned as potential adverse reactions to NUCYNTA\\\\u2122, according to the provided document?\",\"What clinical signs should patients undergoing thiazide therapy be monitored for in terms of fluid and electrolyte imbalance, and what are some specific warning signs or symptoms that may indicate such an imbalance?\",\"What is the specific active component found in the foot care cream designed to treat athlete&#x27;s foot located between the toes?\",\"What is the strength of Lisinopril and Hydrochlorothiazide tablets with NDC 69097-969-07?\",\"What is the average duration of the terminal half-life of tapentadol following oral administration, and how does it compare in subjects with varying degrees of renal function?\",\"What are the specific contraindications for the simultaneous use of tizanidine with fluvoxamine and ciprofloxacin, and what potential effects on blood pressure, drowsiness, and psychomotor impairment should be considered?\",\"When did the marketing of the product with NDC:75990-4019-4 officially begin according to the provided document?\",\"What are the potential manifestations of overdosage with candesartan cilexetil, and what supportive treatment should be initiated if symptomatic hypotension occurs?\",\"What are the potential adverse effects on the fetus associated with the use of drugs that act on the renin-angiotensin system during pregnancy, specifically in terms of fetal renal function, morbidity, and mortality?\",\"What are the specific strengths of lisinopril and hydrochlorothiazide in the tablets with NDC:69097-969, and what are the color and shape of these tablets?\",\"How should the dosing regimen for NUCYNTA (tapentadol) be adjusted to maintain adequate pain relief with acceptable tolerability?\",\"What are some of the nervous system disorders observed as adverse reactions during the premarketing evaluation of NUCYNTA\\\\u2122, including symptoms such as disturbance in attention, sedation, dysarthria, and ataxia?\"]],[\"agent_answer\",[\"### **Specific Advantages of Hydrochlorothiazide (HCTZ) in Candesartan Cilexetil Tablets**  \\\\n\\\\nHydrochlorothiazide (HCTZ) enhances the therapeutic effects of **candesartan cilexetil** through the following mechanisms:  \\\\n\\\\n1. **Dual-Pathway Blood Pressure Control**  \\\\n   - **Candesartan** (ARB) dilates blood vessels by blocking angiotensin II receptors.  \\\\n   - **HCTZ** reduces blood volume via **diuresis** (sodium/water excretion), addressing **salt-sensitive hypertension** and volume overload.  \\\\n\\\\n2. **Synergistic Efficacy**  \\\\n   - Greater BP reduction than either drug alone (e.g., **16\\\\u201319 mmHg systolic** and **9\\\\u201311 mmHg diastolic** with 32 mg/25 mg combo).  \\\\n   - **Trough-to-peak ratio of 88%** ensures sustained 24-hour control.  \\\\n\\\\n3. **Mitigation of Adverse Effects**  \\\\n   - Candesartan counters HCTZ-induced **hypokalemia** (by suppressing aldosterone).  \\\\n   - Reduces risks of **hyperuricemia** and **glucose intolerance** compared to HCTZ monotherapy.  \\\\n\\\\n4. **Broad Patient Applicability**  \\\\n   - Effective in **elderly**, **Black patients**, and **salt-sensitive populations** where monotherapy may fail.  \\\\n\\\\n---\\\\n\\\\n### **Strengths of Hydrochlorothiazide in Each Tablet Formulation**  \\\\nThe fixed-dose combinations include **three HCTZ doses**:  \\\\n\\\\n| **Tablet Formulation**      | **HCTZ Strength** | **Key Use Case** | **Physical Description** |  \\\\n|-----------------------------|------------------|------------------|--------------------------|  \\\\n| **16 mg candesartan / 12.5 mg HCTZ** | 12.5 mg | Moderate volume reduction (e.g., stepping up from monotherapy) | Peach, oval, biconvex, scored |  \\\\n| **32 mg candesartan / 12.5 mg HCTZ** | 12.5 mg | Stronger RAAS inhibition with balanced diuresis | Yellow, oval, biconvex, scored |  \\\\n| **32 mg candesartan / 25 mg HCTZ** | 25 mg | Maximal diuresis for salt-sensitive or severe hypertension | Pink, oval, biconvex, scored |  \\\\n\\\\n#### **Inactive Ingredients**  \\\\nAll formulations contain:  \\\\n- Carboxymethylcellulose calcium, lactose monohydrate, corn starch, magnesium stearate, and ferric oxide (yellow).  \\\\n- **16 mg/12.5 mg** and **32 mg/25 mg** tablets add **ferric oxide (reddish-brown)** for color differentiation.  \\\\n\\\\n---\\\\n\\\\n### **Clinical Takeaways**  \\\\n- **12.5 mg HCTZ**: First-line for most patients (balances efficacy/safety).  \\\\n- **25 mg HCTZ**: Reserved for volume-overloaded or resistant hypertension.  \\\\n- **Onset**: Effects within **1\\\\u20132 weeks**, peak by **4 weeks**.  \\\\n\\\\nThis combination leverages **complementary pharmacology** for superior hypertension control while minimizing side effects. Let me know if you&#x27;d like deeper insights into specific trials or pharmacokinetics!\",\"### **Comprehensive Answer: NUCYNTA\\\\u2122 (Tapentadol) \\\\u2013 Abuse Potential, Classification, and Hepatic Precautions**\\\\n\\\\n---\\\\n\\\\n#### **1. Abuse Potential of NUCYNTA\\\\u2122**  \\\\nNUCYNTA\\\\u2122 (tapentadol) has a **high abuse potential**, comparable to other **Schedule II opioids** like hydromorphone and oxycodone. Key points:  \\\\n- **Mechanism**: Acts as a **mu-opioid agonist** (like morphine), with additional norepinephrine reuptake inhibition.  \\\\n- **Abuse Behaviors**: Can be misused via crushing/snorting, injecting, or taking higher doses than prescribed.  \\\\n- **Risk Factors**:  \\\\n  - Psychological dependence, compulsive use, and diversion (illegal redistribution).  \\\\n  - Prescribing information warns:  \\\\n    &gt; *\\\\\"NUCYNTA\\\\u2122 exposes users to risks of opioid addiction, abuse, and misuse, which can lead to overdose and death.\\\\\"*  \\\\n\\\\n**Comparison to Other Opioids**:  \\\\n- Similar abuse liability to **hydromorphone** (per clinical studies).  \\\\n- Higher risk than Schedule III/IV opioids (e.g., tramadol, codeine).  \\\\n\\\\n---\\\\n\\\\n#### **2. Controlled Substance Classification**  \\\\n- **Schedule II (C-II)** under the U.S. Controlled Substances Act (CSA).  \\\\n  - **Implications**:  \\\\n    - Accepted medical use (severe pain) but **strictly regulated**.  \\\\n    - No refills without a new prescription.  \\\\n    - Requires secure storage and monitoring for diversion.  \\\\n- **Why Schedule II?**  \\\\n  - High abuse potential and severe dependence risk.  \\\\n  - Label explicitly states:  \\\\n    &gt; *\\\\\"NUCYNTA\\\\u2122 is a federally controlled substance (C-II) because it can be abused.\\\\\"*  \\\\n\\\\n---\\\\n\\\\n#### **3. Precautions for Hepatic Impairment**  \\\\n##### **Dosing Adjustments by Severity**  \\\\n| **Hepatic Function**       | **Recommendation**                                                                 |  \\\\n|-----------------------------|-----------------------------------------------------------------------------------|  \\\\n| **Mild Impairment**         | No dose adjustment needed.                                                        |  \\\\n| **Moderate Impairment**     | - Start at **50 mg per dose** (max every 8 hours; **150 mg/day**).&lt;br&gt;- Titrate cautiously with close monitoring. |  \\\\n| **Severe Impairment**       | **Avoid use** (no safety data; high risk of toxicity).                            |  \\\\n\\\\n##### **Key Precautions**  \\\\n- **Moderate Impairment**:  \\\\n  - Monitor for **sedation, respiratory depression**, or signs of opioid toxicity.  \\\\n  - Avoid concurrent hepatotoxic drugs (e.g., acetaminophen, alcohol).  \\\\n- **Severe Impairment**:  \\\\n  - Use alternative analgesics (e.g., buprenorphine, fentanyl with dose adjustments).  \\\\n- **Pharmacokinetic Basis**:  \\\\n  - Tapentadol exposure increases **1.5\\\\u20132x in moderate impairment** due to reduced glucuronidation.  \\\\n\\\\n##### **Supporting Evidence**  \\\\n- Prescribing guidelines state:  \\\\n  &gt; *\\\\\"NUCYNTA\\\\u2122 has not been studied in severe hepatic impairment; use is not recommended in this population.\\\\\"*  \\\\n- Elevated serum levels in hepatic dysfunction increase risks of **CNS depression** and overdose.  \\\\n\\\\n---\\\\n\\\\n### **Clinical Takeaway**  \\\\n- **Abuse Risk**: Treat NUCYNTA\\\\u2122 with the same caution as other Schedule II opioids (e.g., hydromorphone).  \\\\n- **Liver Disease**:  \\\\n  - **Mild**: Standard dosing.  \\\\n  - **Moderate**: Conservative dosing + vigilant monitoring.  \\\\n  - **Severe**: Contraindicated\\\\u2014opt for safer alternatives.  \\\\n\\\\nFor hepatic-impaired patients, **baseline LFTs** and **frequent reassessment** are critical to balance pain relief and safety.  \\\\n\\\\nLet me know if you\\\\u2019d like further details on alternatives for hepatic impairment or abuse-deterrent strategies!\",\"Here\\\\u2019s a concise, evidence-based answer synthesizing the provided context and background Q&amp;A:\\\\n\\\\n---\\\\n\\\\n### **Impact of Alcohol on Tizanidine\\\\u2019s Pharmacokinetics (AUC &amp; Cmax)**  \\\\n\\\\n#### **1. Quantified Changes**  \\\\n- **AUC (Area Under the Curve)**: Alcohol increases tizanidine\\\\u2019s systemic exposure by **~20%** (per prescribing data). This indicates prolonged drug action due to slower clearance.  \\\\n- **Cmax (Peak Concentration)**: Alcohol raises tizanidine\\\\u2019s maximum plasma level by **~15%**, intensifying acute effects like sedation.  \\\\n\\\\n#### **2. Mechanism**  \\\\n- **CYP1A2 Inhibition**: Alcohol inhibits CYP1A2, the primary enzyme metabolizing tizanidine, reducing its breakdown and increasing AUC.  \\\\n- **Minor Gastric Effects**: Alcohol may marginally accelerate absorption (contributing to Cmax), but CYP1A2 inhibition dominates.  \\\\n\\\\n#### **3. Clinical Significance**  \\\\n- **Increased Side Effects**: The 20% AUC rise correlates with **more frequent/intense adverse reactions** (e.g., dizziness, hypotension).  \\\\n- **Additive CNS Depression**: Alcohol synergistically enhances tizanidine\\\\u2019s sedative effects, risking impaired alertness or motor function.  \\\\n\\\\n#### **4. Evidence Source**  \\\\n- **Prescribing Data**: Directly states:  \\\\n  &gt; *\\\\u201cAlcohol increased tizanidine\\\\u2019s AUC by ~20% and Cmax by ~15%, associated with increased side effects.\\\\u201d*  \\\\n- **Mechanistic Support**: Background Q&amp;A confirms CYP1A2 inhibition as the key driver, not protein binding or renal excretion.  \\\\n\\\\n#### **5. Recommendations**  \\\\n- **Avoid Alcohol**: To prevent pharmacokinetic (AUC/Cmax) and pharmacodynamic (CNS) risks.  \\\\n- **If Co-Use Occurs**:  \\\\n  - Start tizanidine at a **reduced dose (e.g., 2 mg)**.  \\\\n  - Monitor for **hypotension** and **excessive sedation**.  \\\\n\\\\n---\\\\n\\\\n### **Key Takeaway**  \\\\nAlcohol\\\\u2019s **CYP1A2 inhibition** significantly prolongs tizanidine\\\\u2019s action (\\\\u2191AUC) and amplifies peak effects (\\\\u2191Cmax), heightening safety risks. Strict avoidance is advised.  \\\\n\\\\nLet me know if you\\\\u2019d like further exploration of CYP1A2 kinetics or alternative muscle relaxants!\",\"### Answer:  \\\\nThe **specific active ingredient** in **GRX DYNE povidone-iodine solution** is:  \\\\n- **Povidone Iodine USP, 10% w/v** (equivalent to **1% titratable iodine**).  \\\\n\\\\n#### Concentration Details:  \\\\n- **10% weight/volume (w/v)**:  \\\\n  - This means the solution contains **10 grams of povidone-iodine per 100 mL**.  \\\\n  - The **1% titratable iodine** refers to the biologically active iodine released for antiseptic action.  \\\\n\\\\n#### Confirmed by Context:  \\\\n1. The provided **GRx Dyne Solution Drug Facts** label explicitly states:  \\\\n   - *\\\\\"Active Ingredient: Povidone Iodine USP, 10% w/v (equivalent to 1% titratable Iodine).\\\\\"*  \\\\n2. No other active ingredients are listed in the document or supplementary Q&amp;A pairs.  \\\\n\\\\n#### Additional Notes:  \\\\n- **Regulatory Status**: Marketed as an OTC antiseptic, compliant with FDA regulations (though not individually evaluated by the FDA).  \\\\n- **Purpose**: Used for minor cuts, scrapes, or burns to reduce infection risk.  \\\\n\\\\nFor clarity:  \\\\n- **Active Ingredient**: Only povidone-iodine.  \\\\n- **Concentration**: Strictly **10% w/v** (as confirmed by both the label and prior Q&amp;A).  \\\\n\\\\nLet me know if you need further validation or conversions!\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\",\"No response\"]],[\"reference_answer\",[\"The strengths of hydrochlorothiazide in the candesartan cilexetil and hydrochlorothiazide tablets are 25 mg, 12.5 mg, and 12.5 mg for the different formulations.\",\"NUCYNTA\\\\u2122 contains tapentadol, a mu-opioid agonist and is classified as a Schedule II controlled substance. It has an abuse potential similar to hydromorphone and can be abused, subject to criminal diversion.\",\"Alcohol increased the AUC of tizanidine by approximately 20%, while also increasing its Cmax by approximately 15%. This was associated with an increase in side effects of tizanidine. The CNS depressant effects of tizanidine and alcohol are additive.\",\"The active ingredient in the GRX DYNE povidone iodine solution is Povidone-Iodine.\",\"The most frequent clinical adverse experiences reported in trials with lisinopril and hydrochlorothiazide tablets were dizziness (7.5%), headache (5.2%), cough (3.9%), fatigue (3.7%), and orthostatic effects (3.2%).\",\"The medication tapentadol hydrochloride is available in strengths of 100 mg and 50 mg.\",\"Hydrochlorothiazide is a diuretic and antihypertensive that affects the distal renal tubular mechanism of electrolyte reabsorption. It increases the excretion of sodium and chloride in approximately equivalent amounts.\",\"Lisinopril and hydrochlorothiazide tablets are available in three combinations: 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.\",\"Tizanidine capsules and tizanidine tablets are bioequivalent to each other under fasting conditions, but not under fed conditions. When administered with food, the mean maximal plasma concentration for the capsule is approximately 66% the concentration for the tablet.\",\"Aminotransferase levels should be monitored in patients taking tizanidine due to the risk of hepatocellular liver injury. Monitoring is recommended for baseline and 1 month after the maximum dose is achieved, or if hepatic injury is suspected.\",\"The usual treatment for hypotension caused by an overdose of Lisinopril would be intravenous infusion of normal saline solution.\",\"Candesartan inhibits the pressor effects of angiotensin II infusion in a dose-dependent manner. After 1 week of once-daily dosing with 8 mg of candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak with approximately 50% inhibition persisting for 24 hours.\",\"The efficacy of NUCYNTA\\\\u2122 was evaluated in patients undergoing unilateral, first metatarsal bunionectomy surgery.\",\"Some of the psychiatric disorders listed as adverse reactions to NUCYNTA\\\\u2122 include euphoric mood, disorientation, restlessness, agitation, nervousness, and abnormal thinking.\",\"Some warning signs or symptoms of fluid and electrolyte imbalance that patients receiving thiazide therapy should be observed for include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.\",\"The active ingredient in the foot care cream for athlete&#x27;s foot is butenafine hydrochloride 1%.\",\"The Lisinopril and Hydrochlorothiazide tablets with NDC 69097-969-07 have a strength of 20 mg/12.5 mg.\",\"The terminal half-life of tapentadol after oral administration is on average 4 hours.\",\"The concomitant use of tizanidine with fluvoxamine and ciprofloxacin is contraindicated due to changes in the pharmacokinetics of tizanidine that result in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.\",\"The marketing start date for the product with NDC:75990-4019-4 is 05/01/2011.\",\"The most likely manifestations of overdosage with candesartan cilexetil would be hypotension, dizziness, and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.\",\"The potential adverse effects on the fetus associated with the use of drugs that act on the renin-angiotensin system during pregnancy include reduced fetal renal function, increased fetal and neonatal morbidity and death, oligohydramnios, fetal lung hypoplasia, skeletal deformations, skull hypoplasia, anuria, hypotension, renal failure, and death.\",\"The lisinopril in the tablets with NDC:69097-969 has a strength of 20 mg, while the hydrochlorothiazide has a strength of 12.5 mg.\",\"The recommended dosing regimen for NUCYNTA (tapentadol) for the relief of moderate to severe acute pain is 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. The second dose may be administered as soon as one hour after the first dose on the first day of dosing if adequate pain relief is not attained with the first dose.\",\"Some of the nervous system disorders observed as adverse reactions during the premarketing evaluation of NUCYNTA\\\\u2122 include dizziness, somnolence, tremor, lethargy, insomnia, confusional state, abnormal dreams, anxiety, hypoesthesia, paresthesia, disturbance in attention, sedation, dysarthria, depressed level of consciousness, memory impairment, ataxia, presyncope, syncope, coordination abnormal, and seizure.\"]],[\"id\",[78,12,103,28,45,26,33,50,101,93,49,65,17,10,40,116,51,15,97,85,73,37,53,4,9]],[\"content\",[\"Packaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:62559-661-90\\\\n90 \\\\nin 1 BOTTLE; Type 0: Not a Combination Product\\\\n09/26/2018\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nNDA authorized generic\\\\nNDA021093\\\\n09/26/2018\\\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\\\ncandesartan cilexetil and hydrochlorothiazide tablet\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (So...\",\"as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\\\npatients with the lower range of recommended doses \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n8.6 Renal Impairment\\\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\\\u2122 has not been\\\\nestablished. NUCYNTA\\\\u2122 is not recommended in this population \\\\n[see \\\\nDosage and Adminis...\",\"this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\\\nused with caution in renally impaired patients \\\\n[see Warnings and Precautions ( \\\\n5.7\\\\n) and\\\\nUse in Specific Populations ( \\\\n8.6\\\\n)] \\\\n.\\\\nGender Effects\\\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\\\npharmacokinetic...\",\"Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\\\nkeep out of reach of children. If swallowed get medical help \\\\nor contact a Poison Control Center right away.\\\\nEnter section text here\\\\nGRX DYNE  \\\\npovidone iodine solution\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN OTC DRUG\\\\nItem Code (Source)\\\\nNDC:54162-269\\\\nRoute of Administration\\\\nTOPICAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nPOVIDONE-IODINE\\\\n (UNII: 85...\",\"Nursing Mothers\\\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\\\nrats contains radioactivity following administration of \\\\nC lisinopril. In another study,\\\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\\\nwhether to discontinue nursing and/or disco...\",\"Stat Rx USA\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\ntapentadol hydrochloride\\\\n (UNII: 71204KII53) \\\\n(tapentadol - UNII:H8A007M585)\\\\ntapentadol\\\\n100 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\ncellulose, microcrystalline\\\\n (UNII: OP1R32D61U)\\\\n \\\\nlactose monohydrate\\\\n (UNII: EWQ57Q8I5X)\\\\n \\\\ncroscarmellose sodium\\\\n (UNII: M28OL1HH48)\\\\n \\\\npovidone\\\\n (UNII: FZ989GH94E)\\\\n \\\\nmagnesium stearate\\\\n (UNII: 70097M6I30)\\\\n \\\\npolyvinyl alcohol\\\\n (UNII: 532B59J990)\\\\n \\\\ntitanium dioxide\\\\n (UNII:...\",\"state is prolonged. Older patients, on average, have (approximately doubled) higher\\\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\\\npatients (see \\\\nDOSAGE AND ADMINISTRATION\\\\n). In a multiple dose pharmacokinetic study\\\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\\\nhe...\",\"possible, be discontinued for two to three days before beginning therapy with lisinopril\\\\nto reduce the likelihood of hypotension (See \\\\nWARNINGS\\\\n). If the patient\\\\u2019s blood pressure\\\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\\\nfor at least an additional hour (See \\\\nWARNINGS\\\\n and \\\\nPRECAUTIONS\\\\n...\",\"12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\\\nreduce facilitation of spinal motor neurons.\\\\n12.3 Pharmacokinetics\\\\nAbsorption and Distribution\\\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\\\n...\",\"Tizanidine is an \\\\u03b1 \\\\n-adrenergic agonist that can produce hypotension. Syncope has been\\\\nreported in the post marketing setting. The chance of significant hypotension may\\\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\\\na supine to fixed upright position may be at increased risk for hypotension and\\\\northostatic effects.\\\\nMonitor for hypotension when tizanidine is used in patients...\",\"Lisinopril\\\\n \\\\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\\\nnormal saline solution.\\\\nLisinopril can be removed by hemodialysis (see \\\\nWARNINGS, Anaphylactoid Reaction\\\\nDuring Membrane Exposure\\\\n).\\\\nHydrochlorothiazide\\\\n \\\\nOral administration of a single oral dose of 10 g/kg to mice and rats w...\",\"Geriatric\\\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\\\u2265 65 years). \\\\nThe plasma\\\\nconcentration of candesartan was higher in the elderly (C\\\\n was approximately 50% higher, and AUC\\\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\\\nThe\\\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\\\nNo initia...\",\"14 CLINICAL STUDIES\\\\nThe efficacy and safety of NUCYNTA\\\\u2122 in the treatment of moderate to severe acute pain has been\\\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\\\u2122...\",\"Psychiatric disorders:\\\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\\\nabnormal\\\\nRenal and urinary disorders:\\\\n urinary hesitation, pollakiuria\\\\nRespiratory, thoracic and mediastinal disorders: \\\\noxygen saturation decreased, cough, dyspnea,\\\\nrespiratory depression\\\\nSkin and subcutaneous tissue disorders: \\\\nurticaria\\\\nVascular disorders:\\\\n blood pressure decreased\\\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\\\nNUCYNTA\\\\u2122,...\",\"be due to this mechanism, it can be corrected by volume expansion.\\\\nHydrochlorothiazide\\\\n \\\\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\\\nshould be performed at appropriate intervals.\\\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\\\nSerum and urine electrolyte determinations are particularly important when the patient is\\\\nvomiting exc...\",\"RITE \\\\nAID \\\\n \\\\nPHARMACY\\\\nclinically proven to cure \\\\nmost athlete&#x27;s foot between the toes\\\\nfoot care \\\\nbutenafine\\\\nhydrochloride cream 1%\\\\nantifungal\\\\nNET WT 0.42 OZ (12 g)\\\\n\\\\u00ae\",\"Protect from excessive light and humidity.\\\\n*AN69 is a registered trademark of Hospal Ltd.\\\\nManufactured by:\\\\nInvaGen Pharmaceuticals, Inc.\\\\n(a subsidiary of Cipla Ltd.)\\\\nHauppauge, NY 11788\\\\nManufactured for:\\\\nCipla USA, Inc.\\\\n10 Independence Boulevard, Suite 300\\\\nWarren, NJ 07059\\\\nRevised: 10/2021\\\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\\\u2013 10 mg/12.5 mg\\\\nNDC 69097-968-07                      Rx Only\\\\nLisinopril and\\\\nHydrochlorothiazide\\\\nTablets, USP\\\\n10 mg/12.5 mg\\\\n100 Tablets\\\\nCipla\\\\nNDC 69097-969-07             ...\",\"extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\\\naround 1.25 hours after dosing.\\\\nDose-proportional increases in the C\\\\n and AUC values of tapentadol have been observed over the 50\\\\nto 150 mg dose range.\\\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\\\nglucuronide, which are primarily determined by the do...\",\"Paresthesia\\\\nRash\\\\nTremor\\\\n7 DRUG INTERACTIONS\\\\n7.1 Fluvoxamine\\\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\\\npsychomotor impairment. \\\\n[see Contraindications ( \\\\n4\\\\n) and Clinical Pharmacology ( \\\\n12.3\\\\n)]\\\\n7.2 Ciprofloxacin\\\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\\\npharmacokinetics of ...\",\"Certus Medical, Inc.\\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nGLYCERIN\\\\n (UNII: PDC6A3C0OX)\\\\n \\\\nSODIUM PHOSPHATE, DIBASIC\\\\n (UNII: GR686LBA74)\\\\n \\\\nNONOXYNOL-10\\\\n (UNII: K7O76887AP)\\\\n \\\\nDIMETHICONE\\\\n (UNII: 92RU3N3Y1O)\\\\n \\\\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\\\n (UNII: S38J6RZN16)\\\\n \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start Date\\\\nMarketing End Date\\\\n1\\\\nNDC:75990-4019-4\\\\n2 mL in 1 POUCH\\\\nMarketing Information\\\\nMarketing Category\\\\nApplication Number or Monograph Citation\\\\nMarketing Start Date\\\\nMarketing End Date\\\\nOT...\",\"melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\\\nfor white patients taking a cumulative dose of \\\\u226550,000 mg the risk increase was approximately 1\\\\nadditional SCC case for every 6,700 patients per year.\\\\nSkin:\\\\n \\\\nerythema multiforme including S...\",\"myocardial infarction or cerebrovascular accident.\\\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\\\nresponse is not a contraindication to further doses which usually can be given without\\\\ndifficulty once the blood pressure has increased after volume expansion.\\\\nLeukopenia/Neutropenia/Agranulocytosis:\\\\n Another angiotensin-converting enzyme\\\\ninhibitor, captopril, has been shown to ca...\",\"Product Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:69097-968\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nLISINOPRIL\\\\n (UNII: E7199S1YWR) \\\\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\\\nLISINOPRIL\\\\n10 mg\\\\nHYDROCHLOROTHIAZIDE\\\\n (UNII: 0J48LPH2TH) \\\\n(HYDROCHLOROTHIAZIDE -\\\\nUNII:0J48LPH2TH)\\\\nHYDROCHLOROTHIAZIDE\\\\n12.5 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\\\n (UNII: L11K75P92J)\\\\n \\\\nMAN...\",\"8.7 Hepatic Impairment\\\\n9 DRUG ABUSE AND DEPENDENCE\\\\n9.1 Controlled Substance\\\\n9.2 Abuse\\\\n9.3 Dependence\\\\n10 OVERDOSAGE\\\\n10.1 Human Experience\\\\n10.2 Management of Overdose\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n13 NON-CLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\n14 CLINICAL STUDIES\\\\n14.1 Orthopedic Surgery \\\\u2013 Bunionectomy\\\\n14.2 End-Stage Degenerative Joint Disea...\",\"*\\\\nInfections and infestations\\\\n  Nasopharyngitis\\\\n1\\\\n&lt;1\\\\n  Upper respiratory tract infection\\\\n1\\\\n&lt;1\\\\n  Urinary tract infection\\\\n1\\\\n&lt;1\\\\nMetabolism and nutrition disorders\\\\n  Decreased appetite\\\\n2\\\\n0\\\\nMusculoskeletal and connective tissue\\\\ndisorders\\\\n  Arthralgia\\\\n1\\\\n&lt;1\\\\nNervous system disorders\\\\n  Dizziness\\\\n24\\\\n8\\\\n  Somnolence\\\\n15\\\\n3\\\\n  Tremor\\\\n1\\\\n&lt;1\\\\n  Lethargy\\\\n1\\\\n&lt;1\\\\nPsychiatric disorders\\\\n  Insomnia\\\\n2\\\\n&lt;1\\\\n  Confusional state\\\\n1\\\\n0\\\\n  Abnormal dreams\\\\n1\\\\n&lt;1\\\\n  Anxiety\\\\n1\\\\n&lt;1\\\\nSkin and subcutaneous tissue disorders\\\\n  Pruritus\\\\n5\\\\n1\\\\n  Hyp...\"]],[\"color\",[\"#ba0e0e\",\"#ba0e0e\",\"#0a980a\",\"#0a980a\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\",\"#ba0e0e\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1099\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1100\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1095\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1096\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1097\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p1113\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1104\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1105\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1106\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[117],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p1114\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p1115\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1110\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1111\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p1112\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p1067\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p1082\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p1083\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p1084\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p1085\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p1090\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p1091\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p1058\",\"attributes\":{\"renderers\":[{\"id\":\"p1098\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1077\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1078\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1079\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1080\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p1072\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p1073\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p1074\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p1075\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1076\",\"attributes\":{\"axis\":{\"id\":\"p1072\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p1081\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p1077\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p1101\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1102\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"False\"},\"renderers\":[{\"id\":\"p1098\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p1103\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p1098\"}],\"index\":2}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p1119\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p1116\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p1117\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p1118\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"nbREQZyzDkFmYiFBBLU5QfTXVEE=\"},\"shape\":[5],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"wp2uP50ayz9Wx41A6bjxQBGD0kA=\"},\"shape\":[5],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Tizanidine Hydrochloride\",\"NUCYNTA Safety\",\"Pharmaceutical Products\",\"ACE Inhibitors and mTOR Inhibitors\",\"Candesartan Cilexetil and Hydrochlorothiazide\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"93a4ab16-8796-4dd8-b36b-cb9de240f92f\",\"roots\":{\"p1124\":\"bec693a0-e70a-433e-a555-cef60209a71a\"},\"root_ids\":[\"p1124\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"bec693a0-e70a-433e-a555-cef60209a71a\" data-root-id=\"p1124\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x71b965ea3f20>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_chain_decomposition, testset=testset, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "d52164a6",
   "metadata": {},
   "source": [
    "#### Step Back"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 107,
   "id": "8d29bfdc",
   "metadata": {},
   "outputs": [],
   "source": [
    "examples = [\n",
    "    {\n",
    "        \"input\": \"Can I take ibuprofen if I’m pregnant?\",\n",
    "        \"output\": \"What are the risks of taking ibuprofen during pregnancy?\",\n",
    "    },\n",
    "    {\n",
    "        \"input\": \"Will Paracetamol interact with my blood pressure medication?\",\n",
    "        \"output\": \"What drug interactions involve Paracetamol?\",\n",
    "    }]\n",
    "\n",
    "example_prompt = ChatPromptTemplate.from_messages([\n",
    "    (\"human\", \"{input}\"),\n",
    "    (\"ai\", \"{output}\"),\n",
    "])\n",
    "few_shot_prompt = FewShotChatMessagePromptTemplate(\n",
    "    example_prompt=example_prompt,\n",
    "    examples=examples,\n",
    ")\n",
    "\n",
    "step_back_template = ChatPromptTemplate.from_messages([\n",
    "    (\"system\", \"You are an expert in medicine drugs. Your task is to step back and paraphrase a question to a more generic step-back question, which is easier to answer. Here are a few examples:\"),\n",
    "    few_shot_prompt,\n",
    "    (\"user\", \"{question}\"),\n",
    "])\n",
    "generate_queries_step_back = step_back_template | call_asi_one | StrOutputParser()\n",
    "\n",
    "response_prompt_template = \"\"\"You are an expert in medicine drugs. I am going to ask you a question. Your response should be comprehensive and not contradicted with the following context if they are relevant. Otherwise, ignore them if they are not relevant.\n",
    "\n",
    "# {normal_context}\n",
    "# {step_back_context}\n",
    "\n",
    "# Original Question: {question}\n",
    "# Answer:\"\"\"\n",
    "response_prompt = ChatPromptTemplate.from_template(response_prompt_template)\n",
    "\n",
    "def answer_fn_chain_step_back(question):\n",
    "    chain_step_back = (\n",
    "        {\n",
    "            \"normal_context\": RunnableLambda(lambda x: x[\"question\"]) | retriever,\n",
    "            \"step_back_context\": generate_queries_step_back | retriever,\n",
    "            \"question\": lambda x: x[\"question\"],\n",
    "        }\n",
    "        | response_prompt\n",
    "        | call_asi_one\n",
    "        | StrOutputParser()\n",
    "    )\n",
    "    return chain_step_back.invoke({\"question\": question})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 108,
   "id": "c2c921ea",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "227dd6c3162b450d93924a813f650fc4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "661f37564f62414d841fd82ab48b81d8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"c68341e7-7387-4a09-b2e6-5bf4039f1c13\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"c68341e7-7387-4a09-b2e6-5bf4039f1c13\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"c68341e7-7387-4a09-b2e6-5bf4039f1c13\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">100%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Your RAG system is performing perfectly, scoring 1.0 in all evaluated areas; no immediate action is needed. Continually monitor the system for consistent performance and consider expanding the knowledge base for future scalability.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"1c280af6-fdf3-4a02-bcfe-9ca525cfd81e\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p3409\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p3411\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p3418\",\"attributes\":{\"factors\":[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3419\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p3420\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p3416\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3438\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3406\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3407\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3408\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"AAAAAAAAWUAAAAAAAABZQA==\"},\"shape\":[2],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"colors\",[\"#a50026\",\"#a50026\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3439\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3440\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3435\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3436\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3437\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3447\",\"attributes\":{\"data_source\":{\"id\":\"p3406\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3448\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3449\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3444\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3445\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3446\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3457\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3451\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3452\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3453\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3458\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3459\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p3454\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p3455\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p3456\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p3417\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p3431\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p3426\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p3427\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p3428\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3429\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3421\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3422\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3423\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3424\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3425\",\"attributes\":{\"axis\":{\"id\":\"p3421\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3430\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p3426\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p3450\",\"attributes\":{\"location\":100.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p3460\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3461\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p3457\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"1c280af6-fdf3-4a02-bcfe-9ca525cfd81e\",\"roots\":{\"p3409\":\"dc2a4ea6-84af-4162-8343-51820291bf80\"},\"root_ids\":[\"p3409\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"dc2a4ea6-84af-4162-8343-51820291bf80\" data-root-id=\"p3409\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"2af4d445-d9ff-440d-a58a-f6c16e4734b3\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p3340\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p3271\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p3220\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p3229\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p3230\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3231\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3232\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p3227\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3260\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3217\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3218\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3219\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154]],[\"content\",[\"ATRIPLA ACCESS- efavirenz, emtricitabine, and tenofovir disoproxil\\\\nfumarate tablet, film coated \\\\n \\\\nGilead Sciences, Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ATRIPLA safely and\\\\neffectively. See full prescribing information for ATRIPLA.\\\\nATRIPLA\\\\u2122 (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets, for oral use\\\\nGILEAD ACCESS PROGRAM\\\\nInitial U.S. Approval: 2006\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION O...\",\"WARNINGS AND PRECAUTIONS\\\\nRash: Discontinue if severe rash develops. (\\\\n5.2\\\\n, \\\\n6.1\\\\n)\\\\nHepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying\\\\nhepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are\\\\ntaking medications associated with liver toxicity. Among reported cases of hepatic failure, a few\\\\noccurred in patients with no pre-existing hepatic disease. (\\\\n5.3\\\\n, \\\\n6.2\\\\n, \\\\n8.7\\\\n)\\\\nRisk of adverse reactions or loss of ...\",\"2.1 Testing Prior to Initiation and During Treatment with ATRIPLA\\\\n2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg\\\\n2.3 Not Recommended in Patients with Moderate or Severe Renal Impairment\\\\n2.4 Not Recommended in Patients with Moderate to Severe Hepatic Impairment\\\\n2.5 Dosage Adjustment with Rifampin\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and\\\\nHBV\\\\n5.2 Ra...\",\"16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B\\\\nSevere acute exacerbations of hepatitis B virus (HBV) have been\\\\nreported in patients who are coinfected with HIV-1 and HBV and have\\\\ndiscontinued products containing emtricitabine (FTC) and/or tenofovir\\\\ndisoproxil fumarate (TDF), which are components of ATRIPLA.\\\\nClosely monitor hepatic function with both clinical and laboratory follow-\\\\nup f...\",\"ATRIPLA is a three-drug fixed-dose combination product containing 600 mg of efavirenz\\\\n(EFV), 200 mg of emtricitabine (FTC), and 300 mg of tenofovir disoproxil fumarate (TDF).\\\\nThe recommended dosage of ATRIPLA in \\\\nadults and pediatric patients weighing at least\\\\n40 kg\\\\n is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may\\\\nimprove the tolerability of nervous system symptoms \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n2.3 Not Recommended in Patients with Moderate or Severe Ren...\",\"closely monitored, with both clinical and laboratory follow-up for at least several months\\\\nafter stopping treatment with ATRIPLA. If appropriate, initiation of anti-hepatitis B\\\\ntherapy may be warranted, especially in patients with advanced liver disease or cirrhosis,\\\\nsince posttreatment exacerbation of hepatitis may lead to hepatic decompensation and\\\\nliver failure.\\\\n5.2 Rash\\\\nIn controlled clinical trials, 26% (266/1,008) of adult subjects treated with 600 mg EFV\\\\nexperienced new-onset skin rash co...\",\"[see \\\\nDosage and Administration (2.1)\\\\n].\\\\n Consider discontinuing ATRIPLA in patients with\\\\npersistent elevations of serum transaminases to greater than five times the upper limit\\\\nof the normal range.\\\\nDiscontinue ATRIPLA if elevation of serum transaminases is accompanied by clinical\\\\nsigns or symptoms of hepatitis or hepatic decompensation \\\\n[see \\\\nAdverse Reactions\\\\n(6.1)\\\\n].\\\\n5.4 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug\\\\nInteractions\\\\nThe concomitant use of ATRIPLA and other d...\",\"discontinued or interrupted treatment because of one or more of these selected\\\\npsychiatric symptoms. There have also been occasional postmarketing reports of death\\\\nby suicide, delusions, and psychosis-like behavior, although a causal relationship to the\\\\nuse of EFV cannot be determined from these reports. Postmarketing cases of catatonia\\\\nhave also been reported and may be associated with increased EFV exposure. Patients\\\\nwith serious psychiatric adverse experiences should seek immediate medical ev...\",\"Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal\\\\ntubular injury with severe hypophosphatemia), has been reported with the use of TDF, a\\\\ncomponent of ATRIPLA \\\\n[see \\\\nAdverse Reactions (6.2)\\\\n].\\\\nPrior to initiation and during use of ATRIPLA, on a clinically appropriate schedule, assess\\\\nserum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all\\\\npatients. In patients with chronic kidney disease, also assess serum phosphorus.\\\\nATRIPLA is...\",\"considered for adult and pediatric patients who have a history of pathologic bone\\\\nfracture or other risk factors for osteoporosis or bone loss. Although the effect of\\\\nsupplementation with calcium and vitamin D was not studied, such supplementation may\\\\nbe beneficial for all patients. If bone abnormalities are suspected, then appropriate\\\\nconsultation should be obtained.\\\\nMineralization Defects\\\\nCases of osteomalacia associated with proximal renal tubulopathy, manifested as bone\\\\npain or pain in extre...\",\"enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and\\\\n\\\\\"cushingoid appearance,\\\\\" has been observed in patients receiving antiretroviral therapy,\\\\nincluding EFV. The mechanism and long-term consequences of these events are\\\\ncurrently unknown. A causal relationship has not been established.\\\\n6 ADVERSE REACTIONS\\\\nThe following adverse reactions are discussed in other sections of the labeling:\\\\nSevere Acute Exacerbations of Hepatitis B in Patients Coinfected with HIV-1 and...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nDizziness\\\\n8%\\\\n7%\\\\nUpper respiratory tract infections\\\\n8%\\\\n5%\\\\nSinusitis\\\\n8%\\\\n4%\\\\nRash Event\\\\n7%\\\\n9%\\\\nHeadache\\\\n6%\\\\n5%\\\\nInsomnia\\\\n5%\\\\n7%\\\\nAnxiety\\\\n5%\\\\n4%\\\\nNasopharyngitis\\\\n5%\\\\n3%\\\\nVomiting\\\\n2%\\\\n5%\\\\nIn Study 073, subjects with stable, virologic suppression on antiretroviral therapy and no\\\\nhistory of virologic failure were randomized to receive ATRIPLA or to stay on their\\\\nbaseline regimen. The adverse reactions observed in Study 073 were generally\\\\nconsistent with those seen in Study 934 and those seen with the individ...\",\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"subjects treated with EFV and fixed-dose zidovudine/lamivudine were hepatitis B surface\\\\nantigen or hepatitis C antibody positive. Among these coinfected subjects, one subject\\\\n(1/19) in the EFV, FTC, and TDF arm had elevations in transaminases to greater than five\\\\ntimes ULN through 144 weeks. In the fixed-dose zidovudine/lamivudine arm, two\\\\nsubjects (2/20) had elevations in transaminases to greater than five times ULN through\\\\n144 weeks. No HBV and/or HCV coinfected subject discontinued from the t...\",\"Dyspnea\\\\nSkin and Subcutaneous Tissue Disorders\\\\n \\\\nFlushing, erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome\\\\nEmtricitabine\\\\n:\\\\n No postmarketing adverse reactions have been identified for inclusion in\\\\nthis section.\\\\nTenofovir DF:\\\\nImmune System Disorders\\\\n \\\\nAllergic reaction, including angioedema\\\\nMetabolism and Nutrition Disorders\\\\n \\\\nLactic acidosis, hypokalemia, hypophosphatemia\\\\nRespiratory, Thoracic, and Mediastinal Disorders\\\\n \\\\nDyspnea\\\\nGastrointestinal Disorders\\\\n \\\\nPancreatitis,...\",\"There is limited information available on the potential for a pharmacodynamic interaction\\\\nbetween EFV and drugs that prolong the QTc interval. QTc prolongation has been\\\\nobserved with the use of EFV \\\\n[see \\\\nClinical Pharmacology (12.2)\\\\n].\\\\n Consider alternatives to\\\\nATRIPLA when coadministered with a drug with a known risk of Torsade de Pointes.\\\\n7.2 Drugs Affecting Renal Function\\\\nFTC and tenofovir are primarily eliminated by the kidneys\\\\n[see \\\\nClinical Pharmacology\\\\n(12.3)\\\\n].\\\\n Coadministration of ATRI...\",\"the increased indinavir metabolism due to\\\\nEFV.\\\\nProtease inhibitor:\\\\n  darunavir/ritonavir\\\\n\\\\u2191 tenofovir\\\\nMonitor patients receiving ATRIPLA\\\\nconcomitantly with ritonavir-boosted\\\\ndarunavir for TDF-associated adverse\\\\nreactions. Discontinue ATRIPLA in\\\\npatients who develop TDF-associated\\\\nadverse reactions.\\\\n  lopinavir/ritonavir\\\\n\\\\u2193 lopinavir\\\\n\\\\u2191 tenofovir\\\\nDo not use once daily administration of\\\\nlopinavir/ritonavir. Dose increase of\\\\nlopinavir/ritonavir is recommended for all\\\\npatients when coadministered with ...\",\"NRTI:\\\\n  didanosine\\\\n\\\\u2191 didanosine\\\\nreceiving TDF with didanosine 400 mg\\\\ndaily. \\\\nIn patients weighing greater than 60 kg,\\\\nreduce the didanosine dose to 250 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nIn patients weighing less than 60 kg,\\\\nreduce the didanosine dose to 200 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nWhen coadministered, ATRIPLA and\\\\nVidex EC may be taken under fasted\\\\nconditions or with a light meal (less than\\\\n400 kcal, 20% fat).\\\\nNNRTI:\\\\n  Other NNRTIs\\\\n\\\\u2191 or \\\\u2193 efavirenz\\\\nand/or NNRTI\\\\nCombini...\",\"Anticoagulant:\\\\n  warfarin\\\\n\\\\u2191 or \\\\u2193 warfarin\\\\nPlasma concentrations and effects\\\\npotentially increased or decreased by\\\\nEFV.\\\\nAnticonvulsants:\\\\n  carbamazepine\\\\n\\\\u2193 carbamazepine\\\\n\\\\u2193 efavirenz\\\\nThere are insufficient data to make a\\\\ndose recommendation for ATRIPLA.\\\\nAlternative anticonvulsant treatment\\\\nshould be used.\\\\n  phenytoin\\\\n  phenobarbital\\\\n\\\\u2193 anticonvulsant\\\\n\\\\u2193 efavirenz\\\\nPotential for reduction in anticonvulsant\\\\nand/or EFV plasma levels; periodic\\\\nmonitoring of anticonvulsant plasma\\\\nlevels should be conducted...\",\"artemether/lumefantrine\\\\n  atovaquone/proquanil\\\\n\\\\u2193 dihydroartemisinin\\\\n\\\\u2193 lumefantrine\\\\n\\\\u2193 atovaquone\\\\n\\\\u2193 proguanil\\\\nrisk of QT interval prolongation \\\\n[see\\\\nWarnings and Precautions (5.4)\\\\n]\\\\n.\\\\nConcomitant administration of\\\\natovaquone/proguanil with ATRIPLA is\\\\nnot recommended.\\\\nCalcium channel\\\\nblockers:\\\\n  diltiazem\\\\n\\\\u2193 diltiazem\\\\n\\\\u2193 desacetyl\\\\ndiltiazem\\\\n\\\\u2193 N-monodes-\\\\nmethyl diltiazem\\\\nDiltiazem dose adjustments should be\\\\nguided by clinical response (refer to the\\\\nfull prescribing information for diltiazem).\\\\nNo dose ...\",\"*\\\\ntacrolimus, sirolimus, and\\\\nothers metabolized by\\\\nCYP3A\\\\nsuppressant\\\\nmay be required. Close monitoring of\\\\nimmunosuppressant concentrations for\\\\nat least 2 weeks (until stable\\\\nconcentrations are reached) is\\\\nrecommended when starting or stopping\\\\ntreatment with ATRIPLA.\\\\nNarcotic analgesic:\\\\n  methadone\\\\n\\\\u2193 methadone\\\\nCoadministration of EFV in HIV-1 infected\\\\nindividuals with a history of injection drug\\\\nuse resulted in signs of opiate\\\\nwithdrawal. Methadone dose was\\\\nincreased by a mean of 22% to alleviate...\",\"for EFV, FTC, or TDF compared with the background rate for major birth defects of\\\\n2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects\\\\nProgram (MACDP) \\\\n(see \\\\nData\\\\n)\\\\n.\\\\nThe rate of miscarriage is not reported in the APR. The estimated background rate of\\\\nmiscarriage in clinically recognized pregnancies in the U.S. general population is 15-20%.\\\\nThe background risk of major birth defects and miscarriage for the indicated population\\\\nis unknown. The APR uses the MACDP as t...\",\"Animal Data\\\\nEfavirenz:\\\\n Effects of EFV on embryo-fetal development have been studied in three\\\\nnonclinical species (cynomolgus monkeys, rats, and rabbits). In monkeys, EFV 60\\\\nmg/kg/day was administered to pregnant females throughout pregnancy (gestation\\\\nDays 20 through 150). The maternal systemic drug exposures (AUC) were 1.3 times the\\\\nexposures at the RHD, with fetal umbilical venous drug concentrations approximately\\\\n0.7 times the maternal values. Three fetuses of 20 fetuses/infants had one or m...\",\"Based on limited published data, EFV, FTC, and tenofovir have been shown to be present\\\\nin human breast milk.\\\\nIt is not known if the components of ATRIPLA affect milk production or have effects on\\\\nthe breastfed child. Because of the potential for: (1) HIV transmission (in HIV-negative\\\\ninfants); (2) developing viral resistance (in HIV-positive infants); and (3) adverse\\\\nreactions in a breastfed infant similar to those seen in adults, instruct mothers not to\\\\nbreastfeed if they are receiving ATRIPLA....\",\"8.7 Hepatic Impairment\\\\nATRIPLA is not recommended for patients with moderate or severe hepatic impairment\\\\nbecause there are insufficient data to determine an appropriate dose. Patients with mild\\\\nhepatic impairment may be treated with ATRIPLA at the approved dose. Because of the\\\\nextensive cytochrome P450-mediated metabolism of EFV and limited clinical experience\\\\nin patients with hepatic impairment, caution should be exercised in administering\\\\nATRIPLA to these patients \\\\n[see \\\\nDosage and Administra...\",\"Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It\\\\nis practically insoluble in water (less than 10 \\\\u00b5g/mL).\\\\nEmtricitabine:\\\\n The chemical name of FTC is 5-fluoro-1-(2\\\\nR\\\\n,5\\\\nS\\\\n)-[2-(hydroxymethyl)-1,3-\\\\noxathiolan-5-yl]cytosine. FTC is the (-) enantiomer of a thio analog of cytidine, which\\\\ndiffers from other cytidine analogs in that it has a fluorine in the 5-position.\\\\nIt has a molecular formula of C\\\\nH\\\\nFN\\\\nO\\\\nS and a molecular weight of 247.24. It has the\\\\nfollo...\",\"12.1 Mechanism of Action\\\\nATRIPLA is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF \\\\n[see\\\\nMicrobiology (12.4)\\\\n].\\\\n12.2 Pharmacodynamics\\\\nCardiac Electrophysiology\\\\nEfavirenz:\\\\n \\\\nThe effect of EFV on the QTc interval was evaluated in an open-label, positive\\\\nand placebo-controlled, fixed single sequence 3-period, 3-treatment crossover QT study\\\\nin 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean C\\\\n of EFV in\\\\nsubjects with CYP2B6 *6/*6 genotype following the administration o...\",\"Tenofovir DF:\\\\n \\\\nFollowing oral administration of a single 300 mg dose of TDF to HIV-1\\\\ninfected subjects in the fasted state, maximum serum concentrations (C\\\\n) were\\\\nachieved in 1.0 \\\\u00b1 0.4 hrs (mean \\\\u00b1 SD) and C\\\\n and AUC values were 296 \\\\u00b1 90 ng/mL\\\\nand 2287 \\\\u00b1 685 ng\\\\u2219hr/mL, respectively. The oral bioavailability of tenofovir from TDF in\\\\nfasted subjects is approximately 25%. Less than 0.7% of tenofovir binds to human\\\\nplasma proteins in vitro, and the binding is independent of concentration over the ran...\",\"daily dose of 200 mg.\\\\nTenofovir DF:\\\\n Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1\\\\ninfected pediatric subjects (12 to less than 18 years). Mean \\\\u00b1 SD C\\\\n and AUC\\\\n are\\\\n0.38 \\\\u00b1 0.13 \\\\u03bcg/mL and 3.39 \\\\u00b1 1.22 \\\\u03bcg\\\\u2219hr/mL, respectively. Tenofovir exposure\\\\nachieved in these pediatric subjects receiving oral daily doses of TDF 300 mg was similar\\\\nto exposures achieved in adults receiving once-daily doses of TDF 300 mg.\\\\nGeriatric Patients\\\\nPharmacokinetics of EFV, FTC, and tenofovir have not...\",\"concentrations well above those achieved clinically. Coadministration of EFV with drugs\\\\nprimarily metabolized by CYP2C9, CYP2C19, CYP3A or CYP2B6 isozymes may result in\\\\naltered plasma concentrations of the coadministered drug. Drugs which induce CYP3A\\\\nand CYP2B6 activity would be expected to increase the clearance of EFV resulting in\\\\nlowered plasma concentrations.\\\\nDrug interaction trials were performed with EFV and other drugs likely to be\\\\ncoadministered or drugs commonly used as probes for phar...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\nCarbamazepine\\\\n200 mg qd \\\\u00d7 3\\\\ndays, 200 mg bid\\\\n\\\\u00d7 3 days, then\\\\n400 mg qd \\\\u00d7 15\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 35\\\\ndays\\\\n14\\\\n\\\\u2193 21\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 26)\\\\n\\\\u2193 36\\\\n(\\\\u2193 32 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 47\\\\n(\\\\u2193 41 to\\\\n\\\\u2193 53)\\\\nDiltiazem\\\\n240 mg \\\\u00d7 14\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 28\\\\ndays\\\\n12\\\\n\\\\u2191 16\\\\n(\\\\u2191 6 to \\\\u2191\\\\n26)\\\\n\\\\u2191 11\\\\n(\\\\u2191 5 to \\\\u2191\\\\n18)\\\\n\\\\u2191 13\\\\n(\\\\u2191 1 to \\\\u2191\\\\n26)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg\\\\nqd \\\\u00d7 9\\\\ndays\\\\nNA\\\\n\\\\u2191 38\\\\n\\\\u2191 44\\\\nNA\\\\n300 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 mg\\\\nqd \\\\u00d7 7\\\\ndays\\\\nNA\\\\n\\\\u2193 14\\\\n \\\\n(\\\\u2193 7 to \\\\u2193\\\\n21)\\\\n\\\\u2194\\\\nNA\\\\n400 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 m...\",\"meal\\\\n7\\\\u201320\\\\n300 mg\\\\nqd/ritonavir 100\\\\nmg qd d 1\\\\u201310\\\\n(pm), then 400\\\\nmg qd/ritonavir\\\\n100 mg qd d 11\\\\u2013\\\\n24 (pm)\\\\n(simultaneous\\\\nwith EFV)\\\\n600 mg qd\\\\nwith a light\\\\nsnack d\\\\n11\\\\u201324 (pm)\\\\n14\\\\n\\\\u2191 17\\\\n(\\\\u2191 8 to \\\\u2191\\\\n27)\\\\n\\\\u2194\\\\n\\\\u2193 42\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 51)\\\\nIndinavir\\\\n1000 mg q8h \\\\u00d7\\\\n10 days\\\\n600 mg qd\\\\n\\\\u00d7 10 days\\\\n20\\\\nAfter morning dose\\\\n\\\\u2194\\\\n\\\\u2193 33\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 39)\\\\n\\\\u2193 39\\\\n \\\\n(\\\\u2193 24 to\\\\n\\\\u2193 51)\\\\nAfter afternoon dose\\\\n\\\\u2194\\\\n\\\\u2193 37\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 46)\\\\n\\\\u2193 52\\\\n \\\\n(\\\\u2193 47 to\\\\n\\\\u2193 57)\\\\nAfter evening dose\\\\n\\\\u2193 29\\\\n \\\\n(\\\\u2193 11 to\\\\n\\\\u2193 43)\\\\n\\\\u2193 46\\\\n \\\\n(\\\\u2193 37 to\\\\n\\\\u2193 54)\\\\n\\\\u2193 57\\\\n \\\\n(\\\\u2193 50 to\\\\n\\\\u2193 63)\\\\nLopinavir/ritona...\",\"days\\\\n\\\\u00d7 16 days\\\\nto \\\\u2191 8)\\\\n25)\\\\n58)\\\\nSimeprevir\\\\n150 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n23\\\\n\\\\u2193 51\\\\n(\\\\u2193 46 to\\\\n\\\\u2193 56)\\\\n\\\\u2193 71\\\\n(\\\\u2193 67 to\\\\n\\\\u2193 74)\\\\n\\\\u2193 91\\\\n(\\\\u2193 88 to\\\\n\\\\u2193 92)\\\\nLedipasvir/sofosbuvir\\\\n90/400 mg qd \\\\u00d7\\\\n14 days\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\nLedipasvir\\\\n15\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 43)\\\\nSofosbuvir\\\\n\\\\u2194\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2194\\\\n\\\\u2194\\\\n\\\\u2194\\\\nSofosbuvir\\\\n400 mg qd single\\\\ndose\\\\n600 mg qd\\\\n\\\\u00d714 days\\\\n16\\\\n\\\\u2193 19\\\\n(\\\\u2193 40 to\\\\n\\\\u2191 10)\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2193 23\\\\n(\\\\u2193 16 to\\\\n\\\\u2193 30)\\\\n\\\\u2193 16\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 8)\\\\nNA\\\\nSofosbuvir/velpatasvir\\\\n400/100 mg qd \\\\u00d7\\\\n14 days\\\\n600...\",\"120 mg tablets (6\\\\n4-tablet doses\\\\nover 3 days)\\\\nArtemether\\\\n\\\\u2193 21\\\\u2193 38\\\\n\\\\u2193 51\\\\nNA\\\\ndihydroartemisinin\\\\n\\\\u2194\\\\n\\\\u2193 46\\\\nNA\\\\nlumefantrine\\\\n\\\\u219321\\\\nNA\\\\nAtorvastatin\\\\n10 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 14\\\\n(\\\\u2193 1 to \\\\u2193\\\\n26)\\\\n\\\\u2193 43\\\\n(\\\\u2193 34 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 69\\\\n(\\\\u2193 49 to\\\\n\\\\u2193 81)\\\\nTotal active (including\\\\nmetabolites)\\\\n\\\\u2193 15\\\\n(\\\\u2193 2 to \\\\u2193\\\\n26)\\\\n\\\\u2193 32\\\\n(\\\\u2193 21 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 48\\\\n(\\\\u2193 23 to\\\\n\\\\u2193 64)\\\\nPravastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n13\\\\n\\\\u2193 32\\\\n(\\\\u2193 59 to\\\\n\\\\u2191 12)\\\\n\\\\u2193 44\\\\n(\\\\u2193 26 to\\\\n\\\\u2193 57)\\\\n\\\\u2193 19\\\\n(\\\\u2193 0 to \\\\u2193\\\\n35)\\\\nSimvastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 7...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\n\\\\u00f0\\\\n\\\\u00f8\\\\n\\\\u00fd\\\\n\\\\u00a3\\\\nMethadone\\\\nmaintenance 35\\\\u2013\\\\n100 mg daily\\\\n\\\\u00d7 14\\\\u201321\\\\ndays\\\\n11\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 59)\\\\n(\\\\u2193 33 to\\\\n\\\\u2193 66)\\\\nNA\\\\nBupropion\\\\n150 mg single\\\\ndose (sustained-\\\\nrelease)\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 34\\\\n(\\\\u219321 to\\\\n\\\\u219347)\\\\n\\\\u2193 55\\\\n(\\\\u219348 to\\\\n\\\\u219362)\\\\nNA\\\\nHydroxybupropion\\\\n\\\\u2191 50\\\\n(\\\\u2191 20 to\\\\n\\\\u2191 80)\\\\n\\\\u2194\\\\nNA\\\\nSertraline\\\\n50 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 29\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 39\\\\n(\\\\u2193 27 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 46\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 58)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg qd\\\\n\\\\u00d7 9 days\\\\nNA\\\\n\\\\u2193 61\\\\n\\\\u2193 77\\\\nN...\",\"no clinically significant drug interactions have been observed between TDF and abacavir,\\\\nEFV, FTC, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral\\\\ncontraceptives, ribavirin, saquinavir/ritonavir, sofosbuvir, or tacrolimus in trials\\\\nconducted in healthy volunteers.\\\\nFollowing multiple dosing to HIV-negative subjects receiving either chronic methadone\\\\nmaintenance therapy, oral contraceptives, or single doses of ribavirin, steady-state\\\\ntenofovir pharmacokinetics we...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\nTable 7 Drug Interactions: Changes in Pharmacokinetic Parameters for\\\\nCoadministered Drug in the Presence of TDF\\\\nCoadministered\\\\nDrug\\\\nDose of\\\\nCoadministered\\\\nDrug (mg)\\\\nN\\\\nMean % Change of Coadministered\\\\nDrug Pharmacokinetic Parameters\\\\n \\\\n(90% CI)\\\\nC\\\\nAUC\\\\nC\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\nAtazanavir\\\\n400 once daily \\\\u00d7\\\\n14 days\\\\n34\\\\n\\\\u2193 21\\\\n(\\\\u2193 27 to \\\\u2193 14)\\\\n\\\\u2193 25\\\\n(\\\\u2193 30 to \\\\u2193 19)\\\\n\\\\u2193 40\\\\n(\\\\u2193 48 to \\\\u2193 32)\\\\nAtazanavir/ritonavir\\\\n300/100 once daily\\\\n\\\\u00d7 42 days\\\\n10\\\\n\\\\u2193 28\\\\n(\\\\u2193 50 to \\\\u2191 5)\\\\n\\\\u2193 25\\\\n \\\\n(\\\\u2193 42 to \\\\u2193 3)\\\\n\\\\u2193 23\\\\n \\\\n(\\\\u2193 46 to \\\\u2191 10)\\\\nDa...\",\"Efavirenz:\\\\n \\\\nEFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1.\\\\nEfavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1\\\\nreverse transcriptase. HIV-2 RT and human cellular DNA polymerases \\\\u03b1, \\\\u03b2, \\\\u03b3, and \\\\u03b4 are\\\\nnot inhibited by EFV.\\\\nEmtricitabine:\\\\n \\\\nEmtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated\\\\nby cellular enzymes to form FTC 5&#x27;-triphosphate. Emtricitabine 5&#x27;-triphosphate inhibits\\\\nthe activity of the HIV-1 RT by competing wi...\",\"tenofovir were in the range of 0.04\\\\u20138.5 \\\\u00b5M. In drug combination studies of tenofovir\\\\nwith NRTIs (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine),\\\\nNNRTIs (delavirdine, EFV, and nevirapine), and PIs (amprenavir, indinavir, nelfinavir,\\\\nritonavir, and saquinavir), additive to synergistic effects were observed. Tenofovir\\\\ndisplayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O\\\\n(EC\\\\n values ranged from 0.5\\\\u20132.2 \\\\u00b5M) and showed strain-specific ...\",\"susceptibility to FTC was associated with a substitution in the HIV-1 RT gene at codon\\\\n184 which resulted in an amino acid substitution of methionine by valine or isoleucine\\\\n(M184V/I).\\\\nTenofovir DF:\\\\n \\\\nHIV-1 isolates with reduced susceptibility to tenofovir have been selected\\\\nin cell culture. These viruses expressed a K65R substitution in RT and showed a 2- to 4-\\\\nfold reduction in susceptibility to tenofovir.\\\\nCross Resistance\\\\nEfavirenz, Emtricitabine, and Tenofovir DF:\\\\n Cross resistance has been ...\",\"Efavirenz:\\\\n \\\\nLong-term carcinogenicity studies in mice and rats were carried out with EFV.\\\\nMice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of\\\\nhepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas\\\\nwere increased above background in females. No increases in tumor incidence above\\\\nbackground were seen in males. In studies in which rats were administered EFV at\\\\ndoses of 0, 25, 50, or 100 mg/kg/day for 2 years, no increases in tumor incidence\\\\n...\",\"an alteration of the estrous cycle in female rats.\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\nEfavirenz:\\\\n \\\\nNonsustained convulsions were observed in 6 of 20 monkeys receiving EFV at\\\\ndoses yielding plasma AUC values 4- to 13-fold greater than those in humans given the\\\\nrecommended dose.\\\\nTenofovir DF:\\\\n \\\\nTenofovir and TDF administered in toxicology studies to rats, dogs, and\\\\nmonkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed\\\\nin humans caused bone toxicity. In monkeys...\",\"Outcomes\\\\nAt Week 48\\\\nAt Week 144\\\\nFTC+TDF+EFV\\\\n(N=244)\\\\nAZT/3TC+EFV\\\\n(N=243)\\\\nFTC+TDF+\\\\nEFV\\\\n(N=227)\\\\nAZT/3TC+EFV\\\\n(N=229)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\nResponder\\\\n84%\\\\n73%\\\\n71%\\\\n58%\\\\nVirologic failure\\\\n2%\\\\n4%\\\\n3%\\\\n6%\\\\n  Rebound\\\\n1%\\\\n3%\\\\n2%\\\\n5%\\\\n  Never suppressed\\\\n0%\\\\n0%\\\\n0%\\\\n0%\\\\n  Change in antiretroviral\\\\nregimen\\\\n1%\\\\n1%\\\\n1%\\\\n1%\\\\nDeath\\\\n&lt;1%\\\\n1%\\\\n1%\\\\n1%\\\\nDiscontinued due to\\\\nadverse event\\\\n4%\\\\n9%\\\\n5%\\\\n12%\\\\nDiscontinued for other\\\\nreasons\\\\n10%\\\\n14%\\\\n20%\\\\n22%\\\\nThrough Week 48, 84% and 73% of subjects in the FTC + TDF group and the\\\\nzidovudine/lamivudine group, respectiv...\",\"22-73 years); 88% were male, 68% were white, 29% were Black or African-American,\\\\nand 3% were of other races. At baseline, median CD4\\\\n cell count was 516 cells/mm\\\\n,\\\\nand 96% had HIV-1 RNA &lt;50 copies/mL. The median time since onset of antiretroviral\\\\ntherapy was 3 years, and 88% of subjects were receiving their first antiretroviral\\\\nregimen at trial enrollment.\\\\nAt Week 48, 89% and 87% of subjects who switched to ATRIPLA maintained HIV RNA\\\\n&lt;200 copies/mL and &lt;50 copies/mL, respectively, compared to 88...\",\"Interactions (7)\\\\n]\\\\n.\\\\nPsychiatric Symptoms\\\\nInform patients that serious psychiatric symptoms including severe depression,\\\\nsuicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms,\\\\nand catatonia have been reported in patients receiving EFV, a component of ATRIPLA\\\\n[see \\\\nWarnings and Precautions (5.5)\\\\n]\\\\n.\\\\nAdvise patients to seek immediate medical evaluation if they experience severe\\\\npsychiatric adverse experiences.\\\\nAdvise patients to inform their physician of any history o...\",\"Convulsions\\\\nInform patients that convulsions have been reported with the use of EFV, a component\\\\nof ATRIPLA. Patients who are receiving concomitant anticonvulsant medications primarily\\\\nmetabolized by the liver may require periodic monitoring of plasma levels \\\\n[see \\\\nWarnings\\\\nand Precautions (5.10)\\\\n and \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\nLactic Acidosis and Severe Hepatomegaly\\\\nInform patients that lactic acidosis and severe hepatomegaly with steatosis, including\\\\nfatal cases, have been reported. Treatmen...\",\"Patient Information\\\\n \\\\nATRIPLA\\\\u2122 (uh TRIP luh)\\\\n(efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets\\\\nWhat is the most important information I should know about ATRIPLA?\\\\nATRIPLA can cause serious side effects, including:\\\\nWorsening of hepatitis B virus (HBV) infection.\\\\n Your healthcare provider will\\\\ntest you for HBV before starting treatment with ATRIPLA. If you have HBV infection\\\\nand take ATRIPLA, your HBV may get worse (flare-up) if you stop taking ATRIPLA. \\\\nA\\\\n\\\\\"flare-up\\\\\" is when yo...\",\"be pregnant during treatment with ATRIPLA.\\\\nFemales who are able to become pregnant should use 2 effective\\\\nforms of birth control (contraception) during treatment with ATRIPLA\\\\nand for 12 weeks after stopping treatment.\\\\nA barrier form of birth control should always be used along with\\\\nanother type of birth control\\\\n. Barrier forms of birth control may include\\\\ncondoms, contraceptive sponges, diaphragm with spermicide, and cervical cap.\\\\nBirth control methods that contain the hormone progesterone such ...\",\"See \\\\\"\\\\nWhat is the most important information I should know about\\\\nATRIPLA?\\\\n\\\\\"\\\\nRash.\\\\n Rash is a serious side effect, but may also be common. Rashes will usually go\\\\naway without any change in your treatment. Tell your healthcare provider right away\\\\nif you develop a rash during treatment with ATRIPLA.\\\\nSevere liver problems. I\\\\nn rare cases, severe liver problems can happen that can\\\\nlead to death. \\\\nTell your healthcare provider right away if you get these\\\\nsymptoms:\\\\n skin or the white part of your eyes ...\",\"provider right away if you develop any of these symptoms:\\\\nweakness or being more tired than\\\\nusual\\\\nbeing short of breath or fast\\\\nbreathing\\\\ncold or blue hands and feet\\\\nfast or abnormal heartbeat\\\\nunusual muscle pain\\\\nstomach pain with nausea and vomiting\\\\nfeel dizzy or lightheaded\\\\nChanges in your immune system (Immune Reconstitution Syndrome) can\\\\nhappen when an HIV-1 infected person starts taking HIV-1 medicines.\\\\n Your\\\\nimmune system may get stronger and begin to fight infections that have been hidden...\",\"respective owners.\\\\n\\\\u00a9 2019 Gilead Sciences, LLC. All rights reserved.\\\\n21937-GS-020A\\\\nPRINCIPAL DISPLAY PANEL - 30 Tablet Bottle Label\\\\n61958-1601-3\\\\n30 tablets\\\\nATRIPLA\\\\u2122\\\\n(efavirenz 600 mg/emtricitabine 200 mg/\\\\ntenofovir disoproxil fumarate 300 mg)\\\\ntablets\\\\nGILEAD ACCESS PROGRAM\\\\nNote to pharmacist: Do not cover ALERT box with pharmacy label.\\\\nALERT: Find out about medicines that\\\\nshould NOT be taken with ATRIPLA\\\\nRx only\\\\nPOM\\\\nATRIPLA ACCESS  \\\\nefavirenz, emtricitabine, and tenofovir disoproxil fumarate tabl...\",\"Gilead Sciences, Inc.\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nEFAVIRENZ\\\\n (UNII: JE6H2O27P8) \\\\n(EFAVIRENZ - UNII:JE6H2O27P8)\\\\nEFAVIRENZ\\\\n600 mg\\\\nEMTRICITABINE\\\\n (UNII: G70B4ETF4S) \\\\n(EMTRICITABINE - UNII:G70B4ETF4S)\\\\nEMTRICITABINE\\\\n200 mg\\\\nTENOFOVIR DISOPROXIL FUMARATE\\\\n (UNII: OTT9J7900I) \\\\n(TENOFOVIR\\\\nANHYDROUS - UNII:W4HFE001U5)\\\\nTENOFOVIR DISOPROXIL\\\\nFUMARATE\\\\n300 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nHYDROXYPROPYL CELLULOSE (1600000 WAMW)\\\\n (UNII: RF...\",\"APRETUDE- cabotegravir \\\\n \\\\nViiV Healthcare Company\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use APRETUDE safely and\\\\neffectively. See full prescribing information for APRETUDE.\\\\nAPRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use\\\\nInitial U.S. Approval: 2021\\\\nWARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-\\\\nEXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION\\\\nSee full pres...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nADVERSE REACTIONS\\\\nThe most common adverse reactions (all grades) observed in at least 1% of participants receiving\\\\nAPRETUDE were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea,\\\\ndizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back\\\\npain, and upper respiratory tract infection. (\\\\n6.1\\\\n)\\\\nTo report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or\\\\nFDA at 1-800-FDA-1088 or \\\\nwww.fda.go...\",\"5.4 Hypersensitivity Reactions\\\\n5.5 Hepatotoxicity\\\\n5.6 Depressive Disorders\\\\n5.7 Risk of Reduced Drug Concentration of APRETUDE Due to Drug Interactions\\\\n6 ADVERSE REACTIONS\\\\n6.1 Clinical Trials Experience\\\\n6.2 Postmarketing Experience\\\\n7 DRUG INTERACTIONS\\\\n7.1 Use of Other Antiretroviral Drugs after Discontinuation of APRETUDE\\\\n7.2 Potential for Other Drugs to Affect APRETUDE\\\\n7.3 Established and Other Potentially Significant Drug Interactions\\\\n7.4 Drugs without Clinically Significant Interactions with C...\",\"WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR\\\\nHIV-1 PRE\\\\u2011EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1\\\\nINFECTION\\\\nIndividuals must be tested for HIV-1 infection prior to initiating\\\\nAPRETUDE or oral cabotegravir, and with each subsequent injection of\\\\nAPRETUDE, using a test approved or cleared by the FDA for the\\\\ndiagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1\\\\nvariants have been identified with use of APRETUDE by individuals with\\\\nundiagnosed HIV-1 infection. Do not ...\",\"Prior to starting APRETUDE, healthcare providers should carefully select individuals who\\\\nagree to the required injection dosing and testing schedule and counsel individuals about\\\\nthe importance of adherence to scheduled dosing visits to help reduce the risk of\\\\nacquiring HIV-1 infection and development of resistance \\\\n[see Dosage and Administration\\\\n(\\\\n2.1\\\\n), Warnings and Precautions (\\\\n5.1\\\\n, \\\\n5.3\\\\n), Microbiology (\\\\n12.4\\\\n)]\\\\n.\\\\n2.4 Optional Oral Lead-In Dosing to Assess Tolerability of APRETUDE\\\\nThe heal...\",\"Table 2. Recommended Dosing Schedule (Direct to Injection) for Pre-\\\\nExposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg\\\\n Individuals may be given APRETUDE up to 7 days before or after the date the individual\\\\nis scheduled to receive the injections.\\\\nIntramuscular (Gluteal) \\\\nInitiation Injection \\\\n(Month 1 and Month 2)\\\\nIntramuscular (Gluteal) \\\\nContinuation Injection \\\\n(Month 4 and Every 2 Months\\\\nOnwards)\\\\nAPRETUDE\\\\nAPRETUDE\\\\n600-mg (3 mL)\\\\n600-mg (3 mL)\\\\n2.6 Recommended Dosing Schedule ...\",\"Greater than 2 months\\\\nRestart with 600-mg (3-mL) gluteal intramuscular\\\\ninjection of APRETUDE, followed by a second 600-mg\\\\n(3-mL) initiation injection dose 1 month later. Then\\\\ncontinue to follow the every-2-month injection dosing\\\\nschedule thereafter.\\\\nIf third or subsequent\\\\ninjection is missed and time\\\\nsince prior injection is:\\\\nLess than or equal to 3 months\\\\nAdminister 600-mg (3-mL) intramuscular injection of\\\\nAPRETUDE as soon as possible, then continue with\\\\nthe every-2-month injection dosing sched...\",\"3 DOSAGE FORMS AND STRENGTHS\\\\nInjection: Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir\\\\nextended\\\\u2011release injectable suspension.\\\\n4 CONTRAINDICATIONS\\\\nAPRETUDE is contraindicated in individuals:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Comprehensive Management to Reduce the Risk of HIV-1 Infection\\\\nUse APRETUDE for HIV-1 PrEP to reduce the risk of HIV-1 infection as part of a\\\\ncomprehensive prevention strategy including adherence to the administration schedule\\\\nand safer sex practices,...\",\"\\\\u2022\\\\nWhen using APRETUDE for HIV-1 PrEP, HIV-1 testing should be repeated prior to each\\\\ninjection and upon diagnosis of any other STIs \\\\n[see Dosage and Administration (\\\\n2.2\\\\n,\\\\n2.5\\\\n)]\\\\n.\\\\n\\\\u2022\\\\nCounsel individuals without HIV-1 to strictly adhere to the recommended dosing and\\\\ntesting schedule for APRETUDE in order to reduce the risk of HIV-1 acquisition and the\\\\npotential development of resistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n, \\\\n2.5\\\\n),\\\\nMicrobiology (\\\\n12.4\\\\n)]\\\\n. Some individuals, such as adolescents,...\",\"include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) \\\\n[see Adverse\\\\nReactions (\\\\n6.2\\\\n)]\\\\n. Administration of cabotegravir oral lead-in dosing was used in clinical\\\\nstudies to help identify participants who may be at risk of a hypersensitivity reaction.\\\\nRemain vigilant and discontinue APRETUDE if a hypersensitivity reaction is suspected\\\\n[see Dosage and Administration (\\\\n2.4\\\\n), Contraindications (\\\\n4\\\\n), Adverse Reactions (\\\\n6\\\\n)]\\\\n.\\\\nDiscontinue APRETUDE immediately if signs or symptoms o...\",\"6.1 Clinical Trials Experience\\\\nBecause clinical trials are conducted under widely varying conditions, adverse reaction\\\\nrates observed in the clinical trials of a drug cannot be directly compared with rates in\\\\nthe clinical trials of another drug and may not reflect rates observed in practice.\\\\nClinical Trials Experience in Adults\\\\nThe safety assessment of APRETUDE is based on the analysis of data from 2\\\\ninternational, multicenter, double-blind trials, HPTN 083 and HPTN 084 \\\\n[see Clinical\\\\nStudies (\\\\n...\",\"Adverse reactions defined as \\\\u201ctreatment-related\\\\u201d as assessed by the investigator, with\\\\nexception of injection site reactions, where all injection site reactions were reported\\\\nregardless of causality.\\\\n Participants who received injection: HPTN 083, APRETUDE (n = 2,117) and TRUVADA\\\\n(n = 2,081); HPTN 084, APRETUDE (n = 1,519) and TRUVADA (n = 1,516).\\\\n Pyrexia includes pyrexia, feeling hot, chills, influenza-like illness.\\\\n Fatigue includes fatigue, malaise.\\\\n Sleep disorders includes insomnia, abnorm...\",\"grades) in at least 1% of participants who received APRETUDE and experienced at least\\\\none ISR from HPTN 084 are presented in \\\\nTable 5\\\\n.\\\\nTable 5. Injection Site Reactions (All Grades) Reported in at Least 1% of\\\\nParticipants Who Experienced at Least One Injection Site Reaction (All\\\\nCausality) with APRETUDE in Either HPTN 083 or HPTN 084\\\\n Placebo injectable suspension: intralipid 20% fat emulsion.\\\\nInjection Site\\\\nReactions\\\\nHPTN 083\\\\nHPTN 084\\\\nAPRETUDE\\\\n(n = 1,740)\\\\nTRUVADA\\\\n(n = 724)\\\\nAPRETUDE\\\\n(n = 578)\\\\nT...\",\"At the Week 41 and 97 timepoints in HPTN 084, participants who received APRETUDE\\\\ngained a median of 2 kg (IQR; 0.0, 5.0; n = 1,151) and 4 kg (IQR; 0.0, 8.0; n = 216) in\\\\nweight from baseline, respectively. Those who received TRUVADA gained a median of\\\\n1 kg (IQR; -1.0, 4.0; n = 1,131) and 3 kg (IQR; -1.0, 6.0; n = 218) in weight from\\\\nbaseline, respectively.\\\\nLaboratory Abnormalities: \\\\nGrade 3 or 4 post-baseline maximum toxicity laboratory\\\\nabnormalities for HPTN 083 or HPTN 084 are summarized in \\\\nTa...\",\"Nearly 60% of participants with baseline data available had Week 57 data available in\\\\nboth arms of both trials. Within each trial, baseline values were comparable among\\\\nparticipants receiving APRETUDE and TRUVADA.\\\\nHDL cholesterol\\\\nratio\\\\nClinical Trials Experience in Adolescents\\\\nIn adolescents receiving APRETUDE for HIV-1 PrEP, the safety data were comparable to\\\\nthe safety data reported in adults receiving APRETUDE for HIV-1 PrEP \\\\n[see Use in\\\\nSpecific Populations (\\\\n8.4\\\\n)].\\\\n6.2 Postmarketing Experi...\",\"inclusive.\\\\nTable 8. Drug Interactions with APRETUDE\\\\n\\\\u2191 = Increase, \\\\u2193 = Decrease, \\\\u2194 = No change.\\\\nConcomitant Drug\\\\nClass:\\\\nDrug Name\\\\nEffect on\\\\nConcentration\\\\nClinical Comment\\\\nAnticonvulsants:\\\\nCarbamazepine\\\\nOxcarbazepine\\\\nPhenobarbital\\\\nPhenytoin\\\\n\\\\u2193Cabotegravir\\\\nCoadministration is contraindicated with\\\\nAPRETUDE due to potential for significant\\\\ndecreases in plasma concentration of\\\\nAPRETUDE.\\\\nAntimycobacterials:\\\\nRifampin\\\\nRifapentine\\\\n\\\\u2193Cabotegravir\\\\nAntimycobacterial:\\\\nRifabutin\\\\n\\\\u2193Cabotegravir\\\\nWhen rifabutin is s...\",\"4263.\\\\nRisk Summary\\\\nThere are insufficient human data on the use of APRETUDE during pregnancy to\\\\nadequately assess a drug-associated risk of birth defects and miscarriage. Discuss the\\\\nbenefit-risk of using APRETUDE with individuals of childbearing potential or during\\\\npregnancy.\\\\nCabotegravir use in pregnant individuals has not been evaluated. APRETUDE should be\\\\nused during pregnancy only if the expected benefit justifies the potential risk to the\\\\nfetus.\\\\nThe APR has been established to monitor for ...\",\"exposure in humans at the RHD); there were no alterations to growth and development\\\\nof surviving offspring. In a cross-fostering study, similar incidences of stillbirths and\\\\nearly postnatal deaths were observed when rat pups born to cabotegravir-treated\\\\nmothers were nursed from birth by control mothers. There was no effect on neonatal\\\\nsurvival of control pups nursed from birth by cabotegravir-treated mothers. A lower\\\\ndose of 5 mg/kg/day (13 times the exposure at the RHD) was not associated with\\\\n...\",\"APRETUDE. Adolescents may benefit from more frequent visits and counseling to\\\\nsupport adherence to the dosing and testing schedule \\\\n[see Dosage and Administration\\\\n(\\\\n2.2\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)].\\\\nThe safety, efficacy, and pharmacokinetics of APRETUDE in pediatric participants\\\\nyounger than 12 years of age or weighing &lt;35 kg have not been established.\\\\n8.5 Geriatric Use\\\\nNo dose adjustment is required in elderly individuals. There are limited data available on\\\\nthe use of APRETUDE in indiv...\",\"Cabotegravir extended-release injectable suspension is a white to light pink free-flowing\\\\nsuspension for intramuscular injection in a sterile single-dose vial. Each vial contains\\\\n3 mL of the following: cabotegravir 200 mg/mL and the inactive ingredients mannitol\\\\n(35 mg/mL), polyethylene glycol (PEG) 3350 (20 mg/mL), polysorbate 20 (20 mg/mL),\\\\nand Water for Injection.\\\\nThe vial stoppers are not made with natural rubber latex.\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nCabotegravir is an HIV...\",\"CSF = Cerebrospinal fluid.\\\\n When taken orally with a high-fat meal versus fasted, the AUC\\\\n (geometric mean\\\\nratio [90% CI] of cabotegravir are 1.14 [1.02, 1.28]).\\\\n The clinical relevance of CSF-to-plasma concentration ratios is unknown.\\\\nConcentrations were measured at steady-state 1 week after intramuscular\\\\nadministration of cabotegravir extended-release injectable suspensions given monthly or\\\\nevery 2 months.\\\\n Elimination half-life driven by slow absorption rate from the intramuscular injection s...\",\"with HIV-1 (n = 110), the observed cabotegravir geometric mean (5th, 95th percentile)\\\\nC\\\\n (1-week post\\\\u2011initial injection) was 1.89 mcg/mL (0.438, 5.69) and C\\\\n was\\\\n1.43 mcg/mL (0.403, 3.90).\\\\n Pharmacokinetic parameter values represent steady state.\\\\nSpecific Populations\\\\nNo clinically significant differences in the pharmacokinetics of cabotegravir were\\\\nobserved based on age, sex, race/ethnicity, BMI, or UGT1A1 polymorphisms. There are\\\\nno data available for the use of cabotegravir in participants wit...\",\"IM = intramuscular.\\\\n Pharmacokinetic parameter values were based on individual post-hoc estimates from\\\\npopulation pharmacokinetic models in both adolescents with HIV-1 (n = 147) weighing\\\\n35.2 to 98.5 kg and adolescents without HIV-1 (n = 62) weighing 39.9 to 167 kg. \\\\n tau is dosing interval: 24 hours for oral administration, 1 month for the initial injection,\\\\nand 2 months for every 2 months for intramuscular injections of extended-release\\\\ninjectable suspension.\\\\n Oral lead-in pharmacokinetic para...\",\"n = Maximum number of participants with data, CI = Confidence Interval.\\\\nCoadministered\\\\nDrug(s)\\\\nand Dose(s)\\\\nDose of\\\\nCabotegravir\\\\nn\\\\nNo Effect = 1.00\\\\nC\\\\nAUC\\\\nC\\\\n or C\\\\nEtravirine\\\\n30 mg\\\\n12\\\\n1.04\\\\n1.01\\\\n1.00\\\\n    200 mg twice\\\\ndaily\\\\nonce daily\\\\n(0.99, 1.09)\\\\n(0.96, 1.06)\\\\n(0.94, 1.06)\\\\nRifabutin\\\\n30 mg\\\\n12\\\\n0.83\\\\n0.77\\\\n0.74\\\\n    300 mg once\\\\ndaily\\\\nonce daily\\\\n(0.76, 0.90)\\\\n(0.74, 0.83)\\\\n(0.70, 0.78)\\\\nRifampin\\\\n30-mg\\\\n15\\\\n0.94\\\\n0.41\\\\n0.50\\\\n    600 mg once\\\\ndaily\\\\nsingle dose\\\\n(0.87, 1.02)\\\\n(0.36, 0.46)\\\\n(0.44, 0.57)\\\\nRilpivirine\\\\n30 mg\\\\n1...\",\"12.4 Microbiology\\\\nMechanism of Action\\\\nCabotegravir inhibits HIV integrase by binding to the integrase active site and blocking\\\\nthe strand transfer step of retroviral deoxyribonucleic acid (DNA) integration that is\\\\nessential for the HIV replication cycle. The mean 50% inhibitory concentration (IC\\\\n)\\\\nvalue of cabotegravir in a strand transfer assay using purified recombinant HIV-1\\\\nintegrase was 3.0 nM.\\\\nAntiviral Activity in Cell Culture\\\\nCabotegravir exhibited antiviral activity against laboratory s...\",\"cabotegravir exposures below the target concentration. No variants expressing INSTI\\\\nresistance-associated substitutions were detected.\\\\nCross-Resistance\\\\nCross-resistance has been observed among INSTIs. Cabotegravir had reduced\\\\nsusceptibility (&gt;5-fold change) to recombinant HIV-1 strain NL432 viruses harboring the\\\\nfollowing integrase amino acid substitutions: G118R, Q148K, Q148R, T66K+L74M,\\\\nE92Q+N155H, E138A+Q148R, E138K+Q148K/R, G140C+Q148R, G140S+Q148H/K/R,\\\\nY143H+N155H, and Q148R+N155H (range: 5...\",\"in men and transgender women without HIV-1 who have sex with men and have\\\\nevidence of high-risk behavior for HIV-1 infection and HPTN 084 in cisgender women\\\\nwithout HIV-1 at risk of acquiring HIV-1.\\\\nParticipants randomized to receive APRETUDE initiated oral lead-in dosing with 1 oral\\\\ncabotegravir 30-mg tablet and a placebo daily for up to 5 weeks, followed by APRETUDE\\\\n600\\\\u2011mg (3-mL) intramuscular injection at months 1 and 2 and every 2 months\\\\nthereafter and a daily placebo tablet. Participants ra...\",\"Results from all subgroup analyses were consistent with the overall protective effect. A\\\\nlower rate of incident HIV\\\\u20111 infections was observed for participants randomized to\\\\nAPRETUDE compared with participants randomized to TRUVADA (\\\\nTable 15\\\\n).\\\\nTable 15. Incident of HIV-1 Infections by Subgroup in HPTN 083: Extended\\\\nRetrospective Virologic Testing with Readjudicated Endpoints\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence per\\\\n100 Person-\\\\nYears\\\\nAPRETUDE\\\\nPerson-Years\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nP...\",\"mITT from Supplemental Virology Report. \\\\n Cisgender men who have sex with men.\\\\n Transgender women who have sex with men.\\\\nTGW\\\\n0.54\\\\n371\\\\n1.80\\\\n389\\\\n0.34\\\\n(0.08,\\\\n1.56)\\\\nRace (US)\\\\nBlack\\\\n0.58\\\\n691\\\\n2.28\\\\n703\\\\n0.26\\\\n(0.09,\\\\n0.76)\\\\nNon-Black\\\\n0.00\\\\n836\\\\n0.50\\\\n801\\\\n0.11\\\\n(0.00,\\\\n2.80)\\\\nRegion\\\\nUS\\\\n0.26\\\\n1,528\\\\n1.33\\\\n1,504\\\\n0.21\\\\n(0.07,\\\\n0.60)\\\\nLatin\\\\nAmerica\\\\n0.49\\\\n1,020\\\\n1.09\\\\n1,011\\\\n0.47\\\\n(0.17,\\\\n1.35)\\\\nAsia\\\\n0.35\\\\n570\\\\n1.03\\\\n581\\\\n0.39\\\\n(0.08,\\\\n1.82)\\\\nAfrica\\\\n1.08\\\\n93\\\\n2.07\\\\n97\\\\n0.63\\\\n(0.06,\\\\n6.50)\\\\nTrial 201739 (HPTN 084 [NCT03164564])\\\\nIn HPTN 084, a su...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\",\"mITT from Supplemental Virology Report.\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nAPRETUDE\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nPerson-\\\\nYears\\\\nHazard\\\\nRatio\\\\n(95% CI)\\\\nAge\\\\n&lt;25 years\\\\n0.23\\\\n868\\\\n2.34\\\\n853\\\\n0.12\\\\n(0.03, 0.46)\\\\n\\\\u226525 years\\\\n0.09\\\\n1,093\\\\n1.46\\\\n1,093\\\\n0.09\\\\n(0.02, 0.49)\\\\nBody Mass Index\\\\n&lt;30\\\\n0.22\\\\n1,385\\\\n1.88\\\\n1,435\\\\n0.12\\\\n(0.04, 0.38)\\\\n\\\\u226530\\\\n0.00\\\\n575\\\\n1.76\\\\n511\\\\n0.04\\\\n(0.00, 0.93)\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nHow Supplied\\\\nAPRETUDE is supplied in a kit containing one 600-mg/3...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nPotential Risk of Resistance with APRETUDE\\\\nAdvise individuals there is a potential risk of developing resistance to APRETUDE if HIV-1\\\\nis acquired either before or while taking APRETUDE or following discontinuation of\\\\nAPRETUDE \\\\n[see Warnings and Precautions (\\\\n5.2\\\\n)]\\\\n.\\\\nTo minimize this, it is essential that individuals are clinically reassessed for risk of HIV-1\\\\nacquisition and tested frequently to confirm HIV-1 negative status. Advise individuals\\\\nwho are confirmed to have with HIV...\",\"Counsel individuals about the importance of continued medication adherence and\\\\nscheduled visits to help reduce the risk of acquiring HIV-1 infection and development of\\\\nresistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)]\\\\n.\\\\nHypersensitivity Reactions\\\\nAdvise individuals to immediately contact their healthcare provider if they develop a rash.\\\\nInstruct individuals to immediately stop taking APRETUDE and seek medical attention if\\\\nthey develop a rash associated with an...\",\"Warnings and Precautions (\\\\n5.3\\\\n), Use in Specific Populations (\\\\n8.1\\\\n)]\\\\n.\\\\nLactation\\\\nInform individuals that due to the potential for adverse reactions and residual\\\\nconcentrations in the systemic circulation for up to 12 months or longer after\\\\ndiscontinuing injections of APRETUDE, it is recommended that mothers breastfeed only\\\\nif the expected benefit justifies the potential risk to the infant. The benefits and risks of\\\\nAPRETUDE while breastfeeding should be evaluated, including the risk of HIV-1\\\\na...\",\"While you are receiving APRETUDE for HIV-1 PrEP:\\\\n\\\\u2022\\\\n\\\\u2022\\\\nIf you have HIV-1 and receive only APRETUDE, over time your HIV-1 may\\\\nbecome harder to treat.\\\\nWhat is APRETUDE?\\\\nAPRETUDE is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting\\\\nHIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg).\\\\nHIV-1 is the virus that causes acquired immune deficiency syndrome (AIDS).\\\\nIt is not known if APRETUDE is safe and effective in children younger than 12 years o...\",\"\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\nBefore receiving APRETUDE, tell your healthcare provider about all your\\\\nmedical conditions, including if you:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nTell your healthcare provider about all the medicines you take,\\\\n including\\\\nprescription and over-the-counter medicines, vitamins, and herbal supplements.\\\\nSome medicines may interact with APRETUDE. Keep a list of your medicines and show it\\\\nto your healthcare provider and pharmacist when you get a new medicine.\\\\nYou can ask your healthcare provider or pharmacist fo...\",\"What are the possible side effects of APRETUDE?\\\\nAPRETUDE may cause serious side effects including:\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\nThe most common side effects of APRETUDE include:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAllergic reactions.\\\\n Call your healthcare provider right away if you develop a rash\\\\nwith APRETUDE. \\\\nStop receiving APRETUDE and get medical help right away\\\\nif you develop a rash with any of the following signs or symptoms:\\\\n\\\\u25cb   fever\\\\n\\\\u25cb   generally ill feeling\\\\n\\\\u25cb   tiredness\\\\n\\\\u25cb   mu...\",\"These are not all the possible side effects of APRETUDE.\\\\nCall your doctor for medical advice about side effects. You may report side effects to\\\\nFDA at 1-800-FDA-1088.\\\\nGeneral information about the safe and effective use of APRETUDE.\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Patient\\\\nInformation leaflet. You can ask your pharmacist or healthcare provider for information\\\\nabout APRETUDE that is written for health professionals.\\\\nWhat are the ingredients in APRETUDE?...\",\"Overview:\\\\nA complete dose of APRETUDE requires 1 injection: 600-mg (3 mL) of cabotegravir.\\\\nAPRETUDE is a suspension that does not need further dilution or reconstitution.\\\\nCarefully follow these instructions when preparing the suspension for injection to avoid\\\\nleakage.\\\\nAPRETUDE is for gluteal intramuscular use only.\\\\nNote:\\\\n The ventrogluteal site is recommended.\\\\n Storage information\\\\nStore at 2\\\\u00b0C to 25\\\\u00b0C (36\\\\u00b0F to 77\\\\u00b0F). Exposure up to 30\\\\u00b0C (86\\\\u00b0F) permitted.\\\\nDo not \\\\nfreeze.\\\\nPrior to administration:\\\\n...\",\"\\\\u2022\\\\nYour pack contains:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nConsider the individual\\\\u2019s build and use medical judgment to select an appropriate\\\\ninjection needle length.\\\\nYou will also need:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\ntemperature prior to administration (not to exceed 30\\\\u00b0C [86\\\\u00b0F]).\\\\nOnce APRETUDE has been drawn into the syringe, the medicine can remain in the\\\\nsyringe for up to 2 hours before injection. The filled syringe should not be placed in\\\\nthe refrigerator. If the medicine remains in the syringe for more than 2 hours, the\\\\nfilled syringe and ne...\",\"Preparation:\\\\n1. Inspect the vial.\\\\nFigure A\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n\\\\u2022\\\\n2. Shake the vial vigorously.\\\\nFigure B\\\\n\\\\u2022\\\\n3. Inspect suspension.\\\\nFigure C\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n4. Remove the vial cap.\\\\nCheck that the\\\\nexpiration date has\\\\nnot passed. \\\\nSee\\\\nFigure A.\\\\nInspect the vial\\\\nimmediately. If you\\\\ncan see foreign\\\\nmatter, do not use\\\\nthe product.\\\\nNote:\\\\n The vial has a\\\\nbrown tint to the\\\\nglass.\\\\nDo not\\\\n use if the\\\\nexpiration date has\\\\npassed.\\\\nIf the pack has been\\\\nstored in the\\\\nrefrigerator, allow the\\\\nmedication to come to\\\\nroom temperature.\\\\nHold...\",\"Figure D\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n5. Peel open the vial adapter.\\\\nFigure E\\\\n\\\\u2022\\\\n \\\\n \\\\n6. Place vial on flat surface and attach the vial adapter.\\\\nFigure F\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n7. Lift off the packaging.\\\\nRemove the cap from\\\\nthe vial. \\\\nSee Figure\\\\nD.\\\\nWipe the rubber\\\\nstopper with an\\\\nalcohol wipe.\\\\nDo not\\\\n allow\\\\nanything to touch the\\\\nrubber stopper after\\\\nwiping it.\\\\nPeel off the paper\\\\nbacking from the vial\\\\nadapter packaging.\\\\nSee Figure E.\\\\nNote:\\\\n Do not remove\\\\nthe adapter from its\\\\npackaging for the\\\\nnext step. The\\\\nadapter \\\\nwill not\\\\n fall\\\\nout wh...\",\"Figure G\\\\n\\\\u2022\\\\n8. Prepare the syringe.\\\\nFigure H\\\\n\\\\u2022\\\\n\\\\u2022\\\\n9. Attach the syringe.\\\\nFigure I\\\\n\\\\u2022\\\\n\\\\u2022\\\\n10. Press the plunger.\\\\nLift off the vial\\\\nadapter packaging, as\\\\nshown.\\\\n See Figure\\\\nG.\\\\nRemove the syringe\\\\nfrom its packaging.\\\\nDraw 1 mL of air into\\\\nthe syringe. This will\\\\nmake it easier to draw\\\\nup the medicine later.\\\\nSee Figure H.\\\\nHold the vial adapter\\\\nand vial firmly, as\\\\nshown.\\\\nScrew the syringe\\\\nfirmly onto the vial\\\\nadapter. \\\\nSee Figure\\\\nI.\",\"Figure J\\\\n\\\\u2022\\\\n11. Slowly draw up the dose.\\\\nFigure K\\\\n\\\\u2022\\\\n \\\\n12. Unscrew the syringe.\\\\nFigure L\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n13. Attach the needle.\\\\nPress the plunger all\\\\nthe way down to push\\\\nthe air into the vial.\\\\nSee Figure J.\\\\nInvert the syringe and\\\\nvial and slowly\\\\nwithdraw as much of\\\\nthe medicine as\\\\npossible into the\\\\nsyringe. There may be\\\\nmore medicine than\\\\nthe dose amount.\\\\nSee Figure K.\\\\nNote:\\\\n Keep the\\\\nsyringe upright to\\\\navoid leakage.\\\\nHold the syringe\\\\nplunger firmly in place\\\\nas shown to prevent\\\\nleakage. It is normal\\\\nto fee...\",\"Figure M\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nInjection:\\\\n14. Prepare the injection site.\\\\nFigure N\\\\n \\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n15. Remove the cap.\\\\nPeel open the needle\\\\npackaging part way to\\\\nexpose the needle\\\\nbase.\\\\nKeeping the syringe\\\\nupright, firmly twist\\\\nthe syringe onto the\\\\nneedle.\\\\nRemove the needle\\\\npackaging from the\\\\nneedle. \\\\nSee Figure\\\\nM.\\\\nAPRETUDE must be\\\\nadministered to a\\\\ngluteal site. \\\\nSee\\\\nFigure N\\\\n.\\\\nSelect from the\\\\nfollowing areas for the\\\\ninjection:\\\\nVentrogluteal, as\\\\nshown\\\\n(recommended)\\\\nDorsogluteal, not\\\\nshown (upper outer\\\\nquadrant)\\\\nNote...\",\"Figure O\\\\n\\\\u2022\\\\n\\\\u2022\\\\n16. Remove extra liquid from the syringe.\\\\nFigure P\\\\n\\\\u2022\\\\n \\\\n17. Stretch the skin.\\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\nFold the needle guard\\\\naway from the needle.\\\\nSee Figure O.\\\\nPull off the injection\\\\nneedle cap.\\\\nHold the syringe with\\\\nthe needle pointing\\\\nup. Press the plunger\\\\nto the 3 mL dosing\\\\nmark to remove extra\\\\nliquid and any air\\\\nbubbles. \\\\nSee Figure\\\\nP.\\\\nNote:\\\\n Clean the\\\\ninjection site with an\\\\nalcohol wipe. Allow the\\\\nskin to air dry before\\\\ncontinuing.\\\\nUse the z-track\\\\ninjection technique to\\\\nminimize medicine\\\\nleakage ...\",\"Figure Q\\\\n18. Insert the needle.\\\\nFigure R\\\\n\\\\u2022\\\\n19. Inject the dose of medicine.\\\\nFigure S\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n20. Assess the injection site.\\\\nInsert the needle to\\\\nits full depth, or deep\\\\nenough to reach the\\\\nmuscle. \\\\nSee Figure\\\\nR.\\\\nStill holding the skin\\\\nstretched \\\\u2013 slowly\\\\npress the plunger all\\\\nthe way down. \\\\nSee\\\\nFigure S.\\\\nEnsure the syringe is\\\\nempty.\\\\nWithdraw the needle\\\\nand release the\\\\nstretched skin\\\\nimmediately.\",\"Figure T\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n21. Make the needle safe.\\\\nFigure U\\\\n\\\\u2022\\\\nFigure V\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAfter injection:\\\\n22. Dispose safely.\\\\nApply pressure to the\\\\ninjection site using a\\\\ngauze pad. \\\\nSee\\\\nFigure T.\\\\nA small bandage may\\\\nbe used if bleeding\\\\noccurs.\\\\nDo not\\\\n massage the\\\\narea.\\\\nFold the needle guard\\\\nover the needle. \\\\nSee\\\\nFigure U.\\\\nGently apply pressure\\\\nusing a hard surface\\\\nto lock the needle\\\\nguard in place.\\\\nThe needle guard will\\\\nmake a click when it\\\\nlocks. \\\\nSee Figure V.\",\"Figure W\\\\n\\\\u2022\\\\nQuestions and Answers\\\\n1.\\\\n \\\\n2.\\\\n3.\\\\n4.\\\\nManufactured for:\\\\nViiV Healthcare\\\\nDurham, NC 27701\\\\nTrademarks are owned by or licensed to the ViiV Healthcare group of companies.\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\nAPR:5IFU\\\\n \\\\nDispose of used\\\\nneedle, syringe, vial,\\\\nand vial adapter\\\\naccording to local\\\\nhealth and safety\\\\nlaws. \\\\nSee Figure W.\\\\nIf the pack has been stored in the refrigerator, is it safe to warm the\\\\nvial up to room temperature more quickly?\\\\n \\\\nThe vial should be broug...\",\"Principal Display Panel\\\\nNDC 49702-264-23\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nFor gluteal intramuscular use only.\\\\nHealthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 2/24\\\\n\\\\u00a92024 ViiV H...\",\"Principal Display Panel\\\\nNDC 49702-280-63\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nSample-Not for Sale\\\\nFor gluteal intramuscular use only.\",\"Healthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 5/24\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\n62000000094179\",\"APRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-264\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-264-\\\\n23\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n12/20/2021\",\"Quantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\nTotal Product Quantity\\\\nPart 1\\\\n1 VIAL\\\\n3 mL\\\\nPart 1 of 1\\\\nCABOTEGRAVIR  \\\\ncabotegravir injection, suspension, extended release\\\\nProduct Information\\\\nItem Code (Source)\\\\nNDC:49702-238\\\\nRoute of Administration\\\\nINTRAMUSCULAR\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCABOTEGRAVIR\\\\n (UNII: HMH0132Z1Q) \\\\n(CABOTEGRAVIR - UNII:HMH0132Z1Q)\\\\nCABOTEGRAVIR\\\\n200 mg  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)...\",\"NDA\\\\nNDA215499\\\\n12/20/2021\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nNDA\\\\nNDA215499\\\\n12/20/2021\\\\nAPRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-280\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-280-\\\\n63\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n03/31/2024\\\\nQuantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\n...\",\"ViiV Healthcare Company\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYSORBATE 20\\\\n (UNII: 7T1F30V5YH)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nWHITE (white to light pink)\\\\nScore\\\\n    \\\\nShape\\\\nSize\\\\nFlavor\\\\nImprint Code\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-238-\\\\n61\\\\n3 mL in 1 VIAL; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Mono...\",\"ISENTRESS- raltegravir tablet, film coated \\\\n \\\\nNuCare Pharmaceuticals,Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ISENTRESS safely and\\\\neffectively. See full prescribing information for ISENTRESS. \\\\nISENTRESS \\\\n (raltegravir) film-coated tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) chewable tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) for oral suspension \\\\nInitial U.S. Approval: 2007\\\\nINDICATIONS AND USAGE\\\\nISENTRESS is...\",\"The most common adverse reactions of moderate to severe intensity (\\\\u22652%) are insomnia, headache,\\\\ndizziness, nausea and fatigue ( \\\\n6.1\\\\n).\\\\nCreatine kinase elevations were observed in subjects who received ISENTRESS. Myopathy and\\\\nrhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or\\\\nrhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions\\\\nand patients with a history of rhabdomyolysis, myopathy or increased serum cre...\",\"8.5 Geriatric Use\\\\n8.6 Use in Patients with Hepatic Impairment\\\\n8.7 Use in Patients with Renal Impairment\\\\n10 OVERDOSAGE\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n12.4 Microbiology\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n14.1 \\\\nTreatment-Na\\\\u00efve Adult Subjects\\\\n14.2 Treatment-Experienced Adult Subjects\\\\n14.3 Pediatric Subjects\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT ...\",\"Each single-use packet for oral suspension contains 100 mg of raltegravir which is\\\\nsuspended in 5 mL of water giving a final concentration of 20 mg/mL.\\\\n2.2 Adults\\\\nFor the treatment of adult patients with HIV-1 infection, the dosage of ISENTRESS is one\\\\n400 mg film-coated tablet administered orally, twice daily.\\\\n2.3 Pediatrics\\\\nIf at least 25 kg:\\\\n One 400 mg film-coated tablet orally, twice daily.\\\\nIf unable to swallow a tablet, consider the chewable tablet, as specified in Table 1.\\\\nTable 1: Alterna...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n11 to less than 14 \\\\n4 mL (80 mg) twice\\\\ndaily\\\\n3 \\\\u00d7 25 mg twice daily\\\\n14 to less than 20 \\\\n5 mL (100 mg) twice\\\\ndaily\\\\n1 \\\\u00d7 100 mg twice\\\\ndaily\\\\n20 to less than 25\\\\n1.5 \\\\u00d7 100 mg \\\\n twice\\\\ndaily\\\\n2.4 Method of Administration\\\\nISENTRESS Film-Coated Tablets\\\\nFilm-Coated Tablets must be swallowed whole\\\\nISENTRESS Chewable Tablets\\\\nChewable Tablets may be chewed or swallowed whole\\\\nISENTRESS For Oral Suspension\\\\nEach single-use ISENTRESS packet for oral suspension contains 100 mg of raltegravir\\\\nwhich is to be sus...\",\"None\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Skin and Hypersensitivity Reactions\\\\nSevere, potentially life-threatening, and fatal skin reactions have been reported. These\\\\ninclude cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.\\\\nHypersensitivity reactions have also been reported and were characterized by rash,\\\\nconstitutional findings, and sometimes, organ dysfunction, including hepatic failure.\\\\nDiscontinue ISENTRESS and other suspect agents immediately if signs or symptoms of\\\\nsevere...\",\"STARTMRK (Protocol 021) with ISENTRESS 400 mg twice daily in combination with a fixed\\\\ndose of emtricitabine 200 mg (+) tenofovir 300 mg, (N=281) versus efavirenz (EFV) 600\\\\nmg at bedtime in combination with emtricitabine (+) tenofovir, (N=282). During double-\\\\nblind treatment, the total follow-up for subjects receiving ISENTRESS 400 mg twice daily\\\\n+ emtricitabine (+) tenofovir was 1104 patient-years and 1036 patient-years for\\\\nsubjects receiving efavirenz 600 mg at bedtime + emtricitabine (+) tenof...\",\"Analysis)\\\\nRandomized Study Protocol\\\\n021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm (Unit)\\\\nLimit\\\\nISENTRESS\\\\n400 mg \\\\nTwice Daily +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 281)\\\\nEfavirenz 600\\\\nmg \\\\nAt Bedtime +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 282)\\\\nHematology\\\\nAbsolute neutrophil count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n0.75 - 0.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n0.50 - 0.749\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&lt;0.50\\\\n1%\\\\n1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n1%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n1%\\\\n...\",\"ULN = Upper limit of normal range\\\\nLipids, Change from Baseline\\\\nChanges from baseline in fasting lipids are shown in Table 5.\\\\nTable 5: Lipid Values, Mean Change from Baseline, Protocol 021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm\\\\nISENTRESS 400 mg \\\\nTwice Daily + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 207\\\\nEfavirenz 600 mg \\\\nAt Bedtime + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 187\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean\\\\nMean\\\\nChange\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean...\",\"OBT. The median duration of therapy in these trials was 96 weeks for subjects receiving\\\\nISENTRESS and 38 weeks for subjects receiving placebo. The total exposure to\\\\nISENTRESS was 708 patient-years versus 244 patient-years on placebo. The rates of\\\\ndiscontinuation due to adverse events were 4% in subjects receiving ISENTRESS and 5%\\\\nin subjects receiving placebo.\\\\nClinical ADRs were considered by investigators to be causally related to ISENTRESS +\\\\nOBT or placebo + OBT. Clinical ADRs of moderate to s...\",\"Grade 4\\\\n&lt;0.50\\\\n1%\\\\n&lt;1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n3%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n25 - 49.999\\\\n1%\\\\n&lt;1%\\\\n  Grade 4\\\\n&lt;25\\\\n1%\\\\n&lt;1%\\\\nBlood chemistry\\\\nFasting (non-random) serum glucose test (mg/dL)\\\\n  Grade 2\\\\n126 - 250\\\\n10%\\\\n7%\\\\n  Grade 3\\\\n251 - 500\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&gt;500\\\\n0%\\\\n0%\\\\nTotal serum bilirubin\\\\n  Grade 2\\\\n1.6 - 2.5 \\\\u00d7 ULN\\\\n6%\\\\n3%\\\\n  Grade 3\\\\n2.6 - 5.0 \\\\u00d7 ULN\\\\n3%\\\\n3%\\\\n  Grade 4\\\\n&gt;5.0 \\\\u00d7 ULN\\\\n1%\\\\n0%\\\\nSerum aspartate aminotransferase...\",\"ULN = Upper limit of normal range\\\\nLess Common Adverse Reactions Observed in Treatment-Na\\\\u00efve and Treatment-\\\\nExperienced Studies\\\\nThe following ADRs occurred in &lt;2% of treatment-na\\\\u00efve or treatment-experienced\\\\nsubjects receiving ISENTRESS in a combination regimen. These events have been\\\\nincluded because of their seriousness, increased frequency on ISENTRESS compared\\\\nwith efavirenz or placebo, or investigator&#x27;s assessment of potential causal relationship.\\\\nGastrointestinal Disorders: \\\\nabdominal pain, ...\",\"upper limit of normal (ULN). In general the safety profile of ISENTRESS in subjects with\\\\nhepatitis B and/or hepatitis C virus co-infection was similar to that in subjects without\\\\nhepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT\\\\nabnormalities were higher in the subgroup with hepatitis B and/or hepatitis C virus co-\\\\ninfection for all treatment groups. At 96 weeks, in treatment-experienced subjects,\\\\nGrade 2 or higher laboratory abnormalities that represent a wors...\",\"patients with underlying liver disease and/or concomitant medications\\\\nMusculoskeletal and Connective Tissue Disorders:\\\\n rhabdomyolysis\\\\nNervous System Disorders: \\\\ncerebellar ataxia\\\\nPsychiatric Disorders: \\\\nanxiety, paranoia\\\\n7 DRUG INTERACTIONS\\\\n7.1 Effect of Raltegravir on the Pharmacokinetics of Other Agents\\\\nRaltegravir does not inhibit (IC \\\\n&gt;100 \\\\u00b5M) CYP1A2, CYP2B6, CYP2C8, CYP2C9,\\\\nCYP2C19, CYP2D6 or CYP3A \\\\nin vitro\\\\n. Moreover, \\\\nin vitro\\\\n, raltegravir did not induce\\\\nCYP1A2, CYP2B6 or CYP3A4. A mid...\",\"rifampin\\\\n\\\\u2193\\\\ndaily during coadministration\\\\nwith rifampin. There are no\\\\ndata to guide co-\\\\nadministration of ISENTRESS\\\\nwith rifampin in patients below\\\\n18 years of age \\\\n[see \\\\nDosage\\\\nand Administration (2.1)\\\\n].\\\\n7.3 Drugs without Clinically Significant Interactions with ISENTRESS\\\\nIn drug interaction studies, raltegravir did not have a clinically meaningful effect on the\\\\npharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine,\\\\ntenofovir, etravirine, darunavir/ritonavir, or boce...\",\"8.3 Nursing Mothers\\\\nBreastfeeding is not recommended while taking ISENTRESS. In addition, it is\\\\nrecommended that HIV-1-infected mothers not breastfeed their infants to avoid risking\\\\npostnatal transmission of HIV-1.\\\\nIt is not known whether raltegravir is secreted in human milk. However, raltegravir is\\\\nsecreted in the milk of lactating rats. Mean drug concentrations in milk were\\\\napproximately 3-fold greater than those in maternal plasma at a maternal dose of 600\\\\nmg/kg/day in rats. There were no ef...\",\"evidence of toxicity.\\\\nIn the event of an overdose, it is reasonable to employ the standard supportive\\\\nmeasures, e.g., remove unabsorbed material from the gastrointestinal tract, employ\\\\nclinical monitoring (including obtaining an electrocardiogram), and institute supportive\\\\ntherapy if required. The extent to which ISENTRESS may be dialyzable is unknown.\\\\n11 DESCRIPTION\\\\nISENTRESS contains raltegravir potassium, a human immunodeficiency virus integrase\\\\nstrand transfer inhibitor. The chemical name fo...\",\"fructose, hydroxypropyl cellulose, hypromellose 2910/6cP, magnesium stearate,\\\\nmannitol, medium chain triglycerides, monoammonium glycyrrhizinate, natural and\\\\nartificial flavors (orange, banana, and masking that contains aspartame), oleic acid, PEG\\\\n400, saccharin sodium, sodium citrate dihydrate, sodium stearyl fumarate, sorbitol,\\\\nsucralose and yellow iron oxide.\\\\nEach packet of ISENTRESS for oral suspension 100 mg, contains 108.6 mg of raltegravir\\\\n(as potassium salt), equivalent to 100 mg of ralt...\",\"formulation comparison study in healthy adult volunteers, the chewable tablet and oral\\\\nsuspension have higher oral bioavailability compared to the 400 mg film-coated tablet.\\\\nIn subjects who received 400 mg twice daily alone, raltegravir drug exposures were\\\\ncharacterized by a geometric mean AUC \\\\n of 14.3 \\\\u00b5M\\\\u2219hr and C \\\\n of 142 nM.\\\\nConsiderable variability was observed in the pharmacokinetics of raltegravir. For\\\\nobserved C \\\\nin Protocols 018 and 019, the coefficient of variation (CV) for inter-\\\\nsubje...\",\"approximately 70% of the total radioactivity; the remaining radioactivity in plasma was\\\\naccounted for by raltegravir-glucuronide. Studies using isoform-selective chemical\\\\ninhibitors and cDNA-expressed UDP-glucuronosyltransferases (UGT) show that UGT1A1\\\\nis the main enzyme responsible for the formation of raltegravir-glucuronide. Thus, the\\\\ndata indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-\\\\nmediated glucuronidation.\\\\nSpecial Populations\\\\nPediatric\\\\nTwo pediatric fo...\",\"*\\\\n\\\\u2020\\\\nkg\\\\nTable 2\\\\n3 to less\\\\nthan 20\\\\nkg\\\\nOral\\\\nsuspension\\\\nWeight\\\\nbased\\\\ndosing, see\\\\nTable 2\\\\n19\\\\n24.5 ( \\\\n43%\\\\n)\\\\n113 ( \\\\n69%\\\\n)\\\\nThe pharmacokinetics of raltegravir in infants under 4 weeks of age has not been\\\\nestablished.\\\\nAge\\\\nThe effect of age (18 years and older) on the pharmacokinetics of raltegravir was\\\\nevaluated in the composite analysis. No dosage adjustment is necessary.\\\\nRace\\\\nThe effect of race on the pharmacokinetics of raltegravir in adults was evaluated in the\\\\ncomposite analysis. No dosage adjustmen...\",\"with wild-type genotype, the geometric mean ratio (90% CI) of AUC was 1.41 (0.96,\\\\n2.09).\\\\nDrug Interactions\\\\n [see \\\\nDrug Interactions (7)\\\\n]\\\\nTable 10: Effect of Other Agents on the Pharmacokinetics of Raltegravir in\\\\nAdults\\\\nCoadministered\\\\nDrug\\\\nCoadministered\\\\nDrug\\\\nDose/Schedule\\\\nRaltegravir \\\\nDose/Schedule\\\\nRatio (90% Confidence\\\\nInterval) of Raltegravir\\\\nPharmacokinetic Parameters\\\\nwith/without Coadministered\\\\nDrug; \\\\nNo Effect = 1.00\\\\nn\\\\nC \\\\nAUC\\\\nC \\\\naluminum and\\\\nmagnesium\\\\nhydroxide antacid\\\\n20 mL single\\\\ndose gi...\",\"boceprevir\\\\n800 mg three\\\\ntimes daily\\\\n400 mg single\\\\ndose\\\\n22\\\\n(0.91-\\\\n1.36)\\\\n(0.88-\\\\n1.22)\\\\n(0.45-\\\\n1.23)\\\\ncalcium carbonate\\\\nantacid\\\\n3000 mg single\\\\ndose given with\\\\nraltegravir\\\\n400 mg twice\\\\ndaily\\\\n24\\\\n0.48 \\\\n(0.36,\\\\n0.63)\\\\n0.45 \\\\n(0.35,\\\\n0.57)\\\\n0.68 \\\\n(0.53,\\\\n0.87)\\\\nefavirenz\\\\n600 mg daily\\\\n400 mg single\\\\ndose\\\\n9\\\\n0.64\\\\n(0.41,\\\\n0.98)\\\\n0.64\\\\n(0.52,\\\\n0.80)\\\\n0.79\\\\n(0.49,\\\\n1.28)\\\\netravirine\\\\n200 mg twice\\\\ndaily\\\\n400 mg twice\\\\ndaily\\\\n19\\\\n0.89\\\\n(0.68,\\\\n1.15)\\\\n0.90\\\\n(0.68,\\\\n1.18)\\\\n0.66\\\\n(0.34,\\\\n1.26)\\\\nomeprazole\\\\n20 mg daily\\\\n400 mg single\\\\ndose\\\\n14 \\\\n(10\\\\nf...\",\"Raltegravir at concentrations of 31 \\\\u00b1 20 nM resulted in 95% inhibition (EC \\\\n) of viral\\\\nspread (relative to an untreated virus-infected culture) in human T-lymphoid cell cultures\\\\ninfected with the cell-line adapted HIV-1 variant H9IIIB. In addition, 5 clinical isolates of\\\\nHIV-1 subtype B had EC \\\\n values ranging from 9 to 19 nM in cultures of mitogen-\\\\nactivated human peripheral blood mononuclear cells. In a single-cycle infection assay,\\\\nraltegravir inhibited infection of 23 HIV-1 isolates represen...\",\"dolutegravir.\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nCarcinogenicity studies of raltegravir in mice did not show any carcinogenic potential. At\\\\nthe highest dose levels, 400 mg/kg/day in females and 250 mg/kg/day in males, systemic\\\\nexposure was 1.8-fold (females) or 1.2-fold (males) greater than the AUC (54 \\\\u00b5M\\\\u2219hr) at\\\\nthe 400-mg twice daily human dose. Treatment-related squamous cell carcinoma of\\\\nnose/nasopharynx was observed in female rats dosed with 6...\",\"Protocol 021\\\\n400 mg Twice\\\\nDaily\\\\n600 mg At\\\\nBedtime\\\\n(N = 281)\\\\n(N = 282)\\\\nGender\\\\n  Male\\\\n81%\\\\n82%\\\\n  Female\\\\n19%\\\\n18%\\\\nRace\\\\n  White\\\\n41%\\\\n44%\\\\n  Black\\\\n12%\\\\n8%\\\\n  Asian\\\\n13%\\\\n11%\\\\n  Hispanic\\\\n21%\\\\n24%\\\\n  Native American\\\\n&lt;1%\\\\n&lt;1%\\\\n  Multiracial\\\\n12%\\\\n13%\\\\nRegion\\\\n  Latin America\\\\n35%\\\\n34%\\\\n  Southeast Asia\\\\n12%\\\\n10%\\\\n  North America\\\\n29%\\\\n32%\\\\n  EU/Australia\\\\n23%\\\\n23%\\\\nAge (years)\\\\n  18-64\\\\n99%\\\\n99%\\\\n  \\\\u226565\\\\n1%\\\\n1%\\\\n  Mean (SD)\\\\n38 (9)\\\\n37 (10)\\\\n  Median (min, max)\\\\n37 (19 to 67)\\\\n36 (19 to 71)\\\\nCD4+ Cell Count (cells/microL)\\\\n  Mean (SD)\\\\n219 (124)\\\\n2...\",\"Notes: \\\\nISENTRESS and Efavirenz were administered with emtricitabine (+) tenofovir \\\\nN = Number of subjects in each group.\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n  Hepatitis B or C Positive \\\\n6%\\\\n6%\\\\nWeek 240 outcomes from Protocol 021 are shown in Table 12.\\\\nTable 12: Virologic Outcomes of Randomized Treatment\\\\nof Protocol 021 at 240 Weeks\\\\nISENTRESS\\\\n400 mg \\\\nTwice\\\\nDaily \\\\n(N = 281)\\\\nEfavirenz \\\\n600 mg \\\\nAt\\\\nBedtime \\\\n(N = 282)\\\\nDifference \\\\n(ISENTRESS \\\\u2013\\\\nEfavirenz) (CI)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with\\\\nHIV-1 RNA less\\\\nthan 50\\\\ncopies/mL\\\\n66%\\\\n60%\\\\n6.6% \\\\n(-1.4%...\",\"14.2 Treatment-Experienced Adult Subjects\\\\nBENCHMRK 1 and BENCHMRK 2 are Phase 3 studies to evaluate the safety and\\\\nantiretroviral activity of ISENTRESS 400 mg twice daily in combination with an optimized\\\\nbackground therapy (OBT), versus OBT alone, in HIV-1-infected subjects, 16 years or\\\\nolder, with documented resistance to at least 1 drug in each of 3 classes (NNRTIs,\\\\nNRTIs, PIs) of antiretroviral therapies. Randomization was stratified by degree of\\\\nresistance to PI (1PI vs. &gt;1PI) and the use of...\",\"*\\\\nvirus\\\\n83%\\\\n84%\\\\nHepatitis B virus only\\\\n8%\\\\n3%\\\\nHepatitis C virus only\\\\n8%\\\\n12%\\\\nCo-infection of\\\\nHepatitis B and C\\\\nvirus\\\\n1%\\\\n1%\\\\nStratum\\\\nEnfuvirtide in OBT\\\\n38%\\\\n38%\\\\nResistant to \\\\u22652 PI\\\\n97%\\\\n95%\\\\nTable 14 compares the characteristics of optimized background therapy at baseline in\\\\nthe group receiving ISENTRESS 400 mg twice daily and subjects in the control group.\\\\nTable 14: Characteristics of Optimized Background\\\\nTherapy at Baseline\\\\nRandomized Studies \\\\nProtocol 018 and 019\\\\nISENTRESS\\\\n400 mg Twice\\\\nDaily + OBT\\\\nPl...\",\"Week 96 outcomes for the 699 subjects randomized and treated with the\\\\nrecommended dose of ISENTRESS 400 mg twice daily or placebo in the pooled\\\\nBENCHMRK 1 and 2 studies are shown in Table 15.\\\\nTable 15: Virologic Outcomes of Randomized Treatment\\\\nof Protocols 018 and 019 at 96 Weeks (Pooled Analysis)\\\\nISENTRESS \\\\n400 mg Twice\\\\nDaily + OBT \\\\n(N = 462)\\\\nPlacebo + OBT \\\\n(N = 237)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with HIV-1\\\\nRNA less than 50\\\\ncopies/mL\\\\n55%\\\\n27%\\\\nVirologic Failure \\\\n35%\\\\n66%\\\\nNo virologic data at\\\\nWeek 96 Window\\\\nReas...\",\"&lt;50 copies/mL \\\\nAt Week 96\\\\nn\\\\nISENTRESS \\\\n400 mg \\\\nTwice Daily +\\\\nOBT \\\\n(N = 462) \\\\nn\\\\nPlacebo +\\\\nOBT \\\\n(N = 237)\\\\n*\\\\nPhenotypic Sensitivity Score (PSS) \\\\n0\\\\n67\\\\n43\\\\n43\\\\n5\\\\n1\\\\n144\\\\n58\\\\n71\\\\n23\\\\n2\\\\n142\\\\n61\\\\n66\\\\n32\\\\n3 or more\\\\n85\\\\n48\\\\n48\\\\n42\\\\nGenotypic Sensitivity Score (GSS) \\\\n0\\\\n116\\\\n39\\\\n65\\\\n5\\\\n1\\\\n177\\\\n62\\\\n95\\\\n26\\\\n2\\\\n111\\\\n61\\\\n49\\\\n53\\\\n3 or more\\\\n51\\\\n49\\\\n23\\\\n35\\\\nSwitch of Suppressed Subjects from Lopinavir (+) Ritonavir to Raltegravir\\\\nThe SWITCHMRK 1 &amp; 2 Phase 3 studies evaluated HIV-1 infected subjects receiving\\\\nsuppressive therapy (HIV-1 RNA &lt;50 cop...\",\"children. This study enrolled 126 treatment experienced children and adolescents 2 to\\\\n18 years of age. Subjects were stratified by age, enrolling adolescents first and then\\\\nsuccessively younger children. Subjects were enrolled into cohorts according to age and\\\\nreceived the following formulations: Cohort I (12 to less than 18 years old), 400 mg film-\\\\ncoated tablet; Cohort IIa (6 to less than 12 years old), 400 mg film-coated tablet; Cohort\\\\nIIb (6 to less than 12 years old), chewable tablet; Cohor...\",\"copies/mL. The mean CD4 count (percent) increase from baseline to Week 48 was 492\\\\ncells/mm \\\\n(7.8%).\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nISENTRESS tablets 400 mg are pink, oval-shaped, film-coated tablets with \\\\\"227\\\\\" on one\\\\nside. They are supplied as follows:\\\\nNDC\\\\n 68071-2113-6 \\\\nbottles of 6\\\\nStorage and Handling\\\\n400 mg Film-coated Tablets, Chewable Tablets and For Oral Suspension\\\\nStore at 20-25\\\\u00b0C (68-77\\\\u00b0F); excursions permitted to 15-30\\\\u00b0C (59-86\\\\u00b0F). See USP\\\\nControlled Room Temperature.\\\\nChewable Ta...\",\"General Dosing Instructions\\\\nInstruct patients that if they miss a dose of ISENTRESS, they should take it as soon as\\\\nthey remember. If they do not remember until it is time for the next dose, instruct them\\\\nto skip the missed dose and go back to the regular schedule. Instruct patients not to\\\\ndouble their next dose or take more than the prescribed dose.\\\\nFilm-Coated Tablets and Chewable Tablets\\\\nInform patients that the chewable tablet forms can be chewed or swallowed whole, but\\\\nthe film-coated table...\",\"Whitehouse Station, NJ 08889, USA\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nAll rights reserved.\\\\nuspi-mk0518-mf-1502r030\\\\nPatient Information\\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfilm-coated tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nchewable tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfor oral suspension\\\\nRead this Patient Information before you start taking I...\",\"Ask your doctor if you have any questions on how to prevent passing HIV to other\\\\npeople.\\\\nWhat should I tell my doctor before taking ISENTRESS?\\\\nBefore you take ISENTRESS, tell your doctor if you:\\\\nhave liver problems\\\\nhave a history of a muscle disorder called rhabdomyolysis or myopathy\\\\nhave increased levels of creatine kinase in your blood\\\\nhave phenylketonuria (PKU). ISENTRESS chewable tablets contain phenylalanine as\\\\npart of the artificial sweetener, aspartame. The artificial sweetener may be har...\",\"is time for your next dose, skip the missed dose and go back to your regular\\\\nschedule. Do not double your next dose or take more ISENTRESS than prescribed.\\\\nIf you take too much ISENTRESS, call your doctor or go to the nearest hospital\\\\nemergency room right away.\\\\nWhat are the possible side effects of ISENTRESS?\\\\nISENTRESS can cause serious side effects including:\\\\nSerious skin reactions and allergic reactions. \\\\nSome people who take\\\\nISENTRESS develop serious skin reactions and allergic reactions that...\",\"kidney stones\\\\nindigestion or stomach area pain\\\\nvomiting\\\\nsuicidal thoughts and actions\\\\nweakness\\\\nTell your doctor right away if you get unexplained muscle pain, tenderness, or weakness\\\\nwhile taking ISENTRESS. These may be signs of a rare serious muscle problem that can\\\\nlead to kidney problems.\\\\nTell your doctor if you have any side effect that bothers you or that does not go away.\\\\nThese are not all the possible side effects of ISENTRESS. For more information, ask your\\\\ndoctor or pharmacist.\\\\nCall you...\",\"Inactive ingredients:\\\\n calcium phosphate dibasic anhydrous, hypromellose 2208,\\\\nlactose monohydrate, magnesium stearate, microcrystalline cellulose, poloxamer 407\\\\n(contains 0.01% butylated hydroxytoluene as antioxidant), sodium stearyl fumarate.\\\\nThe film coating contains:\\\\n black iron oxide, polyethylene glycol 3350, polyvinyl\\\\nalcohol, red iron oxide, talc and titanium dioxide.\\\\nISENTRESS chewable tablets:\\\\nActive ingredient: \\\\nraltegravir\\\\nInactive ingredients:\\\\n ammonium hydroxide, crospovidone, ethy...\",\"more information about ISENTRESS.\\\\nYour doctor will decide the right dose based on your child&#x27;s weight.\\\\nAsk your doctor or pharmacist if you have any questions about how to mix or give\\\\nISENTRESS for oral suspension to your child.\\\\nEach ISENTRESS for oral suspension kit contains the following supplies (see\\\\nFigure A\\\\n):\\\\n2 reusable mixing cups with attached lids\\\\n2 reusable 5 mL dosing syringes\\\\n60 foil packets containing ISENTRESS for oral suspension\\\\nFor each dose of ISENTRESS for oral suspension you w...\",\"Step 2. \\\\nFill the dosing syringe. Start with the plunger pushed all the way inside the\\\\nbarrel of the syringe. Insert the tip of the syringe into the water and pull back on the\\\\nplunger to the 5 mL marking on the barrel of the syringe (see \\\\nFigure C\\\\n).\\\\nStep 3. \\\\nPour out remaining water from mixing cup (see \\\\nFigure D\\\\n).\",\"Step 4. \\\\nAdd the 5 mL of water from the dosing syringe back into the mixing cup by\\\\npressing down on the plunger (see \\\\nFigure E\\\\n).\\\\nStep 5. \\\\nOpen 1 foil packet. There is a notch that you can use to tear open the foil\\\\npacket, or you may use scissors to cut along the dotted line. Pour entire contents into\\\\nmixing cup (see \\\\nFigure F\\\\n).\",\"Step 6. \\\\nClose the attached lid to seal the mixing cup (see \\\\nFigure G\\\\n). It will snap shut.\\\\nStep 7. \\\\nSwirl the mixing cup to mix using a gentle circular motion for 30-60 seconds\\\\n(see \\\\nFigure H\\\\n). \\\\nDo not\\\\n turn the mixing cup upside down. The liquid will be cloudy.\\\\nStep 8. \\\\nOpen the mixing cup. Put the tip of the syringe into the liquid and \\\\npull back\\\\nthe plunger to the mL marking that matches your child&#x27;s prescribed dose\\\\n(see \\\\nFigure I\\\\n). Your child&#x27;s dose may be different from the one shown in ...\",\"How should I give a dose of ISENTRESS for oral suspension?\\\\nStep 9.\\\\n Place the tip of the dosing syringe in your child&#x27;s mouth and turn it toward\\\\neither cheek. Gently push down on the plunger to give the medicine (see \\\\nFigure J\\\\n). Give\\\\nthe dose of ISENTRESS oral suspension to your child within 30 minutes of mixing. If you\\\\nare not able to give your child&#x27;s dose within 30 minutes of mixing, pour the unused\\\\nmedicine into the trash. You will need to mix a new dose.\\\\nHow should I dispose of leftover IS...\",\"Step 11. \\\\nRemove plunger from the barrel of the dosing syringe. Hand wash the dosing\\\\nsyringe and mixing cup with warm water and dish soap. Rinse with water and air dry\\\\n(see \\\\nFigure L\\\\n).\\\\nHow should I store ISENTRESS for oral suspension?\\\\nStore ISENTRESS for oral suspension at room temperature between 68\\\\u00b0F to 77\\\\u00b0F\\\\n(20\\\\u00b0C to 25\\\\u00b0C).\\\\nStore in the original container. Do not open the foil packets until ready for use.\\\\nKeep ISENTRESS for oral suspension and all medicines out of the reach of\\\\nchildren.\\\\nFor m...\",\"Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nWhitehouse Station, NJ 08889, USA\\\\nIssued December 2013\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2013 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc. \\\\nAll rights reserved.\\\\nifu-mk0518-mf-1312r000\\\\nISENTRESS  \\\\nraltegravir tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION\\\\nDRUG\\\\nItem Code\\\\n(Source)\\\\nNDC:68071-2113(NDC:0006-\\\\n0227)\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredi...\",\"NuCare Pharmaceuticals,Inc.\\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLOXAMER 407\\\\n (UNII: TUF2IVW3M2)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYVINYL ALCOHOL\\\\n (UNII: 532B59J990)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)\\\\n \\\\nSODIUM STEARYL FUMARATE\\\\n (UNII: 7CV7WJK4UI)\\\\n \\\\nTALC\\\\n (UNII: 7SEV7J4R1U)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\npink (pink)\\\\nScore\\\\nno score\\\\nShape\\\\nOVAL (oval-shaped)\\\\nSize\\\\n16mm\\\\nFlavor\\\\nImprint Code\\\\n227\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem C...\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#98df8a\",\"#999\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ffbb78\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\"],\"shape\":[155],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3261\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3262\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3257\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3258\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3259\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p3228\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p3243\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p3244\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p3245\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p3246\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p3247\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p3252\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p3253\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3238\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3239\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3240\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3241\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3233\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3234\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3235\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3236\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3237\",\"attributes\":{\"axis\":{\"id\":\"p3233\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3242\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p3238\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p3263\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3264\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Drug Interactions\"},\"renderers\":[{\"id\":\"p3260\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3265\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Therapy Side Effects\"},\"renderers\":[{\"id\":\"p3260\"}],\"index\":10}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3266\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Drug Interactions\"},\"renderers\":[{\"id\":\"p3260\"}],\"index\":29}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3267\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"HIV-1 PrEP Safety\"},\"renderers\":[{\"id\":\"p3260\"}],\"index\":52}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3268\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Medication Injection Preparation\"},\"renderers\":[{\"id\":\"p3260\"}],\"index\":58}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3269\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p3260\"}],\"index\":7}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3270\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Raltegravir Side Effects\"},\"renderers\":[{\"id\":\"p3260\"}],\"index\":108}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p3339\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p3276\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p3285\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p3286\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3287\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3288\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p3283\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3315\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3272\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3273\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3274\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"8hy7v8DvrcA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"lI3LwBPH+cA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"correctness\",[true,true]],[\"questions\",[\"What percentage of pediatric subjects experienced a Grade 3 or 4 rash when compared to adults in the study?\",\"What was the hazard ratio (with 95% confidence interval) for incident HIV-1 infections among participants who received APRETUDE compared to those who received TRUVADA, based on the extended retrospective virologic testing results?\"]],[\"agent_answer\",[\"Based on the provided context from **doc_0.pdf**, the comparative incidence of **Grade 3 or 4 rash** in pediatric subjects versus adults is as follows:  \\\\n\\\\n- **Pediatric subjects**: **3% (6/182)** experienced Grade 3 or 4 rash.  \\\\n- **Adults**: **0.9%** experienced Grade 3 or 4 rash.  \\\\n\\\\n### Key Points:  \\\\n1. The pediatric group had a **higher severity of rash** (Grade 3/4) compared to adults.  \\\\n2. Overall rash incidence (any grade) was also higher in pediatric subjects (32% vs. 26% in adults).  \\\\n\\\\nThis data is specific to **Atripla (efavirenz/emtricitabine/tenofovir DF)** and aligns with warnings in the prescribing information. No contradictions or additional relevant data were found in the other provided document (doc_2.pdf).  \\\\n\\\\nLet me know if you\\\\u2019d like further details!\",\"Based on the extended retrospective virologic testing results from the provided documents, here are the hazard ratios (HR) with 95% confidence intervals (CI) for incident HIV-1 infections comparing APRETUDE (cabotegravir) to TRUVADA:\\\\n\\\\n1. **HPTN 083 Study** (Page 26 / 27):  \\\\n   - **HR (95% CI): 0.31 (0.16, 0.58)**  \\\\n   - Superiority *p*-value: **0.0003**  \\\\n   - APRETUDE group: 12 HIV-1 infections (incidence rate: 0.37 per 100 person-years).  \\\\n   - TRUVADA group: 39 HIV-1 infections (incidence rate: 1.22 per 100 person-years).  \\\\n\\\\n2. **HPTN 084 Study** (Page 29 / 30):  \\\\n   - **HR (95% CI): 0.10 (0.04, 0.27)**  \\\\n   - *p*-value: **&lt;0.0001**  \\\\n   - APRETUDE group: 3 HIV-1 infections (incidence rate: 0.15 per 100 person-years).  \\\\n   - TRUVADA group: 36 HIV-1 infections (incidence rate: 1.85 per 100 person-years).  \\\\n\\\\n### Interpretation:  \\\\n- Both studies demonstrated a statistically significant reduction in HIV-1 infection risk with APRETUDE compared to TRUVADA.  \\\\n- The narrower confidence intervals in HPTN 083 suggest greater precision in that estimate.  \\\\n- The updated HRs account for reclassification of prevalent infections (1 in each study initially attributed to APRETUDE).  \\\\n\\\\nLet me know if you\\\\u2019d like further analysis of the clinical implications!\"]],[\"reference_answer\",[\"In the study, 3% (6/182) of pediatric subjects experienced a Grade 3 or 4 rash, while only 0.9% of adults reported the same severity of rash.\",\"The hazard ratio for incident HIV-1 infections between participants receiving APRETUDE and TRUVADA was 0.10 (with a 95% CI of 0.04, 0.27), indicating a lower rate of infections in the APRETUDE group.\"]],[\"id\",[12,81]],[\"content\",[\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\"]],[\"color\",[\"#0a980a\",\"#0a980a\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3316\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3317\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3312\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3313\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3314\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3329\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3320\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3321\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3322\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3330\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3331\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3326\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3327\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3328\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p3284\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p3299\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p3300\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p3301\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p3302\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p3307\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p3308\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p3275\",\"attributes\":{\"renderers\":[{\"id\":\"p3315\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3294\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3295\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3296\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3297\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3289\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3290\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3291\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3292\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3293\",\"attributes\":{\"axis\":{\"id\":\"p3289\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3298\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p3294\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p3318\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3319\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p3315\"}],\"index\":0}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p3335\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3332\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3333\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3334\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"Xu3LwBlQ+8DXmYLA8rhBwBOkIsAvK9m/\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"VJP3wGZewMATu1LALg61wL8ZAsE6B9fA\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"2af4d445-d9ff-440d-a58a-f6c16e4734b3\",\"roots\":{\"p3340\":\"cf868099-bcb6-4191-979c-6339cb874630\"},\"root_ids\":[\"p3340\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"cf868099-bcb6-4191-979c-6339cb874630\" data-root-id=\"p3340\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x1f589699910>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_chain_step_back, testset=testset, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "85523c5b",
   "metadata": {},
   "source": [
    "#### HyDE"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 111,
   "id": "b31d21ef",
   "metadata": {},
   "outputs": [],
   "source": [
    "hyde_template = \"\"\"Please write a scientific paper passage to answer the question\n",
    "Question: {question}\n",
    "Passage:\"\"\"\n",
    "prompt_hyde = ChatPromptTemplate.from_template(hyde_template)\n",
    "\n",
    "generate_docs_for_retrieval = (\n",
    "    prompt_hyde | call_asi_one | StrOutputParser()\n",
    ")\n",
    "\n",
    "chain_hyde = (\n",
    "    prompt_rag\n",
    "    | call_asi_one\n",
    "    | StrOutputParser()\n",
    ")\n",
    "\n",
    "def answer_fn_chain_hyde(question):\n",
    "    pseudo_doc = generate_docs_for_retrieval.invoke({\"question\": question})\n",
    "    \n",
    "    retrieved_docs = retriever.invoke(pseudo_doc)\n",
    "    \n",
    "    return chain_hyde.invoke({\n",
    "        \"context\": retrieved_docs,\n",
    "        \"question\": question\n",
    "    })"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 112,
   "id": "ee27687b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "3abd94d56bd5446f931ab74228fbdbe7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Asking questions to the agent:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "aea739edfd214c72a118bc4fb6faffb0",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "CorrectnessMetric evaluation:   0%|          | 0/2 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "    <style>\n",
       "        .bk-notebook-logo {\n",
       "            display: block;\n",
       "            width: 20px;\n",
       "            height: 20px;\n",
       "            background-image: url(data:image/png;base64,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);\n",
       "        }\n",
       "    </style>\n",
       "    <div>\n",
       "        <a href=\"https://bokeh.org\" target=\"_blank\" class=\"bk-notebook-logo\"></a>\n",
       "        <span id=\"b24a6067-13ed-4b29-a0f1-9c37dac00d47\">Loading BokehJS ...</span>\n",
       "    </div>\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/javascript": "'use strict';\n(function(root) {\n  function now() {\n    return new Date();\n  }\n\n  const force = true;\n\n  if (typeof root._bokeh_onload_callbacks === \"undefined\" || force === true) {\n    root._bokeh_onload_callbacks = [];\n    root._bokeh_is_loading = undefined;\n  }\n\nconst JS_MIME_TYPE = 'application/javascript';\n  const HTML_MIME_TYPE = 'text/html';\n  const EXEC_MIME_TYPE = 'application/vnd.bokehjs_exec.v0+json';\n  const CLASS_NAME = 'output_bokeh rendered_html';\n\n  /**\n   * Render data to the DOM node\n   */\n  function render(props, node) {\n    const script = document.createElement(\"script\");\n    node.appendChild(script);\n  }\n\n  /**\n   * Handle when an output is cleared or removed\n   */\n  function handleClearOutput(event, handle) {\n    function drop(id) {\n      const view = Bokeh.index.get_by_id(id)\n      if (view != null) {\n        view.model.document.clear()\n        Bokeh.index.delete(view)\n      }\n    }\n\n    const cell = handle.cell;\n\n    const id = cell.output_area._bokeh_element_id;\n    const server_id = cell.output_area._bokeh_server_id;\n\n    // Clean up Bokeh references\n    if (id != null) {\n      drop(id)\n    }\n\n    if (server_id !== undefined) {\n      // Clean up Bokeh references\n      const cmd_clean = \"from bokeh.io.state import curstate; print(curstate().uuid_to_server['\" + server_id + \"'].get_sessions()[0].document.roots[0]._id)\";\n      cell.notebook.kernel.execute(cmd_clean, {\n        iopub: {\n          output: function(msg) {\n            const id = msg.content.text.trim()\n            drop(id)\n          }\n        }\n      });\n      // Destroy server and session\n      const cmd_destroy = \"import bokeh.io.notebook as ion; ion.destroy_server('\" + server_id + \"')\";\n      cell.notebook.kernel.execute(cmd_destroy);\n    }\n  }\n\n  /**\n   * Handle when a new output is added\n   */\n  function handleAddOutput(event, handle) {\n    const output_area = handle.output_area;\n    const output = handle.output;\n\n    // limit handleAddOutput to display_data with EXEC_MIME_TYPE content only\n    if ((output.output_type != \"display_data\") || (!Object.prototype.hasOwnProperty.call(output.data, EXEC_MIME_TYPE))) {\n      return\n    }\n\n    const toinsert = output_area.element.find(\".\" + CLASS_NAME.split(' ')[0]);\n\n    if (output.metadata[EXEC_MIME_TYPE][\"id\"] !== undefined) {\n      toinsert[toinsert.length - 1].firstChild.textContent = output.data[JS_MIME_TYPE];\n      // store reference to embed id on output_area\n      output_area._bokeh_element_id = output.metadata[EXEC_MIME_TYPE][\"id\"];\n    }\n    if (output.metadata[EXEC_MIME_TYPE][\"server_id\"] !== undefined) {\n      const bk_div = document.createElement(\"div\");\n      bk_div.innerHTML = output.data[HTML_MIME_TYPE];\n      const script_attrs = bk_div.children[0].attributes;\n      for (let i = 0; i < script_attrs.length; i++) {\n        toinsert[toinsert.length - 1].firstChild.setAttribute(script_attrs[i].name, script_attrs[i].value);\n        toinsert[toinsert.length - 1].firstChild.textContent = bk_div.children[0].textContent\n      }\n      // store reference to server id on output_area\n      output_area._bokeh_server_id = output.metadata[EXEC_MIME_TYPE][\"server_id\"];\n    }\n  }\n\n  function register_renderer(events, OutputArea) {\n\n    function append_mime(data, metadata, element) {\n      // create a DOM node to render to\n      const toinsert = this.create_output_subarea(\n        metadata,\n        CLASS_NAME,\n        EXEC_MIME_TYPE\n      );\n      this.keyboard_manager.register_events(toinsert);\n      // Render to node\n      const props = {data: data, metadata: metadata[EXEC_MIME_TYPE]};\n      render(props, toinsert[toinsert.length - 1]);\n      element.append(toinsert);\n      return toinsert\n    }\n\n    /* Handle when an output is cleared or removed */\n    events.on('clear_output.CodeCell', handleClearOutput);\n    events.on('delete.Cell', handleClearOutput);\n\n    /* Handle when a new output is added */\n    events.on('output_added.OutputArea', handleAddOutput);\n\n    /**\n     * Register the mime type and append_mime function with output_area\n     */\n    OutputArea.prototype.register_mime_type(EXEC_MIME_TYPE, append_mime, {\n      /* Is output safe? */\n      safe: true,\n      /* Index of renderer in `output_area.display_order` */\n      index: 0\n    });\n  }\n\n  // register the mime type if in Jupyter Notebook environment and previously unregistered\n  if (root.Jupyter !== undefined) {\n    const events = require('base/js/events');\n    const OutputArea = require('notebook/js/outputarea').OutputArea;\n\n    if (OutputArea.prototype.mime_types().indexOf(EXEC_MIME_TYPE) == -1) {\n      register_renderer(events, OutputArea);\n    }\n  }\n  if (typeof (root._bokeh_timeout) === \"undefined\" || force === true) {\n    root._bokeh_timeout = Date.now() + 5000;\n    root._bokeh_failed_load = false;\n  }\n\n  const NB_LOAD_WARNING = {'data': {'text/html':\n     \"<div style='background-color: #fdd'>\\n\"+\n     \"<p>\\n\"+\n     \"BokehJS does not appear to have successfully loaded. If loading BokehJS from CDN, this \\n\"+\n     \"may be due to a slow or bad network connection. Possible fixes:\\n\"+\n     \"</p>\\n\"+\n     \"<ul>\\n\"+\n     \"<li>re-rerun `output_notebook()` to attempt to load from CDN again, or</li>\\n\"+\n     \"<li>use INLINE resources instead, as so:</li>\\n\"+\n     \"</ul>\\n\"+\n     \"<code>\\n\"+\n     \"from bokeh.resources import INLINE\\n\"+\n     \"output_notebook(resources=INLINE)\\n\"+\n     \"</code>\\n\"+\n     \"</div>\"}};\n\n  function display_loaded(error = null) {\n    const el = document.getElementById(\"b24a6067-13ed-4b29-a0f1-9c37dac00d47\");\n    if (el != null) {\n      const html = (() => {\n        if (typeof root.Bokeh === \"undefined\") {\n          if (error == null) {\n            return \"BokehJS is loading ...\";\n          } else {\n            return \"BokehJS failed to load.\";\n          }\n        } else {\n          const prefix = `BokehJS ${root.Bokeh.version}`;\n          if (error == null) {\n            return `${prefix} successfully loaded.`;\n          } else {\n            return `${prefix} <b>encountered errors</b> while loading and may not function as expected.`;\n          }\n        }\n      })();\n      el.innerHTML = html;\n\n      if (error != null) {\n        const wrapper = document.createElement(\"div\");\n        wrapper.style.overflow = \"auto\";\n        wrapper.style.height = \"5em\";\n        wrapper.style.resize = \"vertical\";\n        const content = document.createElement(\"div\");\n        content.style.fontFamily = \"monospace\";\n        content.style.whiteSpace = \"pre-wrap\";\n        content.style.backgroundColor = \"rgb(255, 221, 221)\";\n        content.textContent = error.stack ?? error.toString();\n        wrapper.append(content);\n        el.append(wrapper);\n      }\n    } else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(() => display_loaded(error), 100);\n    }\n  }\n\n  function run_callbacks() {\n    try {\n      root._bokeh_onload_callbacks.forEach(function(callback) {\n        if (callback != null)\n          callback();\n      });\n    } finally {\n      delete root._bokeh_onload_callbacks\n    }\n    console.debug(\"Bokeh: all callbacks have finished\");\n  }\n\n  function load_libs(css_urls, js_urls, callback) {\n    if (css_urls == null) css_urls = [];\n    if (js_urls == null) js_urls = [];\n\n    root._bokeh_onload_callbacks.push(callback);\n    if (root._bokeh_is_loading > 0) {\n      console.debug(\"Bokeh: BokehJS is being loaded, scheduling callback at\", now());\n      return null;\n    }\n    if (js_urls == null || js_urls.length === 0) {\n      run_callbacks();\n      return null;\n    }\n    console.debug(\"Bokeh: BokehJS not loaded, scheduling load and callback at\", now());\n    root._bokeh_is_loading = css_urls.length + js_urls.length;\n\n    function on_load() {\n      root._bokeh_is_loading--;\n      if (root._bokeh_is_loading === 0) {\n        console.debug(\"Bokeh: all BokehJS libraries/stylesheets loaded\");\n        run_callbacks()\n      }\n    }\n\n    function on_error(url) {\n      console.error(\"failed to load \" + url);\n    }\n\n    for (let i = 0; i < css_urls.length; i++) {\n      const url = css_urls[i];\n      const element = document.createElement(\"link\");\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.rel = \"stylesheet\";\n      element.type = \"text/css\";\n      element.href = url;\n      console.debug(\"Bokeh: injecting link tag for BokehJS stylesheet: \", url);\n      document.body.appendChild(element);\n    }\n\n    for (let i = 0; i < js_urls.length; i++) {\n      const url = js_urls[i];\n      const element = document.createElement('script');\n      element.onload = on_load;\n      element.onerror = on_error.bind(null, url);\n      element.async = false;\n      element.src = url;\n      console.debug(\"Bokeh: injecting script tag for BokehJS library: \", url);\n      document.head.appendChild(element);\n    }\n  };\n\n  function inject_raw_css(css) {\n    const element = document.createElement(\"style\");\n    element.appendChild(document.createTextNode(css));\n    document.body.appendChild(element);\n  }\n\n  const js_urls = [\"https://cdn.bokeh.org/bokeh/release/bokeh-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-widgets-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-tables-3.4.3.min.js\", \"https://cdn.bokeh.org/bokeh/release/bokeh-mathjax-3.4.3.min.js\"];\n  const css_urls = [];\n\n  const inline_js = [    function(Bokeh) {\n      Bokeh.set_log_level(\"info\");\n    },\nfunction(Bokeh) {\n    }\n  ];\n\n  function run_inline_js() {\n    if (root.Bokeh !== undefined || force === true) {\n      try {\n            for (let i = 0; i < inline_js.length; i++) {\n      inline_js[i].call(root, root.Bokeh);\n    }\n\n      } catch (error) {display_loaded(error);throw error;\n      }if (force === true) {\n        display_loaded();\n      }} else if (Date.now() < root._bokeh_timeout) {\n      setTimeout(run_inline_js, 100);\n    } else if (!root._bokeh_failed_load) {\n      console.log(\"Bokeh: BokehJS failed to load within specified timeout.\");\n      root._bokeh_failed_load = true;\n    } else if (force !== true) {\n      const cell = $(document.getElementById(\"b24a6067-13ed-4b29-a0f1-9c37dac00d47\")).parents('.cell').data().cell;\n      cell.output_area.append_execute_result(NB_LOAD_WARNING)\n    }\n  }\n\n  if (root._bokeh_is_loading === 0) {\n    console.debug(\"Bokeh: BokehJS loaded, going straight to plotting\");\n    run_inline_js();\n  } else {\n    load_libs(css_urls, js_urls, function() {\n      console.debug(\"Bokeh: BokehJS plotting callback run at\", now());\n      run_inline_js();\n    });\n  }\n}(window));",
      "application/vnd.bokehjs_load.v0+json": ""
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<!DOCTYPE html>\n",
       "\n",
       "\n",
       "<style>\n",
       "    body{\n",
       "  background: #18181B;\n",
       "}\n",
       "\n",
       ".main{\n",
       "  font-family: \"Noto Sans\", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, \"Helvetica Neue\", Arial, sans-serif, \"Apple Color Emoji\", \"Segoe UI Emoji\", \"Segoe UI Symbol\", \"Noto Color Emoji\";\n",
       "  color: #FDFDFD;\n",
       "}\n",
       "\n",
       "h1 {\n",
       "  font-size: 2.5rem;\n",
       "  color: white;\n",
       "}\n",
       "\n",
       "h3 {\n",
       "  font-size: 1.5rem;\n",
       "  background: #0c087c;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border: 1px solid #6b7280;}\n",
       "\n",
       ".extended-title{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#gsk-overview{\n",
       "  display:flex;\n",
       "}\n",
       "\n",
       "h4 {\n",
       "  font-size: 1rem;\n",
       "  background: #27272A;\n",
       "  padding: 10px;\n",
       "  margin: 0px;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "h2 {\n",
       "  font-size: 1.5rem;\n",
       "  margin-top: 3px;\n",
       "  color:#000000;\n",
       "}\n",
       "\n",
       ".header{\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       ".header > * {\n",
       "  margin-inline: 20px;\n",
       "}\n",
       "\n",
       ".flex-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding:10px;\n",
       "  border: 1px solid #27272A;\n",
       "}\n",
       "\n",
       ".flex-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "progress[value] {\n",
       "  --background: #6D6D6D;\n",
       "  -webkit-appearance: none;\n",
       "  -moz-appearance: none;\n",
       "  appearance: none;\n",
       "  border: none;\n",
       "  height: 4px;\n",
       "  margin: 0 10px;\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--background);\n",
       "}\n",
       "\n",
       "progress[value]::-webkit-progress-value {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "progress[value]::-moz-progress-bar {\n",
       "  border-radius: 10em;\n",
       "  background: var(--color);\n",
       "}\n",
       "\n",
       "label {\n",
       "  font-size: 20px;\n",
       "  font-weight: bold;\n",
       "  display: block;\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".tab {\n",
       "  overflow: hidden;\n",
       "  border: 1px solid #27272A;\n",
       "  background-color: #27272A;\n",
       "}\n",
       "\n",
       ".tab button {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size:1.2rem;\n",
       "}\n",
       "\n",
       ".tab div {\n",
       "  background-color: inherit;\n",
       "  float: left;\n",
       "  border: none;\n",
       "  outline: none;\n",
       "  cursor: pointer;\n",
       "  padding: 14px 16px;\n",
       "  transition: 0.3s;\n",
       "  color: #ffffff;\n",
       "  font-size: 1.2rem;\n",
       "}\n",
       "\n",
       ".tab button:hover {\n",
       "  background-color: #18181B;\n",
       "}\n",
       "\n",
       ".tab-title{\n",
       "  font-size: 1.5rem;\n",
       "  font-weight: bold;\n",
       "  margin-bottom:-5px;\n",
       "}\n",
       "\n",
       ".tab button.active {\n",
       "  background-color: #18181B;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  border-bottom: 1px solid #18181B;\n",
       "  border-left: 1px solid #6b7280;\n",
       "  border-right: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       ".tabcontent {\n",
       "  display: none;\n",
       "  padding: 6px 12px;\n",
       "  background: #18181B;\n",
       "  border: 1px solid #27272A;\n",
       "  border-top: 1px solid #6b7280;\n",
       "  margin-top: -2px;\n",
       "}\n",
       "\n",
       "#gsk-advice {\n",
       "  display: flex;\n",
       "  justify-content: center;\n",
       "}\n",
       "\n",
       "#gsk-metrics{\n",
       "  width:100%;\n",
       "}\n",
       "\n",
       "#recommendation {\n",
       "  margin-top: 20px;\n",
       "  padding: 20px;\n",
       "  border-radius: 10px;\n",
       "  background-color: #e1ce86;\n",
       "  color: #27272A;\n",
       "  width:95%;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  font-size: 12pt;\n",
       "}\n",
       "\n",
       ".separator {\n",
       "  margin: 20px 0;\n",
       "}\n",
       "\n",
       ".separator-border {\n",
       "  margin: 20px 0;\n",
       "  border-bottom: 1px solid #6b7280;\n",
       "}\n",
       "\n",
       "#gsk-rag{\n",
       "  margin: 32px 28px;\n",
       "  padding: 12px 24px;\n",
       "  background-color: #111516;\n",
       "}\n",
       "\n",
       ".section-container {\n",
       "  margin-bottom: 32px;\n",
       "}\n",
       "\n",
       "  .components-container {\n",
       "    display: flex;\n",
       "    flex-flow: row wrap;\n",
       "    align-items: flex-start;\n",
       "    gap: 0 32px;\n",
       "  }\n",
       "\n",
       "    .component-card {\n",
       "      background-color: #14191B;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "\n",
       "    .component-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #B1B1B1;\n",
       "      padding-bottom: 8px;\n",
       "    }\n",
       "\n",
       "    .component-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "    }\n",
       "      \n",
       "      .text-green {\n",
       "        color: #04B543;\n",
       "      }\n",
       "      \n",
       "      .text-orange {\n",
       "        color: #E76E0F;\n",
       "      }\n",
       "      \n",
       "      .text-red {\n",
       "        color: #EA3829;\n",
       "      }\n",
       "\n",
       "      .tooltip {\n",
       "        position: relative;\n",
       "        display: inline-block;\n",
       "      }\n",
       "\n",
       "      .tooltip .tooltiptext {\n",
       "        visibility: hidden;\n",
       "        width: 120px;\n",
       "        background-color: #464646;\n",
       "        color: #E6E6E6;\n",
       "        text-align: center;\n",
       "        border-radius: 6px;\n",
       "        position: absolute;\n",
       "        z-index: 1;\n",
       "        top: 150%;\n",
       "        left: 50%;\n",
       "        margin-left: -60px;\n",
       "        font-size: 12px;\n",
       "        padding: 12px;\n",
       "      }\n",
       "      \n",
       "      .tooltip .tooltiptext::after {\n",
       "        content: \"\";\n",
       "        position: absolute;\n",
       "        bottom: 100%;\n",
       "        left: 50%;\n",
       "        margin-left: -5px;\n",
       "        border-width: 5px;\n",
       "        border-style: solid;\n",
       "        border-color: transparent transparent black transparent;\n",
       "      }\n",
       "      \n",
       "      .tooltip:hover .tooltiptext {\n",
       "        visibility: visible;\n",
       "      }\n",
       "\n",
       "    .overall-card {\n",
       "      background-color: #026836;\n",
       "      border-radius: 16px;\n",
       "      padding: 28px 32px 32px 32px;\n",
       "      display: flex;\n",
       "      flex-flow: column;\n",
       "      align-items: center;\n",
       "      justify-content: center;\n",
       "      margin-top: 32px;\n",
       "      flex-grow: 1;\n",
       "    }\n",
       "  \n",
       "    .overall-title {\n",
       "      font-size: 12px;\n",
       "      font-weight: 500;\n",
       "      color: #E6E6E6;\n",
       "      padding: 14px 0 8px 0;\n",
       "      text-transform: uppercase;\n",
       "     }\n",
       "  \n",
       "    .overall-value {\n",
       "      font-size: 32px;\n",
       "      font-weight: 500;\n",
       "      padding-bottom: 12px;\n",
       "      color: #E6E6E6;\n",
       "    }\n",
       "\n",
       ".section-title {\n",
       "  font-size: 12px;\n",
       "  color: #B1B1B1;\n",
       "  margin-bottom: 20px;\n",
       "  text-align: left;\n",
       "  width: 100%;\n",
       "}\n",
       "\n",
       ".section-content {\n",
       "  color: #E6E6E6;\n",
       "  font-size: 20px;\n",
       "  line-height: 1.5;\n",
       "}\n",
       "\n",
       ".section-card {\n",
       "  background-color: #14191B;\n",
       "  border-radius: 16px;\n",
       "  padding: 28px 32px 32px 32px;\n",
       "  display: flex;\n",
       "  flex-flow: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       ".correctness-indicator{\n",
       "  padding: 20px;\n",
       "  border-radius: 50px;\n",
       "  font-size: 16pt;\n",
       "  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;\n",
       "  text-align: center;\n",
       "}\n",
       "\n",
       ".metric-title{\n",
       "  margin: -2px;\n",
       "  border-bottom: none;\n",
       "}\n",
       "\n",
       ".hist-row {\n",
       "  display: flex;\n",
       "  flex-direction: row;\n",
       "  padding: 10px;\n",
       "  justify-content: space-around;\n",
       "  width: 85%;\n",
       "}\n",
       "\n",
       ".hist-row>div {\n",
       "  flex: auto;\n",
       "  box-sizing: border-box;\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  justify-content: center;\n",
       "  align-items: center;\n",
       "  padding-left: 1%;\n",
       "  padding-right: 1%;\n",
       "}\n",
       "\n",
       ".tab-row{\n",
       "  display: flex;\n",
       "  flex-direction: column;\n",
       "  align-items: center;\n",
       "}\n",
       "\n",
       "#component-table{\n",
       "  width:50%;\n",
       "  margin-top: 10px;\n",
       "}\n",
       "\n",
       ".green{\n",
       "  background-color: #0a980a;\n",
       "}\n",
       "\n",
       ".orange {\n",
       "  background-color: #e5b62a;\n",
       "}\n",
       "\n",
       ".red {\n",
       "  background-color: #ba0e0e;\n",
       "}\n",
       "\n",
       ".progress-green {\n",
       "  --color: #04B543;\n",
       "}\n",
       "\n",
       ".progress-orange {\n",
       "  --color: #E76E0F;\n",
       "}\n",
       "\n",
       ".progress-red {\n",
       "  --color: #EA3829;\n",
       "}\n",
       "\n",
       ".corr-plot{\n",
       "  flex: 1;\n",
       "  padding-left: 2%;\n",
       "}\n",
       "\n",
       ".tooltip-text {\n",
       "  position: absolute;\n",
       "  display: none;\n",
       "  visibility: hidden;\n",
       "  z-index: 1;\n",
       "  top: 100%;\n",
       "  left: 0%;\n",
       "  width: 100%;\n",
       "  color: white;\n",
       "  font-size: 12px;\n",
       "  background-color: #2d3d4c;\n",
       "  border-radius: 10px;\n",
       "  padding: 10px 15px 10px 15px;\n",
       "}\n",
       "\n",
       "#fade {\n",
       "  opacity: 1;\n",
       "  transition: opacity 0.5s;\n",
       "}\n",
       "\n",
       "#delay {\n",
       "  opacity: 0;\n",
       "  transition: opacity 0.2s;\n",
       "  transition-delay: 1s;\n",
       "}\n",
       "\n",
       "td {\n",
       "  position: relative;\n",
       "}\n",
       "\n",
       "tr:hover .tooltip-text {\n",
       "  display: block;\n",
       "  visibility: visible;\n",
       "}\n",
       "\n",
       ".tr:hover #fade {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".tr:hover #delay {\n",
       "  opacity: 1;\n",
       "}\n",
       "\n",
       ".callout {\n",
       "  padding: 0.5rem 1rem 0.5rem 3rem;\n",
       "  background: #D9EDF9;\n",
       "  border: 3px solid #0088D1;\n",
       "  color: #272eb5;\n",
       "  position: relative;\n",
       "  max-width: 40rem;\n",
       "  border-radius: 10px;\n",
       "  margin-top: 10%;\n",
       "  font-size: 11pt;\n",
       "}\n",
       "\n",
       ".callout-icon {\n",
       "  content: \"\";\n",
       "\n",
       "  /* SVG via a data URI! */\n",
       "  background-size: cover;\n",
       "  width: 1.5rem;\n",
       "  height: 1.5rem;\n",
       "  display: block;\n",
       "  position: absolute;\n",
       "  left: 0.9rem;\n",
       "  top: 1.1rem;\n",
       "}\n",
       "\n",
       ".callout-icon svg{\n",
       "  fill: #016ca7;\n",
       "}\n",
       ".callout p+p {\n",
       "  margin-top: 1em;\n",
       "}\n",
       "\n",
       ".callout a {\n",
       "  color: #272eb5;\n",
       "  font-weight: bold;\n",
       "}\n",
       "\n",
       "#gsk-logo {\n",
       "  padding-top: 10px;\n",
       "}\n",
       "</style>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js\" integrity=\"sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf\" crossorigin=\"anonymous\"></script>\n",
       "<script src=\"https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js\" integrity=\"sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A\" crossorigin=\"anonymous\"></script>\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "\n",
       "<div class=\"main\">\n",
       "    <div id=\"gsk-rag\" class=\"dark:text-white dark:bg-zinc-800 rounded border border-gray-500\">\n",
       "        <div class=\"header border-b border-b-gray-500\">\n",
       "            \n",
       "                <svg xmlns=\"http://www.w3.org/2000/svg\" width=\"60\" height=\"30\" viewBox=\"0 0 30 15\" fill=\"none\" id=\"gsk-logo\">\n",
       "                    <path fill=\"#fff\" fill-rule=\"evenodd\"\n",
       "                        d=\"M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z\"\n",
       "                        clip-rule=\"evenodd\" />\n",
       "                </svg>\n",
       "            <h1>RAG Evaluation Toolkit</h1>\n",
       "        </div>\n",
       "        \n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"components-container\">\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">GENERATOR</div>\n",
       "                    <div class=\"component-value tooltip  text-orange \">\n",
       "                        50.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Generator is the LLM inside the RAG to generate the answers.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=50.0 class=\" progress-orange \">50.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">RETRIEVER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">REWRITER</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">ROUTING</div>\n",
       "                    <div class=\"component-value tooltip  text-green \">\n",
       "                        100.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The Router filters the query of the user based on his intentions (intentions detection).</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=100.0 class=\" progress-green \">100.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"component-card\">\n",
       "                    <div class=\"component-title\">KNOWLEDGE_BASE</div>\n",
       "                    <div class=\"component-value tooltip  text-red \">\n",
       "                        0.0%\n",
       "                            <span class=\"tooltiptext\" id=\"fade\">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>\n",
       "                    </div>\n",
       "                    <div class=\"component-bar\">\n",
       "                        <progress max=\"100\" value=0.0 class=\" progress-red \">0.0%</progress>\n",
       "                    </div>\n",
       "                </div>\n",
       "                \n",
       "                <div class=\"overall-card\">\n",
       "                    <div class=\"overall-title\">Overall Correctness Score</div>\n",
       "                    <div class=\"overall-value\">50%</div>\n",
       "                </div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">RECOMMENDATION</div>\n",
       "                <span class=\"section-content\">Focus on enhancing the Generator&#39;s ability to handle complex questions, particularly those related to HIV-1 PrEP Safety, as it currently lacks the sophistication to manage paraphrased or nuanced queries related to this topic. Additionally, review and potentially improve the coverage and alignment of this topic in the knowledge base.</span>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">CORRECTNESS BY TOPIC</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"cc024247-7867-4d6b-8c4f-ee0b68a09862\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p3656\",\"attributes\":{\"height\":350,\"width_policy\":\"max\",\"x_range\":{\"type\":\"object\",\"name\":\"DataRange1d\",\"id\":\"p3658\",\"attributes\":{\"start\":0}},\"y_range\":{\"type\":\"object\",\"name\":\"FactorRange\",\"id\":\"p3665\",\"attributes\":{\"factors\":[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3666\"},\"y_scale\":{\"type\":\"object\",\"name\":\"CategoricalScale\",\"id\":\"p3667\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p3663\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3685\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3653\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3654\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3655\"},\"data\":{\"type\":\"map\",\"entries\":[[\"correctness\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"AAAAAAAAWUAAAAAAAAAAAA==\"},\"shape\":[2],\"dtype\":\"float64\",\"order\":\"little\"}],[\"metadata_values\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"colors\",[\"#006837\",\"#a50026\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3686\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3687\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3682\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3683\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3684\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"#1f77b4\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"#14191B\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3694\",\"attributes\":{\"data_source\":{\"id\":\"p3653\"},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3695\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3696\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3691\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3692\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"HBar\",\"id\":\"p3693\",\"attributes\":{\"y\":{\"type\":\"field\",\"field\":\"metadata_values\"},\"height\":{\"type\":\"value\",\"value\":0.85},\"right\":{\"type\":\"field\",\"field\":\"correctness\"},\"line_color\":{\"type\":\"value\",\"value\":\"white\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"value\",\"value\":\"#78BBFA\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3704\",\"attributes\":{\"visible\":false,\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3698\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3699\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3700\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",[0]],[\"y\",[0]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3705\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3706\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p3701\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p3702\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.1,\"line_width\":2,\"line_dash\":[6]}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Line\",\"id\":\"p3703\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"line_color\":\"#EA3829\",\"line_alpha\":0.2,\"line_width\":2,\"line_dash\":[6]}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p3664\",\"attributes\":{\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p3678\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":[[\"topic\",\"@metadata_values\"],[\"Correctness\",\"@correctness{0.00}\"]]}}]}},\"toolbar_location\":null,\"left\":[{\"type\":\"object\",\"name\":\"CategoricalAxis\",\"id\":\"p3673\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"CategoricalTicker\",\"id\":\"p3674\"},\"formatter\":{\"type\":\"object\",\"name\":\"CategoricalTickFormatter\",\"id\":\"p3675\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3676\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3668\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3669\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3670\"},\"axis_label\":\"Correctness (%)\",\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3671\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3672\",\"attributes\":{\"axis\":{\"id\":\"p3668\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3677\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p3673\"},\"grid_line_color\":\"#E0E0E0\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Span\",\"id\":\"p3697\",\"attributes\":{\"location\":50.0,\"dimension\":\"height\",\"line_color\":\"#EA3829\",\"line_width\":2,\"line_dash\":[6]}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p3707\",\"attributes\":{\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3708\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Correctness on the entire Testset\"},\"renderers\":[{\"id\":\"p3704\"}]}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"cc024247-7867-4d6b-8c4f-ee0b68a09862\",\"roots\":{\"p3656\":\"b50d6afb-bf13-427b-84cf-aade3cfcf264\"},\"root_ids\":[\"p3656\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"b50d6afb-bf13-427b-84cf-aade3cfcf264\" data-root-id=\"p3656\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "                <div class=\"section-title\">KNOWLEDGE BASE OVERVIEW</div>\n",
       "                    <script type=\"text/javascript\">\n",
       "        (function() {\n",
       "  const fn = function() {\n",
       "    Bokeh.safely(function() {\n",
       "      (function(root) {\n",
       "        function embed_document(root) {\n",
       "        const docs_json = '{\"4059558e-4609-4337-ae1c-8b20cf5c60a1\":{\"version\":\"3.4.3\",\"title\":\"Bokeh Application\",\"roots\":[{\"type\":\"object\",\"name\":\"Tabs\",\"id\":\"p3587\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"tabs\":[{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p3517\",\"attributes\":{\"title\":\"Topic exploration\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p3466\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p3475\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p3476\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3477\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3478\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p3473\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3506\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3463\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3464\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3465\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Drug Interactions\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Antiretroviral Therapy Side Effects\",\"Others\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Others\",\"Others\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"HIV-1 PrEP Safety\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Raltegravir Side Effects\",\"Others\"]],[\"id\",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154]],[\"content\",[\"ATRIPLA ACCESS- efavirenz, emtricitabine, and tenofovir disoproxil\\\\nfumarate tablet, film coated \\\\n \\\\nGilead Sciences, Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ATRIPLA safely and\\\\neffectively. See full prescribing information for ATRIPLA.\\\\nATRIPLA\\\\u2122 (efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets, for oral use\\\\nGILEAD ACCESS PROGRAM\\\\nInitial U.S. Approval: 2006\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION O...\",\"WARNINGS AND PRECAUTIONS\\\\nRash: Discontinue if severe rash develops. (\\\\n5.2\\\\n, \\\\n6.1\\\\n)\\\\nHepatotoxicity: Monitor liver function tests before and during treatment in patients with underlying\\\\nhepatic disease, including hepatitis B or C coinfection, marked transaminase elevations, or who are\\\\ntaking medications associated with liver toxicity. Among reported cases of hepatic failure, a few\\\\noccurred in patients with no pre-existing hepatic disease. (\\\\n5.3\\\\n, \\\\n6.2\\\\n, \\\\n8.7\\\\n)\\\\nRisk of adverse reactions or loss of ...\",\"2.1 Testing Prior to Initiation and During Treatment with ATRIPLA\\\\n2.2 Recommended Dosage for Adults and Pediatric Patients Weighing at Least 40 kg\\\\n2.3 Not Recommended in Patients with Moderate or Severe Renal Impairment\\\\n2.4 Not Recommended in Patients with Moderate to Severe Hepatic Impairment\\\\n2.5 Dosage Adjustment with Rifampin\\\\n3 DOSAGE FORMS AND STRENGTHS\\\\n4 CONTRAINDICATIONS\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Acute Exacerbation of Hepatitis B in Patients Coinfected with HIV-1 and\\\\nHBV\\\\n5.2 Ra...\",\"16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT COUNSELING INFORMATION\\\\n*\\\\nFULL PRESCRIBING INFORMATION\\\\nWARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B\\\\nSevere acute exacerbations of hepatitis B virus (HBV) have been\\\\nreported in patients who are coinfected with HIV-1 and HBV and have\\\\ndiscontinued products containing emtricitabine (FTC) and/or tenofovir\\\\ndisoproxil fumarate (TDF), which are components of ATRIPLA.\\\\nClosely monitor hepatic function with both clinical and laboratory follow-\\\\nup f...\",\"ATRIPLA is a three-drug fixed-dose combination product containing 600 mg of efavirenz\\\\n(EFV), 200 mg of emtricitabine (FTC), and 300 mg of tenofovir disoproxil fumarate (TDF).\\\\nThe recommended dosage of ATRIPLA in \\\\nadults and pediatric patients weighing at least\\\\n40 kg\\\\n is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may\\\\nimprove the tolerability of nervous system symptoms \\\\n[see \\\\nClinical Pharmacology (12.3)\\\\n]\\\\n.\\\\n2.3 Not Recommended in Patients with Moderate or Severe Ren...\",\"closely monitored, with both clinical and laboratory follow-up for at least several months\\\\nafter stopping treatment with ATRIPLA. If appropriate, initiation of anti-hepatitis B\\\\ntherapy may be warranted, especially in patients with advanced liver disease or cirrhosis,\\\\nsince posttreatment exacerbation of hepatitis may lead to hepatic decompensation and\\\\nliver failure.\\\\n5.2 Rash\\\\nIn controlled clinical trials, 26% (266/1,008) of adult subjects treated with 600 mg EFV\\\\nexperienced new-onset skin rash co...\",\"[see \\\\nDosage and Administration (2.1)\\\\n].\\\\n Consider discontinuing ATRIPLA in patients with\\\\npersistent elevations of serum transaminases to greater than five times the upper limit\\\\nof the normal range.\\\\nDiscontinue ATRIPLA if elevation of serum transaminases is accompanied by clinical\\\\nsigns or symptoms of hepatitis or hepatic decompensation \\\\n[see \\\\nAdverse Reactions\\\\n(6.1)\\\\n].\\\\n5.4 Risk of Adverse Reactions or Loss of Virologic Response Due to Drug\\\\nInteractions\\\\nThe concomitant use of ATRIPLA and other d...\",\"discontinued or interrupted treatment because of one or more of these selected\\\\npsychiatric symptoms. There have also been occasional postmarketing reports of death\\\\nby suicide, delusions, and psychosis-like behavior, although a causal relationship to the\\\\nuse of EFV cannot be determined from these reports. Postmarketing cases of catatonia\\\\nhave also been reported and may be associated with increased EFV exposure. Patients\\\\nwith serious psychiatric adverse experiences should seek immediate medical ev...\",\"Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal\\\\ntubular injury with severe hypophosphatemia), has been reported with the use of TDF, a\\\\ncomponent of ATRIPLA \\\\n[see \\\\nAdverse Reactions (6.2)\\\\n].\\\\nPrior to initiation and during use of ATRIPLA, on a clinically appropriate schedule, assess\\\\nserum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all\\\\npatients. In patients with chronic kidney disease, also assess serum phosphorus.\\\\nATRIPLA is...\",\"considered for adult and pediatric patients who have a history of pathologic bone\\\\nfracture or other risk factors for osteoporosis or bone loss. Although the effect of\\\\nsupplementation with calcium and vitamin D was not studied, such supplementation may\\\\nbe beneficial for all patients. If bone abnormalities are suspected, then appropriate\\\\nconsultation should be obtained.\\\\nMineralization Defects\\\\nCases of osteomalacia associated with proximal renal tubulopathy, manifested as bone\\\\npain or pain in extre...\",\"enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and\\\\n\\\\\"cushingoid appearance,\\\\\" has been observed in patients receiving antiretroviral therapy,\\\\nincluding EFV. The mechanism and long-term consequences of these events are\\\\ncurrently unknown. A causal relationship has not been established.\\\\n6 ADVERSE REACTIONS\\\\nThe following adverse reactions are discussed in other sections of the labeling:\\\\nSevere Acute Exacerbations of Hepatitis B in Patients Coinfected with HIV-1 and...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nDizziness\\\\n8%\\\\n7%\\\\nUpper respiratory tract infections\\\\n8%\\\\n5%\\\\nSinusitis\\\\n8%\\\\n4%\\\\nRash Event\\\\n7%\\\\n9%\\\\nHeadache\\\\n6%\\\\n5%\\\\nInsomnia\\\\n5%\\\\n7%\\\\nAnxiety\\\\n5%\\\\n4%\\\\nNasopharyngitis\\\\n5%\\\\n3%\\\\nVomiting\\\\n2%\\\\n5%\\\\nIn Study 073, subjects with stable, virologic suppression on antiretroviral therapy and no\\\\nhistory of virologic failure were randomized to receive ATRIPLA or to stay on their\\\\nbaseline regimen. The adverse reactions observed in Study 073 were generally\\\\nconsistent with those seen in Study 934 and those seen with the individ...\",\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"subjects treated with EFV and fixed-dose zidovudine/lamivudine were hepatitis B surface\\\\nantigen or hepatitis C antibody positive. Among these coinfected subjects, one subject\\\\n(1/19) in the EFV, FTC, and TDF arm had elevations in transaminases to greater than five\\\\ntimes ULN through 144 weeks. In the fixed-dose zidovudine/lamivudine arm, two\\\\nsubjects (2/20) had elevations in transaminases to greater than five times ULN through\\\\n144 weeks. No HBV and/or HCV coinfected subject discontinued from the t...\",\"Dyspnea\\\\nSkin and Subcutaneous Tissue Disorders\\\\n \\\\nFlushing, erythema multiforme, photoallergic dermatitis, Stevens-Johnson syndrome\\\\nEmtricitabine\\\\n:\\\\n No postmarketing adverse reactions have been identified for inclusion in\\\\nthis section.\\\\nTenofovir DF:\\\\nImmune System Disorders\\\\n \\\\nAllergic reaction, including angioedema\\\\nMetabolism and Nutrition Disorders\\\\n \\\\nLactic acidosis, hypokalemia, hypophosphatemia\\\\nRespiratory, Thoracic, and Mediastinal Disorders\\\\n \\\\nDyspnea\\\\nGastrointestinal Disorders\\\\n \\\\nPancreatitis,...\",\"There is limited information available on the potential for a pharmacodynamic interaction\\\\nbetween EFV and drugs that prolong the QTc interval. QTc prolongation has been\\\\nobserved with the use of EFV \\\\n[see \\\\nClinical Pharmacology (12.2)\\\\n].\\\\n Consider alternatives to\\\\nATRIPLA when coadministered with a drug with a known risk of Torsade de Pointes.\\\\n7.2 Drugs Affecting Renal Function\\\\nFTC and tenofovir are primarily eliminated by the kidneys\\\\n[see \\\\nClinical Pharmacology\\\\n(12.3)\\\\n].\\\\n Coadministration of ATRI...\",\"the increased indinavir metabolism due to\\\\nEFV.\\\\nProtease inhibitor:\\\\n  darunavir/ritonavir\\\\n\\\\u2191 tenofovir\\\\nMonitor patients receiving ATRIPLA\\\\nconcomitantly with ritonavir-boosted\\\\ndarunavir for TDF-associated adverse\\\\nreactions. Discontinue ATRIPLA in\\\\npatients who develop TDF-associated\\\\nadverse reactions.\\\\n  lopinavir/ritonavir\\\\n\\\\u2193 lopinavir\\\\n\\\\u2191 tenofovir\\\\nDo not use once daily administration of\\\\nlopinavir/ritonavir. Dose increase of\\\\nlopinavir/ritonavir is recommended for all\\\\npatients when coadministered with ...\",\"NRTI:\\\\n  didanosine\\\\n\\\\u2191 didanosine\\\\nreceiving TDF with didanosine 400 mg\\\\ndaily. \\\\nIn patients weighing greater than 60 kg,\\\\nreduce the didanosine dose to 250 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nIn patients weighing less than 60 kg,\\\\nreduce the didanosine dose to 200 mg\\\\nwhen it is coadministered with ATRIPLA.\\\\nWhen coadministered, ATRIPLA and\\\\nVidex EC may be taken under fasted\\\\nconditions or with a light meal (less than\\\\n400 kcal, 20% fat).\\\\nNNRTI:\\\\n  Other NNRTIs\\\\n\\\\u2191 or \\\\u2193 efavirenz\\\\nand/or NNRTI\\\\nCombini...\",\"Anticoagulant:\\\\n  warfarin\\\\n\\\\u2191 or \\\\u2193 warfarin\\\\nPlasma concentrations and effects\\\\npotentially increased or decreased by\\\\nEFV.\\\\nAnticonvulsants:\\\\n  carbamazepine\\\\n\\\\u2193 carbamazepine\\\\n\\\\u2193 efavirenz\\\\nThere are insufficient data to make a\\\\ndose recommendation for ATRIPLA.\\\\nAlternative anticonvulsant treatment\\\\nshould be used.\\\\n  phenytoin\\\\n  phenobarbital\\\\n\\\\u2193 anticonvulsant\\\\n\\\\u2193 efavirenz\\\\nPotential for reduction in anticonvulsant\\\\nand/or EFV plasma levels; periodic\\\\nmonitoring of anticonvulsant plasma\\\\nlevels should be conducted...\",\"artemether/lumefantrine\\\\n  atovaquone/proquanil\\\\n\\\\u2193 dihydroartemisinin\\\\n\\\\u2193 lumefantrine\\\\n\\\\u2193 atovaquone\\\\n\\\\u2193 proguanil\\\\nrisk of QT interval prolongation \\\\n[see\\\\nWarnings and Precautions (5.4)\\\\n]\\\\n.\\\\nConcomitant administration of\\\\natovaquone/proguanil with ATRIPLA is\\\\nnot recommended.\\\\nCalcium channel\\\\nblockers:\\\\n  diltiazem\\\\n\\\\u2193 diltiazem\\\\n\\\\u2193 desacetyl\\\\ndiltiazem\\\\n\\\\u2193 N-monodes-\\\\nmethyl diltiazem\\\\nDiltiazem dose adjustments should be\\\\nguided by clinical response (refer to the\\\\nfull prescribing information for diltiazem).\\\\nNo dose ...\",\"*\\\\ntacrolimus, sirolimus, and\\\\nothers metabolized by\\\\nCYP3A\\\\nsuppressant\\\\nmay be required. Close monitoring of\\\\nimmunosuppressant concentrations for\\\\nat least 2 weeks (until stable\\\\nconcentrations are reached) is\\\\nrecommended when starting or stopping\\\\ntreatment with ATRIPLA.\\\\nNarcotic analgesic:\\\\n  methadone\\\\n\\\\u2193 methadone\\\\nCoadministration of EFV in HIV-1 infected\\\\nindividuals with a history of injection drug\\\\nuse resulted in signs of opiate\\\\nwithdrawal. Methadone dose was\\\\nincreased by a mean of 22% to alleviate...\",\"for EFV, FTC, or TDF compared with the background rate for major birth defects of\\\\n2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects\\\\nProgram (MACDP) \\\\n(see \\\\nData\\\\n)\\\\n.\\\\nThe rate of miscarriage is not reported in the APR. The estimated background rate of\\\\nmiscarriage in clinically recognized pregnancies in the U.S. general population is 15-20%.\\\\nThe background risk of major birth defects and miscarriage for the indicated population\\\\nis unknown. The APR uses the MACDP as t...\",\"Animal Data\\\\nEfavirenz:\\\\n Effects of EFV on embryo-fetal development have been studied in three\\\\nnonclinical species (cynomolgus monkeys, rats, and rabbits). In monkeys, EFV 60\\\\nmg/kg/day was administered to pregnant females throughout pregnancy (gestation\\\\nDays 20 through 150). The maternal systemic drug exposures (AUC) were 1.3 times the\\\\nexposures at the RHD, with fetal umbilical venous drug concentrations approximately\\\\n0.7 times the maternal values. Three fetuses of 20 fetuses/infants had one or m...\",\"Based on limited published data, EFV, FTC, and tenofovir have been shown to be present\\\\nin human breast milk.\\\\nIt is not known if the components of ATRIPLA affect milk production or have effects on\\\\nthe breastfed child. Because of the potential for: (1) HIV transmission (in HIV-negative\\\\ninfants); (2) developing viral resistance (in HIV-positive infants); and (3) adverse\\\\nreactions in a breastfed infant similar to those seen in adults, instruct mothers not to\\\\nbreastfeed if they are receiving ATRIPLA....\",\"8.7 Hepatic Impairment\\\\nATRIPLA is not recommended for patients with moderate or severe hepatic impairment\\\\nbecause there are insufficient data to determine an appropriate dose. Patients with mild\\\\nhepatic impairment may be treated with ATRIPLA at the approved dose. Because of the\\\\nextensive cytochrome P450-mediated metabolism of EFV and limited clinical experience\\\\nin patients with hepatic impairment, caution should be exercised in administering\\\\nATRIPLA to these patients \\\\n[see \\\\nDosage and Administra...\",\"Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It\\\\nis practically insoluble in water (less than 10 \\\\u00b5g/mL).\\\\nEmtricitabine:\\\\n The chemical name of FTC is 5-fluoro-1-(2\\\\nR\\\\n,5\\\\nS\\\\n)-[2-(hydroxymethyl)-1,3-\\\\noxathiolan-5-yl]cytosine. FTC is the (-) enantiomer of a thio analog of cytidine, which\\\\ndiffers from other cytidine analogs in that it has a fluorine in the 5-position.\\\\nIt has a molecular formula of C\\\\nH\\\\nFN\\\\nO\\\\nS and a molecular weight of 247.24. It has the\\\\nfollo...\",\"12.1 Mechanism of Action\\\\nATRIPLA is a fixed-dose combination of antiviral drugs EFV, FTC, and TDF \\\\n[see\\\\nMicrobiology (12.4)\\\\n].\\\\n12.2 Pharmacodynamics\\\\nCardiac Electrophysiology\\\\nEfavirenz:\\\\n \\\\nThe effect of EFV on the QTc interval was evaluated in an open-label, positive\\\\nand placebo-controlled, fixed single sequence 3-period, 3-treatment crossover QT study\\\\nin 58 healthy subjects enriched for CYP2B6 polymorphisms. The mean C\\\\n of EFV in\\\\nsubjects with CYP2B6 *6/*6 genotype following the administration o...\",\"Tenofovir DF:\\\\n \\\\nFollowing oral administration of a single 300 mg dose of TDF to HIV-1\\\\ninfected subjects in the fasted state, maximum serum concentrations (C\\\\n) were\\\\nachieved in 1.0 \\\\u00b1 0.4 hrs (mean \\\\u00b1 SD) and C\\\\n and AUC values were 296 \\\\u00b1 90 ng/mL\\\\nand 2287 \\\\u00b1 685 ng\\\\u2219hr/mL, respectively. The oral bioavailability of tenofovir from TDF in\\\\nfasted subjects is approximately 25%. Less than 0.7% of tenofovir binds to human\\\\nplasma proteins in vitro, and the binding is independent of concentration over the ran...\",\"daily dose of 200 mg.\\\\nTenofovir DF:\\\\n Steady-state pharmacokinetics of tenofovir were evaluated in 8 HIV-1\\\\ninfected pediatric subjects (12 to less than 18 years). Mean \\\\u00b1 SD C\\\\n and AUC\\\\n are\\\\n0.38 \\\\u00b1 0.13 \\\\u03bcg/mL and 3.39 \\\\u00b1 1.22 \\\\u03bcg\\\\u2219hr/mL, respectively. Tenofovir exposure\\\\nachieved in these pediatric subjects receiving oral daily doses of TDF 300 mg was similar\\\\nto exposures achieved in adults receiving once-daily doses of TDF 300 mg.\\\\nGeriatric Patients\\\\nPharmacokinetics of EFV, FTC, and tenofovir have not...\",\"concentrations well above those achieved clinically. Coadministration of EFV with drugs\\\\nprimarily metabolized by CYP2C9, CYP2C19, CYP3A or CYP2B6 isozymes may result in\\\\naltered plasma concentrations of the coadministered drug. Drugs which induce CYP3A\\\\nand CYP2B6 activity would be expected to increase the clearance of EFV resulting in\\\\nlowered plasma concentrations.\\\\nDrug interaction trials were performed with EFV and other drugs likely to be\\\\ncoadministered or drugs commonly used as probes for phar...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\nCarbamazepine\\\\n200 mg qd \\\\u00d7 3\\\\ndays, 200 mg bid\\\\n\\\\u00d7 3 days, then\\\\n400 mg qd \\\\u00d7 15\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 35\\\\ndays\\\\n14\\\\n\\\\u2193 21\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 26)\\\\n\\\\u2193 36\\\\n(\\\\u2193 32 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 47\\\\n(\\\\u2193 41 to\\\\n\\\\u2193 53)\\\\nDiltiazem\\\\n240 mg \\\\u00d7 14\\\\ndays\\\\n600 mg\\\\nqd \\\\u00d7 28\\\\ndays\\\\n12\\\\n\\\\u2191 16\\\\n(\\\\u2191 6 to \\\\u2191\\\\n26)\\\\n\\\\u2191 11\\\\n(\\\\u2191 5 to \\\\u2191\\\\n18)\\\\n\\\\u2191 13\\\\n(\\\\u2191 1 to \\\\u2191\\\\n26)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg\\\\nqd \\\\u00d7 9\\\\ndays\\\\nNA\\\\n\\\\u2191 38\\\\n\\\\u2191 44\\\\nNA\\\\n300 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 mg\\\\nqd \\\\u00d7 7\\\\ndays\\\\nNA\\\\n\\\\u2193 14\\\\n \\\\n(\\\\u2193 7 to \\\\u2193\\\\n21)\\\\n\\\\u2194\\\\nNA\\\\n400 mg po q12h\\\\ndays 2\\\\u20137\\\\n300 m...\",\"meal\\\\n7\\\\u201320\\\\n300 mg\\\\nqd/ritonavir 100\\\\nmg qd d 1\\\\u201310\\\\n(pm), then 400\\\\nmg qd/ritonavir\\\\n100 mg qd d 11\\\\u2013\\\\n24 (pm)\\\\n(simultaneous\\\\nwith EFV)\\\\n600 mg qd\\\\nwith a light\\\\nsnack d\\\\n11\\\\u201324 (pm)\\\\n14\\\\n\\\\u2191 17\\\\n(\\\\u2191 8 to \\\\u2191\\\\n27)\\\\n\\\\u2194\\\\n\\\\u2193 42\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 51)\\\\nIndinavir\\\\n1000 mg q8h \\\\u00d7\\\\n10 days\\\\n600 mg qd\\\\n\\\\u00d7 10 days\\\\n20\\\\nAfter morning dose\\\\n\\\\u2194\\\\n\\\\u2193 33\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 39)\\\\n\\\\u2193 39\\\\n \\\\n(\\\\u2193 24 to\\\\n\\\\u2193 51)\\\\nAfter afternoon dose\\\\n\\\\u2194\\\\n\\\\u2193 37\\\\n \\\\n(\\\\u2193 26 to\\\\n\\\\u2193 46)\\\\n\\\\u2193 52\\\\n \\\\n(\\\\u2193 47 to\\\\n\\\\u2193 57)\\\\nAfter evening dose\\\\n\\\\u2193 29\\\\n \\\\n(\\\\u2193 11 to\\\\n\\\\u2193 43)\\\\n\\\\u2193 46\\\\n \\\\n(\\\\u2193 37 to\\\\n\\\\u2193 54)\\\\n\\\\u2193 57\\\\n \\\\n(\\\\u2193 50 to\\\\n\\\\u2193 63)\\\\nLopinavir/ritona...\",\"days\\\\n\\\\u00d7 16 days\\\\nto \\\\u2191 8)\\\\n25)\\\\n58)\\\\nSimeprevir\\\\n150 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n23\\\\n\\\\u2193 51\\\\n(\\\\u2193 46 to\\\\n\\\\u2193 56)\\\\n\\\\u2193 71\\\\n(\\\\u2193 67 to\\\\n\\\\u2193 74)\\\\n\\\\u2193 91\\\\n(\\\\u2193 88 to\\\\n\\\\u2193 92)\\\\nLedipasvir/sofosbuvir\\\\n90/400 mg qd \\\\u00d7\\\\n14 days\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\nLedipasvir\\\\n15\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 34\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 43)\\\\nSofosbuvir\\\\n\\\\u2194\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2194\\\\n\\\\u2194\\\\n\\\\u2194\\\\nSofosbuvir\\\\n400 mg qd single\\\\ndose\\\\n600 mg qd\\\\n\\\\u00d714 days\\\\n16\\\\n\\\\u2193 19\\\\n(\\\\u2193 40 to\\\\n\\\\u2191 10)\\\\n\\\\u2194\\\\nNA\\\\nGS-331007\\\\n\\\\u2193 23\\\\n(\\\\u2193 16 to\\\\n\\\\u2193 30)\\\\n\\\\u2193 16\\\\n(\\\\u2193 24 to\\\\n\\\\u2193 8)\\\\nNA\\\\nSofosbuvir/velpatasvir\\\\n400/100 mg qd \\\\u00d7\\\\n14 days\\\\n600...\",\"120 mg tablets (6\\\\n4-tablet doses\\\\nover 3 days)\\\\nArtemether\\\\n\\\\u2193 21\\\\u2193 38\\\\n\\\\u2193 51\\\\nNA\\\\ndihydroartemisinin\\\\n\\\\u2194\\\\n\\\\u2193 46\\\\nNA\\\\nlumefantrine\\\\n\\\\u219321\\\\nNA\\\\nAtorvastatin\\\\n10 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 14\\\\n(\\\\u2193 1 to \\\\u2193\\\\n26)\\\\n\\\\u2193 43\\\\n(\\\\u2193 34 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 69\\\\n(\\\\u2193 49 to\\\\n\\\\u2193 81)\\\\nTotal active (including\\\\nmetabolites)\\\\n\\\\u2193 15\\\\n(\\\\u2193 2 to \\\\u2193\\\\n26)\\\\n\\\\u2193 32\\\\n(\\\\u2193 21 to\\\\n\\\\u2193 41)\\\\n\\\\u2193 48\\\\n(\\\\u2193 23 to\\\\n\\\\u2193 64)\\\\nPravastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n13\\\\n\\\\u2193 32\\\\n(\\\\u2193 59 to\\\\n\\\\u2191 12)\\\\n\\\\u2193 44\\\\n(\\\\u2193 26 to\\\\n\\\\u2193 57)\\\\n\\\\u2193 19\\\\n(\\\\u2193 0 to \\\\u2193\\\\n35)\\\\nSimvastatin\\\\n40 mg qd \\\\u00d7 4\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 15 days\\\\n14\\\\n\\\\u2193 7...\",\"NA = not available\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\n\\\\u00f0\\\\n\\\\u00f8\\\\n\\\\u00fd\\\\n\\\\u00a3\\\\nMethadone\\\\nmaintenance 35\\\\u2013\\\\n100 mg daily\\\\n\\\\u00d7 14\\\\u201321\\\\ndays\\\\n11\\\\n(\\\\u2193 25 to\\\\n\\\\u2193 59)\\\\n(\\\\u2193 33 to\\\\n\\\\u2193 66)\\\\nNA\\\\nBupropion\\\\n150 mg single\\\\ndose (sustained-\\\\nrelease)\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 34\\\\n(\\\\u219321 to\\\\n\\\\u219347)\\\\n\\\\u2193 55\\\\n(\\\\u219348 to\\\\n\\\\u219362)\\\\nNA\\\\nHydroxybupropion\\\\n\\\\u2191 50\\\\n(\\\\u2191 20 to\\\\n\\\\u2191 80)\\\\n\\\\u2194\\\\nNA\\\\nSertraline\\\\n50 mg qd \\\\u00d7 14\\\\ndays\\\\n600 mg qd\\\\n\\\\u00d7 14 days\\\\n13\\\\n\\\\u2193 29\\\\n(\\\\u2193 15 to\\\\n\\\\u2193 40)\\\\n\\\\u2193 39\\\\n(\\\\u2193 27 to\\\\n\\\\u2193 50)\\\\n\\\\u2193 46\\\\n(\\\\u2193 31 to\\\\n\\\\u2193 58)\\\\nVoriconazole\\\\n400 mg po q12h\\\\n\\\\u00d7 1 day then 200\\\\nmg po q12h \\\\u00d7 8\\\\ndays\\\\n400 mg qd\\\\n\\\\u00d7 9 days\\\\nNA\\\\n\\\\u2193 61\\\\n\\\\u2193 77\\\\nN...\",\"no clinically significant drug interactions have been observed between TDF and abacavir,\\\\nEFV, FTC, entecavir, indinavir, lamivudine, lopinavir/ritonavir, methadone, nelfinavir, oral\\\\ncontraceptives, ribavirin, saquinavir/ritonavir, sofosbuvir, or tacrolimus in trials\\\\nconducted in healthy volunteers.\\\\nFollowing multiple dosing to HIV-negative subjects receiving either chronic methadone\\\\nmaintenance therapy, oral contraceptives, or single doses of ribavirin, steady-state\\\\ntenofovir pharmacokinetics we...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\nTable 7 Drug Interactions: Changes in Pharmacokinetic Parameters for\\\\nCoadministered Drug in the Presence of TDF\\\\nCoadministered\\\\nDrug\\\\nDose of\\\\nCoadministered\\\\nDrug (mg)\\\\nN\\\\nMean % Change of Coadministered\\\\nDrug Pharmacokinetic Parameters\\\\n \\\\n(90% CI)\\\\nC\\\\nAUC\\\\nC\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\n\\\\u00b6\\\\n#\\\\n\\\\u00de\\\\n\\\\u00df\\\\n\\\\u00e0\\\\n\\\\u00e8\\\\nAtazanavir\\\\n400 once daily \\\\u00d7\\\\n14 days\\\\n34\\\\n\\\\u2193 21\\\\n(\\\\u2193 27 to \\\\u2193 14)\\\\n\\\\u2193 25\\\\n(\\\\u2193 30 to \\\\u2193 19)\\\\n\\\\u2193 40\\\\n(\\\\u2193 48 to \\\\u2193 32)\\\\nAtazanavir/ritonavir\\\\n300/100 once daily\\\\n\\\\u00d7 42 days\\\\n10\\\\n\\\\u2193 28\\\\n(\\\\u2193 50 to \\\\u2191 5)\\\\n\\\\u2193 25\\\\n \\\\n(\\\\u2193 42 to \\\\u2193 3)\\\\n\\\\u2193 23\\\\n \\\\n(\\\\u2193 46 to \\\\u2191 10)\\\\nDa...\",\"Efavirenz:\\\\n \\\\nEFV is a non-nucleoside reverse transcriptase (RT) inhibitor of HIV-1.\\\\nEfavirenz activity is mediated predominantly by noncompetitive inhibition of HIV-1\\\\nreverse transcriptase. HIV-2 RT and human cellular DNA polymerases \\\\u03b1, \\\\u03b2, \\\\u03b3, and \\\\u03b4 are\\\\nnot inhibited by EFV.\\\\nEmtricitabine:\\\\n \\\\nEmtricitabine, a synthetic nucleoside analog of cytidine, is phosphorylated\\\\nby cellular enzymes to form FTC 5&#x27;-triphosphate. Emtricitabine 5&#x27;-triphosphate inhibits\\\\nthe activity of the HIV-1 RT by competing wi...\",\"tenofovir were in the range of 0.04\\\\u20138.5 \\\\u00b5M. In drug combination studies of tenofovir\\\\nwith NRTIs (abacavir, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine),\\\\nNNRTIs (delavirdine, EFV, and nevirapine), and PIs (amprenavir, indinavir, nelfinavir,\\\\nritonavir, and saquinavir), additive to synergistic effects were observed. Tenofovir\\\\ndisplayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, G, and O\\\\n(EC\\\\n values ranged from 0.5\\\\u20132.2 \\\\u00b5M) and showed strain-specific ...\",\"susceptibility to FTC was associated with a substitution in the HIV-1 RT gene at codon\\\\n184 which resulted in an amino acid substitution of methionine by valine or isoleucine\\\\n(M184V/I).\\\\nTenofovir DF:\\\\n \\\\nHIV-1 isolates with reduced susceptibility to tenofovir have been selected\\\\nin cell culture. These viruses expressed a K65R substitution in RT and showed a 2- to 4-\\\\nfold reduction in susceptibility to tenofovir.\\\\nCross Resistance\\\\nEfavirenz, Emtricitabine, and Tenofovir DF:\\\\n Cross resistance has been ...\",\"Efavirenz:\\\\n \\\\nLong-term carcinogenicity studies in mice and rats were carried out with EFV.\\\\nMice were dosed with 0, 25, 75, 150, or 300 mg/kg/day for 2 years. Incidences of\\\\nhepatocellular adenomas and carcinomas and pulmonary alveolar/bronchiolar adenomas\\\\nwere increased above background in females. No increases in tumor incidence above\\\\nbackground were seen in males. In studies in which rats were administered EFV at\\\\ndoses of 0, 25, 50, or 100 mg/kg/day for 2 years, no increases in tumor incidence\\\\n...\",\"an alteration of the estrous cycle in female rats.\\\\n13.2 Animal Toxicology and/or Pharmacology\\\\nEfavirenz:\\\\n \\\\nNonsustained convulsions were observed in 6 of 20 monkeys receiving EFV at\\\\ndoses yielding plasma AUC values 4- to 13-fold greater than those in humans given the\\\\nrecommended dose.\\\\nTenofovir DF:\\\\n \\\\nTenofovir and TDF administered in toxicology studies to rats, dogs, and\\\\nmonkeys at exposures (based on AUCs) greater than or equal to 6-fold those observed\\\\nin humans caused bone toxicity. In monkeys...\",\"Outcomes\\\\nAt Week 48\\\\nAt Week 144\\\\nFTC+TDF+EFV\\\\n(N=244)\\\\nAZT/3TC+EFV\\\\n(N=243)\\\\nFTC+TDF+\\\\nEFV\\\\n(N=227)\\\\nAZT/3TC+EFV\\\\n(N=229)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n\\\\u00a7\\\\nResponder\\\\n84%\\\\n73%\\\\n71%\\\\n58%\\\\nVirologic failure\\\\n2%\\\\n4%\\\\n3%\\\\n6%\\\\n  Rebound\\\\n1%\\\\n3%\\\\n2%\\\\n5%\\\\n  Never suppressed\\\\n0%\\\\n0%\\\\n0%\\\\n0%\\\\n  Change in antiretroviral\\\\nregimen\\\\n1%\\\\n1%\\\\n1%\\\\n1%\\\\nDeath\\\\n&lt;1%\\\\n1%\\\\n1%\\\\n1%\\\\nDiscontinued due to\\\\nadverse event\\\\n4%\\\\n9%\\\\n5%\\\\n12%\\\\nDiscontinued for other\\\\nreasons\\\\n10%\\\\n14%\\\\n20%\\\\n22%\\\\nThrough Week 48, 84% and 73% of subjects in the FTC + TDF group and the\\\\nzidovudine/lamivudine group, respectiv...\",\"22-73 years); 88% were male, 68% were white, 29% were Black or African-American,\\\\nand 3% were of other races. At baseline, median CD4\\\\n cell count was 516 cells/mm\\\\n,\\\\nand 96% had HIV-1 RNA &lt;50 copies/mL. The median time since onset of antiretroviral\\\\ntherapy was 3 years, and 88% of subjects were receiving their first antiretroviral\\\\nregimen at trial enrollment.\\\\nAt Week 48, 89% and 87% of subjects who switched to ATRIPLA maintained HIV RNA\\\\n&lt;200 copies/mL and &lt;50 copies/mL, respectively, compared to 88...\",\"Interactions (7)\\\\n]\\\\n.\\\\nPsychiatric Symptoms\\\\nInform patients that serious psychiatric symptoms including severe depression,\\\\nsuicide attempts, aggressive behavior, delusions, paranoia, psychosis-like symptoms,\\\\nand catatonia have been reported in patients receiving EFV, a component of ATRIPLA\\\\n[see \\\\nWarnings and Precautions (5.5)\\\\n]\\\\n.\\\\nAdvise patients to seek immediate medical evaluation if they experience severe\\\\npsychiatric adverse experiences.\\\\nAdvise patients to inform their physician of any history o...\",\"Convulsions\\\\nInform patients that convulsions have been reported with the use of EFV, a component\\\\nof ATRIPLA. Patients who are receiving concomitant anticonvulsant medications primarily\\\\nmetabolized by the liver may require periodic monitoring of plasma levels \\\\n[see \\\\nWarnings\\\\nand Precautions (5.10)\\\\n and \\\\nDrug Interactions (7.3)\\\\n]\\\\n.\\\\nLactic Acidosis and Severe Hepatomegaly\\\\nInform patients that lactic acidosis and severe hepatomegaly with steatosis, including\\\\nfatal cases, have been reported. Treatmen...\",\"Patient Information\\\\n \\\\nATRIPLA\\\\u2122 (uh TRIP luh)\\\\n(efavirenz, emtricitabine, and tenofovir disoproxil fumarate) tablets\\\\nWhat is the most important information I should know about ATRIPLA?\\\\nATRIPLA can cause serious side effects, including:\\\\nWorsening of hepatitis B virus (HBV) infection.\\\\n Your healthcare provider will\\\\ntest you for HBV before starting treatment with ATRIPLA. If you have HBV infection\\\\nand take ATRIPLA, your HBV may get worse (flare-up) if you stop taking ATRIPLA. \\\\nA\\\\n\\\\\"flare-up\\\\\" is when yo...\",\"be pregnant during treatment with ATRIPLA.\\\\nFemales who are able to become pregnant should use 2 effective\\\\nforms of birth control (contraception) during treatment with ATRIPLA\\\\nand for 12 weeks after stopping treatment.\\\\nA barrier form of birth control should always be used along with\\\\nanother type of birth control\\\\n. Barrier forms of birth control may include\\\\ncondoms, contraceptive sponges, diaphragm with spermicide, and cervical cap.\\\\nBirth control methods that contain the hormone progesterone such ...\",\"See \\\\\"\\\\nWhat is the most important information I should know about\\\\nATRIPLA?\\\\n\\\\\"\\\\nRash.\\\\n Rash is a serious side effect, but may also be common. Rashes will usually go\\\\naway without any change in your treatment. Tell your healthcare provider right away\\\\nif you develop a rash during treatment with ATRIPLA.\\\\nSevere liver problems. I\\\\nn rare cases, severe liver problems can happen that can\\\\nlead to death. \\\\nTell your healthcare provider right away if you get these\\\\nsymptoms:\\\\n skin or the white part of your eyes ...\",\"provider right away if you develop any of these symptoms:\\\\nweakness or being more tired than\\\\nusual\\\\nbeing short of breath or fast\\\\nbreathing\\\\ncold or blue hands and feet\\\\nfast or abnormal heartbeat\\\\nunusual muscle pain\\\\nstomach pain with nausea and vomiting\\\\nfeel dizzy or lightheaded\\\\nChanges in your immune system (Immune Reconstitution Syndrome) can\\\\nhappen when an HIV-1 infected person starts taking HIV-1 medicines.\\\\n Your\\\\nimmune system may get stronger and begin to fight infections that have been hidden...\",\"respective owners.\\\\n\\\\u00a9 2019 Gilead Sciences, LLC. All rights reserved.\\\\n21937-GS-020A\\\\nPRINCIPAL DISPLAY PANEL - 30 Tablet Bottle Label\\\\n61958-1601-3\\\\n30 tablets\\\\nATRIPLA\\\\u2122\\\\n(efavirenz 600 mg/emtricitabine 200 mg/\\\\ntenofovir disoproxil fumarate 300 mg)\\\\ntablets\\\\nGILEAD ACCESS PROGRAM\\\\nNote to pharmacist: Do not cover ALERT box with pharmacy label.\\\\nALERT: Find out about medicines that\\\\nshould NOT be taken with ATRIPLA\\\\nRx only\\\\nPOM\\\\nATRIPLA ACCESS  \\\\nefavirenz, emtricitabine, and tenofovir disoproxil fumarate tabl...\",\"Gilead Sciences, Inc.\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nEFAVIRENZ\\\\n (UNII: JE6H2O27P8) \\\\n(EFAVIRENZ - UNII:JE6H2O27P8)\\\\nEFAVIRENZ\\\\n600 mg\\\\nEMTRICITABINE\\\\n (UNII: G70B4ETF4S) \\\\n(EMTRICITABINE - UNII:G70B4ETF4S)\\\\nEMTRICITABINE\\\\n200 mg\\\\nTENOFOVIR DISOPROXIL FUMARATE\\\\n (UNII: OTT9J7900I) \\\\n(TENOFOVIR\\\\nANHYDROUS - UNII:W4HFE001U5)\\\\nTENOFOVIR DISOPROXIL\\\\nFUMARATE\\\\n300 mg\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nCROSCARMELLOSE SODIUM\\\\n (UNII: M28OL1HH48)\\\\n \\\\nHYDROXYPROPYL CELLULOSE (1600000 WAMW)\\\\n (UNII: RF...\",\"APRETUDE- cabotegravir \\\\n \\\\nViiV Healthcare Company\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use APRETUDE safely and\\\\neffectively. See full prescribing information for APRETUDE.\\\\nAPRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use\\\\nInitial U.S. Approval: 2021\\\\nWARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-\\\\nEXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1 INFECTION\\\\nSee full pres...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nADVERSE REACTIONS\\\\nThe most common adverse reactions (all grades) observed in at least 1% of participants receiving\\\\nAPRETUDE were injection site reactions, diarrhea, headache, pyrexia, fatigue, sleep disorders, nausea,\\\\ndizziness, flatulence, abdominal pain, vomiting, myalgia, rash, decreased appetite, somnolence, back\\\\npain, and upper respiratory tract infection. (\\\\n6.1\\\\n)\\\\nTo report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or\\\\nFDA at 1-800-FDA-1088 or \\\\nwww.fda.go...\",\"5.4 Hypersensitivity Reactions\\\\n5.5 Hepatotoxicity\\\\n5.6 Depressive Disorders\\\\n5.7 Risk of Reduced Drug Concentration of APRETUDE Due to Drug Interactions\\\\n6 ADVERSE REACTIONS\\\\n6.1 Clinical Trials Experience\\\\n6.2 Postmarketing Experience\\\\n7 DRUG INTERACTIONS\\\\n7.1 Use of Other Antiretroviral Drugs after Discontinuation of APRETUDE\\\\n7.2 Potential for Other Drugs to Affect APRETUDE\\\\n7.3 Established and Other Potentially Significant Drug Interactions\\\\n7.4 Drugs without Clinically Significant Interactions with C...\",\"WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR\\\\nHIV-1 PRE\\\\u2011EXPOSURE PROPHYLAXIS (PrEP) IN UNDIAGNOSED HIV-1\\\\nINFECTION\\\\nIndividuals must be tested for HIV-1 infection prior to initiating\\\\nAPRETUDE or oral cabotegravir, and with each subsequent injection of\\\\nAPRETUDE, using a test approved or cleared by the FDA for the\\\\ndiagnosis of acute or primary HIV-1 infection. Drug-resistant HIV-1\\\\nvariants have been identified with use of APRETUDE by individuals with\\\\nundiagnosed HIV-1 infection. Do not ...\",\"Prior to starting APRETUDE, healthcare providers should carefully select individuals who\\\\nagree to the required injection dosing and testing schedule and counsel individuals about\\\\nthe importance of adherence to scheduled dosing visits to help reduce the risk of\\\\nacquiring HIV-1 infection and development of resistance \\\\n[see Dosage and Administration\\\\n(\\\\n2.1\\\\n), Warnings and Precautions (\\\\n5.1\\\\n, \\\\n5.3\\\\n), Microbiology (\\\\n12.4\\\\n)]\\\\n.\\\\n2.4 Optional Oral Lead-In Dosing to Assess Tolerability of APRETUDE\\\\nThe heal...\",\"Table 2. Recommended Dosing Schedule (Direct to Injection) for Pre-\\\\nExposure Prophylaxis in Adults and Adolescents Weighing at Least 35 kg\\\\n Individuals may be given APRETUDE up to 7 days before or after the date the individual\\\\nis scheduled to receive the injections.\\\\nIntramuscular (Gluteal) \\\\nInitiation Injection \\\\n(Month 1 and Month 2)\\\\nIntramuscular (Gluteal) \\\\nContinuation Injection \\\\n(Month 4 and Every 2 Months\\\\nOnwards)\\\\nAPRETUDE\\\\nAPRETUDE\\\\n600-mg (3 mL)\\\\n600-mg (3 mL)\\\\n2.6 Recommended Dosing Schedule ...\",\"Greater than 2 months\\\\nRestart with 600-mg (3-mL) gluteal intramuscular\\\\ninjection of APRETUDE, followed by a second 600-mg\\\\n(3-mL) initiation injection dose 1 month later. Then\\\\ncontinue to follow the every-2-month injection dosing\\\\nschedule thereafter.\\\\nIf third or subsequent\\\\ninjection is missed and time\\\\nsince prior injection is:\\\\nLess than or equal to 3 months\\\\nAdminister 600-mg (3-mL) intramuscular injection of\\\\nAPRETUDE as soon as possible, then continue with\\\\nthe every-2-month injection dosing sched...\",\"3 DOSAGE FORMS AND STRENGTHS\\\\nInjection: Single-dose vial containing 600 mg/3 mL (200 mg/mL) of cabotegravir\\\\nextended\\\\u2011release injectable suspension.\\\\n4 CONTRAINDICATIONS\\\\nAPRETUDE is contraindicated in individuals:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Comprehensive Management to Reduce the Risk of HIV-1 Infection\\\\nUse APRETUDE for HIV-1 PrEP to reduce the risk of HIV-1 infection as part of a\\\\ncomprehensive prevention strategy including adherence to the administration schedule\\\\nand safer sex practices,...\",\"\\\\u2022\\\\nWhen using APRETUDE for HIV-1 PrEP, HIV-1 testing should be repeated prior to each\\\\ninjection and upon diagnosis of any other STIs \\\\n[see Dosage and Administration (\\\\n2.2\\\\n,\\\\n2.5\\\\n)]\\\\n.\\\\n\\\\u2022\\\\nCounsel individuals without HIV-1 to strictly adhere to the recommended dosing and\\\\ntesting schedule for APRETUDE in order to reduce the risk of HIV-1 acquisition and the\\\\npotential development of resistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n, \\\\n2.5\\\\n),\\\\nMicrobiology (\\\\n12.4\\\\n)]\\\\n. Some individuals, such as adolescents,...\",\"include Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) \\\\n[see Adverse\\\\nReactions (\\\\n6.2\\\\n)]\\\\n. Administration of cabotegravir oral lead-in dosing was used in clinical\\\\nstudies to help identify participants who may be at risk of a hypersensitivity reaction.\\\\nRemain vigilant and discontinue APRETUDE if a hypersensitivity reaction is suspected\\\\n[see Dosage and Administration (\\\\n2.4\\\\n), Contraindications (\\\\n4\\\\n), Adverse Reactions (\\\\n6\\\\n)]\\\\n.\\\\nDiscontinue APRETUDE immediately if signs or symptoms o...\",\"6.1 Clinical Trials Experience\\\\nBecause clinical trials are conducted under widely varying conditions, adverse reaction\\\\nrates observed in the clinical trials of a drug cannot be directly compared with rates in\\\\nthe clinical trials of another drug and may not reflect rates observed in practice.\\\\nClinical Trials Experience in Adults\\\\nThe safety assessment of APRETUDE is based on the analysis of data from 2\\\\ninternational, multicenter, double-blind trials, HPTN 083 and HPTN 084 \\\\n[see Clinical\\\\nStudies (\\\\n...\",\"Adverse reactions defined as \\\\u201ctreatment-related\\\\u201d as assessed by the investigator, with\\\\nexception of injection site reactions, where all injection site reactions were reported\\\\nregardless of causality.\\\\n Participants who received injection: HPTN 083, APRETUDE (n = 2,117) and TRUVADA\\\\n(n = 2,081); HPTN 084, APRETUDE (n = 1,519) and TRUVADA (n = 1,516).\\\\n Pyrexia includes pyrexia, feeling hot, chills, influenza-like illness.\\\\n Fatigue includes fatigue, malaise.\\\\n Sleep disorders includes insomnia, abnorm...\",\"grades) in at least 1% of participants who received APRETUDE and experienced at least\\\\none ISR from HPTN 084 are presented in \\\\nTable 5\\\\n.\\\\nTable 5. Injection Site Reactions (All Grades) Reported in at Least 1% of\\\\nParticipants Who Experienced at Least One Injection Site Reaction (All\\\\nCausality) with APRETUDE in Either HPTN 083 or HPTN 084\\\\n Placebo injectable suspension: intralipid 20% fat emulsion.\\\\nInjection Site\\\\nReactions\\\\nHPTN 083\\\\nHPTN 084\\\\nAPRETUDE\\\\n(n = 1,740)\\\\nTRUVADA\\\\n(n = 724)\\\\nAPRETUDE\\\\n(n = 578)\\\\nT...\",\"At the Week 41 and 97 timepoints in HPTN 084, participants who received APRETUDE\\\\ngained a median of 2 kg (IQR; 0.0, 5.0; n = 1,151) and 4 kg (IQR; 0.0, 8.0; n = 216) in\\\\nweight from baseline, respectively. Those who received TRUVADA gained a median of\\\\n1 kg (IQR; -1.0, 4.0; n = 1,131) and 3 kg (IQR; -1.0, 6.0; n = 218) in weight from\\\\nbaseline, respectively.\\\\nLaboratory Abnormalities: \\\\nGrade 3 or 4 post-baseline maximum toxicity laboratory\\\\nabnormalities for HPTN 083 or HPTN 084 are summarized in \\\\nTa...\",\"Nearly 60% of participants with baseline data available had Week 57 data available in\\\\nboth arms of both trials. Within each trial, baseline values were comparable among\\\\nparticipants receiving APRETUDE and TRUVADA.\\\\nHDL cholesterol\\\\nratio\\\\nClinical Trials Experience in Adolescents\\\\nIn adolescents receiving APRETUDE for HIV-1 PrEP, the safety data were comparable to\\\\nthe safety data reported in adults receiving APRETUDE for HIV-1 PrEP \\\\n[see Use in\\\\nSpecific Populations (\\\\n8.4\\\\n)].\\\\n6.2 Postmarketing Experi...\",\"inclusive.\\\\nTable 8. Drug Interactions with APRETUDE\\\\n\\\\u2191 = Increase, \\\\u2193 = Decrease, \\\\u2194 = No change.\\\\nConcomitant Drug\\\\nClass:\\\\nDrug Name\\\\nEffect on\\\\nConcentration\\\\nClinical Comment\\\\nAnticonvulsants:\\\\nCarbamazepine\\\\nOxcarbazepine\\\\nPhenobarbital\\\\nPhenytoin\\\\n\\\\u2193Cabotegravir\\\\nCoadministration is contraindicated with\\\\nAPRETUDE due to potential for significant\\\\ndecreases in plasma concentration of\\\\nAPRETUDE.\\\\nAntimycobacterials:\\\\nRifampin\\\\nRifapentine\\\\n\\\\u2193Cabotegravir\\\\nAntimycobacterial:\\\\nRifabutin\\\\n\\\\u2193Cabotegravir\\\\nWhen rifabutin is s...\",\"4263.\\\\nRisk Summary\\\\nThere are insufficient human data on the use of APRETUDE during pregnancy to\\\\nadequately assess a drug-associated risk of birth defects and miscarriage. Discuss the\\\\nbenefit-risk of using APRETUDE with individuals of childbearing potential or during\\\\npregnancy.\\\\nCabotegravir use in pregnant individuals has not been evaluated. APRETUDE should be\\\\nused during pregnancy only if the expected benefit justifies the potential risk to the\\\\nfetus.\\\\nThe APR has been established to monitor for ...\",\"exposure in humans at the RHD); there were no alterations to growth and development\\\\nof surviving offspring. In a cross-fostering study, similar incidences of stillbirths and\\\\nearly postnatal deaths were observed when rat pups born to cabotegravir-treated\\\\nmothers were nursed from birth by control mothers. There was no effect on neonatal\\\\nsurvival of control pups nursed from birth by cabotegravir-treated mothers. A lower\\\\ndose of 5 mg/kg/day (13 times the exposure at the RHD) was not associated with\\\\n...\",\"APRETUDE. Adolescents may benefit from more frequent visits and counseling to\\\\nsupport adherence to the dosing and testing schedule \\\\n[see Dosage and Administration\\\\n(\\\\n2.2\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)].\\\\nThe safety, efficacy, and pharmacokinetics of APRETUDE in pediatric participants\\\\nyounger than 12 years of age or weighing &lt;35 kg have not been established.\\\\n8.5 Geriatric Use\\\\nNo dose adjustment is required in elderly individuals. There are limited data available on\\\\nthe use of APRETUDE in indiv...\",\"Cabotegravir extended-release injectable suspension is a white to light pink free-flowing\\\\nsuspension for intramuscular injection in a sterile single-dose vial. Each vial contains\\\\n3 mL of the following: cabotegravir 200 mg/mL and the inactive ingredients mannitol\\\\n(35 mg/mL), polyethylene glycol (PEG) 3350 (20 mg/mL), polysorbate 20 (20 mg/mL),\\\\nand Water for Injection.\\\\nThe vial stoppers are not made with natural rubber latex.\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\nCabotegravir is an HIV...\",\"CSF = Cerebrospinal fluid.\\\\n When taken orally with a high-fat meal versus fasted, the AUC\\\\n (geometric mean\\\\nratio [90% CI] of cabotegravir are 1.14 [1.02, 1.28]).\\\\n The clinical relevance of CSF-to-plasma concentration ratios is unknown.\\\\nConcentrations were measured at steady-state 1 week after intramuscular\\\\nadministration of cabotegravir extended-release injectable suspensions given monthly or\\\\nevery 2 months.\\\\n Elimination half-life driven by slow absorption rate from the intramuscular injection s...\",\"with HIV-1 (n = 110), the observed cabotegravir geometric mean (5th, 95th percentile)\\\\nC\\\\n (1-week post\\\\u2011initial injection) was 1.89 mcg/mL (0.438, 5.69) and C\\\\n was\\\\n1.43 mcg/mL (0.403, 3.90).\\\\n Pharmacokinetic parameter values represent steady state.\\\\nSpecific Populations\\\\nNo clinically significant differences in the pharmacokinetics of cabotegravir were\\\\nobserved based on age, sex, race/ethnicity, BMI, or UGT1A1 polymorphisms. There are\\\\nno data available for the use of cabotegravir in participants wit...\",\"IM = intramuscular.\\\\n Pharmacokinetic parameter values were based on individual post-hoc estimates from\\\\npopulation pharmacokinetic models in both adolescents with HIV-1 (n = 147) weighing\\\\n35.2 to 98.5 kg and adolescents without HIV-1 (n = 62) weighing 39.9 to 167 kg. \\\\n tau is dosing interval: 24 hours for oral administration, 1 month for the initial injection,\\\\nand 2 months for every 2 months for intramuscular injections of extended-release\\\\ninjectable suspension.\\\\n Oral lead-in pharmacokinetic para...\",\"n = Maximum number of participants with data, CI = Confidence Interval.\\\\nCoadministered\\\\nDrug(s)\\\\nand Dose(s)\\\\nDose of\\\\nCabotegravir\\\\nn\\\\nNo Effect = 1.00\\\\nC\\\\nAUC\\\\nC\\\\n or C\\\\nEtravirine\\\\n30 mg\\\\n12\\\\n1.04\\\\n1.01\\\\n1.00\\\\n    200 mg twice\\\\ndaily\\\\nonce daily\\\\n(0.99, 1.09)\\\\n(0.96, 1.06)\\\\n(0.94, 1.06)\\\\nRifabutin\\\\n30 mg\\\\n12\\\\n0.83\\\\n0.77\\\\n0.74\\\\n    300 mg once\\\\ndaily\\\\nonce daily\\\\n(0.76, 0.90)\\\\n(0.74, 0.83)\\\\n(0.70, 0.78)\\\\nRifampin\\\\n30-mg\\\\n15\\\\n0.94\\\\n0.41\\\\n0.50\\\\n    600 mg once\\\\ndaily\\\\nsingle dose\\\\n(0.87, 1.02)\\\\n(0.36, 0.46)\\\\n(0.44, 0.57)\\\\nRilpivirine\\\\n30 mg\\\\n1...\",\"12.4 Microbiology\\\\nMechanism of Action\\\\nCabotegravir inhibits HIV integrase by binding to the integrase active site and blocking\\\\nthe strand transfer step of retroviral deoxyribonucleic acid (DNA) integration that is\\\\nessential for the HIV replication cycle. The mean 50% inhibitory concentration (IC\\\\n)\\\\nvalue of cabotegravir in a strand transfer assay using purified recombinant HIV-1\\\\nintegrase was 3.0 nM.\\\\nAntiviral Activity in Cell Culture\\\\nCabotegravir exhibited antiviral activity against laboratory s...\",\"cabotegravir exposures below the target concentration. No variants expressing INSTI\\\\nresistance-associated substitutions were detected.\\\\nCross-Resistance\\\\nCross-resistance has been observed among INSTIs. Cabotegravir had reduced\\\\nsusceptibility (&gt;5-fold change) to recombinant HIV-1 strain NL432 viruses harboring the\\\\nfollowing integrase amino acid substitutions: G118R, Q148K, Q148R, T66K+L74M,\\\\nE92Q+N155H, E138A+Q148R, E138K+Q148K/R, G140C+Q148R, G140S+Q148H/K/R,\\\\nY143H+N155H, and Q148R+N155H (range: 5...\",\"in men and transgender women without HIV-1 who have sex with men and have\\\\nevidence of high-risk behavior for HIV-1 infection and HPTN 084 in cisgender women\\\\nwithout HIV-1 at risk of acquiring HIV-1.\\\\nParticipants randomized to receive APRETUDE initiated oral lead-in dosing with 1 oral\\\\ncabotegravir 30-mg tablet and a placebo daily for up to 5 weeks, followed by APRETUDE\\\\n600\\\\u2011mg (3-mL) intramuscular injection at months 1 and 2 and every 2 months\\\\nthereafter and a daily placebo tablet. Participants ra...\",\"Results from all subgroup analyses were consistent with the overall protective effect. A\\\\nlower rate of incident HIV\\\\u20111 infections was observed for participants randomized to\\\\nAPRETUDE compared with participants randomized to TRUVADA (\\\\nTable 15\\\\n).\\\\nTable 15. Incident of HIV-1 Infections by Subgroup in HPTN 083: Extended\\\\nRetrospective Virologic Testing with Readjudicated Endpoints\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence per\\\\n100 Person-\\\\nYears\\\\nAPRETUDE\\\\nPerson-Years\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nP...\",\"mITT from Supplemental Virology Report. \\\\n Cisgender men who have sex with men.\\\\n Transgender women who have sex with men.\\\\nTGW\\\\n0.54\\\\n371\\\\n1.80\\\\n389\\\\n0.34\\\\n(0.08,\\\\n1.56)\\\\nRace (US)\\\\nBlack\\\\n0.58\\\\n691\\\\n2.28\\\\n703\\\\n0.26\\\\n(0.09,\\\\n0.76)\\\\nNon-Black\\\\n0.00\\\\n836\\\\n0.50\\\\n801\\\\n0.11\\\\n(0.00,\\\\n2.80)\\\\nRegion\\\\nUS\\\\n0.26\\\\n1,528\\\\n1.33\\\\n1,504\\\\n0.21\\\\n(0.07,\\\\n0.60)\\\\nLatin\\\\nAmerica\\\\n0.49\\\\n1,020\\\\n1.09\\\\n1,011\\\\n0.47\\\\n(0.17,\\\\n1.35)\\\\nAsia\\\\n0.35\\\\n570\\\\n1.03\\\\n581\\\\n0.39\\\\n(0.08,\\\\n1.82)\\\\nAfrica\\\\n1.08\\\\n93\\\\n2.07\\\\n97\\\\n0.63\\\\n(0.06,\\\\n6.50)\\\\nTrial 201739 (HPTN 084 [NCT03164564])\\\\nIn HPTN 084, a su...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\",\"mITT from Supplemental Virology Report.\\\\nSubgroup\\\\nAPRETUDE\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nAPRETUDE\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nIncidence\\\\nper 100\\\\nPerson-\\\\nYears\\\\nTRUVADA\\\\nPerson-\\\\nYears\\\\nHazard\\\\nRatio\\\\n(95% CI)\\\\nAge\\\\n&lt;25 years\\\\n0.23\\\\n868\\\\n2.34\\\\n853\\\\n0.12\\\\n(0.03, 0.46)\\\\n\\\\u226525 years\\\\n0.09\\\\n1,093\\\\n1.46\\\\n1,093\\\\n0.09\\\\n(0.02, 0.49)\\\\nBody Mass Index\\\\n&lt;30\\\\n0.22\\\\n1,385\\\\n1.88\\\\n1,435\\\\n0.12\\\\n(0.04, 0.38)\\\\n\\\\u226530\\\\n0.00\\\\n575\\\\n1.76\\\\n511\\\\n0.04\\\\n(0.00, 0.93)\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nHow Supplied\\\\nAPRETUDE is supplied in a kit containing one 600-mg/3...\",\"\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nPotential Risk of Resistance with APRETUDE\\\\nAdvise individuals there is a potential risk of developing resistance to APRETUDE if HIV-1\\\\nis acquired either before or while taking APRETUDE or following discontinuation of\\\\nAPRETUDE \\\\n[see Warnings and Precautions (\\\\n5.2\\\\n)]\\\\n.\\\\nTo minimize this, it is essential that individuals are clinically reassessed for risk of HIV-1\\\\nacquisition and tested frequently to confirm HIV-1 negative status. Advise individuals\\\\nwho are confirmed to have with HIV...\",\"Counsel individuals about the importance of continued medication adherence and\\\\nscheduled visits to help reduce the risk of acquiring HIV-1 infection and development of\\\\nresistance \\\\n[see Dosage and Administration (\\\\n2.3\\\\n), Warnings and Precautions (\\\\n5.1\\\\n)]\\\\n.\\\\nHypersensitivity Reactions\\\\nAdvise individuals to immediately contact their healthcare provider if they develop a rash.\\\\nInstruct individuals to immediately stop taking APRETUDE and seek medical attention if\\\\nthey develop a rash associated with an...\",\"Warnings and Precautions (\\\\n5.3\\\\n), Use in Specific Populations (\\\\n8.1\\\\n)]\\\\n.\\\\nLactation\\\\nInform individuals that due to the potential for adverse reactions and residual\\\\nconcentrations in the systemic circulation for up to 12 months or longer after\\\\ndiscontinuing injections of APRETUDE, it is recommended that mothers breastfeed only\\\\nif the expected benefit justifies the potential risk to the infant. The benefits and risks of\\\\nAPRETUDE while breastfeeding should be evaluated, including the risk of HIV-1\\\\na...\",\"While you are receiving APRETUDE for HIV-1 PrEP:\\\\n\\\\u2022\\\\n\\\\u2022\\\\nIf you have HIV-1 and receive only APRETUDE, over time your HIV-1 may\\\\nbecome harder to treat.\\\\nWhat is APRETUDE?\\\\nAPRETUDE is a prescription medicine used for HIV-1 PrEP to reduce the risk of getting\\\\nHIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kg).\\\\nHIV-1 is the virus that causes acquired immune deficiency syndrome (AIDS).\\\\nIt is not known if APRETUDE is safe and effective in children younger than 12 years o...\",\"\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\nBefore receiving APRETUDE, tell your healthcare provider about all your\\\\nmedical conditions, including if you:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nTell your healthcare provider about all the medicines you take,\\\\n including\\\\nprescription and over-the-counter medicines, vitamins, and herbal supplements.\\\\nSome medicines may interact with APRETUDE. Keep a list of your medicines and show it\\\\nto your healthcare provider and pharmacist when you get a new medicine.\\\\nYou can ask your healthcare provider or pharmacist fo...\",\"What are the possible side effects of APRETUDE?\\\\nAPRETUDE may cause serious side effects including:\\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n \\\\n\\\\u2022\\\\nThe most common side effects of APRETUDE include:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAllergic reactions.\\\\n Call your healthcare provider right away if you develop a rash\\\\nwith APRETUDE. \\\\nStop receiving APRETUDE and get medical help right away\\\\nif you develop a rash with any of the following signs or symptoms:\\\\n\\\\u25cb   fever\\\\n\\\\u25cb   generally ill feeling\\\\n\\\\u25cb   tiredness\\\\n\\\\u25cb   mu...\",\"These are not all the possible side effects of APRETUDE.\\\\nCall your doctor for medical advice about side effects. You may report side effects to\\\\nFDA at 1-800-FDA-1088.\\\\nGeneral information about the safe and effective use of APRETUDE.\\\\nMedicines are sometimes prescribed for purposes other than those listed in a Patient\\\\nInformation leaflet. You can ask your pharmacist or healthcare provider for information\\\\nabout APRETUDE that is written for health professionals.\\\\nWhat are the ingredients in APRETUDE?...\",\"Overview:\\\\nA complete dose of APRETUDE requires 1 injection: 600-mg (3 mL) of cabotegravir.\\\\nAPRETUDE is a suspension that does not need further dilution or reconstitution.\\\\nCarefully follow these instructions when preparing the suspension for injection to avoid\\\\nleakage.\\\\nAPRETUDE is for gluteal intramuscular use only.\\\\nNote:\\\\n The ventrogluteal site is recommended.\\\\n Storage information\\\\nStore at 2\\\\u00b0C to 25\\\\u00b0C (36\\\\u00b0F to 77\\\\u00b0F). Exposure up to 30\\\\u00b0C (86\\\\u00b0F) permitted.\\\\nDo not \\\\nfreeze.\\\\nPrior to administration:\\\\n...\",\"\\\\u2022\\\\nYour pack contains:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nConsider the individual\\\\u2019s build and use medical judgment to select an appropriate\\\\ninjection needle length.\\\\nYou will also need:\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\ntemperature prior to administration (not to exceed 30\\\\u00b0C [86\\\\u00b0F]).\\\\nOnce APRETUDE has been drawn into the syringe, the medicine can remain in the\\\\nsyringe for up to 2 hours before injection. The filled syringe should not be placed in\\\\nthe refrigerator. If the medicine remains in the syringe for more than 2 hours, the\\\\nfilled syringe and ne...\",\"Preparation:\\\\n1. Inspect the vial.\\\\nFigure A\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n \\\\n\\\\u2022\\\\n2. Shake the vial vigorously.\\\\nFigure B\\\\n\\\\u2022\\\\n3. Inspect suspension.\\\\nFigure C\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n4. Remove the vial cap.\\\\nCheck that the\\\\nexpiration date has\\\\nnot passed. \\\\nSee\\\\nFigure A.\\\\nInspect the vial\\\\nimmediately. If you\\\\ncan see foreign\\\\nmatter, do not use\\\\nthe product.\\\\nNote:\\\\n The vial has a\\\\nbrown tint to the\\\\nglass.\\\\nDo not\\\\n use if the\\\\nexpiration date has\\\\npassed.\\\\nIf the pack has been\\\\nstored in the\\\\nrefrigerator, allow the\\\\nmedication to come to\\\\nroom temperature.\\\\nHold...\",\"Figure D\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n5. Peel open the vial adapter.\\\\nFigure E\\\\n\\\\u2022\\\\n \\\\n \\\\n6. Place vial on flat surface and attach the vial adapter.\\\\nFigure F\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n7. Lift off the packaging.\\\\nRemove the cap from\\\\nthe vial. \\\\nSee Figure\\\\nD.\\\\nWipe the rubber\\\\nstopper with an\\\\nalcohol wipe.\\\\nDo not\\\\n allow\\\\nanything to touch the\\\\nrubber stopper after\\\\nwiping it.\\\\nPeel off the paper\\\\nbacking from the vial\\\\nadapter packaging.\\\\nSee Figure E.\\\\nNote:\\\\n Do not remove\\\\nthe adapter from its\\\\npackaging for the\\\\nnext step. The\\\\nadapter \\\\nwill not\\\\n fall\\\\nout wh...\",\"Figure G\\\\n\\\\u2022\\\\n8. Prepare the syringe.\\\\nFigure H\\\\n\\\\u2022\\\\n\\\\u2022\\\\n9. Attach the syringe.\\\\nFigure I\\\\n\\\\u2022\\\\n\\\\u2022\\\\n10. Press the plunger.\\\\nLift off the vial\\\\nadapter packaging, as\\\\nshown.\\\\n See Figure\\\\nG.\\\\nRemove the syringe\\\\nfrom its packaging.\\\\nDraw 1 mL of air into\\\\nthe syringe. This will\\\\nmake it easier to draw\\\\nup the medicine later.\\\\nSee Figure H.\\\\nHold the vial adapter\\\\nand vial firmly, as\\\\nshown.\\\\nScrew the syringe\\\\nfirmly onto the vial\\\\nadapter. \\\\nSee Figure\\\\nI.\",\"Figure J\\\\n\\\\u2022\\\\n11. Slowly draw up the dose.\\\\nFigure K\\\\n\\\\u2022\\\\n \\\\n12. Unscrew the syringe.\\\\nFigure L\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n13. Attach the needle.\\\\nPress the plunger all\\\\nthe way down to push\\\\nthe air into the vial.\\\\nSee Figure J.\\\\nInvert the syringe and\\\\nvial and slowly\\\\nwithdraw as much of\\\\nthe medicine as\\\\npossible into the\\\\nsyringe. There may be\\\\nmore medicine than\\\\nthe dose amount.\\\\nSee Figure K.\\\\nNote:\\\\n Keep the\\\\nsyringe upright to\\\\navoid leakage.\\\\nHold the syringe\\\\nplunger firmly in place\\\\nas shown to prevent\\\\nleakage. It is normal\\\\nto fee...\",\"Figure M\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\nInjection:\\\\n14. Prepare the injection site.\\\\nFigure N\\\\n \\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n15. Remove the cap.\\\\nPeel open the needle\\\\npackaging part way to\\\\nexpose the needle\\\\nbase.\\\\nKeeping the syringe\\\\nupright, firmly twist\\\\nthe syringe onto the\\\\nneedle.\\\\nRemove the needle\\\\npackaging from the\\\\nneedle. \\\\nSee Figure\\\\nM.\\\\nAPRETUDE must be\\\\nadministered to a\\\\ngluteal site. \\\\nSee\\\\nFigure N\\\\n.\\\\nSelect from the\\\\nfollowing areas for the\\\\ninjection:\\\\nVentrogluteal, as\\\\nshown\\\\n(recommended)\\\\nDorsogluteal, not\\\\nshown (upper outer\\\\nquadrant)\\\\nNote...\",\"Figure O\\\\n\\\\u2022\\\\n\\\\u2022\\\\n16. Remove extra liquid from the syringe.\\\\nFigure P\\\\n\\\\u2022\\\\n \\\\n17. Stretch the skin.\\\\n \\\\n\\\\u2022\\\\n\\\\u2022\\\\nFold the needle guard\\\\naway from the needle.\\\\nSee Figure O.\\\\nPull off the injection\\\\nneedle cap.\\\\nHold the syringe with\\\\nthe needle pointing\\\\nup. Press the plunger\\\\nto the 3 mL dosing\\\\nmark to remove extra\\\\nliquid and any air\\\\nbubbles. \\\\nSee Figure\\\\nP.\\\\nNote:\\\\n Clean the\\\\ninjection site with an\\\\nalcohol wipe. Allow the\\\\nskin to air dry before\\\\ncontinuing.\\\\nUse the z-track\\\\ninjection technique to\\\\nminimize medicine\\\\nleakage ...\",\"Figure Q\\\\n18. Insert the needle.\\\\nFigure R\\\\n\\\\u2022\\\\n19. Inject the dose of medicine.\\\\nFigure S\\\\n\\\\u2022\\\\n\\\\u2022\\\\n\\\\u2022\\\\n20. Assess the injection site.\\\\nInsert the needle to\\\\nits full depth, or deep\\\\nenough to reach the\\\\nmuscle. \\\\nSee Figure\\\\nR.\\\\nStill holding the skin\\\\nstretched \\\\u2013 slowly\\\\npress the plunger all\\\\nthe way down. \\\\nSee\\\\nFigure S.\\\\nEnsure the syringe is\\\\nempty.\\\\nWithdraw the needle\\\\nand release the\\\\nstretched skin\\\\nimmediately.\",\"Figure T\\\\n\\\\u2022\\\\n\\\\u2022\\\\n \\\\n21. Make the needle safe.\\\\nFigure U\\\\n\\\\u2022\\\\nFigure V\\\\n\\\\u2022\\\\n\\\\u2022\\\\nAfter injection:\\\\n22. Dispose safely.\\\\nApply pressure to the\\\\ninjection site using a\\\\ngauze pad. \\\\nSee\\\\nFigure T.\\\\nA small bandage may\\\\nbe used if bleeding\\\\noccurs.\\\\nDo not\\\\n massage the\\\\narea.\\\\nFold the needle guard\\\\nover the needle. \\\\nSee\\\\nFigure U.\\\\nGently apply pressure\\\\nusing a hard surface\\\\nto lock the needle\\\\nguard in place.\\\\nThe needle guard will\\\\nmake a click when it\\\\nlocks. \\\\nSee Figure V.\",\"Figure W\\\\n\\\\u2022\\\\nQuestions and Answers\\\\n1.\\\\n \\\\n2.\\\\n3.\\\\n4.\\\\nManufactured for:\\\\nViiV Healthcare\\\\nDurham, NC 27701\\\\nTrademarks are owned by or licensed to the ViiV Healthcare group of companies.\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\nAPR:5IFU\\\\n \\\\nDispose of used\\\\nneedle, syringe, vial,\\\\nand vial adapter\\\\naccording to local\\\\nhealth and safety\\\\nlaws. \\\\nSee Figure W.\\\\nIf the pack has been stored in the refrigerator, is it safe to warm the\\\\nvial up to room temperature more quickly?\\\\n \\\\nThe vial should be broug...\",\"Principal Display Panel\\\\nNDC 49702-264-23\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nFor gluteal intramuscular use only.\\\\nHealthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 2/24\\\\n\\\\u00a92024 ViiV H...\",\"Principal Display Panel\\\\nNDC 49702-280-63\\\\nApretude\\\\n(cabotegravir extended-release injectable suspension)\\\\n600 mg/3 mL\\\\n(200 mg/mL)\\\\nRx Only\\\\nSample-Not for Sale\\\\nFor gluteal intramuscular use only.\",\"Healthcare Professional Administration Only.\\\\nContents:\\\\n1 Single-dose vial\\\\n1 Vial adapter\\\\n1 Syringe\\\\n1 Injection needle (23 gauge, 1 \\\\u00bd inch)\\\\nPrescribing Information\\\\nPatient Information\\\\nInstructions for Use\\\\nEnsure vial adapter is used correctly.\\\\nViiV Healthcare\\\\n600 mg/ 3 mL Kit\\\\nMade in Singapore and Belgium\\\\nRev. 5/24\\\\n\\\\u00a92024 ViiV Healthcare group of companies or its licensor.\\\\n62000000094179\",\"APRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-264\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-264-\\\\n23\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n12/20/2021\",\"Quantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\nTotal Product Quantity\\\\nPart 1\\\\n1 VIAL\\\\n3 mL\\\\nPart 1 of 1\\\\nCABOTEGRAVIR  \\\\ncabotegravir injection, suspension, extended release\\\\nProduct Information\\\\nItem Code (Source)\\\\nNDC:49702-238\\\\nRoute of Administration\\\\nINTRAMUSCULAR\\\\nActive Ingredient/Active Moiety\\\\nIngredient Name\\\\nBasis of Strength\\\\nStrength\\\\nCABOTEGRAVIR\\\\n (UNII: HMH0132Z1Q) \\\\n(CABOTEGRAVIR - UNII:HMH0132Z1Q)\\\\nCABOTEGRAVIR\\\\n200 mg  in 1 mL\\\\nInactive Ingredients\\\\nIngredient Name\\\\nStrength\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)...\",\"NDA\\\\nNDA215499\\\\n12/20/2021\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Monograph\\\\nCitation\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\nNDA\\\\nNDA215499\\\\n12/20/2021\\\\nAPRETUDE  \\\\ncabotegravir kit\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION DRUG\\\\nItem Code (Source)\\\\nNDC:49702-280\\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-280-\\\\n63\\\\n1 \\\\nin 1 CARTON; Type 1: Convenience Kit of Co-\\\\nPackage\\\\n03/31/2024\\\\nQuantity of Parts\\\\nPart #\\\\nPackage Quantity\\\\n...\",\"ViiV Healthcare Company\\\\nMANNITOL\\\\n (UNII: 3OWL53L36A)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYSORBATE 20\\\\n (UNII: 7T1F30V5YH)\\\\n \\\\nWATER\\\\n (UNII: 059QF0KO0R)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\nWHITE (white to light pink)\\\\nScore\\\\n    \\\\nShape\\\\nSize\\\\nFlavor\\\\nImprint Code\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem Code\\\\nPackage Description\\\\nMarketing Start\\\\nDate\\\\nMarketing End\\\\nDate\\\\n1\\\\nNDC:49702-238-\\\\n61\\\\n3 mL in 1 VIAL; Type 0: Not a Combination\\\\nProduct\\\\nMarketing Information\\\\nMarketing\\\\nCategory\\\\nApplication Number or Mono...\",\"ISENTRESS- raltegravir tablet, film coated \\\\n \\\\nNuCare Pharmaceuticals,Inc.\\\\n----------\\\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\\\nThese highlights do not include all the information needed to use ISENTRESS safely and\\\\neffectively. See full prescribing information for ISENTRESS. \\\\nISENTRESS \\\\n (raltegravir) film-coated tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) chewable tablets, for oral use \\\\nISENTRESS \\\\n (raltegravir) for oral suspension \\\\nInitial U.S. Approval: 2007\\\\nINDICATIONS AND USAGE\\\\nISENTRESS is...\",\"The most common adverse reactions of moderate to severe intensity (\\\\u22652%) are insomnia, headache,\\\\ndizziness, nausea and fatigue ( \\\\n6.1\\\\n).\\\\nCreatine kinase elevations were observed in subjects who received ISENTRESS. Myopathy and\\\\nrhabdomyolysis have been reported. Use with caution in patients at increased risk of myopathy or\\\\nrhabdomyolysis, such as patients receiving concomitant medications known to cause these conditions\\\\nand patients with a history of rhabdomyolysis, myopathy or increased serum cre...\",\"8.5 Geriatric Use\\\\n8.6 Use in Patients with Hepatic Impairment\\\\n8.7 Use in Patients with Renal Impairment\\\\n10 OVERDOSAGE\\\\n11 DESCRIPTION\\\\n12 CLINICAL PHARMACOLOGY\\\\n12.1 Mechanism of Action\\\\n12.2 Pharmacodynamics\\\\n12.3 Pharmacokinetics\\\\n12.4 Microbiology\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\n14 CLINICAL STUDIES\\\\n14.1 \\\\nTreatment-Na\\\\u00efve Adult Subjects\\\\n14.2 Treatment-Experienced Adult Subjects\\\\n14.3 Pediatric Subjects\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\n17 PATIENT ...\",\"Each single-use packet for oral suspension contains 100 mg of raltegravir which is\\\\nsuspended in 5 mL of water giving a final concentration of 20 mg/mL.\\\\n2.2 Adults\\\\nFor the treatment of adult patients with HIV-1 infection, the dosage of ISENTRESS is one\\\\n400 mg film-coated tablet administered orally, twice daily.\\\\n2.3 Pediatrics\\\\nIf at least 25 kg:\\\\n One 400 mg film-coated tablet orally, twice daily.\\\\nIf unable to swallow a tablet, consider the chewable tablet, as specified in Table 1.\\\\nTable 1: Alterna...\",\"*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n11 to less than 14 \\\\n4 mL (80 mg) twice\\\\ndaily\\\\n3 \\\\u00d7 25 mg twice daily\\\\n14 to less than 20 \\\\n5 mL (100 mg) twice\\\\ndaily\\\\n1 \\\\u00d7 100 mg twice\\\\ndaily\\\\n20 to less than 25\\\\n1.5 \\\\u00d7 100 mg \\\\n twice\\\\ndaily\\\\n2.4 Method of Administration\\\\nISENTRESS Film-Coated Tablets\\\\nFilm-Coated Tablets must be swallowed whole\\\\nISENTRESS Chewable Tablets\\\\nChewable Tablets may be chewed or swallowed whole\\\\nISENTRESS For Oral Suspension\\\\nEach single-use ISENTRESS packet for oral suspension contains 100 mg of raltegravir\\\\nwhich is to be sus...\",\"None\\\\n5 WARNINGS AND PRECAUTIONS\\\\n5.1 Severe Skin and Hypersensitivity Reactions\\\\nSevere, potentially life-threatening, and fatal skin reactions have been reported. These\\\\ninclude cases of Stevens-Johnson syndrome and toxic epidermal necrolysis.\\\\nHypersensitivity reactions have also been reported and were characterized by rash,\\\\nconstitutional findings, and sometimes, organ dysfunction, including hepatic failure.\\\\nDiscontinue ISENTRESS and other suspect agents immediately if signs or symptoms of\\\\nsevere...\",\"STARTMRK (Protocol 021) with ISENTRESS 400 mg twice daily in combination with a fixed\\\\ndose of emtricitabine 200 mg (+) tenofovir 300 mg, (N=281) versus efavirenz (EFV) 600\\\\nmg at bedtime in combination with emtricitabine (+) tenofovir, (N=282). During double-\\\\nblind treatment, the total follow-up for subjects receiving ISENTRESS 400 mg twice daily\\\\n+ emtricitabine (+) tenofovir was 1104 patient-years and 1036 patient-years for\\\\nsubjects receiving efavirenz 600 mg at bedtime + emtricitabine (+) tenof...\",\"Analysis)\\\\nRandomized Study Protocol\\\\n021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm (Unit)\\\\nLimit\\\\nISENTRESS\\\\n400 mg \\\\nTwice Daily +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 281)\\\\nEfavirenz 600\\\\nmg \\\\nAt Bedtime +\\\\nEmtricitabine\\\\n(+) Tenofovir \\\\n(N = 282)\\\\nHematology\\\\nAbsolute neutrophil count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n0.75 - 0.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n0.50 - 0.749\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&lt;0.50\\\\n1%\\\\n1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n1%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n1%\\\\n...\",\"ULN = Upper limit of normal range\\\\nLipids, Change from Baseline\\\\nChanges from baseline in fasting lipids are shown in Table 5.\\\\nTable 5: Lipid Values, Mean Change from Baseline, Protocol 021\\\\nLaboratory\\\\nParameter\\\\nPreferred\\\\nTerm\\\\nISENTRESS 400 mg \\\\nTwice Daily + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 207\\\\nEfavirenz 600 mg \\\\nAt Bedtime + Emtricitabine\\\\n(+) Tenofovir \\\\nN = 187\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nChange\\\\nfrom\\\\nBaseline\\\\nat \\\\nWeek\\\\n240\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean\\\\nMean\\\\nChange\\\\nBaseline \\\\nMean\\\\nWeek\\\\n240 \\\\nMean...\",\"OBT. The median duration of therapy in these trials was 96 weeks for subjects receiving\\\\nISENTRESS and 38 weeks for subjects receiving placebo. The total exposure to\\\\nISENTRESS was 708 patient-years versus 244 patient-years on placebo. The rates of\\\\ndiscontinuation due to adverse events were 4% in subjects receiving ISENTRESS and 5%\\\\nin subjects receiving placebo.\\\\nClinical ADRs were considered by investigators to be causally related to ISENTRESS +\\\\nOBT or placebo + OBT. Clinical ADRs of moderate to s...\",\"Grade 4\\\\n&lt;0.50\\\\n1%\\\\n&lt;1%\\\\nHemoglobin (gm/dL)\\\\n  Grade 2\\\\n7.5 - 8.4\\\\n1%\\\\n3%\\\\n  Grade 3\\\\n6.5 - 7.4\\\\n1%\\\\n1%\\\\n  Grade 4\\\\n&lt;6.5\\\\n&lt;1%\\\\n0%\\\\nPlatelet count (10 \\\\n/\\\\u00b5L)\\\\n  Grade 2\\\\n50 - 99.999\\\\n3%\\\\n5%\\\\n  Grade 3\\\\n25 - 49.999\\\\n1%\\\\n&lt;1%\\\\n  Grade 4\\\\n&lt;25\\\\n1%\\\\n&lt;1%\\\\nBlood chemistry\\\\nFasting (non-random) serum glucose test (mg/dL)\\\\n  Grade 2\\\\n126 - 250\\\\n10%\\\\n7%\\\\n  Grade 3\\\\n251 - 500\\\\n3%\\\\n1%\\\\n  Grade 4\\\\n&gt;500\\\\n0%\\\\n0%\\\\nTotal serum bilirubin\\\\n  Grade 2\\\\n1.6 - 2.5 \\\\u00d7 ULN\\\\n6%\\\\n3%\\\\n  Grade 3\\\\n2.6 - 5.0 \\\\u00d7 ULN\\\\n3%\\\\n3%\\\\n  Grade 4\\\\n&gt;5.0 \\\\u00d7 ULN\\\\n1%\\\\n0%\\\\nSerum aspartate aminotransferase...\",\"ULN = Upper limit of normal range\\\\nLess Common Adverse Reactions Observed in Treatment-Na\\\\u00efve and Treatment-\\\\nExperienced Studies\\\\nThe following ADRs occurred in &lt;2% of treatment-na\\\\u00efve or treatment-experienced\\\\nsubjects receiving ISENTRESS in a combination regimen. These events have been\\\\nincluded because of their seriousness, increased frequency on ISENTRESS compared\\\\nwith efavirenz or placebo, or investigator&#x27;s assessment of potential causal relationship.\\\\nGastrointestinal Disorders: \\\\nabdominal pain, ...\",\"upper limit of normal (ULN). In general the safety profile of ISENTRESS in subjects with\\\\nhepatitis B and/or hepatitis C virus co-infection was similar to that in subjects without\\\\nhepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT\\\\nabnormalities were higher in the subgroup with hepatitis B and/or hepatitis C virus co-\\\\ninfection for all treatment groups. At 96 weeks, in treatment-experienced subjects,\\\\nGrade 2 or higher laboratory abnormalities that represent a wors...\",\"patients with underlying liver disease and/or concomitant medications\\\\nMusculoskeletal and Connective Tissue Disorders:\\\\n rhabdomyolysis\\\\nNervous System Disorders: \\\\ncerebellar ataxia\\\\nPsychiatric Disorders: \\\\nanxiety, paranoia\\\\n7 DRUG INTERACTIONS\\\\n7.1 Effect of Raltegravir on the Pharmacokinetics of Other Agents\\\\nRaltegravir does not inhibit (IC \\\\n&gt;100 \\\\u00b5M) CYP1A2, CYP2B6, CYP2C8, CYP2C9,\\\\nCYP2C19, CYP2D6 or CYP3A \\\\nin vitro\\\\n. Moreover, \\\\nin vitro\\\\n, raltegravir did not induce\\\\nCYP1A2, CYP2B6 or CYP3A4. A mid...\",\"rifampin\\\\n\\\\u2193\\\\ndaily during coadministration\\\\nwith rifampin. There are no\\\\ndata to guide co-\\\\nadministration of ISENTRESS\\\\nwith rifampin in patients below\\\\n18 years of age \\\\n[see \\\\nDosage\\\\nand Administration (2.1)\\\\n].\\\\n7.3 Drugs without Clinically Significant Interactions with ISENTRESS\\\\nIn drug interaction studies, raltegravir did not have a clinically meaningful effect on the\\\\npharmacokinetics of the following: hormonal contraceptives, methadone, lamivudine,\\\\ntenofovir, etravirine, darunavir/ritonavir, or boce...\",\"8.3 Nursing Mothers\\\\nBreastfeeding is not recommended while taking ISENTRESS. In addition, it is\\\\nrecommended that HIV-1-infected mothers not breastfeed their infants to avoid risking\\\\npostnatal transmission of HIV-1.\\\\nIt is not known whether raltegravir is secreted in human milk. However, raltegravir is\\\\nsecreted in the milk of lactating rats. Mean drug concentrations in milk were\\\\napproximately 3-fold greater than those in maternal plasma at a maternal dose of 600\\\\nmg/kg/day in rats. There were no ef...\",\"evidence of toxicity.\\\\nIn the event of an overdose, it is reasonable to employ the standard supportive\\\\nmeasures, e.g., remove unabsorbed material from the gastrointestinal tract, employ\\\\nclinical monitoring (including obtaining an electrocardiogram), and institute supportive\\\\ntherapy if required. The extent to which ISENTRESS may be dialyzable is unknown.\\\\n11 DESCRIPTION\\\\nISENTRESS contains raltegravir potassium, a human immunodeficiency virus integrase\\\\nstrand transfer inhibitor. The chemical name fo...\",\"fructose, hydroxypropyl cellulose, hypromellose 2910/6cP, magnesium stearate,\\\\nmannitol, medium chain triglycerides, monoammonium glycyrrhizinate, natural and\\\\nartificial flavors (orange, banana, and masking that contains aspartame), oleic acid, PEG\\\\n400, saccharin sodium, sodium citrate dihydrate, sodium stearyl fumarate, sorbitol,\\\\nsucralose and yellow iron oxide.\\\\nEach packet of ISENTRESS for oral suspension 100 mg, contains 108.6 mg of raltegravir\\\\n(as potassium salt), equivalent to 100 mg of ralt...\",\"formulation comparison study in healthy adult volunteers, the chewable tablet and oral\\\\nsuspension have higher oral bioavailability compared to the 400 mg film-coated tablet.\\\\nIn subjects who received 400 mg twice daily alone, raltegravir drug exposures were\\\\ncharacterized by a geometric mean AUC \\\\n of 14.3 \\\\u00b5M\\\\u2219hr and C \\\\n of 142 nM.\\\\nConsiderable variability was observed in the pharmacokinetics of raltegravir. For\\\\nobserved C \\\\nin Protocols 018 and 019, the coefficient of variation (CV) for inter-\\\\nsubje...\",\"approximately 70% of the total radioactivity; the remaining radioactivity in plasma was\\\\naccounted for by raltegravir-glucuronide. Studies using isoform-selective chemical\\\\ninhibitors and cDNA-expressed UDP-glucuronosyltransferases (UGT) show that UGT1A1\\\\nis the main enzyme responsible for the formation of raltegravir-glucuronide. Thus, the\\\\ndata indicate that the major mechanism of clearance of raltegravir in humans is UGT1A1-\\\\nmediated glucuronidation.\\\\nSpecial Populations\\\\nPediatric\\\\nTwo pediatric fo...\",\"*\\\\n\\\\u2020\\\\nkg\\\\nTable 2\\\\n3 to less\\\\nthan 20\\\\nkg\\\\nOral\\\\nsuspension\\\\nWeight\\\\nbased\\\\ndosing, see\\\\nTable 2\\\\n19\\\\n24.5 ( \\\\n43%\\\\n)\\\\n113 ( \\\\n69%\\\\n)\\\\nThe pharmacokinetics of raltegravir in infants under 4 weeks of age has not been\\\\nestablished.\\\\nAge\\\\nThe effect of age (18 years and older) on the pharmacokinetics of raltegravir was\\\\nevaluated in the composite analysis. No dosage adjustment is necessary.\\\\nRace\\\\nThe effect of race on the pharmacokinetics of raltegravir in adults was evaluated in the\\\\ncomposite analysis. No dosage adjustmen...\",\"with wild-type genotype, the geometric mean ratio (90% CI) of AUC was 1.41 (0.96,\\\\n2.09).\\\\nDrug Interactions\\\\n [see \\\\nDrug Interactions (7)\\\\n]\\\\nTable 10: Effect of Other Agents on the Pharmacokinetics of Raltegravir in\\\\nAdults\\\\nCoadministered\\\\nDrug\\\\nCoadministered\\\\nDrug\\\\nDose/Schedule\\\\nRaltegravir \\\\nDose/Schedule\\\\nRatio (90% Confidence\\\\nInterval) of Raltegravir\\\\nPharmacokinetic Parameters\\\\nwith/without Coadministered\\\\nDrug; \\\\nNo Effect = 1.00\\\\nn\\\\nC \\\\nAUC\\\\nC \\\\naluminum and\\\\nmagnesium\\\\nhydroxide antacid\\\\n20 mL single\\\\ndose gi...\",\"boceprevir\\\\n800 mg three\\\\ntimes daily\\\\n400 mg single\\\\ndose\\\\n22\\\\n(0.91-\\\\n1.36)\\\\n(0.88-\\\\n1.22)\\\\n(0.45-\\\\n1.23)\\\\ncalcium carbonate\\\\nantacid\\\\n3000 mg single\\\\ndose given with\\\\nraltegravir\\\\n400 mg twice\\\\ndaily\\\\n24\\\\n0.48 \\\\n(0.36,\\\\n0.63)\\\\n0.45 \\\\n(0.35,\\\\n0.57)\\\\n0.68 \\\\n(0.53,\\\\n0.87)\\\\nefavirenz\\\\n600 mg daily\\\\n400 mg single\\\\ndose\\\\n9\\\\n0.64\\\\n(0.41,\\\\n0.98)\\\\n0.64\\\\n(0.52,\\\\n0.80)\\\\n0.79\\\\n(0.49,\\\\n1.28)\\\\netravirine\\\\n200 mg twice\\\\ndaily\\\\n400 mg twice\\\\ndaily\\\\n19\\\\n0.89\\\\n(0.68,\\\\n1.15)\\\\n0.90\\\\n(0.68,\\\\n1.18)\\\\n0.66\\\\n(0.34,\\\\n1.26)\\\\nomeprazole\\\\n20 mg daily\\\\n400 mg single\\\\ndose\\\\n14 \\\\n(10\\\\nf...\",\"Raltegravir at concentrations of 31 \\\\u00b1 20 nM resulted in 95% inhibition (EC \\\\n) of viral\\\\nspread (relative to an untreated virus-infected culture) in human T-lymphoid cell cultures\\\\ninfected with the cell-line adapted HIV-1 variant H9IIIB. In addition, 5 clinical isolates of\\\\nHIV-1 subtype B had EC \\\\n values ranging from 9 to 19 nM in cultures of mitogen-\\\\nactivated human peripheral blood mononuclear cells. In a single-cycle infection assay,\\\\nraltegravir inhibited infection of 23 HIV-1 isolates represen...\",\"dolutegravir.\\\\n13 NONCLINICAL TOXICOLOGY\\\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\\\nCarcinogenicity studies of raltegravir in mice did not show any carcinogenic potential. At\\\\nthe highest dose levels, 400 mg/kg/day in females and 250 mg/kg/day in males, systemic\\\\nexposure was 1.8-fold (females) or 1.2-fold (males) greater than the AUC (54 \\\\u00b5M\\\\u2219hr) at\\\\nthe 400-mg twice daily human dose. Treatment-related squamous cell carcinoma of\\\\nnose/nasopharynx was observed in female rats dosed with 6...\",\"Protocol 021\\\\n400 mg Twice\\\\nDaily\\\\n600 mg At\\\\nBedtime\\\\n(N = 281)\\\\n(N = 282)\\\\nGender\\\\n  Male\\\\n81%\\\\n82%\\\\n  Female\\\\n19%\\\\n18%\\\\nRace\\\\n  White\\\\n41%\\\\n44%\\\\n  Black\\\\n12%\\\\n8%\\\\n  Asian\\\\n13%\\\\n11%\\\\n  Hispanic\\\\n21%\\\\n24%\\\\n  Native American\\\\n&lt;1%\\\\n&lt;1%\\\\n  Multiracial\\\\n12%\\\\n13%\\\\nRegion\\\\n  Latin America\\\\n35%\\\\n34%\\\\n  Southeast Asia\\\\n12%\\\\n10%\\\\n  North America\\\\n29%\\\\n32%\\\\n  EU/Australia\\\\n23%\\\\n23%\\\\nAge (years)\\\\n  18-64\\\\n99%\\\\n99%\\\\n  \\\\u226565\\\\n1%\\\\n1%\\\\n  Mean (SD)\\\\n38 (9)\\\\n37 (10)\\\\n  Median (min, max)\\\\n37 (19 to 67)\\\\n36 (19 to 71)\\\\nCD4+ Cell Count (cells/microL)\\\\n  Mean (SD)\\\\n219 (124)\\\\n2...\",\"Notes: \\\\nISENTRESS and Efavirenz were administered with emtricitabine (+) tenofovir \\\\nN = Number of subjects in each group.\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\n  Hepatitis B or C Positive \\\\n6%\\\\n6%\\\\nWeek 240 outcomes from Protocol 021 are shown in Table 12.\\\\nTable 12: Virologic Outcomes of Randomized Treatment\\\\nof Protocol 021 at 240 Weeks\\\\nISENTRESS\\\\n400 mg \\\\nTwice\\\\nDaily \\\\n(N = 281)\\\\nEfavirenz \\\\n600 mg \\\\nAt\\\\nBedtime \\\\n(N = 282)\\\\nDifference \\\\n(ISENTRESS \\\\u2013\\\\nEfavirenz) (CI)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with\\\\nHIV-1 RNA less\\\\nthan 50\\\\ncopies/mL\\\\n66%\\\\n60%\\\\n6.6% \\\\n(-1.4%...\",\"14.2 Treatment-Experienced Adult Subjects\\\\nBENCHMRK 1 and BENCHMRK 2 are Phase 3 studies to evaluate the safety and\\\\nantiretroviral activity of ISENTRESS 400 mg twice daily in combination with an optimized\\\\nbackground therapy (OBT), versus OBT alone, in HIV-1-infected subjects, 16 years or\\\\nolder, with documented resistance to at least 1 drug in each of 3 classes (NNRTIs,\\\\nNRTIs, PIs) of antiretroviral therapies. Randomization was stratified by degree of\\\\nresistance to PI (1PI vs. &gt;1PI) and the use of...\",\"*\\\\nvirus\\\\n83%\\\\n84%\\\\nHepatitis B virus only\\\\n8%\\\\n3%\\\\nHepatitis C virus only\\\\n8%\\\\n12%\\\\nCo-infection of\\\\nHepatitis B and C\\\\nvirus\\\\n1%\\\\n1%\\\\nStratum\\\\nEnfuvirtide in OBT\\\\n38%\\\\n38%\\\\nResistant to \\\\u22652 PI\\\\n97%\\\\n95%\\\\nTable 14 compares the characteristics of optimized background therapy at baseline in\\\\nthe group receiving ISENTRESS 400 mg twice daily and subjects in the control group.\\\\nTable 14: Characteristics of Optimized Background\\\\nTherapy at Baseline\\\\nRandomized Studies \\\\nProtocol 018 and 019\\\\nISENTRESS\\\\n400 mg Twice\\\\nDaily + OBT\\\\nPl...\",\"Week 96 outcomes for the 699 subjects randomized and treated with the\\\\nrecommended dose of ISENTRESS 400 mg twice daily or placebo in the pooled\\\\nBENCHMRK 1 and 2 studies are shown in Table 15.\\\\nTable 15: Virologic Outcomes of Randomized Treatment\\\\nof Protocols 018 and 019 at 96 Weeks (Pooled Analysis)\\\\nISENTRESS \\\\n400 mg Twice\\\\nDaily + OBT \\\\n(N = 462)\\\\nPlacebo + OBT \\\\n(N = 237)\\\\n*\\\\n\\\\u2020\\\\n\\\\u2021\\\\nSubjects with HIV-1\\\\nRNA less than 50\\\\ncopies/mL\\\\n55%\\\\n27%\\\\nVirologic Failure \\\\n35%\\\\n66%\\\\nNo virologic data at\\\\nWeek 96 Window\\\\nReas...\",\"&lt;50 copies/mL \\\\nAt Week 96\\\\nn\\\\nISENTRESS \\\\n400 mg \\\\nTwice Daily +\\\\nOBT \\\\n(N = 462) \\\\nn\\\\nPlacebo +\\\\nOBT \\\\n(N = 237)\\\\n*\\\\nPhenotypic Sensitivity Score (PSS) \\\\n0\\\\n67\\\\n43\\\\n43\\\\n5\\\\n1\\\\n144\\\\n58\\\\n71\\\\n23\\\\n2\\\\n142\\\\n61\\\\n66\\\\n32\\\\n3 or more\\\\n85\\\\n48\\\\n48\\\\n42\\\\nGenotypic Sensitivity Score (GSS) \\\\n0\\\\n116\\\\n39\\\\n65\\\\n5\\\\n1\\\\n177\\\\n62\\\\n95\\\\n26\\\\n2\\\\n111\\\\n61\\\\n49\\\\n53\\\\n3 or more\\\\n51\\\\n49\\\\n23\\\\n35\\\\nSwitch of Suppressed Subjects from Lopinavir (+) Ritonavir to Raltegravir\\\\nThe SWITCHMRK 1 &amp; 2 Phase 3 studies evaluated HIV-1 infected subjects receiving\\\\nsuppressive therapy (HIV-1 RNA &lt;50 cop...\",\"children. This study enrolled 126 treatment experienced children and adolescents 2 to\\\\n18 years of age. Subjects were stratified by age, enrolling adolescents first and then\\\\nsuccessively younger children. Subjects were enrolled into cohorts according to age and\\\\nreceived the following formulations: Cohort I (12 to less than 18 years old), 400 mg film-\\\\ncoated tablet; Cohort IIa (6 to less than 12 years old), 400 mg film-coated tablet; Cohort\\\\nIIb (6 to less than 12 years old), chewable tablet; Cohor...\",\"copies/mL. The mean CD4 count (percent) increase from baseline to Week 48 was 492\\\\ncells/mm \\\\n(7.8%).\\\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\\\nISENTRESS tablets 400 mg are pink, oval-shaped, film-coated tablets with \\\\\"227\\\\\" on one\\\\nside. They are supplied as follows:\\\\nNDC\\\\n 68071-2113-6 \\\\nbottles of 6\\\\nStorage and Handling\\\\n400 mg Film-coated Tablets, Chewable Tablets and For Oral Suspension\\\\nStore at 20-25\\\\u00b0C (68-77\\\\u00b0F); excursions permitted to 15-30\\\\u00b0C (59-86\\\\u00b0F). See USP\\\\nControlled Room Temperature.\\\\nChewable Ta...\",\"General Dosing Instructions\\\\nInstruct patients that if they miss a dose of ISENTRESS, they should take it as soon as\\\\nthey remember. If they do not remember until it is time for the next dose, instruct them\\\\nto skip the missed dose and go back to the regular schedule. Instruct patients not to\\\\ndouble their next dose or take more than the prescribed dose.\\\\nFilm-Coated Tablets and Chewable Tablets\\\\nInform patients that the chewable tablet forms can be chewed or swallowed whole, but\\\\nthe film-coated table...\",\"Whitehouse Station, NJ 08889, USA\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nAll rights reserved.\\\\nuspi-mk0518-mf-1502r030\\\\nPatient Information\\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfilm-coated tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nchewable tablets\\\\n \\\\nISENTRESS\\\\n (\\\\neye \\\\nsen\\\\n tris \\\\n) \\\\n(raltegravir) \\\\nfor oral suspension\\\\nRead this Patient Information before you start taking I...\",\"Ask your doctor if you have any questions on how to prevent passing HIV to other\\\\npeople.\\\\nWhat should I tell my doctor before taking ISENTRESS?\\\\nBefore you take ISENTRESS, tell your doctor if you:\\\\nhave liver problems\\\\nhave a history of a muscle disorder called rhabdomyolysis or myopathy\\\\nhave increased levels of creatine kinase in your blood\\\\nhave phenylketonuria (PKU). ISENTRESS chewable tablets contain phenylalanine as\\\\npart of the artificial sweetener, aspartame. The artificial sweetener may be har...\",\"is time for your next dose, skip the missed dose and go back to your regular\\\\nschedule. Do not double your next dose or take more ISENTRESS than prescribed.\\\\nIf you take too much ISENTRESS, call your doctor or go to the nearest hospital\\\\nemergency room right away.\\\\nWhat are the possible side effects of ISENTRESS?\\\\nISENTRESS can cause serious side effects including:\\\\nSerious skin reactions and allergic reactions. \\\\nSome people who take\\\\nISENTRESS develop serious skin reactions and allergic reactions that...\",\"kidney stones\\\\nindigestion or stomach area pain\\\\nvomiting\\\\nsuicidal thoughts and actions\\\\nweakness\\\\nTell your doctor right away if you get unexplained muscle pain, tenderness, or weakness\\\\nwhile taking ISENTRESS. These may be signs of a rare serious muscle problem that can\\\\nlead to kidney problems.\\\\nTell your doctor if you have any side effect that bothers you or that does not go away.\\\\nThese are not all the possible side effects of ISENTRESS. For more information, ask your\\\\ndoctor or pharmacist.\\\\nCall you...\",\"Inactive ingredients:\\\\n calcium phosphate dibasic anhydrous, hypromellose 2208,\\\\nlactose monohydrate, magnesium stearate, microcrystalline cellulose, poloxamer 407\\\\n(contains 0.01% butylated hydroxytoluene as antioxidant), sodium stearyl fumarate.\\\\nThe film coating contains:\\\\n black iron oxide, polyethylene glycol 3350, polyvinyl\\\\nalcohol, red iron oxide, talc and titanium dioxide.\\\\nISENTRESS chewable tablets:\\\\nActive ingredient: \\\\nraltegravir\\\\nInactive ingredients:\\\\n ammonium hydroxide, crospovidone, ethy...\",\"more information about ISENTRESS.\\\\nYour doctor will decide the right dose based on your child&#x27;s weight.\\\\nAsk your doctor or pharmacist if you have any questions about how to mix or give\\\\nISENTRESS for oral suspension to your child.\\\\nEach ISENTRESS for oral suspension kit contains the following supplies (see\\\\nFigure A\\\\n):\\\\n2 reusable mixing cups with attached lids\\\\n2 reusable 5 mL dosing syringes\\\\n60 foil packets containing ISENTRESS for oral suspension\\\\nFor each dose of ISENTRESS for oral suspension you w...\",\"Step 2. \\\\nFill the dosing syringe. Start with the plunger pushed all the way inside the\\\\nbarrel of the syringe. Insert the tip of the syringe into the water and pull back on the\\\\nplunger to the 5 mL marking on the barrel of the syringe (see \\\\nFigure C\\\\n).\\\\nStep 3. \\\\nPour out remaining water from mixing cup (see \\\\nFigure D\\\\n).\",\"Step 4. \\\\nAdd the 5 mL of water from the dosing syringe back into the mixing cup by\\\\npressing down on the plunger (see \\\\nFigure E\\\\n).\\\\nStep 5. \\\\nOpen 1 foil packet. There is a notch that you can use to tear open the foil\\\\npacket, or you may use scissors to cut along the dotted line. Pour entire contents into\\\\nmixing cup (see \\\\nFigure F\\\\n).\",\"Step 6. \\\\nClose the attached lid to seal the mixing cup (see \\\\nFigure G\\\\n). It will snap shut.\\\\nStep 7. \\\\nSwirl the mixing cup to mix using a gentle circular motion for 30-60 seconds\\\\n(see \\\\nFigure H\\\\n). \\\\nDo not\\\\n turn the mixing cup upside down. The liquid will be cloudy.\\\\nStep 8. \\\\nOpen the mixing cup. Put the tip of the syringe into the liquid and \\\\npull back\\\\nthe plunger to the mL marking that matches your child&#x27;s prescribed dose\\\\n(see \\\\nFigure I\\\\n). Your child&#x27;s dose may be different from the one shown in ...\",\"How should I give a dose of ISENTRESS for oral suspension?\\\\nStep 9.\\\\n Place the tip of the dosing syringe in your child&#x27;s mouth and turn it toward\\\\neither cheek. Gently push down on the plunger to give the medicine (see \\\\nFigure J\\\\n). Give\\\\nthe dose of ISENTRESS oral suspension to your child within 30 minutes of mixing. If you\\\\nare not able to give your child&#x27;s dose within 30 minutes of mixing, pour the unused\\\\nmedicine into the trash. You will need to mix a new dose.\\\\nHow should I dispose of leftover IS...\",\"Step 11. \\\\nRemove plunger from the barrel of the dosing syringe. Hand wash the dosing\\\\nsyringe and mixing cup with warm water and dish soap. Rinse with water and air dry\\\\n(see \\\\nFigure L\\\\n).\\\\nHow should I store ISENTRESS for oral suspension?\\\\nStore ISENTRESS for oral suspension at room temperature between 68\\\\u00b0F to 77\\\\u00b0F\\\\n(20\\\\u00b0C to 25\\\\u00b0C).\\\\nStore in the original container. Do not open the foil packets until ready for use.\\\\nKeep ISENTRESS for oral suspension and all medicines out of the reach of\\\\nchildren.\\\\nFor m...\",\"Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc.\\\\n \\\\nWhitehouse Station, NJ 08889, USA\\\\nIssued December 2013\\\\nFor patent information: www.merck.com/product/patent/home.html\\\\nCopyright \\\\u00a9 2013 Merck Sharp &amp; Dohme Corp., a subsidiary of \\\\nMerck &amp; Co., Inc. \\\\nAll rights reserved.\\\\nifu-mk0518-mf-1312r000\\\\nISENTRESS  \\\\nraltegravir tablet, film coated\\\\nProduct Information\\\\nProduct Type\\\\nHUMAN PRESCRIPTION\\\\nDRUG\\\\nItem Code\\\\n(Source)\\\\nNDC:68071-2113(NDC:0006-\\\\n0227)\\\\nRoute of Administration\\\\nORAL\\\\nActive Ingredi...\",\"NuCare Pharmaceuticals,Inc.\\\\nCELLULOSE, MICROCRYSTALLINE\\\\n (UNII: OP1R32D61U)\\\\n \\\\nPOLOXAMER 407\\\\n (UNII: TUF2IVW3M2)\\\\n \\\\nPOLYETHYLENE GLYCOL 3350\\\\n (UNII: G2M7P15E5P)\\\\n \\\\nPOLYVINYL ALCOHOL\\\\n (UNII: 532B59J990)\\\\n \\\\nFERRIC OXIDE RED\\\\n (UNII: 1K09F3G675)\\\\n \\\\nSODIUM STEARYL FUMARATE\\\\n (UNII: 7CV7WJK4UI)\\\\n \\\\nTALC\\\\n (UNII: 7SEV7J4R1U)\\\\n \\\\nTITANIUM DIOXIDE\\\\n (UNII: 15FIX9V2JP)\\\\n \\\\nProduct Characteristics\\\\nColor\\\\npink (pink)\\\\nScore\\\\nno score\\\\nShape\\\\nOVAL (oval-shaped)\\\\nSize\\\\n16mm\\\\nFlavor\\\\nImprint Code\\\\n227\\\\nContains\\\\n    \\\\nPackaging\\\\n#\\\\nItem C...\"]],[\"color\",{\"type\":\"ndarray\",\"array\":[\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#2ca02c\",\"#2ca02c\",\"#98df8a\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#ffbb78\",\"#98df8a\",\"#999\",\"#98df8a\",\"#98df8a\",\"#98df8a\",\"#999\",\"#2ca02c\",\"#2ca02c\",\"#2ca02c\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#999\",\"#999\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#1f77b4\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ffbb78\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#aec7e8\",\"#aec7e8\",\"#aec7e8\",\"#ff7f0e\",\"#ff7f0e\",\"#ff7f0e\",\"#999\"],\"shape\":[155],\"dtype\":\"object\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3507\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3508\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3503\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3504\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3505\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p3474\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p3489\",\"attributes\":{\"renderers\":\"auto\",\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}},{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p3490\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p3491\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p3492\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p3493\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p3498\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p3499\"}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3484\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3485\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3486\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3487\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3479\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3480\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3481\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3482\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3483\",\"attributes\":{\"axis\":{\"id\":\"p3479\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3488\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p3484\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p3509\",\"attributes\":{\"title\":\"Knowledge Base Tospics\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3510\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Drug Interactions\"},\"renderers\":[{\"id\":\"p3506\"}],\"index\":0}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3511\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Antiretroviral Therapy Side Effects\"},\"renderers\":[{\"id\":\"p3506\"}],\"index\":10}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3512\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Drug Interactions\"},\"renderers\":[{\"id\":\"p3506\"}],\"index\":29}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3513\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"HIV-1 PrEP Safety\"},\"renderers\":[{\"id\":\"p3506\"}],\"index\":52}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3514\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Medication Injection Preparation\"},\"renderers\":[{\"id\":\"p3506\"}],\"index\":58}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3515\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Others\"},\"renderers\":[{\"id\":\"p3506\"}],\"index\":7}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3516\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"Raltegravir Side Effects\"},\"renderers\":[{\"id\":\"p3506\"}],\"index\":108}}]}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}},{\"type\":\"object\",\"name\":\"TabPanel\",\"id\":\"p3586\",\"attributes\":{\"title\":\"Failures\",\"child\":{\"type\":\"object\",\"name\":\"Figure\",\"id\":\"p3522\",\"attributes\":{\"sizing_mode\":\"stretch_width\",\"x_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p3531\",\"attributes\":{\"start\":-8.817975640296936,\"end\":3.2607107162475586}},\"y_range\":{\"type\":\"object\",\"name\":\"Range1d\",\"id\":\"p3532\",\"attributes\":{\"start\":-11.069392323493958,\"end\":0.2476651668548584}},\"x_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3533\"},\"y_scale\":{\"type\":\"object\",\"name\":\"LinearScale\",\"id\":\"p3534\"},\"title\":{\"type\":\"object\",\"name\":\"Title\",\"id\":\"p3529\",\"attributes\":{\"text_color\":\"#E0E0E0\",\"text_font\":\"Helvetica\",\"text_font_size\":\"14pt\"}},\"outline_line_color\":\"#E0E0E0\",\"outline_line_alpha\":0.25,\"renderers\":[{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3561\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3518\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3519\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3520\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"8hy7v8DvrcA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"lI3LwBPH+cA=\"},\"shape\":[2],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"Antiretroviral Therapy Side Effects\",\"HIV-1 PrEP Safety\"]],[\"correctness\",[true,false]],[\"questions\",[\"What percentage of pediatric subjects experienced a Grade 3 or 4 rash when compared to adults in the study?\",\"What was the hazard ratio (with 95% confidence interval) for incident HIV-1 infections among participants who received APRETUDE compared to those who received TRUVADA, based on the extended retrospective virologic testing results?\"]],[\"agent_answer\",[\"The percentage of pediatric subjects who experienced a Grade 3 or 4 rash was 3% (6/182), compared to 0.9% of adults in the study.\",\"The hazard ratio (with 95% confidence interval) for incident HIV-1 infections among participants who received APRETUDE compared to those who received TRUVADA was 0.12 (0.05, 0.31). After further testing, it was found that one of the infections in the APRETUDE group was prevalent, which resulted in a 90% reduction in the risk of HIV-1 incident infection relative to TRUVADA.\"]],[\"reference_answer\",[\"In the study, 3% (6/182) of pediatric subjects experienced a Grade 3 or 4 rash, while only 0.9% of adults reported the same severity of rash.\",\"The hazard ratio for incident HIV-1 infections between participants receiving APRETUDE and TRUVADA was 0.10 (with a 95% CI of 0.04, 0.27), indicating a lower rate of infections in the APRETUDE group.\"]],[\"id\",[12,81]],[\"content\",[\"exception of a higher incidence of rash, which was reported in 32% (59/182) of pediatric\\\\nsubjects compared to 26% of adults, and a higher frequency of Grade 3 or 4 rash\\\\nreported in 3% (6/182) of pediatric subjects compared to 0.9% of adults \\\\n[see \\\\nWarnings\\\\nand Precautions (5.2)\\\\n]\\\\n.\\\\nEmtricitabine:\\\\n \\\\nIn addition to the adverse reactions reported in adults, anemia and\\\\nhyperpigmentation were observed in 7% and 32%, respectively, of pediatric subjects\\\\nwho received treatment with FTC in the larger of ...\",\"mITT from Supplemental Virology Report.\\\\nFollowing the primary analysis, extended retrospective virologic testing was performed\\\\nto better characterize the timing of HIV-1 infections. As a result, 1 of the 4 HIV-1\\\\nincident infections in participants receiving APRETUDE was determined to be a prevalent\\\\ninfection. The original hazard ratio (95% CI) from the primary analysis is 0.12 (0.05,\\\\n0.31).\\\\n(N = 1,613)\\\\n(N = 1,610)\\\\nP\\\\n Value\\\\nPerson-years\\\\n1,960\\\\n1,946\\\\nHIV-1 incident infections\\\\n(incidence rate per 10...\"]],[\"color\",[\"#0a980a\",\"#ba0e0e\"]]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3562\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3563\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3558\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.7},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.7}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3559\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3560\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"field\",\"field\":\"color\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"line_width\":{\"type\":\"value\",\"value\":2},\"fill_color\":{\"type\":\"field\",\"field\":\"color\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"field\",\"field\":\"color\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}},{\"type\":\"object\",\"name\":\"GlyphRenderer\",\"id\":\"p3576\",\"attributes\":{\"data_source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3567\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3568\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3569\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"OjtEwO/0NMBqtxzAgeA8wMn8NMBFuQ/ATmUIwBCitb85NRLAyWcNwBqW87/B3bG/8hy7v8io7L98gN6/SEYvwOgAPcBYwEDAPswMwGb5K8Bdk96/RNaQv8KStr/DJwjAfOdBwMyaG8BxuyLAxU8YwA/kCcBTeiDA4GxLwE1iVcBtRzPASPM9wIdDQMBFWU3AVSBgwD214L9oqum/rQbjv1OcmL9nuOy/BLdtwP2eL8Adi9W/ZgNGwFrUacDvsmDAQupVwJfGaMBQ5WrAHO2BwDAW3cCtLNbAKp3OwNdy18C23eXAwMLhwPgh/cBIYd3ATavVwEW6zMCBR7HAIVKkwKitssCcmZvAt0zAwGbxyMCRTsHAm6DIwAII2MCRjLrAUdinwGR7u8BWOqPAApSJwIwOpMATPbrAeDCswHCMtcAA2KLAwO+twAnn4sAhIN3AoKzNwJmC6cCz3efAzzLtwOQW8MC6ZPjA8IL6wDdbAMHSmePAjgjxwJoy/MBOe+/ANTsHwYYdBMFZVQXBYOIAwSYMBMFjUebAIOfiwC486sDPldHA6NrIwNdzzMCFQsHAdOSKwH7OhsBQQ4jAI46ZwL4hm8Ay82LAPrlBwNTNHcBmeibAFgwwwOc6QMCWr1TAhyxkwIVsisClA33ATwqJwKMBk8B7U5PAZc6UwLUglcB4lo7ACUGEwAB4gMCQi3XA9U9QwCY/L8B+9S7AjkREwEWhU8CTm0DAcddvwKYXfMD/SIHAXp+ZwKC6kcBVOovAw+N9wBLnkcAWEqbA39unwN618cBkZunAWbD6wDZkscCjua/Acx+pwFR8t8A=\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"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\"},\"shape\":[155],\"dtype\":\"float32\",\"order\":\"little\"}]]}}},\"view\":{\"type\":\"object\",\"name\":\"CDSView\",\"id\":\"p3577\",\"attributes\":{\"filter\":{\"type\":\"object\",\"name\":\"AllIndices\",\"id\":\"p3578\"}}},\"glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3573\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}},\"nonselection_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3574\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.1},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.1},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.1}}},\"muted_glyph\":{\"type\":\"object\",\"name\":\"Scatter\",\"id\":\"p3575\",\"attributes\":{\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"size\":{\"type\":\"value\",\"value\":6},\"line_color\":{\"type\":\"value\",\"value\":\"grey\"},\"line_alpha\":{\"type\":\"value\",\"value\":0.2},\"fill_color\":{\"type\":\"value\",\"value\":\"grey\"},\"fill_alpha\":{\"type\":\"value\",\"value\":0.2},\"hatch_color\":{\"type\":\"value\",\"value\":\"grey\"},\"hatch_alpha\":{\"type\":\"value\",\"value\":0.2}}}}}],\"toolbar\":{\"type\":\"object\",\"name\":\"Toolbar\",\"id\":\"p3530\",\"attributes\":{\"logo\":\"grey\",\"tools\":[{\"type\":\"object\",\"name\":\"PanTool\",\"id\":\"p3545\"},{\"type\":\"object\",\"name\":\"WheelZoomTool\",\"id\":\"p3546\",\"attributes\":{\"renderers\":\"auto\"}},{\"type\":\"object\",\"name\":\"BoxZoomTool\",\"id\":\"p3547\",\"attributes\":{\"overlay\":{\"type\":\"object\",\"name\":\"BoxAnnotation\",\"id\":\"p3548\",\"attributes\":{\"syncable\":false,\"level\":\"overlay\",\"visible\":false,\"left\":{\"type\":\"number\",\"value\":\"nan\"},\"right\":{\"type\":\"number\",\"value\":\"nan\"},\"top\":{\"type\":\"number\",\"value\":\"nan\"},\"bottom\":{\"type\":\"number\",\"value\":\"nan\"},\"left_units\":\"canvas\",\"right_units\":\"canvas\",\"top_units\":\"canvas\",\"bottom_units\":\"canvas\",\"line_color\":\"black\",\"line_alpha\":1.0,\"line_width\":2,\"line_dash\":[4,4],\"fill_color\":\"lightgrey\",\"fill_alpha\":0.5}}}},{\"type\":\"object\",\"name\":\"ResetTool\",\"id\":\"p3553\"},{\"type\":\"object\",\"name\":\"SaveTool\",\"id\":\"p3554\"},{\"type\":\"object\",\"name\":\"HoverTool\",\"id\":\"p3521\",\"attributes\":{\"renderers\":[{\"id\":\"p3561\"}],\"tooltips\":\"\\\\n    &lt;div style=\\\\\"width:400px;\\\\\"&gt;\\\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\\\n    &lt;/div&gt;\\\\n    \"}}]}},\"left\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3540\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3541\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3542\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3543\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"below\":[{\"type\":\"object\",\"name\":\"LinearAxis\",\"id\":\"p3535\",\"attributes\":{\"ticker\":{\"type\":\"object\",\"name\":\"BasicTicker\",\"id\":\"p3536\",\"attributes\":{\"mantissas\":[1,2,5]}},\"formatter\":{\"type\":\"object\",\"name\":\"BasicTickFormatter\",\"id\":\"p3537\"},\"axis_label_standoff\":10,\"axis_label_text_color\":\"#E0E0E0\",\"axis_label_text_font\":\"Helvetica\",\"axis_label_text_font_size\":\"1.25em\",\"axis_label_text_font_style\":\"normal\",\"major_label_policy\":{\"type\":\"object\",\"name\":\"AllLabels\",\"id\":\"p3538\"},\"major_label_text_color\":\"#E0E0E0\",\"major_label_text_font\":\"Helvetica\",\"major_label_text_font_size\":\"1.025em\",\"axis_line_color\":\"#E0E0E0\",\"axis_line_alpha\":0,\"major_tick_line_color\":\"#E0E0E0\",\"major_tick_line_alpha\":0,\"minor_tick_line_color\":\"#E0E0E0\",\"minor_tick_line_alpha\":0}}],\"center\":[{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3539\",\"attributes\":{\"axis\":{\"id\":\"p3535\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Grid\",\"id\":\"p3544\",\"attributes\":{\"dimension\":1,\"axis\":{\"id\":\"p3540\"},\"grid_line_color\":\"white\",\"grid_line_alpha\":0.25}},{\"type\":\"object\",\"name\":\"Legend\",\"id\":\"p3564\",\"attributes\":{\"title\":\"Question Correctness\",\"title_text_color\":\"#B1B1B1\",\"title_text_font_style\":\"bold\",\"border_line_alpha\":0,\"background_fill_color\":\"#111516\",\"background_fill_alpha\":0.5,\"label_text_color\":\"#E0E0E0\",\"label_text_font\":\"Helvetica\",\"label_text_font_size\":\"1.025em\",\"label_standoff\":8,\"glyph_width\":15,\"spacing\":8,\"items\":[{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3565\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"False\"},\"renderers\":[{\"id\":\"p3561\"}],\"index\":1}},{\"type\":\"object\",\"name\":\"LegendItem\",\"id\":\"p3566\",\"attributes\":{\"label\":{\"type\":\"value\",\"value\":\"True\"},\"renderers\":[{\"id\":\"p3561\"}],\"index\":0}}]}},{\"type\":\"object\",\"name\":\"LabelSet\",\"id\":\"p3582\",\"attributes\":{\"level\":\"glyph\",\"source\":{\"type\":\"object\",\"name\":\"ColumnDataSource\",\"id\":\"p3579\",\"attributes\":{\"selected\":{\"type\":\"object\",\"name\":\"Selection\",\"id\":\"p3580\",\"attributes\":{\"indices\":[],\"line_indices\":[]}},\"selection_policy\":{\"type\":\"object\",\"name\":\"UnionRenderers\",\"id\":\"p3581\"},\"data\":{\"type\":\"map\",\"entries\":[[\"x\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"Xu3LwBlQ+8DXmYLA8rhBwBOkIsAvK9m/\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"y\",{\"type\":\"ndarray\",\"array\":{\"type\":\"bytes\",\"data\":\"VJP3wGZewMATu1LALg61wL8ZAsE6B9fA\"},\"shape\":[6],\"dtype\":\"float32\",\"order\":\"little\"}],[\"topic\",[\"HIV-1 PrEP Safety\",\"Medication Injection Preparation\",\"Raltegravir Side Effects\",\"Drug Interactions\",\"Antiretroviral Drug Interactions\",\"Antiretroviral Therapy Side Effects\"]]]}}},\"x\":{\"type\":\"field\",\"field\":\"x\"},\"y\":{\"type\":\"field\",\"field\":\"y\"},\"text\":{\"type\":\"field\",\"field\":\"topic\"},\"text_color\":{\"type\":\"value\",\"value\":\"#B1B1B1\"},\"text_font_size\":{\"type\":\"value\",\"value\":\"12pt\"},\"text_font_style\":{\"type\":\"value\",\"value\":\"bold\"},\"text_align\":{\"type\":\"value\",\"value\":\"center\"}}}],\"background_fill_color\":\"#14191B\",\"border_fill_color\":\"#15191C\"}}}}],\"tabs_location\":\"below\"}}]}}';\n",
       "        const render_items = [{\"docid\":\"4059558e-4609-4337-ae1c-8b20cf5c60a1\",\"roots\":{\"p3587\":\"c7f9d35c-3107-478f-9701-7c2cdd51893c\"},\"root_ids\":[\"p3587\"]}];\n",
       "        root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "        }\n",
       "        if (root.Bokeh !== undefined) {\n",
       "          embed_document(root);\n",
       "        } else {\n",
       "          let attempts = 0;\n",
       "          const timer = setInterval(function(root) {\n",
       "            if (root.Bokeh !== undefined) {\n",
       "              clearInterval(timer);\n",
       "              embed_document(root);\n",
       "            } else {\n",
       "              attempts++;\n",
       "              if (attempts > 100) {\n",
       "                clearInterval(timer);\n",
       "                console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "              }\n",
       "            }\n",
       "          }, 10, root)\n",
       "        }\n",
       "      })(window);\n",
       "    });\n",
       "  };\n",
       "  if (document.readyState != \"loading\") fn();\n",
       "  else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "})();\n",
       "    </script>\n",
       "\n",
       "                <div id=\"c7f9d35c-3107-478f-9701-7c2cdd51893c\" data-root-id=\"p3587\" style=\"display: contents;\"></div>\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        <div class=\"section-container\">\n",
       "            <div class=\"section-card\">\n",
       "\n",
       "                <div class=\"section-title\">SELECTED METRICS</div>\n",
       "\n",
       "                \n",
       "\n",
       "            </div>\n",
       "        </div>\n",
       "\n",
       "        \n",
       "    </div>\n",
       "</div>\n",
       "\n",
       "\n",
       "\n",
       "<script type=\"text/javascript\">\n",
       "    function opentab(evt, name) {\n",
       "    // Declare all variables\n",
       "    let i, tabcontent, tablinks;\n",
       "\n",
       "    // Get all elements with class=\"tabcontent\" and hide them\n",
       "    tabcontent = document.getElementsByClassName(\"tabcontent\");\n",
       "    for (i = 0; i < tabcontent.length; i++) {\n",
       "        tabcontent[i].style.display = \"none\";\n",
       "    }\n",
       "\n",
       "    // Get all elements with class=\"tablinks\" and remove the class \"active\"\n",
       "    tablinks = document.getElementsByClassName(\"tablinks\");\n",
       "    for (i = 0; i < tablinks.length; i++) {\n",
       "        tablinks[i].className = tablinks[i].className.replace(\" active\", \"\");\n",
       "    }\n",
       "\n",
       "    // Show the current tab, and add an \"active\" class to the button that opened the tab\n",
       "    document.getElementById(name).style.display = \"block\";\n",
       "    evt.currentTarget.className += \" active\";\n",
       "}\n",
       "</script>\n"
      ],
      "text/plain": [
       "<giskard.rag.report.RAGReport at 0x1f589665880>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "report = evaluate(answer_fn_chain_hyde, testset=testset, knowledge_base=knowledge_base)\n",
    "display(report)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "6cfd9899",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 1200x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import numpy as np\n",
    "\n",
    "def plot_comparative_c_kb():\n",
    "    # Modele\n",
    "    models = [\n",
    "        \"Asi-mini RAG\", \"Asi-mini\",\n",
    "        \"Gpt-3.5 RAG\", \"Gpt-3.5\",\n",
    "        \"Llama3 RAG\", \"Llama3\"\n",
    "    ]\n",
    "\n",
    "    # Valorile medii\n",
    "    c_values = [66.00, 20.00, 72.00, 67.00, 60.67, 12.00]\n",
    "    kb_values = [77.56, 53.13, 86.82, 85.04, 70.31, 73.93]\n",
    "\n",
    "    # Setări pentru poziționarea barelor\n",
    "    x = np.arange(len(models))\n",
    "    width = 0.35  # lățimea fiecărei bare\n",
    "\n",
    "    # Creare grafic\n",
    "    fig, ax = plt.subplots(figsize=(12, 6))\n",
    "    bars1 = ax.bar(x - width/2, c_values, width, label='Corectitudine (C %)', color='teal')\n",
    "    bars2 = ax.bar(x + width/2, kb_values, width, label='Knowledge Base (KB %)', color='orange')\n",
    "\n",
    "    # Etichete peste fiecare bară\n",
    "    for bar in bars1:\n",
    "        height = bar.get_height()\n",
    "        ax.annotate(f'{height:.1f}%',\n",
    "                    xy=(bar.get_x() + bar.get_width() / 2, height),\n",
    "                    xytext=(0, 3), textcoords=\"offset points\",\n",
    "                    ha='center', va='bottom', fontsize=9)\n",
    "\n",
    "    for bar in bars2:\n",
    "        height = bar.get_height()\n",
    "        ax.annotate(f'{height:.1f}%',\n",
    "                    xy=(bar.get_x() + bar.get_width() / 2, height),\n",
    "                    xytext=(0, 3), textcoords=\"offset points\",\n",
    "                    ha='center', va='bottom', fontsize=9)\n",
    "\n",
    "    # Etichete și format\n",
    "    ax.set_ylabel('Procent (%)')\n",
    "    ax.set_xlabel('Model')\n",
    "    ax.set_title('Comparativ Corectitudine și Knowledge Base - Medie per Model')\n",
    "    ax.set_xticks(x)\n",
    "    ax.set_xticklabels(models, rotation=45, ha='right')\n",
    "    ax.legend()\n",
    "\n",
    "    plt.tight_layout()\n",
    "    plt.show()\n",
    "\n",
    "# Apelează funcția\n",
    "plot_comparative_c_kb()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "eae8d6e6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "image/png": "iVBORw0KGgoAAAANSUhEUgAAA90AAAJOCAYAAACqS2TfAAAAOnRFWHRTb2Z0d2FyZQBNYXRwbG90bGliIHZlcnNpb24zLjEwLjMsIGh0dHBzOi8vbWF0cGxvdGxpYi5vcmcvZiW1igAAAAlwSFlzAAAPYQAAD2EBqD+naQAAu6JJREFUeJzs3Xl8DWf///F3kE32EAkSQawlRNGUWFINaajSqq3UvrS2omprrQ2pKkXFrpTb0mqV0pvW0qh9T7hLY19KY08iyCbn94ef8+2RINEcx/J6Ph7nUeeaOdd8rskczdvMXGNlMBgMAgAAAAAAuS6PpQsAAAAAAOBZRegGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGgBwaP368SpYsqbx58yogIMDS5cAC5s+fLysrK506dSrHnx05cqSsrKxyv6gcCA4OVnBwsEVrsJTixYurQ4cOudpnhw4dVLx48Vzt81GdOnVKVlZWmj9/vqVLeSymTZumV155RUePHtXx48f12muvadq0adn+fFb760n4jgJ4thC6ATz17gaguy87OzuVKVNGvXr10oULF3J1W7/++qsGDhyooKAgzZs3T2PHjs3V/p8khw4d0siRIx8pWD4pxo4dqxUrVli6jGfe4sWLNWnSJEuXYVbnz5/XyJEjFR0dbelSzObmzZsaOXKkoqKiLF1KtrVo0ULnzp1TmTJlVKpUKZ04cUItW7a0dFkAYCKfpQsAgNwyevRolShRQsnJydqyZYumT5+u//73v/rf//6n/Pnz58o2Nm7cqDx58mju3LmysbHJlT6fVIcOHdKoUaMUHBz8xJzFy6mxY8fq7bffVtOmTS1dyjNt8eLF+t///qe+fftauhSzOX/+vEaNGqXixYtnusJl9uzZysjIsExh9/D19dWtW7dkbW2d48/evHlTo0aNkqSn5kqIggUL6o8//tCBAwckSZUqVcrR2P/N/gKA7CJ0A3hmhIWFqVq1apKkLl26qECBApo4caJWrlyp1q1b/6u+b968qfz58+vixYuyt7fPtcBtMBiUnJwse3v7XOkPz5en8fhJTk6WjY2N8uR5di62e5IC292rfZ4kN27ckIODg9n6t7a2VtWqVXP0mfT0dGVkZMjGxsas++tp/I4CyH3Pzv/xAOAe9erVkySdPHnS2Paf//xHVatWlb29vdzd3dWqVSudPXvW5HPBwcGqWLGi9u7dqzp16ih//vwaOnSorKysNG/ePN24ccN4Kfvd+wDT09P16aefys/PT7a2tipevLiGDh2qlJQUk76LFy+u119/Xb/88ouqVasme3t7zZw5U1FRUbKystJ3332nUaNGqWjRonJyctLbb7+thIQEpaSkqG/fvipUqJAcHR3VsWPHTH3PmzdP9erVU6FChWRra6sXXnhB06dPz7Rf7tawZcsWvfTSS7Kzs1PJkiW1YMEC4zrz589X8+bNJUmvvPKKcbx3LztduXKlGjVqpCJFisjW1lZ+fn769NNPdfv27Yf+XO7eL3nkyBG1bdtWLi4u8vDw0LBhw2QwGHT27Fk1adJEzs7O8vLy0oQJEzL1kZKSohEjRqhUqVKytbWVj4+PBg4caLJPrKysdOPGDX3zzTfG+v95L+/+/fsVFhYmZ2dnOTo66tVXX9WOHTsybeuPP/5QvXr1ZG9vL29vb4WHh9/3rOaaNWtUu3ZtOTg4yMnJSY0aNdIff/zx0H3yb4+fB5k1a5b8/Pxkb2+vl156SZs3b85yvezs06wEBwfr559/1unTp437+e6VEXeP66VLl+qTTz5R0aJFlT9/fiUmJurq1asaMGCA/P395ejoKGdnZ4WFhSkmJsak/39+N8aMGSNvb2/Z2dnp1Vdf1bFjx0zWPXr0qJo1ayYvLy/Z2dnJ29tbrVq1UkJCwn3rz04dUVFRql69uiSpY8eOmb7/Wd3TnZGRoUmTJqlChQqys7OTp6enunfvrmvXrj1wf0rSgQMH1KFDB5UsWVJ2dnby8vJSp06ddOXKlYd+Nqt7lDt06CBHR0edO3dOTZs2laOjozw8PDRgwADjd/bUqVPy8PCQJI0aNco4xpEjRxr7+fPPP/X222/L3d1ddnZ2qlatmn766SeT7d+93WfTpk3q0aOHChUqJG9vb+PyadOmqUKFCrK1tVWRIkXUs2dPxcfHZxpHZGSkSpYsaXLc3jsXwa1bt/TJJ5/oxRdflIuLixwcHFSnTh399ttvWe6TL774QpMmTTJ+zw4dOpTte+DN+R0F8OzjTDeAZ9bx48clSQUKFJAkjRkzRsOGDVOLFi3UpUsXXbp0SV999ZXq1Kmj/fv3y9XV1fjZK1euKCwsTK1atVLbtm3l6empatWqadasWdq1a5fmzJkjSapZs6akO2fWv/nmG7399tv68MMPtXPnTkVEROjw4cP68ccfTeqKjY1V69at1b17d3Xt2lVly5Y1LouIiJC9vb0GDx6sY8eO6auvvpK1tbXy5Mmja9euaeTIkdqxY4fmz5+vEiVKaPjw4cbPTp8+XRUqVNAbb7yhfPnyadWqVerRo4cyMjLUs2dPkxqOHTumt99+W507d1b79u319ddfq0OHDqpataoqVKigOnXqqE+fPpoyZYqGDh2q8uXLS5Lxv/Pnz5ejo6P69+8vR0dHbdy4UcOHD1diYqLGjx+frZ9Py5YtVb58eX322Wf6+eefFR4eLnd3d82cOVP16tXTuHHjtGjRIg0YMEDVq1dXnTp1JN0JM2+88Ya2bNmibt26qXz58jp48KC+/PJLHTlyxHgP98KFC9WlSxe99NJL6tatmyTJz89P0p0gXbt2bTk7O2vgwIGytrbWzJkzFRwcrE2bNikwMFCSFBcXp1deeUXp6ekaPHiwHBwcNGvWrCzPWi1cuFDt27dXaGioxo0bp5s3b2r69OmqVauW9u/f/8BL9HPr+LnX3Llz1b17d9WsWVN9+/bViRMn9MYbb8jd3V0+Pj7G9bK7T7Py8ccfKyEhQX/99Ze+/PJLSZKjo6PJOp9++qlsbGw0YMAApaSkyMbGRocOHdKKFSvUvHlzlShRQhcuXNDMmTNVt25dHTp0SEWKFDHp47PPPlOePHk0YMAAJSQk6PPPP1ebNm20c+dOSVJqaqpCQ0OVkpKi3r17y8vLS+fOndPq1asVHx8vFxeXLOs/ceLEQ+soX768Ro8ereHDh6tbt26qXbu2pP/7/mele/fumj9/vjp27Kg+ffro5MmTmjp1qvbv36+tW7c+8Oz4unXrdOLECXXs2FFeXl76448/NGvWLP3xxx/asWPHI03ydfv2bYWGhiowMFBffPGF1q9frwkTJsjPz0/vv/++PDw8NH36dL3//vt688039dZbb0m6c7m2dOc7ExQUpKJFixq/C999952aNm2qH374QW+++abJ9nr06CEPDw8NHz5cN27ckHTnH9xGjRqlkJAQvf/++4qNjdX06dO1e/duk30yffp09erVS7Vr11a/fv106tQpNW3aVG5ubiYB/sqVK/r666/1zjvvqFu3bkpISNDcuXMVGhqqXbt2ZboNYN68eUpOTla3bt1ka2srd3f3bN8WYK7vKIDnhAEAnnLz5s0zSDKsX7/ecOnSJcPZs2cNS5cuNRQoUMBgb29v+OuvvwynTp0y5M2b1zBmzBiTzx48eNCQL18+k/a6desaJBlmzJiRaVvt27c3ODg4mLRFR0cbJBm6dOli0j5gwACDJMPGjRuNbb6+vgZJhrVr15qs+9tvvxkkGSpWrGhITU01trdu3dpgZWVlCAsLM1m/Ro0aBl9fX5O2mzdvZqo3NDTUULJkSZO2uzX8/vvvxraLFy8abG1tDR9++KGxbdmyZQZJht9++y1Tv1ltq3v37ob8+fMbkpOTMy37pxEjRhgkGbp162ZsS09PN3h7exusrKwMn332mbH92rVrBnt7e0P79u2NbQsXLjTkyZPHsHnzZpN+Z8yYYZBk2Lp1q7HNwcHB5LN3NW3a1GBjY2M4fvy4se38+fMGJycnQ506dYxtffv2NUgy7Ny509h28eJFg4uLi0GS4eTJkwaDwWC4fv26wdXV1dC1a1eT7cTFxRlcXFxM2u+O/67cOH6ykpqaaihUqJAhICDAkJKSYmyfNWuWQZKhbt26xrac7NOsNGrUKNPxaDD833FdsmTJTMdMcnKy4fbt2yZtJ0+eNNja2hpGjx6dqY/y5cubjGPy5MkGSYaDBw8aDAaDYf/+/QZJhmXLlj2wVl9fX5NjIrt17N692yDJMG/evEx9tm/f3mT8mzdvNkgyLFq0yGS9tWvXZtl+r6y+X0uWLMn0vc3KyZMnM9XZvn17gyST8RgMBkOVKlUMVatWNb6/dOmSQZJhxIgRmfp99dVXDf7+/ibf74yMDEPNmjUNpUuXNrbd/fu4Vq1ahvT0dGP7xYsXDTY2NoYGDRqY7O+pU6caJBm+/vprg8FgMKSkpBgKFChgqF69uiEtLc243vz58zMdt6mpqSbHhMFgMFy9etXg4eFh6NSpU6Z94uzsbLh48eJD99fj+o4CeH5weTmAZ0ZISIg8PDzk4+OjVq1aydHRUT/++KOKFi2q5cuXKyMjQy1atNDly5eNLy8vL5UuXTrT5Yi2trbq2LFjtrb73//+V5LUv39/k/YPP/xQkvTzzz+btJcoUUKhoaFZ9tWuXTuTM2CBgYEyGAzq1KmTyXqBgYE6e/as0tPTjW3/PPuakJCgy5cvq27dujpx4kSmy2tfeOEF49k6SfLw8FDZsmV14sSJh4733m1dv35dly9fVu3atXXz5k39+eef2eqjS5cuxj/nzZtX1apVk8FgUOfOnY3trq6umepatmyZypcvr3Llypn8LO/eTnDvz/Jet2/f1q+//qqmTZuqZMmSxvbChQvrnXfe0ZYtW5SYmCjpzs/25Zdf1ksvvWRcz8PDQ23atDHpc926dYqPj1fr1q1NasqbN68CAwMfWFNuHj//tGfPHl28eFHvvfeeyRwEHTp0yHTW99/u04dp3759pqsDbG1tjfd13759W1euXJGjo6PKli2rffv2ZeqjY8eOJuO4e/zePTbujumXX37RzZs3s11bTuvIjmXLlsnFxUX169c32Z9Vq1aVo6PjQ/fnP/dVcnKyLl++rJdfflmSHrkmSXrvvfdM3teuXTtb3/mrV69q48aNatGihfH7fvnyZV25ckWhoaE6evSozp07Z/KZrl27Km/evMb369evV2pqqvr27WtyP3/Xrl3l7OxsPM737NmjK1euqGvXrsqX7/8uyGzTpo3c3NxMtmFtbW1yTKSmpsre3l41a9bMcj81a9bMeAl9TpjrOwrg+cHl5QCeGZGRkSpTpozy5csnT09PlS1b1vjL3dGjR2UwGFS6dOksP3vvpZ5FixbN9mRpp0+fVp48eVSqVCmTdi8vL7m6uur06dMm7SVKlLhvX8WKFTN5fzdI/PNS4LvtGRkZSkhIMF4+v3XrVo0YMULbt2/PFDoSEhJMgta925EkNze3bN1vKt251PSTTz7Rxo0bjQH1n9vKjqzGamdnp4IFC2Zq/+e9rEePHtXhw4fv+8vzxYsXH7jdS5cu6ebNm1le8lm+fHllZGTo7NmzqlChgk6fPm281Pyf7v3s0aNHJf3fPAL3cnZ2vm89uXn83NuvpEzHvLW1tck/Ntyt/9/s04fJquaMjAxNnjxZ06ZN08mTJ03mA7h7TP/TvcfL3QB295gtUaKE+vfvr4kTJ2rRokWqXbu23njjDeO8AfeT0zqy4+jRo0pISFChQoWyXP6w/Xn16lWNGjVKS5cuzbRudr9f97Kzs8v0883ud/7YsWMyGAwaNmyYhg0bluU6Fy9eVNGiRY3v7/2Z3z0e7/3u2NjYqGTJksbld/977/chX758Wd6i8e233+rLL7/U4cOHTf4uyuqYy+53517m+o4CeH4QugE8M1566SXj7OX3ysjIkJWVldasWWNy9uWue+9BfZSZZrN7n+WD+s6qtge1GwwGSXfuX3/11VdVrlw5TZw4UT4+PrKxsdF///tfffnll5nuW3xYfw8SHx+vunXrytnZWaNHj5afn5/s7Oy0b98+DRo0KNv3SGZVQ3bqysjIkL+/vyZOnJjluvf+A8XjcHfMCxculJeXV6bl/zxjdz+5cfw8KnPv06xqHjt2rIYNG6ZOnTrp008/lbu7u/LkyaO+fftmeQxl59iYMGGCOnTooJUrV+rXX39Vnz59FBERoR07dpjcC/xv6siOjIwMFSpUSIsWLcpy+cPOtrZo0ULbtm3TRx99pICAADk6OiojI0OvvfbaI9d0v/2XHXe3OWDAgPuewb03kD6O2bqXLl2q1q1bq1WrVho0aJAKFSqkvHnzasSIEYqNjc20/r+tyZLfUQBPN0I3gOeCn5+fDAaDSpQooTJlyuRq376+vsrIyNDRo0eNE41J0oULFxQfHy9fX99c3V5WVq1apZSUFP30008mZwT/zWXB9/sFMyoqSleuXNHy5cuNk5tJprPEm5Ofn59iYmL06quvPvSX4KyWe3h4KH/+/Fn+Uv7nn38qT548xpDp6+trPIv9T/d+9u4EbYUKFVJISEi2x3J3G+Y4fu5+7ujRoyZn4NPS0nTy5ElVrlzZpP7s7tOsPMpnvv/+e73yyiuaO3euSXt8fHymqx1ywt/fX/7+/vrkk0+0bds2BQUFacaMGQoPD/9XdeRkjH5+flq/fr2CgoJyHMCuXbumDRs2aNSoUSYTJWZ1HOa2+43x7pUR1tbWOT6+77p7PMbGxppcaZGamqqTJ08a+7273rFjx/TKK68Y10tPT9epU6eME7tJd85ylypVSkuWLDHZ1vXr1x+pxgfVbum/4wE83binG8Bz4a233lLevHk1atSoTGdzDQZDth7Fcz8NGzaUJE2aNMmk/e5Zw0aNGj1y39l19yzWP8eWkJCgefPmPXKfd5+re+/jfLLaVmpqqqZNm/bI28qJFi1a6Ny5c5o9e3amZbdu3TLOlCzdGUNW9Tdo0EArV67UqVOnjO0XLlzQ4sWLVatWLePl4A0bNtSOHTu0a9cu43qXLl3KdAYzNDRUzs7OGjt2rNLS0jLVdenSpfuOx1zHT7Vq1eTh4aEZM2YoNTXV2D5//vxM+yQn+zQrDg4OOb7sOW/evJm+i8uWLct0b3B2JSYmmsxxIN0J4Hny5HngY8+yW8f9vg9ZadGihW7fvq1PP/0007L09PQH9pHV90vKfHyYQ/78+SVlHmOhQoUUHBysmTNn6u+//870uQcd33eFhITIxsZGU6ZMMRnb3LlzlZCQYDzOq1WrpgIFCmj27NkmP89FixZluhTeyspKGRkZJmf/d+7cmeWj//6NJ+HveABPN850A3gu+Pn5KTw8XEOGDDE+fsbJyUknT57Ujz/+qG7dumnAgAGP1HflypXVvn17zZo1y3jp9a5du/TNN9+oadOmJmdrzKVBgwaysbFR48aN1b17dyUlJWn27NkqVKhQlr8kZ0dAQIDy5s2rcePGKSEhQba2tqpXr55q1qwpNzc3tW/fXn369JGVlZUWLlyYrUvTc8O7776r7777Tu+9955+++03BQUF6fbt2/rzzz/13XffGZ+PK0lVq1bV+vXrNXHiRBUpUkQlSpRQYGCgwsPDtW7dOtWqVUs9evRQvnz5NHPmTKWkpOjzzz83bmvgwIFauHChXnvtNX3wwQfGR4b5+vrqwIEDxvWcnZ01ffp0vfvuu3rxxRfVqlUreXh46MyZM/r5558VFBSkqVOnZjkecx0/1tbWCg8PV/fu3VWvXj21bNlSJ0+e1Lx58zLd052TfZqVqlWr6ttvv1X//v1VvXp1OTo6qnHjxg+s7/XXX9fo0aPVsWNH1axZUwcPHtSiRYsy1ZZdGzduVK9evdS8eXOVKVNG6enpWrhwofLmzatmzZr96zr8/Pzk6uqqGTNmyMnJSQ4ODgoMDMzy/t26deuqe/fuioiIUHR0tBo0aCBra2sdPXpUy5Yt0+TJk/X2229nWY+zs7Pq1Kmjzz//XGlpaSpatKh+/fXXx3Ilib29vV544QV9++23KlOmjNzd3VWxYkVVrFhRkZGRqlWrlvz9/dW1a1eVLFlSFy5c0Pbt2/XXX39ler76vTw8PDRkyBCNGjVKr732mt544w3FxsZq2rRpql69utq2bSvpzj3eI0eOVO/evVWvXj21aNFCp06d0vz58+Xn52dyNr5Ro0b68ccf9dZbb+mNN97QiRMnFBkZqRdeeEFJSUm5tl+ehL/jATzlHvd06QCQ2+4+omb37t0PXfeHH34w1KpVy+Dg4GBwcHAwlCtXztCzZ09DbGyscZ26desaKlSokOXns3pkmMFgMKSlpRlGjRplKFGihMHa2trg4+NjGDJkSKbHZ/n6+hoaNWqU6fN3H4t07+OO7je2u4+0uXTpkrHtp59+MlSqVMlgZ2dnKF68uGHcuHGGr7/+2uTRVg+qoW7duiaP4zEYDIbZs2cbSpYsacibN6/J48O2bt1qePnllw329vaGIkWKGAYOHGj45Zdf7vuIsYfVbjDcf99m9fNITU01jBs3zlChQgWDra2twc3NzVC1alXDqFGjDAkJCcb1/vzzT0OdOnUM9vb2Bkkmj4rat2+fITQ01ODo6GjInz+/4ZVXXjFs27Yt0/YPHDhgqFu3rsHOzs5QtGhRw6effmqYO3dupv1qMNz5OYaGhhpcXFwMdnZ2Bj8/P0OHDh0Me/bsyTT+f/q3x8+DTJs2zVCiRAmDra2toVq1aobff/89y591dvdpVpKSkgzvvPOOwdXV1SDJ+Pis+x3XBsOdR3V9+OGHhsKFCxvs7e0NQUFBhu3bt2eq7X593PuopxMnThg6depk8PPzM9jZ2Rnc3d0Nr7zyimH9+vUmn8vqkWHZqcNgMBhWrlxpeOGFFwz58uUz2fa9jwy7a9asWYaqVasa7O3tDU5OTgZ/f3/DwIEDDefPn3/g/vzrr78Mb775psHV1dXg4uJiaN68ueH8+fP3fZzXg/bL3fqy+m5ldSxu27bNULVqVYONjU2m7R0/ftzQrl07g5eXl8Ha2tpQtGhRw+uvv274/vvvjes87O/jqVOnGsqVK2ewtrY2eHp6Gt5//33DtWvXMq03ZcoUg6+vr8HW1tbw0ksvGbZu3WqoWrWq4bXXXjOuk5GRYQgPDzcUK1bMYGtra6hSpYph9erVmX4ed/fJ+PHjs7W/Hvd3FMCzz8pgeEynJgAAAIBHkJGRIQ8PD7311ltZ3gYBAE8y7ukGADxQVFSUypUrp61bt1q6FMDijh49qnLlyum7776zdCnPrOTk5Ey3qyxYsEBXr15VcHCwZYoCgH+Be7oBAA+0YcMGSVLNmjUtXAlgeb///rsuXrxonFwLuW/Hjh3q16+fmjdvrgIFCmjfvn2aO3euKlasqObNm1u6PADIMUI3AOCBtm7dqv79+z/SY6GAZ83WrVv13nvvydHR0dKlPLOKFy8uHx8fTZkyRVevXpW7u7vatWunzz77TDY2NpYuDwByjHu6AQAAAAAwE+7pBgAAAADATAjdAAAAAACYyTN/T3dGRobOnz8vJycn7kcEAAAAAOQKg8Gg69evq0iRIsqT5/7ns5/50H3+/Hn5+PhYugwAAAAAwDPo7Nmz8vb2vu/yZz50Ozk5SbqzI5ydnS1cDQAAAADgWZCYmCgfHx9j5ryfZz50372k3NnZmdANAAAAAMhVD7uNmYnUAAAAAAAwE0I3AAAAAABmQugGAAtxdHQ0eVlbW6tSpUrG5cePH1dYWJjc3NxUtGhRff7559nq98KFC3J3d1dAQICx7fbt23r33Xfl6uqqWrVq6fz588Zl27ZtU3BwsAwGQ66NDQAAAHc88/d0Z9ft27eVlpZm6TKAx8ba2lp58+a1dBnPtaSkJJP3lSpVUqtWrSTd+TvpjTfeUNOmTfXTTz/pxIkTql+/vry9vfXOO+88sN9evXqpSpUqunLlirFt+fLlOnXqlC5cuKChQ4cqIiJCX331ldLS0tS7d28tWrSIxyoCAACYwXMfug0Gg+Li4hQfH2/pUoDHztXVVV5eXoStJ8CuXbt06NAhdejQQZIUGxur2NhYjRgxQtbW1ipbtqw6d+6sWbNmPTB0r1y5UlevXtW7776rSZMmGdtPnDihWrVqydbWVvXr19eUKVMkSePHj1fjxo1Vrlw5cw4PAADgufXch+67gbtQoULKnz8/4QPPBYPBoJs3b+rixYuSpMKFC1u4IsydO1dhYWEqUqSIJCkjI0OSTC75zsjI0IEDB+7bR0JCgvr376+1a9dq69atJsv8/f01duxY3bp1Sxs2bJC/v7+OHTumZcuWaceOHWYYEQAAAKTnPHTfvn3bGLgLFChg6XKAx8re3l6SdPHiRRUqVIhLzS3oxo0bWrp0qRYsWGBsK1u2rIoXL67hw4dr9OjROnbsmL7++mslJibet5+BAweqQ4cOKl26dKbQ3bBhQ23btk2BgYGqWLGiIiMj1bJlS02ePFmrV6/WV199JXt7e02cOFHly5c321gBAACeN8916L57D3f+/PktXAlgGXeP/bS0NEK3BS1btkz58+dXo0aNjG3W1tZauXKl+vXrp6JFi8rb21sdO3bUzJkzs+xj8+bN2rp1q/bt23ff7YSHhys8PFyStHDhQhUrVkwVK1ZUpUqVdPDgQcXExKhTp07avn177g4QAADgOfZch+67uKQczyuO/SfDnDlz1L59e+XLZ/pXcoUKFfTrr78a3w8aNEh169bNso8NGzboxIkTxsvTU1JSdOvWLRUsWFAHDx40uYXgypUrGjdunDZv3qwjR47Ix8dHbm5uqlGjhmJiYswwQgAAgOcXoRsALCg2Nlbbtm3TvHnzMi07cOCA/Pz8ZG1trdWrV+vrr7/Whg0bsuynf//+6tKli/H9smXLNGfOHP3yyy8qVKiQyboDBgzQxx9/LDc3N/n6+urIkSM6d+6c9u/fLz8/v9wdIAAAwHPOos/pvn37toYNG6YSJUrI3t5efn5++vTTT00mDjIYDBo+fLgKFy4se3t7hYSE6OjRoxasGs+6DRs2qHz58rp9+/Yj97F27VoFBAQYJ8MC7mfu3LmqXbu2SpcunWnZd999p2LFisnNzU1ffPGFVqxYYfIc77CwMI0dO1aS5OzsLG9vb+PLzc1N1tbW8vb2Nrl1ICoqSnFxcWrdurUkycvLS8OGDVNAQIA++OADRUZGmnnEAAAAzxcrwz8T7mM2duxYTZw4Ud98840qVKigPXv2qGPHjhozZoz69OkjSRo3bpwiIiL0zTffqESJEho2bJgOHjyoQ4cOyc7O7qHbSExMlIuLixISEuTs7GyyLDk5WSdPnlSJEiVM+qq9un/uDvQhNr8+McefiYuL05gxY/Tzzz/r3LlzKlSokAICAtS3b1+9+uqrZqjy35k/f7769u37VDyarWrVqurfv7/atGkjSdq/f786deqko0eP6pVXXtE333wjd3d3SVJ6eroCAwM1ffp0vfTSSyb9VK9eXX369NG777772MeQXff7DgAAAAB4sAdlzX+y6Jnubdu2qUmTJmrUqJGKFy+ut99+Ww0aNNCuXbsk3TnLPWnSJH3yySdq0qSJKlWqpAULFuj8+fNasWKFJUu3qFOnTqlq1arauHGjxo8fr4MHD2rt2rV65ZVX1LNnz0fuNzU1Ncv2uxPOPQ+2bNmi48ePq1mzZsa2Ll26qF69etq3b58SEhKMZxYlacKECQoKCsoUuCWpQ4cOxmchAwAAAHg+WTR016xZUxs2bNCRI0ckSTExMdqyZYvCwsIkSSdPnlRcXJxCQkKMn3FxcVFgYOBzPbtujx49ZGVlpV27dqlZs2YqU6aMKlSooP79+5s8b/fMmTNq0qSJHB0d5ezsrBYtWujChQvG5SNHjlRAQIDmzJljcqbTyspK06dP1xtvvCEHBweNGTNGkrRy5Uq9+OKLsrOzU8mSJTVq1Cilp6cb+4uPj1f37t3l6ekpOzs7VaxYUatXr1ZUVJQ6duyohIQEWVlZycrKSiNHjpQkFS9eXGPHjlWnTp3k5OSkYsWKadasWSbjPXv2rFq0aCFXV1e5u7urSZMmOnXqlHF5VFSUXnrpJTk4OMjV1VVBQUE6ffq0pDvH1CuvvCInJyc5OzuratWq2rNnz3337dKlS1W/fn2Ts76HDx9W165dVaZMGbVu3VqHDx+WJJ04cUJz58417p97NW7cWHv27NHx48fvuz0AAAAAzzaLhu7BgwerVatWKleunKytrVWlShX17dvXeFlvXFycJMnT09Pkc56ensZl90pJSVFiYqLJ61ly9epVrV27Vj179pSDg0Om5a6urpKkjIwMNWnSRFevXtWmTZu0bt06nThxQi1btjRZ/9ixY/rhhx+0fPlyRUdHG9tHjhypN998UwcPHlSnTp20efNmtWvXTh988IEOHTqkmTNnav78+cbAmZGRobCwMG3dulX/+c9/dOjQIX322WfKmzevatasqUmTJsnZ2Vl///23/v77bw0YMMC4rQkTJqhatWrav3+/evTooffff1+xsbGS7pxlDw0NlZOTk/GRSI6OjnrttdeUmpqq9PR0NW3aVHXr1tWBAwe0fft2devWzTgrd5s2beTt7a3du3dr7969Gjx4sKytre+7fzdv3qxq1aqZtFWuXFnr1q1Tenq6NmzYYLyn9r333tPnn38uJyenLPsqVqyYPD09tXnz5vtuDwAAAMCzzaKzl3/33XdatGiRFi9erAoVKig6Olp9+/ZVkSJF1L59+0fqMyIiQqNGjcrlSp8cx44dk8FgULly5R643oYNG3Tw4EGdPHlSPj4+kqQFCxaoQoUK2r17t6pXry7pziXlCxYskIeHh8nn33nnHXXs2NH4vlOnTho8eLDx51KyZEl9+umnGjhwoEaMGKH169dr165dOnz4sMqUKWNc5y4XFxdZWVnJy8srU60NGzZUjx49JN15JNKXX36p3377TWXLltW3336rjIwMzZkzxxik582bJ1dXV0VFRalatWpKSEjQ66+/bpx1uXz58sa+z5w5o48++si4v7KarOqfTp8+bXzk0l1z5sxRjx499MUXXygoKEhDhgzRwoULlT9/flWvXl2hoaE6fvy4WrVqZXwG8l1FihQxnnUHAAAA8Pyx6Jnujz76yHi229/fX++++6769euniIgISTIGtH9eEn33fVbhTZKGDBmihIQE4+vs2bPmHcRjlt157w4fPiwfHx9j4JakF154Qa6ursbLoyXJ19c3U+CWlOlsb0xMjEaPHi1HR0fjq2vXrvr777918+ZNRUdHy9vb2xi4c+KfszHfDeYXL140bvfYsWNycnIybtfd3V3Jyck6fvy43N3d1aFDB4WGhqpx48aaPHmy/v77b2N/dx+jFBISos8+++yhl3rfunUr04RiFSpU0KZNm3T69GktXrxYaWlpGjFihKZOnarevXurZs2aiomJ0fLly7Vq1SqTz9rb2+vmzZs53icAAAAAng0WDd03b95UnjymJeTNm9f4mKUSJUrIy8vL5Lm0iYmJ2rlzp2rUqJFln7a2tnJ2djZ5PUtKly4tKysr/fnnn7nSX1aXqGfVnpSUpFGjRik6Otr4OnjwoI4ePSo7OzvZ29s/cg33Xu5tZWVlPAaSkpJUtWpVk+1GR0fryJEjeueddyTdOfO9fft21axZU99++63KlCljvLd95MiR+uOPP9SoUSNt3LhRL7zwgn788cf71lKwYEFdu3btgfX2799fffv2lbe3t6KiotS8eXM5ODioUaNGioqKMln36tWrWf6jBgAAAIDng0UvL2/cuLHGjBmjYsWKqUKFCtq/f78mTpyoTp06SboTvvr27avw8HCVLl3a+MiwIkWKqGnTppYs3WLc3d0VGhqqyMhI9enTJ1M4jo+Pl6urq8qXL6+zZ8/q7NmzxrPdhw4dUnx8vF544YUcb/fFF19UbGysSpUqleXySpUq6a+//tKRI0eyPNttY2PzSM+9fvHFF/Xtt9+qUKFCD/wHlCpVqqhKlSoaMmSIatSoocWLF+vll1+WJJUpU0ZlypRRv3791Lp1a82bN09vvvnmffs5dOjQfbezYcMGHT58WPPmzZN051nzd2d3v3eW97tn46tUqZKjMePp1XXaVUuXYBGze7hbugQAAPD/OTo6mrxPSUlR+fLldeDAAWPbTz/9pOHDh+vo0aNycXHR8OHD9d5772Xq6+LFi+rXr582bdqkxMRE+fn5adSoUXrjjTck3flduEOHDlq1apUqVqyo7777znir5rZt2zR06FD99ttvxttEn1cWPdP91Vdf6e2331aPHj1Uvnx5DRgwQN27d9enn35qXGfgwIHq3bu3unXrpurVqyspKUlr1659rp8pHBkZqdu3b+ull17SDz/8oKNHj+rw4cOaMmWK8QqAkJAQ+fv7q02bNtq3b5927dqldu3aqW7dupkuHc+O4cOHa8GCBRo1apT++OMPHT58WEuXLtUnn3wiSapbt67q1KmjZs2aad26dTp58qTWrFmjtWvXSrozS3lSUpI2bNigy5cvZ/uS6zZt2qhgwYJq0qSJNm/erJMnTyoqKkp9+vTRX3/9pZMnT2rIkCHavn27Tp8+rV9//VVHjx5V+fLldevWLfXq1UtRUVE6ffq0tm7dqt27d5vc832v0NBQbdmyJctlycnJ6tWrl2bNmmW8QiMoKEiRkZGKiYnRDz/8oKCgIOP6O3bskK2t7X2vygAAAAByW1JSksmrfPnyatWqlXH52rVr1aNHD02aNEmJiYn6448/FBwcfN++qlSpoh07dig+Pl6jR49W69atjSepli9frlOnTunChQsKDAw03iaclpam3r17a8aMGc994JYsHLqdnJw0adIknT59Wrdu3dLx48cVHh4uGxsb4zpWVlYaPXq04uLilJycrPXr1z/SfcPPkpIlS2rfvn165ZVX9OGHH6pixYqqX7++NmzYoOnTp0u6s99WrlwpNzc31alTRyEhISpZsqS+/fbbR9pmaGioVq9erV9//VXVq1fXyy+/rC+//FK+vr7GdX744QdVr15drVu31gsvvKCBAwcaz27XrFlT7733nlq2bCkPDw99/vnn2dpu/vz59fvvv6tYsWJ66623VL58eXXu3FnJyclydnZW/vz59eeffxofndatWzf17NlT3bt3V968eXXlyhW1a9dOZcqUUYsWLRQWFvbAifbatGmjP/74wzh7+j+NGjVKjRo1UkBAgLFtypQpio6OVp06ddS4cWOT53svWbJEbdq0Uf78+bM1VgAAACA37dq1S4cOHVKHDh2MbcOGDdPw4cMVHBysvHnzys3N7b6TNJcsWVIDBgyQt7e38uTJo8aNG6ts2bLGWzlPnDihWrVqydbWVvXr1zfOnzR+/Hg1btz4oZM/Py+sDNmdmesplZiYKBcXFyUkJGS6PDk5OVknT540eUY18NFHHykxMVEzZ8585D4uX76ssmXLas+ePSpRokQuVpe7+A7kLi4vBwAAT5Lu3bvr/Pnzxsl+b9y4IScnJw0bNkxLlixRYmKiateurSlTpqhw4cIP7e/ixYvy9fU1Pmb3v//9r8aOHat169Zp+PDhypMnj7p27armzZsbr/p8lj0oa/6TRc90A0+ijz/+WL6+vsbJ3B7FqVOnNG3atCc6cAMAAODZdePGDS1dulRdunQxtl27dk0Gg0ErVqzQunXrdOzYMdna2qpt27YP7S81NVWtWrVSixYtjLerNmzYUMHBwQoMDNS5c+c0ePBg9ejRQ5MnT9bq1asVHByssLAwk6cnPY8sOpEa8CRydXXV0KFD/1Uf1apVe6R75wEAAIDcsGzZMuXPn1+NGjUytt2dZK1Pnz7G20RHjRql0qVL68aNG/d9slFqaqrefvtt5c+fX7NnzzZZFh4ervDwcEnSwoULVaxYMVWsWFGVKlXSwYMHFRMTo06dOmn79u3mGOZTgdANAAAAAM+YOXPmqH379sqX7/8in6urq4oVK5bl+ve76zg1NVXNmzdXamqqVq5caTL/1j9duXJF48aN0+bNm3XkyBH5+PjIzc1NNWrUUExMzL8f0FOMy8sBAAAA4BkSGxurbdu2qXPnzpmWdevWTV999ZXOnTunW7duafTo0Xr11VczPWpMujMLeYsWLXTjxg2tWLHigfdoDxgwQB9//LHc3Nzk6+urI0eO6Ny5c1q3bp38/PxydXxPG850AwAAAMAzZO7cuapdu7ZKly6dadngwYN19epVVa5cWZL0yiuvaOHChcblYWFhql27toYOHapt27Zp5cqVsrOzU8GCBY3rDB061OR2zKioKMXFxal169aSJC8vLw0bNkwBAQFydnbWvHnzzDXUpwKzlzNzM55jfAdyF7OXAwAAPD+YvRwAAAAAAAsjdAMAAAAAYCaEbgAAAAAAzITQjVxx6tQpWVlZKTo6+l/1ExwcrL59++ZKTU+r2NhYeXl56fr164/cx6FDh+Tt7a0bN27kYmUAAAAAcorZy7PwuCdDyukkRB06dFB8fLxWrFhhbPv+++/Vtm1bjRkzRh9++GEuV/jssbKyMv45b968KlKkiN5++21FREQ88FEIj8OQIUPUu3dvOTk5SbrzDxrt2rXT3r17VbVqVS1YsEDFixc3rv/666+rY8eOatasmbHthRde0Msvv6yJEydq2LBhj3sIAAAAAP4/znQ/A+bMmaM2bdpo+vTpBO4cmDdvnv7++2+dPHlS06ZN08KFCxUeHm7Rms6cOaPVq1erQ4cOxrYPP/xQRYsWVXR0tAoXLqwBAwYYl3377bfKkyePSeC+q2PHjpo+fbrS09MfR+kAAAAAskDofsp9/vnn6t27t5YuXaqOHTsa24ODg9WnTx8NHDhQ7u7u8vLy0siRI00+e+bMGTVp0kSOjo5ydnZWixYtdOHCBUlSQkKC8ubNqz179kiSMjIy5O7urpdfftn4+f/85z/y8fG5b23/+9//FBYWJkdHR3l6eurdd9/V5cuXjctv3Lihdu3aydHRUYULF9aECRMy9fH333+rUaNGsre3V4kSJbR48WIVL15ckyZNMq4THx+vLl26yMPDQ87OzqpXr55iYmIeuu9cXV3l5eUlHx8fvf7662rSpIn27dtnXH78+HE1adJEnp6ecnR0VPXq1bV+/XqTPqZNm6bSpUvLzs5Onp6eevvtt43LMjIyFBERoRIlSsje3l6VK1fW999//8CavvvuO1WuXFlFixY1th0+fFjt27dX6dKl1aFDBx0+fNg47k8++USRkZFZ9lW/fn1dvXpVmzZteui+AAAAAGAeXF7+FBs0aJCmTZum1atX69VXX820/JtvvlH//v21c+dObd++XR06dFBQUJDq16+vjIwMY+DetGmT0tPT1bNnT7Vs2VJRUVFycXFRQECAoqKiVK1aNR08eFBWVlbav3+/kpKSjJ+rW7dulrXFx8erXr166tKli7788kvdunVLgwYNUosWLbRx40ZJ0kcffaRNmzZp5cqVKlSokIYOHap9+/YpICDA2E+7du10+fJlRUVFydraWv3799fFixdNttW8eXPZ29trzZo1cnFx0cyZM/Xqq6/qyJEjcnfP3qX7R44c0caNG03OMCclJalhw4YaM2aMbG1ttWDBAjVu3FixsbEqVqyY9uzZoz59+mjhwoWqWbOmrl69qs2bNxs/HxERof/85z+aMWOGSpcurd9//11t27aVh4fHfffb5s2bVa1aNZO2ypUra/369WrQoIF+/fVXVapUybj/evbsed9/+LCxsVFAQIA2b96c5fEBAACAJ9/jvvX1SZHTW3CfZITup9SaNWu0cuVKbdiwQfXq1ctynUqVKmnEiBGSpNKlS2vq1KnasGGD6tevrw0bNujgwYM6efKkMbQtWLBAFSpU0O7du1W9enUFBwcrKipKAwYMUFRUlOrXr68///xTW7Zs0WuvvaaoqCgNHDgwy21PnTpVVapU0dixY41tX3/9tXx8fHTkyBEVKVJEc+fO1X/+8x9jIPzmm2/k7e1tXP/PP//U+vXrtXv3bmMQnTNnjkqXLm1cZ8uWLdq1a5cuXrxovBf7iy++0IoVK/T999+rW7du992HrVu3Vt68eZWenq6UlBS9/vrrGjJkiHF55cqVVblyZeP7Tz/9VD/++KN++ukn9erVS2fOnJGDg4Nef/11OTk5ydfXV1WqVJEkpaSkaOzYsVq/fr1q1KghSSpZsqS2bNmimTNn3jd0nz59OlPo/uKLL9S9e3cVL15clSpV0syZM/X7778rOjpa48aNU4sWLbRnzx41aNBAU6ZMkY2NjfGzRYoU0enTp++7DwAAAACYF6H7KVWpUiVdvnxZI0aM0EsvvSRHR8cs1/mnwoULG88SHz58WD4+PiZnSV944QW5urrq8OHDql69uurWrau5c+fq9u3b2rRpkxo0aCAvLy9FRUWpUqVKOnbsmIKDg7OsLyYmRr/99luWdR0/fly3bt1SamqqAgMDje3u7u4qW7as8X1sbKzy5cunF1980dhWqlQpubm5mWwnKSlJBQoUMNnGrVu3dPz48Sxru+vLL79USEiIbt++rWPHjql///569913tXTpUkl3znSPHDlSP//8s/7++2+lp6fr1q1bOnPmjKQ7l2/7+vqqZMmSeu211/Taa6/pzTffVP78+XXs2DHdvHlT9evXN9lmamqqMZhn5datW7KzszNpK1q0qFavXm18n5KSotDQUH3zzTcKDw+Xk5OTYmNj9dprr2nmzJnq3bu3cV17e3vdvHnzgfsBAAAAgPkQup9SRYsW1ffff69XXnlFr732mtasWWOc7foua2trk/dWVlbKyMjI9jbq1Kmj69eva9++ffr99981duxYeXl56bPPPlPlypVVpEgRk7PO/5SUlKTGjRtr3LhxmZYVLlxYx44dy3YdD5KUlKTChQsrKioq0zJXV9cHftbLy0ulSpWSJJUtW1bXr19X69atFR4erlKlSmnAgAFat26dvvjiC5UqVUr29vZ6++23lZqaKklycnLSvn37FBUVpV9//VXDhw/XyJEjtXv3biUlJUmSfv75Z5P7syU9cHb0ggUL6tq1aw+se+zYsWrQoIGqVq2qrl27Kjw8XNbW1nrrrbe0ceNGk9B99epV+fn5PbA/AAAAAOZD6H6K+fr6atOmTcbgvXbt2kzB+37Kly+vs2fP6uzZs8az3YcOHVJ8fLxeeOEFSXdCa6VKlTR16lRZW1urXLlyKlSokFq2bKnVq1ff9xJpSXrxxRf1ww8/qHjx4sqXL/Nh5ufnJ2tra+3cuVPFihWTJF27dk1Hjhwx9lu2bFmlp6dr//79qlq1qiTp2LFjJqH0xRdfVFxcnPLly2fyGK1HkTdvXkl3zjZL0tatW9WhQwe9+eabku4E/FOnTpl8Jl++fAoJCVFISIhGjBghV1dXbdy4UfXr15etra3OnDnzwP10rypVqujQoUP3XX748GEtXrzY+Dz027dvKy0tTZKUlpam27dvm6z/v//9z2RyNwAAAACPF7OXP+V8fHwUFRWlixcvKjQ0VImJidn6XEhIiPz9/dWmTRvt27dPu3btUrt27VS3bl2Te4qDg4O1aNEiY3B0d3dX+fLl9e233z4wTPbs2VNXr15V69attXv3bh0/fly//PKLOnbsqNu3b8vR0VGdO3fWRx99pI0bN+p///ufOnTooDx5/u+QLFeunEJCQtStWzft2rVL+/fvV7du3WRvb298znZISIhq1Kihpk2b6tdff9WpU6e0bds2ffzxx8aZ1+8nPj5ecXFxOn/+vDZt2qTRo0erTJkyKl++vKQ798EvX75c0dHRiomJ0TvvvGNypcDq1as1ZcoURUdH6/Tp01qwYIEyMjJUtmxZOTk5acCAAerXr5+++eYbHT9+XPv27dNXX32lb7755r41hYaGavv27ZnCsyQZDAZ169ZNX375pRwcHCRJQUFBmj17tg4fPqwFCxYoKCjIuP6pU6d07tw5hYSEPHA/AAAAADAfQvczwNvbW1FRUbp8+XK2g7eVlZVWrlwpNzc31alTRyEhISpZsqS+/fZbk/Xq1q2r27dvm9y7HRwcnKntXkWKFNHWrVt1+/ZtNWjQQP7+/urbt69cXV2NwXr8+PGqXbu2GjdurJCQENWqVct4RvuuBQsWyNPTU3Xq1NGbb76prl27ysnJyXjfs5WVlf773/+qTp066tixo8qUKaNWrVrp9OnT8vT0fOA+6NixowoXLixvb2+1bt1aFSpU0Jo1a4xn5idOnCg3NzfVrFlTjRs3VmhoqMn95a6urlq+fLnq1aun8uXLa8aMGVqyZIkqVKgg6c7Ea8OGDVNERITKly+v1157TT///LNKlChx35rCwsKUL1++TI8mk6RZs2bJ09NTr7/+urFt5MiRSk5OVmBgoEqVKqWePXsaly1ZskQNGjSQr6/vA/cDAAAAAPOxMhgMBksXYU6JiYlycXFRQkKCnJ2dTZYlJyfr5MmTKlGiRKbJq/Bk+uuvv+Tj46P169c/s4/BioyM1E8//aRffvnlkftITU1V6dKltXjxYpOz3/fiO5C7eKQHAADIbfx+8eR6UNb8J+7pxhNt48aNSkpKkr+/v/7++28NHDhQxYsXV506dSxdmtl0795d8fHxun79erbv0b/XmTNnNHTo0AcGbgAAAADmR+jGEy0tLU1Dhw7ViRMn5OTkpJo1a2rRokWZZmZ/luTLl08ff/zxv+qjVKlSxpnZAQAAAFgOoRtPtNDQUIWGhlq6DAAAAAB4JEykBgAAAACAmRC6AQAAAAAwE0K3ZPLsZeB5wrEPAAAAmNdzfU+3jY2N8uTJo/Pnz8vDw0M2NjaysrKydFmA2RkMBqWmpurSpUvKkyePbGxsLF0SAAAA8Ex6rkN3njx5VKJECf399986f/68pcsBHrv8+fOrWLFiypOHi14AAAAAc3iuQ7d052x3sWLFlJ6ertu3b1u6HOCxyZs3r/Lly8fVHQAAAIAZPfehW5KsrKxkbW39TD/7GQAAAADw+HFNKQAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAAAAAAzIXQDAAAAAGAmhG4AAAAAAMyE0A0AAAAAgJkQugEAAAAAMBNCNwAAAAAAZmLR0F28eHFZWVllevXs2VOSlJycrJ49e6pAgQJydHRUs2bNdOHCBUuWDAAAAABAtlk0dO/evVt///238bVu3TpJUvPmzSVJ/fr106pVq7Rs2TJt2rRJ58+f11tvvWXJkgEAAAAAyLZ8lty4h4eHyfvPPvtMfn5+qlu3rhISEjR37lwtXrxY9erVkyTNmzdP5cuX144dO/Tyyy9bomQAAAAAALLtibmnOzU1Vf/5z3/UqVMnWVlZae/evUpLS1NISIhxnXLlyqlYsWLavn27BSsFAAAAACB7LHqm+59WrFih+Ph4dejQQZIUFxcnGxsbubq6mqzn6empuLi4+/aTkpKilJQU4/vExERzlAsAAAAAwEM9MWe6586dq7CwMBUpUuRf9RMRESEXFxfjy8fHJ5cqBAAAAAAgZ56I0H369GmtX79eXbp0MbZ5eXkpNTVV8fHxJuteuHBBXl5e9+1ryJAhSkhIML7Onj1rrrIBAADwjPnpp58UEBAgBwcHFSlSRDNmzDAumzNnjsqWLSsHBwcVL15cK1euzLKPzZs3y9HR0eSVJ08e9enTR5J0+/Ztvfvuu3J1dVWtWrV0/vx542e3bdum4OBgGQwG8w4UwGPzRITuefPmqVChQmrUqJGxrWrVqrK2ttaGDRuMbbGxsTpz5oxq1Khx375sbW3l7Oxs8gIAAAAeZu3aterRo4cmTZqkxMRE/fHHHwoODpYkzZo1SxMmTNDSpUuVlJSknTt3yt/fP8t+ateuraSkJOPr+PHjyps3r1q1aiVJWr58uU6dOqULFy4oMDBQERERkqS0tDT17t1bM2bMkJWV1WMZMwDzs/g93RkZGZo3b57at2+vfPn+rxwXFxd17txZ/fv3l7u7u5ydndW7d2/VqFGDmcsBAACQ64YNG6bhw4cbg7abm5vc3Nx0+/ZtDR8+XAsWLFCVKlUk3ZlnKLu++eYblS5dWjVr1pQknThxQrVq1ZKtra3q16+vKVOmSJLGjx+vxo0bq1y5crk7MAAWZfEz3evXr9eZM2fUqVOnTMu+/PJLvf7662rWrJnq1KkjLy8vLV++3AJVAgAA4Fl248YN7d27V+fOnVOZMmXk5eWl5s2b6++//1ZsbKwuXLigffv2qXjx4vL29lbXrl2zPWHv119/rc6dOxvf+/v7a/Pmzbp165Y2bNggf39/HTt2TMuWLdOQIUPMNUQAFmLx0N2gQQMZDAaVKVMm0zI7OztFRkbq6tWrunHjhpYvX/7A+7kBAACAR3Ht2jUZDAatWLFC69at07Fjx2Rra6u2bdvq6tWrku6cLNqzZ4+io6N18uRJ9evX76H9bt68WSdOnFC7du2MbQ0bNlRwcLACAwN17tw5DR48WD169NDkyZO1evVqBQcHKywsTIcPHzbbeAE8Pha/vBwAAACwNEdHR0lSnz595OvrK0kaNWqUSpcurdGjR0u6M2FvwYIFjX9u3br1Q/udO3eu3njjDXl4eJi0h4eHKzw8XJK0cOFCFStWTBUrVlSlSpV08OBBxcTEqFOnTtq+fXuujRGAZRC6AQAA8NxzdXVVsWLFslxWqVIl2dnZ5bjPxMRELVu2TD/88MN917ly5YrGjRunzZs368iRI/Lx8ZGbm5tq1KihmJiYHG8TwJPH4peXAwAAAE+Cbt266auvvtK5c+d069YtjR49Wq+++qqcnJzUtm1bjRs3TteuXVN8fLzGjRunJk2aPLC/JUuWqECBAmrQoMF91xkwYIA+/vhjubm5ydfXV0eOHNG5c+e0bt06+fn55fYQAVgAoRsAAACQNHjwYL366quqXLmyfHx8dPPmTS1cuFCSNGnSJBUpUkQlSpRQ2bJl5evrq4kTJxo/W6FCBS1atMikv7lz56pjx47KkyfrX7mjoqIUFxdnvEzdy8tLw4YNU0BAgD744ANFRkaaaaQAHicrg8FgsHQR5pSYmCgXFxclJCTwzG4AZtV12lVLl2ARs3u4W7oEAACeWfx+8eTKbtbkTDcAAAAAAGZC6AYAAAAAwEwI3QAAAAAAmAmhGwAAAAAAMyF0AwAAAABgJoRuAAAAAADMJJ+lCwAAAAByG49ZAvCk4Ew3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzMTiofvcuXNq27atChQoIHt7e/n7+2vPnj3G5QaDQcOHD1fhwoVlb2+vkJAQHT161IIVAwAAAACQPRYN3deuXVNQUJCsra21Zs0aHTp0SBMmTJCbm5txnc8//1xTpkzRjBkztHPnTjk4OCg0NFTJyckWrBwAAAAAgIfLZ8mNjxs3Tj4+Ppo3b56xrUSJEsY/GwwGTZo0SZ988omaNGkiSVqwYIE8PT21YsUKtWrV6rHXDAAAAABAdln0TPdPP/2katWqqXnz5ipUqJCqVKmi2bNnG5efPHlScXFxCgkJMba5uLgoMDBQ27dvz7LPlJQUJSYmmrwAAAAAALAEi4buEydOaPr06SpdurR++eUXvf/+++rTp4+++eYbSVJcXJwkydPT0+Rznp6exmX3ioiIkIuLi/Hl4+Nj3kEAAAAAAHAfFg3dGRkZevHFFzV27FhVqVJF3bp1U9euXTVjxoxH7nPIkCFKSEgwvs6ePZuLFQMAAAAAkH0WDd2FCxfWCy+8YNJWvnx5nTlzRpLk5eUlSbpw4YLJOhcuXDAuu5etra2cnZ1NXgAAAAAAWIJFQ3dQUJBiY2NN2o4cOSJfX19JdyZV8/Ly0oYNG4zLExMTtXPnTtWoUeOx1goAAAAAQE5ZdPbyfv36qWbNmho7dqxatGihXbt2adasWZo1a5YkycrKSn379lV4eLhKly6tEiVKaNiwYSpSpIiaNm1qydIBAAAAAHgoi4bu6tWr68cff9SQIUM0evRolShRQpMmTVKbNm2M6wwcOFA3btxQt27dFB8fr1q1amnt2rWys7OzYOUAAAAAADycRUO3JL3++ut6/fXX77vcyspKo0eP1ujRox9jVQAAAAAA/HsWvacbAAAAAIBnGaEbAAAAAAAzIXQDAAAAAGAmhG4AAAAAAMyE0A0AAAAAgJkQugEAAAAAMBNCNwAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAAAAAAzIXQDAAAAAGAmhG4AAAAAAMyE0A0AAAAAgJkQugEAAAAAMBNCNwAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAAAAAAzIXQDAAAAAGAmhG4AAAAAAMyE0A0AAAAAgJkQugEAAAAAMBNCNwAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAD8Kx06dJCNjY0cHR2Nr+3btxuXp6WlqVevXnJzc5O7u7t69+6t9PT0+/Z37tw5NW3aVAUKFFDBggXVokULXbp0ybh80qRJKlSokEqVKqXff//d2B4fH68KFSqYrAsAgKURugEAwL/Wo0cPJSUlGV81atQwLgsPD9eWLVt06NAh/fHHH9q8ebPGjh1737569uwpSTp9+rROnjyp5ORk9enTR5IUFxen8PBwxcTEaOLEicZ1JWnQoEEaMGCAPDw8zDRKAAByjtANAADM6uuvv9Ynn3yiwoULq3Dhwvr44481d+7c+65/4sQJtWjRQo6OjnJyclLLli118OBBSXeCeOnSpVW4cGE1aNBAx48flyRt3bpVR48eVceOHR/LmAAAyC5CNwAA+NcWLFggd3d3VahQQRMmTFBGRoYk6dq1a/rrr78UEBBgXDcgIEBnzpxRQkJCln31799fy5YtU0JCguLj47VkyRI1btxYklS6dGmdPHlSf/31l9atWyd/f3+lpaWpT58+mjFjhtnHCQBAThG6AQDAv9KnTx/Fxsbq0qVLmjt3riZPnqzJkydLkpKSkiRJrq6uxvXv/vn69etZ9hcUFKSLFy8a7wG/du2ahgwZIklyd3fXV199paZNm+rLL7/UnDlzNG7cODVt2lRpaWkKCwtTcHCwfvzxR/MNGACAHCB0AwCAf+XFF1+Uh4eH8ubNq5dfflmDBw/Wt99+K0lydHSUJJOz2nf/7OTklKmvjIwM1a9fX0FBQcb7w4OCgtSgQQPjOs2bN9eePXu0ceNG2dnZafny5Ro0aJA6d+6sIUOG6Mcff1SfPn107do1cw4bAIBsIXQDAIBclSfP//164ebmJm9vb0VHRxvboqOj5ePjIxcXl0yfvXr1qk6fPq0+ffoof/78yp8/v3r37q2dO3fq8uXLmdZ///33NWXKFNnY2CgmJkaBgYHGbR49etQs4wMAICcI3QAA4F/57rvvlJiYKIPBoD179uizzz5Ts2bNjMs7duyoMWPGKC4uTnFxcRo7dqy6dOmSZV8FCxZUqVKlFBkZqeTkZCUnJysyMlLe3t4qWLCgybrffPON/Pz8VKtWLUlSyZIltW7dOp0/f15Hjx6Vr6+v+QYNAEA25bN0AQAA4Ok2depUdevWTenp6SpatKh69OihDz/80Lh82LBhunLlisqXLy9Jatu2rYYOHWpc/t5770mScSK0lStXql+/fipatKgyMjJUpUoV/fTTTybbvHz5ssaPH68tW7YY2yIjI9WpUyclJSVpxIgR8vT0NNuYAQDILiuDwWCwdBHmlJiYKBcXFyUkJMjZ2dnS5QB4hnWddtXSJVjE7B7uli4BADLh72Q8KziWn1zZzZpcXg4AAAAAgJkQugEAAAAAMBNCNwAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAAAwDPr1q1bKlWqlFxdXY1thw4d0quvvio3Nzd5eXmpW7duunnz5n37SExM1DvvvCNnZ2d5enrq008/NVn+0Ucfyd3dXZUrV9ahQ4eM7SdOnFBAQICSk5NzfVx4elj0Od0jR47UqFGjTNrKli2rP//8U5KUnJysDz/8UEuXLlVKSopCQ0M1bdo0nrsJAICZPK+PppGejsfTAMi54cOHy9fXV5cvXza2vfPOO6pZs6bWrFmjhIQEvf766/r0008VERGRZR+9e/fW1atXdebMGV28eFEhISHy9fVVu3bttHv3bq1YsUKnTp3S/PnzNWjQIK1atUqS1KNHD02cOFF2dnaPZax4Mln8THeFChX0999/G19btmwxLuvXr59WrVqlZcuWadOmTTp//rzeeustC1YLAAAA4Gmxd+9erV27VoMGDTJpP3HihNq2bSsbGxt5eHjojTfe0MGDB7Ps4+bNm1q6dKnCw8Pl6uqqMmXKqHfv3po7d66xr2rVqsnZ2VkNGjTQ8ePHJUmLFy+Wl5eX6tWrZ95B4oln8dCdL18+eXl5GV8FCxaUJCUkJGju3LmaOHGi6tWrp6pVq2revHnatm2bduzYYeGqAQAAADzJ0tPT1bVrV0VGRsrGxsZk2YABA7RgwQLdunVLcXFx+vHHH9W4ceMs+4mNjVVqaqoCAgKMbQEBATpw4IAkqWLFitqzZ4/i4+O1fv16+fv769q1axo7dqwmTJhgtvHh6WHx0H306FEVKVJEJUuWVJs2bXTmzBlJd/5VKi0tTSEhIcZ1y5Urp2LFimn79u337S8lJUWJiYkmLwAAAADPl/Hjx6tKlSqqU6dOpmVhYWHasmWLnJycVLhwYfn4+KhTp05Z9pOUlCQHBwfly/d/d+a6urrq+vXrku5cufvBBx8oODhYv/zyi7744gt99NFHGjRokA4dOqR69erp1VdfNbmiF88Xi4buwMBAzZ8/X2vXrtX06dN18uRJ1a5dW9evX1dcXJxsbGxMJjyQJE9PT8XFxd23z4iICLm4uBhfPj4+Zh4FAAAAgCfJsWPHNGPGDI0fPz7TsmvXrikkJERdu3bVzZs3dfXqVTk4OKht27ZZ9uXo6KibN28qPT3d2JaQkCAnJyfj+169eik6OlqrVq3SyZMndebMGbVp00bvvPOO5syZo1mzZqlNmzYyGAy5P1g88Sw6kVpYWJjxz5UqVVJgYKB8fX313Xffyd7e/pH6HDJkiPr37298n5iYSPAGAAAAniNbtmzRhQsXVKZMGUlSWlqarl+/roIFC+rnn3/WrVu31KdPH1lZWcnGxkbdu3c3ySb/VLZsWVlbWysmJkZVq1aVJEVHR8vf3z/Tuqmpqerbt6++++47Xbp0Senp6SpZsqRx2aVLl1SoUCEzjRpPKotfXv5PdycmOHbsmLy8vJSamqr4+HiTdS5cuCAvL6/79mFraytnZ2eTFwAAAIDnR4sWLXTs2DFFR0crOjpac+bMkZOTk6Kjo1W+fHk5Ojpq2rRpSk9P1/Xr1zV79mxVqVIly77y58+vli1batiwYUpISNDRo0f11VdfqUuXLpnWjYiIUPPmzVWqVCkVLFhQKSkpiomJ0YEDB5SamqoCBQqYe+h4Aj1RoTspKUnHjx9X4cKFVbVqVVlbW2vDhg3G5bGxsTpz5oxq1KhhwSoBAAAAPMny588vb29v48vDw0NWVlby9vaWs7OzVq1apSVLlqhgwYIqXry44uPj9c033xg/HxYWprFjxxrfT506VS4uLvL29lZQUJA6d+6sdu3amWwzNjZWq1at0oABAyRJefPm1fTp0xUWFqawsDDNnDlTefPmfTw7AE8Ui15ePmDAADVu3Fi+vr46f/68RowYobx586p169ZycXFR586d1b9/f7m7u8vZ2Vm9e/dWjRo19PLLL1uybAAAAABPkeDgYJMraIOCgh44sdmaNWtM3js7O2vJkiUP3EbZsmW1Z88ek7aWLVuqZcuWOS8Yz5Qche6MjAxt2rRJmzdv1unTp3Xz5k15eHioSpUqCgkJyfG903/99Zdat26tK1euyMPDQ7Vq1dKOHTvk4eEhSfryyy+VJ08eNWvWTCkpKQoNDdW0adNytA0AAAAAACwlW6H71q1bmjBhgqZPn66rV68qICBARYoUkb29vY4dO6YVK1aoa9euatCggYYPH57tM9FLly594HI7OztFRkYqMjIyW/0BAAAAAPAkyVboLlOmjGrUqKHZs2erfv36sra2zrTO6dOntXjxYrVq1Uoff/yxunbtmuvFAgAAAADwNMlW6P71119Vvnz5B67j6+urIUOGaMCAATpz5kyuFAcAAAAAwNMsW7OXPyxw/5O1tbX8/PweuSAAAAAAAJ4Vjzx7eXp6umbOnKmoqCjdvn1bQUFB6tmzp+zs7HKzPgAAAAAAnlqPHLr79OmjI0eO6K233lJaWpoWLFigPXv2PHQqfQAAAADIidqr+1u6BIspp08sXQL+pWyH7h9//FFvvvmm8f2vv/6q2NhY4wPeQ0NDeX42AAAAAAD/kK17uiXp66+/VtOmTXX+/HlJ0osvvqj33ntPa9eu1apVqzRw4EBVr17dbIUCAAAAAPC0yXboXrVqlVq3bq3g4GB99dVXmjVrlpydnfXxxx9r2LBh8vHx0eLFi81ZKwAAAAAAT5Vsh25JatmypXbt2qWDBw8qNDRUbdu21d69exUdHa3IyEh5eHiYq04AAJ4at27dUqlSpeTq6ppp2YULF+Tu7q6AgIAH9nH+/Hk1bNhQDg4OKlasmGbPnm1cdvv2bb377rtydXVVrVq1jFehSdK2bdsUHBwsg8GQW8MBAAD/Qo5CtyS5urpq1qxZGj9+vNq1a6ePPvpIycnJ5qgNAICn0vDhw+Xr65vlsl69eqlKlSoP7aN169by8vLSxYsXtWzZMn300UfatGmTJGn58uU6deqULly4oMDAQEVEREiS0tLS1Lt3b82YMUNWVla5NyAAAPDIsh26z5w5oxYtWsjf319t2rRR6dKltXfvXuXPn1+VK1fWmjVrzFknAABPhb1792rt2rUaNGhQpmUrV67U1atX9e677z6wj+PHj2vLli2KiIiQg4ODAgMD1aZNG3399deSpBMnTqhWrVqytbVV/fr1dfz4cUnS+PHj1bhxY5UrVy73BwYAAB5JtkN3u3btlCdPHo0fP16FChVS9+7dZWNjo1GjRmnFihWKiIhQixYtzFkrAABPtPT0dHXt2lWRkZGysbExWZaQkKD+/ftrxowZD+3nwIEDKly4sDw9PY1tAQEBOnDggCTJ399fmzdv1q1bt7Rhwwb5+/vr2LFjWrZsmYYMGZK7gwIAAP9KtkP3nj17NGbMGL322muaOHGi8X/8klS+fHn9/vvvCgkJMUuRAAA8DcaPH68qVaqoTp06mZYNHDhQHTp0UOnSpR/aT1JSUqb7wV1dXXX9+nVJUsOGDRUcHKzAwECdO3dOgwcPVo8ePTR58mStXr1awcHBCgsL0+HDh3NlXAAA4NFl+zndVatW1fDhw9W+fXutX79e/v7+mdbp1q1brhYHAMDT4tixY5oxY4b279+fadnmzZu1detW7du3L1t9OTo6KiEhwaQtISFBTk5Oxvfh4eEKDw+XJC1cuFDFihVTxYoVValSJR08eFAxMTHq1KmTtm/f/i9GBQAA/q1sh+4FCxboww8/VL9+/RQQEKCZM2easy4AAJ4qW7Zs0YULF1SmTBlJdyY1u379ugoWLKjq1avrxIkTKlKkiCQpJSVFt27dUsGCBXXw4EEVLlzYpK9KlSrp/PnzunjxogoVKiRJio6OzvIfvK9cuaJx48Zp8+bNOnLkiHx8fOTm5qYaNWooJibGzKMGAAAPk+3Q7evrq++//96ctQAA8NRq0aKFyW1W27dvV5cuXRQdHS1nZ2clJiYaly1btkxz5szRL7/8YgzV/+Tn56egoCANHTpUU6ZM0f/+9z8tWrRIK1asyLTugAED9PHHH8vNzU2+vr46cuSIzp07p/3798vPz88sYwUAANmXrdB948YNOTg4ZLvTnK4PAMDTLn/+/MqfP7/xvYeHh6ysrOTt7S1JcnZ2Ni5zc3OTtbW1cZkkVahQQUOHDlWbNm0kSUuWLFGXLl3k4eEhd3d3ff7556pbt67JNqOiohQXF6fWrVtLkry8vDRs2DAFBATI2dlZ8+bNM9t4AQBA9mRrIrVSpUrps88+099//33fdQwGg9atW6ewsDBNmTIl1woEAOBpFBwcrPj4+CyXdejQQdHR0SZtf/zxhzFwS1LRokW1Zs0a3bhxQ2fPnlXXrl2z3Ma9j+zs27evLl26pOPHj2c5oRsAAHi8snWmOyoqSkOHDtXIkSNVuXJlVatWTUWKFJGdnZ2uXbumQ4cOafv27cqXL5+GDBmi7t27m7tuAAAAAACeeNkK3WXLltUPP/ygM2fOaNmyZdq8ebO2bdtmnASmSpUqmj17tsLCwpQ3b15z1wwAAAAAwFMh2xOpSVKxYsX04Ycf6sMPPzRXPQAAAAAAPDOydU83AAAAAADIOUI3AAAAAABmQugGAAAAAMBMCN0AAAAAAJhJjiZSk6QzZ87Ix8dHVlZWJu0Gg0Fnz55VsWLFcq04AAAspfbq/pYuwSLK6RNLlwAAwDMlx2e6S5QooUuXLmVqv3r1qkqUKJErRQEAAAAA8CzIceg2GAyZznJLUlJSkuzs7HKlKAAAAAAAngXZvry8f/87l9lZWVlp2LBhyp8/v3HZ7du3tXPnTgUEBOR6gQAAAAAAPK2yfaZ7//792r9/vwwGgw4ePGh8v3//fv3555+qXLmy5s+fb8ZS8SC3bt1SqVKl5OrqamxLTEzUO++8I2dnZ3l6eurTTz99YB8PW/+jjz6Su7u7KleurEOHDhnbT5w4oYCAACUnJ+fqmAAAAADgaZftM92//fabJKljx46aPHmynJ2dzVYUcm748OHy9fXV5cuXjW29e/fW1atXdebMGV28eFEhISHy9fVVu3btsuzjQevv3r1bK1as0KlTpzR//nwNGjRIq1atkiT16NFDEydO5PYCAAAAALhHju/pnjdvHoH7CbN3716tXbtWgwYNMrbdvHlTS5cuVXh4uFxdXVWmTBn17t1bc+fOzbKPh61/4sQJVatWTc7OzmrQoIGOHz8uSVq8eLG8vLxUr1498w8UAAAAAJ4yOQ7dN27c0LBhw1SzZk2VKlVKJUuWNHnh8UpPT1fXrl0VGRkpGxsbY3tsbKxSU1NN7rMPCAjQgQMHsuznYetXrFhRe/bsUXx8vNavXy9/f39du3ZNY8eO1YQJE8wyNgAAAAB42uX4Od1dunTRpk2b9O6776pw4cJZzmSOx2f8+PGqUqWK6tSpo6ioKGN7UlKSHBwclC/f//2IXV1ddf369Sz7edj6FSpU0AcffKDg4GD5+Pho2rRp+uijjzRo0CAdOnRII0aMkJWVlUaNGqVatWqZZ7AAAAAA8JTJcehes2aNfv75ZwUFBZmjHuTAsWPHNGPGDO3fvz/TMkdHR928eVPp6enGIJ2QkCAnJ6cs+8rO+r169VKvXr0kSb///rvOnDmjNm3ayNfXV5s2bZLBYFC9evV06tQp/jEGAAAAAPQIl5e7ubnJ3d3dHLUgh7Zs2aILFy6oTJkyKliwoJo0aaLExEQVLFhQiYmJsra2VkxMjHH96Oho+fv7Z9lX2bJls71+amqq+vbtq2nTpunSpUtKT09XyZIl5efnp9TUVF26dCn3BwsAAAAAT6Ech+5PP/1Uw4cP182bN81RD3KgRYsWOnbsmKKjoxUdHa05c+bIyclJ0dHRqlGjhlq2bKlhw4YpISFBR48e1VdffaUuXbpk2Vf+/PmzvX5ERISaN2+uUqVKqWDBgkpJSVFMTIwOHDig1NRUFShQwNxDBwAAAICnQo4vL58wYYKOHz8uT09PFS9eXNbW1ibL9+3bl2vF4cHy58+v/PnzG997eHjIyspK3t7ekqSpU6eqe/fu8vb2lr29vXr16mXyuLCwsDDVrl1bQ4cOzdb60p0J11atWqXt27dLkvLmzavp06crLCxMVlZWmjlzpvLmzWvuoQMAAADAUyHHobtp06ZmKAO5ITg4WPHx8cb3zs7OWrJkyX3XX7Nmjcn7h60v3bkMfc+ePSZtLVu2VMuWLXNeMAAAAAA843IcukeMGGGOOgAAAAAAeObk+J5uSYqPj9ecOXM0ZMgQXb16VdKdy8rPnTuXq8UBAAAAAPA0y3HoPnDggMqUKaNx48bpiy++MF7OvHz5cg0ZMuSRC/nss89kZWWlvn37GtuSk5PVs2dPFShQQI6OjmrWrJkuXLjwyNsAAAAAAOBxynHo7t+/vzp06KCjR4/Kzs7O2N6wYUP9/vvvj1TE7t27NXPmTFWqVMmkvV+/flq1apWWLVumTZs26fz583rrrbceaRsAAAAAADxuOQ7du3fvVvfu3TO1Fy1aVHFxcTkuICkpSW3atNHs2bPl5uZmbE9ISNDcuXM1ceJE1atXT1WrVtW8efO0bds27dixI8fbAQAAAADgcctx6La1tVViYmKm9iNHjsjDwyPHBfTs2VONGjVSSEiISfvevXuVlpZm0l6uXDkVK1bM+LiqrKSkpCgxMdHkBQAAAACAJeR49vI33nhDo0eP1nfffSdJsrKy0pkzZzRo0CA1a9YsR30tXbpU+/bt0+7duzMti4uLk42NjVxdXU3aPT09H3hGPSIiQqNGjcpRHU+K2qv7W7oEi9j8+kRLlwAAAAAAZpHjM90TJkxQUlKSChUqpFu3bqlu3boqVaqUnJycNGbMmGz3c/bsWX3wwQdatGiRyb3h/9aQIUOUkJBgfJ09ezbX+gYAAAAAICdyfKbbxcVF69at09atWxUTE6OkpCS9+OKLmS4Pf5i9e/fq4sWLevHFF41tt2/f1u+//66pU6fql19+UWpqquLj403Odl+4cEFeXl737dfW1la2trY5HRYAAAAAALkux6H7rqCgIAUFBT3yhl999VUdPHjQpK1jx44qV66cBg0aJB8fH1lbW2vDhg3Gy9ZjY2N15swZ1ahR45G3CwAAAADA45Lj0N2nTx+VKlVKffr0MWmfOnWqjh07pkmTJmWrHycnJ1WsWNGkzcHBQQUKFDC2d+7cWf3795e7u7ucnZ3Vu3dv1ahRQy+//HJOywYAAAAA4LHL8T3dP/zwQ5ZnuGvWrKnvv/8+V4q668svv9Trr7+uZs2aqU6dOvLy8tLy5ctzdRsAAAAAAJhLjs90X7lyRS4uLpnanZ2ddfny5X9VTFRUlMl7Ozs7RUZGKjIy8l/1CwAAAACAJeT4THepUqW0du3aTO1r1qxRyZIlc6UoAAAAAACeBTk+092/f3/16tVLly5dUr169SRJGzZs0IQJE7J9PzcAAAAAAM+DHIfuTp06KSUlRWPGjNGnn34qSSpevLimT5+udu3a5XqBAAAAAAA8rR7pkWHvv/++3n//fV26dEn29vZydHTM7boAAAAAAHjqPfJzui9duqTY2FhJUrly5VSwYMFcKwoAAAAAgGdBjidSu3Hjhjp16qTChQurTp06qlOnjgoXLqzOnTvr5s2b5qgRAAAAAICnUo5Dd//+/bVp0yatWrVK8fHxio+P18qVK7Vp0yZ9+OGH5qgRAAAAAICnUo4vL//hhx/0/fffKzg42NjWsGFD2dvbq0WLFpo+fXpu1gcAAAAAwFMrx2e6b968KU9Pz0zthQoV4vJyAAAAAAD+Icehu0aNGhoxYoSSk5ONbbdu3dKoUaNUo0aNXC0OAAAAAICnWY4vL580aZJee+01eXt7q3LlypKkmJgY2dnZ6Zdffsn1AgEAAAAAeFrlOHT7+/vr6NGjWrRokf78809JUuvWrdWmTRvZ29vneoEAAAAAADytchS609LSVK5cOa1evVpdu3Y1V00AAAAAADwTcnRPt7W1tcm93AAAAAAA4P5yPJFaz549NW7cOKWnp5ujHgAAAAAAnhk5vqd79+7d2rBhg3799Vf5+/vLwcHBZPny5ctzrTgAAAAAAJ5mOQ7drq6uatasmTlqAQAAAADgmZLj0D1v3jxz1AEAAAAAwDMn2/d0Z2RkaNy4cQoKClL16tU1ePBg3bp1y5y1AQAAAADwVMt26B4zZoyGDh0qR0dHFS1aVJMnT1bPnj3NWRuA50jv3r3l4+MjZ2dnFS1aVH379lVqaqouXryoNm3ayNvbW87OzqpSpYp++umnB/Z1/vx5NWzYUA4ODipWrJhmz55tXHb79m29++67cnV1Va1atXT+/Hnjsm3btik4OFgGg8Fs4wQAAMDzJduhe8GCBZo2bZp++eUXrVixQqtWrdKiRYuUkZFhzvoAPCd69OihP//8U4mJiYqJiVFMTIw+//xzJSUlqUqVKtqxY4fi4+M1evRotW7dWocOHbpvX61bt5aXl5cuXryoZcuW6aOPPtKmTZsk3Zns8dSpU7pw4YICAwMVEREhSUpLS1Pv3r01Y8YMWVlZPZYxAwAA4NmX7dB95swZNWzY0Pg+JCREVlZWJmeJAOBRlS9f3vg0BIPBoDx58ujo0aMqWbKkBgwYIG9vb+XJk0eNGzdW2bJltWPHjiz7OX78uLZs2aKIiAg5ODgoMDBQbdq00ddffy1JOnHihGrVqiVbW1vVr19fx48flySNHz9ejRs3Vrly5R7PgAEAAPBcyHboTk9Pl52dnUmbtbW10tLScr0oAM+nzz77TI6OjipUqJBiYmLUu3fvTOtcvHhRhw8fVqVKlbLs48CBAypcuLA8PT2NbQEBATpw4IAkyd/fX5s3b9atW7e0YcMG+fv769ixY1q2bJmGDBlinoEBAADguZXt2csNBoM6dOggW1tbY1tycrLee+89k2d185xuAI9q8ODBGjx4sA4fPqxFixbJy8vLZHlqaqpatWqlFi1aqFq1aln2kZSUJFdXV5M2V1dXXb9+XZLUsGFDbdu2TYGBgapYsaIiIyPVsmVLTZ48WatXr9ZXX30le3t7TZw4UeXLlzfLOAEAAPD8yHbobt++faa2tm3b5moxACDdudS8cuXK6tChg9avXy/pTuB+++23lT9/fpOJ0e7l6OiohIQEk7aEhAQ5OTkZ34eHhys8PFyStHDhQhUrVkwVK1ZUpUqVdPDgQcXExKhTp07avn27GUYHAACA50m2QzfP58aTpnfv3lqxYoUxUDVv3lyff/65bGxslJiYqPfee0+rV6+Wvb29evXqpWHDht23r7179+qDDz7QgQMHVLBgQY0cOVLt2rWTdGe26w4dOmjVqlWqWLGivvvuOxUpUkTSndmuhw4dqt9++43Jt3JZWlqajh49KulO4G7evLlSU1O1cuVK2djY3PdzlSpV0vnz53Xx4kUVKlRIkhQdHS1/f/9M6165ckXjxo3T5s2bdeTIEfn4+MjNzU01atRQTEyMeQYGAACA50q27+kGnjT3m+1auhPIr169qjNnzmjz5s2aPXu2FixYkGU/8fHxatiwodq2batr165pyZIl6t27t7Zs2SKJ2a4fh6SkJM2bN0/x8fEyGAw6ePCgwsPDFRoaqrS0NLVo0UI3btzQihUrTG5xyYqfn5+CgoI0dOhQ3bx5U7t27dKiRYvUuXPnTOsOGDBAH3/8sdzc3OTr66sjR47o3LlzWrdunfz8/Mw1XAAAADxHCN14at1vtuubN29q6dKlCg8Pl6urq8qUKaPevXtr7ty5Wfazbds22dra6r333lPevHkVGBiot956S3PmzJHEbNePg5WVlRYvXiw/Pz85OTmpSZMmatSokSZNmqRt27Zp5cqV2rp1qwoWLChHR0c5Ojpq7Nixxs9XqFBBixYtMr5fsmSJzp07Jw8PDzVr1kyff/656tata7LNqKgoxcXFqXXr1pIkLy8vDRs2TAEBAfrggw8UGRn5eAYPAACAZ1q2Ly8HnkSfffaZwsPDdePGDRUoUEDjxo1TbGysUlNTFRAQYFwvICDAJKT9U0ZGhgwGQ6a2gwcPSroz2/XYsWOznO36fo+tQs44ODho3bp1WS6rW7dupp/Pvf744w+T90WLFtWaNWse+Jng4GAFBwebtPXt21d9+/Z9aL0AAABAdnGmG0+1wYMHKykpSYcOHdJ7770nLy8vJSUlycHBQfny/d+/Kf1z9up71ahRQzdu3NDUqVOVlpamrVu36scff1RiYqKkO7NdBwcHKzAwUOfOndPgwYPVo0cP42zXwcHBCgsL0+HDhx/LmAEAAAA8PQjdeCb8c7ZrR0dH3bx5U+np6cbl985e/U8FChTQqlWrtHjxYnl5eWnw4MHq2LGjChQoYFwnPDxcBw4c0OLFi7V69WrjbNcffPCBfvzxRw0aNEidOnUy+zgBAAAAPF24vBzPjLuzXZctW1bW1taKiYlR1apVJd1/9uq7goKCtG3bNuP7li1bZroHWGK2awAAAAA5w5luPJUeNNt1/vz51bJlSw0bNkwJCQk6evSovvrqK3Xp0uW+/e3fv18pKSm6deuWZs+eraioqCzv7WW2awAAAAA5QejGU+lBs11L0tSpU+Xi4iJvb28FBQWpc+fOxuduS1JYWJjJxGpTpkyRp6enPDw8tGzZMm3cuNH4LO67mO0aAAAAQE5xeTmeSg+a7VqSnJ2dtWTJkvsuv3dm63nz5mnevHkP3CazXQMAAADIKUI3gFxVe3V/S5dgMeX0iaVLAAAAwBOGy8sBAAAAADATQjcAAAAAAGZC6AYAAAAAwEwI3QAAAAAAmAmhGwAAAAAAM7Ho7OXTp0/X9OnTderUKUlShQoVNHz4cIWFhUmSkpOT9eGHH2rp0qVKSUlRaGiopk2bJk9PTwtWjdzWddpVS5dgMbN7uFu6BAAAAABmZNEz3d7e3vrss8+0d+9e7dmzR/Xq1VOTJk30xx9/SJL69eunVatWadmyZdq0aZPOnz+vt956y5IlAwAAAACQbRY90924cWOT92PGjNH06dO1Y8cOeXt7a+7cuVq8eLHq1asnSZo3b57Kly+vHTt26OWXX7ZEyQAAAAAAZNsTc0/37du3tXTpUt24cUM1atTQ3r17lZaWppCQEOM65cqVU7FixbR9+3YLVgoAAAAAQPZY9Ey3JB08eFA1atRQcnKyHB0d9eOPP+qFF15QdHS0bGxs5OrqarK+p6en4uLi7ttfSkqKUlJSjO8TExPNVToAAAAAAA9k8TPdZcuWVXR0tHbu3Kn3339f7du316FDhx65v4iICLm4uBhfPj4+uVgtAAAAAADZZ/HQbWNjo1KlSqlq1aqKiIhQ5cqVNXnyZHl5eSk1NVXx8fEm61+4cEFeXl737W/IkCFKSEgwvs6ePWvmEQAAAAAAkDWLh+57ZWRkKCUlRVWrVpW1tbU2bNhgXBYbG6szZ86oRo0a9/28ra2tnJ2dTV4AAAAAAFiCRe/pHjJkiMLCwlSsWDFdv35dixcvVlRUlH755Re5uLioc+fO6t+/v9zd3eXs7KzevXurRo0azFwOAAAAAHgqWDR0X7x4Ue3atdPff/8tFxcXVapUSb/88ovq168vSfryyy+VJ08eNWvWTCkpKQoNDdW0adMsWTIAAAAAANlm0dA9d+7cBy63s7NTZGSkIiMjH1NFAAAAAADknifunm4AAAAAAJ4VhG4AAAAAAMyE0A0AAAAAgJkQugEAAAAAMBNCNwAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAAAAAAzIXQDAAAAAGAmhG4AAAAAAMyE0A0AAAAAgJkQugEAAAAAMBNCNwAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAAAAAAzIXQDAAAAAGAmhG4AAAAAAMyE0A0AAAAAgJkQugEAAAAAMBNCNwAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAAAAAAzIXQDAAAAAGAmhG4AAAAAAMyE0A0AAAAAgJkQugEAAAAAMBNCNwAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAAAAAAzIXQDAAAAAGAmhG4AAAAAAMyE0A0AAAAAgJkQugEAAAAAMBNCNwAAAAAAZkLoBgAAAADATAjdAAAAAACYCaEbAAAAAAAzIXQDAAAAAGAmFg3dERERql69upycnFSoUCE1bdpUsbGxJuskJyerZ8+eKlCggBwdHdWsWTNduHDBQhUDAAAAAJB9Fg3dmzZtUs+ePbVjxw6tW7dOaWlpatCggW7cuGFcp1+/flq1apWWLVumTZs26fz583rrrbcsWDUAAAAAANmTz5IbX7t2rcn7+fPnq1ChQtq7d6/q1KmjhIQEzZ07V4sXL1a9evUkSfPmzVP58uW1Y8cOvfzyy5YoGwAAAACAbHmi7ulOSEiQJLm7u0uS9u7dq7S0NIWEhBjXKVeunIoVK6bt27dbpEYAAAAAALLLome6/ykjI0N9+/ZVUFCQKlasKEmKi4uTjY2NXF1dTdb19PRUXFxclv2kpKQoJSXF+D4xMdFsNQMAAAAA8CBPzJnunj176n//+5+WLl36r/qJiIiQi4uL8eXj45NLFQIAAAAAkDNPROju1auXVq9erd9++03e3t7Gdi8vL6Wmpio+Pt5k/QsXLsjLyyvLvoYMGaKEhATj6+zZs+YsHQAAAACA+7Jo6DYYDOrVq5d+/PFHbdy4USVKlDBZXrVqVVlbW2vDhg3GttjYWJ05c0Y1atTIsk9bW1s5OzubvAAAAAAAsASL3tPds2dPLV68WCtXrpSTk5PxPm0XFxfZ29vLxcVFnTt3Vv/+/eXu7i5nZ2f17t1bNWrUYOZyAAAAAMATz6Khe/r06ZKk4OBgk/Z58+apQ4cOkqQvv/xSefLkUbNmzZSSkqLQ0FBNmzbtMVcKAAAAAEDOWfzy8qxedwO3JNnZ2SkyMlJXr17VjRs3tHz58vvezw0AAIB/Z+rUqapWrZpsbW3VtGnTTMvnzJmjsmXLysHBQcWLF9fKlSvv29f58+fVsGFDOTg4qFixYpo9e7Zx2e3bt/Xuu+/K1dVVtWrV0vnz543Ltm3bpuDgYBkMhlwdGwBYwhMxkRoAAACeDEWKFNEnn3yirl27Zlo2a9YsTZgwQUuXLlVSUpJ27twpf3//+/bVunVreXl56eLFi1q2bJk++ugjbdq0SZK0fPlynTp1ShcuXFBgYKAiIiIkSWlpaerdu7dmzJghKysr8wwSAB4jQjcAAACM3nrrLTVt2lQFCxY0ab99+7aGDx+uyZMnq0qVKrKyspKnp6dKliyZZT/Hjx/Xli1bFBERIQcHBwUGBqpNmzb6+uuvJUknTpxQrVq1ZGtrq/r16+v48eOSpPHjx6tx48YqV66ceQcKAI8JoRsAAAAPFRsbqwsXLmjfvn0qXry4vL291bVrVyUmJma5/oEDB1S4cGF5enoa2wICAnTgwAFJkr+/vzZv3qxbt25pw4YN8vf317Fjx7Rs2TINGTLksYwJAB4HQjcAAAAe6urVq5Kk9evXa8+ePYqOjtbJkyfVr1+/LNdPSkqSq6urSZurq6uuX78uSWrYsKGCg4MVGBioc+fOafDgwerRo4cmT56s1atXKzg4WGFhYTp8+LBZxwUA5mbR2csBAADwdHB0dJQkDRkyxHjp+ZAhQ9S6dev7rp+QkGDSlpCQICcnJ+P78PBwhYeHS5IWLlyoYsWKqWLFiqpUqZIOHjyomJgYderUSdu3bzfHkADgsSB0AwAA4KHKli0rOzu7bK9fqVIlnT9/XhcvXlShQoUkSdHR0VlOvHblyhWNGzdOmzdv1pEjR+Tj4yM3NzfVqFFDMTExuTYGALAELi8HAACAUXp6upKTk5Wenq6MjAwlJycrNTVV9vb2atu2rcaNG6dr164pPj5e48aNU5MmTbLsx8/PT0FBQRo6dKhu3rypXbt2adGiRercuXOmdQcMGKCPP/5Ybm5u8vX11ZEjR3Tu3DmtW7dOfn5+5h4yAJgVoRsAAABG4eHhsre315gxY7Rq1SrZ29urQYMGkqRJkyapSJEiKlGihMqWLStfX19NnDjR+NkKFSpo0aJFxvdLlizRuXPn5OHhoWbNmunzzz9X3bp1TbYXFRWluLg442XqXl5eGjZsmAICAvTBBx8oMjLyMYwaAMyHy8sBAABgNHLkSI0cOTLLZQ4ODpo/f/59P/vHH3+YvC9atKjWrFnzwO0FBwcrODjYpK1v377q27dvNqoFgCcfZ7oBAAAAADATQjcAAAAAAGZC6AYAAAAAwEwI3QAAAAAAmAmhGwAAAAAAMyF0AwAAAABgJjwyDAAA4BlWe3V/S5dgEeX0iaVLAABJnOkGAAAAAMBsCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJiJRUP377//rsaNG6tIkSKysrLSihUrTJYbDAYNHz5chQsXlr29vUJCQnT06FHLFAsAAAAAQA5ZNHTfuHFDlStXVmRkZJbLP//8c02ZMkUzZszQzp075eDgoNDQUCUnJz/mSgEAAAAAyLl8ltx4WFiYwsLCslxmMBg0adIkffLJJ2rSpIkkacGCBfL09NSKFSvUqlWrx1kqAAAAAAA59sTe033y5EnFxcUpJCTE2Obi4qLAwEBt3779vp9LSUlRYmKiyQsAAAAAAEt4YkN3XFycJMnT09Ok3dPT07gsKxEREXJxcTG+fHx8zFonAAAAAAD388SG7kc1ZMgQJSQkGF9nz561dEkAAAAAgOfUExu6vby8JEkXLlwwab9w4YJxWVZsbW3l7Oxs8gIAAAAAwBKe2NBdokQJeXl5acOGDca2xMRE7dy5UzVq1LBgZQAAAAAAZI9FZy9PSkrSsWPHjO9Pnjyp6Ohoubu7q1ixYurbt6/Cw8NVunRplShRQsOGDVORIkXUtGlTyxUNAAAAAEA2WTR079mzR6+88orxff/+/SVJ7du31/z58zVw4EDduHFD3bp1U3x8vGrVqqW1a9fKzs7OUiUDAAAAAJBtFg3dwcHBMhgM911uZWWl0aNHa/To0Y+xKgAAAAAAcscTe083AAAAAABPO0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwE0I3AAAAAABmQugGAAAAAMBMCN0AAAAAAJgJoRsAAAAAADMhdAMAAAAAYCaEbgAAAAAAzITQDQAAAACAmRC6AQAAAAAwk6cidEdGRqp48eKys7NTYGCg/l979x1f0/0/cPx1b3ZCSFEzNrUqtVdsbQiKWEmrIfghaOwdIWaN2BSxtyhCjRo1G9QMIkaM1AoJImSvz+8Pj9xvruDb9lu9V7yfj0cfzT3n3JP34eOc8/7M06dPGzokIYQQQgghhBDivzL6pHvz5s0MHjyYcePGcf78eRwcHHByciIyMtLQoQkhhBBCCCGEEO9k9En3rFmz+L//+z88PDyoUKECixcvxtramhUrVhg6NCGEEEIIIYQQ4p1MDR3AuyQnJ3Pu3DlGjRql26bVamnWrBknT55843eSkpJISkrSfY6JiQHgxYsX7zfYf0BqfNJ/PygbSk4w/r+b9+XFC6P+J/i3fKzlGD7espwdyzF8vGX5Yy3HIGU5u/lYy7KU4+xHyrLxysgxlVLvPE6j/tsRBvTw4UMKFy7MiRMnqFOnjm778OHDOXr0KL///nuW74wfPx5fX99/M0whhBBCCCGEEB+pe/fuUaRIkbfuN/7qg79o1KhRDB48WPc5PT2dZ8+ekSdPHjQajQEjE2/y4sUL7O3tuXfvHra2toYOR4i/TcqyyA6kHIvsQsqyyC6kLBs3pRQvX76kUKFC7zzOqJPuvHnzYmJiwuPHj/W2P378mAIFCrzxOxYWFlhYWOhty5079/sKUfxDbG1t5UYisgUpyyI7kHIssgspyyK7kLJsvHLlyvVfjzHqidTMzc2pVq0av/76q25beno6v/76q153cyGEEEIIIYQQwhgZdUs3wODBg+natSvVq1enZs2azJkzh7i4ODw8PAwdmhBCCCGEEEII8U5Gn3R37tyZqKgofHx8ePToEV988QW//PIL+fPnN3Ro4h9gYWHBuHHjsgwJEOJDI2VZZAdSjkV2IWVZZBdSlrMHo569XAghhBBCCCGE+JAZ9ZhuIYQQQgghhBDiQyZJtxBCCCGEEEII8Z5I0i2EEEIIIYQQQrwnknQLIYQQQgghhBDviSTdQgghhBBCCCHEeyJJtxBCCCGE+CCkp6cbOgQh/jGyiNTHQ5Ju8V7IQ1EIIYQQ/zSt9tWr66ZNm3j+/LlhgxHib1q3bh0XLlxAo9EYOhTxL5GkW7wXGQ/FQ4cO8ezZM6nJEx+ct1UcSVkWHxKpABXZwevJ9dGjRxkxYgTW1taGCUiI/4G/vz/u7u5ERkYaOhTxL5KkW7wX6enpnD9/nmbNmnH37l00Go0kK+KDkZ6erqs4Onr0KLt37+bevXukpaVJWRYfDKWUrhyvWLECLy8vfvzxR0JCQgwcmRB/nqenJ/Xq1ePRo0e6bUoprKys0Gg0pKamGjA6If6apUuX4unpyfbt23FyctLbJ5Wk2Zsk3eK90Gq1VK1alZYtWzJ58mQSExOlC434IGROVIYOHco333xD586dad++PfPmzSMpKUkSb2H0lFK6e663tzfDhg0jNDSU2bNnM2jQIA4ePGjgCIX4cwYOHEhSUhLffPMNERERALx8+ZIcOXJgZmaGiYmJgSMU4s9ZunQpXl5eBAQE0KZNG932sWPH8uzZM927h8ie5G9X/CNeT0BSUlIAaNu2LeHh4boaaqnFE8Ysc6Jy7Ngxjh8/zk8//cSFCxf44osvCAgIYPr06ZJ4C6OXUY4vXrxIREQEe/bs4eDBgyxevJhcuXIxduxYDhw4YOAohXg3pRSfffYZ+/bt486dO3Tu3JknT54QExODjY0NgFToiw/CmTNn6NOnD7NmzcLFxUW3vUOHDmzZskX33iyyL42St0bxP8qcqBw9epRq1aqRI0cOABITE6lQoQItWrRg4cKFhgxTiD9t27Zt7NmzBzs7O2bMmAFAXFwcY8aM4dSpU7Rq1Yphw4ZhYWGhV/6FMCYBAQHMnDkTCwsLdu7ciZ2dHfCqQmnevHlERETg6+tLs2bNDBypEFllHuYDcPPmTb788ksqV65Ms2bNWLx4MW5ubpibm1OwYEGSkpK4ffs2Hh4elClTxoCRC5HVzZs36dOnD7du3SIoKIhChQrRvn17bty4wa5duyhWrJi8T2Rz0tIt/ifp6em6G8SWLVsYMWIElSpVYsOGDQQHB2NpacmECRMIDg6WcYTigxAfH8/SpUvZuHEjV65c0W23sbFhypQp1KlTh7179zJ27FhSUlLkASmMVkpKCqampoSEhHDr1i3d9gYNGjBgwACKFClCnz59OHPmjAGjFCKrzAn3oUOHuHLlCqVLl+bgwYNcvXqVAQMGkCdPHoKCgtixYwfr169n7dq1nD9/npIlSxo4eiFeydyuWbp0aZYvX06pUqWoVasWTk5OhIeHs2PHjiwJ98mTJ2WugmxIWrrF35b5BjF27FguX77MuHHjWLt2LUFBQTx9+hQPDw+KFy/O+PHjmTp1Kh06dJCaPGFU3lQenzx5wuDBgzl58iSDBw+md+/euhfA+Ph4+vXrh5mZGUuWLJGyLIzC662CGX7++Wd++OEHcubMyaRJk6hevbpu38GDBzly5Ai+vr4yLlYYjcz35BEjRrB37166d+9O9+7dsbW15fbt27Rt2xYbGxt27NjBp59+muUcaWlpUqaFUUhPTyclJQULCwsA7t+/z4ABA9i+fTtHjhyhQYMGpKamYmpqCqD7HBQUJO8X2Ywk3eJvyfxQPHLkCAMGDGD58uW6F7pr164RHBzMuHHjqFKlCgEBAZQvX56DBw9SsGBBQ4YuhE7mROXBgwfY2NiQkpJCvnz5iIyMpH///kRERODu7k7Pnj11ZT4xMRFzc3O0Wq1UIgmDy1yOjx07RlJSEikpKTg7OwOwY8cO5s+fj6WlJb6+vlSrVi3LOSRJEcZm+vTpzJgxg8DAQL744gvdGG6A27dv07RpU4oXL87atWspXLiw7j4s92RhDE6ePMnp06cJDAwkZ86cNG/enHbt2lGwYEHu3r1Lz549CQ0N5ciRI5QuXZq0tDS+/vpr7ty5Q3BwMObm5oa+BPEPk6Rb/E+2bdvGzp07sba2ZtGiRSQlJelq8wAePnzI5cuXWb9+PXv27GHVqlW0atXqra0yQvxbMr+Y+fr6smvXLqKjo8mdOzdjxoyhXbt2REVF0a9fPyIiIujWrRvdu3fXe5mTciyMybBhw9i8eTMACQkJlC9fnpUrV1KqVCm2bdvG4sWLsbKyYtSoUdSuXdvA0QrxZkopYmJi6NSpE+3bt6d37966+3Xme+7t27f5/PPP8fDwYMGCBQaOWoj/WLt2LVOmTNHNLZCUlMSBAwdo3rw548aNo1atWjx48IBu3bpx7do1jh49yrBhwwgJCSEkJAQzMzO91m+RTSgh/qa4uDj11VdfKWtra9W4cWPd9rS0NKWUUunp6XrHu7i4qEaNGv2rMQrx3/j6+qpPPvlEbd68WS1ZskR5enoqrVarFi9erJRSKiIiQnXu3Fl99tlnaufOnQaOVog3W7JkicqTJ486e/asunnzprpy5YqqWLGiqly5soqKilJKKbVlyxZVpUoVNWzYMANHK8S7vXjxQpUqVUrNmzcvy76EhAR18+ZNpZRSDx48UKmpqf92eEK81eLFi5WVlZVau3at7t6bkpKidu/erczNzVXTpk3VtWvXlFJK3blzRzk5OSmNRqPKli2rkpOTdceL7EeSbvGnZSTTmUVGRip3d3dVpEgRNXfuXN0xmY/NuIns3btX1ahRQ0VGRv47AQvxmri4OL3Pz58/V46OjmrJkiW6benp6WratGlKo9GoI0eOKKWUevTokRo7dqy83AmjsG/fPpWUlKS3beDAgcrd3V0p9Z8Kz9jYWFWiRAnVqVMn3XFHjhx5471cCGORnp6unj17pipXrqw8PT2VUvrvFMHBwWrQoEHq/v37um1ybxbGYNmyZcrc3Fxt375dKfWfcpmRRO/fv1+Zm5ur0aNH675z48YNNXHiRN0xknBnX9IvUvwpmbt0XblyhdDQUK5fv06+fPmYPXs29erVIyAggOXLl6OUQqvV6tbkNjMzA2Dnzp08fvxYxqkIg3BycmLChAl62xISErhy5YquTKpXFZF4eXnh5OTEtm3bSElJIX/+/EyYMAETExPS0tIMEb4QAMycORNvb2/dfTVDeHg49+7dA16tW5yUlISNjQ0+Pj5cvnyZhw8fAtCwYUO9+7MQhpS5HGbM1qzRaLCzs2P06NEsWbKE2bNn64b1xMbGMmrUKMLDwylUqJDuuzIfgTAkpRRxcXEMHjyYEiVKUL9+feBVuVRKYWpqSnp6Ol9++SW9e/dm5cqVPH78GIAyZcrg7e2NqampdCnP5iTpFv9VRhINr2Yp79ixIx06dKBu3bpMnDiRXLlysWDBAgoXLsyaNWtYsWKF3nfg1SQ95ubmbNmyhVy5chnqUsRHbPr06fj6+gKQnJwMQIECBfjqq68ICAjg4cOHaDQaNBoNlpaW5MyZk+jo6CzJjbzcCUMaOnQoJ06cQKPREBISQnx8PAA9e/bk+vXr+Pv7A+jm1jA3N8fMzAxLS0u988hcBMLQMlfmL1iwgP/7v/+jdevWbNiwgadPn9K5c2f8/PwYMmQITk5ONG/enObNm3Pv3j02b96MRqPRW5JJCEOysbHh1KlTREVF4eHhwe3btwF0FUYZ///888+Jj48nJSUlyzkk4c7e5Kkr/quMG8UPP/zA4sWLWbx4MSEhIXTs2JFJkyZx6dIl8ubNq0u8Z8yYwa5du/TOYWJiwpw5c6hZs6YhLkEIHBwcsLCwYMaMGbRr144XL14A0KJFC6Kjo5k1axZPnjzRtRJGRUXJTPvCqCQlJQGvXswOHDhA5cqV2bp1KykpKVSvXp2vv/6aFStWMH/+fNLT03nw4AHr16+nePHi2NnZGTh6IfRlJNwjR47E19eXYsWKkStXLmbNmsW4ceN48uQJAwcO5NixY1SuXJmSJUvSsmVLLly4oJtoSmYpF4amMk3KWr58eY4ePcqRI0cYNGiQLvHOOA4gIiKCOnXq6PXUEB8JQ/VrFx+WlJQU1a5dO7V8+XKllFJbt25VdnZ2atGiRUqpVxObKPVq0ilvb28ZXyWMxuvjVw8fPqysra2Vm5ubbr6BadOmqZo1a6rSpUsrV1dXVaNGDVWxYkUZWyWMRuZ76tWrV5VSSvXu3VvlyJFDrV27VimlVFhYmBo8eLCys7NTn376qfrss89U1apVdeVcxnILY7NmzRpVqlQpde7cOaXUq7lftFqtKl++vOrRo4d69OiRUirrOFd5xxDGZsqUKWrv3r1KKaVCQkKUra2t+vrrr9WtW7d0xzx9+lQ5OTmpMWPGGCpMYUCyZJh4I/XaOpfPnj2jcuXKBAQEkJ6eTosWLZgxYwZ9+vQhKSkJHx8f3Nzc+OKLL3TfkXVfhaFl7r546dIlChYsSL58+Th58iTOzs58+eWXbNiwAVNTU44cOcKxY8cIDw/H3t6esWPHyhgrYRT279/PmjVrWLduHQMGDCA4OJj9+/djYWFB3759WblyJf7+/nTp0oXExEQeP37MsWPH+PTTT2nWrBkmJiZSjoVRWr9+PTdu3MDX15fAwEC6d+/OpEmTePr0KX5+fri5ueHj4yO9joRRS0pKolOnTlhZWbFs2TJy5MjB1atXqV27Ng0bNmThwoXY29vTunVrIiMjCQoKwtTUVNaU/8hI0i3eKTY2lhw5cgDw/fffc+nSJc6cOcPChQvx8PAAIDIyks6dO+Pm5kavXr3kJiKMQuaE29vbm6CgIPr370/Lli2xtLTkxIkTODs789VXX7FmzZosY14BSVSEwSUlJeHv78/SpUsxMTEhPDyc06dP69Z/BXSJ97Jly2jXrh3W1tZ655AKUGEMMr8bZPwcGxtLbGwsGo0GZ2dn3NzcGDp0KM+ePaNKlSoopejduzdjxowxcPRCvNuPP/7I3LlzOXTokK7r+NWrV6lTpw5NmjQhOjqahw8f6tbhlvvyx0fGdIu3mjNnDs7OzroZcevVq8ejR4+oX78+7du3ByA6Oppu3bqRlpZGjx49ACThFkYhI+EeM2YMS5cuZfjw4TRp0kSXXNetW5ddu3axf/9+evTowfPnz7OcQxJuYSjOzs5cvHgRCwsL+vfvj729PRcvXqRhw4a6hDtjjPeiRYvw8PCgT58+rF+/XjdRYAZ5sROGlnn8dVJSEnFxcQDkyJGDAgUKEB4ezpMnT2jcuDHwn3Gv48ePZ9SoUQaLW4g/y9PTE0tLS8aPHw+8qlgqX748J0+eJDAwkHv37ukS7tTUVLkvf4Qk6RZv1bRpUy5fvkz//v158uQJrq6ueHh4EBUVRbVq1XBycsLJyYlHjx7x66+/ynJKwuicPXuWgIAAAgMDadGiBaampty4cYPVq1dz/vx5HB0d2b17Nxs3bmTOnDmGDlcIAP744w8qV65M+fLlddvq16/PqFGjePDgAd26dQNezVCekJAAvEq827Vrx4YNG2RZRmE0Dh8+DPynAnPSpEk4OTlRvXp1hg8fzpkzZwCwsrIiZ86c7Nixg3PnzjFixAi0Wi0eHh6yxJ0wGvv27SM6Ohp41bK9bds23dJf8CrxvnLlCvfv30ej0ZCSkkL58uW5d+8e169f1yXcUqH/cZLu5QLQ74qb+fPVq1dp0KABNWrUYP369djZ2XHs2DFOnDhBTEwMJUuWxMPDQ8a+CqPwejkODQ2lY8eOzJ49m3z58rF8+XL279+PUooHDx5w4MAB6tWrR0hICOXKlZPyK4zOrFmzqFu3LrVr1yYxMRF/f39WrFiBg4MDq1atAl6V+8uXL+Pg4JDl34AQhrJ582bc3NxYuXIlXbt2ZerUqcycOZMBAwag1Wrx9/enYsWKeHl54eTkxPDhw9m1axcxMTEUL16co0ePYmZmJkPWhFF4+fIltWvXJi4ujtOnT+Pu7k5UVBTR0dFMmjSJ2rVrU7BgQYoXL46Pjw/9+vUD9If3SJfyj5sk3ULP3r17adSoEVZWVroHXWhoKA0bNqRmzZqsWLGC/PnzZ/me3EiEMQkLC6N06dL88ccfdOvWjfj4eC5dukT37t1p2rQp1atXp3379vTq1YtevXrpvicVR8LQMifNT58+pUuXLpw6dYpdu3ZRr149YmJiWLduHStXrqRMmTLMmjWLrl27YmNjw/bt27OcQwhDiY2Nxc/Pj4kTJ7J8+XIiIiKoVKkSrVq1AuDatWt4enpiYWHBli1bsLKy4ubNm8TGxlK1alW0Wq3ck4VRCQ0Nxd3dHVNTU/bu3UtsbCwLFy5k586dmJmZ0alTJx48eMDvv//Ojh07KFKkiKFDFsbk354uXRivW7duKY1Go3r06KHi4+OVUkqlp6crpZQ6ffq0srKyUh4eHur27duGDFOId9q1a5fSaDRq+/btSqlXyyvt2LFDHTp0SLfsTHJysqpWrZpavXq1ASMVQl/mJb3i4uKUUkpdv35dffvttypv3rzqt99+U0op9fz5c7Vs2TJVvnx5VahQIVWrVi3dsmBCGJO4uDjl4+OjtFqtsrKyUgEBAUqp/yz5df36dWVtba38/f2zfFeWBRPGIuPenJKSosLDw1W1atVU3bp11bNnz5RSSl28eFFt2bJFlS1bVtnb2yuNRqP27dun910hpKX7I6YyddlKSkrCwsKCPXv24OrqipubG3PmzMHKygqAJ0+e0KhRI0JDQxk6dCjTp083ZOhCAG9v0evatSs7duxg9erVtGnTRrc9MTGRqKgo+vTpQ2RkJKdOnZIeGsIoZC7L06dPJzo6mt69e1O8eHGuXr3KxIkTOXDgAIGBgdSrV4+EhASeP3/O9evXqV+/viwLJoxWbGwsixcvZuTIkYwZMwZfX1/S0tLQaDRotVoaN25M7dq1mTp1qqFDFULP06dPyZMnDwDJycm6+TJatGjBvn37KF++PL/99ht2dnbAq7J+8uRJZs2axZMnT+QdQ+iR/mcfqcwJ99KlS1m8eDHPnz/H2dmZgIAA1q5dy8CBA3WT9FhZWfHll18SHBwsD0ZhFJ49e5Yl4c6oQ1y9ejUuLi506dKFnTt3kpqailKKRYsW0bNnT54/f86JEydk8j9hNDLK8vDhw5k9ezalS5fWzbRfvnx5xo0bR5MmTXBxceHEiRNYWVlRsGBBGjVqpCvHknALY5QjRw569uzJ2LFjmThxIkuWLMHExAStVktSUhKPHj0iZ86chg5TCD3Hjx+nQ4cOHDt2DECXcHfs2FE3J4y1tTWOjo66ydVy5MjBl19+ibe3N4mJiYSEhBgsfmF85An9EcrconL37l2WLFlCfHw8NjY2dO7cmebNm7N161ZcXFy4e/cuderU0U2cNmvWLDQajbSoCIOqUqUKZcqUISAgAIC5c+dSu3ZtatWqpTtmxYoVKKVwd3dn3bp1tGrVihYtWmBnZ4e7u7u0DAqjs2HDBtasWcP+/fupXLky8Grynri4OMqWLcvs2bMZMmQIjo6OXLp0iUqVKum+K60pwhhlvG/kyJGDcePGkZaWhqenJ4cOHaJIkSKEhYWh1WoZPny4oUMVQs+nn36KUopp06ZhY2NDtWrV6NChA9euXWPv3r3Y29uzZs0avvvuOxo2bMjhw4d1reJVqlTh2bNn3Lt3DwcHBwNfiTAW0r38IzZ48GAuX76MUopbt27x/Plzpk2bhqurK7a2tly8eJF+/fphamqKra0tW7dulZlEhcFNmDCBTZs2ERoaCrxKStq3b8/FixfZu3cvVatW1Tu+Tp06REZG8sMPP9CxY0fddpn8Txib+fPn8+uvvxIYGMi1a9fYs2cPixYtInfu3Dg6OuLn58e1a9fYsmULY8eOlfIrjFrGu8JPP/3E8uXL2bFjB8nJycyfPx9fX1+qVKnCxIkTadSokayAIoxSWFgYXl5emJiYEBMTQ1xcHNu2baN48eK6Y65du8ZXX31FgwYNWLduHfBq5n4PDw8uX75MqVKlDBS9MDZyd/tIbd68mZUrV3LkyBFKlCiBra0tbm5u+Pr6AtCpUyccHBzYv38/JiYmmJubSwu3MArW1tbY2NiQmJjIzJkzMTExYevWrbi6uvL111+zc+dOXeKdmppKqVKluHPnDkuWLNFLuiVhEYaUufIy4+fk5GT27dtHv379OHDgAFWrVqVnz57Ex8cTEBDAoEGDqFixIhUrVgSk4kgYh7fNraHRaNi+fTseHh5Mnz4dc3NzzM3N6devHy9evOD48eM0a9YMQIZHCKNUpkwZ5s2bR9++fbl8+TL+/v66hDuj3JcrV47jx4/rzVRuY2NDcHCwJNxCj7R0f6QWLVqEv78/x44dw8bGRvfAdHFx4dixY0yePJlOnTrpJocApIVbGIVdu3YxY8YMXr58SWhoKGFhYdjb2xMfH0/79u0JCQlh+/btVKpUCUtLS7p06YK3tzdly5aVZZSEUcicpCQkJJCWlkaOHDkAmDhxIiEhITRr1oymTZtSsmRJQkJC6NKlC5s2baJcuXKGDF0IPZnL8o0bN4iLi6NixYpotVqePXtG7dq1GTlypN7SjPBqUksLCws0Go28Wwijd+vWLfr164dWq2X06NE4OjoCWSucpGFKvIsk3R+p+fPnM3PmTG7evImZmRnx8fFYW1sTHBxMrVq1KFeuHH379sXNzQ1bW1tDhyuEnvr163PmzBlatmzJkiVLyJs3LwBxcXG4urpy7NgxGjRoQEREBElJSQQHB2NiYiLrFwuDy1wGp02bxi+//MKzZ88oU6YMU6ZMoWzZsrpjlVIkJSXRvn17UlNT2bt3r5RfYZSGDx9OQEAAjx8/pnLlyjRp0oRJkybx8OFD7O3t3/o9SbjFhyKjqzmAt7c39erVM3BE4kMjT++PTEYdi7u7OwCurq7Aqy678GrpsO+++45KlSrh5+dHQEAAMTExhglWiNekpqby/PlzNBoNAwYM4PHjx4waNYo7d+4Ar7p0/fzzzwwdOpSiRYtSp04dLly4oJvdWRIWYWgZZXDs2LHMnDkTZ2dnevTowdWrV2nfvj179+4lPT2d+Ph4pk2bRps2bXj48CG7du1Cq9WSnp5u4CsQAr1yuHHjRgICAliwYAHHjx+nYcOG/Prrr/To0UM3sdTbSMItPhQZXc1NTEwYOHAgly5dMnRI4gMjLd3Z1MWLF984Y2LmsYMHDhygZ8+eVKlShfHjx6OUwtfXl6JFi7J48WL69OnDTz/9hJ+fH+7u7vJwFAb3eqvI3Llz2bhxI5UrV2bUqFGUKFHijd+TLl/CmPzxxx84OTkxZcoUXFxcgFdjWp2cnHjy5AkHDx4kb968zJ49mxs3bjB//nyZaEoYpcDAQC5duoSlpaVuBvLk5GRWrlyJv78/vXr1olevXtKiLbKNq1evsmzZMmbMmCEV+eIvkaQ7GxoyZAjx8fH8+OOPugddeno6Go0GjUbDli1bOH36NKNGjSI0NJTvv/+ex48fY2pqSqFChTh8+DBWVlYADBgwgO+//57SpUsb+KqEeJV0K6X0HnTz5s3TS7yLFy8uL3jCqN25cwdHR0c2bdpE/fr1SUpKwsLCguTkZIoXL07fvn3x9vbW+45MmiaMzYsXL8iTJw9paWn06tWLxYsX6+1v2bIlZmZmBAYGGiZAId4zGbIm/gopKdmQi4sL8+fPB+D+/fvAqy6NGQl3165dKVasGJ988gmOjo5cuHCBvXv3snv3bk6cOIGVlRUJCQnAq5ZESbiFIbxeH5jRnVGr1bJ582YGDRoEgJeXF99++y1Xrlxh+PDhRERESMItjMab6rULFSqEVqtl+/btALqE28zMjIoVK+ruv5lJwi0M7fWybGtrS3h4OCVLluTQoUOcO3dOr9t5gwYNiI6OJj4+/t8OVYh/hSTc4q+Q0pKNZDwQ69Wrh6mpKevXr6dDhw4cO3YMgPDwcHx8fJgxYwb9+/cH/pPIODg48Pnnn6PVaklLS9O1dAthCJlbqh88eAD8p+Jo69atdO/eXa8ref/+/WnVqhV2dnbkz5/fIDEL8bqMHkYAz549IyEhgeTkZCwsLPDx8WHLli1MmzYNQLcsY3R0tG4mcyGMReayHBERwbNnz3j06BGFCxfm8OHDvHjxgkGDBnH8+HHi4+N5/vw5O3fupECBAro5Y4QQ4mMm3cuzkcyJSnx8PGfPnmXixImYm5szevRo6tWrx7Vr12TJGWHUMnfX2rBhA5s3b2bMmDHUrFmTsLAwWrduzYABA/D09MxyfObhFFIDLQwp8/14/Pjx/Prrrzx69AgnJydcXV1xdHTE19eXefPm4ejoSKlSpTh//jxRUVFcvHhRxm4Lo5G5LE+aNIn9+/cTFRVF/vz5GTRoEG3atOH+/fvUqlWL58+f88UXX1CgQAEiIiI4cuQI5ubmMuRHCPHRk7fSbGLnzp2cOXMGgKFDh9KrVy8aNGjA4MGDSU9PZ8KECZw4cUKXcEtdizBGmZPloKAgfvnlF3777Tf8/Py4dOkSxYoVY/PmzbqEG161gGeU54w1XyXhFoaUuVVwwYIFzJ8/ny5duuDi4sLdu3f55ptvOHjwIOPGjWPdunUkJCRw9+5dypUrp0u409LSDHwVQrySUZZ9fHyYM2cOw4YNY/ny5ZiamtKxY0f++OMPihQpwtmzZylYsCC3b9+mR48eHD9+HHNzc5KTkyXhFkJ89KSlOxtIS0ujZcuWnDp1CmdnZ3bt2sXx48d1s5fv3buXefPmkZ6ejre3N/Xr1zdwxEK82+DBg9m5cydt2rQhMjKSwMBAWrRowciRI6latSog67sK43fp0iXmzp3LV199RefOnQEIDQ1l/vz5HDp0iICAgDeuMiGzlAtj8/jxYzp27MiYMWNwcnJi165dfPfdd0yZMgVPT08SExOxtLTkwYMHVKlShc8//5wlS5ZQokQJmY9ACCGQlu4P2vLly3n06BEmJib88ssvWFpasn37dn788UccHBx0LSUtWrTAy8sLU1NTpk6dysGDBw0cuRBvFxQUxPr161mzZg1+fn6sXbuWFStWcP36daZOncr58+cBWd9VGLf9+/fj6OiYZebmChUq0KtXL3LkyMGFCxcA/TWPlVKScAuDe709JiYmhpCQECpWrMgvv/yCm5sbU6dOxdPTk4SEBBYuXMjNmzcpXLgw58+f58aNG7i6unL79m0DXYEQQhgXSbo/UGfOnOH//u//mDp1KhERESQkJFCgQAGqVKnCsGHDOHXqFCYmJroHZ4sWLfj++++JjIxk9+7dBo5eiLczNTVFq9ViYWGh29axY0dGjRrFtm3bmD59OqdPnzZghEJk9XqS8tVXX9G/f39evHjBvn37ePz4sW5flSpVsLa25tSpU4D+DLhSmSQMLTIyUlcOly1bRmJiIsWKFaNx48bMmjWLTp064efnR58+fYBX684fO3aM27dvk5qaSpEiRQgKCuLly5eYm5sb8lKEEMJoSNL9gapRowaBgYEsXLiQyZMnY2lpSXBwMCdOnKBq1aq0a9eOU6dO6b3ANWnShHXr1uHn52fAyIV4N61WS2pqqm7W8pSUFAA6d+5MuXLlCAkJYfny5br9Qhha5jHcmVutp0yZwsCBAzlw4ABr1qzhyZMnAMTGxhIfH0/BggUNEq8Qb/Prr79SpUoVQkNDGThwIAMGDODRo0dYWFhQpEgR5syZg7u7O7169QLg5cuXDBkyhISEBJo1a4apqSmpqakULVqU0NBQihUrZuArEkII4yBjuj9AGS94Go2GHTt20K5dO/r27cuYMWMoWLAgKSkptG/fnnPnzrFhwwYqV65Mz549yZ8/P4sWLdKdQyabEob0rjLYs2dPtm/fzsGDB6lSpQoAT548YciQIXz++edMmjSJNWvW8PXXX/+bIQvxTvPnzycoKIgKFSrQuHFj3fwZAwYMYOPGjZQrV45q1aoRHh5OWFgYFy5cwMzMzMBRC/FKxj25bt263Lx5k8TERI4ePaq7BwO0b9+e06dP4+joSN68ebl06RLR0dGcO3cOMzOzN64mIYQQQpLuD07mh1hKSgpmZmYEBgbi4uJCv3798Pb2Jn/+/KSmptKpUyd+/vlnypcvT0pKCpcuXZIXPGEUXl8WLDQ0FCsrKxo2bIijoyPJycm4urqyb98+Ro0aha2tLTt37iQlJYWjR49SrVo1atasyY8//mjgKxHilWnTpjF9+nRat27Nb7/9RokSJejSpQtdu3YFYNSoUUybNg1nZ2eaN29O//79AZk0TRiH/fv3c+bMGbp27cqqVavw8fHB3t6eHTt2UKlSJb0yOmPGDEJCQkhMTKR8+fJ4e3vrWrilLAshxJvJ3fEDk5Fwr1y5kri4OLp3707btm3Ztm0bLi4uALrEe9u2baxfvx541TVXHorCWGQk3CNGjGDVqlU0bdqUsLAw9u/fj5ubG3369GHbtm2MGTOG3bt3Ex8fT7FixQgICADAwsKCzz77zJCXID5yr/fUePDgAVu2bKFJkyZcvHiRadOm4e/vj1KKbt26MXXqVJKTk9mzZw/p6ekkJCRgZWUl92NhcCtXrmTs2LF8/fXXvHjxgrZt29KpUyc8PDzo0KEDq1evpnbt2mg0GrRaLcOGDQP0/w2kpaVJWRZCiHeQO+QHKC0tjc2bNxMZGYm1tTWurq56ibdGo2HkyJEUKlSIb7/9Vu978lAUxuLHH38kICCA3bt3U716dVavXk3Pnj2JiYkhISGBQYMGMXnyZJ4+fYqNjQ2WlpYAjB07lj/++INWrVoZ+ArExypzsnH06FFsbGx4+PAhefPmBcDBwYGRI0fyww8/sHz5cjQaDV27dsXPz4/09HTmz59PfHw8vXv3xs7OzpCXIj5ymzZton///qxcuRInJydy5cql2xcUFET9+vX59ttv2bRpE7Vr1wZg4sSJDB8+XG+yS1kWTAgh3k26l38A0tLSsjzQEhMT8fDw4NatW/Tq1YtvvvkGa2trAgMD6dSpE66ursyZM4dPPvnEQFEL8XYpKSmMGzeO3LlzM3z4cLZv30737t0ZMmQIwcHBnD17lqFDh+q64ALcuHEDPz8/duzYwd69e/XGGQrxb8k8xGfIkCGsWLECgLi4OKZOncqQIUN0x16+fJnp06dz5swZ/Pz8aNmyJQC9evXi9OnTHD58WJJuYTBRUVF06tSJDh060K9fP9322NhYLl68SN68efnss89o2bIlISEhDBgwgH379nHjxg1u3rwpibYQQvwFknR/QG7dukWJEiV0LSyJiYm4u7sTHh5Onz59cHNzw8rKio0bN7Jw4UKOHTsmk6UJo3D48GGOHz9Oeno6jo6ONGvWjIiICNLS0khKSqJly5b07t2bQYMGcfz4cVq3bo2dnR0TJ06kS5cuADx//pyzZ89SsmRJSpYsaeArEh+7O3fu4OLiwpIlS3j58iWbN2/m0KFDDB06VLeUEsC5c+fYtWsX3t7eeknK48ePyZ8/vyFCFwJ4lXQ3atSIyZMn07ZtW+BVD6RDhw6xdetW8ubNS926dQkMDMTd3Z379+9jYWHBzp07s0yaJoQQ4t2kr7ER279/P8+ePcPV1ZVNmzYxfvx4Zs6cibOzM1qtFktLS1avXk3btm2ZOHEiGo2GTp064ebmhpubGyCzlAvDW7ZsGaNHj8bBwYEbN26wYsUKFixYoJt5fMuWLVhYWOiGQiQkJNC4cWMaNWrEN998oztP7ty5adasmUGuQYjM/Pz8OHXqFPXq1aNGjRpoNBqKFi2KjY0Nc+bMQaPR0Lt3bwCqVatGtWrVgFe9ljLGxUrCLYzBixcv2L17N7a2tixatIgbN27g6OjIvn37iImJYfDgwSxYsIA1a9YQFRVF3rx50Wg0Mj+MEEL8RXLHNFJBQUE0b96catWqYW5uTqtWrVi0aBE//PADWq2W5s2bo9VqsbKyws/Pj3r16vHDDz+QJ08evv76a10XSEm4hSEtW7aMfv36sX79ejp06MDhw4dp164dgYGBtGzZEhMTE0xMTIiLi+PQoUM4OTmxYMECPvvsM7y8vNBoNG8cXiGEocTFxfH06VP2799PzZo1dV3Ny5QpQ9++fdFoNMybN4/Y2Fi9ruYg416FccmXLx+rVq2iffv2HDp0iJw5czJnzhwcHBzIkycP0dHR5MmTh8ePH+uOh1dDLCThFkKIv0bumkbqyZMnAFhbW7N8+XKsrKz45ZdfaNWqFRMnTkQppRsfGB0dTYcOHcifP79um6yNKQztyJEj9OrVi/Hjx9OhQwcAGjdujI2NDWFhYcTFxZEjRw6aNWtGxYoVGT16NIMGDaJAgQJs3boVjUaDUkoSFWFQr681bGNjQ58+fbCxsWHs2LHMnj2bQYMGAf9JvDOGQsg6xcLYZawcERsbS4kSJbLsz5kzJ/b29nrbpEwLIcRfJ2O6jZi7uzt3794lT548REZG4u3tTf369WnVqhVJSUl07NiRJk2aMGbMGCpUqMC0adOAN0+8JsS/LSwsjB49emBnZ8fYsWOpXr06Li4u7Nq1i6+++oro6GhsbW1p06YN+fPnx8LCAqUUzZs3x8TERLovCoPLPDwnIiKCxMREXWLy8uVL/Pz88PPzY9KkSQwYMED3vfv371OoUCG0Wq0k3uKDFBUVhYeHB0+ePCEoKEjeKYQQ4n8kSbcRSkpKwsLCgvXr13P06FF69OjB9OnTefToET4+PjRo0ABPT0+OHj1KSkoKRYsW5ejRo5iZmckLnjAqYWFheHl5YWJiQkxMDPHx8axcuZJy5coRFBTE9evX+eGHH0hMTKRjx47Mnz8fkIojYXiZ76U+Pj5s376dqKgoPvnkE4YNG0b79u0xMTFh5syZzJo1i0mTJvH999/rnUPm1BAfmidPnrBs2TJ+++03IiMjCQoKwszMTO7JQgjxP5Kk20gcPnyY27dv06NHD922iIgIatSowcSJE2nRogX9+vXj8ePHjB49GmdnZ8LDw4mIiKBWrVpotVppGRRGKSwsjL59+3LmzBmWLl1Kp06d9PbHxMQQHByMo6OjvNQJozN16lT8/PxYsGABBQsWZPXq1fz+++988803DBo0iISEBH788Ud8fHzYvHkzHTt2NHTIQvxtwcHBjB07llKlSjFz5kxMTU3l3UIIIf4BknQbgcOHD9O0aVMAvvrqK9q2bYujoyOVKlVi06ZNbNiwgQ0bNnD37l18fHx4+vQp3333Hd27d9edQ2qhhTG7desW/fr1Q6vVMnr0aBwdHQGyvMxJORbGQinFy5cvcXZ2plOnTnh5een2eXt7s379elasWEHjxo25f/8+Bw4c4LvvvpPkRHzwnj9/Tq5cuWQiSyGE+AdJvzcjYG9vT/369WncuDFJSUmEhobSqFEj5s6dS0REBHFxcQQHB1OhQgUmTJgAwIULF8hcXyIPRWHMSpUqxfz581FKMXnyZIKCggCyJChSjoUhpaen637O6Fr+8uVL3c9JSUkATJo0iWLFijF37lwAihQpgoeHh65VUIgPWe7cuWUiSyGE+IdJ0m0ESpcujb+/P7lz5yZnzpx8/fXXrF+/nmPHjnHgwAEOHz6Mn58faWlpVKhQgZUrVzJ37lzdQ1GID0GZMmWYN28eJiYmDBw4kEuXLhk6JCF0Mo+/vnPnDgC2trYULlyYjRs3AmBhYUFycjIADg4OWFlZZTmPtHSL7ELmhxFCiH+OJN1GomzZskyZMoWUlBRmzJhBsWLFCAgIYObMmXTv3p3x48djYmKCUorixYuj1WpJT0+Xh6L4oJQpU4YZM2bQoEEDKlWqZOhwhAD0E+4JEybQqVMnDh48CMCMGTO4e/cuLi4uALoZyc+dO0eePHkMFrMQQgghPhwyptvIhIWF0b9/fwDdEmEZZCZckd1ImRbGZMyYMSxbtgx/f38qVqxIqVKlSE1NZd++fXh6emJpaUmJEiWIiYnhxYsXXLp0SVq2hRBCCPFfSdJthDKWWYJXL4EZk04JIYR4P65du0aHDh2YNm0aLVu2zLI/KiqK2bNnk56ejo2NDaNGjZKZnYUQQgjxp0jSbaTCwsIYNGgQjx8/Zvny5VSuXNnQIQkhRLZ1/Phx2rRpw+nTpyldurRuvgyNRkNycjLm5uZZviMzOwshhBDiz5B+nUZKxr4KIcT7kbmuOePnXLlykStXLkJDQ4FXyXbGbOYbN25k+/btWc4jCbcQQggh/gxp6f5AyNhXIYT4371+L01ISMDKyooXL17QtGlTcufOzezZs3WVnampqbRu3ZqiRYuyZMkSQ4UthBBCiA+YJN1CCCE+CpkTbj8/P86dO8f58+fp0aMHrq6uKKWoV68eZcqUoU6dOhQrVowNGzbw7Nkzzp8/L2O3hRBCCPG3SNIthBDiozJq1ChWrlzJiBEjsLGxYcSIETRq1Ijt27dz69YtpkyZwrlz58iRIwfFixdn5cqVmJmZyRhuIYQQQvwtUm0vhBDio3H27Fm2bdtGYGAgtWvX5uzZs7x8+ZJ27doBUKpUKZYvX05KSgqJiYnkzJkTQGYpF0IIIcTfJoOEhRBCfDTS0tKwtbWldu3aBAQE0LhxY+bPn4+7uzuxsbEcPHiQuLg4zMzMdAm3UkoSbiGEEEL8bZJ0CyGEyJYePXrE5cuXWbduHSEhIURHR2Nra8uDBw9YunQpvXr1Ytq0aXh6egLw+++/s2jRIh48eKB3Ho1GY4jwhRBCCJFNSNW9EEKIbGfbtm0sX76c8+fPEx8fT0pKCl9++SVjxozB1dWVPn36MG7cOPr27QtAUlISc+bMwcLCgtKlSxs4eiGEEEJkJzKRmhBCiGzF39+fESNGMGbMGL744guqVavG/Pnz2bBhA0opunbtSkhICCdOnMDX15fo6Gj27NnDgwcPuHDhAmZmZrJMoxBCCCH+MZJ0CyGEyDb8/f3p378/GzduxMXFRW/f5s2bmTFjBjY2Nnh6enL8+HF+/vlnSpcuTcmSJVm8eDGmpqYyaZoQQggh/lGSdAshhMgWjhw5QpMmTRg/fjw+Pj5kPN7S0tJ0SfS8efPw8fFhxYoVuLi4EBUVRb58+XTnkIRbCCGEEP806TsnhBAiWyhcuDCOjo6cP3+e48ePo9Fo0Gg0mJqakp6eDoCXlxf29vYcPHgQgNy5c+u+L7OUCyGEEOJ9kKRbCCFEtlCmTBmWL19OUlISkydP5rffftPty5iB/MWLFyQmJlKwYEEAzMzMshwjhBBCCPFPkqRbCCFEtlGmTBnmzZuHRqNh0qRJBAUF6e2/ffs2RYoUoXbt2gDICCshhBBCvG8yplsIIUS2ExYWhpeXF0opxowZQ/369UlNTaVNmzZotVp27Nghs5MLIYQQ4l8hSbcQQohsKSPx1mq1jB49mlmzZnHt2jWCg4NlWTAhhBBC/Gsk6RZCCJFthYWFMWjQIPbv30/JkiW5fPkyZmZmMku5EEIIIf41knQLIYTI1q5du8aiRYuYNWuWrMMthBBCiH+dJN1CCCE+GpJwCyGEEOLfJkm3EEIIIYQQQgjxnsgMMkIIIYQQQgghxHsiSbcQQgghhBBCCPGeSNIthBBCCCGEEEK8J5J0CyGEEEIIIYQQ74kk3UIIIYQQQgghxHsiSbcQQgghhBBCCPGeSNIthBBCGJEjR46g0Wh4/vy5btuQIUPw9/cHYPTo0SxYsOAvn3fVqlXkzp37H4rSeBQvXpw5c+YYzXmEEEKI10nSLYQQ4qPTrVs3NBoNffr0ybKvX79+aDQaunXr9qfP96ZE+Z/UvXt3xo4di5mZGVu2bKFz587v5fe8S/HixdFoNG/976/8eRnS2yofzpw5Q69evf79gIQQQmR7poYOQAghhDAEe3t7Nm3axOzZs7GysgIgMTGRDRs2ULRoUQNHp69ixYrcv3+fyMhIChQogFb779eZnzlzhrS0NABOnDhB+/btuX79Ora2tgC6P8MMKSkpmJmZ/etx/l358uUzdAhCCCGyKWnpFkII8VGqWrUq9vb2bNu2Tbdt27ZtFC1alCpVqugdm56eztSpUylRogRWVlY4ODjw008/ARAeHk7jxo0BsLOz02v1TUpKwsvLi08//RRLS0scHR05c+aM3rn37NlD2bJlsbKyonHjxoSHh+vtj4qKwtXVlWLFilG6dGkcHBzYuHHjf72+VatWUbRoUaytrWnXrh1Pnz7NcsyOHTuoWrUqlpaWlCxZEl9fX1JTU994vnz58lGgQAEKFCjAJ598AsCnn35KgQIFSExMJHfu3GzevJmGDRtiaWnJ+vXrefr0KW5ubhQuXBhra2s+//zzLLE3atQILy8vhg8fzieffEKBAgUYP368br9SivHjx1O0aFEsLCwoVKgQXl5eb73uWbNm8fnnn2NjY4O9vT19+/YlNjYWeNUjwcPDg5iYGF0Lfcbver17+fPnz+nZsyf58uXD1taWJk2acPHixf/65y6EEEK8TpJuIYQQH63u3buzcuVK3ecVK1bg4eGR5bipU6eyZs0aFi9ezJUrVxg0aBBdunTh6NGj2Nvbs3XrVgCuX79OREQEc+fOBWD48OFs3bqV1atXc/78eUqXLo2TkxPPnj0D4N69e7i4uNC6dWuCg4Pp2bMnI0eO1PvdCQkJ1KhRg927dxMSEoKnpyfu7u6cPn36rdf1+++/06NHD/r3709wcDCNGzdm0qRJesccP34cd3d3BgwYQGhoKEuWLGHVqlVMnjz57/1hAiNHjmTAgAFcvXoVJycnEhMTqVatmi72Xr168d1332WJffXq1djY2PD7778zffp0JkyYwIEDBwDYunUrs2fPZsmSJYSFhREYGMjnn3/+1hi0Wi3z5s3jypUrrF69mkOHDjF8+HAA6taty5w5c7C1tSUiIoKIiAiGDh36xvN07NiRyMhI9u7dy7lz56hatSpNmzbV/d0JIYQQf5oSQgghPjJdu3ZVbdq0UZGRkcrCwkKFh4er8PBwZWlpqaKiolSbNm1U165dlVJKJSYmKmtra3XixAm9c/To0UO5ubkppZQ6fPiwAlR0dLRuf2xsrDIzM1Pr16/XbUtOTlaFChVS06dPV0opNWrUKFWhQgW9844YMSLLuV7XqlUrNWTIkLfud3NzU87OznrbOnfurHLlyqX73LRpUzVlyhS9Y9auXasKFiz41vNmeP1679y5owA1Z86c//rdli1b6sXesGFD5ejoqHdMjRo11IgRI5RSSvn5+amyZcuq5OTkN56vWLFiavbs2W/9fVu2bFF58uTRfV65cqXen8ObznP8+HFla2urEhMT9Y4pVaqUWrJkybsuTwghhMhCxnQLIYT4aOXLl4+WLVuyatUqlFK0bNmSvHnz6h1z8+ZN4uPj+fLLL/W2JycnZ+mGntmtW7dISUmhXr16um1mZmbUrFmTq1evAnD16lVq1aql9706derofU5JScHHx4fNmzfz4MEDkpOTgaxjqDO7evUq7dq1y3LeX375Rff54sWLBAUF6bVsp6WlkZiYSHx8PNbW1m89/9tUr15d73NaWhpTpkwhICBAF3tSUlKWc1euXFnvc8GCBYmMjARetTjPmTOHkiVL0rx5c5ydnWndujWmpm9+hTl48CBTp07l2rVrvHjxgtTU1L98TRcvXiQ2NpY8efLobU9ISODWrVt/6hxCCCFEBkm6hRBCfNS6d+9O//79AVi4cGGW/RnjgXfv3k3hwoX19llYWLz3+KZPn86qVasICAjgiy++IGfOnLi6upKYmPg/nTc2NhZfX19cXFyy7LO0tPxb57SxsdH7PGPGDObOncucOXN046wHDhyoqzjI8PqEaxqNhvT0dODVhHfXr1/n4MGDHDhwgL59+zJjxgyOHj2a5Xvh4eG0atUKT09PJk+ezCeffMJvv/1Gjx49SE5O/tNJd2xsLAULFuTIkSNZ9mXHZdeEEEK8X5J0CyGE+Kg1b96c5ORkNBoNTk5OWfZXqFABCwsL7t69S8OGDd94DnNzcwDd7N4ApUqVwtzcnKCgIIoVKwa8arU+c+YMAwcOBKB8+fLs3LlT71ynTp3S+3zy5ElatWpF/fr1ddsuXbpE2bJl33pN5cuX5/fff3/neatWrcr169cpXbr0W8/zvwoKCqJNmzZ06dIFeDUh3Y0bN6hQocJfOo+VlRWtW7emdevW9OvXj3LlynH58mWqVq2qd9y5c+dIT0/Hz89PN8N7QECA3jHm5uZ6f09vUrVqVR49eoSpqSnFixf/S7EKIYQQr5OkWwghxEfNxMRE193bxMQky/6cOXMydOhQBg0aRHp6Oo6OjsTExBAUFIStrS1du3alWLFiaDQadu3ahbOzM1ZWVuTIkQNPT0+GDRvGJ598QtGiRZk+fTrx8fH06NEDgD59+uDn58ewYcPo2bMn586dY9WqVXq//7PPPuOXX34hJiYGW1tb/Pz8CAsLe2fS7eXlRb169Zg5cyZt2rRh3759el3LAXx8fGjVqhVFixalQ4cOaLVaLl68SEhISJZJ1/6uMmXK8NNPP3HixAns7OyYNWsWjx8//ktJ96pVq0hLS6NWrVpYW1uzbt06rKysdBUZmZUuXZqUlBTmz59P69atCQoKYvHixXrHFC9enNjYWH799VccHBywtrbO0gLerFkz6tSpQ9u2bZk+fTply5bl4cOH7N69m3bt2mXpRi+EEEK8i8xeLoQQ4qNna2urW2/6TSZOnMjYsWOZOnUq5cuXp3nz5uzevZsSJUoAULhwYXx9fRk5ciT58+fXdVf/4YcfaN++Pd999x1Vq1bl5s2b7Nu3Dzs7OwCKFi3K1q1bCQwMxMHBgcWLFzNlyhS93+3t7c1nn31G6dKlKVmyJOHh4XTq1Omd11O7dm38/f2ZO3cuDg4O7N+/H29vb71jnJyc2LVrF/v376dGjRrUrl2b2bNnvzGZ/bu8vb2pWrUqTk5ONGrUiAIFCtC2bdu/dI7cuXPj7+9PvXr1qFy5MgcPHuTnn3/OMt4awMHBgVmzZjFt2jQqVarE+vXrmTp1qt4xdevWpU+fPnTu3Jl8+fIxffr0LOfRaDTs2bOHBg0a4OHhQdmyZXF1deWPP/4gf/78fyl+IYQQQqOUUoYOQgghhBBCCCGEyI6kpVsIIYQQHx0nJye8vLwMHYYQQoiPgLR0CyGEEOKjkpycTOHChbl8+TIFChQwdDhCCCGyOUm6hRBCCPFRSUlJISIigqJFixo6FCGEEB8BSbqFEEIIIYQQQoj3RMZ0CyGEEEIIIYQQ74kk3UIIIYQQQgghxHsiSbcQQgghhBBCCPGeSNIthBBCCCGEEEK8J5J0CyGEEEIIIYQQ74kk3UIIIYQQQgghxHsiSbcQQgghhBBCCPGeSNIthBBCCCGEEEK8J/8PKUtPUBtP+fQAAAAASUVORK5CYII=",
      "text/plain": [
       "<Figure size 1000x600 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import numpy as np\n",
    "\n",
    "def plot_translation_methods():\n",
    "    # Metodele și scorurile\n",
    "    methods = [\"Multi-query\", \"Rag-fusion\", \"Decomposition\", \"Step-back\", \"HyDE\"]\n",
    "    correctness = [40.00, 32.00, 44.00, 16.00, 48.00]\n",
    "    kb = [30.95, 79.36, 50.79, 66.66, 76.19]\n",
    "\n",
    "    x = np.arange(len(methods))\n",
    "    width = 0.35\n",
    "\n",
    "    # Grafic\n",
    "    fig, ax = plt.subplots(figsize=(10, 6))\n",
    "    bars1 = ax.bar(x - width/2, correctness, width, label='Correctness (%)', color='mediumseagreen')\n",
    "    bars2 = ax.bar(x + width/2, kb, width, label='Knowledge Base (%)', color='cornflowerblue')\n",
    "\n",
    "    # Etichete\n",
    "    for bar in bars1:\n",
    "        height = bar.get_height()\n",
    "        ax.annotate(f'{height:.1f}%',\n",
    "                    xy=(bar.get_x() + bar.get_width() / 2, height),\n",
    "                    xytext=(0, 3), textcoords=\"offset points\",\n",
    "                    ha='center', va='bottom', fontsize=9)\n",
    "\n",
    "    for bar in bars2:\n",
    "        height = bar.get_height()\n",
    "        ax.annotate(f'{height:.1f}%',\n",
    "                    xy=(bar.get_x() + bar.get_width() / 2, height),\n",
    "                    xytext=(0, 3), textcoords=\"offset points\",\n",
    "                    ha='center', va='bottom', fontsize=9)\n",
    "\n",
    "    # Titluri și stil\n",
    "    ax.set_ylabel('Procent (%)')\n",
    "    ax.set_xlabel('Metodă de Translație')\n",
    "    ax.set_title('Performanța metodelor de translație a interogărilor')\n",
    "    ax.set_xticks(x)\n",
    "    ax.set_xticklabels(methods, rotation=45, ha='right')\n",
    "    ax.legend()\n",
    "\n",
    "    plt.tight_layout()\n",
    "    plt.show()\n",
    "\n",
    "# Apelează funcția\n",
    "plot_translation_methods()\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
